<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12634183
    </Internal_Number>
    <TrialID>NCT05590260
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>Prevention of Iron Deficiency Anemia Post-delivery
    </Public_title>
    <Scientific_title>Prevention of Iron Deficiency Anemia Post-delivery (PRIORITY Trial): A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research
    </Scientific_title>
    <Acronym>PRIORITY
    </Acronym>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220929
    </Date_registration3>
    <Date_registration>29/09/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05590260
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>January 1, 2023
    </Date_enrollement>
    <Target_size>4800
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Bangladesh;Congo, The Democratic Republic of the;Guatemala;India;Kenya;Pakistan;Zambia;Bangladesh;Congo, The Democratic Republic of the;Guatemala;India;Kenya;Pakistan;Zambia
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Richard J Derman, MD, MPH;Elizabeth McClure, PhD
    </Contact_Lastname>
    <Contact_Email>;mcclure@rti.org
    </Contact_Email>
    <Contact_Tel>;919 316 3773
    </Contact_Tel>
    <Contact_Affiliation>Thomas Jefferson University, Philadelphia, PA;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Established pregnancy &gt;20 weeks gestation by LMP and/or clinical assessment and/ Or&#x0D;&lt;br&gt;             USG&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age: 15 years (or lower limit age eligible*) to 49 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Confirmed moderate anemia (Hb 7.0 to 9.9 g/dL, 6-48 hour after delivery based on a&#x0D;&lt;br&gt;             venous blood sample on Hemocue®)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Deliver in participating study hospital or health facility&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Plans to remain in study area for duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  IV Iron infusion received in past 3 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindication to iron supplementation (some examples may include hemolytic anemia,&#x0D;&lt;br&gt;             allergy, severe infection)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Blood transfusion already received or scheduled during the current hospital admission&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known diagnosis of pre-existing depression or other psychiatric illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stillbirth, major congenital anomaly, or neonatal loss prior to randomization&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women testing positive and previously untreated for malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presenting with symptomatic anemia with dyspnea or fatigue and need for immediate&#x0D;&lt;br&gt;             correction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women with known hemoglobinopathy (sickle cell disease or thalassemia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of severe allergic conditions such as severe asthma or known drug allergies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women presenting with any illness/condition requiring immediate medical care per&#x0D;&lt;br&gt;             physician's assessment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Postpartum Anemia
    </Condition>
    <Intervention>Drug: IV iron infusion;Drug: Oral iron tablets
    </Intervention>
    <Primary_outcome>Number of women with non-anemic hemaglobin levels (Hb &gt;11 g/dL)
    </Primary_outcome>
    <Secondary_outcome>Number of maternal deaths;Number of women who receive a blood transfusion post-discharge;Number of women who experience a postpartum hemorrhage requiring transfusion or major surgery;Number of women with hospitalization;Number of women with documentation of postpartum complications;Number of women screening positive for postpartum depression;Number of women with severe fatigue;Differences between treatment groups in infant-mother bonding scale scores;Differences in quality of life assessment scores;Prevalence of severe/moderate/mild anemia among women;Maternal - Change resulting in severe/moderate/mild anemia by treatment arm;Maternal - Hemoglobin concentration by mode of delivery;Maternal - Differences in ferritin and inflammatory markers by treatment group;Number of neonatal infant deaths;Number of infants with hospitalization;Number of women exclusive breastfeeding rate and intend to continue breastfeeding through 12 months post-delivery
    </Secondary_outcome>
    <Secondary_ID>CP PRIORITY
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Thomas Jefferson University;University of North Carolina;Kinshasa School of Public Health;University of Alabama at Birmingham;University Teaching Hospital, Lusaka, Zambia;University of Colorado, Denver;Institute of Nutrition of Central America and Panama;University of Virginia;International Centre for Diarrhoeal Disease Research, Bangladesh;Columbia University;Aga Khan University;Boston University;Lata Medical Research Foundation, Nagpur;Indiana University;Moi University;RTI International;Bill and Melinda Gates Foundation;KLE University Jawaharlal Nehru Medical College
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12578363
    </Internal_Number>
    <TrialID>NCT05562102
    </TrialID>
    <Last_Refreshed_on>10 October 2022
    </Last_Refreshed_on>
    <Public_title>TyVECO: Surveillance Protocol
    </Public_title>
    <Scientific_title>An Open-label Effectiveness Study of a Typhoid Conjugate Vaccine in Kisantu, Democratic Republic of Congo (TyVECO) - Step 3: Surveillance Protocol
    </Scientific_title>
    <Acronym>TyVECO
    </Acronym>
    <Primary_sponsor>International Vaccine Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220928
    </Date_registration3>
    <Date_registration>28/09/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05562102
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 9, 2021
    </Date_enrollement>
    <Target_size>48000
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Octavie Lungaya, PhD
    </Contact_Lastname>
    <Contact_Email>octmetila@yahoo.fr
    </Contact_Email>
    <Contact_Tel>+243-815-181-121
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        At health center:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients of all ages currently living in the catchment area of the health center&#x0D;&lt;br&gt;             presenting to healthcare facility with objective fever of at least 38.0°C tympanic or&#x0D;&lt;br&gt;             37.5 °C axillary OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients of all ages currently living in the catchment area of the health center&#x0D;&lt;br&gt;             presenting to healthcare facility with reported fever =3 consecutive days within 7&#x0D;&lt;br&gt;             days of presentation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        At Hospital:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Suspicion of intestinal perforation/peritonitis due to typhoid fever requiring surgery&#x0D;&lt;br&gt;             for patients living in and outside the catchment area (even in the absence of&#x0D;&lt;br&gt;             laboratory confirmation) OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients living in the catchment area of the hospital with invasive salmonellosis&#x0D;&lt;br&gt;             confirmed through blood-culture surveillance embedded in routine patient cares&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who do not provide informed consent&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Typhoid Fever;Intestinal Perforation
    </Condition>
    <Intervention>Biological: Typbar-TCV, Bharat Biotech
    </Intervention>
    <Primary_outcome>Typhoid fever
    </Primary_outcome>
    <Secondary_ID>2020-004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12633672
    </Internal_Number>
    <TrialID>NCT05559099
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>Tecovirimat for Treatment of Monkeypox Virus
    </Public_title>
    <Scientific_title>A Randomized, Placebo-controlled, Double-blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Adult and Pediatric Patients With Monkeypox Virus Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220923
    </Date_registration3>
    <Date_registration>23/09/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05559099
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 10, 2022
    </Date_enrollement>
    <Target_size>450
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Jean-Jacques Muyembe-Tamfum, MD PhD;Veronique Nussenblatt, MD ScM MHS
    </Contact_Lastname>
    <Contact_Email>;veronique.nussenblatt@nih.gov
    </Contact_Email>
    <Contact_Tel>;+1-240-812-2075
    </Contact_Tel>
    <Contact_Affiliation>Kinshasa University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        This study has no age restriction.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Laboratory-confirmed monkeypox infection as determined by PCR obtained from blood,&#x0D;&lt;br&gt;             oropharynx, or skin lesion within 48 hours of screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Monkeypox illness of any duration provided that the patient has at least one active,&#x0D;&lt;br&gt;             not yet scabbed, lesion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight =3 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Men and non-pregnant women of reproductive potential must agree to use effective means&#x0D;&lt;br&gt;             of contraception when engaging in sexual activities that can result in pregnancy, from&#x0D;&lt;br&gt;             the time of enrollment through the end of study participation. Acceptable methods of&#x0D;&lt;br&gt;             contraception include the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Hormonal contraception&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Male or female condom&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Diaphragm or cervical cap with a spermicide&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Intrauterine device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stated willingness to comply with all study procedures (including required inpatient&#x0D;&lt;br&gt;             stay) and availability for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to provide informed consent personally or by a legally or culturally&#x0D;&lt;br&gt;             acceptable representative if the patient is unable to do so&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current or planned use of a meglitinide (repaglinide, nateglinide)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Planned use of midazolam while on study drug&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe anemia, defined as hemoglobin &lt;7 g/dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current or planned use of another investigational drug at any point during study&#x0D;&lt;br&gt;             participation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who, in the judgement of the investigator, will be at significantly increased&#x0D;&lt;br&gt;             risk as a result of participation in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants who are unable to safely swallow oral medications, such as those who are&#x0D;&lt;br&gt;             at risk of aspiration&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Monkeypox
    </Condition>
    <Intervention>Drug: Tecovirimat Oral Capsule;Drug: Placebo
    </Intervention>
    <Primary_outcome>Time to lesion resolution
    </Primary_outcome>
    <Secondary_outcome>Number of days to the first of 2 consecutive negative MPXV test results;Mortality within the first 28 days post-randomization;Number of days to the first negative MPXV PCR result;Number of days to participant death;Frequency of solicited clinical symptoms;Duration of solicited clinical symptoms;Incidence of serious adverse events requiring drug discontinuation;Incidence of adverse events requiring drug discontinuation;Incidence of other adverse events;Incidence of bacterial infections
    </Secondary_outcome>
    <Secondary_ID>PALM 007
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12507083
    </Internal_Number>
    <TrialID>NCT05433350
    </TrialID>
    <Last_Refreshed_on>29 August 2022
    </Last_Refreshed_on>
    <Public_title>Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
    </Public_title>
    <Scientific_title>Pharmacokinetic, Efficacy, Safety, and Tolerability Study of a Single Dose of Acoziborole Under Fasting Conditions in Paediatric Patients From 1 to 14 Years of Age and With g-HAT: a Multicentre, Open-label Study
    </Scientific_title>
    <Acronym>OXA005
    </Acronym>
    <Primary_sponsor>Drugs for Neglected Diseases
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220615
    </Date_registration3>
    <Date_registration>15/06/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05433350
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Year
    </Inclusion_agemin>
    <Inclusion_agemax>14 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 15, 2022
    </Date_enrollement>
    <Target_size>35
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Victor Kande Betu Ku Mesu, Dr;Antoine Tarral, Dr
    </Contact_Lastname>
    <Contact_Email>;antoine.tarral@dndi.org
    </Contact_Email>
    <Contact_Tel>;+41 22 906 92 60
    </Contact_Tel>
    <Contact_Affiliation>Ministry of Public Health, Hygiene and Prevention, Kinshasa;
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12633014
    </Internal_Number>
    <TrialID>NCT05419687
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>Violence Against Health Care Workers in Fragile Settings
    </Public_title>
    <Scientific_title>Violence Against Health Care Workers: Understanding Context Through Citizen Science and Measuring a De-escalation Training Intervention Effectiveness in Eastern Democratic Republic of Congo and Iraq
    </Scientific_title>
    <Acronym>VIA-H
    </Acronym>
    <Primary_sponsor>Swiss Tropical &amp; Public Health Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220610
    </Date_registration3>
    <Date_registration>10/06/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05419687
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2022
    </Date_enrollement>
    <Target_size>798
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Health Services Research. Masking: Double (Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Iraq;Congo, The Democratic Republic of the;Iraq
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Sonja Merten, MD MPH PhD
    </Contact_Lastname>
    <Contact_Email>sonja.merten@swisstph.ch
    </Contact_Email>
    <Contact_Tel>+41 61 284 83 87
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HCWs from selected participating health facilities in DRC, junior doctors during their&#x0D;&lt;br&gt;             first year resident and permanent health care staff from participating secondary&#x0D;&lt;br&gt;             hospitals in Iraq&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HCWs and junior medical doctors and permanent health care staff must have been&#x0D;&lt;br&gt;             employed/ or worked as HCW/ medical doctors or as permanent health care staff for at&#x0D;&lt;br&gt;             least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All above participants must have completed the written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &lt;18 years; cognitive impairment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Workplace Violence
    </Condition>
    <Intervention>Behavioral: Training in de-escalating violence;Behavioral: Code of conduct delivered via a warning board
    </Intervention>
    <Primary_outcome>Incidence and severity of self-reported non-physical aggression;Incidence and severity of self-reported physical aggression
    </Primary_outcome>
    <Secondary_outcome>Level of confidence in coping with patient aggression;Level of post-traumatic stress disorders (PTSD) among HCWs;Level of burnout among HCWs;Psychological empathy among HCWs;Absenteeism;Intent to leave among HCWs;Economic cost of the intervention;Productivity loss (presenteeism);Health care workers health-related quality of life
    </Secondary_outcome>
    <Secondary_ID>70198
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>International Committee of the Red Cross (ICRC);Catholic University of Bukavu, Democratic Republic of Congo;Al-Mustansiriyah University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12595280
    </Internal_Number>
    <TrialID>CTRI/2022/06/043138
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Effect of azithromycin on neurodevlopment in children of two years who does not cry at birth
    </Public_title>
    <Scientific_title>Single Oral Dose of Azithromycin 2gm to Prevent Maternal Peri-partum Infection and Newborn Sepsis in Laboring women (A-PLUS Trial): Repurposing Azithromycin as a Neuro-protector: A Neurodevelopmental Follow-up Secondary Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Thrasher Research Foundation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220609
    </Date_registration3>
    <Date_registration>09-06-2022
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=41983
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>30-06-2022
    </Date_enrollement>
    <Target_size>400
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Democratic Republic of the Congo;Guatemala;India;Pakistan;Zambia
    </Countries>
    <Contact_Firstname>Dr Shivaprasad S Goudar
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Womens and Childrens Health Research Unit, First floor,  JNMC Campus Nehru Nagar Belagavi 
    </Contact_Address>
    <Contact_Email>sgoudar@jnmc.edu
    </Contact_Email>
    <Contact_Tel>9448126371
    </Contact_Tel>
    <Contact_Affiliation>J N Medical College, KLE Academy of Higher Education and Research
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Survivor of birth asphyxia (more than or equal to 34 weeks of gestational age) with no, mild, moderate or severe hypoxic ischemic encephalopathy (categorized by neurological examination using the Modified Sarnat Score) born to a mother who received either a single oral dose of 2 grams of azithromycin or placebo during labor as part of the A-PLUS RCT and willing to participate in neurodevelopmental assessment at 24(plus or minus 1) months of age.  &lt;br/ &gt;&#x0D;&lt;br&gt;Birth asphyxia is defined as any of the following- received positive pressure ventilation at birth and or a 5-min Apgar score less than 7
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Prenatally or postnatally diagnosed or suspected genetic disorders, neurologic diseases, and other diseases that affect neurodevelopment
    </Exclusion_Criteria>
    <Condition>Health Condition 1: P229- Respiratory distress of newborn, unspecified&#x0D;

    </Condition>
    <Intervention>Intervention1: Azithromycin: Dose-2 g &lt;br&gt;Frequency-Single dose &lt;br&gt;Route of administration-Oral Duration of therapy-A single, prophylactic&lt;br&gt;intrapartum oral dose of&lt;br&gt;azithromycin&lt;br&gt;Control Intervention1: Placebo: A single intrapartum oral dose&lt;br&gt;of an identical appearing&lt;br&gt;placebo&lt;br&gt;
    </Intervention>
    <Primary_outcome>BSID-III Cognitive Composite Score (CCS) at 24(plus or minus 1) months corrected ageTimepoint: 24 months of age
    </Primary_outcome>
    <Secondary_outcome>ASQ-3 and the Family Care Indicators questionnaire at 24(plus or minus 1) months corrected ageTimepoint: 24 months of age;Childrens outcome- Neurodevlopment outcome by gender, stunting, Infant Child Feeding Index and breastfeeding durationTimepoint: 24 months of age
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>J N Medical College KLE Academy of Higher Education and Research, JNMC Campus, Nehru Nagar, Belagavi Karanataka
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/04/2022;15/04/2022;19/07/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethics Review Committee, Lata Medical Research Foundation Nagpur;Institutional Ethics Committee, KLE Academy of Higher Education and Research, Belagavi;SNMC Institutional Ethics Committee on Human Subjects Research
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12363188
    </Internal_Number>
    <TrialID>NCT05378880
    </TrialID>
    <Last_Refreshed_on>20 June 2022
    </Last_Refreshed_on>
    <Public_title>Optimising Community Antibiotic Use and Infection Control With Behavioural Interventions in Burkina Faso and DR Congo
    </Public_title>
    <Scientific_title>Optimisation de l'Usage d'Antibiotiques et contrôle Des Infections au Niveau Communautaire Par un Paquet d'Interventions Ciblant le Comportement au Burkina Faso et en République Démocratique du Congo
    </Scientific_title>
    <Acronym>CABU-B/C
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220513
    </Date_registration3>
    <Date_registration>13/05/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05378880
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 18, 2022
    </Date_enrollement>
    <Target_size>2200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Burkina Faso;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Marianne AB van der Sande, PhD Pr
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institute of Tropical Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Patient exit surveys&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Visitor to a medicine dispenser for his/her own health or that of someone else,&#x0D;&lt;br&gt;             regardless of disease or age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having just completed a visit to a medicine dispenser in a study cluster who agreed to&#x0D;&lt;br&gt;             participate in the study Exclusion Criteria: none&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Simulated patient visits (dispensers)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prescribe or dispense medicines in a community pharmacy, medicine store, or other&#x0D;&lt;br&gt;             private clinic or outlet within the selected study clusters;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Consented at the start of the study to participate in the intervention bundle&#x0D;&lt;br&gt;             evaluation Exclusion Criteria: none&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Faecal Enterobacteriaceae carriage and transmission (members of selected households) and&#x0D;&lt;br&gt;        household surveys (household heads) Inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Member of a household in a study cluster (resident for &gt;/= 3 months);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agreement of the household head for all household members (including children) to&#x0D;&lt;br&gt;             participate to the collection of four stool samples during the study period, through&#x0D;&lt;br&gt;             informed written consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individual informed consent (plus assent for adolescent participants) for each&#x0D;&lt;br&gt;             participating household member;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  be in good physical health (no current infectious disease); Exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inhabitant of study clusters who planned to move or be absent during the following&#x0D;&lt;br&gt;             year;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Temporary exclusion: Ongoing infectious disease or ongoing treatment for an infectious&#x0D;&lt;br&gt;             disease. Field workers will return to collect stools once the patient has recovered&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Antimicrobial Stewardship;Drug Resistance, Bacterial
    </Condition>
    <Intervention>Behavioral: Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission
    </Intervention>
    <Primary_outcome>Change in the provision of Watch antibiotics;Change in quality of care
    </Primary_outcome>
    <Secondary_outcome>Change in rate of person-to-person transmission and duration of carriage of ESBL-producing E.coli within households;Change in hygiene practices and exposures;Change in dispensing of underdosed antibiotic courses
    </Secondary_outcome>
    <Secondary_ID>JPMIR2021-053;1559/22
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut de Recherche en Sciences de la Sante, Burkina Faso;Centre de Recherche en Santé de Kimpese;Universiteit Antwerpen;Institut Pasteur;University of Oxford;University of Cambridge
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12345288
    </Internal_Number>
    <TrialID>NCT05311891
    </TrialID>
    <Last_Refreshed_on>6 June 2022
    </Last_Refreshed_on>
    <Public_title>Variants of SARS-CoV-2 Causing COVID-19 in Africa
    </Public_title>
    <Scientific_title>Variants of SARS-CoV-2 in Central and West Africa: Frequency of Circulating Viruses and Implications for the Management and Control of the Pandemic
    </Scientific_title>
    <Acronym>South-Spike
    </Acronym>
    <Primary_sponsor>ANRS, Emerging Infectious Diseases
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220323
    </Date_registration3>
    <Date_registration>23/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05311891
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2022
    </Date_enrollement>
    <Target_size>12600
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Burkina Faso;Chad;Congo;Côte D'Ivoire;Gabon;Mali;Burkina Faso;Chad;Congo;Côte D'Ivoire;Gabon;Mali
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major subject (cf. country)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presenting for a SARS-COV-2 diagnosis, whether symptomatic or not&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not objecting to participating in the research&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  NA&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>COVID-19
    </Condition>
    <Intervention>Diagnostic Test: RT PCR
    </Intervention>
    <Primary_outcome>Number of SARS-CoV-2 sequences generated partially and in whole genome
    </Primary_outcome>
    <Secondary_outcome>Number of individuals tested positive for COVID-19;Number of new SARS-CoV-2 variants identify
    </Secondary_outcome>
    <Secondary_ID>ANRS 0136s
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut de Recherche pour le Developpement;Institut National de la Santé Et de la Recherche Médicale, France
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12594757
    </Internal_Number>
    <TrialID>CTRI/2022/03/041310
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>An adaptive randomized active-controlled open-label sequential&#x0D;
cohort multicenter study to evaluate the efficacy safety&#x0D;
tolerability and pharmacokinetics of intravenous cipargamin&#x0D;
(KAE609) in adult and pediatric participants with severe&#x0D;
Plasmodium falciparum malaria
    </Public_title>
    <Scientific_title>An adaptive, randomized, active-controlled, open-label, sequential&#x0D;
cohort, multicenter study to evaluate the efficacy, safety,&#x0D;
tolerability, and pharmacokinetics of intravenous cipargamin&#x0D;
(KAE609) in adult and pediatric participants with severe&#x0D;
Plasmodium falciparum malaria (KARISMA Ã¢â?¬â?? KAE609Ã¢â?¬â?¢s Role in&#x0D;
Severe Malaria) - NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Novartis Healthcare Pvt Ltd
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220323
    </Date_registration3>
    <Date_registration>23-03-2022
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=49651
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-04-2022
    </Date_enrollement>
    <Target_size>192
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Rwanda;Democratic Republic of the Congo;Gabon;India;Nigeria;Burkina Faso;Kenya;Malawi;Mozambique;Tanzania;Uganda
    </Countries>
    <Contact_Firstname>Murugananthan K
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Novartis Healthcare Private Limited 7th floor , Inspire BKC G Block, BKC Main Road Bandra Kurla Complex Bandra (East), Mumbai India Mumbai MAHARASHTRA  India 
    </Contact_Address>
    <Contact_Email>murugananthan.k@novartis.com
    </Contact_Email>
    <Contact_Tel>9122250243544
    </Contact_Tel>
    <Contact_Affiliation>Novartis Healthcare PVTLTD
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Cohort 1: Participants aged Ã¢â?°Â¥ 12 years with moderately severe malaria as defined in &lt;br/ &gt;&#x0D;&lt;br&gt;Barnes et al 2004 (prostration and/or repeated vomiting) without presence of other signs of &lt;br/ &gt;&#x0D;&lt;br&gt;severe malaria (Section 16.4) and with high P. falciparum parasitemia (60,000-250,000 &lt;br/ &gt;&#x0D;&lt;br&gt;parasites per Ã?Â¼l). &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Subsequent Cohorts 2 to 5: Participants diagnosed with severe malaria as defined in &lt;br/ &gt;&#x0D;&lt;br&gt;Section 16.4 (modified version of severe malaria criteria in WHO 2014) and P. &lt;br/ &gt;&#x0D;&lt;br&gt;falciparum parasite count of Ã¢â?°Â¥ 5000 per Ã?Â¼l &lt;br/ &gt;&#x0D;&lt;br&gt;Cohort 2: Participants aged Ã¢â?°Â¥ 12 years &lt;br/ &gt;&#x0D;&lt;br&gt;Cohort 3: Participants aged 6 -  &lt;12 years &lt;br/ &gt;&#x0D;&lt;br&gt;Cohort 4: Participants aged 2 -  &lt; 6 years &lt;br/ &gt;&#x0D;&lt;br&gt;Cohort 5: Participants aged Ã¢â?°Â¥6 months -  &lt;2 years &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;2. Written informed consent form must be obtained prior to any study related procedure. If &lt;br/ &gt;&#x0D;&lt;br&gt;the participant is unable to read and write or otherwise incapable of signing an informed &lt;br/ &gt;&#x0D;&lt;br&gt;consent, then a witnessed consent according to local ethical standards is permitted &lt;br/ &gt;&#x0D;&lt;br&gt;(formally documented and witnessed, ideally via an independent trusted witness). &lt;br/ &gt;&#x0D;&lt;br&gt;Participants aged  &lt; 18 years, who are capable of providing assent, must provide assent &lt;br/ &gt;&#x0D;&lt;br&gt;with parental/legal guardian consent or as per local ethical guidelines. The participant or &lt;br/ &gt;&#x0D;&lt;br&gt;parent/legal guardian (in case of pediatric participants) is able to understand and comply &lt;br/ &gt;&#x0D;&lt;br&gt;with protocol requirements, instructions and protocol-stated restrictions for their child and &lt;br/ &gt;&#x0D;&lt;br&gt;is likely to complete the study as planned.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1 Mixed plasmodium infections &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;2 Treatment with any antimalarial drug (including quinine or artemisinin derivative) or any antibiotic with known antimalarial activity within 12 hours of screening &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;3 Known underlying illness, surgical or medical condition not related to ongoing episode of malaria which might jeopardize the patientÃ¢â?¬â?¢s health &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;4 Known or suspected case of active infections or concurrent febrile illness such as HIV, TB, Typhoid, COVID-19 etc. &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;5 Known h/o ECG abnormalities indicating significant risk to safety of participants-Clinically significant cardiac arrhythmias-H/o familial long QT syndrome or Torsades de Pointes-QTcF  &gt; 450 ms in males and QTcF  &gt; 460 ms in females &lt;br/ &gt;&#x0D;&lt;br&gt; aged  Ã¢â?°Â¥ 12 years old and QTcF  &gt; 450 ms in females aged  &lt; 12 years &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;6 Severe malnutrition Ã¢â?¬â?? In accordance with WHO guidelines  &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;7 Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;8 Participants taking prohibited medications as per protocol &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;9 Pregnant or nursing (lactating) women &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;10 Female of child bearing potential and sexually active males unless they are using one of the highly effective contraception methods (refer protocol section 5.2) during dosing and one week after last IV dose &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Exclusion criteria for Cohort 1: &lt;br/ &gt;&#x0D;&lt;br&gt;1. ALT  &gt; 5 x the upper limit of normal range (ULN), regardless the level of total &lt;br/ &gt;&#x0D;&lt;br&gt;bilirubin &lt;br/ &gt;&#x0D;&lt;br&gt;2. ALT  &gt; 3 x ULN and total bilirubin is  &gt; 3 mg/dL &lt;br/ &gt;&#x0D;&lt;br&gt;3. Body weight of  &lt; 35 kg or  &gt; 75 kg &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Exclusion criteria for Cohort 2: &lt;br/ &gt;&#x0D;&lt;br&gt;1. Body weight of  &lt; 35 kg or  &gt;75 kg &lt;br/ &gt;&#x0D;&lt;br&gt;2. Participants diagnosed as moderately severe malaria due to repeated vomiting without &lt;br/ &gt;&#x0D;&lt;br&gt;presence of any of the symptoms of severe malaria. &lt;br/ &gt;&#x0D;&lt;br&gt; &lt;br/ &gt;&#x0D;&lt;br&gt;Exclusion criteria for Cohorts 3 to 5: &lt;br/ &gt;&#x0D;&lt;br&gt;1. Body weight of  &lt; 5 kg &lt;br/ &gt;&#x0D;&lt;br&gt;2. Participants diagnosed as moderately severe malaria due to repeated vomiting without &lt;br/ &gt;&#x0D;&lt;br&gt;presence of any of the symptoms of severe malaria.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B508- Other severe and complicated Plasmodium falciparum malaria&#x0D;

    </Condition>
    <Intervention>Intervention1: KAE609 20 mg: Minimum of two doses; q24h (to be administered at 0 hour and 24 hours) and not exceeding three doses (Dose 3 at 48 hours) followed by oral medication (CoartemÃ?Â® bid for 3 days)&lt;br&gt;Intervention2: KAE609 40 mg: Minimum of two doses; q24h (to be administered at 0 hour and 24 hours) and not exceeding three doses (Dose 3 at 48 hours) followed by oral medication (CoartemÃ?Â® bid for 3 days)&lt;br&gt;Control Intervention1: Artesunate 60 mg/vial: 0, 12, and 24 h and q24h for maximum 8 doses (7 days) according to label and until oral medication (CoartemÃ?Â® bid for 3 days) can be given according to label&lt;br&gt;
    </Intervention>
    <Primary_outcome>To assess the efficacy of IV cipargaminTimepoint: Variable: A binary outcome indicating Ã¢â?°Â¥ 90% reduction in P. falciparum parasite at 12 hours (H12) after first IV dose as compared to baseline.
    </Primary_outcome>
    <Secondary_outcome>To assess clinical outcomeTimepoint: Proportion of participants with clinical success over time. Clinical success at 48 hours is considered as the key secondary endpoint,for the secondary estimand.;To assess the presence/absence of individual signs of severe malariaTimepoint: Proportion of participants with individual signs of severe malaria over time;To assess the risk of hemolysisTimepoint: Proportion of participants developing hemolysis (early and delayed) after treatment;To assess the risk of long term neurological sequelaeTimepoint: Proportion of participants with neurological sequelae at Day 29;To evaluate parasite clearance dynamicsTimepoint: Proportions of participants with Ã¢â?°Â¥ 90% parasite reduction at 24 and 48 hours &lt;br/ &gt;&#x0D;&lt;br&gt;PCE slope half-life &lt;br/ &gt;&#x0D;&lt;br&gt;Time to P. falciparum parasite clearance (PCT) &lt;br/ &gt;&#x0D;&lt;br&gt;P. falciparum parasite reduction ratios (PRR) at 12, 24 and 48 hours &lt;br/ &gt;&#x0D;&lt;br&gt;Proportion of participants with recrudescence and reinfection by Day 29 &lt;br/ &gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>CKAE609B12201 Version 00 dated 14 October 2020
    </Secondary_ID>
    <Source_Support>Novartis Pharma AG, Novartis Campus 4056 Ã¢â?¬â? Basel, Switzerland
    </Source_Support>
    <Ethics_review_status>Not Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;29/01/2021;27/11/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>IEC-CWS HOSPITAL INSTITUTIONAL ETHICS COMMITTEE-Dr Sanjib;Institute ethics comittee,AIIMS-Dr Sunil;Nirmal Hospital Ethics Committee, Dr Nirmal C
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12602714
    </Internal_Number>
    <TrialID>PACTR202203780981413
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Improving the diagnosis of malaria in pregnant women
    </Public_title>
    <Scientific_title>PHASE 3 EVALUATION OF AN INNOVATIVE SIMPLE MOLECULAR TEST FOR THE DIAGNOSIS OF MALARIA AND FOLLOW-UP OF TREATMENT EFFICACY IN PREGNANT WOMEN IN SUB-SAHARAN AFRICA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Academic Medical Centre at the University of Amsterdam
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220316
    </Date_registration3>
    <Date_registration>16/03/2022
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=22547
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>18 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>03/01/2022
    </Date_enrollement>
    <Target_size>1016
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Crossover: all participants receive all interventions in different sequence during study,Non-randomised
    </Study_design>
    <Phase>Phase-2
    </Phase>
    <Countries>Burkina Faso;Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Petra
    </Contact_Firstname>
    <Contact_Lastname>Mens
    </Contact_Lastname>
    <Contact_Address>Meibergdreef 9
    </Contact_Address>
    <Contact_Email>p.f.mens@amsterdamumc.nl
    </Contact_Email>
    <Contact_Tel>+3120655454
    </Contact_Tel>
    <Contact_Affiliation>Senior scientist Malaria
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	Gestation =16 weeks and &lt;37 weeks as assessed by ultrasound when possible, uterine height or late menstrual period; &#x0D;&lt;br&gt;2.	Age: =18 years (DRC) or Age: =15 years (Burkina Faso); &#x0D;&lt;br&gt;3.	Residence within the health facility catchment area; &#x0D;&lt;br&gt;4.	Ability to provide written informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.	Not meeting the above criteria &#x0D;&lt;br&gt;2.	Known history of allergy to SP or to an ACT&#x0D;&lt;br&gt;3.	An ongoing antibioprophylaxis with cotrimoxazole, &#x0D;&lt;br&gt;4.	Current issue requiring hospital admission (including severe malaria as defined by WHO) &#x0D;&lt;br&gt;5.	Pregnancy at high risk.  
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;Standard diagnostic procedure;Experimental diagnostic procedure
    </Intervention>
    <Primary_outcome>sensitivity, specificity, negative and positive predictive values of mini-dbPCR-NALFIA test to detect malaria infection in pregnant women compared to routine diagnostic procedures in place
    </Primary_outcome>
    <Secondary_outcome>To determine the utility of the mini-dbPCR-NALFIA test in monitoring treatment efficacy, parasite clearance will be assessed by mini-dbPCR-NALFIA and compared with qPCR Burkina Faso;sensitivity, specificity, negative and positive predictive values of mini-dbPCR-NALFIA test compared to ultra sensitive RDT for the diagnosis of malaria in pregnant women DRC
    </Secondary_outcome>
    <Source_Support>European and Developing Countries Clinical Trials Partnership;AMC Medical Research BV
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/06/2021;03/07/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>kouetafla@yahoo.com;feli1munday@yahoo.fr
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite de ethique pour la recherche de sante de ministere de la sante Burkina Faso;Comite National de Ethique de la Sante
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+22625333594;+243998419816
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>kouetafla@yahoo.com;feli1munday@yahoo.fr
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12293432
    </Internal_Number>
    <TrialID>NCT05313139
    </TrialID>
    <Last_Refreshed_on>30 May 2022
    </Last_Refreshed_on>
    <Public_title>Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers
    </Public_title>
    <Scientific_title>Surveillance of rVSV-ZEBOV Vaccine-induced Immunity Against Ebola Virus in Previously Vaccinated Health Care Workers &lt; EBOSURV &gt;
    </Scientific_title>
    <Acronym>EBOSURV
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220315
    </Date_registration3>
    <Date_registration>15/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05313139
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 13, 2021
    </Date_enrollement>
    <Target_size>245
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Mulangu Sabue, Prof;Kavunga Hugo, Prof;Mukadi Daniel, MD;Laurene Peckeu-Abboud, PhD
    </Contact_Lastname>
    <Contact_Email>;;;lpeckeu@itg.be
    </Contact_Email>
    <Contact_Tel>;;;+32 3 247 66 66
    </Contact_Tel>
    <Contact_Affiliation>Institut National de Recherche Biomédicale (INRB), Kinshasa;Institut National de Recherche Biomédicale (INRB), Goma;Institut National de Recherche Biomédicale (INRB), Goma;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is willing and able to give informed consent for participation in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject can be contacted by phone, email or physical address&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is aged 18 years or above&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject must have a ID card (or other identification document)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For vaccinated group:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - Subject must be receiving the rVSV-ZEBOV vaccine (first or second dose) at time of&#x0D;&lt;br&gt;        inclusion OR has received a first rVSV-ZEBOV vaccine dose prior to inclusion of which&#x0D;&lt;br&gt;        vaccination date and brand is known&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For unvaccinated group (controls):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subject must NOT have received the rVSV-ZEBOV vaccine nor had any prior close contact with&#x0D;&lt;br&gt;        EBOV patients&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject was previously diagnosed with EVD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has any contraindication to venipuncture, as determined by clinical judgement&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Immune Response
    </Condition>
    <Primary_outcome>EBOV glycoprotein (GP)-specific T and B cell Spot Forming Units;EBOV glycoprotein (GP)-specific T and B cell Spot Forming Units;EBOV glycoprotein (GP)-specific T and B cell Spot Forming Units
    </Primary_outcome>
    <Secondary_outcome>Geometric mean titers (GMT) of GP-specific IgG and neutralizing antibodies (nAb);Geometric mean titers (GMT) of GP-specific IgG and neutralizing antibodies (nAb);Geometric mean titers (GMT) of GP-specific IgG and neutralizing antibodies (nAb);Seroprevalence status based on GP specific antibodies (Ab);Seroprevalence status based on GP specific antibodies (Ab);Seroprevalence status based on GP specific antibodies (Ab);Phenotypic and isotypic classification of GP-responsive T and B cells, respectively;Phenotypic and isotypic classification of GP-responsive T and B cells, respectively;Phenotypic and isotypic classification of GP-responsive T and B cells, respectively;Correlation coefficients between humoral and cellular responses;Correlation coefficients between humoral and cellular responses;Correlation coefficients between humoral and cellular responses;Effect of age, vaccination history, comorbidities and coinfections on serological and cellular titers and on composite immune index, expressed as strong, moderate and limited immunity
    </Secondary_outcome>
    <Secondary_ID>1521/21
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11987265
    </Internal_Number>
    <TrialID>ISRCTN48721236
    </TrialID>
    <Last_Refreshed_on>7 March 2022
    </Last_Refreshed_on>
    <Public_title>NeoSep1: a study to determine the ranking of existing and new antibiotics combinations to treat newborn babies who are in hospital with severe sepsis
    </Public_title>
    <Scientific_title>An open-label randomised controlled trial comparing novel combination and existing antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase (NeoSep1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Global Antibiotic Research &amp; Development Partnership
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220224
    </Date_registration3>
    <Date_registration>24/02/2022
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN48721236
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/08/2022
    </Date_enrollement>
    <Target_size>3060
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Phase III, multicentre, personalized randomized controlled trial (PRACTical) incorporating a Sequential Multiple Assignment Randomised Trial (SMART) design (Treatment)
    </Study_design>
    <Phase>Phase III
    </Phase>
    <Countries>Brazil;Congo, Democratic Republic;India;Kenya;Pakistan;South Africa;Switzerland;Uganda
    </Countries>
    <Contact_Firstname>Nathalie
    </Contact_Firstname>
    <Contact_Lastname>Khavessian
    </Contact_Lastname>
    <Contact_Address>
                    Global Antibiotic Research and Development Partnership (GARDP)
                    15 Chemin Camille-Vidart
                
    </Contact_Address>
    <Contact_Email>mrcctu.neosep@ucl.ac.uk
    </Contact_Email>
    <Contact_Tel>+41 22 555 1912
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Currently admitted to hospital&lt;br&gt;                2. Aged =28 days (post-natal age)&lt;br&gt;                3. Weight &gt;1000 g&lt;br&gt;                4. Clinical diagnosis of a new episode of sepsis together with planned treatment with IV antibiotics&lt;br&gt;                5. At moderate to high risk of death from this episode of sepsis, based on a neonatal sepsis severity score (NeoSep Severity Score) developed using baseline clinical information and subsequent mortality from the NeoOBS study; specifically, a baseline assessment NeoSep Severity Score of 4 or higher&lt;br&gt;                6. Can receive at least 2 of the potential treatment options, ensuring randomisation is possible (Part 2 only)&lt;br&gt;                7. IV antibiotics about to be started or not received &gt;24 h of IV antibiotics for this episode of neonatal sepsis at the point of randomisation&lt;br&gt;                8. Parent/guardian willing and able to provide consent (written or, if their baby is severely ill, verbal consent confirmed by written consent as soon as possible). Verbal consent allows for the administration of first-line antibiotics at no or minimal delay.&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. A serious, non-infective co-morbidity including major congenital abnormalities (other than prematurity), anticipated to cause death within this admission&lt;br&gt;                2. Previously enrolled in this trial&lt;br&gt;                3. Current participation in any other clinical study of an Investigational Medicinal Product (IMP) that is a systemic drug, unless it has received prior approval by the NeoSep1 Trial Management Group (TMG)&lt;br&gt;                4. Known contraindication to any of the trial antibiotics on the randomisation list for the relevant neonatal sub-population in that site&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Neonatal sepsis &lt;br&gt;Infections and Infestations
    </Condition>
    <Intervention>&lt;br&gt;                Randomisation:&lt;br&gt;                Treatment allocation (Part 1 only): Run-in sequential treatment cohort:&lt;br&gt;                1. Fosfomycin?and amikacin&lt;br&gt;                2. Flomoxef and amikacin&lt;br&gt;                3. Flomoxef and?fosfomycin&lt;br&gt;&lt;br&gt;                Randomisation (Part 2 only): The main empiric treatment trial (Part 2) will use a novel tailored randomised controlled trial (PRACTical) design, in which each neonate is randomised  to pre-defined first-line regimens that are considered clinically acceptable for that specific site and neonatal sub-population. The design will also incorporate a Sequential Multiple Assignment Randomised Trial (SMART) design to allow randomisation to second-line treatment where indicated. For the second randomisation, personalised randomisation lists will be determined by the neonate’s first randomised regimen and what is clinically appropriate for that specific site.&lt;br&gt;&lt;br&gt;                Dosing:&lt;br&gt;                Dosing will depend on the treatment regimen given at enrolment (part 1) or randomisation (part 2). The following provides a summary on the proposed dosing&lt;br&gt;                1. Amikacin: 15 mg/kg total daily dose for sepsis; 15 mg/kg total daily dose for suspected/confirmed meningitis&lt;br&gt;                2. Ampicillin/amoxicillin: 100-150 mg/kg total daily dose for sepsis; 200-400 mg/kg total daily dose for suspected/confirmed meningitis; 2-3 divided doses per day&lt;br&gt;                3. Benzylpenicillin: 100,000-200,000 IU/kg total daily dose for sepsis; 100,000-200,000 IU/kg total daily dose for suspected/confirmed meningitis; 2-4 divided doses per day&lt;br&gt;                4. Cefotaxime: 100-150 mg/kg total daily dose for sepsis; 150-200mg/kg total daily dose for suspected/confirmed meningitis; 2-3 divided doses per day&lt;br&gt;                5. Ce
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Part 1:&lt;br&gt;                1. PK parameters derived for fosfomycin and flomoxef using the population PK model using Day 1 PK samples taken at 5 min, 30 min, and 4 h post-treatment or 15 min, 1 h, and 6 h post-treatment from the population:&lt;br&gt;                1.1. Clearance (CL)&lt;br&gt;                1.2. Central volume of distribution (V)&lt;br&gt;                1.3. Postnatal maturation function parameters: fraction of size and scaled clearance at birth (Fm) and the rate of postnatal maturation of clearance (Km)&lt;br&gt;&lt;br&gt;                Part 2:&lt;br&gt;                1. 28-day mortality??measured from patient records at 28 days&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Part 1:&lt;br&gt;                1. PK parameters derived for fosfomycin and flomoxef using the population PK model using PK samples taken on Day 1 and Day 5:&lt;br&gt;                1.1. Maximum plasma concentration (Cmax)&lt;br&gt;                1.2. Time to Cmax (Tmax)&lt;br&gt;                1.3. Apparent terminal elimination half-life (t1/2)&lt;br&gt;                1.4. Area under the plasma concentration-time curve from 0 to last observed time point (AUC0–last)&lt;br&gt;                1.5. Area Under the Curve to infinity (AUC(0–8))&lt;br&gt;                1.6. Volume of distribution at steady state (Vss)&lt;br&gt;                2. Potential PK/PD relationships using PK and PD samples taken on Day 1 and Day 5:&lt;br&gt;                2.1. Free drug AUC ratio to Minimum Inhibitory Concentration (MIC) (fosfomycin)&lt;br&gt;                2.2. Fraction of time for free concentration above MIC (flomoxef)&lt;br&gt;                3. Safety measured using the following:&lt;br&gt;                3.1. Incidence of Grade 3/4 adverse events (AEs) based on the International Neonatal Consortium Neonatal Adverse Event Severity Scale (NAESS) measured from patient records between baseline and 28 days&lt;br&gt;                3.2. Incidence of AEs of any grade related to?antibiotics? measured from patient records throughout the study&lt;br&gt;                3.3. Modification of antibiotics for adverse reactions measured from patient records throughout the study&lt;br&gt;&lt;br&gt;                Part 2:&lt;br&gt;                1. Efficacy measured using the following:&lt;br&gt;                1.1. Clinical status measured using a clinical recovery score based on data from the NeoOBS observational study (NeoSep Recovery Score) at 3, 7, 14, and 28 days after randomisation&lt;br&gt;                1.2. Clinically appropriate need for additional antibiotics beyond the first randomised treatment measured from patient records between the first randomised treatment and the end of the study&lt;br&gt;                1.3. Clinically appropriate need for additional antibiotics beyond the first randomised and second (for failure) treatment  measured from patient records between the second randomised treatment and the end of the study&lt;br&gt;                1.4. Cure, defined as clinical improvement and no need for further antibiotic treatment for the original sepsis episode, measured using clinical assessment at the test of cure (TOC) visit (Day 14 ±3 days after randomisation)&lt;br&gt;                1.5. Length of stay during the index?hospitalisation measured from patient records between hospital admission and discharge&lt;br&gt;                1.6. Systemic antibiotic exposure (days on antibiotics) during the index?hospitalisation measured from patient records between hospital admission and discharge&lt;br&gt;                1.7. 90-day mortality? measured from patient records at 90 days&lt;br&gt;                1.8. Change in C-reactive protein at baseline, 3, and 7 days (selected sites based on availability)&lt;br&gt;                2. Safety measured using the following:&lt;br&gt;                2.1.  Incidence of Grade 3/4 adverse events (AEs) based on the International Neonatal Consortium Neonatal Adverse Event Severity Scale (NAESS) measured from patient records between baseline and 28 days&lt;br&gt;                2.2. Incidence of AEs of any grade related to?antibiotics? measured from patient records throughout the study&lt;br&gt;                2.3. Modification of antibiotics for adverse reactions measured from patient records throughout the study&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;v1.0
    </Secondary_ID>
    <Source_Support>Global Antibiotic Research &amp; Development Partnership
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/10/2026
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12094874
    </Internal_Number>
    <TrialID>ISRCTN15258669
    </TrialID>
    <Last_Refreshed_on>4 April 2022
    </Last_Refreshed_on>
    <Public_title>Effectiveness of a reduced dose of ready-to-use therapeutic food (RUTF) in the management of uncomplicated severe acute malnutrition (SAM)
    </Public_title>
    <Scientific_title>Effectiveness of a reduced dose of ready-to-use therapeutic food (RUTF) in children under 5 years of age suffering from uncomplicated severe acute malnutrition (SAM) compared to a standard dose: a randomized, controlled, non-inferiority trial in real-life conditions in Bonzola and Nzaba Health Zones, city of Mbuji-Mayi, Kasai Oriental, DRC, in 2021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Action Against Hunger
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220125
    </Date_registration3>
    <Date_registration>25/01/2022
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN15258669
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>19/08/2021
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional randomized controlled non-inferiority trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Children aged 6 to 59 months&lt;br&gt;                2. Only one child per sibling included in the study&lt;br&gt;                3. Severe acute malnutrition (weight-height index &lt;-3 Z-score and/or mid-upper arm circumference &lt;115 mm and/or bilateral edema (+: edema localized to the lower limbs; ++: edema localized to the lower and upper limbs)&lt;br&gt;                4. Without medical complications&lt;br&gt;                5. With conclusive appetite test&lt;br&gt;                6. Living in the selected health zone&lt;br&gt;                7. Consent to participate in the study (informed consent)&lt;br&gt;                8. When there are several participants in the same sibling, only the first to be included in the study will be randomized. The others will automatically be included in the same group as the first one without being randomized and will not be taken into account in the analyses&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Inconclusive appetite test&lt;br&gt;                2. Siblings of SAM children: any SAM child whose brother or sister (same father, same mother) is already enrolled in the study. Be careful, he/she will have to receive the same dose as his/her brother or sister outside the study in order not to create a bias with different doses within the same family&lt;br&gt;                3. Declared allergy to peanut and/or milk&lt;br&gt;                4. Previously treated for SAM in the past 6 months, including readmissions after program dropout, relapses and medical transfers&lt;br&gt;                5. Malformation or disability or chronic pathologies that can affect food intake, such as cleft palate, cerebral palsy, trisomy 2, sickle cell anemia&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Severe acute malnutrition without medical complications &lt;br&gt;Nutritional, Metabolic, Endocrine
    </Condition>
    <Intervention>&lt;br&gt;                Current intervention as of 31/01/2022:&lt;br&gt;                This study is a non-inferiority randomized controlled trial. Randomization will be done at the individual level in each of the 14 study health areas. Block randomization of varying sizes will be used. After randomization, participants will be randomly assigned to either the control or intervention group. Each participant will receive the dose of RUTF corresponding to the group to which he/she belongs: standard dose for the control group and reduced dose for the intervention group. Both groups will receive the same dose of RUTF for the first 2 weeks. Then in the intervention group, the reduction in the dose of RUTF will occur from the third week of treatment. The intervention will be started concomitantly in both groups.  The dose reduction will range from 13 to 53% depending on weight. In addition to nutritional management, participants will also receive routine medical treatment.&lt;br&gt;&lt;br&gt;                After recovery (according to the admission criteria, if P/T =- 1.5 z-score at two consecutive weighings, and PB =125 mm and absence of nutritional oedema for 14 days), follow-up of participants will be performed every 15 days until 3 months after discharge as planned in the national protocol. During this follow-up, the children will receive medical treatment if needed according to symptoms (malaria, etc) and a nutritional product (fortified flour or Ready-to-use Supplementary Food [RUSF]) if available. Children who develop complications during treatment will be referred to the Intensive Therapeutic Nutritional Unit (UNTI) and then reintegrated into their study group after the complication has been resolved.&lt;br&gt;&lt;br&gt;                During the course of the study, a qualitative survey using focus groups, in-depth i
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Current primary outcome measure as of 25/03/2022:&lt;br&gt;                Weight gain velocity (g/kg/d) measured using scales weekly from admission to discharge&lt;br&gt;&lt;br&gt;                Previous primary outcome measure as of 31/01/2022:&lt;br&gt;                Weight (kg) measured using scales weekly between admission and discharge, and then fortnightly after discharge for up to 3 months&lt;br&gt;&lt;br&gt;&lt;br&gt;                Previous primary outcome measure:&lt;br&gt;                Weight (kg) measured using scales at admission, at discharge, and then every 15 days up to 3 months&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Current secondary outcome measures as of 31/01/2022:&lt;br&gt;                1. Acceptance of a reduced dose during SAM treatment by health care personnel and the community measured using discussion groups, in-depth interviews, and direct observation using interview and focus group guides as well as observation grids in November 2021. This survey will assess the perceptions of families and health care providers on the amount of RUTF received, consumption and use practices, and their attitude towards a possible dose reduction.&lt;br&gt;                2. Relapse rate measured as the proportion of children treated for SAM and declared cured who revert to SAM within 3 months of completing treatment, using anthropometric measurements including weight (kg), height (cm), and arm circumference (mm) taken using scales, height chart and tape measure at 3 months after treatment&lt;br&gt;                3. Psychomotor development measured using the Psychomotor Development Index (PDI) at admission, discharge, and 6 months after treatment&lt;br&gt;                4. Duration of the edema melting measured as the number of days taken for the lower limbs of SAM children to return to their normal volume using a tape measure at all study visits&lt;br&gt;                5. Length of stay measured as the number of days between admission and discharge (with discharge occurring at PB=12.5 cm and/or PT =-3 z-score and/or edema melt). The maximum length of stay is 12 weeks or 3 months&lt;br&gt;                6. The cure rate measured as meeting the cure criteria according to admission category during two consecutive visits and no edema during two visits in two consecutive weeks measured using PT index (=-1.5) or PB (=125 mm) and edema at all study visits&lt;br&gt;                7. The dropout rate measured as the proportion of children confirmed alive who missed two successive visits, at all study visits. The abandonment is confirmed once after the visit of the RECO which confirms that the child is alive despite his 2 absences during the weekly visits. Children who have been abandoned will be followed up to 3 months after the abandonment. For children who can be found, offer the caregivers a small snack at a single appointment 3 months after abandonment to take the anthropometric measurements.&lt;br&gt;                8. Death rate measured as the proportion of children randomized to the study who died during the intervention at any time&lt;br&gt;                9. Cost savings (average cost saved and cost saved per child treated) measured by comparing the cost of treatment for children in care and declared cured in the two groups using the direct costs of drugs and RUTF (purchase, transport, transport, and storage) to assess the cost for each child, the HR costs involved in the care, the non-medical costs (food and transport. beneficiaries), and indirect costs (loss of productivity) throughout the trial&lt;br&gt;                10. Prevalence of stunting and being underweight measured using anthropometric measurements including weight (kg), height (cm), and arm circumference (mm) taken using scales, height chart, and tape measure at the end of the treatment.&lt;br&gt;&lt;br&gt;&lt;br&gt;                Previous secondary outcome measures:&lt;br&gt;                1. Acceptance of a reduced dose during SAM treatment by health care personnel and the community: this involves assessing the perceptions of families and health care providers on the amount of RUTF received, consumption and use practices and their attitude towards a possible dose reduction. Assessed using a qualitative approach by organizing discussion groups, in-depth interviews and direct observation using interview and focus group guides as well as observation grids. This survey was conducted in November 2021&lt;br&gt;                2. Relapse rate: the proportion of children treated for SAM and declared cured who revert to SAM within 3 months of completing treatment, assessed using anthropometric measurements including weight (kg), height (cm) and arm circumference (mm) taken using scales, height chart and tape measure&lt;br&gt;                3. Psychomotor development: this sub-study aims to assess the proportion of children with psychomotor developmental delay (PDD) and to monitor their progress during treatment. Psychomotor developmental delay (PDD) refers to impairments in the acquisition of skills and competencies in the areas of language, cognitive, motor, and social interaction. PDD corresponds to a score of less than 70% in two of the four domains of Psychomotor Development (DPM) at admission, discharge, and 6 months after treatment. In this substudy, it is expected that the DPM of children with Psychomotor Development Delay (RDPM) will improve after treatment simply as a result of medical and nutritional intervention without any specific action on the DPM during treatment.&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Foreign, Commonwealth and Development Office
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 31/07/2021, Ethics Committee of the School of Public Health, University of Kinshasa (Campus Université de Kinshasa, DRC; +243 817 493 194; espsec_unikin@yahoo.fr), ref: ESP/CE/127/2021
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/08/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12576742
    </Internal_Number>
    <TrialID>NCT05256017
    </TrialID>
    <Last_Refreshed_on>10 October 2022
    </Last_Refreshed_on>
    <Public_title>Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
    </Public_title>
    <Scientific_title>Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Non-parasitologically Confirmed Subjects: a Multicentre Randomised Double-blind Placebo-controlled Study
    </Scientific_title>
    <Acronym>OXA004
    </Acronym>
    <Primary_sponsor>Drugs for Neglected Diseases
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220117
    </Date_registration3>
    <Date_registration>17/01/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05256017
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 30, 2021
    </Date_enrollement>
    <Target_size>1200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Guinea;Congo, The Democratic Republic of the;Guinea
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Victor Kande Betu Ku Mesu, Dr.;Antoine TARRAL, Dr.
    </Contact_Lastname>
    <Contact_Email>;antoine.tarral@dndi.org
    </Contact_Email>
    <Contact_Tel>;+41 22 906 92 60
    </Contact_Tel>
    <Contact_Affiliation>Ministry of Public Health, Hygiene and Prevention, Kinshasa;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed the informed consent form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  15 years of age or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  CATT test or HAT sero-K-set RDT positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parasitology negative (in blood and/or lymph if lymphadenopathy is present)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky Performance Status above 70&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to ingest oral tablets&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known address and/or contact details provided&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be able to comply with the schedule of follow-up visits and other requirements of&#x0D;&lt;br&gt;             the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agreement to be hospitalised upon enrolment for at least 5 days (in order to receive&#x0D;&lt;br&gt;             in-ward post-treatment observational follow-up through the first 5 days after&#x0D;&lt;br&gt;             treatment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agreement to not take part in any other clinical trials during the participation in&#x0D;&lt;br&gt;             this study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For women of childbearing potential:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Must agree to have protected sexual relations to avoid becoming pregnant from&#x0D;&lt;br&gt;                  enrolment up to 3 months after dosing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Negative urine pregnancy tests&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals parasitologically confirmed in blood and/or lymph&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previously treated for g-HAT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malnutrition, defined as body mass index (BMI) &lt;16 kg/m2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breast-feeding women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For women of childbearing potential:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Urine pregnancy test positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Do not accept contraceptive protection from enrolment up to 3 months after dosing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical condition and/or abnormal laboratory results that&#x0D;&lt;br&gt;             could, in the opinion of the Investigator, jeopardise the subject's safety or&#x0D;&lt;br&gt;             participation in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Additional exclusion criteria for the TrypSkin exploratory sub-study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Rejection to participate in the exploratory sub-study in the signed ICF&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known diabetes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known haemophilia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Trypanosomiasis, African;Trypanosoma Brucei Gambiense; Infection;Sleeping Sickness
    </Condition>
    <Intervention>Drug: Acoziborole;Drug: Placebo
    </Intervention>
    <Primary_outcome>Occurrence of treatment-emergent adverse events (TEAEs)
    </Primary_outcome>
    <Secondary_outcome>Occurrence of adverse events (AEs);Change from baseline in biochemistry parameter: Alanine Aminotransferase;Change from baseline in biochemistry parameter: Albumin;Change from baseline in biochemistry parameter: Alkaline Phosphatase;Change from baseline in biochemistry parameter: Aspartate Aminotransferase;Change from baseline in biochemistry parameter: Calcium;Change from baseline in biochemistry parameter: Chloride;Change from baseline in biochemistry parameter: Creatinine;Change from baseline in biochemistry parameter: Glucose;Change from baseline in biochemistry parameter: Potassium;Change from baseline in biochemistry parameter: Sodium;Change from baseline in biochemistry parameter: Total Bilirubin;Change from baseline in biochemistry parameter: Total Carbon Dioxide;Change from baseline in biochemistry parameter: Total Protein;Change from baseline in biochemistry parameter: Blood Urea Nitrogen;Change from baseline in hematology parameter: hemoglobin;Change from baseline in hematology parameter: Platelets;Change from baseline in hematology parameter: white blood cells;Change from baseline in ECG (Electrocardiogram) parameter: heart rate (HR);Change from baseline in ECG (Electrocardiogram) parameter: RR interval;Change from baseline in ECG (Electrocardiogram) parameter: PR interval;Change from baseline in ECG (Electrocardiogram) parameter: QRS interval;Change from baseline in ECG (Electrocardiogram) parameter: QT interval;Change from baseline in ECG (Electrocardiogram) parameter: QTc interval;Blood concentration of acoziborole at Day 5 and Month 1;Correlation between ?QTc measurements and acoziborole concentrations in blood at Day 5
    </Secondary_outcome>
    <Secondary_ID>DNDi-OXA-04-HAT
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12602581
    </Internal_Number>
    <TrialID>PACTR202203582920839
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).
    </Public_title>
    <Scientific_title>A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Victoria Biomedical Research Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211213
    </Date_registration3>
    <Date_registration>13/12/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=19319
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>18 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>04/04/2022
    </Date_enrollement>
    <Target_size>1950
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomization,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-2
    </Phase>
    <Countries>Kenya;Congo;Rwanda
    </Countries>
    <Contact_Firstname>Lucas
    </Contact_Firstname>
    <Contact_Lastname>Otieno Tina
    </Contact_Lastname>
    <Contact_Address>Kisumu County Hospital
    </Contact_Address>
    <Contact_Email>Itina@vibriafrica.org
    </Contact_Email>
    <Contact_Tel>00254720597654
    </Contact_Tel>
    <Contact_Affiliation>Public enquiries 
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: To be eligible for the study, each HIV (+) participants must satisfy all of the following criteria:&#x0D;&lt;br&gt;1. Adolescent male or female aged = 12 to 17 years at screening and adult male or female aged = 18 to 64 years at screening (inclusive).&#x0D;&lt;br&gt;2. Written informed consent (and assent if adolescent), after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee. For participants who cannot read or write, the consent must be witnessed by a literate third party not involved in study conduct.&#x0D;&lt;br&gt;3. Comply with study procedures, including potential home visits for COVID-19 follow-up.&#x0D;&lt;br&gt;4. Has completed a primary homologous vaccination series at least 3 months but no more than 6 months prior to enrollment. Vaccinations allowed include:&#x0D;&lt;br&gt;a) mRNA (Moderna mRNA-1273 or Pfizer/BNT) – primary series is 2 doses&#x0D;&lt;br&gt;b) Adenovector 26 (Janssen Ad26COVS1) – primary series is 1 dose;&#x0D;&lt;br&gt;c) Inactivated whole virus (Sinopharm-BIBP) – primary series is 2 doses;&#x0D;&lt;br&gt;5. Female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [i.e, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months or documented plasma follicle-stimulating hormone level =40 mIU/mL]) must agree to consistently use an effective method of contraception from enrolment and agree to continue adequate contraception until 12 weeks after vaccination:a. Condoms (male or female)&#x0D;&lt;br&gt;b. Diaphragm with spermicide&#x0D;&lt;br&gt;c. Cervical cap with spermicide&#x0D;&lt;br&gt;d. Intrauterine device&#x0D;&lt;br&gt;e. Oral or patch contraceptives&#x0D;&lt;br&gt;f. Hormonal Contraceptives implants or injection e.g., Norplant®, Depo-Provera®.&#x0D;&lt;br&gt;g. Abstinence, as a form of contraception, is acceptable if in line with the participant’s lifestyle.&#x0D;&lt;br&gt;NOTE: Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Theseprocedures and laboratory test results must be confirmed by physical examination, by participant recall of specific date and hospital/facility of procedure, or by medical documentation of said procedure.6. Medically stable at screening, as determined by the investigator (based on review of health status, vital signs, medical history, and targeted physical examination). Acceptable Vital signs as determined by the Principal Investigator or designee.&#x0D;&lt;br&gt;7. Receiving highly active antiretroviral therapy (HAART) and using the same regimen the past 8 weeks before screening. Changes in antiretroviral dosage within 8 weeks prior to entering the study are permitted. In addition, the exchange of pharmacological formulation (e.g., the conventional formulation for combination formulations) is allowed. If regimen has changed then the participant can be reconsidered for inclusion once the 8 weeks has passed.&#x0D;&lt;br&gt;8. An HIV-1 viral load &lt; 1000 copies/mL and/or CD4 Count = 200 cells/mm3 within 3 months before randomization. May be taken during screening or utilize medical testing from clinic.&#x0D;&lt;br&gt;9. Documentation of HIV test result by HIV rapid test or assay as per the Ministry of Health guidelines in the respective countries irrespective of HIV status.&#x0D;&lt;br&gt;Each HIV (-) participant must meet all the following criteria to be enrolled in this study:&#x0D;&lt;br&gt;1. Male or female aged = 18 to 64 years at screening, inclusive.&#x0D;&lt;br&gt;2. Willing and able to give informed consent prior to study enrolment and co
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Participants with any of the following criteria will be excluded:&#x0D;&lt;br&gt;1. Any ongoing, symptomatic acute illness requiring medical or surgical care or chronic illness of moderate or severe grade including HIV Stage III/IV or chronic illness/disease that is not stable (at the discretion of the investigator). Acute illness is a temporary exclusion for which the participant may be re-evaluated once they improve or recover.&#x0D;&lt;br&gt;2. Use of a heterologous COVID-19 primary series at the platform level (mRNA, Adenovector and inactivated vaccine).&#x0D;&lt;br&gt;3. Unstable or Severe Chronic disease inclusive of:&#x0D;&lt;br&gt;a. Hypertension (elevated blood pressure [SBP&gt;155mmHg or DBP&gt;100mmHg]). Note that participants can be retested once after resting or return on another day for retesting. Participants may also have anti-hypertensive medication adjusted and may be reassessed after at least 2 weeks.b. Congestive heart failure (CHF) stage 3 or greater or diagnosed cardiovascular disease that is not controlled using medication in the past 6 months.&#x0D;&lt;br&gt;c. Chronic obstructive pulmonary disease (COPD) with a history of an acute exacerbations repeated in the past 2 years. Note: If participant has been stable the last 6 months and are not Gold stage 3 or greater, they may be included.&#x0D;&lt;br&gt;d. Asthma stage 4 and/or unstable cases with asthma therapy adjustments in the past that 2 months.&#x0D;&lt;br&gt;e. Type 1 or any type 2 diabetes (adult onset) with an HbA1c &gt; 8.5 in the last 6 months. Any participant with diabetes is required to have an AIC value in last 6 months. Adolescents may not be diabetic.&#x0D;&lt;br&gt;f. Chronic kidney disease requiring dialysis or GFR &lt;30 (may use associated creatinine based on age and gender)&#x0D;&lt;br&gt;g. Chronic hepatic disease with evidence of hepatic compromise. Includes known Hepatitis B or C.&#x0D;&lt;br&gt;h. Chronic or serious neurological diseases (e.g. cerebrovascular disease (including transient ischemic attacks), autoimmune disorders, neurologic deterioration (including dementia), Guillain Barre syndrome)&#x0D;&lt;br&gt;4. Cognitive impairment – congenital or acquired&#x0D;&lt;br&gt;5. Participation in research involving an investigational product (drug/biologic/device) within 30 days prior to first study vaccination. Exception is if participant in a follow up safety phase and the investigation product has been given &gt; 6months previously.&#x0D;&lt;br&gt;6. Prior receipt of an Ebola vaccine i.e., Ad26.ZEBOV/MVA-BN-Filo vaccines.&#x0D;&lt;br&gt;7. Received any other vaccine within 4 weeks prior to first study vaccination or planned vaccination within 2 weeks after study vaccination (exception for mass vaccination campaigns). Participants may be revaluated after the window has passed.&#x0D;&lt;br&gt;8. Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital), excluding HIV. Note: Stable endocrine disorders that have a confirmed autoimmune etiology (e.g., thyroid, pancreatic), including stable diabetes are allowed.&#x0D;&lt;br&gt;9. Chronic administration (&gt;14 continuous days) of immunosuppressant, systemic glucocorticosteroids, or other immune-modifying drugs within 60 days prior to first study vaccination, excluding HAART. Note: An immunosuppressant dose of glucocorticoid is defined as a systemic dose = 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.10. Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination, excluding HAART.&#x0D;&lt;br&gt;11. Temporary exclusion: Acute respiratory and/or non-respiratory illness consistent with po
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;COVID-19;COVID-19
    </Condition>
    <Intervention>;Janssen Ad26COVS1;Novavax NVX CoV2373;Janssen Ad26COVS1;Novavax NVX CoV2373;Janssen Ad26COVS1;Novavax NVX CoV2373
    </Intervention>
    <Primary_outcome> To evaluate reactogenicity (solicited adverse events (AEs) Ad26.COV2S1 and NVX-CoV2372 following boosting.                                                                                                                                                                                                                                                                                                                                                                                                                                                       ;To evaluate Serious Adverse events related to vaccination of Ad26.COV2S1 or NVX-CoV2372 during the entire study.;To evaluate the immunogenicity of Ad26.COV2S1 and NVX-CoV2372 vaccines at day 28
    </Primary_outcome>
    <Secondary_outcome>To evaluate all unsolicited AEs post-vaccination through 28 days and treatment emergent adverse events through 85 days in all participants.;To evaluate safety in terms of adverse events of special interest (AESIs) following vaccination, for HIV (+) participants through end of study.;To describe severe adverse events through end of study in all participants.&#x0D;&lt;br&gt;;To compare the immunogenicity of heterologous boost in participants at Day 28 (IgG ELISA and neutralization);To compare the durability of response through end of study (IgG ELISA and neutralization);To evaluate mucosal immunogenicity of heterologous boost in participants at Day 28 (S-IgA ELISA).
    </Secondary_outcome>
    <Source_Support>Coalition for Epidemic Preparedness Innovation
    </Source_Support>
    <Ethics_review_status>Not approved;Not approved;Not approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900;01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>info.kenya@amref.org;info@rnecrwanda.org;matsiegpb@yahoo.fr
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>AMREF Ethics and Scientific Review Committee;Rwanda National Ethics Committee;National Committee of Health Ethics 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0054206994000;00250788592004;002425512117
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>info.kenya@amref.org;info@rnecrwanda.org;matsiegpb@yahoo.fr
    </Ethics_review_contact_email>
    <results_url_link>To be updated once available
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12552731
    </Internal_Number>
    <TrialID>NCT05166850
    </TrialID>
    <Last_Refreshed_on>3 October 2022
    </Last_Refreshed_on>
    <Public_title>Preventative Intervention for Cholera for 7 Days
    </Public_title>
    <Scientific_title>Evidence Based Targeted Water Sanitation, and Hygiene Interventions to Reduce Cholera in Hotspots in the Democratic Republic of the Congo
    </Scientific_title>
    <Acronym>PICHA-7
    </Acronym>
    <Primary_sponsor>Johns Hopkins Bloomberg School of Public Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211208
    </Date_registration3>
    <Date_registration>08/12/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05166850
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 22, 2021
    </Date_enrollement>
    <Target_size>2900
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Christine Marie George, PhD;Christine Marie George, PhD;Justin Cikomola, MD
    </Contact_Lastname>
    <Contact_Email>;cmgeorge@jhu.edu;cikomola.cirhuza@ucbukavu.ac.cd
    </Contact_Email>
    <Contact_Tel>;(202) 657-5798;+243 814479302
    </Contact_Tel>
    <Contact_Affiliation>Associate Professor;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diarrhea patients presenting with three or more loose stools over a 24h period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having no running water inside of their home&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Plan to reside in Bukavu for the next 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a child &lt;5 years in their household&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a working mobile phone in the household&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No one will be excluded because of age, sex, religion, or sexual preference&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presenting at the health facility with a fever (COVID-19 prevention)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cholera;Water-Related Diseases;Diarrhea Infectious
    </Condition>
    <Intervention>Behavioral: PICHA7 mHealth program;Other: Standard Arm
    </Intervention>
    <Primary_outcome>Diarrhea among household members
    </Primary_outcome>
    <Secondary_outcome>Child development for children under 5 years of age;Handwashing with soap at stool and food related events;Free chlorine concentration in stored drining water;Presence of Vibrio cholerae and E. coli in stored drinking water;WASH psychosocial factors;non-baseline cholera infections confirmed by bacterial culture among household members of cholera patients;Height-for-age among children under 2 years of age;Height-for-age among children under 5 years of age;Weight-for-age among children under 2 years of age;Weight-for-age among children under 5 years of age;Weight-for-height among children under 2 years of age;Weight-for-height among children under 5 years of age
    </Secondary_outcome>
    <Secondary_ID>IRB00009848
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of New Mexico;Wellcome Sanger Institute
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12544239
    </Internal_Number>
    <TrialID>NCT05140278
    </TrialID>
    <Last_Refreshed_on>26 September 2022
    </Last_Refreshed_on>
    <Public_title>Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate
    </Public_title>
    <Scientific_title>Convenience and Cost-aspects of a New 1-step Reconstitution Injectable Artesunate Compared to Conventional 2-step Injectable Artesunate for the Treatment of Severe Falciparum Malaria: a Multi-centre Study
    </Scientific_title>
    <Acronym>1STEP-AS
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211117
    </Date_registration3>
    <Date_registration>17/11/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05140278
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3 Months
    </Inclusion_agemin>
    <Inclusion_agemax>16 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 18, 2022
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Caterina Fanello, Ph D;Samwell Gesase, MD;Tom Peto;Caterina I FANELLO, PhD
    </Contact_Lastname>
    <Contact_Email>;;Tom@tropmedres.ac;caterina.fanello@ndm.ox.ac.uk
    </Contact_Email>
    <Contact_Tel>;;+662 203 6333;+447900278768
    </Contact_Tel>
    <Contact_Affiliation>Kinshasa School of Public Health;Magunga District Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Part 1:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male and female children aged &gt;3months and &lt;16 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of severe P. falciparum malaria; or parasitological confirmed P.&#x0D;&lt;br&gt;             falciparum hyperparasitaemia &gt;350,000/ uL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Positive malaria test result, by rapid diagnostic test RDT.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight of 5 kg or greater.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent by the parent or guardian.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Part 2:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Study staff and health staff&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Study staff who prepare and administer Artesunate injection to patients in the study&#x0D;&lt;br&gt;             or health staff who have not administer the Artesunate injection to patients in the&#x0D;&lt;br&gt;             study by themselves but are either aware of malaria treatment, Artesunate injection,&#x0D;&lt;br&gt;             or have observed the treat-ment provided to severe malaria patients.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent by the study staff and health staff&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Study staff for a short video-record&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Study staff who would like to participate in the video record of a procedure to show&#x0D;&lt;br&gt;             how 1-step and 2-step Artesunate injections are prepared and administered.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent by the study staff&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Policymakers and stakeholders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Those who are working in the National Malaria Control Program (NMCP) or relevant&#x0D;&lt;br&gt;             organizations (WHO, INGOs/NGOs) within the country.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent by the potential participant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Part 1:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in other intervention studies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergy to artemisinin derivatives.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known history of parenteral treatment for severe malaria for the current episode of&#x0D;&lt;br&gt;             illness before admission. Treatment before admission with an oral antimalarial drug&#x0D;&lt;br&gt;             (used for the treatment of uncomplicated malaria) or a single dose of pre-referral&#x0D;&lt;br&gt;             rectal artesunate are not exclusion criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Part 2:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Study staff and health staff; Policymakers and stakeholders; Study staff and health staff&#x0D;&lt;br&gt;        for a short video-record&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unwilling to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to communicate&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Severe Malaria
    </Condition>
    <Intervention>Drug: Argesun 60mg (1 step parenteral artesunate);Drug: Artesun 60mg (2-step parenteral artesunate)
    </Intervention>
    <Primary_outcome>Time to administration of treatment comparing 1-step vs. conventional 2-step parenteral artesunate formulations;Costs of administration of 1-step vs. conventional 2-step parenteral artesunate formulations
    </Primary_outcome>
    <Secondary_outcome>Implementation perspective assessment of 1-step formulation of parenteral artesunate;Practicability assessment of 1-step formulation of parenteral artesunate;Satisfaction assessment of 1-step formulation of parenteral artesunate
    </Secondary_outcome>
    <Secondary_ID>MAL21006
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.;University of Kinshasa;National Institute for Medical Research, Tanzania
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11599401
    </Internal_Number>
    <TrialID>ISRCTN65876428
    </TrialID>
    <Last_Refreshed_on>15 November 2021
    </Last_Refreshed_on>
    <Public_title>Assessing the use of Mapping for Health (M4H) data for immunisation programme implementation and associated impact on coverage, equity, and cost-effectiveness in the Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Large-scale effectiveness study of the effective use of Mapping for Health Data on immunisation coverage and equity in the Democratic Republic of Congo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Gavi
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20211103
    </Date_registration3>
    <Date_registration>03/11/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN65876428
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/11/2021
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single-centre three province quasi-experimental interventional study (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname>Patricia
    </Contact_Firstname>
    <Contact_Lastname>Mechael
    </Contact_Lastname>
    <Contact_Address>
                    4101 Albemarle St NW
                    Apt 521
                
    </Contact_Address>
    <Contact_Email>patty@healthenabled.org
    </Contact_Email>
    <Contact_Tel>+1 9732228252
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Essential Programme for Immunisation administrators, supervisors, and vaccinators and associated individuals engaged in the generation and/or use of M4H geospatial data for immunisation microplanning, macroplanning, and service delivery.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Those who do not provide consent to participate in the study.
    </Exclusion_Criteria>
    <Condition>Routine immunisation &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>&lt;br&gt;                There is a control province and two intervention provinces, where sites will be stratified and then randomly selected for inclusion in the intervention strength study based on immunisation coverage and equity at baseline, urban/rural, and connectivity status.&lt;br&gt;&lt;br&gt;                Intervention:&lt;br&gt;                Immunisation microplans with geospatial data, updated immunisation targets based on geospatial modeled population estimates, and population mobility data.&lt;br&gt;&lt;br&gt;                Control:&lt;br&gt;                Standard practice or status quo in the control province - immunisation microplans without geospatial data and immunisation targets based on census data.&lt;br&gt;&lt;br&gt;&lt;br&gt;                The overall structure of the research study includes three provinces - one province selected for inclusion to assess M4H geospatial data interventions with gender-specific activities in a subset of Health Zones and Health Areas, namely Kasai; another M4H province selected to assess effects of M4H geospatial data interventions without gender, namely Lomami; and a control site to compare both M4H sites, namely Kasai Central.  In addition, the protocol includes prioritization and segmentation of primary research participants, Essential Programme for Immunisation (EPI) staff and affiliates, for the intervention strength survey and qualitative in-depth interviews (where possible engaging with equal numbers of male and female EPI managers, supervisors, and vaccinators) as well as in the secondary analyses of immunisation coverage and equity surveys (gender-disaggregated analyses of birth cohorts). Each study arm will be segmented into the following categories (urban, rural, per-urban, conflict, and high/low/moderate connectivity) and a random selection of Health Areas will be chosen for inclusion 
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Measured at the end of the study:&lt;br&gt;                1. Acceptance of M4H geospatial data in micro planning and macro planning- measured as the percent of Provinces and Health Zones EPI Managers who state that they intend to use M4H geospatial data in EPI programme planning and implementation&lt;br&gt;                2. Use of M4H geospatial data in micro planning and macro-planning - measured as the percent of Health Zone EPI Managers who include the M4H geospatial data in their micro plans&lt;br&gt;                3. Use of M4H data in immunisation programme delivery - measured as the percent of Health Area EPI supervisors and vaccinators who use the M4H geospatial data to manage the implementation of the routine immunisation programme/ all eligible Health Area EPI supervisors and vaccinators&lt;br&gt;                4. Effects of M4H data on immunisation programme outcomes - measured as change in immunisation coverage and equity through secondary analyses of immunisation survey data from baseline to end-line (pre/ post-intervention) in Health Areas as correlated to the percentages of acceptance and use of M4H geospatial data&lt;br&gt;                5. Cost-effectiveness of M4H data on immunisation programme outcomes - measured in Lives Saved using the Lives Saved Tool and Disability-Adjusted Life-years alongside change in immunisation coverage and equity through secondary analyses of immunisation survey data from baseline to end-line (pre/ post-intervention) in Health Areas as correlated to the percentages of acceptance and use of M4H geospatial data&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>Gender associated affects in the creation, acceptance, and use of M4H geospatial data- measured through a Rapid Ethnographic Study of the gender intervention and through gender-related questions and disaggregation of respondents by gender as correlated to the percentages of acceptance and use of M4H geospatial data at the end of the study
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>GAVI Alliance
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 27/07/2021, Kinshasa School of Public Health Internal Review Board (BP 11850 Kinshasa, DRC; +243 817 493194; espsec_unikin@yahoo.fr), ref: none provided
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/12/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12344509
    </Internal_Number>
    <TrialID>NCT05096091
    </TrialID>
    <Last_Refreshed_on>6 June 2022
    </Last_Refreshed_on>
    <Public_title>International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
    </Public_title>
    <Scientific_title>International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
    </Scientific_title>
    <Acronym>InVITE
    </Acronym>
    <Primary_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211026
    </Date_registration3>
    <Date_registration>26/10/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05096091
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 16, 2021
    </Date_enrollement>
    <Target_size>10000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the;Guinea;Indonesia;Liberia;Mali;Mexico;Mongolia;Congo, The Democratic Republic of the;Guinea;Indonesia;Liberia;Mali;Mexico;Mongolia
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Renee Ridzon, MD;Irini Sereti, MD;Sally Hunsberger, PhD;Sally Hunsberger, PhD
    </Contact_Lastname>
    <Contact_Email>;;;sally.hunsberger@nih.gov
    </Contact_Email>
    <Contact_Tel>;;;240-699-5257
    </Contact_Tel>
    <Contact_Affiliation>National Institute of Allergy and Infectious Diseases (NIAID);National Institute of Allergy and Infectious Diseases (NIAID);National Institute of Allergy and Infectious Diseases (NIAID);
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18 years of age or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to provide informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Enrollment within one day (before or after) of receipt of COVID-19 vaccine.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness to be evaluated (including collection of blood and nasopharyngeal samples)&#x0D;&lt;br&gt;             during the prescribed study visits and/or during acute illness consistent with&#x0D;&lt;br&gt;             SARS-CoV-2 infection during the study period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness to allow storage of biological samples for research testing as outlined in&#x0D;&lt;br&gt;             this protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any acute or chronic condition that, in the opinion of the investigator, is a&#x0D;&lt;br&gt;             contraindication to participation in this study; for example, acute febrile illness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to comply with study visits.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>COVID-19
    </Condition>
    <Primary_outcome>1. To characterize immunogenicity (by measurement of anti-Spike [S] antibody [Ab]) of available COVID-19 vaccines in the overall study population, in each of the countries and in defined subgroups
    </Primary_outcome>
    <Secondary_outcome>Evaluate duration of immunogenicity;Evaluate immunogenicity in predefined subgroups (by age, body mass index [BMI], comorbidities, HIV, breakthrough infection, or evidence of prior infection with SARS-CoV-2).;Characterize virus causing breakthrough infections using viral genomic sequencing.;Compare immunogenicity between different vaccines.;Evaluate infection rates after vaccination.
    </Secondary_outcome>
    <Secondary_ID>InVITE 01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI);National Institute of Health Research and Development, Ministry of Health Republic of Indonesia;Partnership for Research on Ebola Virus in Liberia (PREVAIL);University Clinical Research Center, Mali;National Institute of Medical Sciences and Nutrition, Salvador Zubiran;Onom Foundation and Liver Center
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11615588
    </Internal_Number>
    <TrialID>NCT05119426
    </TrialID>
    <Last_Refreshed_on>22 November 2021
    </Last_Refreshed_on>
    <Public_title>Effectiveness of a Typhoid Conjugate Vaccine in DRC
    </Public_title>
    <Scientific_title>An Open-label Effectiveness Study of a Typhoid Conjugate Vaccine in Kisantu, Democratic Republic of Congo (TyVECO) - Step 2: Typhoid Conjugate Vaccine (TCV) Mass-vaccination Campaign
    </Scientific_title>
    <Acronym>TyVECO
    </Acronym>
    <Primary_sponsor>International Vaccine Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211018
    </Date_registration3>
    <Date_registration>18/10/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05119426
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>9 Months
    </Inclusion_agemin>
    <Inclusion_agemax>15 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2022
    </Date_enrollement>
    <Target_size>48000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Florian Marks, PhD;Octavie Lunguya, PhD;Justin Im, MSc;Octavie Lunguya, PhD
    </Contact_Lastname>
    <Contact_Email>;;justin.im@ivi.int;octmetila@yahoo.fr
    </Contact_Email>
    <Contact_Tel>;;+82-10-3296-0711;+243 815 181 121
    </Contact_Tel>
    <Contact_Affiliation>University of Cambridge;Institut National de Research Biomédicale;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent/guardian willing and able to provide informed consent; assent will be sought&#x0D;&lt;br&gt;             for participants between 12 and &lt;16 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident of the defined study area, Kisantu Health Zone at the time of vaccination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 9 months and &lt;16 years (i.e., =15 years and 364 days) on the day of&#x0D;&lt;br&gt;             vaccination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant has a known allergy to any of the vaccine components,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any medical reason perceived to increase risk to health posed by vaccination as judged&#x0D;&lt;br&gt;             by a medical professional&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Self-reported pregnancy in females greater or equal to 11 years of age who have&#x0D;&lt;br&gt;             reported menarche&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Typhoid Fever
    </Condition>
    <Intervention>Biological: Vi-TT
    </Intervention>
    <Primary_outcome>Direct vaccine effectiveness of Typbar-TCV®
    </Primary_outcome>
    <Secondary_outcome>Overall vaccine effectiveness of Typbar-TCV®;Total vaccine effectiveness of Typbar-TCV®;Indirect vaccine effectiveness of Typbar-TCV®;Safety profile of Typbar-TCV®;Feasibility of a single-dose Typbar-TCV® mass campaign in Kisantu, DRC
    </Secondary_outcome>
    <Secondary_ID>2021-009
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;University of Cambridge;Institute of Tropical Medicine, Belgium
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11491108
    </Internal_Number>
    <TrialID>NCT05072613
    </TrialID>
    <Last_Refreshed_on>18 October 2021
    </Last_Refreshed_on>
    <Public_title>Monitoring Pregnant Women for Antimalarial Drug Resistance
    </Public_title>
    <Scientific_title>Pregnant Women Attending Antenatal Care Services as a Sentinel Population for Antimalarial Drug Resistance Genetic Surveillance in Africa
    </Scientific_title>
    <Acronym>MIRANDA
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210927
    </Date_registration3>
    <Date_registration>27/09/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05072613
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 30, 2021
    </Date_enrollement>
    <Target_size>7080
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Caterina Fanello;Caterina Fanello
    </Contact_Lastname>
    <Contact_Email>caterina.fanello@ndm.ox.ac.uk;caterina.fanello@ndm.ox.ac.uk
    </Contact_Email>
    <Contact_Tel>+447900278768;
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy OR for children age &lt;14 years old and in primary school&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refusal to participate (i.e., consent is not given by the participant for women or by&#x0D;&lt;br&gt;             the parents in the case of children)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Other: Malaria screening
    </Intervention>
    <Primary_outcome>Compare the frequency of Plasmodium falciparum mutations associated with antimalarial drug resistance in the population of pregnant women with that of children.
    </Primary_outcome>
    <Secondary_outcome>Evaluate the acceptability of the intervention;Compare malaria prevalence in pregnant women with that of in children throughout the year.
    </Secondary_outcome>
    <Secondary_ID>548-21
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health;Wellcome Sanger Institute
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12272854
    </Internal_Number>
    <TrialID>NCT05067166
    </TrialID>
    <Last_Refreshed_on>16 May 2022
    </Last_Refreshed_on>
    <Public_title>Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP
    </Public_title>
    <Scientific_title>Open-Label, Expanded Access Protocol of a Human Monoclonal Antibody, Ansuvimab (mAb114), Administered as an Investigational Therapeutic to Ebola-Infected Patients or as a High-Risk Ebola Post-Expo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ridgeback Biotherapeutics, LP
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210923
    </Date_registration3>
    <Date_registration>23/09/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05067166
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 17, 2022
    </Date_enrollement>
    <Target_size/>
    <Study_type>Expanded Access
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the;Sierra Leone;Congo, The Democratic Republic of the;Sierra Leone
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Jean Jacques Muyembe-Tamfum, MD,PhD;Sabue Mulangu, MD,DTMH,PhD
    </Contact_Lastname>
    <Contact_Email>;EAP-requests@ridgebackbio.com
    </Contact_Email>
    <Contact_Tel>;1 833 846 3789
    </Contact_Tel>
    <Contact_Affiliation>INRB;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female with laboratory confirmed (based on local standard of care) EBOV&#x0D;&lt;br&gt;             infection or with recent high-risk EBOV exposure as determined by a treating Physician&#x0D;&lt;br&gt;             or designee.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to provide proof of identity to the satisfaction of the clinical team&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to complete the informed consent process personally, or if the&#x0D;&lt;br&gt;             patient is unable to do so, then informed consent completed by a legally-authorized&#x0D;&lt;br&gt;             representative according to local laws and regulations.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - Any medical condition that, in the opinion of the Treating Physician, would place the&#x0D;&lt;br&gt;        patient at an unreasonably increased risk through participation in this treatment protocol.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hemorrhagic Fever, Ebola
    </Condition>
    <Intervention>Drug: Ansuvimab
    </Intervention>
    <Secondary_ID>Ansuvimab EAP-2020-DRC
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11403848
    </Internal_Number>
    <TrialID>ISRCTN49881357
    </TrialID>
    <Last_Refreshed_on>27 September 2021
    </Last_Refreshed_on>
    <Public_title>Cluster randomized trial of community based trauma healing on sexual and physical violence victimization of women and perpetration by men in the Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Impact evaluation of Community Based Trauma Healing in the Democratic Republic of Congo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University of Chicago
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210915
    </Date_registration3>
    <Date_registration>15/09/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN49881357
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2019
    </Date_enrollement>
    <Target_size>2400
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cluster randomized (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: All residents from selected villages are eligible to participate
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Residents outside randomly selected 80 villages
    </Exclusion_Criteria>
    <Condition>Reduction of sexual and physical IPV and non partner victimization &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>&lt;br&gt;                Intervention: Community Based Trauma Healing in DRC&lt;br&gt;                We evaluate the impact of Community Based Trauma Healing (CBTH), a program implemented in Eastern DRC, as a core strategy to help strengthen community capacity to support the trauma healing process and increase individual mental health, and reduce GBV in a (post)-conflict context. CBTH was part of a wider Tushinde Ujeuri programme activities that where targeting communities in Nyangezi, Katana and Walikale Health Zones in Eastern DRC. These other activities included legal support (such as a legal clinic, legal aid, working with a paralegal), medical support (such as visiting a health center, training of service providers, care and services for GBV survivors, family planning services), psychological support (such as speaking to a service provider or counselor) and economic support (village savings and loan programs or microcredit) and were available to all communities in the Health Zones.&lt;br&gt;                During January 2019 -  December 2020, in 80 randomly selected villages, Search for Common Ground (SFCG) implemented the CBTH program. At its core CBTH includes several steps:&lt;br&gt;                1. Recruiting Trauma Healing Champions. In each community, SFGC recruited and trained local mobilizers, so called Trauma Healing Champions (THCs). Identification and training of THC occurred between January and March 2019.  As eligibility criteria these should be a member of the community; are trusted by community members; have meeting facilitation skills, should be sensitive of issues related to equitable representation of the local population (for instance, ensuring that multiple tribes and religions are represented); know the conflict issues and GBV issues that affect the community welfare; be a l
    </Intervention>
    <Primary_outcome>&lt;br&gt;                All outcomes measured at baseline and post-intervention (1.5 years since programming started):&lt;br&gt;                1. Past-year IPV physical and sexual victimization (women) measured by bespoke questionnaire&lt;br&gt;                2. Past-year non-partner physical and sexual violence victimization (women) measured by bespoke questionnaire&lt;br&gt;                3. Past-year physical and sexual IPV perpetration (men) measured by bespoke questionnaire&lt;br&gt;                4. Past-year non-partner physical and sexual violence perpetration (men) measured by bespoke questionnaire&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                All outcomes measured at baseline and post-intervention (1.5 years since programming started):&lt;br&gt;                1. Depression and anxiety measured using the Depression and Anxiety Scale&lt;br&gt;                2. PTSD measured using the 16-item Harvard Trauma Questionnaire (HTQ-16)&lt;br&gt;                3. Service uptake measured using a bespoke questionnaire&lt;br&gt;                4. Emotional IPV measured using a bespoke questionnaire&lt;br&gt;                5. Individual Resilience (relational) measured using a bespoke questionnaire&lt;br&gt;                6. Gender equitable attitudes measured using a bespoke questionnaire&lt;br&gt;                7. Community Resilience (relational) measured using a bespoke questionnaire&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;18.08.13
    </Secondary_ID>
    <Source_Support>United States Agency for International Development
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 09/10/2018, NORC Institutional Review Board (55 East Monroe Street, Chicago, IL, USA; +1 773-256-6000; no email provided), ref: IRB00000967, Project Number 7554.059.01, IRB Protocol Number 18.08.13
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/07/2021
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11753975
    </Internal_Number>
    <TrialID>NCT05039307
    </TrialID>
    <Last_Refreshed_on>21 December 2021
    </Last_Refreshed_on>
    <Public_title>Prevention of Type 2 Diabetes and Gestational Diabetes Among Women of Reproductive Age in Kisantu, Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Prevention of Type 2 Diabetes and Gestational Diabetes Among Women of Reproductive Age in Kisantu, Democratic Republic of Congo
    </Scientific_title>
    <Acronym>KIS-Antwerp
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210819
    </Date_registration3>
    <Date_registration>19/08/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05039307
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>October 4, 2021
    </Date_enrollement>
    <Target_size>288
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jean C. Kalobu, MD; MPH;José L. Peñalvo, PhD;Diana M. Sagastume, MSc
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>Memisa;Institute of Tropical Medicine;Institute of Tropical Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-pregnant or (first trimester) pregnant women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of reproductive age (18-49 years old)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Without a previous diagnosis of type 1 diabetes or T2DM (confirmed by a random glucose&#x0D;&lt;br&gt;             test)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women with active gestational diabetes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adult males, and children and adolescents &lt;18 years old of both sexes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-existent severe chronic conditions (e.g. chronic liver or kidney disease, chronic&#x0D;&lt;br&gt;             obstructive pulmonary disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Living outside of the surrounding catchment areas of the 6 healthcare centers.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women internationally displaced, without a permanent home or identified physical&#x0D;&lt;br&gt;             address.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women planning to move elsewhere in the following 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women that do not provide a written Informed Consent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Diabetes Mellitus, Type 2;Gestational Diabetes
    </Condition>
    <Intervention>Behavioral: Educational and motivational strategy
    </Intervention>
    <Primary_outcome>Change from baseline in the adherence to a healthy lifestyle score at 24 months;Change from baseline in the adherence to a healthy lifestyle score at 12 months
    </Primary_outcome>
    <Secondary_outcome>Change from baseline in the minimum diet diversity of women (MDD-W) questionnaire at 24 months;Change from baseline in the minimum diet diversity of women (MDD-W) questionnaire at 12 months;Change from baseline in the International Physical Activity Questionnaire at 24 months;Change from baseline in the International Physical Activity Questionnaire at 12 months;Change from baseline in weight at 24 months;Change from baseline in weight at 12 months;Change from baseline in Body mass index (BMI) at 24 months;Change from baseline in Body mass index (BMI) at 12 months;Change from baseline in waist circumference at 24 months;Change from baseline in waist circumference at 12 months;Change from baseline in glycemia at 24 months;Change from baseline in glycemia at 12 months;Change from baseline in systolic and diastolic blood pressure at 24 months;Change from baseline in systolic and diastolic blood pressure at 12 months
    </Secondary_outcome>
    <Secondary_ID>1482/21
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Memisa, Belgium
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11577712
    </Internal_Number>
    <TrialID>NCT05097677
    </TrialID>
    <Last_Refreshed_on>8 November 2021
    </Last_Refreshed_on>
    <Public_title>Follow-up of Covid-19 Long Term Sequelae
    </Public_title>
    <Scientific_title>ORCHESTRA WP2 - Follow-up of Covid-19 Long Term Sequelae
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Azienda Ospedaliera Universitaria Integrata Verona
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210816
    </Date_registration3>
    <Date_registration>16/08/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05097677
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>14 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 16, 2021
    </Date_enrollement>
    <Target_size>7500
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Belgium;Congo;France;Italy;Netherlands;Spain;Belgium;Congo;France;Italy;Netherlands;Spain
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Evelina Tacconelli, Professor;Evelina Tacconelli, Professor
    </Contact_Lastname>
    <Contact_Email>;evelina.tacconelli@univr.it
    </Contact_Email>
    <Contact_Tel>;+390458128283
    </Contact_Tel>
    <Contact_Affiliation>Universita di Verona;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any comorbidity&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Laboratory confirmed SARS-CoV-2 infection by PCR diagnosis from nasopharynx,&#x0D;&lt;br&gt;             oropharynx, bronchoalveolar lavage, stool, or blood. Rapid tests are an acceptable&#x0D;&lt;br&gt;             alternative.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person (or attorney or deputy who has been authorized to make the decision for&#x0D;&lt;br&gt;             patients who lack capacity) consent to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person over 14 years of ages&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of consent to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of laboratory confirmed SARS-CoV-2 infection.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person under 14 years of ages&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>COVID-19 Pneumonia;COVID-19 Respiratory Infection;COVID-19 Acute Bronchitis;COVID-19 Acute Respiratory Distress Syndrome;COVID-19 Lower Respiratory Infection;Covid19;Corona Virus Infection;Coronavirus;Coronavirus Infections;SARS-CoV2 Infection;SARS-CoV-2 Acute Respiratory Disease;SARS-Associated Coronavirus;SARS Pneumonia;SARS (Severe Acute Respiratory Syndrome);SARS (Disease);Coronavirus Pneumonia;Coronavirus Disease 2019;Coronavirus Sars-Associated
    </Condition>
    <Intervention>Other: Not applicable (observational study)
    </Intervention>
    <Primary_outcome>Clinical assessments of COVID-19 sequelae;Laboratory assessments of COVID-19 sequelae;Radiological assessments of COVID-19 sequelae;Length of COVID-19 sequelae;Association between SARS-CoV-2 variants and COVID-19 sequelae;Association between immunological patterns and COVID-19 sequelae;COVID-19 reinfections;Patterns of intestinal microbiome after SARS-CoV-2 infection;Patterns of pulmonary microbiome after SARS-CoV-2 infection;Human and viral genetic markers related to disease severity
    </Primary_outcome>
    <Secondary_ID>ORCHESTRA WP2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Bologna;Institut National de la Santé Et de la Recherche Médicale, France;Universiteit Antwerpen;University of Sao Paulo;Barcelona Institute for Global Health;Fondation pour la Recherche Médicale;Andaluz Health Service;Charite University, Berlin, Germany;CINECA consorzio universitario italiano;University Medical Center Groningen;Hospital Universitario Virgen Macarena
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12092868
    </Internal_Number>
    <TrialID>NCT05012280
    </TrialID>
    <Last_Refreshed_on>4 April 2022
    </Last_Refreshed_on>
    <Public_title>Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID)
    </Public_title>
    <Scientific_title>Malaria as a Protection Factor Against Severe COVID-19 in the Democratic Republic of Congo (Palu-COVID)
    </Scientific_title>
    <Acronym>Palu-COVID
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210720
    </Date_registration3>
    <Date_registration>20/07/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05012280
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 4, 2021
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Laurens Liesenborghs, Dr;Dieudonné Mumba, Pr
    </Contact_Lastname>
    <Contact_Email>lliesenborghs@itg.be;mumbadieudonne@yahoo.fr
    </Contact_Email>
    <Contact_Tel>+32 475311904;
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        INCLUSION CRITERIA&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        To be eligible, study patients must meet the following criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For cases:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be at least 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have an RT-PCR confirmed SARS-CoV-2 infection within 72 hours prior to inclusion.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have given informed consent or that of their guardian/ representative to participate&#x0D;&lt;br&gt;             in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed as a severe COVID-19 case according to the following criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Presenting clinical signs of pneumonia: fever, cough, dyspnea or crepitations AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Presenting at least one of the following signs:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Respiratory rate &gt; 30 cycles/min OR Severe respiratory distress or SpO2 &lt; 90% on room air&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be admitted to a care unit for COVID-19&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Residing in the health zone for at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For controls:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be at least 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a PCR-confirmed SARS-CoV-2 infection within 72 hours prior to inclusion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have given informed consent to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed as a non-severe COVID-19 case according to the following criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Be asymptomatic OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Symptomatic, but no evidence of severe pneumonia Respiratory rate &gt; 30 cycles/min&#x0D;&lt;br&gt;                  OR Severe respiratory distress or SpO2 &lt; 90% on room air&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not be admitted to a care unit for COVID-19.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Reside in the study health area for at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        To be eligible, study patients cannot meet the following criteria for cases and controls:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has a contraindication to venipuncture, as determined by clinical judgment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is vaccinated against SARS-CoV-2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject has been infected with SARS-CoV-2 in the past and now presents with&#x0D;&lt;br&gt;             reinfection&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Covid19;Paludism
    </Condition>
    <Primary_outcome>Malaria antibody level
    </Primary_outcome>
    <Secondary_outcome>Anti-malaria IgG antibody levels;The cellular response against malaria;Proportions of acute malaria infection;Clinical characteristics;Clinical characteristics;Clinical characteristics;Clinical characteristics;Clinical characteristics;Clinical characteristics;Clinical characteristics;Clinical characteristics;Clinical characteristics;Clinical characteristics;Clinical status;SARS-COV-2 specific cellular response;SARS-COV-2 specific humoral immune response;SARS-COV-2 specific humoral immune response;Antiviral cytokine release levels;Antiviral cytokine release levels
    </Secondary_outcome>
    <Secondary_ID>Palu-COVID
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12517828
    </Internal_Number>
    <TrialID>ISRCTN45167024
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>Eczema monitoring online via questionnaires
    </Public_title>
    <Scientific_title>Evaluation of the effect of symptom monitoring with patient-reported outcome measures on clinical outcomes in eczema: an online, parallel-group randomised controlled trial (EMO trial)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University of Nottingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210629
    </Date_registration3>
    <Date_registration>29/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN45167024
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>14/09/2021
    </Date_enrollement>
    <Target_size>266
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Online parallel-group randomized controlled clinical trial (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Self-report or parent/carer report of eczema diagnosis by a healthcare professional&lt;br&gt;                2. Person aged 1 year or older&lt;br&gt;                3. Able and willing to provide informed consent&lt;br&gt;                4. If under 16 years old, a parent/carer needs to provide informed consent on behalf of the child&lt;br&gt;                5. Able to read and understand written English&lt;br&gt;                6. Have access to the internet and to an internet-enabled device&lt;br&gt;                7. POEM score of 3 or above at eligibility screening&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Unable/unwilling to provide informed consent&lt;br&gt;                2. Currently taking part in another eczema clinical trial&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Eczema &lt;br&gt;Skin and Connective Tissue Diseases &lt;br&gt;Dermatitis and eczema
    </Condition>
    <Intervention>This is a methodological trial and there will be no treatment intervention involved. The intervention will be the online Patient Oriented Eczema Measure (POEM) questionnaire. Eligible participants will be randomised online and assigned to either the intervention group or to the control group using the REDCap software. The randomisation schedule will be based on computer-generated codes using random permuted blocks of varying size, stratified by age and baseline disease severity. The PhD student will deal with participant queries, thus she will have access to group allocation, but the other trial team members and the trial statistician will remain blinded. Participants in the intervention group (weekly group) will be asked to complete the POEM questionnaire weekly for 8 weeks. The control group will not receive the intervention.
    </Intervention>
    <Primary_outcome>Eczema severity measured by the self-reported or proxy (parent/carer reported) POEM questionnaire score at baseline and 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Adherence to eczema treatment use, assessed in two ways:&lt;br&gt;                1.1. Eczema treatment use assessed by the emollient and topical corticosteroid use questionnaire over the last week from baseline to 8 weeks&lt;br&gt;                1.2. Eczema treatment use assessed by the overall eczema treatment use questionnaire 2 months prior to joining the study and at the end of the study at 8 weeks&lt;br&gt;                2. Missing data: the proportion of fully completed questionnaires at 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;EMO 120421
    </Secondary_ID>
    <Source_Support>University of Nottingham
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 23/04/2021, Faculty of Medicine &amp; Health Science Research Ethics Committee, University of Nottingham (Faculty Hub, Room E41, E Floor, Medical School, Queen's Medical Centre Campus, Nottingham University Hospitals, Nottingham, NG7 2UH, UK; +44 (0) 115 74 85060; FMHS-ResearchEthics@nottingham.ac.uk), ref: 239-0421
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>03/04/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12592792
    </Internal_Number>
    <TrialID>CTRI/2021/06/034432
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Preterm Birth Prevention Study follow-up in looking at Neurodevelopmental delay
    </Public_title>
    <Scientific_title>Aspirin Supplementation for Pregnancy Indicated Risk Reduction in Nulliparas (ASPIRIN): Neurodevelopmental Follow-up Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Thrasher Research Fund
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210628
    </Date_registration3>
    <Date_registration>28-06-2021
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=56008
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-07-2021
    </Date_enrollement>
    <Target_size>620
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Democratic Republic of the Congo;Guatemala;India;Pakistan;Zambia
    </Countries>
    <Contact_Firstname>Dr Shivaprasad S Goudar
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Womens and Childrens Health Research Unit KLE Academy of Higher Education and Research J N Medical College Nehru Nagar&#x0D;
Belgaum Nehru Nagar, Belgaum,Karnataka,India
    </Contact_Address>
    <Contact_Email>sgoudar@jnmc.edu
    </Contact_Email>
    <Contact_Tel>9448126371
    </Contact_Tel>
    <Contact_Affiliation>KLE Academy of Higher Education and Researchs J N Medical College
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. For a prior study sponsored by the Global Network for WomenÃ¢â?¬â?¢s and ChildrenÃ¢â?¬â?¢s Health Research, the  childÃ¢â?¬â?¢s parents gave permission to re-contact. &lt;br/ &gt;&#x0D;&lt;br&gt;2. The childÃ¢â?¬â?¢s parent/guardian is willing and able to provide consent for the child and willing also to participate in the childÃ¢â?¬â?¢s assessment (e.g., by providing answers to ASQ-3 and the Family Resources and Context questionnaire). &lt;br/ &gt;&#x0D;&lt;br&gt;3. The child will be between 33 and 39 months of age at time of assessment. &lt;br/ &gt;&#x0D;&lt;br&gt;4. The child does not have a significant congenital anomaly (e.g., blindness or deafness) that would affect development or preclude them from completing the BSID-III. This will be left at the discretion of the Senior Foreign Investigator (SFI) with the ability to consult with the Working Committee as needed. &lt;br/ &gt;&#x0D;&lt;br&gt;5. Other significant medical conditions that would preclude the child from completing a BSID III are absent. This will be left to the discretion of the Senior Foreign Investigator who will have  the ability to consult with the Working Committee as needed.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children not meeting the inclusion criteria will be excluded. Likewise, children may be excluded at the discretion of the site investigator out of concern for the childÃ¢â?¬â?¢s wellbeing (e.g. distress with testing).
    </Exclusion_Criteria>
    <Condition>Health Condition 1: P073- Preterm [premature] newborn [other]&#x0D;

    </Condition>
    <Intervention/>
    <Primary_outcome>Results of the BSID-III- specifically the motor, cognitive and language componentsTimepoint: up to 39 months of life
    </Primary_outcome>
    <Secondary_outcome>Outcomes of Ages and Stages Questionaire-3Timepoint: up to 39 months of life;Record family care indicators and  resources to understand the family contextTimepoint: up to 39 months of life
    </Secondary_outcome>
    <Secondary_ID>GN-LDA.FU 0.1;NCT02409680
    </Secondary_ID>
    <Source_Support>Thrasher Research Fund
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/06/2021;28/05/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethics Review Committee, Lata Medical Research Foundation Nagpur;Institutional Ethics Committee, KLE Academy of Higher Education and Research, Belagavi
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12291809
    </Internal_Number>
    <TrialID>NCT04941209
    </TrialID>
    <Last_Refreshed_on>30 May 2022
    </Last_Refreshed_on>
    <Public_title>imPulse™ Una Infrasound-to-ultrasound E-stethoscope
    </Public_title>
    <Scientific_title>imPulse™ Una Infrasound-to-ultrasound E-stethoscope 2-minute to Result COVID-19 Self-directed &amp; Point-of-care Screening Test
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Level 42 AI, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210620
    </Date_registration3>
    <Date_registration>20/06/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04941209
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 11, 2021
    </Date_enrollement>
    <Target_size>702
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the;India;Senegal;Congo, The Democratic Republic of the;India;Senegal
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand and willingness to comply with study procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inpatient Cases - hospitalized patients with positive COVID-19 PCR test, collected&#x0D;&lt;br&gt;             from a respiratory sample within the last 7 days, AND pulmonary symptoms within 72&#x0D;&lt;br&gt;             hours of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Outpatient Cases - participant being screened for COVID-19 with positive COVID-19 PCR&#x0D;&lt;br&gt;             test respiratory sample Controls - Outpatients with negative COVID-19 PCR test&#x0D;&lt;br&gt;             respiratory sample and no pulmonary diagnosis or symptoms Cases or Control not able to&#x0D;&lt;br&gt;             sit or stand will be allowed to participate in just the parts of the staircase exam&#x0D;&lt;br&gt;             they're capable of doing.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Assisted ventilation, including high flow nasal cannula, or ventilator support&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to comply with study procedures, defined at investigator's discretion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants with any visible skin infections or open wounds in areas where the&#x0D;&lt;br&gt;             imPulse™ Una device would be applied&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Covid19;COVID-19 Pneumonia;COVID-19 Respiratory Infection;COVID-19 Acute Respiratory Distress Syndrome;Mass Screening;Corona Virus Infection;Vaccine Virus Shedding
    </Condition>
    <Intervention>Device: imPulse™ Una infrasound-to-ultrasound e-stethoscope;Diagnostic Test: (PPA &gt;95%) FDA EUA RT-PCR;Radiation: HR-CT-scan
    </Intervention>
    <Primary_outcome>Digital vibroacoustic biomarker diagnostic performance characteristics
    </Primary_outcome>
    <Secondary_outcome>imPulse™ Una infrasound-to-ultrasound e-stethoscope device safety
    </Secondary_outcome>
    <Secondary_ID>L42AI-20210003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Asian Institute of Public Health;Institut de Recherche en Santé de Surveillance Epidemiologique et de Formation (IRESSEF);Laboratoire de la foundation Gombes
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12373275
    </Internal_Number>
    <TrialID>ISRCTN12329547
    </TrialID>
    <Last_Refreshed_on>27 June 2022
    </Last_Refreshed_on>
    <Public_title>Trial of a digital depression management application: juli
    </Public_title>
    <Scientific_title>Randomised control trial of a digital depression management application: juli                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210608
    </Date_registration3>
    <Date_registration>08/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN12329547
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/06/2021
    </Date_enrollement>
    <Target_size>476
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional placebo-controlled randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary
    </Countries>
    <Contact_Firstname>Bettina
    </Contact_Firstname>
    <Contact_Lastname>Dührkoop
    </Contact_Lastname>
    <Contact_Address>
                    Juli Health
                    23 Beach Ave
                
    </Contact_Address>
    <Contact_Email>bd@juli.co
    </Contact_Email>
    <Contact_Tel>+44 (0)20 7679 9736
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Depression with PHQ-8 score &gt;4 at baseline&lt;br&gt;                2. Age 18 to 65 years (inclusive)&lt;br&gt;                3. English speakers&lt;br&gt;                4. Have an iPhone&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. PHQ-8 &lt;5 at baseline&lt;br&gt;                2. Children&lt;br&gt;                3. Non-English speakers&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Depression &lt;br&gt;Mental and Behavioural Disorders &lt;br&gt;Depressive episode, unspecified
    </Condition>
    <Intervention>&lt;br&gt;                Participants will be randomly allocated using an online tool to receive the juli app or treatment as usual plus an attention placebo control app.&lt;br&gt;&lt;br&gt;                The participant will use the juli app for 8 weeks and complete a depression symptoms questionnaire every 2 weeks (four in total). Participants will also be asked to complete a wellbeing questionnaire at 4 and 8 weeks and a user satisfaction questionnaire at 8 weeks. These are all standardised questionnaires, commonly used for research (the 8-item Patient Health Questionnaire, the 12-item Short Form survey of health-related quality of life and the Mobile Health App Usability Questionnaire).&lt;br&gt;&lt;br&gt;                The full version of the app presents the participant with graphical displays of some data automatically generated from their phone and smartwatch. The types of data are:&lt;br&gt;                1. Sleep – time in bed and time asleep&lt;br&gt;                2. Activity – steps and flights of stairs climbed&lt;br&gt;                3. Heart rate variability – the variation in the time interval between heartbeats&lt;br&gt;                4. Workouts – periods of exercise&lt;br&gt;                5. Oxygen saturation&lt;br&gt;                6. Menstrual cycle&lt;br&gt;&lt;br&gt;                It also presents them with external data: weather, pollen count and air quality (provided via geolocation). It asks the participant to rate how they are feeling and answer questions about their mood on a daily basis. It allows them to set a medication reminder, and add notes to a journal. It presents them with correlations between these different types of data and helps them to identify things that make their mood better or worse.&lt;br&gt;&lt;br&gt;                Participants allocated to the dummy version of the app will be asked to rate how they are feeling on a daily basis, but will not
    </Intervention>
    <Primary_outcome>Depression symptoms measured using the eight-item Patient Health Questionnaire (PHQ-8) at 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Depression symptoms measured using the PHQ-8 at 2, 4 and 6 weeks&lt;br&gt;                2. Health-related quality of life measured using Short Form 12 (SF-12) Item at 4 and 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Juli Health
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 07/06/2021, UCL Research Ethics Committee (Office of the Vice-Provost (Research), University College London, 2 Taviton St, London, WC1E 6BT, UK; +44 (0)20 7679 8717; ethics@ucl.ac.uk), ref: 19413/001
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/08/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12373274
    </Internal_Number>
    <TrialID>ISRCTN87679686
    </TrialID>
    <Last_Refreshed_on>27 June 2022
    </Last_Refreshed_on>
    <Public_title>Trial of a digital asthma management application: juli
    </Public_title>
    <Scientific_title>Randomised controlled trial of a digital asthma management application: juli                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210608
    </Date_registration3>
    <Date_registration>08/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN87679686
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/06/2021
    </Date_enrollement>
    <Target_size>180
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional placebo-controlled randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Bettina
    </Contact_Firstname>
    <Contact_Lastname>Dührkoop
    </Contact_Lastname>
    <Contact_Address>
                    juli Health
                    23 Beach Ave
                
    </Contact_Address>
    <Contact_Email>bd@juli.co
    </Contact_Email>
    <Contact_Tel>+44 (0)20 7679 9736
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Asthma with Asthma Control Test score&lt;20 at baseline&lt;br&gt;                2. Age 18 to 65 (inclusive)&lt;br&gt;                3. English speaker&lt;br&gt;                4. Have an iPhone&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Asthma Control Test&gt;19 at baseline&lt;br&gt;                2. Children&lt;br&gt;                3. Non-English speakers&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Reduction of asthma symptoms in adults with asthma &lt;br&gt;Respiratory &lt;br&gt;Asthma
    </Condition>
    <Intervention>&lt;br&gt;                Use of juli app vs treatment as usual (plus attention placebo control app).&lt;br&gt;&lt;br&gt;                juli app: Participants will be prompted to open the app each day via an automated alert. They will be asked to rate how they are feeling on a scale using 5 emojis and track number of shortness of breath episodes, rescue inhaler usage and night time waking with shortness of breath. The app will gather information via Apple HealthKit; sleep, activity, workouts, oxygen saturation. It will present this data to the participant and show associations with asthma symptoms. It will make recommendations about these parameters to guide healthy behaviours and will use external data sources (weather, air quality, pollen count) to guide these recommendations. The app has a medication reminder function that can be set by the participants to improve medication adherence. Participants are also encouraged to engage in journaling via the app, especially in relation to exacerbating or reliving factors for asthma symptoms.&lt;br&gt;&lt;br&gt;                Attention placebo control app: Participants will be prompted to open the app each day via an automated alert and rate how they are feeling on a scale using 5 emojis.&lt;br&gt;&lt;br&gt;                The participant will use the app for eight weeks and complete an asthma questionnaire every two weeks (four in total). Participants will also be asked to complete a well-being questionnaire at four and eight weeks and a user satisfaction questionnaire at eight weeks.&lt;br&gt;
    </Intervention>
    <Primary_outcome>Asthma symptoms measured using the Asthma Control Test at 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Asthma symptoms measured using the Asthma Control Test at 2, 4, and 6 weeks&lt;br&gt;                2. Short Form 12 Item health-related quality of life at 4 and 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>juli Health
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 07/06/2021, UCL Research Ethics (Office of the Vice-Provost (Research), University College London, 2 Taviton St, London, WC1E 6BT, UK; +44 (0)20 7679 8717; ethics@ucl.ac.uk), ref: 19413/001
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/08/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12352615
    </Internal_Number>
    <TrialID>NCT04913610
    </TrialID>
    <Last_Refreshed_on>13 June 2022
    </Last_Refreshed_on>
    <Public_title>Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
    </Public_title>
    <Scientific_title>A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 Given for 7 or 14 Days or in Combination With Albendazole in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics; Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>AbbVie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210530
    </Date_registration3>
    <Date_registration>30/05/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04913610
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 29, 2021
    </Date_enrollement>
    <Target_size>444
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>ABBVIE INC.;ABBVIE CALL CENTER
    </Contact_Lastname>
    <Contact_Email>;abbvieclinicaltrials@abbvie.com
    </Contact_Email>
    <Contact_Tel>;844-663-3742
    </Contact_Tel>
    <Contact_Affiliation>AbbVie;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Onchocerca volvulus infection at time of Screening:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Presence of at least one excisable subcutaneous nodule/ onchocercoma detected on&#x0D;&lt;br&gt;                  palpation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  O. volvulus infection diagnosed by skin snip method: documented mfpositivity on&#x0D;&lt;br&gt;                  skin assessment on at least 2 out of 4 skin snips.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight &gt; 40 kg at Screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For women of child-bearing potential, acceptance of the requirement to use a highly&#x0D;&lt;br&gt;             effective form of birth control from Day 0 until at least 1 month after the final&#x0D;&lt;br&gt;             intake of study drug (Part 1: day 43; Part 2: 1 month after the administration of&#x0D;&lt;br&gt;             ivermectin or matching placebo at the Month 6 visit). Choice of birth control method&#x0D;&lt;br&gt;             must be clearly documented.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in any studies other than purely observational studies within 3 months&#x0D;&lt;br&gt;             prior to Screening, or during the trial, or within 5 times the half-life of the drug&#x0D;&lt;br&gt;             tested in the previous clinical trial or is currently in the follow-up period for any&#x0D;&lt;br&gt;             clinical trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any vaccination within 4 weeks prior to investigational medicinal product (IMP)&#x0D;&lt;br&gt;             administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute infection and/or febrile illness requiring therapy within 14 days prior to IMP&#x0D;&lt;br&gt;             administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Administration of medication or herbal preparations as follows:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Administration of any medication (with the exception of diclofenac, paracetamol,&#x0D;&lt;br&gt;                  ibuprofen and aspirin) or herbal preparation within 14 days prior to IMP&#x0D;&lt;br&gt;                  administration;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Use of strong CYP3A inhibitors or inducers including but not limited to&#x0D;&lt;br&gt;                  ritonavir, ketoconazole, rifampicin, phenytoin, phenobarbital, carbamazepine,&#x0D;&lt;br&gt;                  cimetidine within 14 days or 10 half-lives, whichever is longer, prior to IMP&#x0D;&lt;br&gt;                  administration;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Use of other drugs known to interact with albendazole i.e. praziquantel,&#x0D;&lt;br&gt;                  theophylline or dexamethasone, within 14 days or 10 half-lives, whichever is&#x0D;&lt;br&gt;                  longer, prior to IMP administration;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Antifilarial therapies, or medication that may have an antifilarial effect.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Requirement for and inability to avoid ivermectin during the first 6 months after IMP&#x0D;&lt;br&gt;             administration. Requirement for albendazole during the first 28 days after IMP&#x0D;&lt;br&gt;             administration or more than one dose per year thereafter given in MDA.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any of the following at Screening, that could interfere with the&#x0D;&lt;br&gt;             objectives of the trial or the safety of the participant, in the opinion of the&#x0D;&lt;br&gt;             Investigator:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Abnormal physical examination or laboratory findings;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Any clinically significant medical condition. Including, but not limited to&#x0D;&lt;br&gt;                  significant acute or chronic liver or kidney condition or cardiovascular disease,&#x0D;&lt;br&gt;                  active infection, current or previous epilepsy, known human immunodeficiency&#x0D;&lt;br&gt;                  virus infection, disclosed by review of medical history or concomitant&#x0D;&lt;br&gt;                  medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ophthalmological history or conditions that could interfere with the objectives of the&#x0D;&lt;br&gt;             trial or compromise the safety of the subject in the opinion of the Investigator,&#x0D;&lt;br&gt;             assessed at Screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of drug or alcohol abuse within 6 months prior to IMP administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of alcohol or drugs of abuse within 24 hours before IMP administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant history of cardiac abnormality, and/or relevant pathological&#x0D;&lt;br&gt;             abnormalities in the ECG in the screening period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abnormal laboratory test results at Screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of severe drug allergy, non-allergic drug reactions, severe adverse reaction&#x0D;&lt;br&gt;             to any drug, or multiple drug allergies.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known hypersensitivity to any ingredient of the IMPs, including the active ingredient&#x0D;&lt;br&gt;             of ABBV-4083, macrolides, albendazole or to ivermectin or to any medication used&#x0D;&lt;br&gt;             during the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Blood donation within 8 weeks prior to Screening or blood transfusion received within 1&#x0D;&lt;br&gt;        year prior to Screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Coincidental infection with high Loa loa load and/or Mansonella species or Wuchereria&#x0D;&lt;br&gt;             bancrofti, based on positive laboratory test at Screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current hyperreactive onchodermatitis or severe manifestation due to onchocerciasis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other past or current condition that the Investigator feels would exclude the&#x0D;&lt;br&gt;             participant from the study or place the subject at undue risk.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For women of child-bearing potential: pregnant, based on date of last menstrual&#x0D;&lt;br&gt;             period, and pregnancy test prior to first intake of IMP, or breastfeeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unwilling or unable to comply with the requirements of the study protocol for the&#x0D;&lt;br&gt;             entire duration of the study, in the opinion of the Investigator.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to participate in the study as per local law, if applicable.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Onchocerciasis
    </Condition>
    <Intervention>Drug: ABBV-4083;Drug: Placebo for ABBV-4083;Drug: Albendazole;Drug: Placebo for Albendazole;Drug: Placebo for Ivermectin;Drug: Ivermectin
    </Intervention>
    <Primary_outcome>Part 1: Status of Each Live Female Adult Worm as Without Wolbachia Endobacteria;Part 2: Status of Each Participant as Without Skin Microfilariae
    </Primary_outcome>
    <Secondary_outcome>Part 2: Percentage of Live Female Adult Worms per Participant;Part 2: Perentage of Live Female Adult Worms With Only Degenerated Embryos in Uterus per Participant;Part 1: Percentage of Live Female Adult Worms With Only Degenerated Embryos in the Uterus per Participant;Part 1: Percentage of Live Female Adult Worms out of all Female Adult Worms per Participant;Part 1: Absence of Microfilariae in Nodular Tissue per Participant;Part 1: Status of Each Participant as Without Skin Microfilariae or not;Part 1: Reduction in Skin Microfilarial Density Compared to Baseline (Week 0);Part 1: Status of Each Live Adult Worm as Without Wolbachia Endobacteria or not;Part 2: Status of Each Participant as Without Skin Microfilariae or not;Part 2: Reduction in Skin Microfilarial Density Compared to Baseline (Week 0);Part 2: Absence of Microfilariae in Nodular Tissue per Participant;Part 2: Status of Each Live Adult Female Worm as Without Wolbachia Endobacteria or not;Part 2: Status of Each Live Adult Worm as Without Wolbachia Endobacteria or not
    </Secondary_outcome>
    <Secondary_ID>DNDi-TYL-01;B18-894
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Drugs for Neglected Diseases initiative
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12602310
    </Internal_Number>
    <TrialID>PACTR202105884908295
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
    </Public_title>
    <Scientific_title>Realizing Effectiveness Across Continents with Hydroxyurea (REACH): A Phase I/II Pilot Study of Hydroxyurea for Children with Sickle Cell Anemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Cincinnati Childrens Hospital Medical Center
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210512
    </Date_registration3>
    <Date_registration>12/05/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=15867
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Month(s)
    </Inclusion_agemin>
    <Inclusion_agemax>23 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/06/2014
    </Date_enrollement>
    <Target_size>600
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Crossover: all participants receive all interventions in different sequence during study,Non-randomised,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-2
    </Phase>
    <Countries>Angola;Congo;Kenya;Uganda
    </Countries>
    <Contact_Firstname>Susan 
    </Contact_Firstname>
    <Contact_Lastname>Stuber
    </Contact_Lastname>
    <Contact_Address>3333 Burnet Ave
    </Contact_Address>
    <Contact_Email>susan.stuber@cchmc.org
    </Contact_Email>
    <Contact_Tel>15136364200
    </Contact_Tel>
    <Contact_Affiliation>Project Manager
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Pediatric patients with documented sickle cell anemia (typically HbSS supported by hemoglobin electrophoresis, complete blood count, and peripheral blood smear)&#x0D;&lt;br&gt;2. Age range of 1.00-9.99 years, inclusive, at the time of enrollment&#x0D;&lt;br&gt;3. Weight at least 10.0 kg at the time of enrollment&#x0D;&lt;br&gt;4. Parent or guardian willing and able to provide written informed consent, with child's verbal assent as per local IRB/Ethics Board requirements&#x0D;&lt;br&gt;5. Willingness to comply with all study-related treatments, evaluations, and follow-up
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Known medical condition making participation ill-advised, (e.g., acute or chronic infectious disease, HIV, or malignancy)&#x0D;&lt;br&gt;2. Acute or chronic severe malnutrition determined by impaired growth parameters as defined by WHO (weight for length/height or weight-for-length/height &gt;3 z-scores below the median WHO growth standards, as defined in Appendix I)&#x0D;&lt;br&gt;3. Pre-existing severe hematological toxicity (temporary exclusions)&#x0D;&lt;br&gt;     a. Anemia: Hb &lt;4.0 gm/dL&#x0D;&lt;br&gt;     b. Anemia: Hb &lt;6.0 gm/dL with ARC &lt;100 x 109/L&#x0D;&lt;br&gt;     c. Reticulocytopenia: ARC &lt;80 x 109/L with Hb &lt;7.0 gm/dL&#x0D;&lt;br&gt;     d. Thrombocytopenia: Platelets &lt;80 x 109/L&#x0D;&lt;br&gt;     e. Neutropenia: ANC &lt;1.0 x 109/L&#x0D;&lt;br&gt;4. Blood transfusion within 60 days before enrollment (temporary exclusion)&#x0D;&lt;br&gt;5. Hydroxyurea use within 6 months before enrollment
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Haematological Disorders;Haematological Disorders
    </Condition>
    <Intervention>;Hydroxyurea;None
    </Intervention>
    <Primary_outcome>Percentage of Participants With Dose Limiting Toxic Events  An expected toxicity rate of 20% and acceptable toxicity rate of 30% were used for statistical calculations. After 53 participants at each site complete 3 months of therapy, if = 15 participants have hematologic toxicity there is no early evidence against safety. If = 15 of the initial participants experience toxicity, this is early evidence against safety. Future participants will begin at a lower dose of hydroxyurea (10 ± 2.5 mg/kg), with another 53 participants recruited of the same safety analysis. Upon final analysis of 133 participants at the same starting dose, safety for fixed-dose hydroxyurea can be concluded
    </Primary_outcome>
    <Secondary_outcome>Efficacy of Hydroxyurea   The efficacy of hydroxyurea will be primarily assessed through fetal hemoglobin (HbF), comparing treatment with baseline values. Additional measures of laboratory efficacy will include changes in Hb, MCV, WBC, ANC, ARC, and bilirubin. Clinical events such as vaso-occlusive pain will be captured as secondary outcomes.;Medication Adherence and the Ability for Families to Adhere to Monthly Clinic Visits  Hydroxyurea treatment will be dispensed only 35 days at a time, requiring a clinic visit every 4 ± 1 weeks. Medication adherence and the ability for families to adhere to monthly clinic visits are important feasibility outcomes
    </Secondary_outcome>
    <Source_Support>National Institutes of Health 
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/12/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>orcra@cchmc.org
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Cincinnati Childrens Hospital Medical Center Institutional Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>15136364200
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>orcra@cchmc.org
    </Ethics_review_contact_email>
    <results_date_posted>12/05/2021
    </results_date_posted>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12432104
    </Internal_Number>
    <TrialID>NCT04888377
    </TrialID>
    <Last_Refreshed_on>29 July 2022
    </Last_Refreshed_on>
    <Public_title>ASPIRIN: Neurodevelopmental Follow-up Trial
    </Public_title>
    <Scientific_title>Aspirin Supplementation for Pregnancy Indicated Risk Reduction in Nulliparas (ASPIRIN): Neurodevelopmental Follow-up Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210428
    </Date_registration3>
    <Date_registration>28/04/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04888377
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>33 Months
    </Inclusion_agemin>
    <Inclusion_agemax>39 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2021
    </Date_enrollement>
    <Target_size>666
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;Congo, The Democratic Republic of the;Guatemala;India;Pakistan;Zambia;Congo, The Democratic Republic of the;Guatemala;India;Pakistan;United States;Zambia;United States;Congo, The Democratic Republic of the;Guatemala;India;Pakistan;Zambia;Congo, The Democratic Republic of the;Guatemala;India;Pakistan;United States;Zambia;United States;Congo, The Democratic Republic of the;Guatemala;India;Pakistan;Zambia;Congo, The Democratic Republic of the;Guatemala;India;Pakistan;United States;Zambia;United States;Congo, The Democratic Republic of the;Guatemala;India;Pakistan;Zambia;Congo, The Democratic Republic of the;Guatemala;India;Pakistan;United States;Zambia
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Elizabeth McClure, PhD;Elizabeth McClure, PhD;Elizabeth McClure, PhD;Elizabeth McClure, PhD
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>RTI International;RTI International;RTI International;RTI International
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10967591
    </Internal_Number>
    <TrialID>NCT04853186
    </TrialID>
    <Last_Refreshed_on>24 May 2021
    </Last_Refreshed_on>
    <Public_title>Impact Study of Cholera Vaccination in Endemic Areas - Clinical Surveillance
    </Public_title>
    <Scientific_title>Cholera Control in Endemic Regions of Africa: Clinical Surveillance and Cholera Shedding Study in the Context of Mass Vaccination Campaigns, Democratic Republic of the Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Epicentre
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210416
    </Date_registration3>
    <Date_registration>16/04/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04853186
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 11, 2021
    </Date_enrollement>
    <Target_size>3000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Klaudia PORTEN;Francesco Luquero;Anais BROBAN;Anais BROBAN
    </Contact_Lastname>
    <Contact_Email>;;anais.broban@epicentre.msf.org;anais.broban@epicentre.msf.org
    </Contact_Email>
    <Contact_Tel>;;+33140215429;0140215429
    </Contact_Tel>
    <Contact_Affiliation>Epicentre;GAVI;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        For Surveillance in study CTCs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All patients presenting at the time of the study to any selected Cholera Treatment&#x0D;&lt;br&gt;             Center/Cholera Treatment Unit (CTC/CTU), matching the case definition and giving&#x0D;&lt;br&gt;             his/her consent (or assent for children 8 to 17 years old) to participate in the study&#x0D;&lt;br&gt;             will be eligible.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who decline to participate will be excluded from the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Follow up of individuals with active cholera shedding:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. present to any selected CTC/CTU, match the case definition, participate to the&#x0D;&lt;br&gt;             clinical surveillance activity and test positive to RDT OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Be a household member of a person respecting inclusion criteria 1. AND for whom the&#x0D;&lt;br&gt;             head of the household has provided verbal consent to participate AND giving his/her&#x0D;&lt;br&gt;             consent (or assent for children 8 to 17 years old) to participate in the study will be&#x0D;&lt;br&gt;             eligible.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - Individuals who decline to participate will be excluded from the study, as well as&#x0D;&lt;br&gt;        households for whom the head of the household (and his or her representative) decline the&#x0D;&lt;br&gt;        participation of his/her household.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cholera
    </Condition>
    <Primary_outcome>To better characterize cholera transmission in cholera hotspot in Africa and assess the impact of a large vaccination campaign reaching high coverage on sustained control of cholera transmission for at least two years.
    </Primary_outcome>
    <Secondary_outcome>1. To retrospectively study surveillance data, and prospectively measure cholera incidence rates of medically-attended confirmed cases following the mass vaccination campaign in two cholera hotspots in Africa.;2. To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment.;3. To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household.;4. To describe the global genetic diversity of V. cholerae strains in the study areas and within households affected by cholera.
    </Secondary_outcome>
    <Secondary_ID>215689/Z/19/Z;2104-WT
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Wellcome Trust;Medecins Sans Frontieres, Netherlands;Ministry of Public Health, Democratic Republic of the Congo;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12602285
    </Internal_Number>
    <TrialID>PACTR202104845356660
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Developing Triple Artemisinin Combination Therapies Trial in Africa
    </Public_title>
    <Scientific_title>A multi-centre randomised controlled non-inferiority trial to compare the efficacy, safety and tolerability of Triple Artemisinin-based Combination Therapies versus first-line ACTs + placebo for the treatment of uncomplicated Plasmodium falciparum malaria in Africa&#x0D;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210414
    </Date_registration3>
    <Date_registration>14/04/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=15824
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Month(s)
    </Inclusion_agemin>
    <Inclusion_agemax>23 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/09/2020
    </Date_enrollement>
    <Target_size>3240
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomization,Sealed opaque envelopes
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Burkina Faso;Gambia;Guinea;Niger;Nigeria;Democratic Republic of the Congo;Rwanda;Tanzania
    </Countries>
    <Contact_Firstname>Mehul
    </Contact_Firstname>
    <Contact_Lastname>Dhorda
    </Contact_Lastname>
    <Contact_Address>420/6 Ratchawithi Road, Ratchathewi
    </Contact_Address>
    <Contact_Email>Mehul@tropmedres.ac
    </Contact_Email>
    <Contact_Tel>+6622036333
    </Contact_Tel>
    <Contact_Affiliation>Project Coordinator
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: • Male or female, aged =6 months to &lt;12 years (For Gambia, Rwanda sites only: =6 months)&#x0D;&lt;br&gt;• Ability to take oral medication&#x0D;&lt;br&gt;• Acute uncomplicated P. falciparum monoinfection&#x0D;&lt;br&gt;• Asexual P. falciparum parasitaemia: 1,000/µL to =10% parasitaemia, determined on a peripheral blood film (At Gambia, Rwanda sites only: For subjects =12 years – 1000/µL to 200,000/µL)&#x0D;&lt;br&gt;• Fever defined as = 37.5°C tympanic temperature or a history of fever within the last 24 hours&#x0D;&lt;br&gt;• Written informed consent by the subject or by the parent/guardian in case of children lower than the age of consent and assent if required (per local regulations)&#x0D;&lt;br&gt;• Willingness and ability of the subjects or parents/guardians to comply with the study protocol for the duration of the study&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: ?Signs of severe malaria (adapted from WHO criteria)&#x0D;&lt;br&gt;?Patients not fulfilling criteria for severe malaria but with another indication for parenteral antimalarial treatment at the discretion of the treating physician&#x0D;&lt;br&gt;?Haematocrit &lt;15% at screening (For Gambia, Rwanda sites only: For subjects =12 years – Haematocrit &lt;20% at screening)&#x0D;&lt;br&gt;?Subjects who have received artemisinin or a derivative within the previous 7 days OR lumefantrine or amodiaquine within the previous 14 days OR mefloquine or piperaquine within the previous 30 days&#x0D;&lt;br&gt;?In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the last 14 days.&#x0D;&lt;br&gt;?Acute illness other than malaria requiring systemic treatment;&#x0D;&lt;br&gt;?Severe acute malnutrition (in Niger only – only those patients with Severe Acute Malnutrition and complications requiring inpatient nutritional treatment will be excluded)&#x0D;&lt;br&gt;?Known HIV infection&#x0D;&lt;br&gt;?Known tuberculosis infection&#x0D;&lt;br&gt;?For females: post-menarche (For Gambia, Rwanda sites only: females who are pregnant, trying to get pregnant or are lactating)&#x0D;&lt;br&gt;?History of allergy or known contraindication to any of the study drugs, including neuropsychiatric disorders and epilepsy&#x0D;&lt;br&gt;?Previous splenectomy&#x0D;&lt;br&gt;?Enrolment in DeTACT in the previous 3 months&#x0D;&lt;br&gt;?Participation in another interventional study in the previous 3 months
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;Artemether Lumefantrine;Artesunate Mefloquine;Artemether Lumefantrine Amodiaquine;Artesunate Mefloquine Piperaquine
    </Intervention>
    <Primary_outcome>42-day efficacy defined as PCR-corrected adequate clinical and parasitological response (ACPR).&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>For safety and tolerability: Incidence of adverse events and serious adverse events within the first 42 days including markers of hepatic, renal or bone marrow toxicity; cardiotoxicity, in particular QT or QTc-interval above 500 ms at timepoint H4 and H52/H64 and between these time points; change in haemoglobin concentration at day 3, 7, 28, stratified for G6PD status/genotype; proportion of subjects requiring retreatment due to vomiting within 1 hour after administration of the study drugs; proportion of subjects that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event ;For efficacy: 63-day PCR corrected and uncorrected efficacy; 42-day PCR uncorrected efficacy; parasite clearance half-life assessed by microscopy as primary parameter to determine parasite clearance; proportion of subjects with microscopically detectable P. falciparum parasitaemia at Day 3; fever clearance time (i.e. the time taken for the tympanic temperature to fall below 37.5 ºC in  patients who were febrile at inclusion); proportion of subjects with gametocytaemia during and after treatment stratified by presence of gametocytes at enrolment.&#x0D;&lt;br&gt;;For PK/PD interactions: Pharmacokinetic profiles and interactions (including Cmax and AUC) of artemisinin-derivatives and partner drugs in ACT and TACT treated subjects in correlation with pharmacodynamics measures of drug efficacy; day 7 plasma levels of partner drugs in correlation with treatment efficacy and treatment arm 
    </Secondary_outcome>
    <Source_Support>Foreign and Commonwealth Development Office 
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>25/04/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>oxtrec@admin.ox.ac.uk
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Oxford Tropical Research Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+44186528210
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>oxtrec@admin.ox.ac.uk
    </Ethics_review_contact_email>
    <results_url_link>https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12602282
    </Internal_Number>
    <TrialID>PACTR202104600961505
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Tylamac phase-II study for the treatment of onchocerciasis
    </Public_title>
    <Scientific_title>A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 given for 7 or 14 Days or in Combination with Albendazole in Subjects with Onchocerca volvulus Infection, comprising:&#x0D;
Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics;&#x0D;
Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics&#x0D;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Drugs for Neglected
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210412
    </Date_registration3>
    <Date_registration>12/04/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=15819
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>30/04/2021
    </Date_enrollement>
    <Target_size>444
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Central randomisation by phone/fax
    </Study_design>
    <Phase>Phase-2
    </Phase>
    <Countries>Congo;Congo
    </Countries>
    <Contact_Firstname>Virginie
    </Contact_Firstname>
    <Contact_Lastname>Pillet
    </Contact_Lastname>
    <Contact_Address>chemin Camille-VIDART
    </Contact_Address>
    <Contact_Email>vpillet@dndi.org
    </Contact_Email>
    <Contact_Tel>+41225551958
    </Contact_Tel>
    <Contact_Affiliation>Clinical Project Manager
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Written, signed (or thumb-printed) and dated informed consent.&#x0D;&lt;br&gt;2. Men and women with Onchocerca volvulus infection, 18 to 65 years of age inclusive at time of Screening:&#x0D;&lt;br&gt;i. Presence of at least one excisable subcutaneous nodule/onchocercoma detected on palpation;&#x0D;&lt;br&gt;ii. O. volvulus infection diagnosed by skin snip method: documented mf-positivity on skin assessment on at least 2 out of 4 skin snips.&#x0D;&lt;br&gt;3. Body weight &gt; 40 kg at Screening.&#x0D;&lt;br&gt;4. For women of child-bearing potential, acceptance of requirement to use highly effective birth control from Day 0 until at least 1 month after the final intake of IMP.&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Main exclusion criteria&#x0D;&lt;br&gt;1. Administration of medication or herbal preparations as follows:&#x0D;&lt;br&gt;i. Any medication or herbal preparation within 14 days prior to IMP administration; &#x0D;&lt;br&gt;ii. Strong CYP3A inhibitors or inducers within 14 days or 10 half-lives, whichever is longer, prior to IMP administration.&#x0D;&lt;br&gt;iii. Other drugs known to interact with albendazole, within 14 days or 10 half-lives, whichever is longer, prior to IMP administration;&#x0D;&lt;br&gt;iv. The following antifilarial therapies, or medication that may have an antifilarial effect: • ivermectin; = 6 months prior to IMP administration;&#x0D;&lt;br&gt;and/or • doxycycline, = 1 year prior to IMP administration: more than 2-week course;&#x0D;&lt;br&gt;and/or • any other anti-Wolbachia treatments, = 1 year prior to IMP administration: more than 2-week course;&#x0D;&lt;br&gt;and/or • moxidectin, = 2 years prior to IMP administration;&#x0D;&lt;br&gt;v. Other preventive chemotherapy, e.g. as part of an MDA program, within 14 days prior to IMP administration;&#x0D;&lt;br&gt;2. Requirement for albendazole during the first 28 days after IMP administration or more than one dose per year thereafter given in MDA;&#x0D;&lt;br&gt;3. Presence of any of the following at Screening:&#x0D;&lt;br&gt;i. Abnormal physical and/or neurological examination or laboratory findings;&#x0D;&lt;br&gt;ii. Any clinically significant medical condition including, significant acute or chronic liver or kidney condition or cardiovascular disease, active infection, current or previous epilepsy, known human immunodeficiency virus (HIV) infection, disclosed by review of medical history or concomitant medication;&#x0D;&lt;br&gt;4. Ophthalmological history or conditions that could interfere with the objectives of the trial or the safety of the subject.&#x0D;&lt;br&gt;5. Clinically significant history of cardiac abnormality, and/or relevant pathological abnormalities on the ECG at Screening.&#x0D;&lt;br&gt;6. Known hypersensitivity to any ingredient of the IMPs, including the active ingredient of ABBV-4083, macrolides, albendazole or to ivermectin or to any medication used during the study (e.g. for eye examination).&#x0D;&lt;br&gt;7. Coincidental infection with other endemic filarial parasite (Loa loa &gt; 8 000 mf/mL, Mansonella species or Wuchereria bancrofti), based on positive laboratory test at Screening.&#x0D;&lt;br&gt;8. Current hyperreactive onchodermatitis or severe manifestation due to onchocerciasis.&#x0D;&lt;br&gt;9. For women of child-bearing potential: pregnant or breastfeeding.&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Onchocerciasis;Onchocerciasis
    </Condition>
    <Intervention>;Part 1 Arm A ABBV 4083;Part 1 Arm B ABBV 4083;Part 1 Arm C ABBV 4083 and albendazole;Part 1 Arm D ABBV 4083 and albendazole;Part 1 Arm E albendazole;Part 2 Basic Arm K ABBV 4083 plus or minus albendazole plus ivermectin ;Part 2 Basic Arm L ABBV 4083 plus or minus albendazole;Part 2 Basic Arm M ABBV 4083 plus or minus albendazole plus or minus ivermectin;Part 2 Basic Arm N1 Placebo and Ivermectin
    </Intervention>
    <Primary_outcome>Part 1. Status of each live female adult worm as without Wolbachia endobacteria or not, as assessed by immunohistology of nodules;Part 2. Status of each subject as without skin microfilariae or not, as assessed across all skin snips in subject
    </Primary_outcome>
    <Secondary_outcome>Part 1. Proportion of live female adult worms with only degenerated embryos in the uterus per subject ;Part 1. Proportion of live female adult worms out of all female adult worms per subject ;Part 1. Absence of microfilariae in nodular tissue per subject ;Part 1. Status of each subject as without skin microfilariae or not;Part 1. Reduction in skin microfilarial density (defined as mean number of microfilariae/mg per subject) as compared to baseline;Part 1. Status of each live adult worm as without Wolbachia endobacteria or not, as assessed by PCR;Part 2. Proportion of live female adult worms per subject;Part 2. Proportion of live female adult worms with only degenerated embryos in uterus per subject ;Secondary efficacy  Part 2. Status of each subject as without skin microfilariae or not at all;Secondary efficacy Part 2. Reduction in skin microfilarial density as compared to baseline;Secondary efficacy   Part 2. Absence of microfilariae in nodular tissue per subject ;Secondary efficacy    Part 2. Status of each live adult female worm as without Wolbachia endobacteria or not, assessed by immunohistology;Secondary efficacy   Part 2. Status of each live adult worm as without Wolbachia endobacteria or not, as assessed by PCR;Exploratory   Parts 1 and 2. Absence of Wolbachia in skin microfilariae per subject, as assessed by PCR;Exploratory   Parts 1 and 2. Decline in number of Wolbachia in skin microfilariae per subject compared to baseline, as assessed by PCR;Exploratory   Parts 1 and 2. Microfilaria levels in cornea and anterior chamber per subject;Exploratory  Parts 1 and 2. Presence, severity and clinical evolution of onchocerciasis ocular disease and onchocerciasis skin disease in each subject;Safety   Parts 1 and 2. Adverse events, physical and skin examination findings, vital signs, ECG, clinical laboratory parameters including haematology, biochemistry, urine analysis and ophthalmological analysis;Pharmacokinetic  Part 1 ABBV 4083 and albendazole sulfoxide AUCtau, Cmax, Cmin, CL and t½;Pharmacokinetic	Part 2. ABBV 4083 and albendazole sulfoxide AUCtau, Cmax, Cmin, CL and t½;Pharmacokinetic outcome 	Relationship between presence or absence of Wolbachia in female adult worms in each subject with respect to ABBV-4083 and albendazole sulfoxide PK parameters;Pharmacokinetic	Relationship between status of adult female worms with respect to ABBV-4083 and albendazole sulfoxide PK parameters;Pharmacokinetic outcome	Relationship between presence or absence of skin microfilariae with respect to ABBV-4083 and albendazole sulfoxide PK parameters;Pharmacokinetic outcome	Relationship between reduction in skin microfilarial density over time in relation to ABBV-4083 and albendazole sulfoxide concentrations
    </Secondary_outcome>
    <Secondary_ID>DNDi TYL 01;B18 894
    </Secondary_ID>
    <Source_Support>Drugs for Neglected Diseases Initiative
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/01/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>cnesrdcongo@gmail.com
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>National Health Ethics Committee 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+243998419816
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>cnesrdcongo@gmail.com
    </Ethics_review_contact_email>
    <results_url_link>Summary of results will be shared once clinical study report is available
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12535125
    </Internal_Number>
    <TrialID>NCT04850677
    </TrialID>
    <Last_Refreshed_on>19 September 2022
    </Last_Refreshed_on>
    <Public_title>Treating Non-typhoidal Salmonella Bloodstream Infections in Children Under Five in DR Congo: a Cohort Study
    </Public_title>
    <Scientific_title>Treating Non-typhoidal Salmonella Bloodstream Infections in Children Under Five in DR Congo: a Cohort Study - TreNTS
    </Scientific_title>
    <Acronym>TreNTS
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210407
    </Date_registration3>
    <Date_registration>07/04/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04850677
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>28 Days
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2021
    </Date_enrollement>
    <Target_size>1884
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Bieke Tack, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institute of Tropical Medicine Antwerp
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be a child &gt; 28 days and &lt; 5 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be admitted to Kisantu Hospital&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a blood culture sampled upon hospital admission&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having a caregiver willing and able to provide written informed consent, which will be&#x0D;&lt;br&gt;             requested as soon as possible after screening of the other three eligibility criteria.&#x0D;&lt;br&gt;             By consenting with study participation of the child, the caregiver agrees to that the&#x0D;&lt;br&gt;             child participates in the study procedures at presentation in the hospital, during&#x0D;&lt;br&gt;             hospital admission and during 1 month after discharge.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Child died and caregiver left the hospital before enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Child and caregiver left the hospital before enrollment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Blood-stream Infections;Salmonella Infection Non-Typhoid
    </Condition>
    <Intervention>Other: Observational Cohort
    </Intervention>
    <Primary_outcome>Clinical failure (fever);Clinical failure (death)
    </Primary_outcome>
    <Secondary_outcome>In-hospital survival;Overall survival;Time to fever clearance;Length of hospital stay;Microbiological cure;Possible disease recurrence
    </Secondary_outcome>
    <Secondary_ID>ITM202007
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Hôpital St. Luc Kisantu;KU Leuven;International Vaccine Institute
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10819122
    </Internal_Number>
    <TrialID>NCT04815174
    </TrialID>
    <Last_Refreshed_on>12 April 2021
    </Last_Refreshed_on>
    <Public_title>Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease
    </Public_title>
    <Scientific_title>Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease
    </Scientific_title>
    <Acronym>EVISTA
    </Acronym>
    <Primary_sponsor>Alliance for International Medical Action
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210317
    </Date_registration3>
    <Date_registration>17/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04815174
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2018
    </Date_enrollement>
    <Target_size>711
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Laboratory confirmed Ebola Virus Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Ebola Virus Disease
    </Condition>
    <Intervention>Other: Standard of Care
    </Intervention>
    <Primary_outcome>Mortality
    </Primary_outcome>
    <Secondary_ID>ALIMA01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12431277
    </Internal_Number>
    <TrialID>NCT04783051
    </TrialID>
    <Last_Refreshed_on>29 July 2022
    </Last_Refreshed_on>
    <Public_title>Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)
    </Public_title>
    <Scientific_title>Comparison of IST Using Ultra-sensitive Malaria Rapid Diagnostic Test and Pyronaridine - Artesunate - PYRAMAX®) to Standard IPT Sulfadoxine-pyrimethamine to Prevent Malaria in Pregnant Women Living in Endemic Areas
    </Scientific_title>
    <Acronym>ULTRAPYRAPREG
    </Acronym>
    <Primary_sponsor>University of Kinshasa
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210227
    </Date_registration3>
    <Date_registration>27/02/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04783051
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>May 6, 2021
    </Date_enrollement>
    <Target_size>250
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the
    </Countries>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10750449
    </Internal_Number>
    <TrialID>ISRCTN56646695
    </TrialID>
    <Last_Refreshed_on>22 March 2021
    </Last_Refreshed_on>
    <Public_title>Integrating self-affirmation content into a smoking cessation mobile app
    </Public_title>
    <Scientific_title>Integrating the use of self-affirmation content into a mobile app to promote quit attempts with text-based smoking cessation intervention messaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>National Cancer Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210212
    </Date_registration3>
    <Date_registration>12/02/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN56646695
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>07/03/2018
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized 2 x 2 factorial design (integrated affirmation: affirmation texts present versus absent; baseline affirmation: questionnaire present versus absent) (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Elizabeth
    </Contact_Firstname>
    <Contact_Lastname>Seaman
    </Contact_Lastname>
    <Contact_Address>600 Peachtree St NE #1000
    </Contact_Address>
    <Contact_Email>eseaman@cdcfoundation.org
    </Contact_Email>
    <Contact_Tel>+1 (0)4438524139
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                A randomly selected proportion of users who downloaded the free version of the Smoke Free-Quit Smoking Now mobile application during the study period (initially 10% and then increased to 30% to achieve recruitment goals) are shown a consent form and invited to participate in this study. Once participants who opted in completed the baseline assessment, their eligibility was determined. In order to participate, app users had to be:&lt;br&gt;                1. Adults (between the ages of 18-98)&lt;br&gt;                2. Selected a cessation date after the day they downloaded the app but not more than 14 days in the future&lt;br&gt;                3. Completed the baseline assessment&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Under 18 years or over 98 years old&lt;br&gt;                2. Selected a quit date more than 14 days in the future or more than 1 day in the past&lt;br&gt;                3. Paid for additional app features (Pro users)&lt;br&gt;                4. Did not complete the baseline assessment&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Smoking cessation among current smokers &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>Two types of self-affirmation inductions (Integrated, Baseline) were added to a publicly available smoking cessation mobile application (Smoke-Free Quit Smoking Now). All users who met the inclusion criteria, provided consent to participate and completed a baseline assessment, were randomized to 1 of 4 conditions. Half of the participants were randomly assigned to complete a self-affirmation induction upon study entry. Orthogonally, half of the participants were randomly assigned to receive self-affirming text notifications during their quit attempt or to receive conventional notifications. The induction and the text notifications were fully automated, and all data were collected through self-assessments in the mobile application. Self-reported smoking cessation was assessed 1 month and 3 months following study entry.
    </Intervention>
    <Primary_outcome>Smoking cessation measured through self-assessments in the mobile application: past-week cessation at 1 month, past-month cessation at 1 month, past-week cessation at 3 months, and past-month cessation at 3 months
    </Primary_outcome>
    <Secondary_outcome>Optimism and baseline mood states (happiness, anger, anxiousness, hopefulness, sadness) measured through self-assessments in the mobile application at baseline 
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;17CN039
    </Secondary_ID>
    <Source_Support>National Cancer Institute
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 12/04/2018, the National Institutes of Health Intramural Institutional Review Board (Office of Human Subjects Research Protections, 6700B Rockledge Drive, Suite 4300, Bethesda, MD 20817, USA; +1 301 402 3713; irb@od.nih.gov), ref: #17CN039
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>06/03/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12092036
    </Internal_Number>
    <TrialID>NCT04760678
    </TrialID>
    <Last_Refreshed_on>4 April 2022
    </Last_Refreshed_on>
    <Public_title>Febrile Illness in Kinshasa and Kimpese
    </Public_title>
    <Scientific_title>Clinical Aspects, Severity, Management and Outcome of Febrile Illnesses in the Democratic Republic Congo (DRC).
    </Scientific_title>
    <Acronym>FIKI²
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210212
    </Date_registration3>
    <Date_registration>12/02/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04760678
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>2 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 1, 2021
    </Date_enrollement>
    <Target_size>1500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Emmanuel Bottieau, MD;Emmanuel Bottieau, MD
    </Contact_Lastname>
    <Contact_Email>;ebottieau@itg.be
    </Contact_Email>
    <Contact_Tel>;(0)32476450
    </Contact_Tel>
    <Contact_Affiliation>Institute of Tropical Medicine;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Ongoing and objectified fever at presentation, or documented at home or other health&#x0D;&lt;br&gt;             center within 24 hours prior to presentation, defined by:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Axillary or tympanic temperature &gt; 37.5°C OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Oral or rectal temperature &gt; 38°C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Possibility of contact between the patient (or designated relative) and the study team&#x0D;&lt;br&gt;             on days 7, 14 and 21&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Informed consent signed by the patient (adults) or a legally acceptable representative&#x0D;&lt;br&gt;             (children or patients whose condition does not allow them to sign informed consent),&#x0D;&lt;br&gt;             with the consent of children as young as 12 years of age, whenever possible.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Children less than two months old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Hospitalization &gt; 48 h in the last 14 days (to exclude nosocomial fevers)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Febrile Illness
    </Condition>
    <Intervention>Other: Observational study
    </Intervention>
    <Primary_outcome>Proportion of survival with symptom resolution;CRP values and white blood cell count
    </Primary_outcome>
    <Secondary_outcome>Clinical status according to a 3-category ordinal scale (resolution, non-resolution, death);Inclusion diagnostic assumptions and final diagnoses;Severity of illness;Initial and secondary hospitalization;Length of hospital stay (initial and/or secondary hospitalization);Number of secondary visits;Number and types of laboratory and radiological examinations prescribed / actually performed;Number and types of medications and supportive care prescribed/actually administered.;Malaria detection
    </Secondary_outcome>
    <Secondary_ID>FIKI²
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12602190
    </Internal_Number>
    <TrialID>PACTR202102616421588
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Effect of a Community-Driven Water, Sanitation, and Hygiene Program on Covid-19 knowledge, behavior, and health:&#x0D;
A Randomized Control Trial in the Democratic Republic of Congo &#x0D;

    </Public_title>
    <Scientific_title>Effect of a Community-Driven Water, Sanitation, and Hygiene Program on Covid-19 knowledge, behavior, and health:&#x0D;
A Randomized Control Trial in the Democratic Republic of Congo &#x0D;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Development Impact Evaluation Unit World Bank
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210208
    </Date_registration3>
    <Date_registration>08/02/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=14670
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>0 Day(s)
    </Inclusion_agemin>
    <Inclusion_agemax>1 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/11/2020
    </Date_enrollement>
    <Target_size>1312
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Permuted block randomization,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>John
    </Contact_Firstname>
    <Contact_Lastname>Quattrochi
    </Contact_Lastname>
    <Contact_Address>300 The Fenway
    </Contact_Address>
    <Contact_Email>john.quattrochi@simmons.edu
    </Contact_Email>
    <Contact_Tel>8579997192
    </Contact_Tel>
    <Contact_Affiliation>Assistant Professor of Public Health Simmons University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All 1,312 households that were randomly selected for our earlier survey were included in the target list for follow-up interviews. If the household from the earlier survey round could not be reached by phone, then it could be replaced by a nearby household in the same or a neighboring village. &#x0D;&lt;br&gt;These households were located in 332 villages; the village leader and water committee leader (if a water committee existed) were also interviewed in the first survey round. These individuals were eligible for interviews in the phone survey rounds. In the event that they could not be reached, replacements were handled on a case by case basis. &#x0D;&lt;br&gt;See details on the first survey here: https://www.socialscienceregistry.org/trials/4648
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Households that did not participate in the early survey, or did not meet the criteria for replacement, were not eligible. 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Covid-19, diarrheal disease;Covid-19, diarrheal disease
    </Condition>
    <Intervention>;The Health Villages and Healthy Schools Program;Control group
    </Intervention>
    <Primary_outcome>Covid-like illness. Number of household members in past week with fever, dry cough, difficulty breathing/shortness of breath, or fatigue;Non-Covid illness. Number of sick household members in last seven days [exclude those with Covid symptoms]  ;Child health index. Summary index of proportion of children under five with fever/cough/diarrhea in last two weeks [this will be three separate numbers for each HH with children under 5];Mental health. &lt;br&gt;Summary index of scores to following questions (1=All of the time...6=None of the time):&lt;br&gt;Have you been a very nervous person over the past four weeks ?&lt;br&gt;Have you felt so down in the dumps that nothing could cheer you up over the past four weeks ? &lt;br&gt;Have you felt calm and peaceful over the past four weeks ? (negatively coded)&lt;br&gt;Have you felt downhearted and blue over the past four weeks ? &lt;br&gt;Have you been a happy person over the past four weeks ? (negatively coded)&lt;br&gt;;Vaccine acceptance. If a vaccine for COVID-19 becomes available to you, would you take it?
    </Primary_outcome>
    <Secondary_outcome>Village Covid prevention. Summary index of the following binary variables as reported by households: banned gatherings; community meetings; HH visits; curfew; closed shops; handwashing materials/water; isolation of sick; medical care; wear mask; social distancing;Household Covid prevention. Summary index of the following binary variables from household survey [Have you practiced X in the last two weeks?]: wash hands frequently; avoid physical contact; avoid social gatherings; stay at home; wear mask; keep 1+ meter distance;Respondent Covid Knowledge. Summary index of the following binary variables from household survey [Is X effective to prevent Covid?]: wash hands frequently; avoid physical contact; avoid social gatherings; stay at home; wear mask; keep 1+ meter distance; inject/inhale disinfectant (negative)&#x0D;&lt;br&gt;;Governance. Summary index of Likert variables:&#x0D;&lt;br&gt;A23. Overall, how well do you think the government is doing in its response to the COVID epidemic? [1=very badly...5=very good]&#x0D;&lt;br&gt;A24. How much do you trust the government to respond well to the COVID epidemic? [1=strongly distrust...5=strongly trust]&#x0D;&lt;br&gt;;Livelihoods. Summary index of responses to:&#x0D;&lt;br&gt;A27.a In the past week, how many hours have you spent working on an income generating activity?&#x0D;&lt;br&gt;A27.c In the past week, how many hours has your spouse/partner spent working on an income generating activity for your household? [if applicable]&#x0D;&lt;br&gt;A27.d Has anyone in your household (including you) lost their job (or main source of income) since the coronavirus pandemic began? [negatively coded]&#x0D;&lt;br&gt;A27.e Have you or anyone in your household gained a new job (or main source of income) since the coronavirus pandemic began?&#x0D;&lt;br&gt;A27.f Think of the income you earned each month before the coronavirus pandemic began. How does that compare to the income you are earning now? &#x0D;&lt;br&gt;;Food security.  In the last seven days, how many days (out of 7) did you lack enough food to eat?&#x0D;&lt;br&gt;;Access to health care. Have you or any other person your household delayed, skipped or been unable to complete health care visits since the Coronavirus pandemic began?;Hospital visits. Number of household members who visited hospital in last seven days;Household illnesses. Number of sick household members in last seven days [includes those with Covid symptoms, because no data on symptoms was collected] ;Perceptions of Covid prevention. Summary index of the following binary variables from household survey [Have most people in your village/community practiced X in the last two weeks?]: wash hands frequently; avoid physical contact; avoid social gatherings; stay at home; wear mask; keep 1+ meter distance.;Leader vaccine acceptance. In village leader survey: If a vaccine for COVID-19 becomes available to you, would you take it?&#x0D;&lt;br&gt;;Approval of authorities. 10 outcomes. Do you approve or disapprove of the way that the following people have performed their jobs over the past twelve months, or haven’t you heard enough about them to say?&#x0D;&lt;br&gt;1.	President&#x0D;&lt;br&gt;2.	National Assembly&#x0D;&lt;br&gt;3.	Ministry of Health&#x0D;&lt;br&gt;4.	Provincial Government&#x0D;&lt;br&gt;5.	International NGOs&#x0D;&lt;br&gt;6.	Local NGOs&#x0D;&lt;br&gt;7.	Traditional leaders&#x0D;&lt;br&gt;8.	Health zone officials&#x0D;&lt;br&gt;9.	Health area officials&#x0D;&lt;br&gt;10.	Village chief;Leader vaccine advice. In village leader survey: Will you advise the people in your village to take the Covid vaccine?  &#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Source_Support>UK Foreign Commonwealth and Development Office
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/06/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>reviews@solutionsirb.com
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Solutions IRB
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0018552264472
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>reviews@solutionsirb.com
    </Ethics_review_contact_email>
    <results_url_link>https://www.socialscienceregistry.org/trials/4648
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12602162
    </Internal_Number>
    <TrialID>PACTR202102626263606
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria - KAE609B12201(KARISMA)
    </Public_title>
    <Scientific_title>An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the&#x0D;
efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and pediatric&#x0D;
participants with severe Plasmodium falciparum malaria (KARISMA - KAE609's Role In Severe Malaria)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Novartis Pharma AG
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210122
    </Date_registration3>
    <Date_registration>22/01/2021
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=14630
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>2 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>5 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>28/06/2021
    </Date_enrollement>
    <Target_size>252
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Central randomisation by phone/fax
    </Study_design>
    <Phase>Phase-2
    </Phase>
    <Countries>Democratic Republic of the Congo;Gabon;Cote Divoire;Cote Divoire;Nigeria;Rwanda;India;India;India;Uganda;Kenya;Mozambique
    </Countries>
    <Contact_Firstname>Marc
    </Contact_Firstname>
    <Contact_Lastname>Cousin
    </Contact_Lastname>
    <Contact_Address>Novartis Campus, Forum 3, Novartis Pharma AG
    </Contact_Address>
    <Contact_Email>marc.cousin@novartis.com
    </Contact_Email>
    <Contact_Tel>+41795704543
    </Contact_Tel>
    <Contact_Affiliation>Global Trial Director
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Cohort 1: Participants aged = 12 years with moderately severe malaria as defined in (prostration and/or repeated vomiting) without presence of other signs of severe malaria (and with high P. falciparum parasitemia (60,000-250,000 parasites per µl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Subsequent Cohorts 2 to 5: Participants diagnosed with severe malaria as defined in modified version of WHO criteria and P. falciparum parasite count of = 5000 per µl&#x0D;&lt;br&gt;Cohort 2: Participants aged = 12 years&#x0D;&lt;br&gt;Cohort 3: Participants aged 6 - &lt; 12 years&#x0D;&lt;br&gt;Cohort 4: Participants aged 2 - &lt; 6 years&#x0D;&lt;br&gt;Cohort 5: Participants aged = 6 months - &lt; 2 years
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: To all Cohorts 1 to 5:&#x0D;&lt;br&gt;- Mixed Plasmodium infections&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;- Treatment with quinine or artemisinin derivative or any other antimalarial drug or any antibiotic with known antimalarial activity within 12 hours of screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;- Signs/symptoms of severe malnutrition in accordance with WHO guidelines: &#x0D;&lt;br&gt;1. Under 18 years: &lt;-3 Z-scores of WHO growth standard for weight-for-height/length (in children &lt; 5 years) or BMI for age (5-18 years), or very low mid-upper arm circumference (MUAC &lt; 115 mm in children &lt; 12 years, &lt; 160mm 12-18 years), or bilateral pitting edema&#x0D;&lt;br&gt;2. Over 18 years: BMI &lt; 16 kg/m2 or MUAC &lt; 160mm or bilateral pitting edema&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;- Known underlying illness, surgical or medical condition, which is not related to ongoing event of severe malaria and which might jeopardize the participant's health in case of participation in the study or which might alter the distribution, metabolism or excretion of study treatment. For example:&#x0D;&lt;br&gt;1. neurological or neurodegenerative disorders,&#x0D;&lt;br&gt;2. cardiac, renal, or hepatic disease, diabetes,&#x0D;&lt;br&gt;3. epilepsy, cerebral palsy,   &#x0D;&lt;br&gt;4. known or suspected to be HIV-1 positive and/or receiving antiretroviral treatment&#x0D;&lt;br&gt;5. malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases  &#x0D;&lt;br&gt;6.known or suspected cases of active infections or concurrent febrile illness such as TB, Typhoid, COVID-19 etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;for Cohort 1:&#x0D;&lt;br&gt;- ALT &gt; 5 x the upper limit of normal range (ULN), regardless the level of total bilirubin&#x0D;&lt;br&gt;- Total bilirubin is &gt; 3 mg/dL&#x0D;&lt;br&gt;- Body weight of &lt; 35 kg or &gt;75 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;for Cohort 2:&#x0D;&lt;br&gt;- Body weight of &lt; 35 kg or &gt;75 kg&#x0D;&lt;br&gt;- moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;for Cohorts 3 to 5:&#x0D;&lt;br&gt;- Body weight of &lt; 5 kg&#x0D;&lt;br&gt;- moderately severe malaria due to repeated vomiting without presence of any of the symptoms of severe malaria&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;IV KAE609;IV Artesunate
    </Intervention>
    <Primary_outcome>Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) at 12 hours [ Time Frame: Day 1 (12 Hours) ]&lt;br&gt;A blood draw will be performed at each collection time point for parasitemia assessment.
    </Primary_outcome>
    <Secondary_outcome>4.Percentage of participants with neurological sequelae at Day 29 [ Time Frame: Day 29 ]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Detailed neurological examination will be conducted and relevant medical history collected under the following categories to assess the extent of neurological signs and symptoms at baseline and to monitor the extent of neurological sequelae in follow-up visits:&#x0D;&lt;br&gt;a.Consciousness&#x0D;&lt;br&gt;b.Cranial Nerve Palsy&#x0D;&lt;br&gt;c.Motor system&#x0D;&lt;br&gt;d.Convulsions&#x0D;&lt;br&gt;e.Sense organs (Examination more useful at time of hospital discharge and in follow-up visits)&#x0D;&lt;br&gt;;1. Percentage of participants achieving clinical success over time [ Time Frame: Day 3 (48 Hours), Day 4 to Day 29 ]&#x0D;&lt;br&gt;Clinical success is a composite endpoint based on following criterias:&#x0D;&lt;br&gt;a.Is participant dead or alive&#x0D;&lt;br&gt;b.Presence of asexual parasites (yes/no)&#x0D;&lt;br&gt;c.Presence of any of the key signs of severe malaria (yes/no)&#x0D;&lt;br&gt;;2. Percentage of participants with individual signs of severe malaria over time [ Time Frame: Day 1 to Day 29 ]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Individual signs of severe malaria over time will be monitored for the presence of the following signs of severe malaria during the entire study duration:&#x0D;&lt;br&gt;a.Altered consciousness - Prostration or GCS &lt; 11 for participants &gt; 5 years / BCS &lt; 3 for participants =&lt; 5 years of age&#x0D;&lt;br&gt;b.Renal Impairment - Serum creatinine &gt; 3xULN or &gt; 3 mg/dL or need for renal replacement therapy&#x0D;&lt;br&gt;c.Acidosis - Serum lactate &gt; 4 mmol/L&#x0D;&lt;br&gt;d.Respiratory distress - present or absent&#x0D;&lt;br&gt;e.Severe anemia - Hb &lt; 5 g/dl or Hb &lt; 7g/dl in pediatric and adults respectively or need of blood transfusion&#x0D;&lt;br&gt;f.Jaundice - Serum bilirubin &gt; 3 g/dl&#x0D;&lt;br&gt;g.Hypoglycemia- plasma glucose &lt; 40 mg/dL&#x0D;&lt;br&gt;;3. Percentage of participants developing hemolysis (early and delayed) after treatment [ Time Frame: Day 8 and Day 29 ]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Development (early and delayed) of hemolysis after treatment are defined as follows:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Early Hemolytic anemia is defined as 10% or greater decrease in hemoglobin levels and an increase of LDH levels to &gt;390 U/L, or an increase of &gt;= 10% above baseline occurring up to Day 8 of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Delayed hemolytic anemia might occur &gt; 7 days after initiation of parenteral study drug (IV artesunate or IV cipargamin) during the study period. The event is characterized by a 10% or greater decrease in hemoglobin levels accompanied by increase of LDH levels to &gt;390 U/L, or an increase of &gt;= 10% compared to the values measured at Day 8 of the study.&#x0D;&lt;br&gt;;5.Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) [ Time Frame: Day 2 (24 hours), Day 3 (48 hours) ]&#x0D;&lt;br&gt;A blood draw will be performed at each collection time point for parasitemia assessment;6.Time to parasite clearance (PCT) [ Time Frame: Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours) ]&#x0D;&lt;br&gt;Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 24 hours;7.Time to fever clearance (FCT) [ Time Frame: Day 1 (12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours) ]&#x0D;&lt;br&gt;Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral/tympanic/rectal for at least a further 24 hours.;8.Percentage of participants achieving P. falciparum parasite reduction ratios (PRR) at 12, 24 and 48 hours [ Time Frame: Day 1 (12 hours), Day 2 (24 hours) and Day 3 (48 hours) ]&#x0D;&lt;br&gt;PRR is defined as the ratio of asexual parasite at baseline divided by asexual parasite at post-baseline. If the asexual parasite count at post-baseline is 0, the half value of detection limit will be used to calculate the ratio.;9.Percentage of participants with recrudescence and reinfection [ Time Frame: Day 29 ]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Time to event (recrudescence or reinfection) will be calculated from the time of first study medication to the date of first event if a patient experiences the event and be censored at the time of last parasite assessment if a patient does not experience the event due to whatever reason.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Reinfection is defined as appearance of asexual parasites after clearance of initial infection with a genotype different from those parasites present at baseline.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Recrudescence is defined as appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at baseline.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Reinfection and Recrudescence must be confirmed by PCR analysis.&#x0D;&lt;br&gt;;10.Time to recover from prostration [ Time Frame: Day 1 to Day 29 ]&#x0D;&lt;br&gt;To assess recovery of participants as measured by time (days and hours) to discharge from hospital or recovery from prostration compared to baseline.&#x0D;&lt;br&gt;;11.Time to switch to oral therapy [ Time Frame: Day 3 to Day 29 ]&#x0D;&lt;br&gt;Time to switch participants from IV therapy to Coartem (standard of drug for oral therapy) will be analyzed.;12.Time to discharge from hospital [ Time Frame: Day 3 to Day 29 ]&#x0D;&lt;br&gt;All participants will be hospitalized. Time (Days and Hours) to discharge from hospital will be analyzed.&#x0D;&lt;br&gt;;13.Number of Participants impacted on safety and tolerability assessments [ Time Frame: Day 1 to Day 29 ]&#x0D;&lt;br&gt;Adverse events (AE), Serious Adverse events (SAEs) will be collected from first dosing, Death including whether in-hospital death and routine laboratory assessments will be done up to last follow-up visit or until the event has resolved to baseline grade or better or the event was assessed stable by the investigator or the participant was lost to follow-up or withdrew consent.;14.Observed maximum plasma concentration (Cmax) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.;15.Time of maximum observed drug concentration occurrence (Tmax) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. Tmax will be listed and summarized using descriptive statistics.&#x0D;&lt;br&gt;;16.Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. AUClast will be listed and summarized using descriptive statistics.;17.Area under the concentration time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-inf) will be listed and summarized using descriptive statistics.;18.Area Under the plasma concentration-time Curve from the time 0 to the last observed quantifiable concentration (AUC(0-t)) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-t) will be listed and summarized using descriptive statistics.;19.AUC(0-t) divided by the dose administered (AUC(0- t)/D) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-t)/D will be listed and summarized using descriptive statistics.&#x0D;&lt;br&gt;;20.Terminal elimination half life (T^1/2) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. The half-live will be listed and summarized using descriptive statistics.;21.Total systemic clearance for intravenous administration (CL) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. CL will be listed and summarized using descriptive statistics.;22.volume of distribution during the terminal phase following intravenous elimination (Vz) of IV Cipargamin [ Time Frame: Day 1 - Day 8 ]&#x0D;&lt;br&gt;Blood samples will be collected for activity-based pharmacokinetics characterization. Vz will be listed and summarized using descriptive statistics.
    </Secondary_outcome>
    <Secondary_ID>CKAE609B12201
    </Secondary_ID>
    <Source_Support>Welcome Trust;European and Developing Countries Clinical Trials Partnership EDCTP
    </Source_Support>
    <Ethics_review_status>Not approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;07/12/2020;05/01/2021;28/01/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>cnergabon@gmail.com;lazarpoame@hotmail.com;info@uith.org;espsec_unikin@yahoo.fr
    </Ethics_review_contact_name>
    <Ethics_review_contact_address> Comite National Ethique pour la Recherche CNER;Comite Consultatif National de Bioethique de la Republique de Cote DIvoire;UITH ERC;Universite de Kinshasa
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+24105816968;+22502037504;+2348105657675;+243817493194
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>cnergabon@gmail.com;lazarpoame@hotmail.com;info@uith.org;espsec_unikin@yahoo.fr
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12281128
    </Internal_Number>
    <TrialID>NCT04701996
    </TrialID>
    <Last_Refreshed_on>23 May 2022
    </Last_Refreshed_on>
    <Public_title>Transmission Dynamics of COVID-19 in a Rural Setting of the Democratic Republic of the Congo
    </Public_title>
    <Scientific_title>Transmission Dynamics of COVID-19 in a Rural Setting of the Democratic Republic of the Congo
    </Scientific_title>
    <Acronym>DynaCovid
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210106
    </Date_registration3>
    <Date_registration>06/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04701996
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Month
    </Inclusion_agemin>
    <Inclusion_agemax>99 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 23, 2020
    </Date_enrollement>
    <Target_size>1600
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Raquel Inocencio da Luz, PhD;Raquel Inocencio da Luz, PhD;Delphin Phanzu, PhD
    </Contact_Lastname>
    <Contact_Email>;rinocencio@itg.be;dmavingaphanzu@yahoo.fr
    </Contact_Email>
    <Contact_Tel>;+3232476519;+243 81 948 14 10
    </Contact_Tel>
    <Contact_Affiliation>Insitute of Tropical Medicine;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        In order to be eligible for the sero-survey, study participants must meet the following&#x0D;&lt;br&gt;        criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident of the Kimpese HDSS demographic surveillance area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults 18-50 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  When SARS-CoV-2 transmission is confirmed, all ages will be eligible to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing and able to provide written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        In order to be eligible for the social-mixing survey, study participants must meet the&#x0D;&lt;br&gt;        following criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident of the Kimpese HDSS demographic surveillance area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing and able to provide written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refusal to participation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Covid19
    </Condition>
    <Intervention>Biological: serological surveillance
    </Intervention>
    <Primary_outcome>To predict and monitor the transmission of SARS-CoV-2 in a rural Sub Saharan setting.;To inform intervention strategies targeted at limiting the spread of COVID-19 in a rural Sub Saharan setting.
    </Primary_outcome>
    <Secondary_outcome>To create social contact matrices that can be used to parameterise dynamic transmission models.
    </Secondary_outcome>
    <Secondary_ID>B3002020000141
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Centre de Recherche en Santé de Kimpese;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11050537
    </Internal_Number>
    <TrialID>NCT04699058
    </TrialID>
    <Last_Refreshed_on>21 June 2021
    </Last_Refreshed_on>
    <Public_title>COVID-19 Sero-prevalence Health Care Workers Kinshasa
    </Public_title>
    <Scientific_title>Sero-prevalence and Sero-conversion Study of Health Care Workers and Their Households, Democratic Republic of the Congo
    </Scientific_title>
    <Acronym>PRESTACOV
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201204
    </Date_registration3>
    <Date_registration>04/12/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04699058
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 17, 2020
    </Date_enrollement>
    <Target_size>1650
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Veerle Vanlerberghe, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>ITG
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For Both groups:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to provide written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Being sick or having had COVID-19 is not an exclusion criterion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Health care workers&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Health care worker (all categories from specialist doctors to allied and auxiliary&#x0D;&lt;br&gt;             health workers) of the selected health services&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  foreseen to be employed (or place of internship) for the next three months in he&#x0D;&lt;br&gt;             selected health facility&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Household members&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing not to change the residence during the study period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household member of included Health care workers&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria: not giving consent&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>SARS-CoV Infection;Seroprevalence
    </Condition>
    <Intervention>Diagnostic Test: COVID-antibody test
    </Intervention>
    <Primary_outcome>COVID antibody prevalence in Health care workers (serological test);COVID antibody prevalence in Household members (serological test);Seroconversion COVID Health care workers (serological test);Seroconversion COVID household members (serological test)
    </Primary_outcome>
    <Secondary_outcome>work-related exposure evaluated through a questionnaire and summarized as a score;behavioural risk factors (questionnaire), summarized as a score
    </Secondary_outcome>
    <Secondary_ID>B3002020000144
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10420986
    </Internal_Number>
    <TrialID>ISRCTN95140761
    </TrialID>
    <Last_Refreshed_on>5 January 2021
    </Last_Refreshed_on>
    <Public_title>An international study to investigate rates of death and illness following surgery of the pancreas
    </Public_title>
    <Scientific_title>International Pancreatic Surgery Outcomes Study - PancreasGroup.org                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Royal Free London NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201203
    </Date_registration3>
    <Date_registration>03/12/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN95140761
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2021
    </Date_enrollement>
    <Target_size>3500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational cohort study (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United States Minor Outlying Islands;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Adults 18 years of age or older&lt;br&gt;                2. All indications (including benign and malignant)&lt;br&gt;                3. Open, laparoscopic or robotic&lt;br&gt;                4. Elective or emergency&lt;br&gt;                5. Partial or total pancreatectomies&lt;br&gt;                6. Pancreatic tumour enucleations&lt;br&gt;                7. Procedures with concomitant vascular or other organ resections&lt;br&gt;                8. Pancreatic duct drainage procedures (e.g. Frey, Puestow, or Beger)&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Pancreas or islet cell transplantation&lt;br&gt;                2. Transcutaneous or transgastric imaging-guided ablation (e.g. RFA) or electroporation (e.g. NanoKnife)&lt;br&gt;                3. Endoscopic (e.g. ERCP, stent or lithotripsy) procedures&lt;br&gt;                4. Endoscopic transgastric and surgical necrosectomies&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Patients with pancreatic disease requiring surgery &lt;br&gt;Surgery
    </Condition>
    <Intervention>Participants, agreeing to be part of this study, will be observed from the date of surgery until hospital discharge as well as 90 days after their operation. Fully anonymised data will be collected including the participant, their disease, operation characteristics as well as outcomes, such as events including death and illness.
    </Intervention>
    <Primary_outcome>Mortality rate 90 days postoperatively measured using patient records
    </Primary_outcome>
    <Secondary_outcome>Morbidity as defined by the Clavien-Dindo Classification and measured by the Comprehensive Complications Index ® (CCI®) at 90 days postoperatively measured using patient records
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;RFH287_20-21
    </Secondary_ID>
    <Source_Support>Royal Free Charity - Fiorina Fund
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>No ethics approval required. Registered and approved as an audit by the Royal Free Hospital Quality Governance Department with the ID number RFH287_20-21
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/03/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12551402
    </Internal_Number>
    <TrialID>NCT04675931
    </TrialID>
    <Last_Refreshed_on>3 October 2022
    </Last_Refreshed_on>
    <Public_title>To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
    </Public_title>
    <Scientific_title>An Adaptive, Randomized, Active-controlled, Open-label, Sequential Cohort, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Intravenous Cipargamin (KAE609) in Adult and Pediatric Participants With Severe Plasmodium Falciparum Malaria (KARISMA - KAE609's Role In Severe Malaria)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Novartis Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201201
    </Date_registration3>
    <Date_registration>01/12/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04675931
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 7, 2022
    </Date_enrollement>
    <Target_size>252
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo;Côte D'Ivoire;India;Nigeria;Rwanda;Congo;Côte D'Ivoire;India;Nigeria;Rwanda;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Novartis Pharmaceuticals;Novartis Pharmaceuticals
    </Contact_Lastname>
    <Contact_Email>;novartis.email@novartis.com
    </Contact_Email>
    <Contact_Tel>;+41613241111
    </Contact_Tel>
    <Contact_Affiliation>Novartis Pharmaceuticals;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cohort 1: Participants aged = 12 years with moderately severe malaria as defined in&#x0D;&lt;br&gt;             (prostration and/or repeated vomiting) without presence of other signs of severe&#x0D;&lt;br&gt;             malaria (and with high P. falciparum parasitemia (60,000-250,000 parasites per µl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Subsequent Cohorts 2 to 5: Participants diagnosed with severe malaria as defined&#x0D;&lt;br&gt;                  in modified version of WHO criteria and P. falciparum parasite count of = 5000&#x0D;&lt;br&gt;                  per µl&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Cohort 2: Participants aged = 12 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Cohort 3: Participants aged 6 - &lt; 12 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Cohort 4: Participants aged 2 - &lt; 6 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Cohort 5: Participants aged = 6 months - &lt; 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria applying to all Cohorts 1 to 5:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mixed Plasmodium infections&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment with quinine or artemisinin derivative or any other antimalarial drug or any&#x0D;&lt;br&gt;             antibiotic with known antimalarial activity within 12 hours of screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs/symptoms of severe malnutrition in general accordance with WHO guidelines:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Under 18 years: &lt;-3 Z-scores of WHO growth standard for weight-for-height/length&#x0D;&lt;br&gt;                  (in children &lt; 5 years) or BMI for age (5-18 years), or very low mid-upper arm&#x0D;&lt;br&gt;                  circumference (MUAC &lt; 115 mm in children &lt; 12 years, &lt; 160mm 12-18 years), or&#x0D;&lt;br&gt;                  bilateral pitting edema&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Over 18 years: BMI &lt; 16 kg/m2 or MUAC &lt; 160mm or bilateral pitting edema&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known underlying illness, surgical or medical condition, which is not related to&#x0D;&lt;br&gt;             ongoing event of severe malaria and which might jeopardize the participant's health in&#x0D;&lt;br&gt;             case of participation in the study or which might alter the distribution, metabolism&#x0D;&lt;br&gt;             or excretion of study treatment. For example:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. neurological or neurodegenerative disorders,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. cardiac, renal, or hepatic disease, diabetes,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. epilepsy, cerebral palsy,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. known or suspected to be HIV-1 positive and/or receiving antiretroviral treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. malignancy of any organ system (other than localized basal cell carcinoma of the&#x0D;&lt;br&gt;                  skin or in situ cervical cancer), treated or untreated, within the past 5 years,&#x0D;&lt;br&gt;                  regardless of whether there is evidence of local recurrence or metastases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. known or suspected cases of active infections or concurrent febrile illness such&#x0D;&lt;br&gt;                  as TB, Typhoid, COVID-19 etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Additional exclusion criteria are as follows:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria for Cohort 1:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ALT &gt; 5 x the upper limit of normal range (ULN), regardless the level of total&#x0D;&lt;br&gt;             bilirubin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Total bilirubin is &gt; 3 mg/dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight of &lt; 35 kg or &gt;75 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria for Cohort 2:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight of &lt; 35 kg or &gt;75 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants diagnosed as moderately severe malaria due to repeated vomiting without&#x0D;&lt;br&gt;             presence of any of the symptoms of severe malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria for Cohorts 3 to 5:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight of &lt; 5 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants diagnosed as moderately severe malaria due to repeated vomiting without&#x0D;&lt;br&gt;             presence of any of the symptoms of severe malaria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Severe Malaria
    </Condition>
    <Intervention>Drug: KAE609;Drug: IV Artesunate;Drug: Coartem
    </Intervention>
    <Primary_outcome>Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum) at 12 hours
    </Primary_outcome>
    <Secondary_outcome>Percentage of participants achieving clinical success over time;Percentage of participants with individual signs of severe malaria over time;Percentage of participants developing hemolysis (early and delayed) after treatment;Percentage of participants with neurological sequelae at Day 29;Percentage of participants achieving at least 90% reduction in Plasmodium falciparum (P. falciparum);Time to parasite clearance (PCT);Time to fever clearance (FCT);Percentage of participants achieving P. falciparum parasite reduction ratios (PRR) at 12, 24 and 48 hours;Percentage of participants with recrudescence and reinfection;Time to recover from prostration;Time to switch to oral therapy;Time to discharge from hospital;Number of Participants impacted on safety and tolerability assessments;Observed maximum plasma concentration (Cmax) of IV Cipargamin;Time of maximum observed drug concentration occurrence (Tmax) of IV Cipargamin;Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of IV Cipargamin;Area under the concentration time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of IV Cipargamin;Area Under the plasma concentration-time Curve from the time 0 to the last observed quantifiable concentration (AUC(0-t)) of IV Cipargamin;AUC(0-t) divided by the dose administered (AUC(0- t)/D) of IV Cipargamin;Terminal elimination half life (T^1/2) of IV Cipargamin;Total systemic clearance for intravenous administration (CL) of IV Cipargamin;volume of distribution during the terminal phase following intravenous elimination (Vz) of IV Cipargamin
    </Secondary_outcome>
    <Secondary_ID>217692/Z/19/Z;CKAE609B12201
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Wellcome Trust;European and Developing Countries Clinical Trials Partnership (EDCTP)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12602104
    </Internal_Number>
    <TrialID>PACTR202011812241529
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>EFFICACY AND SAFETY OF PYRONARIDINE-ARTESUNATE (PYRAMAX) FOR THE TREATMENT OF FALCIPARUM MALARIA IN AFRICAN PREGNANT WOMEN
    </Public_title>
    <Scientific_title>EFFICACY AND SAFETY OF PYRONARIDINE-ARTESUNATE (PYRAMAX) FOR THE TREATMENT OF FALCIPARUM MALARIA IN AFRICAN PREGNANT WOMEN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>University of Sciences Techniques and Technologies of Bamako
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201124
    </Date_registration3>
    <Date_registration>24/11/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=14517
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>18 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>01/07/2020
    </Date_enrollement>
    <Target_size>1875
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Simple randomization using a randomization table created by a computer software program,Sealed opaque envelopes
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Burkina Faso;Democratic Republic of the Congo;Mali;Mozambique;Gambia
    </Countries>
    <Contact_Firstname>Boubacar
    </Contact_Firstname>
    <Contact_Lastname>Traore
    </Contact_Lastname>
    <Contact_Address>Point G
    </Contact_Address>
    <Contact_Email>bouba.traore@icermali.org
    </Contact_Email>
    <Contact_Tel>+22320228109
    </Contact_Tel>
    <Contact_Affiliation>Dean of the Faculty of Pharmacy
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	Gestation =16 weeks and &lt;37 weeks as assessed by ultrasound when possible, uterine height or late menstrual period; &#x0D;&lt;br&gt;2.	P. falciparum mono-infection (by microscopy) of any density, regardless of symptoms and HIV status; &#x0D;&lt;br&gt;3.	Haemoglobin =7g/dL; &#x0D;&lt;br&gt;4.	Age: =15 years; &#x0D;&lt;br&gt;5.	Residence within the health facility catchment area; &#x0D;&lt;br&gt;6.	Willing to adhere to study requirements and to deliver at the health facility.&#x0D;&lt;br&gt;7.     Ability to provide written informed consent; if the woman is minor of age/not emancipated, the consent must be given by a parent or legal guardian according to national law (however, in this case, the investigator is responsible to check that the woman herself is also freely willing to take part in the study).&#x0D;&lt;br&gt;8.	For the PK study women should be on first line anti-retroviral treatment (efavirenz-based both in DRC and Mozambique) for at least 6 months. &#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.	Known allergy to the study drugs; &#x0D;&lt;br&gt;2.	History of known pregnancy complications or poor obstetric history such as repeated stillbirths or eclampsia; &#x0D;&lt;br&gt;3.	History or presence of major illnesses likely to influence pregnancy outcome; &#x0D;&lt;br&gt;4.	Any significant illness at the time of screening requiring hospitalization, including &#x0D;&lt;br&gt;a.	Severe malaria; &#x0D;&lt;br&gt;b.	Any sign or symptom suggesting hepatic lesions (e.g. nausea with abdominal pain and icterus) or severe liver disease classified as B or C by the Child-Pugh score; &#x0D;&lt;br&gt;c.	Known history or evidence of clinically significant cardiovascular disorders or family history of long QT syndrome.&#x0D;&lt;br&gt;5.	Intent to move out of the study catchment area before delivery or delivery out of the catchment area; &#x0D;&lt;br&gt;6.	Prior enrolment in the study; &#x0D;&lt;br&gt;7.	Clear evidence of recent (1 week) treatment with antimicrobials with antimalarial activity (azithromycin, clindamycin, tetracycline, quinolones, cotrimoxazole and SP); For HIV-infected pregnant women to be included in the PK sub-study, cotrimoxazole use is not an exclusion criterion. &#x0D;&lt;br&gt;8.	Twin/multiple pregnancy; &#x0D;&lt;br&gt;9.	Known history of G6PD deficiency or sickle cell disease.&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;Pyronaridine Artesunate;Artemether Lumefantrine;Dihydroartemesinin Pyperaquine
    </Intervention>
    <Primary_outcome>PCR-adjusted ACPR at Day 42;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>- Safety profile, including cardiac and hepatic toxicity, and significant changes in relevant laboratory values. &#x0D;&lt;br&gt;- PCR-adjusted ACPR at Day 28 and 63;&#x0D;&lt;br&gt;- PCR-unadjusted ACPR at Day 28, 42 and 63;&#x0D;&lt;br&gt;- Parasite and fever clearance time;&#x0D;&lt;br&gt;- Gametocyte carriage and clearance;&#x0D;&lt;br&gt;- Haematological recovery, namely Hb changes between Day 0 and Days 7, 14, 28, 42, 63 and at delivery;&#x0D;&lt;br&gt;- Prevalence of placenta malaria at delivery (recent, past and chronic infection);&#x0D;&lt;br&gt;- Mean birth weight BW and prevalence of low birth weight (&lt;2,500g) new-borns. 
    </Secondary_outcome>
    <Source_Support>EDCTP
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>31/03/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>keitamamadoumarouf@yahoo.fr
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Faculty of Medicine and Faculty of Pharmacy
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+22320228109
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>keitamamadoumarouf@yahoo.fr
    </Ethics_review_contact_email>
    <results_url_link>https://www.pyrapreg.org/
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12490877
    </Internal_Number>
    <TrialID>ISRCTN46539495
    </TrialID>
    <Last_Refreshed_on>22 August 2022
    </Last_Refreshed_on>
    <Public_title>Prevention of pre-eclampsia through vitamin D supplementation: a single-blinded randomized clinical trial without placebo
    </Public_title>
    <Scientific_title>Pre-eclampsia in Kivu: vitamin D levels and impacts of vitamin D supplementation on obstetric-neonatal outcomes in primigravida                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>University of Lubumbashi
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201117
    </Date_registration3>
    <Date_registration>17/11/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN46539495
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>01/03/2020
    </Date_enrollement>
    <Target_size>672
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single-blinded randomized clinical trial without placebo (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Primipara, monoembryonic pregnancy (=15 weeks of amenorrhoea for pregnant women to be supplemented)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. IMC &lt;17 and = 30 but before pregnancy&lt;br&gt;                2. Pregnant women suffering from calcium urinary lithiasis, renal failure, poorly controlled hypertension, unbalanced diabetes (fasting blood sugar &gt;7 mmol/l or blood sugar &gt;11 mmol/l), hypercalcemia (&gt;2.65 mmol/l) and other phosphocalcic pathologies, bone diseases, lithium intake, digestive malabsorption&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Pre-eclampsia &lt;br&gt;Pregnancy and Childbirth &lt;br&gt;Pre-eclampsia
    </Condition>
    <Intervention>&lt;br&gt;                Patients will be divided into two groups based on gestational age (randomized into two groups).&lt;br&gt;&lt;br&gt;                Supplemented group: 60,000 IU of VITOSSAMIN® D3 (cholecalciferol) orally in one dose per month from the 3rd (=15 weeks of amenorrhoea) to the 8th month of pregnancy, i.e. 360,000 IU in total.&lt;br&gt;                Control group: does not receive a placebo but will be followed in the ANC and will receive an iron supplement and anti-parasitic treatment. These are primigravidae recruited with a pregnancy age exceeding 15 weeks during the recruitment period and not having completed the second trimester.&lt;br&gt;&lt;br&gt;                Blood will be collected at the recruitment stage and at the end of the trial to measure vitamin D and calcium. Laboratory monitoring will be performed twice at the 7th month and at the delivery.&lt;br&gt;&lt;br&gt;                Selection and recruitment visit: During the 3rd month visit between 11 and 14 weeks supplemented pregnant women will be identified and their informed consent (written) obtained. Non-supplemented pregnant women are also selected during the ANC.&lt;br&gt;&lt;br&gt;                Visits: The patients will be followed every month during the normal pregnancy follow-up (PNC)&lt;br&gt;                End of study visit: after the 34th week of pregnancy a blood sample will be collected for maternal and neonatal indicators.&lt;br&gt;
    </Intervention>
    <Primary_outcome>Percentage of patients with preeclampsia during pregnancy, evidenced by the occurrence of hypertension (systolic blood pressure [SBP] greater than or equal to 140 mmHg and/or diastolic blood pressure [DBP] greater than or equal to 90 mmHg, taken twice 4-6 hours apart, at rest) and 2 x proteinuria after 20 weeks of amenorrhoea
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                For the patients:&lt;br&gt;                1. Gestational age for any incident and for preeclampsia, measured during antenatal care or other consultations by taking blood pressure, albuminuria measurement to confirm preeclampsia from recruitment (enrollment) to postpartum&lt;br&gt;                2. Other clinical signs: given the atypical forms of preeclampsia, some clinical signs according to ACOG may allow the diagnosis of preeclampsia in the absence of proteinuria. The occurrence of these signs is monitored from the time of enrolment until delivery by means of an anamnesis, clinical and laboratory examination, and the pregnant woman is monitoring the antenatal care, of which she is aware&lt;br&gt;                3. Incidents (eclampsia, detachment of the normally inserted placenta, maternal death) measured according to clinical, paraclinical (ultrasound and biology) examination from enrolment to postpartum (or death)&lt;br&gt;                4. Serum concentration of 25OH-D, measured using iChroma II analyser (Boditech Med Inc, South Korea), at enrollment when the pregnant woman is carrying a pregnancy of age =14 weeks of amenorrhoea for the gestates to be supplemented and between 34 weeks of amenorrhoea and delivery (thus two samples for each subject), and for the other group after 14 weeks of amenorrhoea and between 34 weeks of amenorrhea and delivery&lt;br&gt;&lt;br&gt;                In newborns:&lt;br&gt;                1. Birth weight measured using scale at birth&lt;br&gt;                2. Height measured using scale at birth&lt;br&gt;                3. Cranial perimeter measured by tape measure by taking the circumference of the head through the glabella just after delivery&lt;br&gt;                4. Intrauterine growth retardation noted at birth but detected by ultrasound as the pregnant woman is following ANC. Confirmation is done at birth with the use of tables&lt;br&gt;                5. Death in utero observed after inclusion in the cohort (as it can occur at any time) and diagnosed by ultrasound before birth&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Investigator initiated and funded
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 08/02/2019, Ethics Committee of the University of Lubumbashi (B.P: 1825 Lubumbashi, Democratic Republic of Congo; +243 (0)995258703, +243 (0)997022438; clubabankulu2017@gmail.com, gabybora2003@yahoo.fr, Eth_med@yahoo.fr), ref: UNILU/CEM/125/2019
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/08/2021
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12630614
    </Internal_Number>
    <TrialID>NCT04634019
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>Financially-Incentives to Improve Provider Compliance
    </Public_title>
    <Scientific_title>Financially-Incentivized Knowledge Assessments to Improve Provider Compliance With Treatment Guidelines: A Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Swiss Tropical &amp; Public Health Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201106
    </Date_registration3>
    <Date_registration>06/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04634019
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2018
    </Date_enrollement>
    <Target_size>600
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Switzerland;Congo, The Democratic Republic of the;Switzerland
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Gil Shapira, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>World Bank
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  all providers working at the 110 facilities selected for the study will be included in&#x0D;&lt;br&gt;             the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  none.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Compliant Behavior;Morbidity;Infant
    </Condition>
    <Intervention>Behavioral: Financially incentivized knowledge assessments
    </Intervention>
    <Primary_outcome>Compliance with integrated management of childhood illness (IMCI) guidelines
    </Primary_outcome>
    <Secondary_outcome>Knowledge regarding IMCI guidelines
    </Secondary_outcome>
    <Secondary_ID>IncentLearn
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>World Bank
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12635176
    </Internal_Number>
    <TrialID>ISRCTN13539303
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>An international registry of coronavirus exposure in pregnancy
    </Public_title>
    <Scientific_title>International Registry of Coronavirus Exposure in Pregnancy (IRCEP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Pregistry LLC
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201030
    </Date_registration3>
    <Date_registration>30/10/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN13539303
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>08/06/2020
    </Date_enrollement>
    <Target_size>25000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Prospective observational study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan
    </Countries>
    <Contact_Firstname>Diego;Sonia
    </Contact_Firstname>
    <Contact_Lastname>Wyszynski;Hernandez-Diaz
    </Contact_Lastname>
    <Contact_Address>
                    1801 Century Park East
                    25th Floor
                ;677 Huntington Avenue
    </Contact_Address>
    <Contact_Email>hello@pregistry.com;shernan@hsph.harvard.edu
    </Contact_Email>
    <Contact_Tel>+1 (747) 200-5468;+1 (617) 432-3942
    </Contact_Tel>
    <Contact_Affiliation>;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Adult pregnant women with clinical confirmation of COVID-19 or tested for SARS-CoV-2 at any time during their pregnancy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Subjects who do not meet the inclusion criteria
    </Exclusion_Criteria>
    <Condition>COVID-19 (SARS-CoV-2 infection) during pregnancy &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)
    </Condition>
    <Intervention>&lt;br&gt;                The IRCEP will be an observational cohort study with prospective and retrospective components. Registration and participation via website or mobile app specially developed for the IRCEP will be voluntary. Women 18 years of age and older will be encouraged to enrol if at any time during pregnancy, they had a test performed for the coronavirus (regardless of the result) or if they had clinical confirmation of COVID-19 in the absence of a SARS-CoV-2 test. Women with confirmed COVID-19 via clinical or test methods will be included in the exposed group and women with a negative test will be included in the control group. Eligible women will be able to enrol at any time during gestation. Given the public health emergency due to the COVID-19 pandemic and the urgent need for data, the IRCEP will also enrol eligible women retrospectively during the first 180 days after delivery (if they delivered after December 2019).&lt;br&gt;&lt;br&gt;                As numbers accumulate, the natural history of COVID-19 during pregnancy will be reported stratified by days since COVID-19 confirmation at enrollment (i.e., from prospective if immediate to retrospective if enrolled after resolution) and the risk of pregnancy outcomes by COVID-19 exposure group will be reported stratified by trimester at enrollment. For the assessment of miscarriages, only participants enrolled during the first trimester will be included and the analyses will be stratified by gestational week at enrollment. For other outcomes, the primary analysis will include all enrollees. However, sensitivity analyses of 1) teratogenicity will be restricted to participants enrolled before an informative prenatal screening was done; 2) late-pregnancy outcomes (e.g. preeclampsia) will be restricted to participants enrolled before 
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Measured by maternal self-report using online questionnaire at baseline:&lt;br&gt;                1. Pregnancy outcomes:&lt;br&gt;                1.1. Miscarriage (or spontaneous abortion)&lt;br&gt;                1.2. Elective termination&lt;br&gt;                1.3. Stillbirth&lt;br&gt;                1.4. Preterm delivery&lt;br&gt;                2. Birth outcomes (measured at additional time points up to 90 days):&lt;br&gt;                2.1. Major structural defects&lt;br&gt;                2.2. Neonatal death&lt;br&gt;                2.3. Admission into the Neonatal Intensive Care Unit&lt;br&gt;                2.4. Maternal obstetric complications&lt;br&gt;                2.5. Post-partum health&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Measured by maternal self-report using online questionnaire:&lt;br&gt;                1. Head circumference (cm) at each time point from baseline to 90 days.&lt;br&gt;                2. Length at birth (cm)&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NCT04366986;Nil known
    </Secondary_ID>
    <Source_Support>Pregistry LLC
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 08/06/2020, Institutional Review Board (IRB) of the Harvard T.H. Chan School of Public Health (90 Smith Street, 3rd Floor Boston, MA 02120, USA; +1 (617) 432-5132; kninsala@hsph.harvard.edu), ref: # IRB20-0622
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/04/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11944399
    </Internal_Number>
    <TrialID>NCT04618523
    </TrialID>
    <Last_Refreshed_on>21 February 2022
    </Last_Refreshed_on>
    <Public_title>Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo
    </Public_title>
    <Scientific_title>Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of the Congo: a Randomized Controlled Trial
    </Scientific_title>
    <Acronym>TET2020
    </Acronym>
    <Primary_sponsor>Ministry of Public Health, Democratic Republic of the Congo
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201022
    </Date_registration3>
    <Date_registration>22/10/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04618523
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 26, 2020
    </Date_enrollement>
    <Target_size>1117
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Gauthier Mesia Kahunu, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Université de Kinshasa
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  children aged 6 to 59 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  monoinfection with Plasmodium falciparum with asexual parasite count of 2,000 to&#x0D;&lt;br&gt;             200,000/µL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  axillary temperature = 37.5 °C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to swallow oral medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability and willingness to comply with the protocol for the duration of the study and&#x0D;&lt;br&gt;             to comply with the study visit schedule;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  informed consent from a parent or aguardian&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  living within the study catchment area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of general danger signs in children aged under 5 years or signs of severe&#x0D;&lt;br&gt;             falciparum malaria according to the definitions of WHO;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  body weight &lt; 5kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hemoglobin level &lt; 5g/ dL or hematocrit &lt; 15%&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of severe malnutrition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of febrile conditions due to diseases other than malaria (e.g. measles, acute&#x0D;&lt;br&gt;             lower respiratory tract infection, severe diarrhoea with dehydration) or other known&#x0D;&lt;br&gt;             underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases,&#x0D;&lt;br&gt;             HIV/AIDS);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  regular medication, which may interfere with antimalarial pharmacokinetics;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  malaria treatment within 2 days prior to recruitment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of hypersensitivity reactions or contraindications to any of the medicines&#x0D;&lt;br&gt;             being tested or used as alternative treatment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: Artesunate-amodiaquine;Drug: Artemether-lumefantrine
    </Intervention>
    <Primary_outcome>PCR adjusted efficacy
    </Primary_outcome>
    <Secondary_outcome>Proportion of adverse events and serious adverse events;Proportion of participants with positive blood smear at day 3
    </Secondary_outcome>
    <Secondary_ID>ASAQ-LA 2019 DRC
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Kinshasa;World Health Organization;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12530559
    </Internal_Number>
    <TrialID>ISRCTN85785540
    </TrialID>
    <Last_Refreshed_on>12 September 2022
    </Last_Refreshed_on>
    <Public_title>Evaluating an app to help people quit smoking
    </Public_title>
    <Scientific_title>Effectiveness of an offer of the Smoke Free smartphone application for smoking cessation compared with no support: the App for Smoking ceSsation Evaluation Trial (ASSET)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201015
    </Date_registration3>
    <Date_registration>15/10/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN85785540
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>20/08/2020
    </Date_enrollement>
    <Target_size>3116
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Aged at least 18 years&lt;br&gt;                2. Able to provide consent&lt;br&gt;                3. English speaker&lt;br&gt;                4. Owns a smartphone&lt;br&gt;                5. Current cigarette smoker&lt;br&gt;                6. Willing to be followed-up by e-mail and complete online questionnaires after 1, 4 and 30 weeks&lt;br&gt;                7. Interested in making a quit attempt within the next month&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Used the Smoke Free app in the past 6 months
    </Exclusion_Criteria>
    <Condition>Smoking cessation &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>&lt;br&gt;                This will be a two-arm individually randomized controlled effectiveness trial. Participants will be adult smokers who are intending to quit in the next 4 weeks, willing to participate in a 30-week study of their smoking and able to provide consent.&lt;br&gt;&lt;br&gt;                Those who are eligible and consent to participate in the trial will be randomized at that point to intervention or comparator conditions. Randomization will be 1:1 at the individual level with no restriction (i.e. no blocking) and will be automated using a random number function.&lt;br&gt;&lt;br&gt;                After consenting, participants in the comparator condition will receive a message encouraging them to make a quit attempt within the next 4 weeks and reminding them of the importance of responding to follow-up requests which are designed to track their progress.&lt;br&gt;&lt;br&gt;                Participants in the intervention condition will receive the same advice as those in the comparator condition plus offer of the full version of the Smoke Free app free of charge, encouragement to use the app and a link to download it. The Smoke Free app is based on behaviour change techniques that would be expected from theory and evidence with face-to-face support to aid smoking cessation. It guides smokers through the first month of their quit attempt by helping them to maintain their resolve by setting a clear goal, monitoring their progress towards that goal and becoming aware of benefits of being smoke-free achieved to date. The app has several components:&lt;br&gt;                1. A calculator which tracks the total amount of money not spent on buying cigarettes and the number of cigarettes not smoked (‘Dashboard')&lt;br&gt;                2. A calendar which tracks the amount of time elapsed since cessation (‘Dashboard')&lt;br&gt;            
    </Intervention>
    <Primary_outcome>Self-reported smoking cessation for at least 26 weeks, assessed 30 weeks after enrolment
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Assessed using self report:&lt;br&gt;                1. Having made at least one quit attempt in the 4 weeks following enrolment in the study&lt;br&gt;                2. Smoking cessation for at least 12 weeks, assessed 4 weeks after enrolment&lt;br&gt;                3. Downloading or using the Smoke Free app at least once, assessed 30 weeks after enrolment&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CEHP/2016/556
    </Secondary_ID>
    <Source_Support>Cancer Research UK
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 06/09/2019, UCL Research Ethics Committee (University College London, 2 Taviton St, London WC1E 6BT, UK. +44 (0)207 6798717; ethics@ucl.ac.uk), ref: CEHP/2016/556
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/12/2021
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12602044
    </Internal_Number>
    <TrialID>PACTR202010781639956
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>The impact of COVID-19 treatment on the type, strength and duration of antibody and cellular immune responses in SARS-CoV-2 patients in sub-Saharan Africa&#x0D;
Ancillary Study of the ANTICOV Study:&#x0D;
An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19
    </Public_title>
    <Scientific_title>The impact of COVID-19 treatment on the type, strength and duration of antibody and cellular immune responses in SARS-CoV-2 patients in sub-Saharan Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>DNDi
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201007
    </Date_registration3>
    <Date_registration>07/10/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13420
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/09/2020
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Dynamic (adaptive) random allocation such as minimization,Central randomisation by phone/fax
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Democratic Republic of the Congo;Equatorial Guinea;Ghana;Kenya;Ethiopia;Mozambique;Sudan
    </Countries>
    <Contact_Firstname>James
    </Contact_Firstname>
    <Contact_Lastname>Arkinstall
    </Contact_Lastname>
    <Contact_Address>15 chemin Louis Dunant
    </Contact_Address>
    <Contact_Email>media@dndi.org
    </Contact_Email>
    <Contact_Tel>+41229069230
    </Contact_Tel>
    <Contact_Affiliation>Head of Communications and Advocacy
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: From the Master study :&#x0D;&lt;br&gt;1.	Male or female patients,&#x0D;&lt;br&gt;2.	Adults over or equal to 18 years of age at the time of screening. Children &gt; 12 years of age may be included if recommended by the DSMB after the first analysis.&#x0D;&lt;br&gt;3.	COVID-19 confirmed by molecular biology for SARS-Cov2 according to national guidelines, based on result within 24 hours prior to screening.&#x0D;&lt;br&gt;4.	Viral syndrome with or without uncomplicated pneumonia, defined as blood oxygen saturation level (SpO2) over or equal to 94%.&#x0D;&lt;br&gt;5.	Corrected QT interval (QTc – Bazett and Fridericia) &lt; 480 msec on ECG.&#x0D;&lt;br&gt;6.	Signed written consent from the patient or his/her representative.&#x0D;&lt;br&gt;7.	Accepting and having the ability to be reached by telephone throughout the study.&#x0D;&lt;br&gt;8.	Having designated a contact person who can be contacted in case of emergency.&#x0D;&lt;br&gt;For the Immuno Ancillary study&#x0D;&lt;br&gt;1.	Able and willing to provide consent for the immunological ancillary study&#x0D;&lt;br&gt;2.	Able and willing to perform all study visits for a duration of 12 months after treatment start&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: From the Master Study&#x0D;&lt;br&gt;1.	Abnormal physical examination findings:&#x0D;&lt;br&gt;•	respiratory rate over or equal to 25 per minute;&#x0D;&lt;br&gt;•	blood pressure &lt; 90/60 mmHg or &gt; 160/100 mmHg;&#x0D;&lt;br&gt;•	body weight &lt; 45 kg for patients over or equal to 18 years of age and age-adapted for children &gt; 12 years of age if inclusion is recommended by the DSMB after the first analysis;&#x0D;&lt;br&gt;•	recurrent diarrhoea or vomiting episodes (&gt; 3 in the last 24 hours) or hypokalaemia (&lt; 3.5 mmol/L).&#x0D;&lt;br&gt;2.	Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.&#x0D;&lt;br&gt;3.	Feeling unwell for more than 7 days prior to screening.&#x0D;&lt;br&gt;4.	Severe cardiopathy or history of arrhythmia, renal or liver insufficiency.&#x0D;&lt;br&gt;5.	History of congenital or acquired long QT-interval, family history of long QT arrythmia, cardiac disease such as heart failure, myocardial infarction, family history of sudden cardiac death, sudden cardiac death, bradycardia &lt; 50 bpm. &#x0D;&lt;br&gt;6.	Past history of retinopathy, such as spots or dark strings floating in the field of vision (floaters), blurred or fluctuating vision, impaired colour vision, dark or empty areas in vision.&#x0D;&lt;br&gt;7.	History of severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.&#x0D;&lt;br&gt;8.	End-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy &lt; 3 months.&#x0D;&lt;br&gt;9.	Pregnancy based on urine pregnancy test at screening or breast-feeding, unless recommended by the Data and Safety Monitoring Board after the first interim analysis.&#x0D;&lt;br&gt;10.	Prior treatment with. lopinavir/ritonavir within 29 days prior to screening except if patients are receiving the same regimen as planned in this study. Patients randomised to lopinavir/ritonavir will stop their current treatment and switch to the IP lopinavir/ ritonavir. If randomised to other arms, patients will continue their current treatment with lopinavir/ritonavir.&#x0D;&lt;br&gt;11.	Prior treatment with hydroxychloroquine within 29 days prior to screening or on-going at screening.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Covid-19;Covid-19
    </Condition>
    <Intervention>;Paracetamol;Hydroxychloroquine;Lopinavir Ritonavir
    </Intervention>
    <Primary_outcome>1)	Seroconversion for SARS-CoV-2 IgM, IgA and IgG by treatment arm and patient outcome;2)	Quantitative levels of antibodies (IgM, IgG, IgA) specific for SARS-CoV-2;3)	Frequency of SARS-CoV-2-specific effector/memory CD4+ and CD8+ T cells ;4)	Proportions of (poly)functional SARS-CoV-2-specific T cells 
    </Primary_outcome>
    <Secondary_outcome>1)	Epitope specificity of IgM, IgA and IgG isotypes targeting SARS-CoV-2;2)	Avidity index and neutralization activity (% neutralization or IC50) in selected participants and time points based on antibody levels and kinetics;3)	Quantitative levels of antibodies (IgM, IgG) against prevalent infections such as malaria and helminths, antibody levels against other respiratory infections, and medical history of TB, HIV and other known comorbidities (e.g. malnutrition).;4)	Quantitative levels and seropositivity of antibodies (e.g. IgM, IgG, IgA) against coronaviruses circulating in participating countries;5)	Positivity for SARS-CoV-2 in saliva (PCR/RDT)
    </Secondary_outcome>
    <Source_Support>DNDi
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>21/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>feli1munday@yahoo.fr
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ministere de la sante publique comite national d ethique et de la sante Republique democratique du Congo CNES
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+243998419816
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>feli1munday@yahoo.fr
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11596381
    </Internal_Number>
    <TrialID>NCT04568499
    </TrialID>
    <Last_Refreshed_on>15 November 2021
    </Last_Refreshed_on>
    <Public_title>Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings
    </Public_title>
    <Scientific_title>Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings: a Prospective Cohort Study in South Sudan and DRC
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins Bloomberg School of Public Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200924
    </Date_registration3>
    <Date_registration>24/09/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04568499
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 27, 2020
    </Date_enrollement>
    <Target_size>592
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the;South Sudan;Congo, The Democratic Republic of the;South Sudan
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Shannon Doocy, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Johns Hopkins Bloomberg School of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Suspected, probable, and confirmed COVID-19 cases presenting for care at participating&#x0D;&lt;br&gt;             health facilities (either by walk-in, referral or transfer) or identified by mobile&#x0D;&lt;br&gt;             contact tracing teams.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals unable or unwilling to give informed consent (e.g., due to mental&#x0D;&lt;br&gt;             impairment)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>COVID-19
    </Condition>
    <Primary_outcome>Hospitalization;Mortality
    </Primary_outcome>
    <Secondary_ID>13736
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>International Medical Corps;Centers for Disease Control and Prevention
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11654627
    </Internal_Number>
    <TrialID>CTRI/2020/09/027709
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Patterns of peritoneal cancer spread from various primary tumors
    </Public_title>
    <Scientific_title>Patterns of Peritoneal Dissemination and Response to Systemic Chemotherapy in Common and Rare Peritoneal Tumors Treated with Cytoreductive Surgery- A Prospective Multi-centric study - PRECINCT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Zydus hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200910
    </Date_registration3>
    <Date_registration>10-09-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46131
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>11-09-2020
    </Date_enrollement>
    <Target_size>1600
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia
    </Countries>
    <Contact_Firstname>Aditi BHATT
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Zydus Hospital Road, Thaltej 
    </Contact_Address>
    <Contact_Email>aditimodi31@gmail.com
    </Contact_Email>
    <Contact_Tel>09686447863
    </Contact_Tel>
    <Contact_Affiliation>Zydus hospital, surgical oncology, room no 5
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	All patients undergoing cytoreductive surgery for peritoneal metastases from colorectal, ovarian, gastric and appendiceal primary tumors and peritoneal mesothelioma will be included.  &lt;br/ &gt;&lt;br&gt;2.	Only patients with biopsy proven PM will be included (pathological evaluation is not mandatory prior to CRS if imaging or exploration confirms the presence of disease).  &lt;br/ &gt;&lt;br&gt;3.	Patient undergoing debulking procedures will be included &lt;br/ &gt;&lt;br&gt;4.	For ovarian cancer, only patients with FIGO stage III-C or IV-A will be included. Patients undergoing surgery at first diagnosis, after NACT and those undergoing surgery for recurrent disease will be included. Patients without peritoneal disease will be excluded.  &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: â?¢	Patients undergoing second look procedures with no evidence of peritoneal metastases will be excluded.  &lt;br/ &gt;&lt;br&gt;â?¢	Patients undergoing palliative procedures that do not involve tumor debulking will be excluded unless the goal of surgery was to obtain a complete cytoreduction i.e. procedures performed with the intention of palliation alone like a diverting oâ??stomy will be excluded.  &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: K669- Disorder of peritoneum, unspecified

    </Condition>
    <Intervention/>
    <Primary_outcome>Disease distribution in the peritoneal cavityTimepoint: At 6 months, after completion of recruitment and at 1 year, 3 years and 5 years from the end of recruitment
    </Primary_outcome>
    <Secondary_outcome>Morphology of peritoneal metastasesTimepoint: At the time of surgery;Overall survivalTimepoint: At 1 year, 3 and 5 years after recruitment;Pathological response to systemic chemotherapyTimepoint: At the time of surgery;Pattern of lymph node involvementTimepoint: At the time of surgery;Progression-free survivalTimepoint: At 1, 3 and 5 years after recruitment
    </Secondary_outcome>
    <Secondary_ID>none
    </Secondary_ID>
    <Source_Support>Zydus hospitaal
    </Source_Support>
    <Ethics_review_status>Not Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;27/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Lyon-sud Ethics Committee;Zydus Hospital Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10376235
    </Internal_Number>
    <TrialID>NCT04537585
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7
    </Public_title>
    <Scientific_title>A Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka® Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRC
    </Scientific_title>
    <Acronym>Tomeka
    </Acronym>
    <Primary_sponsor>Guyguy K Tshima, MD
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200829
    </Date_registration3>
    <Date_registration>29/08/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04537585
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2020
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Guyguy K. Tshima, MD;Guyguy K. Tshima, MD
    </Contact_Lastname>
    <Contact_Email>;guyguytshimakabundi@gmail.com
    </Contact_Email>
    <Contact_Tel>;0015143819264
    </Contact_Tel>
    <Contact_Affiliation>University of Kinshasa;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients eligible for the trial must comply with all of the following at randomization:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age =15 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Current admission under the care of the heart-failure service at the site&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Fulfill Inclusion criteria and accept&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. COVID-19 patients confirmed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. be regular on appointments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. No voluntary patient (see: having signed the informed consent) The criteria for&#x0D;&lt;br&gt;             choosing subjects: subjects who are themselves exposed to the consumption of Vernonia&#x0D;&lt;br&gt;             amygdalina (Kananga, Tshikapa or in Kasaï region). This group can be part of the&#x0D;&lt;br&gt;             cohort. tare: to compare with a no exposure group which is external to the cohort.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Here is the follow-up procedure for the two groups throughout the study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  follow-up modality: visits, letters, work-study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  frequency of contacts: monthly&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  total duration of follow-up: 9 months Patients enrolled in the individual data&#x0D;&lt;br&gt;             investigational study are potential candidates for TOMEKA intervention. As the TOMEKA&#x0D;&lt;br&gt;             protocol does not involve any investigational agents or techniques, patients would be&#x0D;&lt;br&gt;             eligible for dual randomization if they are themselves on stable doses of Vernonia&#x0D;&lt;br&gt;             amygdalina (the investigational herbs drugs may equivalent to Remdesivir).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. COVID-19 suspected clinically&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Children&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Refuse to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Recover when possible the cause of a study exit:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  refusal of follow-up&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  move&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  death If the patient is no longer followed in the study without any cause being&#x0D;&lt;br&gt;                  identified, then he is lost to follow-up.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Covid19
    </Condition>
    <Intervention>Combination Product: Tomeka®;Drug: "Vernonia amygdalina"
    </Intervention>
    <Primary_outcome>Number of participants with treatment-TOMEKA® usage
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in herbs Vernonia amygdalina usage
    </Secondary_outcome>
    <Secondary_ID>TOMEKA
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Centre Médical de Kinshasa (CMK)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12591545
    </Internal_Number>
    <TrialID>CTRI/2020/08/027218
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>COVID-19 prevalence during pregnancy and pregnancy outcomes in low resource settings
    </Public_title>
    <Scientific_title>COVID-19 prevalence during pregnancy and pregnancy outcomes in 8 low and middle-income sites: A Global Network Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200818
    </Date_registration3>
    <Date_registration>18-08-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45967
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-09-2020
    </Date_enrollement>
    <Target_size>16000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Bangladesh;Democratic Republic of the Congo;Guatemala;India;Kenya;Pakistan;Zambia
    </Countries>
    <Contact_Firstname>Dr Shivaprasad S Goudar
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>KLE Academy of Higher Education and Research J N Medical College Nehru Nagar Belgaum Principal Investigator Womens and Childrens Health Research Unit Wing Belgaum 
    </Contact_Address>
    <Contact_Email>sgoudar@jnmc.edu
    </Contact_Email>
    <Contact_Tel>9448126371
    </Contact_Tel>
    <Contact_Affiliation>KLE Academy of Higher Education and Research J N Medical College
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All women in the Maternal Newborn Health Registry will be eligible to be screened for the COVID-19 study at time of enrollment into the MNHR.  This study will follow the same inclusion and exclusion criteria as the MNH Registry (MNHR) to screen &lt;br/ &gt;&#x0D;&lt;br&gt;Pregnant women intending to deliver within study cluster
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Decline to provide consent to include data in the study
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere&#x0D;

    </Condition>
    <Intervention/>
    <Primary_outcome>Prevalence of COVID-19 antibody positive results during pregnancyTimepoint: Up to 42 days postpartum
    </Primary_outcome>
    <Secondary_outcome>Fetal/neonatal outcomes: spontaneous abortion, stillbirth, birth weight and fetal growth restriction, early (7-day) and late (28-day) neonatal death, cause of death, congenital infections, and malformationsTimepoint: Up to 42 days postpartum;Knowledge, attitudes, and practices of pregnant women related to COVID-19 infection during pregnancyTimepoint: Up to 42 days postpartum;Maternal outcomes: rate of infection, timing of infection, types of symptoms, death, cause of deathTimepoint: Up to 42 days postpartum
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Eunice Kennedy Shriver National Institute of Child Health and Human Development&#x0D;
Global Network for Womens and Childrens Health Eunice Kennedy&#x0D;
Shriver National Institute of Child Health and Human Development&#x0D;
(NICHD)USA
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>30/07/2020;08/08/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethics Review Committee, Lata Medical Research Foundation Nagpur;KLE Academy of Higher Education and Research Ã¢â?¬â?? Institutional Ethics Committee on Human Subjects Research Belgaum
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>9662840
    </Internal_Number>
    <TrialID>ISRCTN17717312
    </TrialID>
    <Last_Refreshed_on>17 August 2020
    </Last_Refreshed_on>
    <Public_title>CORONATION: Coronavirus (COVID-19) multinational observational registry
    </Public_title>
    <Scientific_title>Coronavirus (COVID-19) Multinational observational registry (CORONATION)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Cambridge University Hospitals NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200723
    </Date_registration3>
    <Date_registration>23/07/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN17717312
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>30/07/2020
    </Date_enrollement>
    <Target_size>10000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational epidemiological study (Screening)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Kerrie
    </Contact_Firstname>
    <Contact_Lastname>Brusby
    </Contact_Lastname>
    <Contact_Address>
                    Cambridge Clinical Trials Centre (CCTU)
                    Cambridge University Hospitals (CUH) NHS Foundation Trust
                    Addenbrooke’s Hospital
                    Cambridge Biomedical Campus
                    Box 4
    </Contact_Address>
    <Contact_Email>add-tr.coronation@nhs.net
    </Contact_Email>
    <Contact_Tel>+44 (0)1223254472
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                All COVID-19 cases are eligible for inclusion (COVID-19 cases that pre-decease the start of the registry are eligible)&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)
    </Condition>
    <Intervention>&lt;br&gt;                The CORONATION registry is a patient-level disease registry capturing identifiable patient data on UK COVID-19 cases and anonymised or identifiable data on international COVID-19 cases.&lt;br&gt;&lt;br&gt;                Care teams will collect demographic and clinical data on confirmed COVID-19 cases and enter this information into a database. This will be undertaken through a simple enrollment process and linkage with other datasets.&lt;br&gt;&lt;br&gt;                Baseline data collected will include baseline demographic data, baseline clinical data (comorbidities, medication, COVID-19 status and symptoms).&lt;br&gt;
    </Intervention>
    <Primary_outcome>Demographic and clinical data on confirmed COVID-19 cases (comorbidities, medication, COVID-19 status and symptoms) collected regularly from participating centres by entering data into an online portal
    </Primary_outcome>
    <Secondary_outcome>There are no secondary outcome measures
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CCTU0304, IRAS 282239
    </Secondary_ID>
    <Source_Support>Cambridge Biomedical Research Centre 
    </Source_Support>
    <Secondary_Sponsor>University of Cambridge
    </Secondary_Sponsor>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 20/07/2020, University of Cambridge Human Biology Research Ethics Committee (17 Mill Lane, Cambridge, CB2 1RX; +44 (0)1223 766894; cb480@admin.cam.ac.uk), ref: HBREC.2020.32
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>24/04/2025
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11653590
    </Internal_Number>
    <TrialID>CTRI/2020/07/026672
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Mental health affected by COVID-19
    </Public_title>
    <Scientific_title>Mental health among individuals dealing with COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Tata Memorial Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200718
    </Date_registration3>
    <Date_registration>18-07-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45764
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>28-07-2020
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Arjun Singh
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Dr. E Borges Marg, Parel, Mumbai 400012, India Dr. E Borges Marg, Parel, Mumbai 400012, India
    </Contact_Address>
    <Contact_Email>arjun193@gmail.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Tata Memorial Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Confirmed cases of COVID-19 diagnosed using RT-PCR (real-time reverse transcription polymerase chain reaction) &lt;br/ &gt;&lt;br&gt;2. Healthcare workers and patient relatives dealing with COVID-19 patients  &lt;br/ &gt;&lt;br&gt;3. Age between 18-65 years &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Non consenting participants
    </Exclusion_Criteria>
    <Condition>Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

    </Condition>
    <Intervention/>
    <Primary_outcome>PHQ 9 and/or WHO-BREF scoreTimepoint: Cross sectional at the time of administration of questionnaire
    </Primary_outcome>
    <Secondary_outcome>NATimepoint: NA
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Not applicable
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Tata Memorial Hosptial
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11653252
    </Internal_Number>
    <TrialID>CTRI/2020/07/026334
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>A study to find out the current management practices  of Sleep inducing methods, Pain reducing methods, and treatment used for management of serious disturbances in brain functions in patients admitted in intensive care units.
    </Public_title>
    <Scientific_title>Sedation, Analgesia and Delirium MANagement: an international audit of adult medical, surgical, trauma, and neuro-intensive care patients - SANDMAN Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Tata Memorial Centre
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200702
    </Date_registration3>
    <Date_registration>02-07-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44719
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>31-07-2020
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>DrSheila Nainan Myatra
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department of Anesthesia, Critical Care and Pain, Main Building, Second Floor, Tata Memorial Hospital, Dr.E Borges Road, Parel 
    </Contact_Address>
    <Contact_Email>sheila150@hotmail.com
    </Contact_Email>
    <Contact_Tel>9820156070
    </Contact_Tel>
    <Contact_Affiliation>Tata Memorial Centre
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. All adults (â?¥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours will be included. &lt;br/ &gt;&lt;br&gt;2. We will include medical, surgical, and neurological patients.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: There are no exclusion criteria
    </Exclusion_Criteria>
    <Condition>Health Condition 1: R098- Other specified symptoms and signsinvolving the circulatory and respiratory systems

    </Condition>
    <Intervention>Intervention1: NIL: NIL&lt;br&gt;Control Intervention1: NIL: NIL&lt;br&gt;
    </Intervention>
    <Primary_outcome>To capture an overview of sedation, analgesia and delirium management strategies used in intensive care units around the world.Timepoint: 3 months after enrollment
    </Primary_outcome>
    <Secondary_outcome>To describe and compare management between specific ICU patient groups:1 Medical patients (specifically sepsis and acute respiratory distress syndrome (ARDS)) &lt;br/ &gt;&lt;br&gt;2 Surgical patients &lt;br/ &gt;&lt;br&gt;3Trauma and Burns patients &lt;br/ &gt;&lt;br&gt;4 Neurocritical care patients &lt;br/ &gt;&lt;br&gt;5 Cardiogenic shock patients &lt;br/ &gt;&lt;br&gt;6 Patients receiving palliative careTimepoint: 3 months after enrollment;To describe international practice in ICU, and practice variation in the use of drugs, and monitoring for PAD;Timepoint: 3 months after enrollment;To quantify the adherence to the PAD clinical guidelinesTimepoint: 3 months after enrollment
    </Secondary_outcome>
    <Secondary_ID>Project No_900629 Version 3.1_20July2019
    </Secondary_ID>
    <Source_Support>Tata Memorial Hospital, Dr.E Borges Road, Parel Mumbai Maharashtra India 400012
    </Source_Support>
    <Secondary_Sponsor>Not Any
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/06/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12601858
    </Internal_Number>
    <TrialID>PACTR202006537901307
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19
    </Public_title>
    <Scientific_title>An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Drug for Neglected Diseases initiative
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200615
    </Date_registration3>
    <Date_registration>15/06/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>20/07/2020
    </Date_enrollement>
    <Target_size>3000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Dynamic (adaptive) random allocation such as minimization,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Burkina Faso;Burkina Faso;Cameroon;Democratic Republic of the Congo;Democratic Republic of the Congo;Equatorial Guinea;Ethiopia;Ethiopia;Ghana;Guinea;Cote Divoire;Kenya;Kenya;Mozambique;Mozambique;Sudan;Tanzania;Uganda
    </Countries>
    <Contact_Firstname>James
    </Contact_Firstname>
    <Contact_Lastname>Arkinstall
    </Contact_Lastname>
    <Contact_Address>15 chemin louis Dunant
    </Contact_Address>
    <Contact_Email>media@dndi.org
    </Contact_Email>
    <Contact_Tel>0041229069230
    </Contact_Tel>
    <Contact_Affiliation>Head of Communications and Advocacy
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	Male or female patients,&#x0D;&lt;br&gt;2.	Adults &gt; or= 18 years of age at the time of screening. Children &gt; 12 years of age may be included if recommended by the DSMB after the first analysis.&#x0D;&lt;br&gt;3.	COVID-19 confirmed by molecular biology or validated antigenic test available in the country  for SARS-Cov2 according to national guidelines, based on result within 24 hours prior to screening.&#x0D;&lt;br&gt;4.	Viral syndrome with or without uncomplicated pneumonia, defined as blood oxygen saturation level (SpO2) &gt; or= 94%.&#x0D;&lt;br&gt;5.	Criteria removed due to removal of HCQ and Lopinavir/Ritonavir arms&#x0D;&lt;br&gt;6.	Signed written consent from the patient or his/her representative.&#x0D;&lt;br&gt;7.	Accepting and having the ability to be reached by telephone throughout the study.&#x0D;&lt;br&gt;8.	Having designated a contact person who can be contacted in case of emergency.&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.	Abnormal physical examination findings:&#x0D;&lt;br&gt;•	respiratory rate &gt; or= 25 per minute;&#x0D;&lt;br&gt;•	blood pressure &lt; 90/60 mmHg or &gt; 160/100 mmHg;&#x0D;&lt;br&gt;•	body weight &lt; 45 kg for patients &gt; or= 18 years of age and age-adapted for children &gt; 12 years of age if inclusion is recommended by the DSMB after the first analysis;&#x0D;&lt;br&gt;•	recurrent diarrhoea or vomiting episodes (&gt; 3 in the last 24 hours) or hypokalaemia (&lt; 3.5 mmol/L).&#x0D;&lt;br&gt;2	Criteria removed due to removal of HCQ and Lopinavir/Ritonavir arms&#x0D;&lt;br&gt;3.	Feeling unwell for more than 7 days prior to screening.&#x0D;&lt;br&gt;4 to 7	Criteria removed due to removal of HCQ and Lopinavir/Ritonavir arms&#x0D;&lt;br&gt;8.	End-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy &lt; 3 months.&#x0D;&lt;br&gt;9.-13	Criteria removed due to removal of HCQ and Lopinavir/Ritonavir arms&#x0D;&lt;br&gt;14.	On-going treatment at screening with:&#x0D;&lt;br&gt;•	chronic systemic glucocorticosteroid &gt; 40 mg daily;&#x0D;&lt;br&gt;•	immunosuppressive treatment;&#x0D;&lt;br&gt;15.	For any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use.&#x0D;&lt;br&gt;16.	Unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the Investigator or cannot use an inhalation chamber.&#x0D;&lt;br&gt;17.	Any other reason that makes it impossible to monitor the patient during the study.&#x0D;&lt;br&gt;18.	Enrolled in other clinical trials with unregistered drugs  or with registered drug which could interact with any of the study IPs or contra-indicated as concomitant treatment within the past 3 months prior screening.&#x0D;&lt;br&gt;19.	Known pulmonary arterial hypertension (PAH) or fibrosis.&#x0D;&lt;br&gt;20.	Use of concomitant medications that are contraindicated with ciclesonide, known hypersensitivity to ciclesonide or any other ingredient in the formulation.  &#x0D;&lt;br&gt;21........
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;COVID 19;COVID 19
    </Condition>
    <Intervention>;PARACETAMOL;Lopinavir Ritonavir ARM STOPPED;Hydroxychloroquine ARM STOPPED;Nitazoxanide and Ciclesonide;Ivermectin and Amodiaquine Artesunate ;Fluoxetine and Budesonide 
    </Intervention>
    <Primary_outcome>•	SpO2 &lt; or equal to 93% on repeated measurement within 21 days after randomisation of treatment, which will be considered as failure. Death for any reasons occurring within 21 days after randomisation of treatment will be considered as failure.
    </Primary_outcome>
    <Secondary_outcome>•	Mean number and incidence rate of serious adverse events (SAEs) &#x0D;&lt;br&gt;•	Mean number and incidence rate of severe adverse events&#x0D;&lt;br&gt;•	Mean number of discontinuations or temporary suspensions of IP&#x0D;&lt;br&gt;;•	Number of hospitalisations due to severe progression;•	Time to hospitalisation;•	Disease-free status: disease-free based on normalisation of pre-existing symptoms (based on mMRC scale, scale of Clinical progression and clinical symptoms) and SpO2 &gt; or equal to 94 at Day 21 and no hospitalisation for COVID-19 ;•	Occurrence of death related to COVID-19;•	Time to worsening of SpO2 &lt; or equal to  93 within 21 days;•	Failure rate for each study arm (see Primary Endpoint);•	Occurrence of SpO2 &lt; 93 or death or hospitalisation due to COVID-19;•	Sub-group analysis of failure rate for each study arm 
    </Secondary_outcome>
    <Source_Support>DNDi
    </Source_Support>
    <Ethics_review_status>Not approved;Not approved;Not approved;Approved;Not approved;Approved;Not approved;Not approved;Not approved;Not approved;Not approved;Not approved;Not approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900;01/01/1900;12/08/2020;01/01/1900;21/07/2020;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>pedrondongoasumu@yahoo.es;nrerc2019@gmail.com;ethics.research@ghsmail.org;ouedd@yahoo.fr;cnecprot@yahoo.fr;feli1munday@yahoo.fr;oumou45@yahoo.fr;lou.penali@gmail.com;lawtechs@rachieradvs.co.ke;rassulmn@gmail.com;sakinahabou@yahoo.fr;researchnmpb@gmail.com;hellen.opolot@gmail.com
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Equatorial Guinea National Ethics Committee;National Research Ethics Review Committee;Ghana Health Service Ethical Review Committee;Ethics Committee for Research in Health;Comite National Ethique pour la Recherche en Sante HUmaine;Comite National Ethique de la Sante;Comite National Ethique de la Recherche en Sante;National Ethics Committee for Life and Health Sciences;Ethical Review Committee Scientific and Ethics Review Unit;National Committee for Bioethics in Health;Comite Consultatif National Ethique;National Medicines and Poisons Board;Uganda National Council for Science and Technology
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0024022225766;00251118720943;00233503539896;22650324159;000000000000;00243998419816;00224622034851;000000000000;00254202726781;00258823054660;0022796290533;00249912244558;00256702620279
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>pedrondongoasumu@yahoo.es;nrerc2019@gmail.com;ethics.research@ghsmail.org;ouedd@yahoo.fr;cnecprot@yahoo.fr;feli1munday@yahoo.fr;oumou45@yahoo.fr;lou.penali@gmail.com;lawtechs@rachieradvs.co.ke;rassulmn@gmail.com;sakinahabou@yahoo.fr;researchnmpb@gmail.com;hellen.opolot@gmail.com
    </Ethics_review_contact_email>
    <results_url_link>https://anticov.org/
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11575299
    </Internal_Number>
    <TrialID>NCT04425421
    </TrialID>
    <Last_Refreshed_on>8 November 2021
    </Last_Refreshed_on>
    <Public_title>Recommendations for the Treatment of Children With Burkitt's Lymphoma
    </Public_title>
    <Scientific_title>Recommendations for the Treatment of Children With Burkitt's Lymphoma
    </Scientific_title>
    <Acronym>GFALMB2019
    </Acronym>
    <Primary_sponsor>French Africa Pediatric Oncology Group
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200604
    </Date_registration3>
    <Date_registration>04/06/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04425421
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2020
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Madagascar;Mali;Senegal;Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Madagascar;Mali;Senegal
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Chantal Ms BOUDA, Dr.
    </Contact_Lastname>
    <Contact_Email>cgbouda@yahoo.fr
    </Contact_Email>
    <Contact_Tel>00(226)70 10 01 30
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology.&#x0D;&lt;br&gt;        Not possible to follow all the treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Not a B Cell tumor. Child has been previously treated. Child has also another illness which&#x0D;&lt;br&gt;        would render the treatment incompatible. Parents refusal.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Burkitt Lymphoma
    </Condition>
    <Intervention>Other: OBSERVATIONAL
    </Intervention>
    <Primary_outcome>Evaluation of the number of cases with local disease.;Evaluation of the number of cases by stage at the time of diagnosis.;Evaluating the treatment given.;Evaluating the follow up after treatment.;Number of relapse cases
    </Primary_outcome>
    <Secondary_outcome>Application of therapeutic recommendations
    </Secondary_outcome>
    <Secondary_ID>GFA LMB 2019
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11575300
    </Internal_Number>
    <TrialID>NCT04425434
    </TrialID>
    <Last_Refreshed_on>8 November 2021
    </Last_Refreshed_on>
    <Public_title>Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
    </Public_title>
    <Scientific_title>Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
    </Scientific_title>
    <Acronym>GFARB12019
    </Acronym>
    <Primary_sponsor>French Africa Pediatric Oncology Group
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200604
    </Date_registration3>
    <Date_registration>04/06/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04425434
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2020
    </Date_enrollement>
    <Target_size>3000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Madagascar;Mali;Senegal;Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Madagascar;Mali;Senegal
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>FOUSSEYNI Mr TRAORE, Dr;;KARIM Mr ASSANI, Dr.
    </Contact_Lastname>
    <Contact_Email>;drassanik@gmail.com
    </Contact_Email>
    <Contact_Tel>;00243971359726
    </Contact_Tel>
    <Contact_Affiliation>AMCC AND GFAOP;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unilateral intraocular Retinoblastoma (RB)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unilateral extraocular intraorbital (RB)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Bilateral intraocular (RB)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  bilateral intraocular (RB) on one side and extraocular but intraorbital on the other&#x0D;&lt;br&gt;             side.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Externalized tumor mass&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  massive extension to optic nerve up to optical channeltumor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  intracranial extension leptomeninges&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  cerebral parenchyma&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  extension to regional lymph nodes and/or remote metastases.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  cerebrospinal fluid involvement.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Trilateral RB&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Incapacity to followed the whole treatement.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Retinoblastoma
    </Condition>
    <Intervention>Other: OBSERVATIONAL
    </Intervention>
    <Primary_outcome>Number of cases with retinoblastoma in each participating hospital.;Number of cases with stage 2 disease;Feasibility of these therapeutic recommendations in an African setting;Evaluating the treatment given.;follow up
    </Primary_outcome>
    <Secondary_ID>GFAOP RB1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12550869
    </Internal_Number>
    <TrialID>NCT04423484
    </TrialID>
    <Last_Refreshed_on>3 October 2022
    </Last_Refreshed_on>
    <Public_title>Therapeutic Recommendations for Nephroblastoma
    </Public_title>
    <Scientific_title>Therapeutic Recommendations for the Treatment of Children With Nephroblastoma in Africa.
    </Scientific_title>
    <Acronym>GFANEPHRO20
    </Acronym>
    <Primary_sponsor>French Africa Pediatric Oncology Group
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200604
    </Date_registration3>
    <Date_registration>04/06/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04423484
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 1, 2020
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Madagascar;Mali;Senegal;Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Madagascar;Mali;Senegal
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Fatou Binetou Ms DIAGNE AKONDE, Dr;BRENDA Ms MALLON, MSC
    </Contact_Lastname>
    <Contact_Email>;brenda.mallon@gustaveroussy.fr
    </Contact_Email>
    <Contact_Tel>;0033142115411
    </Contact_Tel>
    <Contact_Affiliation>French Africa Pediatric Oncology Group;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Unilateral Nephroblastoma Tumor Not previously treated The general health of the child will&#x0D;&lt;br&gt;        permit treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        .&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the&#x0D;&lt;br&gt;        diagnosis Treatment Refusal&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Nephroblastoma
    </Condition>
    <Intervention>Other: Data collection
    </Intervention>
    <Primary_outcome>Evaluation of the number of cases with local disease.;Evaluation of the number of cases with stage IV disease.;Evaluating the treatment given.;Evaluating the follow up after treatment.
    </Primary_outcome>
    <Secondary_outcome>Why has treatment failed
    </Secondary_outcome>
    <Secondary_ID>GFANEPHRO2020
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10367582
    </Internal_Number>
    <TrialID>NCT04424940
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach
    </Public_title>
    <Scientific_title>TOMEKA® Project Was Sponsored by the University of Kinshasa: it's an Observational Study by Its Reviewed Documentation
    </Scientific_title>
    <Acronym>MD
    </Acronym>
    <Primary_sponsor>University of Kinshasa
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200520
    </Date_registration3>
    <Date_registration>20/05/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04424940
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2020
    </Date_enrollement>
    <Target_size>800
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>GUYGUY KABUNDI TSHIMA, MD;TSHIMA, MD;GUYGUY K. TSHIMA, Dr.
    </Contact_Lastname>
    <Contact_Email>;guyguytshimakabundi@gmail.com;guyguytshimakabundi@gmail.com
    </Contact_Email>
    <Contact_Tel>;15143819264;0015143819264
    </Contact_Tel>
    <Contact_Affiliation>University of Kinshasa;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fulfill Inclusion criteria and accept&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  COVID-19 patients confirmed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  be regular on appointments&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  COVID-19 suspected clinically&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refuse to participate&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>COVID-19
    </Condition>
    <Primary_outcome>Number of participants with treatment-TOMEKA® usage as assessed by Education
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in nutraceuticals usage on the care of the Covid-19 at 9 months
    </Secondary_outcome>
    <Secondary_ID>Tshima Guyguy Kabundi;UKinshasa
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University Ghent;Université de Montréal
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10837505
    </Internal_Number>
    <TrialID>NCT04841031
    </TrialID>
    <Last_Refreshed_on>19 April 2021
    </Last_Refreshed_on>
    <Public_title>Psychosocial and Economic Impacts of Narrative Exposure Therapy for Violence Survivors in Eastern DRC
    </Public_title>
    <Scientific_title>Psychosocial and Economic Impacts of Narrative Exposure Therapy for Violence Survivors in Eastern DRC
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>World Bank
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200507
    </Date_registration3>
    <Date_registration>07/05/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04841031
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>June 29, 2017
    </Date_enrollement>
    <Target_size>1053
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Julia Vaillant, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>World Bank
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  GBV survivors who are screened for commonly found conditions of mental distress&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  More severe cases of mental disorders are ineligible. They are referred to the General&#x0D;&lt;br&gt;             Referral Hospitals or specialized mental health clinics to receive immediate&#x0D;&lt;br&gt;             treatment.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Mental Health Disorder;PTSD;Depression Anxiety Disorder;Gender-based Violence
    </Condition>
    <Intervention>Behavioral: NET Treatment;Other: Alternative Intervention
    </Intervention>
    <Primary_outcome>Post-traumatic Stress Disorder (PTSD) Severity;Depression and Anxiety
    </Primary_outcome>
    <Secondary_outcome>Self-esteem;Management of problems;Local functioning impairment index;Labor force participation;Total Earnings;Saving behavior;Total amount of savings;Decision-making power;Food insecurity;Sharing of housework;Respondent and household asset ownership
    </Secondary_outcome>
    <Secondary_ID>P147489
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Fonds Social de la République Démocratique du Congo;Vivo international e.V.
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12057010
    </Internal_Number>
    <TrialID>ISRCTN80453162
    </TrialID>
    <Last_Refreshed_on>21 March 2022
    </Last_Refreshed_on>
    <Public_title>The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study)
    </Public_title>
    <Scientific_title>The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery. An international cohort study (COVER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University Hospitals Coventry and Warwickshire NHS Trust
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200414
    </Date_registration3>
    <Date_registration>14/04/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN80453162
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>09/04/2020
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational longitudinal study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Ruth;Sandip
    </Contact_Firstname>
    <Contact_Lastname>Benson;Nandhra
    </Contact_Lastname>
    <Contact_Address>Vascular and Endovascular Research Network (President);Vascular and Endovascular Research Network
    </Contact_Address>
    <Contact_Email>vern.arterial.disease@gmail.com;vern.arterial.disease@gmail.com
    </Contact_Email>
    <Contact_Tel>+44 (0)121 4143344;+44 (0)191 2336161
    </Contact_Tel>
    <Contact_Affiliation>;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Any patient with a vascular condition
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>Any vascular condition, including: aortic or other type of aneurysmal disease, peripheral arterial disease, venous disease, vascular malformations, trauma, major haemorrhage, access (for renal dialysis), carotid (and cerebrovascular) disease, any other type of pathology treated by vascular surgeons. &lt;br&gt;Circulatory System
    </Condition>
    <Intervention>&lt;br&gt;                This project is a three-tiered study designed to fully elucidate the impact of the COVID-19 pandemic on vascular surgery across the world.&lt;br&gt;&lt;br&gt;                The aim of Tier 1 is to document how the provision and availability of vascular services evolves over time per unit/region/country.&lt;br&gt;&lt;br&gt;                The aim of Tier 2  is to prospectively capture data on all vascular procedures performed during the pandemic and understand the impact on outcomes in the short and medium-term (up to 1 year).&lt;br&gt;&lt;br&gt;                The aim of Tier 3 is to document (prospectively) deviations from standards of care/practice during the pandemic in vascular patients.&lt;br&gt;&lt;br&gt;                The main objective of the COVER study is to understand and evaluate the impact of the COVID-19 pandemic on global vascular practice and the effect on outcomes for patients presenting/receiving treatment during the pandemic.&lt;br&gt;                Population (patients) – All patients with a vascular pathology.&lt;br&gt;                Outcome of interest – Tier 1: state of vascular services per centre weekly; Tier 2: procedures performed in each centre; Tier 3: assessment of longer-term outcomes.&lt;br&gt;                Time – end of study 12 months after the end of the COVID19 pandemic.&lt;br&gt;&lt;br&gt;                The study is formally supported by the Vascular Society of Great Britain and Ireland (VSGBI),  the British Society for Endovascular Therapy (BSET), the Rouleaux Club, the NIHR, SingVasc and several national vascular surgery societies in Europe, Asia, Australia, New Zealand, and the Americas.&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;br&gt;                1. Structure and processes within the vascular service measured using a novel online questionnaire weekly until the end of data collection&lt;br&gt;                2. Document all vascular surgery and interventional procedures performed using an online purpose-built data collection tool (per centre/patient) at baseline, time/date of surgery, date of discharge from hospital, three, six, and twelve months:&lt;br&gt;                2.1. Type of procedure performed&lt;br&gt;                2.2. Time taken from presentation to the surgical team to intervention&lt;br&gt;                2.3. Mode of referral (primary vs. secondary care)&lt;br&gt;                2.4. Site of surgery – hub or spoke hospital&lt;br&gt;                2.5. Imaging modalities used and timings&lt;br&gt;                2.6. Emergency classification i.e. urgent/emergency/elective&lt;br&gt;                2.7. Operative technique(s) and device(s) used&lt;br&gt;                2.8. Mode(s) of anaesthesia (local, regional, general, locoregional, other)&lt;br&gt;                2.9. Whether suspected or confirmed COVID-19 positive (+ve) at time of surgery, COVID-19 +ve after surgery, or COVID-19 negative (-ve)&lt;br&gt;                2.10. Documentation of changes to usual practice for this specific procedure as per surgeon’s standard protocol (type of procedure, type of anaesthetic, post-procedural destination)&lt;br&gt;                3. Management of all referred urgent vascular cases using the online survey, focusing on:&lt;br&gt;                3.1.  Chronic Limb Threatening Ischaemia (CLTI):&lt;br&gt;                3.1.1. Decision to discharge/admit/refer to a "hot"/emergency clinic&lt;br&gt;                3.1.2. Decision for endovascular or open surgery first&lt;br&gt;                3.1.3. Decision for best medical therapy or palliation or primary amputation&lt;br&gt;                3.2. Carotid disease:&lt;br&gt;                3.2.1. Number of patients managed with best medical therapy (BMT)&lt;br&gt;                3.2.2. Modifications to the indication and decision for carotid endarterectomy (CEA)&lt;br&gt;                3.2.3. Delays to treatment due to lack of theatre/bed availability&lt;br&gt;                3.3. Abdominal Aortic Aneurysm (AAA)&lt;br&gt;                3.3.1. Increasing use of Endovascular repair (if applicable)&lt;br&gt;                3.3.2. Changes to criteria for intervention&lt;br&gt;                3.3.3. Decisions for palliation, i.e. ‘turn down’&lt;br&gt;                3.4. Acute Aortic syndrome (AAS)&lt;br&gt;                3.4.1. Decision to manage in non-critical care beds&lt;br&gt;                3.4.2. Changes to imaging protocol at unit level&lt;br&gt;                3.4.3. Decision to defer surgery&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Collected after surgery has been performed at three, six, and twelve months using patient records:&lt;br&gt;                1.1. Re-admission&lt;br&gt;                1.2. Re-intervention&lt;br&gt;                1.3. All-cause mortality&lt;br&gt;                1.4. Operation-specific morbidity&lt;br&gt;                1.5. Morbidity&lt;br&gt;                1.6. [If COVID-19 +ve] - respiratory outcome, admission to intensive care unit&lt;br&gt;                2. Condition-specific outcomes at 3, 6 months and 1 year:&lt;br&gt;                2.1. CLTI - limb salvage, amputation free survival, all-cause mortality&lt;br&gt;                2.2. Carotid disease - ipsilateral stroke rate, any stroke rate, all-cause mortality&lt;br&gt;                2.3. AAA - aneurysm-related mortality, all-cause mortality&lt;br&gt;                2.4. AAS - complication rate including ruptures, all-cause mortality&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;COVER_01, IRAS 282224
    </Secondary_ID>
    <Source_Support>National Institute for Health Research
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 02/04/2020, Liverpool Central NHS Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8056; liverpoolcentral.rec@hra.nhs.uk), ref: 20/NW/0196
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/04/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11943521
    </Internal_Number>
    <TrialID>NCT04409405
    </TrialID>
    <Last_Refreshed_on>21 February 2022
    </Last_Refreshed_on>
    <Public_title>Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)
    </Public_title>
    <Scientific_title>Evaluation and Support to Ebola Virus Disease Cured Patients and Their Contacts in the Democratic Republic of the Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Institut National de la Santé Et de la Recherche Médicale, France
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200414
    </Date_registration3>
    <Date_registration>14/04/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04409405
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 16, 2020
    </Date_enrollement>
    <Target_size>787
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        In cured population&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults and children after an acute episode declared cured of biologically confirmed&#x0D;&lt;br&gt;             Ebola virus disease (two negative PCRs are required at least 24 hours apart so that a&#x0D;&lt;br&gt;             patient without clinical symptoms can leave the Ebola treatment center),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent signed by at least one of the two parents or the legal guardian&#x0D;&lt;br&gt;             authorizing the child's participation in the study,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Volunteer participant who signed the informed consent for adults.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        In CONTACT population&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 5 years,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be a contact person of a cured patient (ie patient with a proven EVD, and with two&#x0D;&lt;br&gt;             negative PCRs at least 24 hours apart) included in the cohort of Ebola Winners. Based&#x0D;&lt;br&gt;             on WHO recommendations and the Centers for Disease Control and Prevention for the&#x0D;&lt;br&gt;             identification and traceability of contact subjects: a contact person is defined as a&#x0D;&lt;br&gt;             person who encountered the index case during his EVD in his residence, ie having the&#x0D;&lt;br&gt;             same place of life as him,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have not been diagnosed with EVD,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation agreement:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  For adult participants (= 18 years old, emancipated or married): informed consent&#x0D;&lt;br&gt;                  intended for the adult participant signed,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  For minors = 5 years old: informed consent intended for the parent(s)/legal&#x0D;&lt;br&gt;                  guardian signed by at least one of the two parents or the legal guardian and&#x0D;&lt;br&gt;                  assent form intended for the minor participant completed.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        In cellular immunological sub-study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adult participants in the parent study = 18 years old,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept to participate in this sub-study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Negative blood EBOV PCR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of possible follow-up over 12 months from a logistical or geographical point&#x0D;&lt;br&gt;             of view (only for cured patients);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-residents in the DRC;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Impossibility of complying with the requirements and procedures of the study in the&#x0D;&lt;br&gt;             opinion of the investigator;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to consent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Ebola Virus Disease
    </Condition>
    <Primary_outcome>Cured-participant population co-infections;Cured-participant population co-morbidities at any time in the study;Evolution over time of clinical consequences in cured participants;Evolution over time of immunological consequences in cured participants;Evolution over time of virological consequences in cured participants;Description of contact-participants Ebola-virus-exposure risk;Asymptomatic or pauci-symptomatic Ebola infections in contact participants (clinical assessment);Asymptomatic or pauci-symptomatic Ebola infections in contact participants (immunological assessment);Asymptomatic or pauci-symptomatic Ebola infections in contact participants (virological assessment);Evolution over time of peripheral blood mononuclear cells (PBMC) in cured and contact participants (cellular immunological sub-study);Evolution over time of concentration of immune response analytes in cured and contact participants (cellular immunological sub-study);Evolution over time of EBOV-specific T responses in cured and contact participants (cellular immunological sub-study);Evolution over time of gene-expression profile in cured and contact participants (cellular immunological sub-study);Evolution over time of genetic heterogeneity in cured and contact participants (cellular immunological sub-study);Genetic sub-study in cured and contact participants
    </Primary_outcome>
    <Secondary_ID>ESP/CE/287/2019;C19-59
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Institut de Recherche pour le Developpement
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12601720
    </Internal_Number>
    <TrialID>PACTR202108842939734
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Probiotics in children with Severe Acute Malnutrition
    </Public_title>
    <Scientific_title>Effect of Probiotics on morbidity in the community-based treatment of severe acute malnutrition: a randomized controlled study in Congolese children.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>UCLouvain
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200324
    </Date_registration3>
    <Date_registration>24/03/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10900
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Month(s)
    </Inclusion_agemin>
    <Inclusion_agemax>23 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>20/08/2021
    </Date_enrollement>
    <Target_size>400
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using a randomization table created by a computer software program,Sealed opaque envelopes
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo;Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Esto
    </Contact_Firstname>
    <Contact_Lastname>Bahizire
    </Contact_Lastname>
    <Contact_Address>South Kivu
    </Contact_Address>
    <Contact_Email>esto.bahizire@gmail.com
    </Contact_Email>
    <Contact_Tel>+243813148592
    </Contact_Tel>
    <Contact_Affiliation>Nutrition and Public Health Universit Catholique de Bukavu
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Children aged between 6-24 months;&#x0D;&lt;br&gt;Residence in the study area;&#x0D;&lt;br&gt;Uncomplicated SAM criteria: Children with WHZ/WLZ &lt; -2 or MUAC &lt; 115mm; or with edema + (defined as a mild edema on both feet/ankles) or ++ (moderate edema on feet and lower legs, hands or lower arms) without medical complications signs described above;&#x0D;&lt;br&gt;Parental consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children &lt; 6 months or &gt; 24 months;&#x0D;&lt;br&gt;Children with edema +++ (severe edema generalized to feet, legs, hands, arms and face);&#x0D;&lt;br&gt;Complicated SAM (signs described above)&#x0D;&lt;br&gt;Children with chronic debilitating illnesses such as cerebral palsy, congenital heart disease, Down syndrome, cleft lip/palate;&#x0D;&lt;br&gt;Children who have a history of allergies to RUTF;&#x0D;&lt;br&gt;No parental consent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Digestive System &lt;br&gt;Haematological Disorders &lt;br&gt;Nutritional, Metabolic, Endocrine &lt;br&gt;Respiratory;Digestive System;Haematological Disorders;Nutritional, Metabolic, Endocrine;Respiratory
    </Condition>
    <Intervention>;Placebo group;probiotics group
    </Intervention>
    <Primary_outcome>Duration of diarrhea
    </Primary_outcome>
    <Secondary_outcome>Incidence of diarrhea;Incidence of pneumonia;Referrals ;Nutritional recovery;weight gain (in g/kg/day);Nonresponse;RUTFs and probiotics safety
    </Secondary_outcome>
    <Source_Support>Universit Catholique de Bukavu
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/05/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>macece.bagendabanga@ucbukavu.ac.cd
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite Institutionnel d Ethique de la Sante CIES
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+243992838793
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>macece.bagendabanga@ucbukavu.ac.cd
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12525639
    </Internal_Number>
    <TrialID>NCT04311671
    </TrialID>
    <Last_Refreshed_on>12 September 2022
    </Last_Refreshed_on>
    <Public_title>Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas
    </Public_title>
    <Scientific_title>A Randomized, Double Blind, Parallel Group Clinical Trial to Evaluate the Safety of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medicines Development for Global Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200314
    </Date_registration3>
    <Date_registration>14/03/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04311671
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 3, 2021
    </Date_enrollement>
    <Target_size>12500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Tony Ukety, MD, DO, MPH;Sally Kinrade;Tony Ukety
    </Contact_Lastname>
    <Contact_Email>;sally.kinrade@medicinesdevelopment.com;
    </Contact_Email>
    <Contact_Tel>;+6139912 2400;
    </Contact_Tel>
    <Contact_Affiliation>Centre de Recherche en Maladies Tropicales de l'Ituri;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Provision of written informed consent, or assent with parental or guardian written&#x0D;&lt;br&gt;             consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known O. volvulus skin microfilariae density =0 microfilariae/mg skin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Living in an onchocerciasis endemic area.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 12 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All female participants of childbearing potential must commit to the use of a reliable&#x0D;&lt;br&gt;             method of birth control until 3 months after administration of investigational product&#x0D;&lt;br&gt;             (Month 3)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breast-feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any concurrent condition that, in the opinion of the Investigator, would preclude&#x0D;&lt;br&gt;             evaluation of response to treatment or would pose undue risk to the participant's&#x0D;&lt;br&gt;             health.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has received ivermectin or oral diethylcarbamazine (DEC) within 30 days of Baseline.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has received treatment with an investigational agent within the 30 days (or 5&#x0D;&lt;br&gt;             half-lives, whichever is longer) prior to planned investigational product&#x0D;&lt;br&gt;             administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known or suspected allergy to ivermectin or moxidectin or their excipients.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Self-reported planned or ongoing activities within the study period that would make it&#x0D;&lt;br&gt;             unlikely that the participant will be available for follow-up examinations.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infection with Loa loa&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Onchocerciasis
    </Condition>
    <Intervention>Drug: Moxidectin;Drug: Ivermectin
    </Intervention>
    <Primary_outcome>Incidence and severity of treatment emergent adverse events
    </Primary_outcome>
    <Secondary_ID>MDGH-MOX-3002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12601701
    </Internal_Number>
    <TrialID>PACTR202003567524647
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas
    </Public_title>
    <Scientific_title>A randomized, double blind, parallel group clinical trial to evaluate the safety of moxidectin compared with ivermectin in individuals living in onchocerciasis endemic areas.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Medicines Development for Global Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200313
    </Date_registration3>
    <Date_registration>13/03/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10859
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>12 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>15/02/2021
    </Date_enrollement>
    <Target_size>12500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Sealed opaque envelopes
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Sally
    </Contact_Firstname>
    <Contact_Lastname>Kinrade
    </Contact_Lastname>
    <Contact_Address>Level 1, 18 Kavanagh Street
    </Contact_Address>
    <Contact_Email>sally.kinrade@medicinesdevelopment.com
    </Contact_Email>
    <Contact_Tel>+61399122400
    </Contact_Tel>
    <Contact_Affiliation>Moxidectin for Onchocerciasis Project Leader
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	Provision of written informed consent, or assent with parental or guardian written consent.&#x0D;&lt;br&gt;2.	Known O. volvulus skin microfilariae density =0 microfilariae/mg skin&#x0D;&lt;br&gt;3.	Living in an onchocerciasis endemic area.&#x0D;&lt;br&gt;4.	Age = 12 years.&#x0D;&lt;br&gt;5.	All female participants of childbearing potential must commit to the use of a reliable method of birth control until 3 months after administration of investigational product (Month 3). 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.	Pregnant or breast-feeding.&#x0D;&lt;br&gt;2.	Any concurrent condition that, in the opinion of the Investigator, would preclude evaluation of response to treatment or would pose undue risk to the participant's health.&#x0D;&lt;br&gt;3.	Has received ivermectin or oral diethylcarbamazine (DEC) within 30 days of Baseline.&#x0D;&lt;br&gt;4.	Has received treatment with an investigational agent within the 30 days (or 5 half-lives, whichever is longer) prior to planned investigational product administration.&#x0D;&lt;br&gt;5.	Known or suspected allergy to ivermectin or moxidectin or their excipients.&#x0D;&lt;br&gt;6.	Self-reported planned or ongoing activities within the study period that would make it unlikely that the participant will be available for follow-up examinations.&#x0D;&lt;br&gt;7.	Infection with Loa loa 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Onchocerciasis;Onchocerciasis
    </Condition>
    <Intervention>;Moxidectin;Ivermectin
    </Intervention>
    <Primary_outcome>Incidence and severity of treatment emergent adverse events
    </Primary_outcome>
    <Secondary_ID>MDGH MOX 3002
    </Secondary_ID>
    <Source_Support>European and Developing Countries Clinical Trial Partnership;Medicines Development for Global Health
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>26/08/2020;29/09/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>fanfanzeza@gmail.com;ct_ethics@who.int
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>National Committee of Health Ethics;World Health Organization Research Ethics Review Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+243812227298;+41227912111
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>fanfanzeza@gmail.com;ct_ethics@who.int
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12601703
    </Internal_Number>
    <TrialID>PACTR202004639229710
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
    </Public_title>
    <Scientific_title>A randomized, double blind, parallel trial in the Democratic Republic of Congo (DRC) comparing the safety and efficacy of annual or biannual doses of moxidectin or ivermectin for treatment of onchocerciasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Medicines Development for Global Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200313
    </Date_registration3>
    <Date_registration>13/03/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10861
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>12 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>15/02/2021
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Sealed opaque envelopes
    </Study_design>
    <Phase>Phase-3
    </Phase>
    <Countries>Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Sally
    </Contact_Firstname>
    <Contact_Lastname>Kinrade
    </Contact_Lastname>
    <Contact_Address>Level 1, 18 Kavanagh Street
    </Contact_Address>
    <Contact_Email>sally.kinrade@medicinesdevelopment.com
    </Contact_Email>
    <Contact_Tel>+61399122400
    </Contact_Tel>
    <Contact_Affiliation>Moxidectin for Onchocerciasis Project Leader
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	Provision of written informed consent, or assent with parental or guardian written consent.&#x0D;&lt;br&gt;2.	Mean = 10 O. volvulus mf/mg skin, determined by four skin snips.&#x0D;&lt;br&gt;3.	Living in a village selected for the study. &#x0D;&lt;br&gt;4.	Age = 12 years. &#x0D;&lt;br&gt;5.	All female participants of childbearing potential must commit to the use of a reliable method of birth control for the duration of treatment and until 3 months after completion of dosing with investigational product.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.	Pregnant or breast-feeding.&#x0D;&lt;br&gt;2.	Any concurrent condition that, in the opinion of the Investigator, would preclude evaluation of response to treatment or would pose undue risk to the participant's health.&#x0D;&lt;br&gt;3.	Has received ivermectin, oral diethylcarbamazine (DEC) or doxycycline (for &gt; 2 weeks) within 6 months of Baseline.&#x0D;&lt;br&gt;4.	Has received treatment with an investigational agent within the last 30 days (or 5 half-lives, whichever is longer) prior to Baseline.&#x0D;&lt;br&gt;5.	Known or suspected allergy to ivermectin or moxidectin or their excipients.&#x0D;&lt;br&gt;6.	Self-reported planned or ongoing activities within the study period that would make it unlikely that a participant will be available for all planned treatment rounds and follow-up examinations.&#x0D;&lt;br&gt;7.	Weight &gt; 88 kilograms.&#x0D;&lt;br&gt;8.	Infection with Loa loa.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Onchocerciasis;Onchocerciasis
    </Condition>
    <Intervention>;Annual Moxidectin;Biannual Moxidectin;Biannual Ivermectin;Annual Ivermectin
    </Intervention>
    <Primary_outcome>Proportion of full analysis set participants in the moxidectin annual and biannual treatment arms with zero O. volvulus skin microfilariae at both Months 6 and 12; microfilaridermia is determined by the count of four skin snips for each participant at each assessment;Safety across all dose groups will be evaluated by the incidence and severity of adverse events (AEs) and measurement of vital signs up to and including Month 36 and liver function tests up to and including Month 12.
    </Primary_outcome>
    <Secondary_outcome>Sustained microfilariae response, defined as zero O. volvulus skin microfilariae sustained at all post-Baseline assessments;Sustained ocular microfilariae response, defined as zero live O. volvulus microfilariae in the anterior chambers of the eyes at all post-Baseline assessments in those with live microfilariae in the anterior chambers of the eyes before the first treatment;Mean and median percent reduction (from pre-treatment) of skin microfilariae density and live microfilariae in the anterior chambers of the eyes;The proportion of participants in each treatment group with zero skin microfilariae and zero live microfilariae in the anterior chambers of the eyes at each post-Screening assessment;Mean skin microfilariae density at each post-Screening assessment and the mean and mean change from baseline, for the number of live microfilariae in the anterior chambers of the eyes at each post-Screening assessment in those with live microfilariae in the anterior chambers of the eyes before the first treatment
    </Secondary_outcome>
    <Secondary_ID>MDGH MOX 3001
    </Secondary_ID>
    <Source_Support>European and Developing Countries Clinical Trial Partnership;Medicines Development for Global Health
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>26/08/2020;28/09/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>fanfanzeza@gmail.com;ct_ethics@who.int
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>National Committee of Health Ethics;World Health Organization Research Ethics Review Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+243812227298;+41227912111
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>fanfanzeza@gmail.com;ct_ethics@who.int
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12270578
    </Internal_Number>
    <TrialID>NCT04303507
    </TrialID>
    <Last_Refreshed_on>16 May 2022
    </Last_Refreshed_on>
    <Public_title>Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
    </Public_title>
    <Scientific_title>Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)
    </Scientific_title>
    <Acronym>COPCOV
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200306
    </Date_registration3>
    <Date_registration>06/03/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04303507
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>16 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 29, 2020
    </Date_enrollement>
    <Target_size>4646
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Benin;Côte D'Ivoire;Indonesia;Kenya;Mali;Nepal;Pakistan;Thailand;United Kingdom;Zambia;Benin;Côte D'Ivoire;Indonesia;Kenya;Mali;Nepal;Pakistan;Thailand;United Kingdom;Zambia;Bangladesh;Ethiopia;Italy;Lao People's Democratic Republic;Niger
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>William Schilling, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Mahidol Oxford Tropical Medicine Research Unit
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Study Participants The study population is adult healthcare workers and other persons&#x0D;&lt;br&gt;        defined by the site investigator at risk of contracting COVID-19.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Participant is willing and able to give informed consent for participation in the&#x0D;&lt;br&gt;             study and agrees with the study and its conduct&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential&#x0D;&lt;br&gt;             antivirals&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Adults (exact age is dependent on countries) less than 70 years old at the time of&#x0D;&lt;br&gt;             consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Not previously diagnosed with COVID-19&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Not currently symptomatic with an ARI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Participant is a healthcare worker or is a person at risk of contracting COVID-19.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Possesses an internet-enabled smartphone (Android or iOS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Contraindication to taking chloroquine as prophylaxis e.g. known epileptic, known&#x0D;&lt;br&gt;             creatinine clearance &lt; 10 ml/min&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Already taking chloroquine, hydroxychloroquine or 4-aminoquinolines, or history of&#x0D;&lt;br&gt;             these medications within the previous 7 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Taking prohibited medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Known retinal disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Inability to be followed up for the trial period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Known prolonged QT syndrome (however ECG is not required at baseline)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Known pregnancy or women who are actively trying to become pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Prior diagnosis of porphyria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Previously received any dose of COVID-19 vaccine&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        The investigator may consult the physician's guidance documents for any further questions&#x0D;&lt;br&gt;        regarding eligibility of potential participants.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Prohibited medications for the purpose of study enrollment include:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antiarrhythmic medications: digoxin, amiodarone, sotalol, flecainide&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antiparasitic/malarial agents: mefloquine, halofantrine, praziquantel&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antibiotics: levofloxacin, moxifloxacin, ciprofloxacin, azithromycin, clarithromycin,&#x0D;&lt;br&gt;             erythromycin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antifungal drugs: fluconazole, ketoconazole, itraconazole, terfenadine&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychoactive drugs: lithium, quetiapine, chlorpromazine, thioridazine, ziprasidone,&#x0D;&lt;br&gt;             haloperidol, droperidol, methadone&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Migraine treatment: sumatriptan&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antihistamines: astemizole&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antiemetics: prochlorperazine, metoclopramide&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cancer treatments: abiraterone, dabrafenib, dacomitinib, enzalutamide, idelalisib,&#x0D;&lt;br&gt;             mitotane&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other specific drugs: ciclosporin, conivaptan, agalsidase alfa or beta, mifepristone,&#x0D;&lt;br&gt;             stiripentol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        PrincipaI Investigators will also be directed to crediblemeds.org to check other agents&#x0D;&lt;br&gt;        that may prolong QT interval&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>COVID19;Coronavirus;Acute Respiratory Illnesses
    </Condition>
    <Intervention>Drug: Chloroquine or Hydroxychloroquine;Drug: Placebo
    </Intervention>
    <Primary_outcome>Number of symptomatic COVID-19 infections
    </Primary_outcome>
    <Secondary_outcome>Symptoms severity of COVID-19;Number of asymptomatic cases of COVID-19;Number of symptomatic acute respiratory illnesses;Severity of symptomatic acute respiratory illnesses
    </Secondary_outcome>
    <Secondary_ID>VIR20001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11650500
    </Internal_Number>
    <TrialID>CTRI/2020/02/023582
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>An international,observational study to collect information about the practices of blood transfusion followed by doctors working in intensive care units.
    </Public_title>
    <Scientific_title>International Point Prevalence Study of Intensive Care Unit Transfusion Practices (InPUT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Academic Medical Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200225
    </Date_registration3>
    <Date_registration>25-02-2020
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=40701
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>28-02-2020
    </Date_enrollement>
    <Target_size>10000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr Sheila Nainan Myatra
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Room No 5, Department of Anesthesia, Critical care and Pain, Main building, Dr E Borges Road, parel 
    </Contact_Address>
    <Contact_Email>sheila150@hotmail.com
    </Contact_Email>
    <Contact_Tel>9820156070
    </Contact_Tel>
    <Contact_Affiliation>Tata Memorial Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. All adult (age more than 18yrs)patients admitted to the ICU in a pre-specified week
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients younger than 18 years old.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: R69- Illness, unspecified

    </Condition>
    <Intervention>Intervention1: Nil: Nil&lt;br&gt;Control Intervention1: Nil: Nil&lt;br&gt;
    </Intervention>
    <Primary_outcome>1.To describe current transfusion practiceTimepoint: once a day after intensive care unit admission till discharge or maximum upto 28 days
    </Primary_outcome>
    <Secondary_outcome>Differences of transfusion practices between different patient subgroupsTimepoint: Once at the time of data analysis;Differences of transfusion regimes between world regionsTimepoint: Once at the time of data analysis;Mortality and length of stay in the intensive care unitTimepoint: Once a day after intensive care unit admission till discharge or maximum upto 28 days
    </Secondary_outcome>
    <Secondary_ID>Project No 3397 Version 5.0 dated 17 Oct 2019
    </Secondary_ID>
    <Source_Support>Tata Memorial Hospital, Dr.E Borges Road, Parel Mumbai 400012
    </Source_Support>
    <Secondary_Sponsor>Not Any
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/01/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12534052
    </Internal_Number>
    <TrialID>NCT04289688
    </TrialID>
    <Last_Refreshed_on>19 September 2022
    </Last_Refreshed_on>
    <Public_title>Health Itinerary of Young Children With Suspected Bloodstream Infection in Kisantu General Referral Hospital, DR Congo
    </Public_title>
    <Scientific_title>Health Itinerary of Young Children With Suspected Bloodstream Infection in Kisantu General Referral Hospital, DR Congo: a Cohort Study
    </Scientific_title>
    <Acronym>HIT BSI
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200225
    </Date_registration3>
    <Date_registration>25/02/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04289688
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>28 Days
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2021
    </Date_enrollement>
    <Target_size>784
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Bieke Tack
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institute of Tropical Medicine Antwerp
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be a child between 28 days and 5 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be admitted to Kisantu Hospital&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a suspected bloodstream infection, which is defined as the presence of objective&#x0D;&lt;br&gt;             fever, hypothermia or a history of fever during the past 48 hours and at least one of&#x0D;&lt;br&gt;             the following criteria: Hypotension, confusion or increased respiratory rate/Suspicion&#x0D;&lt;br&gt;             of severe localized infection: pneumonia, meningitis, osteomyelitis, complicated&#x0D;&lt;br&gt;             urinary tract infection, abscess, skin/soft tissue infection or abdominal infection/&#x0D;&lt;br&gt;             Suspicion of typhoid fever/ Suspicion of severe malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having a caregiver willing and able to provide written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Bloodstream Infection;Health Care Utilization;Malaria,Falciparum;Salmonella Infection Non-Typhoid;Febrile Illness
    </Condition>
    <Primary_outcome>Describe health itineraries based on the three delays model in hospital admitted children with suspected bloodstream infection;Assess which exposure factors variables are associated with the duration of the health itinerary in hospital admitted children with suspected bloodstream infection
    </Primary_outcome>
    <Secondary_outcome>Assess the association between the duration of the health itinerary and in hospital case fatality in hospital admitted children with suspected bloodstream infection;Describe health itinerary based on the three delays model;Assess which factors influence the duration of the health itinerary, stratified per diagnostic category;Assess the association between the duration of the health itinerary and in hospital case fatality;Assess the diagnostic, therapeutic and referral practices at referring health centers in hospital admitted children with suspected bloodstream infection;Assess the diagnostic and therapeutic practices before hospital admission per health care provider in hospital admitted children with suspected bloodstream infection;Assess the coverage of blood cultures.
    </Secondary_outcome>
    <Secondary_ID>ITM202003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>KU Leuven;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Fund for Scientific Research, Flanders, Belgium;Hôpital Saint-Luc, Kisantu, République Démocratique du Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12534068
    </Internal_Number>
    <TrialID>NCT04300309
    </TrialID>
    <Last_Refreshed_on>19 September 2022
    </Last_Refreshed_on>
    <Public_title>Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates &lt;5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
    </Public_title>
    <Scientific_title>Multicenter, Open-label, Single-arm Study to Evaluate the PK, Safety, Tolerability and Efficacy of a New Artemether:Lumefantrine (2.5 mg:30 mg) Dispersible Tablet in the Treatment of Infants and Neonates &lt;5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
    </Scientific_title>
    <Acronym>CALINA
    </Acronym>
    <Primary_sponsor>Novartis Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200218
    </Date_registration3>
    <Date_registration>18/02/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04300309
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>365 Days
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 21, 2020
    </Date_enrollement>
    <Target_size>44
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Mali;Zambia;Burkina Faso;Congo, The Democratic Republic of the;Mali;Zambia;Congo
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Alfred Tiono;Halidou Tinto;Bernhards Ogutu;Issaka Sagara;Martin Meremikwu;Gildas Wounounou;Christine Manyando;Novartis Pharmaceuticals
    </Contact_Lastname>
    <Contact_Email>;;;;;;;novartis.email@novartis.com
    </Contact_Email>
    <Contact_Tel>;;;;;;;+41613241111
    </Contact_Tel>
    <Contact_Affiliation>Groupement de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso;Unité de Recherche Clinique, CMA St Camille, Nanoro, Burkina Faso;Kondele Children Hospital, Kisumu , Kenya;MRTC, Univ. of Science, Techniques and Technology, Bamako, Mali;Department of Paediatrics, University of Calabar, Calabar, Nigeria;Hôpital Général de Référence St Luc, Kisantu, DR Congo;St Pauls Mission Hospital, Nchelenge, Zambia;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female neonates/infants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Body weight &lt;5 kg but = 2 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. In Cohort 1, infants aged &gt;28 days; in Cohort 2, neonates aged 1 to =28 days (3&#x0D;&lt;br&gt;             subgroups: 1-7 days; 8-14 days; 15-28 days)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Microscopically confirmed diagnosis of P. falciparum malaria (or mixed infections):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  in Cohort 1 of =500 and &lt;100,000 parasites/µL asexual P. falciparum parasitemia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  in Cohort 2 of =100 and &lt;100,000 parasites/µL asexual P. falciparum parasitemia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  in Cohort 2, either congenital or neonatal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  either symptomatic or asymptomatic&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Head circumference &lt; - 2 SD z-score in cm following WHO age and sex-specific reference&#x0D;&lt;br&gt;             curves (suspicion of microcephaly)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Presence of severe malaria (according to WHO 2015 definition)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. HIV status :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  in Cohort 1, patient's or patient's mother's current treatment with ARV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  in Cohort 2, mother's known HIV positive status at patient's birth or mother's&#x0D;&lt;br&gt;                  current treatment with ARV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Presence of the following signs of a critical condition: apnea-bradycardia, sustained&#x0D;&lt;br&gt;             bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely&#x0D;&lt;br&gt;             deteriorated general condition (based on IMCI criteria in sick infants) (WHO 2005)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Presence of any clinically significant neurological condition:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  any episode of convulsion during the present illness (in keeping with the IMCI&#x0D;&lt;br&gt;                  list of general danger signs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  known neurological disorders (e.g. chronic seizure disorders, cerebral palsy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Presence of clinically significant abnormality of the hepatic and renal systems&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patients unable to swallow or whose drinking is impaired&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Known hypersensitivity of the patient or either patient's parent to artemether,&#x0D;&lt;br&gt;             lumefantrine, any of the excipients of Coartem®/Riamet® Dispersible tablet, or to&#x0D;&lt;br&gt;             drugs of similar chemical classes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. History of malabsorption or previous gastrointestinal surgery, or history of radiation&#x0D;&lt;br&gt;             therapy that could affect drug absorption or metabolism, or any other disorder or&#x0D;&lt;br&gt;             history of a condition that could interfere with drug absorption, distribution,&#x0D;&lt;br&gt;             metabolism, or excretion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Known family history of congenital prolongation of the QTc interval or sudden death or&#x0D;&lt;br&gt;             with any other clinical condition known to be associated with prolongation of the QTc&#x0D;&lt;br&gt;             interval such as history of symptomatic cardiac arrhythmias, with clinically relevant&#x0D;&lt;br&gt;             bradycardia or with severe cardiac disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Presence of any age-adjusted clinically or hematologically relevant laboratory and&#x0D;&lt;br&gt;             blood chemistry abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Patients who received any antimalarial drug, including antibiotics with antimalarial&#x0D;&lt;br&gt;             activity, within 14 days of trial start, or any other prohibited drug (see Table 6-2)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Patients who received an investigational drug within 5 half-lives of enrollment or&#x0D;&lt;br&gt;             participated in an investigational study or within 30 days, whichever is longer&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Plasmodium Falciparum Malaria
    </Condition>
    <Intervention>Drug: artemether:lumefantrine (2.5 mg:30 mg)
    </Intervention>
    <Primary_outcome>Artemether Cmax
    </Primary_outcome>
    <Secondary_outcome>Lumefantrine Day 8 concentration (C168h);Artemether AUC;DHA AUC;Lumefantrine Cmax;Lumefantrine AUC;Parasite Clearance Time (PCT);Fever clearance Times (FCT);PCR-corrected Adequate Clinical and Parasitological Response (ACPR);PCR-corrected Adequate Clinical and Parasitological Response (ACPR);PCR-corrected Adequate Clinical and Parasitological Response (ACPR);Uncorrected Adequate Clinical and Parasitological Response (ACPR);Uncorrected Adequate Clinical and Parasitological Response (ACPR);Uncorrected Adequate Clinical and Parasitological Response (ACPR);Uncorrected Adequate Clinical and Parasitological Response (ACPR);Incidence rate of recrudescence and new infections;Incidence rate of serious adverse events;Incidence rate of adverse events;Incidence rate of abnormal laboratory values;Change in head circumference;Neurodevelopmental assessment
    </Secondary_outcome>
    <Secondary_ID>CCOA566B2307
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>European and Developing Countries Clinical Trials Partnership (EDCTP);Medicines for Malaria Venture (MMV), Switzerland;Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso;Institut de Recherche en sciences de la Santé - Unité de Recherche Clinique de Nanoro (IRSS-URCN), Burkina Faso
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10354166
    </Internal_Number>
    <TrialID>NCT04250168
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
    </Public_title>
    <Scientific_title>Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response to Detect Intercurring Bloodstream Infections and Inform Appropriate Antibiotic Treatment
    </Scientific_title>
    <Acronym>Bact_EVD
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200129
    </Date_registration3>
    <Date_registration>29/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04250168
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 11, 2019
    </Date_enrollement>
    <Target_size>43
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Octavia Lunguya;Jan Jacobs
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>INRB;ITM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient admitted in an Ebola Treatment Center (ETC) or Ebola Transit Center (TC)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Laboratory-confirmed (Ebola RT-PCR positive result) EVD diagnosis, or, EVD suspect&#x0D;&lt;br&gt;             patient requiring instant intravenous antibiotic treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing and able to provide written informed consent personally or by a legally&#x0D;&lt;br&gt;             acceptable representative if the patient is unable to do so&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  We do not exclude certain patient groups, but whenever harm is expected from the&#x0D;&lt;br&gt;             additional blood sampling needed for this study, the clinician can opt not to enroll&#x0D;&lt;br&gt;             the patient&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Sepsis Bacterial;Ebola Virus Disease;Bloodstream Infection
    </Condition>
    <Primary_outcome>Determine frequency, causative pathogen, and antibiotic resistance profiles of bacterial bloodstream infections among confirmed EVD patients
    </Primary_outcome>
    <Secondary_outcome>Assess the value of simple biomarker blood tests (WBC + DIFF, CRP, PCT) and Early Warning Scores (EWS) to guide targeted empiric antibiotic treatment and to early detect bacterial bloodstream infections, as compared to bacterial blood culture results;Validate current empiric antibiotic treatment guidelines in EVD care
    </Secondary_outcome>
    <Secondary_ID>1328/19
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Alliance for International Medical Action;Médecins Sans Frontières, France;International Medical Corps;World Health Organization
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10353028
    </Internal_Number>
    <TrialID>NCT04235361
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
    </Public_title>
    <Scientific_title>Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
    </Scientific_title>
    <Acronym>MobEboDRC
    </Acronym>
    <Primary_sponsor>University of Stirling
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200116
    </Date_registration3>
    <Date_registration>16/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04235361
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 15, 2021
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Canada;Congo, The Democratic Republic of the;Germany;Senegal;Canada;Congo, The Democratic Republic of the;Germany;Senegal
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Manfred Weidmann, PhD;Manfred Weidmann, PhD;Sheila Makiala, MD
    </Contact_Lastname>
    <Contact_Email>;m.w.weidmann@stir.ac.uk;shemakiala@yahoo.fr
    </Contact_Email>
    <Contact_Tel>;+441786467873;+243998216400
    </Contact_Tel>
    <Contact_Affiliation>m.w.weidmann@stir.ac.uk;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All subjects (male, female, adults and children) meeting the WHO case definition of&#x0D;&lt;br&gt;             "suspected" and "probable" EVD case eligible for real time RT-PCR assay, according to&#x0D;&lt;br&gt;             the currently used case definition in DRC.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For the prospective evaluation, oral informed consent from the patient/legal guardian&#x0D;&lt;br&gt;             will be requested for eligibility to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  inability to provide consent, samples or condition that could jeopardize the subject's&#x0D;&lt;br&gt;             safety.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Ebola Virus Disease;Malaria;Typhoid Fever;Dengue Fever;Chikungunya Fever;Yellow Fever
    </Condition>
    <Intervention>Diagnostic Test: Differential RPA tests
    </Intervention>
    <Primary_outcome>Recombinase polymerase amplifictaion test result
    </Primary_outcome>
    <Secondary_ID>RIA2018EF-2089;992770
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Institut Pasteur de Dakar;University of Göttingen;Centre de Recheche du Centre Hospitalier Université Laval
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12601592
    </Internal_Number>
    <TrialID>PACTR202004535453508
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Pharmacokinetics, safety, tolerability and efficacy of a new artemether-lumefantrine dispersible tablet in infants and neonates &lt;5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.
    </Public_title>
    <Scientific_title>A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates &lt;5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Novartis Pharma AG
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200115
    </Date_registration3>
    <Date_registration>15/01/2020
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9668
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>0 Day(s)
    </Inclusion_agemin>
    <Inclusion_agemax>1 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>26/10/2020
    </Date_enrollement>
    <Target_size>44
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Non-randomised,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-2
    </Phase>
    <Countries>Burkina Faso;Burkina Faso;Kenya;Mali;Nigeria;Democratic Republic of the Congo;Zambia
    </Countries>
    <Contact_Firstname>Novartis Pharma AG
    </Contact_Firstname>
    <Contact_Lastname>Novartis Pharma AG
    </Contact_Lastname>
    <Contact_Address>Fabrikstrasse 2
    </Contact_Address>
    <Contact_Email>novartis.email@novartis.com
    </Contact_Email>
    <Contact_Tel>+41613241111
    </Contact_Tel>
    <Contact_Affiliation>Trial Director
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male or female neonates / infants&#x0D;&lt;br&gt;2. Body weight &lt;5 kg but = 2kg&#x0D;&lt;br&gt;3. In Cohort 1, infants aged &gt;28 days; in Cohort 2, neonates aged 1 to =28 days (3 subgroups: 15-28 days; 8-14 days; 1-7 days)&#x0D;&lt;br&gt;4. Microscopically confirmed diagnosis of P. falciparum malaria (or mixed infections) &#x0D;&lt;br&gt;• in Cohort 1: of =500 and &lt;100,000 parasites/µL asexual P. falciparum parasitemia&#x0D;&lt;br&gt;• in Cohort 2: of =100 and &lt;100,000 parasites/µL asexual P. falciparum parasitemia&#x0D;&lt;br&gt;• either congenital or neonatal&#x0D;&lt;br&gt;• either symptomatic or asymptomatic
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Head circumference &lt; - 2 SD z-score in cm following WHO age and sex-specific reference curves (suspicion of microcephaly)&#x0D;&lt;br&gt;2. Severe malnutrition&#x0D;&lt;br&gt;3. Presence of severe malaria (according to WHO 2015 definition)&#x0D;&lt;br&gt;4. HIV status: &#x0D;&lt;br&gt;• in Cohort 1 : patient’s or patient's mother's current treatment with ARV&#x0D;&lt;br&gt;• in Cohort 2 : Mother’s known HIV positive status at patient's birth or mother's current treatment with ARV&#x0D;&lt;br&gt;5. Presence of the following signs of a critical condition: apnea-bradycardia, sustained bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely deteriorated general condition (based on IMCI criteria in sick infants, WHO 2005)&#x0D;&lt;br&gt;6. Presence of any clinically significant neurological condition: &#x0D;&lt;br&gt;• any episode of convulsion during the present illness (in keeping with the IMCI list of general danger signs)&#x0D;&lt;br&gt;• known neurological disorders (e.g. chronic seizure disorders, cerebral palsy) &#x0D;&lt;br&gt;7. Presence of clinically significant abnormality of the hepatic and renal systems&#x0D;&lt;br&gt;8. History of malabsorption or previous gastrointestinal surgery, or history of radiation therapy that could affect drug absorption or metabolism, or any other disorder or history of a condition that could interfere with drug absorption, distribution, metabolism, or excretion&#x0D;&lt;br&gt;9. Known hypersensitivity of the patient or either patient's parent to artemether, lumefantrine, any of the excipients of Coartem®/Riamet® Dispersible tablet, or to drugs of similar chemical classes&#x0D;&lt;br&gt;10. Known family history of congenital prolongation of the QTc interval or sudden death or with any other clinical condition known to be associated with prolongation of the QTc interval such as history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease&#x0D;&lt;br&gt;11. Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)&#x0D;&lt;br&gt;12. Presence of any age-adjusted clinically or hematologically relevant laboratory and blood chemistry abnormalities
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria &lt;br&gt;Paediatrics;Malaria;Paediatrics
    </Condition>
    <Intervention>;artemether lumefantrine ;No Control group in this study
    </Intervention>
    <Primary_outcome>Artemether Cmax (represents the higher concentration between the concentrations at 1 hour and 2 hours after first dose)
    </Primary_outcome>
    <Secondary_outcome>Lumefantrine Day 8 concentration (C168h) Artemether AUC, DHA and Lumefantrine Cmax and AUC as appropriate;Serious adverse events (SAEs), adverse events (AEs), and routine safety laboratory assessments;PCR-corrected Adequate Clinical and parasitological Response (ACPR) at Days 15, 29, and 43&#x0D;&lt;br&gt;Uncorrected ACPR at Days 8, 15, 29, and 43&#x0D;&lt;br&gt;Incidence rate of recrudescence and new infections at Days 15, 29 and 43&#x0D;&lt;br&gt;Parasite and Fever clearance Times (PCT and FCT) &#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Source_Support>PAMAfrica research consortium ;European and Developing Countries Clinical Trials Partnership
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>25/03/2020;10/06/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>contact@sante.gov.bf;contact@sante.gov.bf
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite d ethique pour la recherche en sante;Comite d ethique pour la recherche en sante
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0022650366674;0022650366674
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>contact@sante.gov.bf;contact@sante.gov.bf
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11488114
    </Internal_Number>
    <TrialID>NCT04331847
    </TrialID>
    <Last_Refreshed_on>18 October 2021
    </Last_Refreshed_on>
    <Public_title>Abortion-related Morbidity and Mortality in Conflict-affected and Fragile Settings Study
    </Public_title>
    <Scientific_title>AMoCo Study: Abortion-related Morbidity and Mortality in Conflict-affected and Fragile Settings Study
    </Scientific_title>
    <Acronym>AMoCo
    </Acronym>
    <Primary_sponsor>Epicentre
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200114
    </Date_registration3>
    <Date_registration>14/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04331847
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>September 3, 2019
    </Date_enrollement>
    <Target_size>2500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Central African Republic;Congo, The Democratic Republic of the;Nigeria;Central African Republic;Congo, The Democratic Republic of the;Nigeria
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>FETTERS Tamara;PASQUIER Estelle
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Ipas;Epicentre
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        MEDICAL RECORD REVIEW:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  with any signs or symptoms of abortion-related complications, i.e. any signs or&#x0D;&lt;br&gt;             symptoms of complications of spontaneous or induced abortion, whatever the abortion&#x0D;&lt;br&gt;             stage: inevitable, missed, incomplete, complete abortion .&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Or with a presentation primary diagnosis of ectopic pregnancy or molar pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Threatened abortion (defined as vaginal bleeding with a closed cervix after having&#x0D;&lt;br&gt;             excluded the diagnosis of ectopic pregnancy or molar pregnancy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of abortion-related complications and presenting for an unrelated issue&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refusal to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        QUANTITATIVE INTERVIEW:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria: all women included in the medical record review subcomponent and&#x0D;&lt;br&gt;        hospitalized (who stayed overnight or more)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Participation to the interview as potentially harmwful to the woman according to her health&#x0D;&lt;br&gt;        care provider, Refusal to participate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        QUALITATIVE INTERVIEW:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria: Women eligible for the quantitative interview and who experienced at&#x0D;&lt;br&gt;        least 1 criterion of near-miss event or potentially life-threatening conditions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Participation to the interview as potentially harmwful to the woman according to her health&#x0D;&lt;br&gt;        care provider, Refusal to participate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        RAPID FACILITY ASSESSMENT:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Key-informant: the provider in charge of the service providing post-abortion care&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        KAPB SURVEY:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Health professionals (i.e. doctors, midwives, clinical officers, medical officers, nurses,&#x0D;&lt;br&gt;        aidmidwives, aid-nurses) involved in PAC and SAC services in the study site health facility&#x0D;&lt;br&gt;        Literate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Refusal to participate.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Abortion Complication
    </Condition>
    <Primary_outcome>From the Quantitative observational descriptive study:
    </Primary_outcome>
    <Secondary_outcome>Quantitative observational descriptive study: medical record review+quantitative interviews:;Quantitative observational descriptive study: medical record review+quantitative interviews:;Quantitative observational descriptive study: medical record review+quantitative interviews:;Quantitative observational descriptive study: medical record review+quantitative interviews:;Quantitative observational descriptive study: medical record review+quantitative interviews:;Quantitative observational descriptive study: medical record review+quantitative interviews:;Quantitative observational descriptive study: medical record review+quantitative interviews:;Quantitative observational descriptive study: medical record review+quantitative interviews:;Quantitative observational descriptive study: medical record review+quantitative interviews:;Quantitative observational descriptive study: medical record review+quantitative interviews:;Qualitative study (qualitative in-depth interviews):;Qualitative study (qualitative in-depth interviews):;Qualitative study (qualitative in-depth interviews):;Knowledge Attitude Practice and Behavior (KAPB) survey:
    </Secondary_outcome>
    <Secondary_ID>509;18110;Elrha-R2HC
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ipas;Guttmacher Institute;Medecins Sans Frontieres, Netherlands
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12623975
    </Internal_Number>
    <TrialID>ISRCTN14765686
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>Psychological and social impact of promoting positive masculinity in reducing gender-based violence
    </Public_title>
    <Scientific_title>Evaluating the psychological and social impact by promoting positive masculinity through the ‘Living Peace’ intervention (LPiNT) in DRC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>ELRHA
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200106
    </Date_registration3>
    <Date_registration>06/01/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN14765686
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/07/2018
    </Date_enrollement>
    <Target_size>800
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized controlled trial (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Able to understand and give informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Minors
    </Exclusion_Criteria>
    <Condition>Sexual and gender-based violence &lt;br&gt;Not Applicable &lt;br&gt;Sexual assault by bodily force
    </Condition>
    <Intervention>&lt;br&gt;                This study will use a Cluster Randomized Controlled Trial (CRCT) with persons-level and cluster-level outcomes.  The counterfactual is villages that are listed as being eligible for LPint, but where no group therapy sessions are happening. The unit of randomization is an LPint locality (LPint-L), mostly a village, where on average two or three LPint groups of 15 men can be formed. This design allows us to make comparisons between LPint-Ls so we can measure the impact of LPint on the level of communities. From a selected list of eligible LPint-Ls, we will randomly allocate half of the LPint-Ls to the treatment group and half to the control group. All eligible men in a LPint-L, for both treatment and control groups, are recruited in the study.  Concerning the primary aim of measuring the psychological and social impact of LPint, this study will look at GBV reduction and its consequences for the targeted men, their wives/partners, their children and their communities. With regard to the secondary aim assessing whether change in behavior (i.e. reduced GBV) is mediated or moderated by a reduction in symptoms of post-traumatic stress disorder (PTSD) or other psychopathological conditions, the study will use standardized scales of PTSD and other psychopathological conditions to test whether they mediate or moderate the reduction of GBV. Finally, to contextualize empirical findings, we will use qualitative research, with individual and focus group interviews as methods, to understand cultural idioms of distress and cultural explanation models.&lt;br&gt;&lt;br&gt;                A rotary method using papers was used for randomisation of villages.&lt;br&gt;&lt;br&gt;                Through a 16-­session, 16-week group therapeutic intervention. Selected participants sit together in groups of 15 men,
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Collected at baseline, immediately post-therapy (16 weeks), and 1 year post-therapy:&lt;br&gt;                1. The impact on men is measured using a standardised questionnaire (IMAGES survey), interviews (individual and focus group) and fieldwork notes&lt;br&gt;                2. The impact on families is measured using a standardised questionnaire (IMAGES survey), interviews (individual and focus group) and fieldwork notes&lt;br&gt;                3. The impact on communities is measured using a standardised questionnaire (IMAGES survey), interviews (individual and focus group) and fieldwork notes&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Collected at baseline, immediately post-therapy (16-weeks), and one-year post-therapy:&lt;br&gt;                1. Symptoms of PTSD are measured using a standardised questionnaire (IMAGES survey), interviews (individual and focus group) and fieldwork notes&lt;br&gt;                2. Symptoms of depression are measured using a standardised questionnaire (IMAGES survey), interviews (individual and focus group) and fieldwork notes&lt;br&gt;                3. Symptoms of alcohol abuse are measured using a standardised questionnaire (IMAGES survey), interviews (individual and focus group) and fieldwork notes&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;R2HC
    </Secondary_ID>
    <Source_Support>ELRHA
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>
                    1. Approved 15/04/2019, University of Rwanda (UR),  Research Ethical Review Board (PO Box 4285, Kigali, Rwanda; +252574302; jbgahutu@yahoo.com), no ref
                    2. Approved 18/06/2018, Institut Superieur du Lac Research Ethical Commission (PO Box 20, Goma, Democratic Republic of Congo; no tel; islsantementale@gmail.com), no ref
                    3. Approval extended 12/08/2020, University of Rwanda Research Ethical Board (PO Box 4285, Kigali, Rwanda; +252574302/
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/11/2021
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11649335
    </Internal_Number>
    <TrialID>CTRI/2019/12/022417
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Alternative Approach for General Health Issues
    </Public_title>
    <Scientific_title>Frequency Embedded Crystal Ball Water Technology - FECB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Portoworld
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191218
    </Date_registration3>
    <Date_registration>18-12-2019
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=38957
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>20-12-2019
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized Factorial Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Case Record Numbers  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Angola;Argentina;Australia;Bahamas;Bangladesh;Belarus;Belgium;Benin;Bhutan;Botswana;Brazil;Bulgaria;Burundi;Cambodia;Canada;Central African Republic;Chad;China;Colombia;Congo;Croatia;Cuba;Democratic People's Republic of Korea;Ecuador;Egypt;El Salvador;Equatorial Guinea;Ethiopia;France;Gambia;Germany;Greece;Guinea;Guyana;Haiti;Hong Kong;India;Indonesia;Iran (Islamic Republic of);Ireland;Israel;Japan;Kazakhstan;Kuwait;Liberia;Libyan Arab Jamahiriya;Malaysia;Marshall Islands;Mauritius;Mexico;Morocco;Myanmar;Namibia;Nauru;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Saudi Arabia;Serbia ;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Sweden;Syrian Arab Republic;Taiwan;Tajikistan;Tanzania;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>O Mohammed Shadab
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Room No - H 6A , Department of public information and Records  , Portoworld, krupa colony,
First Avenue , Ashok Nagar,Chennai 
    </Contact_Address>
    <Contact_Email>portoworld1@gmail.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Portoworld
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Healthy Induvidual Above the age of 18yrs and Below 70yrs are involved
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Any Induvidual below the age of Five Years and pregnant ladies are exempted from this trial
    </Exclusion_Criteria>
    <Condition/>
    <Intervention>Intervention1: FREQUENCY EMBEEDED WATER: DIFFERENT FREQUENCIES ARE EMBEEDED IN A CRYSTAL BALL AND THEN THE BALL WITH FREQUENCY IS DIPPED IN A DRINKING WATER FOR 10 MINUTES AND THE WATER IS PRESENTED TO PATIENTS&lt;br&gt;Control Intervention1: NOT APPLICABLE: NOT APPLICABLE&lt;br&gt;
    </Intervention>
    <Primary_outcome>General Health AND IMMUNITYTimepoint: 30 days
    </Primary_outcome>
    <Secondary_outcome>Blood sugar becomes NormalTimepoint: 30 days;Metabolism impovedTimepoint: 20 days;Noctonal Pain in joints were reducedTimepoint: 3 months;Testosterone Level increasedTimepoint: 30 days
    </Secondary_outcome>
    <Secondary_ID>IYRF/IND/TN/8947
    </Secondary_ID>
    <Source_Support>Portoworld
H-6A , krupa colony,
First Avenue , Ashok Nagar,Chennai
    </Source_Support>
    <Secondary_Sponsor>Dr Krishnamurthy Kannan
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/07/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>International Youth Research Foundation
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11464617
    </Internal_Number>
    <TrialID>NCT04251351
    </TrialID>
    <Last_Refreshed_on>11 October 2021
    </Last_Refreshed_on>
    <Public_title>Effect of Paracetamol on Kidney Function in Severe Malaria
    </Public_title>
    <Scientific_title>Evaluating the Renoprotective Effect of Paracetamol in Paediatric Severe Malaria: a Randomised Controlled Trial
    </Scientific_title>
    <Acronym>PROTECtS
    </Acronym>
    <Primary_sponsor>University of British Columbia
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191217
    </Date_registration3>
    <Date_registration>17/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04251351
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Year
    </Inclusion_agemin>
    <Inclusion_agemax>14 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 15, 2021
    </Date_enrollement>
    <Target_size>460
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Katherine Plewes, Dr.;Katherine Plewes, Dr.;Marie Onyamboko, Dr.
    </Contact_Lastname>
    <Contact_Email>;katherine@tropmedres.ac;akatshimarie@yahoo.fr
    </Contact_Email>
    <Contact_Tel>;+1-604-603-4033;+243990024201
    </Contact_Tel>
    <Contact_Affiliation>Mahidol Oxford Tropical Medicine Research Unit;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or Female, patients aged 1 to = 14 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Severe P. falciparum malaria, confirmed by positive blood smear with asexual forms of&#x0D;&lt;br&gt;             P. falciparum or positive PfHRP2 rapid diagnostic test (RDT).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Pre-specified modified criteria for severe falciparum malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Upon hospital admission, asexual parasitaemia plus at least ONE of the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Glasgow coma score &lt; 11/15 or Blantyre coma score &lt;3/5 in pre-verbal children&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Generalized convulsions (=2 in 24 hours)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Jaundice (visible jaundice)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Severe anaemia (HCT &lt;15%/Hb&lt;5 g/dL: aged &lt;12) Severe anaemia (HCT &lt;20%/Hb&lt;7 g/dL:&#x0D;&lt;br&gt;                  aged =12)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Hyperparasitaemia (&gt;10%)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Hypoglycaemia (glucose &lt; 2.2 mmol/L; &lt;40 mg/dL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Kidney dysfunction (blood urea &gt; 20 mmol/L)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Acidosis (venous bicarbonate &lt;15 mmol/L or base excess less than -3.3mEq/L)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Venous lactate &gt; 5 mmol/L&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Shock (systolic blood pressure &lt; 70 mmHg (&lt;12 years) &lt;80 mmHg (=12 years) with&#x0D;&lt;br&gt;                  cool extremities or capillary refill &gt;3 seconds)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Respiratory distress (costal indrawing, use of accessory muscles, nasal flaring,&#x0D;&lt;br&gt;                  deep breathing or severe tachypnea (respiratory rate&gt;ULN for age)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Spontaneous bleeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Prostration (inability to set upright, or drink)* Abbreviations: HCT,&#x0D;&lt;br&gt;                  haematocrit; Hb, haemoglobin; *cannot be only severity criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Temperature &gt;38°C on admission or fever during the preceding 48 hours.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Less than 24 hours of antimalarial therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Attending caregiver of participant willing and able to give informed consent for&#x0D;&lt;br&gt;             participation in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        The participant may not enter the trial if ANY of the following apply:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Contraindication or known allergy to paracetamol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Known chronic liver disease or tender hepatomegaly&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Known chronic kidney disease, history of renal replacement therapy or renal biopsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Participants who are already enrolled in another research trial involving an&#x0D;&lt;br&gt;             investigational product or have participated to the same study before&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Severe Malaria;Malaria,Falciparum;Acute Kidney Injury;Paracetamol
    </Condition>
    <Intervention>Drug: Paracetamol;Procedure: Mechanical antipyresis
    </Intervention>
    <Primary_outcome>Acute kidney injury (AKI) or death among patients enrolled without AKI (Composite outcome);Acute kidney injury (AKI) progression or death among patients enrolled with AKI (Composite outcome)
    </Primary_outcome>
    <Secondary_outcome>Number of patients with serious adverse events;Proportion of patients who develop Major Adverse Kidney Events (MAKE) composite;Fever clearance time;Coma recovery;Longitudinal change in renal function;Longitudinal change in markers of hemolysis;Longitudinal change of endothelial activation;Longitudinal change of immune activation;Longitudinal change of AKI biomarker;Parasite (parasites/ul) clearance;Exploratory analysis with sex;Pharmacokinetic properties;Pharmacokinetic properties;Pharmacokinetic properties;Pharmacokinetic properties;Pharmacokinetic properties;Pharmacodynamic relationships;Pharmacodynamic relationships;Pharmacodynamic relationships;Pharmacodynamic relationships;Pharmacodynamic relationships
    </Secondary_outcome>
    <Secondary_ID>H19-03570
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Mahidol Oxford Tropical Medicine Research Unit;Kinshasa Medical Oxford Research Unit
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12573993
    </Internal_Number>
    <TrialID>NCT04186000
    </TrialID>
    <Last_Refreshed_on>10 October 2022
    </Last_Refreshed_on>
    <Public_title>Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola
    </Public_title>
    <Scientific_title>Open-label Phase 2 Study to Evaluate the Immunogenicity and Safety of a Prophylactic Vaccination of Health Care Providers by Administration of a Heterologous Vaccine Regimen Against Ebola in the Democratic Republic of the Congo
    </Scientific_title>
    <Acronym>EBOVAC3DRC
    </Acronym>
    <Primary_sponsor>Universiteit Antwerpen
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191201
    </Date_registration3>
    <Date_registration>01/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04186000
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 18, 2019
    </Date_enrollement>
    <Target_size>699
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Hypolite Mavoko Muhindo, Dr.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Kinshasa, Tropical Medicine Department
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant must pass the Test of Understanding (TOU).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Each participant must sign an informed consent form (ICF) indicating that he or she&#x0D;&lt;br&gt;             understands the purpose of, and procedures required for, the study and is willing to&#x0D;&lt;br&gt;             participate in the study. In case the participant cannot read or write, the procedures&#x0D;&lt;br&gt;             must be explained and informed consent must be witnessed by a trusted literate third&#x0D;&lt;br&gt;             party not involved with the conduct of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be a man or woman aged 18 years or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be a documented health care provider in DRC.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be healthy in the investigator's clinical judgment and on the basis&#x0D;&lt;br&gt;             of vital signs assessed at day 1 screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Before vaccination, a woman must be either:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Of childbearing potential and practicing (or intending to practice) a highly effective&#x0D;&lt;br&gt;        method of birth control consistent with local regulations and/or local culture regarding&#x0D;&lt;br&gt;        the use of birth control methods for participants in clinical studies, beginning at least&#x0D;&lt;br&gt;        28 days prior to vaccination and during the study up to at least 3 months after the first&#x0D;&lt;br&gt;        (or only) vaccination (Ad26.ZEBOV) and 1 month after the MVA-BN-Filo vaccination (if&#x0D;&lt;br&gt;        applicable); and then starting again 14 days before the booster vaccination until 3 months&#x0D;&lt;br&gt;        after the booster vaccination.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        OR Not of childbearing potential: postmenopausal (amenorrhea for at least 12 months without&#x0D;&lt;br&gt;        alternative medical cause); permanently sterilized (eg, bilateral tubal occlusion [which&#x0D;&lt;br&gt;        includes tubal ligation procedures as consistent with local regulations], hysterectomy,&#x0D;&lt;br&gt;        bilateral salpingectomy, bilateral oophorectomy); OR otherwise be incapable of pregnancy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Woman of childbearing potential must have a negative urine ß-human chorionic&#x0D;&lt;br&gt;             gonadotropin (ß-hCG) pregnancy test immediately prior to each study vaccine&#x0D;&lt;br&gt;             administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be available and willing to participate for the duration of the&#x0D;&lt;br&gt;             study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be willing and able to comply with the protocol requirements,&#x0D;&lt;br&gt;             including the prohibitions and restrictions specified in Section 4.3.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must be willing to provide verifiable identification.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant must have a means to be contacted.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known history of Ebola virus disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having received any experimental candidate Ebola vaccine less than 3 months prior to&#x0D;&lt;br&gt;             the screening at the first visit.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having received any experimental candidate Ad26-vaccine in the past. Known allergy or&#x0D;&lt;br&gt;             history of anaphylaxis or other serious adverse reactions to vaccines or vaccine&#x0D;&lt;br&gt;             products (including any of the constituents of the study vaccines [eg, polysorbate 80,&#x0D;&lt;br&gt;             ethylenediaminetetraacetic acid (EDTA) or L-histidine for Ad26.ZEBOV vaccine; and tris&#x0D;&lt;br&gt;             (hydroxymethyl)-amino methane (THAM) for MVA BN-Filo vaccine]), including known&#x0D;&lt;br&gt;             allergy to egg, egg products and aminoglycosides.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of acute illness (this does not include minor illnesses such as mild diarrhea&#x0D;&lt;br&gt;             or mild upper respiratory tract infection) or temperature =38.0ºC on Day 1.&#x0D;&lt;br&gt;             Participants with such symptoms will be excluded from enrollment at that time, but may&#x0D;&lt;br&gt;             be rescheduled for enrollment at a later date if feasible.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breastfeeding women, or women planning to become pregnant while enrolled&#x0D;&lt;br&gt;             in this study until at least 3 months after the Ad26.ZEBOV vaccination or 1 month&#x0D;&lt;br&gt;             after MVA-BN-Filo.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of significant conditions or clinically significant findings at screening or&#x0D;&lt;br&gt;             vital signs for which, in the opinion of the investigator, participation would not be&#x0D;&lt;br&gt;             in the best interest of the participant (eg, compromise the safety or well-being) or&#x0D;&lt;br&gt;             that could prevent, limit, or confound the protocol-specified assessments.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major surgery (per the investigator's judgment) within the 4 weeks prior to screening,&#x0D;&lt;br&gt;             or planned major surgery during the study (from the start of screening onwards).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Post-organ and/or stem cell transplant whether or not with chronic immunosuppressive&#x0D;&lt;br&gt;             therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Received an investigational drug or investigational vaccines or used an invasive&#x0D;&lt;br&gt;             investigational medical device within 3 months prior to screening, or current or&#x0D;&lt;br&gt;             planned participation in another clinical study during the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of chronic urticaria (recurrent hives).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Ebola Virus Disease
    </Condition>
    <Intervention>Biological: Ad26.ZEBOV vaccine
    </Intervention>
    <Primary_outcome>Binding antibody responses post-dose 2 vaccination with MVA-BN-Filo
    </Primary_outcome>
    <Secondary_outcome>Safety of a heterologous vaccine regimen utilizing Ad26.ZEBOV as dose 1, MVA-BN-Filo as dose 2 and Ad26.ZEBOV as booster dose 3;Binding antibody responses after booster vaccination with Ad26.ZEBOV
    </Secondary_outcome>
    <Secondary_ID>EDMS-ERI-176345633;VAC52150EBL2007
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Johnson &amp; Johnson;Ace Africa;Innovative Medicines Initiative;Coalition for Epidemic Preparedness Innovations;University of Kinshasa
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12427738
    </Internal_Number>
    <TrialID>NCT04176029
    </TrialID>
    <Last_Refreshed_on>29 July 2022
    </Last_Refreshed_on>
    <Public_title>Lung Ultrasound in Children With Severe Malaria
    </Public_title>
    <Scientific_title>Point of Care Lung Ultrasound to Differentiate Causes of Respiratory Distress in Children With Severe Malaria
    </Scientific_title>
    <Acronym>LUSiSM
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191121
    </Date_registration3>
    <Date_registration>21/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04176029
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Year
    </Inclusion_agemin>
    <Inclusion_agemax>14 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 9, 2019
    </Date_enrollement>
    <Target_size>124
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the
    </Countries>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>9851040
    </Internal_Number>
    <TrialID>ISRCTN99611164
    </TrialID>
    <Last_Refreshed_on>21 September 2020
    </Last_Refreshed_on>
    <Public_title>Comparative evaluation of standard and dual-treated insecticide bednets in Sud Ubangi, Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Comparative evaluation of standard insecticide-treated bednets and co-treated bednets on malaria prevalence in Sud Ubangi, Democratic Republic of Congo: a cluster-randomised trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Liverpool School of Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191029
    </Date_registration3>
    <Date_registration>29/10/2019
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN99611164
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>01/06/2020
    </Date_enrollement>
    <Target_size>86000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cluster randomised trial  (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Women attending first ANC appointment at a clinic that is taking part in the study and who consent to be enrolled in the study
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Young adolescents (&lt;15 years)&lt;br&gt;                2. Women presenting with symptoms of severe malaria&lt;br&gt;                3. Women suffering from other illness requiring prompt treatment&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Malaria &lt;br&gt;Infections and Infestations &lt;br&gt;Unspecified malaria
    </Condition>
    <Intervention>&lt;br&gt;                A total of 16 clusters (provincial health zones) are involved in the study; clusters were randomised to receive a different type of treated bednet by a member of LSTM staff, who will not be directly involved in the study. All houses within the eight zones allocated to group 1 will receive standard (pyrethroid only) bednet; within the seven zones allocated to group 2 will receive a PBO co-treated bednet. Within the remaining zone, the distribution will be mixed with one part receiving each bednet, as dictated by different numbers of bednets available within the distribution programme.&lt;br&gt;&lt;br&gt;                Bednets, supplied by Against Malaria Foundation, will be distributed in Sud Ubangi by IMA World Health in partnership with SANRU (DRC rural health programme). All households in Sud Ubangi will receive sufficient nets to permit coverage of one net per two occupants. At the time of distribution, nets will be hung over sleeping spaces by the distribution team partners with an accompanying education programme to increase correct usage, care and maintenance of nets by householders. The study team have no role in the distribution or hanging of bednets or the bednet-related education programme.&lt;br&gt;&lt;br&gt;                The study involves:&lt;br&gt;                1. Determination of parasite prevalence in women visiting monthly antenatal clinics&lt;br&gt;                2. Entomological collections for surveillance of insecticide resistance and mosquito abundance and parasite infection&lt;br&gt;                3. Assessment of bednet durability (physical and chemical analysis) and bioefficacy (against mosquitoes) over time&lt;br&gt;&lt;br&gt;                The intervention is not under control of the trial but it is planned by the Ministry of Health to replace the nets after a minimum of 36 months, which could be v
    </Intervention>
    <Primary_outcome>Parasite prevalence (defined as the proportion of positive malaria rapid diagnostic tests) in pregnant women assessed at 0, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months after bednet distribution
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Frequency of molecular markers associated with insecticide resistance in the primary malaria vector mosquito (Anopheles gambiae) is measured from DNA extracted from mosquitoes collected in one half of the study clusters at 0, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months after bednet distribution&lt;br&gt;                2. Mosquito abundance and parasite infection rate (with the infectious sporozoite stage) will be measured in one half of the study clusters at 0, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months after bednet distribution&lt;br&gt;                3. Prevalence and intensity of phenotypic insecticide resistance, assessed using World Health Organization (WHO) tests of insecticide, in 4 study clusters at 0, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months after bednet distribution&lt;br&gt;                4. Bednet durability and bio-efficacy assessed will be measured using WHO guidelines for physical assessment of the area of holes, chemical analysis of insecticide (and PBO) concentrations and capacity of the net material to kill locally-caught mosquitoes in controlled experiments in nets collected from 4 study clusters at 0, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months after bednet distribution&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;SU-ITN_1
    </Secondary_ID>
    <Source_Support>Against Malaria Foundation 
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>
                    1. Approved 24/09/2019, Liverpool School of Tropical Medicine: Research Ethics Committee (Pembroke Place, Liverpool, L3 5QA, UK; Tel: +44(0)151 705 3100), ref: 19-072
                    2. Approved 23/09/2019, University of Kinshasa Research Ethics Committee (Ecole de Sante Publique
                    Comite d'Ethique, Ministere de 1'Enseignement Superieur et Universitaire, Unlversite de Kinshasa Faculte de Medecine: B.P 11850 Kin I, Republique Democratique du Congo)
   
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/05/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11666452
    </Internal_Number>
    <TrialID>NCT04152486
    </TrialID>
    <Last_Refreshed_on>29 November 2021
    </Last_Refreshed_on>
    <Public_title>Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC
    </Public_title>
    <Scientific_title>Evaluation of a Heterologous, Two-dose Preventive Ebola Vaccine for Effectiveness and Safety in the Democratic Republic of the Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>London School of Hygiene and Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191025
    </Date_registration3>
    <Date_registration>25/10/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04152486
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Year
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 14, 2019
    </Date_enrollement>
    <Target_size>20426
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jean-Jacques Muyembe-Tamfum, MD, PhD;Daniel Bausch, MD, PhD;Deborah Watson-Jones, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>L'Institut National de Recherche Biomédicale RDC;London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Must provide a written or witnessed (if illiterate) informed consent form indicating&#x0D;&lt;br&gt;             that he or she understands the reasons for the study and is willing to participate in&#x0D;&lt;br&gt;             the study and be vaccinated. If less than 18 years old, must have a parent or guardian&#x0D;&lt;br&gt;             that is able to meet this criterion.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Must be aged 1 year or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Must be healthy in the investigator's clinical judgment as assessed on the day of&#x0D;&lt;br&gt;             vaccination.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Must be willing to have a photograph taken.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Participant must be available and willing to participate for duration of study visits&#x0D;&lt;br&gt;             and follow up.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Known history of Ebola virus disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Has received any experimental Ebola vaccine less than one month prior to Visit 1.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines&#x0D;&lt;br&gt;             or vaccine products, egg and egg proteins or gentamicin.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Presence of acute illness (excluding minor illnesses such as mild diarrhea or mild&#x0D;&lt;br&gt;             upper respiratory tract infection) or temperature =38.0ºC at Visit 1 (dose 1 visit).&#x0D;&lt;br&gt;             Participants with such symptoms will be temporarily excluded from vaccination at that&#x0D;&lt;br&gt;             time but may be rescheduled for vaccination at a later date if feasible.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Presence of significant conditions or clinically significant findings at the&#x0D;&lt;br&gt;             vaccination visit for which, in the opinion of the investigator, vaccination would not&#x0D;&lt;br&gt;             be in the best interest of the participant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. History of recurrent generalized hives.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Ebola Virus Disease
    </Condition>
    <Intervention>Biological: Ad26.ZEBOV, MVA-BN-Filo vaccine
    </Intervention>
    <Primary_outcome>Numbers and odds of vaccination status in Ebola Virus Diseases cases and in EVD-negative controls.
    </Primary_outcome>
    <Secondary_outcome>Number and proportion of adults and children with solicited and unsolicited serious adverse events.;Number and proportion of adults and children receiving dose 1.;Number and proportion of adults and children receiving dose 2.;Number of participants participating in in-depth interviews and focus group discussions
    </Secondary_outcome>
    <Secondary_ID>DRC-EB-001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Epicentre;Ministère de la Santé de la RDC;Médecins Sans Frontières, France;Coalition for Epidemic Preparedness Innovations;Janssen Vaccines &amp; Prevention B.V.;Public Health England
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12195606
    </Internal_Number>
    <TrialID>NCT04099628
    </TrialID>
    <Last_Refreshed_on>25 April 2022
    </Last_Refreshed_on>
    <Public_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
    </Public_title>
    <Scientific_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
    </Scientific_title>
    <Acronym>DiTECT-HAT-WP3
    </Acronym>
    <Primary_sponsor>Institut de Recherche pour le Developpement
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190919
    </Date_registration3>
    <Date_registration>19/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04099628
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>4 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2019
    </Date_enrollement>
    <Target_size>13747
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Veerle Lejon, PhD, HDR
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institut de Rechercher pour le Développement
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Permanent resident of village (in low to zero prevalence HAT focus) for minimum 1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previously treated for HAT (irrespective of time elapsed since treatment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  &lt; 4 years old&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Human African Trypanosomiasis;Sleeping Sickness;Trypanosoma Brucei Gambiense; Infection;West African Sleeping Sickness;African Trypanosomiases;Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense
    </Condition>
    <Intervention>Diagnostic Test: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
    </Intervention>
    <Primary_outcome>Sensitivity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk;Specificity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on the population at risk
    </Primary_outcome>
    <Secondary_ID>DiTECT-HAT-WP3
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Public Health, Democratic Republic of the Congo;Institut National de Sante Publique;CIRDES;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Institute of Tropical Medicine, Belgium;University of Liverpool
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11399705
    </Internal_Number>
    <TrialID>NCT04049630
    </TrialID>
    <Last_Refreshed_on>27 September 2021
    </Last_Refreshed_on>
    <Public_title>Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
    </Public_title>
    <Scientific_title>Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
    </Scientific_title>
    <Acronym>EOLoa
    </Acronym>
    <Primary_sponsor>Programme National de Lutte contre l'Onchocercose, Republic of the Congo
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190726
    </Date_registration3>
    <Date_registration>26/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04049630
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 16, 2021
    </Date_enrollement>
    <Target_size>255
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written consent written, signed (or with thumbprint) and dated&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged 18 to 65 inclusive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individual microfilarial density = 1mf/mL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight = 40 kg in women and = 45 kg in men; and less than 85 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In good health condition, as determined by the medical questionnaire and the general&#x0D;&lt;br&gt;             clinical examination: absence of acute or chronic infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in any study other than purely observational, in the 4 weeks preceding&#x0D;&lt;br&gt;             this study (determined by the theoretical date of administration of LEV or placebo).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any vaccination in the 4 weeks preceding this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute infection requiring a treatment in the 10 days preceding this study, determined&#x0D;&lt;br&gt;             by the anamnesis during the medical interview (example: pulmonary infection, ENT,&#x0D;&lt;br&gt;             digestive, cutaneous, with implementation of an antibiotic treatment or not)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Warfarin treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment with clozapine, phenythiazines, sulfasalazine, carbamazepine, synthetic&#x0D;&lt;br&gt;             antithyroid, ticlopidine, cimetidine, and gold salts: whether it is a long-term&#x0D;&lt;br&gt;             treatment, or a treatment given in a single dose 10 days before the start of treatment&#x0D;&lt;br&gt;             for the clinical trial (precaution of use compared to the risk of agranulocytosis of&#x0D;&lt;br&gt;             immuno-allergic or toxic origin)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known immunosuppressive pathology&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Past or current history of neurological (including epilepsy) or neuropsychiatric&#x0D;&lt;br&gt;             disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of agranulocytosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Consumption of alcohol, taking cocaine or other drugs of abuse in the 72 hours&#x0D;&lt;br&gt;             preceding the administration of the treatment of the test determined by the anamnesis&#x0D;&lt;br&gt;             during the medical interview&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any condition, in the opinion of the investigator, which exposes the subject to an&#x0D;&lt;br&gt;             undue risk&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known intolerance to levamisole&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who gave blood in the 8 weeks before entry into the study, with a standard&#x0D;&lt;br&gt;             volume (&gt; 500 mL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  During the clinical examination: symptoms, physical signs or biological constants&#x0D;&lt;br&gt;             suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary,&#x0D;&lt;br&gt;             cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to&#x0D;&lt;br&gt;             interfere with the interpretation results of the test. The doctor may then give a&#x0D;&lt;br&gt;             favorable or unfavorable opinion for the inclusion of the participant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Taking IVM and / or LEV during the last six months; and / or mebendazole or&#x0D;&lt;br&gt;             albendazole in the last month&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant and lactating women (based on self-declaration)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Onchocerciasis, Ocular;Loiasis
    </Condition>
    <Intervention>Drug: LEV 1 mg/kg;Drug: LEV 1,5 mg/kg;Drug: LEV 2,5 mg/kg;Drug: Placebo
    </Intervention>
    <Primary_outcome>Safety and tolerability of levamisole;Incidence of adverse events with levamisole
    </Primary_outcome>
    <Secondary_outcome>Efficacy of levamisole;Proportion of individuals without microfilariae of Loa loa
    </Secondary_outcome>
    <Secondary_ID>EOLoa/LEV
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10604681
    </Internal_Number>
    <TrialID>NCT04037332
    </TrialID>
    <Last_Refreshed_on>8 February 2021
    </Last_Refreshed_on>
    <Public_title>Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
    </Public_title>
    <Scientific_title>Monitoring of Molecular Markers of Artemisinin Resistance in Plasmodium Falciparum Malaria: Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
    </Scientific_title>
    <Acronym>Caramal DRM
    </Acronym>
    <Primary_sponsor>Swiss Tropical &amp; Public Health Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190725
    </Date_registration3>
    <Date_registration>25/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04037332
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 27, 2018
    </Date_enrollement>
    <Target_size>916
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the;Nigeria;Uganda;Congo, The Democratic Republic of the;Nigeria;Uganda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Christian Burri;Christian Lengeler, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Swiss TPH, Department of Medicine;Swiss TPH, Department of Epidemiology and Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age below 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  enrolled in CARAMAL Project&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of fever plus danger signs indicative of severe febrile illness / suspected&#x0D;&lt;br&gt;             severe malaria, according to local iCCM guidelines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  positive malaria test result by RDT or microscopy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  written informed consent from a parent or guardian&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  no current malaria infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mixed or mono-infection with a non-P. falciparum species known prior to sample&#x0D;&lt;br&gt;             collection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  no permanent residence in project area&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Severe Malaria
    </Condition>
    <Intervention>Other: Blood sample (combined with malaria RDT) followed by gentoyping analysis
    </Intervention>
    <Primary_outcome>K13-propeller sequence polymorphisms in P. falciparum
    </Primary_outcome>
    <Secondary_ID>P 001-18-2.0
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Clinton Health Access Initiative, Nigeria;Akena Associates Ltd.;Kinshasa School of Public Health;Makerere University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11354500
    </Internal_Number>
    <TrialID>NCT04036708
    </TrialID>
    <Last_Refreshed_on>13 September 2021
    </Last_Refreshed_on>
    <Public_title>Caregiver Training to Prevent Konzo Disease in Children in Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Caregiver Early Child Development Training for Preventing Konzo From Toxic Cassava in the Democratic Republic of Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Michigan State University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190723
    </Date_registration3>
    <Date_registration>23/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04036708
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>4 Years
    </Inclusion_agemin>
    <Inclusion_agemax>99 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 1, 2021
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Michael J Boivin, PhD;Michael J Boivin, PhD;Desire Tshala-Katumbay, MD PhD
    </Contact_Lastname>
    <Contact_Email>;boivin@msu.edu;tshalad@ohsu.edu
    </Contact_Email>
    <Contact_Tel>;(517) 884-0281;
    </Contact_Tel>
    <Contact_Affiliation>Professor;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Kahemba district households with at least 1 child 4 years or younger&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mother is the primary caregiver of child&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of brain injury (infectious, traumatic, birth) in child&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Konzo disease in any family member of household&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy in child&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any neurodisability in child&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Caregiver is unable to participate in the year-long training&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Caregiver or child are presently enrolled in our parent R01 study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malnutrition;Manihot Species Poisoning
    </Condition>
    <Intervention>Behavioral: Wetting method (WTM);Behavioral: Mediational Intervention for Sensitizing Caregivers (MISC)
    </Intervention>
    <Primary_outcome>Change in Mullen Scales of Early Learning (MSEL) scores;Change in infant gaze length using the Fagan Test of Infant Intelligence (FTII);Change in time looking in Early Childhood Vigilance Test (ECVT);Change in the Observed Mediational Interventions (OMI) scores for home-based videos;Change in urine thiocyanite level
    </Primary_outcome>
    <Secondary_outcome>Change in the Home Observation for the Measurement of the Environment (HOME) score;Change in Hopkins Symptoms Checklist-25 (HSCL) scores;Change in Caregiver functional impairment for caregiving daily activities score;Change in upper-motor neuron neurological symptoms of konzo disease;Change in physical growth measures;Change in neurodisability score
    </Secondary_outcome>
    <Secondary_ID>2272
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12260171
    </Internal_Number>
    <TrialID>NCT04012164
    </TrialID>
    <Last_Refreshed_on>9 May 2022
    </Last_Refreshed_on>
    <Public_title>Viral and Microbial Circulation Between Humans, Domesticated and Wild Animals Along an Ecotone, Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Viral and Microbial Circulation Between Humans, Domesticated and Wild Animals Along an Ecotone, Democratic Republic of Congo
    </Scientific_title>
    <Acronym>MICROTONE
    </Acronym>
    <Primary_sponsor>Institut Pasteur
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190702
    </Date_registration3>
    <Date_registration>02/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04012164
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 15, 2019
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Tamara Giles-Vernick;Steve Ahuka Mundeke
    </Contact_Lastname>
    <Contact_Email>tamara.giles-vernick@pasteur.fr;amstev04@yahoo.fr
    </Contact_Email>
    <Contact_Tel>33 1 40 61 39 82;
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 years or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept participation in study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Residing in one of three villages selected&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In good health and able to conduct habitual daily activities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept self-collection of 2g of stool&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept blood collection (2-2.5 ml) by a medical professional&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept to self-collect daily activities and contacts with selected wild and&#x0D;&lt;br&gt;             domesticated animals for five months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept to participate in an anthropological-historical interview on changing practices&#x0D;&lt;br&gt;             and contacts with wild and domesticated animals&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Vulnerable adults will not be included&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who are pregnant or nursing at the time of recruitment and inclusion will not be&#x0D;&lt;br&gt;             included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults declaring themselves ill and unable to conduct their habitual daily activities&#x0D;&lt;br&gt;             will not be included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults with a chronic illness will not be included&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults who have a family member already included in the study will not be included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults refusing either recording of interviews or note-taking during interviews will&#x0D;&lt;br&gt;             not be included.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Zoonotic Disease
    </Condition>
    <Intervention>Biological: blood sampling;Biological: stool collection;Other: Participatory activity and contact investigation;Other: Anthropological and historical interviews
    </Intervention>
    <Primary_outcome>Percentage of gut bacterial genera shared by included people;Percentage of gut bacterial genera shared by selected wild animals;Percentage of gut bacterial genera shared by selected domesticated animals;Percentage of overlap (of viral genera) between human subjects and great apes
    </Primary_outcome>
    <Secondary_outcome>Description of Contact type;Contact frequency investigation
    </Secondary_outcome>
    <Secondary_ID>2017-085
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Centre National de la Recherche Scientifique, France;University Paris 7 - Denis Diderot
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12181272
    </Internal_Number>
    <TrialID>NCT03998839
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>TIPTOP Sulfadoxine-pyrimethamine (SP) Drug Resistance Study
    </Public_title>
    <Scientific_title>Monitoring of Markers of Sulfadoxine-pyrimethamine (SP) Resistance in the Implementation Countries of TIPTOP Project
    </Scientific_title>
    <Acronym>TIPTOP-DRS
    </Acronym>
    <Primary_sponsor>Jhpiego
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190624
    </Date_registration3>
    <Date_registration>24/06/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03998839
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 5, 2018
    </Date_enrollement>
    <Target_size>7200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the;Madagascar;Mozambique;Nigeria;Congo, The Democratic Republic of the;Madagascar;Mozambique;Nigeria
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Elaine Roman, MA
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Jhpiego
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  • Children under five years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Being resident in the project area at the time of the survey.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Clinical signs and symptoms suggestive of malaria infection: fever (axillary&#x0D;&lt;br&gt;                  temperature =37.5ºC) or history of fever in the preceding 24 hours.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not willing to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs or symptoms of severe malaria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria in Pregnancy
    </Condition>
    <Intervention>Other: Community distribution of Sulfadoxine-pyrimethamine (SP)
    </Intervention>
    <Primary_outcome>change in prevalence of molecular markers associated with SP resistance at 36 months;change in prevalence of molecular markers associated with SP resistance at 18 months
    </Primary_outcome>
    <Secondary_ID>TIPTOP_DRS_2019
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Barcelona Institute for Global Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12561543
    </Internal_Number>
    <TrialID>DRKS00017107
    </TrialID>
    <Last_Refreshed_on>4 October 2022
    </Last_Refreshed_on>
    <Public_title>Determinants for the spread of Panton-Valentine leukocidin positive Staphylococcus aureus in Africa
    </Public_title>
    <Scientific_title>Determinants for the spread of Panton-Valentine leukocidin positive Staphylococcus aureus in Africa - STAPH-PVL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Westfälische Wilhelms-Universität Münster
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190528
    </Date_registration3>
    <Date_registration>28/05/2019
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://www.drks.de/DRKS00017107
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>no maximum age
    </Inclusion_agemax>
    <Inclusion_gender>Both, male and female
    </Inclusion_gender>
    <Date_enrollement>01/07/2019
    </Date_enrollement>
    <Target_size>822
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: Other;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Basic research/physiological study;
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Nigeria;Gabon;Congo, the Democratic Republic of the;Germany
    </Countries>
    <Contact_Firstname>Frieder
    </Contact_Firstname>
    <Contact_Lastname>Schaumburg
    </Contact_Lastname>
    <Contact_Address>Domagkstraße 10
    </Contact_Address>
    <Contact_Email>frieder.schaumburg@ukmuenster.de
    </Contact_Email>
    <Contact_Tel>0251-8352752
    </Contact_Tel>
    <Contact_Affiliation>Institut für Medizinische Mikrobiologie, Universitätsklinikum Münster
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. African living in Africa or Caucasian living in Europe; 2. Legal age (=18 years); 3. Signed written informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Known HIV infection; 2. Pregnancy; 3. Regular intake of systemic immunomodulatory drugs (e.g. TNFa antagonist, glucocorticoids etc.); 4. Symptomatic S. aureus infection
    </Exclusion_Criteria>
    <Condition>Susceptibility to PVL;B95.6 - Staphylococcus aureus as the cause of diseases classified to other chapters;U80.00 -
    </Condition>
    <Intervention>Intervention 1: Cross-sectional study: Healthy volunteers will be recruited and screened for S. aureus colonization in the nose and throat. A questionnaire will be used to document risk factors for colonization and the medical history. &lt;br&gt;Blood will be drawn from each participant to isolate peripheral blood mononuclear cells to test the susceptibility to PVL (FACS anaylsis) and to analyse the activation of the inflammasome after exposure to PVL in vitro (ELISA, Western Blot). Serum will be used for the quatification of anti-PVL antibodies and whole blood will be used to screen for polymorphisims in the complement 5 a receptor (sanger sequencing). An association of Africans/caucasians with the clinical endpoints will be tested with descriptive methods (t-test, chi-square test, log-regression).
    </Intervention>
    <Primary_outcome>1. To compare the humoral immune response to PVL (i.e. antibodies, complement) between Africans and Caucasians (Work package 1);&lt;br&gt;2. To compare properties of the C5aR (i.e. avidity to PVL, amino acid sequence) between Africans and Caucasians (Work package 2);&lt;br&gt;3. To compare the cellular response to PVL (i.e. inflammasome activation, cytotoxicity) between Africans and Caucasians (Work package 3);&lt;br&gt;4. To build a sustainable capacity in African research centres to study aspects on the interaction of S. aureus with the human host (Work package 4).
    </Primary_outcome>
    <Secondary_outcome>Not applicable
    </Secondary_outcome>
    <Secondary_ID>2015/409/sS
    </Secondary_ID>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>approved
    </Ethics_review_status>
    <Ethics_review_approval_date>26/08/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10622806
    </Internal_Number>
    <TrialID>NCT03948698
    </TrialID>
    <Last_Refreshed_on>16 February 2021
    </Last_Refreshed_on>
    <Public_title>TB Innovation Project: A Pre- and Post- Implementation Assessment (TIPPI)
    </Public_title>
    <Scientific_title>Evaluation of the Catalyzing Pediatric TB Innovations Project: A Pre- and Post-Implementation Assessment Across Ten Countries
    </Scientific_title>
    <Acronym>TIPPI
    </Acronym>
    <Primary_sponsor>Elizabeth Glaser Pediatric AIDS Foundation
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190510
    </Date_registration3>
    <Date_registration>10/05/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03948698
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2019
    </Date_enrollement>
    <Target_size>3000
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Cameroon;Congo, The Democratic Republic of the;Côte D'Ivoire;India;Kenya;Lesotho;Malawi;Tanzania;Uganda;Zimbabwe;Cameroon;Congo, The Democratic Republic of the;Côte D'Ivoire;India;Kenya;Lesotho;Malawi;Tanzania;Uganda;Zimbabwe
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Jennifer Cohn, MD;Martina Casenghi, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Elizabeth Glaser Pediatric AIDS Foundation;Elizabeth Glaser Pediatric AIDS Foundation
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10&#x0D;&lt;br&gt;             countries and receive TB screening (including screening, diagnosis and treatment for&#x0D;&lt;br&gt;             active TB, and provision of TB preventive therapy).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10&#x0D;&lt;br&gt;             countries and receive TB diagnosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10&#x0D;&lt;br&gt;             countries and receive TB treatment for active TB&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10&#x0D;&lt;br&gt;             countries and receive TB preventive therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        • All pediatric TB patients who enter CaP TB project site in any of the 10 countries and&#x0D;&lt;br&gt;        who are above 15 years old&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tuberculosis;Pediatric
    </Condition>
    <Intervention>Other: Innovative approached to pediatric TB care
    </Intervention>
    <Primary_outcome>Children screened for TB;Children with presumptive TB;Children with presumptive TB referred for lab-based TB diagnosis;Children with presumptive TB tested using GeneXpert;Children initiated on TB preventive therapy;Children completing TB preventive therapy;Children diagnosed with active TB;Time to TB diagnosis;Children initiated on TB treatment;Time to initiation of TB treatment;Children achieving treatment success;TB contacts successfully traced;TB contacts screened negative for TB;TB contacts eligible for preventive therapy
    </Primary_outcome>
    <Secondary_ID>EG0209
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12601267
    </Internal_Number>
    <TrialID>PACTR201905899965726
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Gestational malaria in Kisangani: Efficacy of Mefloquine versus Sulfadoxine-Pyrimethamine in Intermittent Preventive Treatment
    </Public_title>
    <Scientific_title>Mefloquine, the best alternative to replace Sulfadoxine-Pyrimethamine in Intermittent Preventive Treatment : a randomized controlled clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>University of Kisangani
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190508
    </Date_registration3>
    <Date_registration>08/05/2019
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=8121
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>18 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>01/05/2019
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Stratified allocation where factors such as age, gender, center, or previous treatment are used in the stratification,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Nguma Jean Didier
    </Contact_Firstname>
    <Contact_Lastname>Bosenge
    </Contact_Lastname>
    <Contact_Address>500, Avenue Abbe Munyororo
    </Contact_Address>
    <Contact_Email>jdidier.bosenge@unikis.ac.cd
    </Contact_Email>
    <Contact_Tel>+243855206497
    </Contact_Tel>
    <Contact_Affiliation>Searcher
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Pregnant women who will :&#x0D;&lt;br&gt;- begin antenatal visits in medical facilities selected from gestational age between 16 and 18 weeks of amenorrhea, &#x0D;&lt;br&gt;- have not yet received SP prophylaxis during ongoing pregnancy&#x0D;&lt;br&gt;- sign their consent form.&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pregnant women with :&#x0D;&lt;br&gt;- positive HIV serology,&#x0D;&lt;br&gt;- story of morbid neurological and psychiatric, &#x0D;&lt;br&gt;- story of SP allergy&#x0D;&lt;br&gt;- of antimalarial drug(s) use within 15 days prior to selection will be excluded.&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria &lt;br&gt;Pregnancy and Childbirth;Malaria;Pregnancy and Childbirth
    </Condition>
    <Intervention>;Mefloquine;Sulfadoxine Pyrimethamine
    </Intervention>
    <Primary_outcome>- Mefloquine will be well tolerated by Kisangani pregnant women;&lt;br&gt;- Mefloquine will be more effective than SP in pregnant women in Kisangani.&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>- Mefloquine Side-effects will be less frequent  and minors, easy to control;&#x0D;&lt;br&gt;- The prevalence of maternal anemia at delivery will be lower among pregnant women who have taken the Mefloquine compared to those who will use Sulfadoxine-Pyrimethamine;&#x0D;&lt;br&gt;- Placental malaria parasitemia will be lower among pregnant women who have taken the Mefloquine compared to those who will use Sulfadoxine-Pyrimethamine;&#x0D;&lt;br&gt;- The prevalence of low birth will be lower among pregnant women who have taken the Mefloquine compared to those who will use Sulfadoxine-Pyrimethamine.
    </Secondary_outcome>
    <Source_Support>University of Kisangani
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>04/09/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gaspard.esiso@unikis.ac.cd
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethics committee of University of Kisangani
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+243998506536
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gaspard.esiso@unikis.ac.cd
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12288873
    </Internal_Number>
    <TrialID>NCT03923725
    </TrialID>
    <Last_Refreshed_on>30 May 2022
    </Last_Refreshed_on>
    <Public_title>A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
    </Public_title>
    <Scientific_title>A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Africa
    </Scientific_title>
    <Acronym>DeTACT-Africa
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190409
    </Date_registration3>
    <Date_registration>09/04/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03923725
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>12 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2020
    </Date_enrollement>
    <Target_size>3240
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Gambia;Guinea;Nigeria;Niger;Rwanda;Tanzania;Burkina Faso;Congo, The Democratic Republic of the;Gambia;Guinea;Niger;Nigeria;Rwanda;Tanzania
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Mehul Dhorda, Ph.D
    </Contact_Lastname>
    <Contact_Email>Mehul@tropmedres.ac
    </Contact_Email>
    <Contact_Tel>+66 2 203-6333
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female, aged =6 months to &lt;12 years (For Gambia, Rwanda sites only: =6 months)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to take oral medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute uncomplicated P. falciparum monoinfection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Asexual P. falciparum parasitaemia: 1,000/µL to =10% parasitaemia, determined on a&#x0D;&lt;br&gt;             peripheral blood film (At Gambia, Rwanda sites only: For subjects =12 years - 1000/µL&#x0D;&lt;br&gt;             to 200,000/µL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fever defined as = 37.5°C tympanic temperature or a history of fever within the last&#x0D;&lt;br&gt;             24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent by the subject or by parent/guardian in case of children&#x0D;&lt;br&gt;             lower than the age of consent and assent if required (per local regulations)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness and ability of the subjects or parents/guardians to comply with the study&#x0D;&lt;br&gt;             protocol for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of severe malaria (adapted from WHO criteria)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not fulfilling criteria for severe malaria but with another indication for&#x0D;&lt;br&gt;             parenteral antimalarial treatment at the discretion of the treating physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Haematocrit &lt;15% at screening (For Gambia, Rwanda sites only: For subjects =12 years -&#x0D;&lt;br&gt;             Haematocrit &lt;20% at screening)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who have received artemisinin or a derivative within the previous 7 days OR&#x0D;&lt;br&gt;             lumefantrine or amodiaquine within the previous 14 days OR mefloquine or piperaquine&#x0D;&lt;br&gt;             within the previous 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the&#x0D;&lt;br&gt;             last 14 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute illness other than malaria requiring systemic treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe acute malnutrition (in Niger only - only those patients with Severe Acute&#x0D;&lt;br&gt;             Malnutrition and complications requiring inpatient nutritional treatment will be&#x0D;&lt;br&gt;             excluded)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known HIV infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known tuberculosis infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For females: post-menarche (For Gambia, Rwanda sites only: females who are pregnant,&#x0D;&lt;br&gt;             trying to get pregnant or are lactating)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of allergy or known contraindication to any of the study drugs, including&#x0D;&lt;br&gt;             neuropsychiatric disorders and epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous splenectomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Enrolment in DeTACT in the previous 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another interventional study in the previous 3 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Plasmodium Falciparum Malaria (Uncomplicated)
    </Condition>
    <Intervention>Drug: Artemether-lumefantrine+ Amodiaquine (AL+AQ);Drug: Artemether-lumefantrine + placebo (AL+PBO);Drug: Artesunate-mefloquine+piperaquine (AS-MQ+PPQ);Drug: Artesunate-mefloquine+placebo (AS-MQ+PBO)
    </Intervention>
    <Primary_outcome>42 days Efficacy defined as PCR corrected adequate clinical and parasitological response (ACPR).
    </Primary_outcome>
    <Secondary_outcome>63-day PCR corrected and uncorrected efficacy;42-day PCR uncorrected efficacy;Parasite clearance half-life;Proportion of subjects with microscopically detectable P. falciparum parasitaemia;Fever clearance time;Proportion of subjects with gametocytaemia;Incidence of adverse events;Incidence of serious adverse events;Number of cardiotoxicity events;Change in haemoglobin stratified for G6PD status/genotype;Proportion of subjects requiring retreatment due to vomiting;Proportion of subjects that reports completing a full course of observed TACT;Proportion of subjects that reports completing a full course of observed ACT;proportion of subjects that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event.;Pharmacokinetic profiles;Pharmacokinetic interactions;Plasma levels of partner drugs
    </Secondary_outcome>
    <Secondary_ID>MAL18004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Mahidol Oxford Tropical Medicine Research Unit
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12590739
    </Internal_Number>
    <TrialID>CTRI/2019/04/018406
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Azithromycin to Prevent Maternal and Neonatal deaths due to infection in Laboring Women
    </Public_title>
    <Scientific_title>Prevention of maternal and neonatal death/infections with a single oral dose of azithromycin in women in labor (in low- and middle-income countries): a randomized controlled trial - A-PLUS Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190403
    </Date_registration3>
    <Date_registration>03-04-2019
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30299
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-06-2019
    </Date_enrollement>
    <Target_size>34000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Placebo Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Permuted block randomization, variable  Method of allocation concealment:Centralized  Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded
    </Study_design>
    <Phase>Phase 3/ Phase 4
    </Phase>
    <Countries>Bangladesh;Democratic Republic of the Congo;Guatemala;India;Kenya;Pakistan;Zambia
    </Countries>
    <Contact_Firstname>Dr Shivaprasad S Goudar
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Womens and Childrens Health Research Unit KLE Academy of Higher Education and Researchs J N Medical College Nehru Nagar Belgaum Womens and Childrens Health Research Unit KLE Universitys J N Medical College Nehru Nagar Belgaum
    </Contact_Address>
    <Contact_Email>sgoudar@jnmc.edu
    </Contact_Email>
    <Contact_Tel>9448126371
    </Contact_Tel>
    <Contact_Affiliation>KLE Univeristys J N Medical College
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The A-PLUS main trial: &lt;br/ &gt;&#x0D;&lt;br&gt;1.Pregnant women in labor more than or equal to 28 weeks GA (by best estimate) with a pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.  &lt;br/ &gt;&#x0D;&lt;br&gt;2.Admitted to health facility with clear plan for spontaneous or induced delivery. &lt;br/ &gt;&#x0D;&lt;br&gt;3.Live fetus must be confirmed via a fetal heart rate by Doptone prior to randomization.  &lt;br/ &gt;&#x0D;&lt;br&gt;4. More than or equal to 18 years of age. &lt;br/ &gt;&#x0D;&lt;br&gt;5. Have provided written informed consent [Note: written informed consent may be obtained during antenatal care, but verbal re-confirmation may be needed (per local regulations) at the time of randomization] &lt;br/ &gt;&#x0D;&lt;br&gt;Antimicrobial Resistance (AMR) Monitoring Sub-study:  &lt;br/ &gt;&#x0D;&lt;br&gt;1. Randomized and treated mothers or their babies diagnosed with infections up to 6 weeks after delivery &lt;br/ &gt;&#x0D;&lt;br&gt;The A-PLUS Pilot Study on Infection: &lt;br/ &gt;&#x0D;&lt;br&gt;same as for main study
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The A-PLUS main trial: &lt;br/ &gt;&#x0D;&lt;br&gt;1. Non-emancipated minors (as per local regulations) &lt;br/ &gt;&#x0D;&lt;br&gt;2. Evidence of chorioamnionitis or other infection requiring antibiotic therapy at time of eligibility (however, women given single prophylactic antibiotics with no plans to continue after delivery should not be excluded).  &lt;br/ &gt;&#x0D;&lt;br&gt;3. Arrhythmia or known history of cardiomyopathy. &lt;br/ &gt;&#x0D;&lt;br&gt;4. Allergy to azithromycin or other macrolides that is self-reported or documented in the medical record. &lt;br/ &gt;&#x0D;&lt;br&gt;5. Any use of azithromycin, erythromycin, or other macrolide in the 3 days or less prior to randomization. Plan for cesarean delivery prior to randomization. &lt;br/ &gt;&#x0D;&lt;br&gt;6. Preterm labor undergoing management with no immediate plan to proceed to delivery.  &lt;br/ &gt;&#x0D;&lt;br&gt;7. Advanced stage of labor ( &gt;6 cm or 10 cm cervical dilation per local standards) and pushing or too distressed to understand, confirm, or give informed consent regardless of cervical dilation. &lt;br/ &gt;&#x0D;&lt;br&gt;8. Are not capable of giving consent due to other health problems such as obstetric emergencies (for example, antepartum haemorrhage) or mental disorder. &lt;br/ &gt;&#x0D;&lt;br&gt;9. Any other medical conditions that may be considered a contraindication per the judgment of the site investigator. &lt;br/ &gt;&#x0D;&lt;br&gt;10. Previous randomization in the trial. &lt;br/ &gt;&#x0D;&lt;br&gt;The A-PLUS Pilot Study on Infection: &lt;br/ &gt;&#x0D;&lt;br&gt;1. Non-emancipated minors (as per local regulations) &lt;br/ &gt;&#x0D;&lt;br&gt;2. Evidence of chorioamnionitis or other infection requiring antibiotic &lt;br/ &gt;&#x0D;&lt;br&gt;therapy at time of eligibility (however, women given single prophylactic antibiotics with no plans to continue after delivery should &lt;br/ &gt;&#x0D;&lt;br&gt;not be excluded). &lt;br/ &gt;&#x0D;&lt;br&gt;3. Preterm labor undergoing management with no immediate plan to proceed to delivery. &lt;br/ &gt;&#x0D;&lt;br&gt;4. Advanced stage of labor ( &gt;6 cm or 10 cm cervical dilation per local standards) and pushing or too distressed to understand, confirm, or give informed consent regardless of cervical dilation. &lt;br/ &gt;&#x0D;&lt;br&gt;5. Are not capable of giving consent due to other health problems such as obstetric emergencies (for example, antepartum haemorrhage) or mental disorder.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: O85- Puerperal sepsis&#x0D;

    </Condition>
    <Intervention>Intervention1: Azithromycin: Dose-2 g&lt;br&gt;Frequency-Single dose&lt;br&gt;Route of administration-Oral&lt;br&gt;&lt;br&gt;Duration of therapy-A single, prophylactic intrapartum oral dose of azithromycin&lt;br&gt;Control Intervention1: Placebo: A single intrapartum oral dose of an identical appearing placebo&lt;br&gt;
    </Intervention>
    <Primary_outcome>The A-PLUS main trial &lt;br/ &gt;&lt;br&gt;Ã¢â?¬Â¢Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group. &lt;br/ &gt;&lt;br&gt;Ã¢â?¬Â¢Neonatal: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group. &lt;br/ &gt;&lt;br&gt;The A-PLUS Pilot study &lt;br/ &gt;&lt;br&gt;Ã¢â?¬Â¢ Clinical sepsis diagnosed among pregnant/postpartum women and their infants &lt;br/ &gt;&lt;br&gt;Ã¢â?¬Â¢Other maternal infections &lt;br/ &gt;&lt;br&gt;Ã¢â?¬Â¢Frequency and types of pathogens identified by culture &lt;br/ &gt;&lt;br&gt;Ã¢â?¬Â¢Antibiotic useTimepoint: Up to 42 days postpartum
    </Primary_outcome>
    <Secondary_outcome>The A-PLUS sub-study; Monitor antimicrobial resistance and maternal and newborn microbiome effects of the single dose of prophylactic azithromycin by: &lt;br/ &gt;&#x0D;&lt;br&gt;3. Serial microbiome collection and storage of specimens for future testing to monitor maternal and newborn microbiome status of selected sitesTimepoint: up to 6 weeks after delivery;a.Chorioamnionitis: Fever (100.4Ã?Â°F/38Ã?Â°C on two occasions at least 30 minutes apart or Ã¢â?°Â¥102Ã?Â°F/39Ã?Â°C on one occasion) in addition to one or more of the following: fetal tachycardia 160bpm, maternal tachycardia100bpm, uterine tenderness, or purulent lochia prior to deliveryTimepoint: From randomization to delivery;b.	Endometritis: Fever (100.4Ã?Â°F/38Ã?Â°C on two occasions at least 30 minutes apart or Ã¢â?°Â¥102Ã?Â°F/39Ã?Â°C on one occasion) in addition to one or more of uterine tenderness or purulent lochia after deliveryTimepoint: From delivery to 42 days postpartum;c.Other infections: Wound infection of a perineal wound or wound of a subsequent cesarean with or without fever and leading to prescription of antibiotics; abdominopelvic abscess; pneumonia; pyelonephritisTimepoint: Up to 42 days postpartum;d.	Use of subsequent maternal antibiotic therapy after randomization to 6 weeks for any reasonTimepoint: Up to 42 days postpartum;e.	Maternal initial hospital length of stay, defined as the time of admission until initial dischargeTimepoint: up to initial discharge;f.Maternal readmissions within 6 weeks of deliveryTimepoint: Up to 42 days postpartum;g.Maternal admission to special care unitsTimepoint: Up to 42 days postpartum;h.	Maternal GI symptoms including nausea, vomiting, and diarrhea and other reported side effectsTimepoint: Up to 42 days postpartum;Other Neonatal Outcomes &lt;br/ &gt;&#x0D;&lt;br&gt;a.Neonatal initial hospital length of stay. &lt;br/ &gt;&#x0D;&lt;br&gt;b.Neonatal readmissions within 6 weeks of delivery. &lt;br/ &gt;&#x0D;&lt;br&gt;c.Neonatal admission to special care units. &lt;br/ &gt;&#x0D;&lt;br&gt;d.Neonatal death due to sepsis. &lt;br/ &gt;&#x0D;&lt;br&gt;e.Pyloric stenosis within 6 weeks of deliveryTimepoint: Up to 42 days postpartum;The A-PLUS sub-study; Monitor antimicrobial resistance and maternal and newborn microbiome effects of the single dose of prophylactic azithromycin by:  &lt;br/ &gt;&#x0D;&lt;br&gt;1. Clinical monitoring with culture and sensitivity testing from suspected bacterial infections in mothers and newbornsTimepoint: up to 6 weeks after delivery;The A-PLUS sub-study; Monitor antimicrobial resistance and maternal and newborn microbiome effects of the single dose of prophylactic azithromycin by: &lt;br/ &gt;&#x0D;&lt;br&gt;2. Serial susceptibility monitoring of antimicrobial resistance patterns (including azithromycin resistance) from selected maternal and newborn flora through culture and sensitivity testingTimepoint: up to 6 weeks after delivery
    </Secondary_outcome>
    <Secondary_ID>NCT03871491
    </Secondary_ID>
    <Source_Support>Eunice Kennedy Shriver National Institute of Child Health and Human Development;The Bill &amp; Melinda Gates Foundation
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>25/02/2019;17/11/2021;03/10/2019;22/12/2020;12/11/2020;11/12/2020;03/01/2019;03/10/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethics Review Committee, Lata Medical Research Foundation Nagpur;Institutional Ethics Committee Datta Meghe Medical College Ã¢â?¬â?? Shalinitai Meghe Hospital and Research Centre;Institutional Ethics Committee of BLDE Deemed to be University;Institutional Ethics Committee, Datta Meghe Institute of Medical Sciences, Wardha;Institutional Ethics Committee, Government Medical College Nagpur;Institutional Ethics Committee, Mahatma Gandhi Institute of Medical Sciences, Sevagram;KLE University Ã¢â?¬â?? Institutional Ethics Committee on Human Subjects Research Belgaum;SNMC Institutional Ethics Committee on Human Subjects Research
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10726979
    </Internal_Number>
    <TrialID>NCT03897946
    </TrialID>
    <Last_Refreshed_on>16 March 2021
    </Last_Refreshed_on>
    <Public_title>Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC
    </Public_title>
    <Scientific_title>Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of North Carolina, Chapel Hill
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190329
    </Date_registration3>
    <Date_registration>29/03/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03897946
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 20, 2019
    </Date_enrollement>
    <Target_size>569
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Steven R Meshnick, MD, PhD;Peyton J Thompson, MD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>UNC-Chapel Hill;UNC-Chapel Hill
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        MOTHERS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HBsAg+ mothers and HBsAg- mothers will be recruited from the cohort screened during&#x0D;&lt;br&gt;             the AVERT study at 2 maternity centers (Binza and Kingasani) in Kinshasa.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any women who do not intend to stay in Kinshasa for prenatal care through delivery or&#x0D;&lt;br&gt;             who deliver at a facility other than Binza or Kingasani&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women &lt;18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        INFANTS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants born to HBsAg-positive and HBsAg-negative women who receive care at Binza and&#x0D;&lt;br&gt;             Kingasani maternity centers will be recruited for participation in this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-exposed infants (those born to HIV-positive mothers) will be excluded given an&#x0D;&lt;br&gt;             expected difference in immune response in these infants and inability to recruit&#x0D;&lt;br&gt;             enough HIV-exposed infants to be able to detect these differences in immune response&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HBV-unexposed infants weighing &lt;2,000 grams at birth will not be eligible to receive&#x0D;&lt;br&gt;             the birth HBV vaccine. (HBV-exposed infants receive the birth dose vaccine regardless&#x0D;&lt;br&gt;             of birth weight because the potential benefit of preventing mother-to-child&#x0D;&lt;br&gt;             transmission outweighs the potential risk of vaccination in a low birthweight infant.&#x0D;&lt;br&gt;             The research team recognizes that Group B may include a disproportionate number of low&#x0D;&lt;br&gt;             birthweight infants compared to Group C, but will account for this in post-hoc&#x0D;&lt;br&gt;             analyses and if need be, will exclude low birthweight infants from the analysis to&#x0D;&lt;br&gt;             account for potential bias).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants born at a facility other than one of the two maternity centers&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hepatitis B
    </Condition>
    <Intervention>Biological: Birth dose hepatitis B vaccine
    </Intervention>
    <Primary_outcome>Proportion of Infants with Protective Immunity
    </Primary_outcome>
    <Secondary_outcome>Proportion of Infants with Adverse Reactions to the Birth Dose Hepatitis B Vaccine
    </Secondary_outcome>
    <Secondary_ID>18-2793
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>The American Society of Tropical Medicine and Hygiene;Burroughs Wellcome
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12601218
    </Internal_Number>
    <TrialID>PACTR201904546865585
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Practicability of unassisted versus directly assisted blood-based HIV self-testing among high-risk population for HIV infection acquisition in Democratic Republic of the Congo
    </Public_title>
    <Scientific_title>Practicability of unassisted versus directly assisted blood-based HIV self-testing among high-risk population for HIV infection acquisition in Democratic Republic of the Congo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>University of Kisangani
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190329
    </Date_registration3>
    <Date_registration>29/03/2019
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=6032
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>44 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>05/08/2018
    </Date_enrollement>
    <Target_size>422
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomization,Sealed opaque envelopes
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Salomon 
    </Contact_Firstname>
    <Contact_Lastname>Batina
    </Contact_Lastname>
    <Contact_Address>Plateau medical
    </Contact_Address>
    <Contact_Email>agasasalomon@yahoo.fr
    </Contact_Email>
    <Contact_Tel>+243970007241
    </Contact_Tel>
    <Contact_Affiliation>professor at University of Kisangani
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Eligibility was include all of the following criteria: (i) willingness to be tested for HIV infection; (ii) age between 18 and 49 years; (iii) possession of a 24-hour online telephone number; (iv) ignorance of own HIV status; (v) have not been tested for HIV in the last  three months; (vi) reported having at least one unprotected sex in the last six months; (vii) possession of a permanent residence in the city of Kisangani (viii) ability to speak and read in French or vernacular languages (Lingala and Swahili), (viii) high risk for acquiring HIV infection,and (ix) signing of the written consent.  High risk for HIV infection acquisition was defined as sexually active clients with: a history of unprotected intercourse with one or more partners of unknown HIV sero-status within the past 6 months, new sex partners in the past 6 months, symptoms of sexually transmitted infections (STIs) in the same period, commercial sex activity, or being in a known HIV discordant partnership. 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Following criteria was retained: (i) refuse to be tested for HIV infection; (ii) are underage (age &lt;18 years) or older than 49 years old; (iii) do not have 24-hour online telephone number; (v) declare themselves HIV positive; (vi) were tested for HIV in the last three months; (v) are unable to speak and read in French, Lingala and Swahili, and (vi) refuse to sign the written consent. 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;HIV/AIDS;HIV/AIDS
    </Condition>
    <Intervention>;unassisted HIV self testing ;directly assisted HIV self testing
    </Intervention>
    <Primary_outcome>Difference in practicability of self-test kit, comparing the unassisted approach to the directly assisted approach. Practicability was defined as the ability to use the self-test autonomously or with oral assistance until obtaining valid test result (appearance of a control strip on the self-test), and to correctly interpret the HIV self-test result. 
    </Primary_outcome>
    <Secondary_outcome>Secondary outcomes included the proportions of participants who requested for assistance, the return rate, the linkage to post-test counselling, and the linkage to care. 
    </Secondary_outcome>
    <Source_Support>University of Kisangani
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/02/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>contact@espkinshasa.net
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethic committe of University of Kinshasa
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+243851463831
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>contact@espkinshasa.net
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10450957
    </Internal_Number>
    <TrialID>NCT03880591
    </TrialID>
    <Last_Refreshed_on>11 January 2021
    </Last_Refreshed_on>
    <Public_title>Neonatal Hyperbilirubinaemia in the Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Baseline Assessment of Neonatal Hyperbilirubinaemia in a Cohort of New-borns in Kinshasa, Democratic Republic of Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190312
    </Date_registration3>
    <Date_registration>12/03/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03880591
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>60 Minutes
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 7, 2019
    </Date_enrollement>
    <Target_size>306
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Caterina Fanello
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Oxford
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All live male or female new-borns&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mothers of any age, willing and able to give informed consent for participation in the&#x0D;&lt;br&gt;             survey and agree to stay 72 hours in hospital after giving birth&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Newborn health conditions which makes difficult to drawn a blood sample&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Newborn health conditions requiring specific care not compatible with the survey&#x0D;&lt;br&gt;             procedures&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Neonatal Hyperbilirubinemia
    </Condition>
    <Primary_outcome>Prevalence of neonatal hyperbilirubinaemia in a cohort of newborns
    </Primary_outcome>
    <Secondary_outcome>Risk factors for neonatal hyperbilirubinaemia in the mother and the baby
    </Secondary_outcome>
    <Secondary_ID>NEHYA
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12524983
    </Internal_Number>
    <TrialID>NCT03876262
    </TrialID>
    <Last_Refreshed_on>12 September 2022
    </Last_Refreshed_on>
    <Public_title>Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
    </Public_title>
    <Scientific_title>A Randomized, Double Blind, Parallel Trial in the Democratic Republic of Congo (DRC) Comparing the Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Treatment of Onchocerciasis
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medicines Development for Global Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190311
    </Date_registration3>
    <Date_registration>11/03/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03876262
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 3, 2021
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Tony Ukety, MD, DO, MPH;Sally Kinrade;Tony Ukety
    </Contact_Lastname>
    <Contact_Email>;sally.kinrade@medicinesdevelopment.com;
    </Contact_Email>
    <Contact_Tel>;+61 3 9912 2400;
    </Contact_Tel>
    <Contact_Affiliation>Centre de Recherche en Maladies Tropicales de l'Ituri;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Provision of written informed consent, or assent with parental or guardian written&#x0D;&lt;br&gt;             consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mean = 10 O. volvulus microfilariae/mg skin, determined by four skin snips&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Living in a village selected for the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 12 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All female participants of childbearing potential must commit to the use of a reliable&#x0D;&lt;br&gt;             method of birth control for the duration of treatment and until 3 months after&#x0D;&lt;br&gt;             completion of dosing with investigational product.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breast-feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any concurrent condition that, in the opinion of the Investigator, would preclude&#x0D;&lt;br&gt;             evaluation of response to treatment or would pose undue risk to the participant's&#x0D;&lt;br&gt;             health.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has received ivermectin, oral diethylcarbamazine (DEC) or doxycycline (for &gt; 2 weeks)&#x0D;&lt;br&gt;             within 6 months of Baseline.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has received treatment with an investigational agent within the last 30 days (or 5&#x0D;&lt;br&gt;             half-lives, whichever is longer) prior to Baseline.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known or suspected allergy to ivermectin or moxidectin or their excipients.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Self-reported planned or ongoing activities within the study period that would make it&#x0D;&lt;br&gt;             unlikely that a participant will be available for all planned treatment rounds and&#x0D;&lt;br&gt;             follow-up examinations.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight &gt; 88 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infection with Loa loa.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Onchocerciasis
    </Condition>
    <Intervention>Drug: Moxidectin;Drug: Ivermectin
    </Intervention>
    <Primary_outcome>Proportion of moxidectin annual and biannual recipients with sustained microfilarial response at month 12;Incidence and severity of adverse events
    </Primary_outcome>
    <Secondary_outcome>Proportion of participants in all dose groups with sustained microfilariae response;Sustained ocular microfilariae response in all dose groups;Skin microfilarial density in all dose groups;Ocular microfilariae response in all dose groups;Mean skin microfilariae density at each post-Screening assessment
    </Secondary_outcome>
    <Secondary_ID>MDGH-MOX-3001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12618288
    </Internal_Number>
    <TrialID>NCT03871491
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>Azithromycin-Prevention in Labor Use Study (A-PLUS)
    </Public_title>
    <Scientific_title>Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190305
    </Date_registration3>
    <Date_registration>05/03/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03871491
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>September 1, 2020
    </Date_enrollement>
    <Target_size>34000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Bangladesh;Congo, The Democratic Republic of the;Guatemala;India;Kenya;Pakistan;Zambia;Bangladesh;Congo, The Democratic Republic of the;Guatemala;India;Kenya;Pakistan;Zambia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Marion Koso-Thomas, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women in labor =28 weeks Gestational Age (GA) (by best estimate) with a&#x0D;&lt;br&gt;             pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Admitted to health facility with clear plan for spontaneous or induced delivery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Live fetus must be confirmed via a fetal heart rate by Doptone prior to randomization.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  =18 years of age or minors 14-17 years of age in countries where married or pregnant&#x0D;&lt;br&gt;             minors (or their authorized representatives) are legally permitted to give consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have provided written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women in labor =28 weeks GA (by best estimate) with a pregnancy with one or&#x0D;&lt;br&gt;             more live fetuses who plan to deliver vaginally in a facility.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Admitted to health facility with clear plan for spontaneous or induced delivery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Live fetus must be confirmed via presence of a fetal heart rate prior to&#x0D;&lt;br&gt;             randomization.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  =18 years of age or minors 14-17 years of age in countries where married or pregnant&#x0D;&lt;br&gt;             minors (or their authorized representatives) are legally permitted to give consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have provided written informed consent [Note: written informed consent may be obtained&#x0D;&lt;br&gt;             during antenatal care, but verbal re-confirmation may be needed (per local&#x0D;&lt;br&gt;             regulations) at the time of randomization].&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-emancipated minors (as per local regulations)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of chorioamnionitis or other infection requiring antibiotic therapy at time&#x0D;&lt;br&gt;             of eligibility (however, women given single prophylactic antibiotics with no plans to&#x0D;&lt;br&gt;             continue after delivery should not be excluded).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Arrhythmia or known history of cardiomyopathy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Allergy to azithromycin or other macrolides that is self-reported or documented in the&#x0D;&lt;br&gt;             medical record.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any use of azithromycin, erythromycin, or other macrolide in the 3 days or less prior&#x0D;&lt;br&gt;             to randomization.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Plan for cesarean delivery prior to randomization.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Preterm labor undergoing management with no immediate plan to proceed to delivery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Advanced stage of labor (&gt;6 cm or 10 cm cervical dilation per local standards) and&#x0D;&lt;br&gt;             pushing or too distressed to understand, confirm, or give informed consent regardless&#x0D;&lt;br&gt;             of cervical dilation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Are not capable of giving consent due to other health problems such as obstetric&#x0D;&lt;br&gt;             emergencies (for example, antepartum hemorrhage) or mental disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other medical conditions that may be considered a contraindication per the&#x0D;&lt;br&gt;             judgment of the site investigator.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous randomization in the trial.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Maternal Death;Maternal Infections Affecting Fetus or Newborn;Neonatal SEPSIS;Maternal Sepsis During Labor;Neonatal Death;Postpartum Sepsis
    </Condition>
    <Intervention>Drug: Azithromycin;Drug: Placebo
    </Intervention>
    <Primary_outcome>Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.;Neonatal: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group
    </Primary_outcome>
    <Secondary_outcome>Incidence of chorioamnionitis;Incidence of endometritis;Incidence of other infections;Incidence of use of subsequent maternal antibiotic therapy;Maternal initial hospital length of stay;Incidence of maternal readmissions;Incidence of maternal admission to special care units;Incidence of maternal unscheduled visit for care;Incidence of maternal GI symptoms;Incidence of maternal death due to sepsis;Incidence of other neonatal infections (e.g. eye infection, skin infection);Neonatal initial hospital length of stay;Incidence of neonatal readmissions;Incidence of neonatal admission to special care units;Incidence of neonatal unscheduled visit for care;Incidence of neonatal death due to sepsis;Incidence of pyloric stenosis within 42 days of delivery
    </Secondary_outcome>
    <Secondary_ID>CP Azithromycin
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Alabama at Birmingham;University Teaching Hospital, Lusaka, Zambia;University of North Carolina, Chapel Hill;Kinshasa School of Public Health;University of Colorado, Denver;Institute of Nutrition of Central America and Panama;University of Virginia;International Centre for Diarrhoeal Disease Research, Bangladesh;Thomas Jefferson University;Columbia University;Aga Khan University;Boston University;Lata Medical Research Foundation, Nagpur;Indiana University School of Medicine;Moi Univeristy;RTI International;Bill and Melinda Gates Foundation;Jawaharlal Nehru Medical College
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10323610
    </Internal_Number>
    <TrialID>NCT03852303
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy
    </Public_title>
    <Scientific_title>OAETREAT Extra Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy: a
    </Scientific_title>
    <Acronym>OAETREATe
    </Acronym>
    <Primary_sponsor>Universiteit Antwerpen
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190221
    </Date_registration3>
    <Date_registration>21/02/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03852303
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 1, 2017
    </Date_enrollement>
    <Target_size>197
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Robert Colebunders, MD,PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Universiteit Antwerpen
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 5 years and above&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed informed consent form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal neurological development until onset of epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Onset of epilepsy between ages of 5 and 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of microfilaria in skin snip and/or antibodies against Ov16&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ivermectin intake the last 9 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or breastfeeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known or suspected allergy to Ivermectin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Loa Loa microfilariae in blood&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy with known cause (e.g. severe head trauma, perinatal asphyxia, patients with&#x0D;&lt;br&gt;             a history of cerebral malaria, meningitis or encephalitis)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Concomitant acute illness or chronic medication use&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic alcohol/substance use&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Epilepsy
    </Condition>
    <Intervention>Drug: ivermectin
    </Intervention>
    <Primary_outcome>seizure freedom
    </Primary_outcome>
    <Secondary_ID>B300201733349
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>European Research Council
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>7775998
    </Internal_Number>
    <TrialID>ISRCTN75108951
    </TrialID>
    <Last_Refreshed_on>18 March 2019
    </Last_Refreshed_on>
    <Public_title>Does a door-to-door delivery strategy increase the utilisation of insecticide-treated bed nets in the Maniema province, Democratic Republic of Congo?
    </Public_title>
    <Scientific_title>Effect of long lasting insecticide-treated nets distribution with door-to-door delivery strategy combined with hang-up method on the utilisation of nets in the Maniema province, Democratic Republic of Congo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Dongguk University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190218
    </Date_registration3>
    <Date_registration>18/02/2019
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN75108951
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>20/09/2013
    </Date_enrollement>
    <Target_size>2100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional single-centre repeated cross-sectional experimental cluster randomised controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                Anyone who fits any of the following criteria may participate in this study:&lt;br&gt;                1. Children aged under 5&lt;br&gt;                2. Pregnant mothers&lt;br&gt;                3. Family members of the above&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: N/A
    </Exclusion_Criteria>
    <Condition>Health behaviours, attitude, and knowledge about malaria prevention, particularly mosquito net utilisation &lt;br&gt;Not Applicable &lt;br&gt;Health behaviours, attitude, and knowledge about malaria prevention, particularly mosquito net utilisation
    </Condition>
    <Intervention>Health areas will be randomly allocated into either the intervention or the control group in a 1:1 ratio using a computer-generated block randomisation list. In intervention communities, all households receive one visit by members of the village health team. The team deliver ilong lasting insecticide treated bed nets (LLINs) to every household, door-to-door. The nets will be hung-up inside their house. In control communities, the village health team notify the community of the availability of LLINs from one place in the community, and provide them with tokens. LLINs are then distributed to those who visit this specific place.
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Under 5 children’s utilisation of the LLINs during the previous night, assessed by a cross-sectional household survey at the baseline and 12 months after the distribution of LLINs&lt;br&gt;&lt;br&gt;                For the evaluation of the interventions, two cross-sectional household surveys were carried out. The baseline survey was done before the mass distribution in 2013. The end-line survey was conducted 12 months after the distribution of mosquito nets in 2015. The primary outcome is the utilization of insecticide-treated mosquito nets of under-five children at the time of the survey. The measurement was done through direct observation.&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                The following are assessed by a cross-sectional household survey at the baseline and 12 months after the distribution of LLINs:&lt;br&gt;                1. Pregnant women’s utilisation of the LLINs during the previous night&lt;br&gt;                2. Family member’s utilisation of the LLINs during the previous night&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NMPC112015
    </Secondary_ID>
    <Source_Support>The Episcopal Church Center
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Kinshasa University, 09/09/2013, ESP/CE/071/13
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/12/2018
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>8116835
    </Internal_Number>
    <TrialID>ISRCTN14071325
    </TrialID>
    <Last_Refreshed_on>17 June 2019
    </Last_Refreshed_on>
    <Public_title>An international study to investigate rates of death and illness following liver surgery
    </Public_title>
    <Scientific_title>International Snapshot Study on the Outcomes of Liver surgery - LiverGroup.org                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Royal Free London NHS Foundation Trust, UCL Partners
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190213
    </Date_registration3>
    <Date_registration>13/02/2019
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN14071325
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2019
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational snapshot study  (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. All liver surgery indications (including benign and living donor resections, open, laparoscopic or robotic surgery, single wedge resections to extended liver resections, single- or two-stage hepatectomies, procedures with liver volume enhancement such as PVE, PVL, ALPPS, resections involving cold perfusion (ex-situ and ante-situ)&lt;br&gt;                2. Any co-morbidity&lt;br&gt;&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Liver transplantation&lt;br&gt;                2. Imaging-guided RFA, MWA, or other ablation techniques&lt;br&gt;                3. Liver biopsies&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Any indication for liver surgery &lt;br&gt;Surgery
    </Condition>
    <Intervention>The intervention includes any type of liver surgery. The patients's progress will be observed from the day of the operation until hospital discharge as well as up to 90 days postoperatively.
    </Intervention>
    <Primary_outcome>Death recorded up to 90 days postoperatively using the patients' medical records
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Postoperative complications as measured by the Clavien-Dindo Classification, FABIB Liver-Specific Classification and the Comprehensive Complication Index® (CCI®)&lt;br&gt;                2. Liver failure as measured by the FABIB Liver-Specific Classification, the ISGLS criteria and the 50-50 criteria up to 90 days postoperatively&lt;br&gt;                3. Length of hospital stay (defined as the duration of hospitalization from the day of the operation until the day of discharge from the hospital) recorded up to 90 days postoperatively using the patients' medical records&lt;br&gt;                4. Rehospitalization (defined as any readmission to any hospital within 90 days from the operation) assessed using the patients' medical records up to 90 days postoperatively using the patients' medical records&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NCT03768141;v.1.3
    </Secondary_ID>
    <Source_Support>Royal Free Hospital, Universidad de Zaragoza
    </Source_Support>
    <Secondary_Sponsor>Department of Surgery, University Hospital Miguel Servet, University of Zaragoza, Spain
    </Secondary_Sponsor>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>This project is considered as an audit and does not require ethics committee approval in the UK. 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>10/03/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12601141
    </Internal_Number>
    <TrialID>PACTR201901631942297
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Training caregivers to enhance early child neurodevelopment in the prevention of konzo disease from toxic cassava in the Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Training caregivers to enhance early child neurodevelopment in the prevention of konzo disease from toxic cassava in the Democratic Republic of Congo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>University of Kinshasa
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190123
    </Date_registration3>
    <Date_registration>23/01/2019
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=5877
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>0 Month(s)
    </Inclusion_agemin>
    <Inclusion_agemax>23 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>30/06/2018
    </Date_enrollement>
    <Target_size>400
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Simple randomization using a randomization table created by a computer software program,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-0
    </Phase>
    <Countries>Democratic Republic of the Congo;Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Esperance
    </Contact_Firstname>
    <Contact_Lastname>Kashala Abotnes
    </Contact_Lastname>
    <Contact_Address>Lysskar 30 B
    </Contact_Address>
    <Contact_Email>esperance_kashala@yahoo.com
    </Contact_Email>
    <Contact_Tel>+41003043
    </Contact_Tel>
    <Contact_Affiliation>INRB 
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All mother-child dyads with children aged 0-5 years &#x0D;&lt;br&gt;Dyads living in Kahemba (study site) &#x0D;&lt;br&gt;Informed consent to participate in the study
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children with infectious or somatic conditions that can affect early child cognitive development&#x0D;&lt;br&gt;Children with other neurological conditions that can affect early child cognitive development
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Mental and Behavioural Disorders &lt;br&gt;Nervous System Diseases;Mental and Behavioural Disorders;Nervous System Diseases
    </Condition>
    <Intervention>;Wetting method and Mediational Intervention for Sensitizing Children;Wetting method 
    </Intervention>
    <Primary_outcome>The primary outcome will be changes in cassava cyanogenic content by the trainees and Urine thiocyanate level in the children in their MISC/WTM versus WTM only intervention households and enhance early child development and neurocognition of children in the 200 included households. 
    </Primary_outcome>
    <Secondary_outcome>Neurodevelopmental and cognitive performance scores in the children using selected tools for neurocognitive assessments
    </Secondary_outcome>
    <Source_Support>Grand Challenges Canada Saving Brains
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomedicale
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/11/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>cnesrdcongo@gmail.com
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ministry of Health National Ethic Comittee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>00243998419816
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>cnesrdcongo@gmail.com
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12601090
    </Internal_Number>
    <TrialID>PACTR201905606150545
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Ouesso,
    </Public_title>
    <Scientific_title>Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Ouesso,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Health Ministry of Congo
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181206
    </Date_registration3>
    <Date_registration>06/12/2018
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=5776
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>0 Month(s)
    </Inclusion_agemin>
    <Inclusion_agemax>23 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>14/01/2019
    </Date_enrollement>
    <Target_size>176
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Crossover: all participants receive all interventions in different sequence during study,Non-randomised,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Phase-4
    </Phase>
    <Countries>Congo;Congo
    </Countries>
    <Contact_Firstname>Jean Mermoz
    </Contact_Firstname>
    <Contact_Lastname>Youndouka
    </Contact_Lastname>
    <Contact_Address> Lucien FOURNEAU
    </Contact_Address>
    <Contact_Email>jmyoundouka@gmail.com
    </Contact_Email>
    <Contact_Tel>00242055386998
    </Contact_Tel>
    <Contact_Affiliation>National Malaria Control Programme Coordonator
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. age from 6 months to 11 years; &#x0D;&lt;br&gt;2. mono-infection with P. falciparum detected by microscopy; &#x0D;&lt;br&gt;3. parasitaemia of 1000–200,000/microliter asexual forms; &#x0D;&lt;br&gt;4. presence of axillary temperature greater or equal to 37.5 degrees C or history of fever during the past 24 h&#x0D;&lt;br&gt;5. ability to swallow oral medication; &#x0D;&lt;br&gt;6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; &#x0D;&lt;br&gt;7. informed consent from the patient or parent/ guardian of children. &#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according &#x0D;&lt;br&gt;to the definitions of WHO; &#x0D;&lt;br&gt;2. weight under 5 kg; &#x0D;&lt;br&gt;3. Haemoglobin &lt; 6/dl; &#x0D;&lt;br&gt;4. mixed or mono-infection with another Plasmodium species detected by microscopy; &#x0D;&lt;br&gt;5. presence of severe malnutrition defined as a child aged 6-60 months has a mid-upper arm circumference below 115 mm) &#x0D;&lt;br&gt;6. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, &#x0D;&lt;br&gt;severe diarrhoea with dehydration) or other known underlying chronic or severe diseases&#x0D;&lt;br&gt; (e.g. cardiac, renal and hepatic diseases, HIV/AIDS); &#x0D;&lt;br&gt;7. regular medication, which may interfere with antimalarial pharmacokinetics; &#x0D;&lt;br&gt;8. history of hypersensitivity reactions or contraindications to any of the medicine(s)&#x0D;&lt;br&gt; being tested or used as alternative treatment(s); &#x0D;&lt;br&gt; 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;Artemether lumefantrine treatment;artesunate amodiaquine treatment
    </Intervention>
    <Primary_outcome>Percent of treatment failures (early treatment failure + late clinical failure +late parasitological failure). &lt;br&gt;This is composite primary outcome. &lt;br&gt;Enrolled patients will be assessed for parasitological and clinical responses during the 28 days &lt;br&gt;follow-up and treatment outcomes will be classified according to the latest WHO protocol.&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Percent of adverse event following treatment of each drugs will be documented. &#x0D;&lt;br&gt;The known adverse events of: &#x0D;&lt;br&gt;Atemether+lumefantrine are abdominal pain, asthenia, cough, diarrhoea, dizziness, fever,&#x0D;&lt;br&gt; headache, joint and muscle pain, loss of appetite, rush, nausea, vomiting. &#x0D;&lt;br&gt;Artesunate+amodiaquine are abdominal pain, asthenia, cough, diarrhoea, dizziness, &#x0D;&lt;br&gt;insomnia, loss of appetite, nausea, vomiting. &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Parents or guardians of all enrolled children will be asked routinely about previous symptoms &#x0D;&lt;br&gt;and about symptoms that have emerged since the previous follow-up visit. When clinically&#x0D;&lt;br&gt; indicated, patients will be evaluated and treated appropriately. All adverse events will be recorded &#x0D;&lt;br&gt;on the case report form.&#x0D;&lt;br&gt;Prevalence of artemisinin resistance molecular markers (K13). &#x0D;&lt;br&gt;Parasite DNA extracted from the dried blood spots will be analysed by PCR and sequencing &#x0D;&lt;br&gt;for the presence of K13 (molecular marker for artemisinin resistance).&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Source_Support>World health organization Programme mondial de lutte antipaludique
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/08/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>monabekagermain@yahoo.fr
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite Ethique de la Recherche en Science de la Sante
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>00242055516851
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>monabekagermain@yahoo.fr
    </Ethics_review_contact_email>
    <results_url_link>https://www.who.int/malaria/areas/drug_resistance/en/
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10315862
    </Internal_Number>
    <TrialID>NCT03751475
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Optimizing Acute Malnutrition Management in Children Aged 6 to 59 Months in Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Optimized and Simplified Management of Acute Malnutrition in Children Aged 6 to 59 Months: a Community-based Clinical Randomized Controlled Trial in the Democratic Republic of Congo
    </Scientific_title>
    <Acronym>OptiMA-DRC
    </Acronym>
    <Primary_sponsor>Alliance for International Medical Action
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181119
    </Date_registration3>
    <Date_registration>19/11/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03751475
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 22, 2019
    </Date_enrollement>
    <Target_size>1071
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>SHEPHERD SUSAN, MD;BECQUET RENAUD, MPH, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Alliance for International Medical Action;Institut National de la Santé Et de la Recherche Médicale, France
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be between 6 and 59 months old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Meet one of the acute malnutrition criteria defined as follows: PB &lt; 125mm or ratio&#x0D;&lt;br&gt;             Weight/Size (Z-score) &lt;-3 (WHO standard) or Oedema of grade +, ++;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be resident in the health area where the active screening session takes place;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have the free, informed and signed consent of the child's mother or guardian.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children with medical complication or negative appetite test or oedema (grade +++)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children allergic to milk or peanuts;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children suffering from a known chronic pathology such as sickle cell anemia, trisomy&#x0D;&lt;br&gt;             21, congenital heart disease, or neurological condition;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children currently in a malnutrition programme.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Severe Acute Malnutrition;Moderate Acute Malnutrition;Child Malnutrition;Acute Malnutrition;Congo, The Democratic Republic of the;Africa;Randomized Clinical Trial
    </Condition>
    <Intervention>Other: Nutritional Strategy - OptiMA;Other: Effective nutritional standard strategy
    </Intervention>
    <Primary_outcome>Success rate in each arm
    </Primary_outcome>
    <Secondary_outcome>Recovery rate in participants with severe acute malnutrition (WHO definition)
    </Secondary_outcome>
    <Secondary_ID>OptiMA-DRC
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Public Health, Democratic Republic of the Congo;The Innocent Foundation;University of Bordeaux, INSERM, Bordeaux Population Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12180674
    </Internal_Number>
    <TrialID>NCT03799861
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Newborn Heart Rate as a Catalyst for Improved Survival
    </Public_title>
    <Scientific_title>Newborn Heart Rate as a Catalyst for Improved Survival (NeoBeat Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>American Academy of Pediatrics
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181109
    </Date_registration3>
    <Date_registration>09/11/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03799861
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>28 Weeks
    </Inclusion_agemin>
    <Inclusion_agemax>45 Weeks
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 5, 2018
    </Date_enrollement>
    <Target_size>24034
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Carl Bose, MD;Jackie Patterson, MD, MPH;Sara Berkelhamer, MD;Nalini Singhal, MD
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University at Buffalo;University of Calgary
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria: all newborns delivered via vaginal, assisted or operative delivery at&#x0D;&lt;br&gt;        any of 3 participating maternity units in Kinshasa, Democratic Republic of Congo (DRC),&#x0D;&lt;br&gt;        during the study period will be enrolled. All newborns will be included, regardless of:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  intrauterine fetal demise&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  birth weight&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  congenital anomalies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  multiple gestation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  any maternal complication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Newborns transferred to the maternity unit following delivery at a referral hospital&#x0D;&lt;br&gt;             or in the community&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Miscarriages, or previable newborns, defined as gestational age &lt;28 weeks (or if&#x0D;&lt;br&gt;             gestational age is unavailable, birth weight &lt;1,000g) at the time of delivery&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Stillbirth;Neonatal Respiratory Depression;Neonatal Bradycardia;Neonatal Resuscitation
    </Condition>
    <Intervention>Other: Epoch 2: HBB with NeoBeat;Other: Epoch 3: HR-guided HBB
    </Intervention>
    <Primary_outcome>Reported Total Stillbirth Rate
    </Primary_outcome>
    <Secondary_outcome>Effective, Spontaneous Breathing at 3 Minutes
    </Secondary_outcome>
    <Secondary_ID>7200AA18FA00010
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health;Laerdal Global Health;RTI International;Thrasher Research Fund;University of North Carolina, Chapel Hill;Saving Lives at Birth
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11574172
    </Internal_Number>
    <TrialID>NCT03803735
    </TrialID>
    <Last_Refreshed_on>8 November 2021
    </Last_Refreshed_on>
    <Public_title>Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa
    </Public_title>
    <Scientific_title>French African Pediatric Oncology Registry
    </Scientific_title>
    <Acronym>RFAOP
    </Acronym>
    <Primary_sponsor>French Africa Pediatric Oncology Group
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20181108
    </Date_registration3>
    <Date_registration>08/11/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03803735
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2016
    </Date_enrollement>
    <Target_size>10000
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Burkina Faso;Cameroon;Congo, The Democratic Republic of the;Côte D'Ivoire;France;Gabon;Madagascar;Mali;Mauritania;Niger;Senegal;Togo;Burkina Faso;Cameroon;Congo, The Democratic Republic of the;Côte D'Ivoire;France;Gabon;Madagascar;Mali;Mauritania;Niger;Senegal;Togo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Brenda MALLON, MSC
    </Contact_Lastname>
    <Contact_Email>brenda.mallon@gustaveroussy.fr
    </Contact_Email>
    <Contact_Tel>+ 33142115411
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Any child presenting at any one of the participating units for treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Any child with any type of cancer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Any child or adolescent less than 18 years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. No cancer found&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age greater than 18 years -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pediatric Cancer
    </Condition>
    <Primary_outcome>Number of children with a suspicion of any type of cancer in a given unit;VITAL STATUS:;Illness status;Treatment Status
    </Primary_outcome>
    <Secondary_ID>GFAOP
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Gustave Roussy, Cancer Campus, Grand Paris
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12570742
    </Internal_Number>
    <TrialID>DRKS00015745
    </TrialID>
    <Last_Refreshed_on>4 October 2022
    </Last_Refreshed_on>
    <Public_title>NETfacts: A trauma-informed community approach to encounter the cycles of violence
    </Public_title>
    <Scientific_title>NETfacts: A trauma-informed community approach to encounter the cycles of violence - NETfacts                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Universität Konstanz
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20181106
    </Date_registration3>
    <Date_registration>06/11/2018
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://www.drks.de/DRKS00015745
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both, male and female
    </Inclusion_gender>
    <Date_enrollement>05/09/2018
    </Date_enrollement>
    <Target_size>1070
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled trial;. Masking: Blinded (assessor). Control: Other. Assignment: Parallel. Study design purpose: Prevention;
    </Study_design>
    <Phase>I
    </Phase>
    <Countries>Congo, the Democratic Republic of the
    </Countries>
    <Contact_Firstname>Amani
    </Contact_Firstname>
    <Contact_Lastname>Chibashimba
    </Contact_Lastname>
    <Contact_Address>Avenue de Tulpier
    </Contact_Address>
    <Contact_Email>amani.chibashimba@uni-konstanz.de
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Universität Konstanz / vivo international
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Geographically close to Goma (reachable within hours), about 500 community members
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Logistically inaccessible, active fighting
    </Exclusion_Criteria>
    <Condition>Social and clinical factors accelerating the cycles of violence: trauma-related disorders, aggression, acknowledgement and stimatization of survivors. # Attitudes towards survivors, avoidance of trauma-specific facts at individual and societal levels.
    </Condition>
    <Intervention>Intervention 1: NETfacts: Ongoing provision of NET and delivery of a 3 to 4-week trauma-informed community intervention. The latter includes: Development of a community lifeline in a meeting with community members (session 1) followed by a 2-week period in which traumatic events of traumatised individuals (with subclinical symptom severity) are recorded in single exposure sessions conducted according to the NET logic in individual sessions. Reading out narratives of traumatic events that are found critical for the continuation of violence in front of the community members (fact exposure; session 2 and 3). Development of anti-violent action schemes as positive events of the future (session 4). Intervention 2: Control: treatment as usual (may include national and international stabilisation programs and no intervention)
    </Intervention>
    <Primary_outcome>Social: Reduction of violence during the last 3 months assessment at baseline and 3 and 6 months later and if possible after 5 years (Threats to Human Life Scale, THL, Köbach et al., unpublished).&lt;br&gt;Clinical. Number of individuals seeking NET (accumulated cases until baseline, after the intervention and 3 and 6 months later as well as 5 years later if possible).
    </Primary_outcome>
    <Secondary_outcome>General disapproval: subscale of the Social Acknowledgement Questionnaire (SAQ, Märker &amp; Müller, 2004). Attitudes Towards Survivors Scale (ATSS; Ferdowsian et al., 2016). Acceptance of rape myths: short version of the Illinois Rape Myth Acceptance Scale (IRMAS; Paynes et al., 1999). Readiness to rehabilitate bonds to former combatants: adapted Social Reconstruction Scale (SoRS-21; Ajidokovic et al., 2011). Mental health: severity of posttraumatic stress symptoms (PTSD Symptom Scale Interview – 5; Foa &amp; Capaldi, 2013), shame (Shame Variability Questionnaire, SVQ; Brown et al., unpublished), depression (Patient Health Questionnaire, PHQ; Krönke et al., 2003), and appetitive aggression in former combatants (Appetitive Aggression Scale, AAS; Weierstall &amp; Elbert, 2011). Assessment at baseline, post intervention and 3 and 6 months follow up, if possible after 5 years.
    </Secondary_outcome>
    <Secondary_ID>IRB statement 31/2016
    </Secondary_ID>
    <Source_Support>Fonds Social
    </Source_Support>
    <Ethics_review_status>approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/11/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>18/12/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10450546
    </Internal_Number>
    <TrialID>NCT03719586
    </TrialID>
    <Last_Refreshed_on>11 January 2021
    </Last_Refreshed_on>
    <Public_title>Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
    </Public_title>
    <Scientific_title>A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients With Ebola Virus Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181024
    </Date_registration3>
    <Date_registration>24/10/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03719586
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>99 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 21, 2018
    </Date_enrollement>
    <Target_size>1044
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>United States;Congo, The Democratic Republic of the;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Richard T Davey, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>National Institute of Allergy and Infectious Diseases (NIAID)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        -  INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Males or females of any age with documented positive RT-PCR in blood for acute Ebola&#x0D;&lt;br&gt;             virus infection within 3 days prior to enrollment and who have symptoms of any&#x0D;&lt;br&gt;             duration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness of study participant to accept randomization to any assigned treatment&#x0D;&lt;br&gt;             arm.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All males and females of childbearing potential must be willing to use effective&#x0D;&lt;br&gt;             methods of contraception, from time of enrollment until Day 58 of study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must agree not to enroll in another study of an investigational agent prior to&#x0D;&lt;br&gt;             completion of Day 28 of study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to provide informed consent personally, or by a legally acceptable&#x0D;&lt;br&gt;             representative if the patient is unable to do so.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITIERA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who, in the judgment of the investigator, will be unlikely or unable to&#x0D;&lt;br&gt;             comply with the requirements of this protocol through Day 28.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior treatment with any investigational antiviral drug therapy against Ebola virus&#x0D;&lt;br&gt;             infection within 5 half-lives or 30 days, whichever is longer, prior to enrollment.&#x0D;&lt;br&gt;             (Patients who have received an experimental (or, in future, potentially a licensed)&#x0D;&lt;br&gt;             immunization against Ebola virus remain eligible.)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Ebola Virus
    </Condition>
    <Intervention>Drug: ZMapp;Drug: Remdesivir;Drug: MAb114;Drug: REGN-EB3
    </Intervention>
    <Primary_outcome>Mortality
    </Primary_outcome>
    <Secondary_outcome>Time to first negative Ebola virus RT-PCR in blood.;Viremia;Incidence of serious adverse events/AEs
    </Secondary_outcome>
    <Secondary_ID>19-I-0003;190003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11642751
    </Internal_Number>
    <TrialID>CTRI/2018/09/015833
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>International, multi-centre study on comparing management and outcomes of children born with congenital diseases between Low-Â­, Middle-Â­ and Highâ??Income Countries.
    </Public_title>
    <Scientific_title>Management and Outcomes of Congenital Anomalies in Low-Â­, Middle-Â­ and Highâ??Income Countries:
A Multi-centre, International, Prospective Cohort Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Naomi Wright
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180926
    </Date_registration3>
    <Date_registration>26-09-2018
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=28425
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-10-2018
    </Date_enrollement>
    <Target_size>27201
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Afghanistan;Algeria;Angola;Argentina;Australia;Bangladesh;Belgium;Bolivia;Bosnia and Herzegovina;Brazil;Brunei Darussalam;Burundi;Cambodia;Cameroon;Canada;Chile;China;Colombia;Democratic Republic of the Congo;Ecuador;Egypt;Ethiopia;France;Germany;Ghana;Guatemala;India;Indonesia;Iraq;Jordan;Kenya;Lao People's Democratic Republic;Libyan Arab Jamahiriya;Lithuania;Madagascar;Malawi;Malaysia;Mauritania;Mexico;Morocco;Myanmar;Nepal;New Zealand;Nigeria;Other;Pakistan;Peru;Philippines;Poland;Republic of Korea;Rwanda;Saudi Arabia;Singapore;South Africa;Spain;Sudan;Sweden;Switzerland;Tanzania;Thailand;Tunisia;Turkey;Uganda;United Kingdom;United States of America;Uzbekistan;Venezuela (Bolivarian Republic of);Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr Sundeep PT
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Associate Professor, Department of Pediatric Surgery, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 
    </Contact_Address>
    <Contact_Email>vijay.kumar@manipal.edu
    </Contact_Email>
    <Contact_Tel>9845857787
    </Contact_Tel>
    <Contact_Affiliation>Kasturba Medical College, Manipal
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Any neonate, infant or child under the age of 16â??years, presenting for the first time, with one of the study conditions listed below can be included in the study. &lt;br/ &gt;&lt;br&gt;1. Oesophageal atresia with or without tracheoâ??oesophageal atresia &lt;br/ &gt;&lt;br&gt;2. Congenital diaphragmatic hernia &lt;br/ &gt;&lt;br&gt;3. Intestinal atresia &lt;br/ &gt;&lt;br&gt;4. Gastroschisis &lt;br/ &gt;&lt;br&gt;5. Exomphalos (also known as omphalocele) &lt;br/ &gt;&lt;br&gt;6. Anorectal Malformation &lt;br/ &gt;&lt;br&gt;7. Hirschsprungâ??s Disease
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Any child above the age of 16-years. &lt;br/ &gt;&lt;br&gt;2. Any neonate, infant or child with one of the study conditions who has previously received surgery for their condition.  &lt;br/ &gt;&lt;br&gt;3. If they have recently received surgery for their condition, were discharged and then represented with a complication of the surgery during the study period
    </Exclusion_Criteria>
    <Condition>Health Condition 1: Q391- Atresia of esophagus with tracheo-esophageal fistula
Health Condition 2: Q390- Atresia of esophagus without fistula
Health Condition 3: Q422- Congenital absence, atresia and stenosis of anus with fistula
Health Condition 4: Q423- Congenital absence, atresia and stenosis of anus without fistula
Health Condition 5: Q410- Congenital absence, atresia and stenosis of duodenum
Health Condition 6: Q412- Congenital absence, atresia and stenosis of ileum
Health Condition 7: Q411- Congenital absence, atresia and stenosis of jejunum
Health Condition 8: Q428- Congenital absence, atresia and stenosis of other parts of large intestine
Health Condition 9: Q420- Congenital absence, atresia and stenosis of rectum with fistula
Health Condition 10: Q421- Congenital absence, atresia and stenosis of rectum without fistula
Health Condition 11: Q790- Congenital diaphragmatic hernia
Health Condition 12: Q439- Congenital malformation of intestine, unspecified
Health Condition 13: Q792- Exomphalos
Health Condition 14: Q793- Gastroschisis

    </Condition>
    <Intervention>Intervention1: Not Applicable: Not Applicable&lt;br&gt;Control Intervention1: Not Applicable: Not Applicable&lt;br&gt;
    </Intervention>
    <Primary_outcome>All-cause, in-hospital mortality.Timepoint: 30 days following primary intervention or primary admission
    </Primary_outcome>
    <Secondary_outcome>Complications occurring within 30-Â­days of primary intervention including: &lt;br/ &gt;&lt;br&gt;1. Surgical site-Â­infection &lt;br/ &gt;&lt;br&gt;2. Wound dehiscence &lt;br/ &gt;&lt;br&gt;3. Need for re-Â­intervention &lt;br/ &gt;&lt;br&gt;4. Condition specific complications &lt;br/ &gt;&lt;br&gt;5. Condition specific outcome variables &lt;br/ &gt;&lt;br&gt;6. Length of hospital stay (time from admission to death in patients who do not survive) &lt;br/ &gt;&lt;br&gt;7. 30-Â­day post primary intervention mortalityTimepoint: 30 days
    </Secondary_outcome>
    <Secondary_ID>NCT03666767
    </Secondary_ID>
    <Source_Support>Kingâ??s Centre for Global Health and Health Partnerships, Kingâ??s College London, UK;Wellcome Trust
    </Source_Support>
    <Secondary_Sponsor>Ankit Raj Dr Vijay Kumar Dr Sundeep PT
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/08/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12582204
    </Internal_Number>
    <TrialID>NCT03610568
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Global Early Adolescent Study - Kinshasa
    </Public_title>
    <Scientific_title>The Global Early Adolescent Study, Phase 2 | Kinshasa, Democratic Republic on the Congo
    </Scientific_title>
    <Acronym>GEAS_KI
    </Acronym>
    <Primary_sponsor>Johns Hopkins Bloomberg School of Public Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180723
    </Date_registration3>
    <Date_registration>23/07/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03610568
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>14 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 20, 2017
    </Date_enrollement>
    <Target_size>2862
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Caroline Moreau, MD, PhD, MPH
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Johns Hopkins Bloomberg School of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Males and females between the ages of 10-14 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lives within the geographic boundaries of Kimbanseke or Masina&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lives at home with a family (biological, adoptive, or foster)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Attends a school selected for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        INTERVENTION GROUP ONLY&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has indicated interest in participation in the after-school component of the&#x0D;&lt;br&gt;             intervention&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to assent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has obtained informed consent from a parent or guardian to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not between the ages of 10-14&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Does not live within the geographic boundaries of Kimbanseke or Masina&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is homeless or lives on the street&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Attends a school not selected for the study, or does not attend school&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        INTERVENTION GROUP ONLY&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Attends a school selected for the study but has not indicated interest in&#x0D;&lt;br&gt;             participation in the after-school component of the intervention&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to assent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has not obtained informed consent from a parent or guardian to participate in the&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Gender Relations;Reproductive Health
    </Condition>
    <Intervention>Behavioral: Growing up GREAT! Intervention
    </Intervention>
    <Primary_outcome>Contraceptive use as assessed by self-reported use at last sex from the Global Early Adolescent Study Questionnaire;Exposure to gender-based violence in the past 6 months as assessed by self-report from the Global Early Adolescent Study Questionnaire
    </Primary_outcome>
    <Secondary_outcome>Gender-equitable attitudes and beliefs from the Global Early Adolescent Study Questionnaire
    </Secondary_outcome>
    <Secondary_ID>7510
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Save the Children;Bill and Melinda Gates Foundation;Institute for Reproductive Health, Georgetown University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11641611
    </Internal_Number>
    <TrialID>CTRI/2018/07/014693
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>A registry based study on treatment and survival of Retinoblatoma diagnosed children patients from different parts of the world
    </Public_title>
    <Scientific_title>Global Retinoblastoma Presentation 2017. - GRP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>NA
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180702
    </Date_registration3>
    <Date_registration>02-07-2018
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26126
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>02-07-2018
    </Date_enrollement>
    <Target_size>450
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Zimbabwe;Argentina;Armenia;Australia;Bangladesh;Benin;Brazil;Burundi;Canada;Chile;China;Cote d'Ivoire;Czech Republic;Democratic Republic of the Congo;Denmark;Ecuador;Egypt;Estonia;Ethiopia;Finland;France;Germany;Haiti;Honduras;Hungary;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Italy;Jamaica;Japan;Jordan;Kenya;Kyrgyzstan;Latvia;Lebanon;Lithuania;Malawi;Malaysia;Mali;Mexico;Morocco;Myanmar;Nepal;Netherlands;Nigeria;Pakistan;Panama;Paraguay;Peru;Philippines;Poland;Portugal;Republic of Korea;Russian Federation;Saudi Arabia;Singapore;Slovenia;South Africa;Spain;Sri Lanka;Sudan;Swaziland;Sweden;Switzerland;Thailand;Turkey;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uzbekistan;Viet Nam;Yemen;Zambia
    </Countries>
    <Contact_Firstname>Tushar Vora
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Tata Memorial Hospital,Department of Medical Oncology,Main building ground foor,OPD no.80, room no.14,Dr.E.borges Road,Parel, Mumbai.400012 
    </Contact_Address>
    <Contact_Email>tusharsvora@yahoo.com
    </Contact_Email>
    <Contact_Tel>9920428153
    </Contact_Tel>
    <Contact_Affiliation>Tata Memorial Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Participating center: in which treatment-naÃ¯ve Rb patients are seen and treated by any means. There is no lower or upper limit to the number of Rb patients seen in a center in order for it to become a participating center in the study. We are aiming to reach out and include as many Rb centers from around the world.  &lt;br/ &gt;&lt;br&gt;Subjects: All Rb patients that presented to a participating center from 01/01/2017-31/12/2017 and were offered/received treatment of any type (i.e. focal therapy, surgery, chemotherapy, radiotherapy, palliative approach (i.e. no intervention)).  &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients that presented following primary treatment given/offered elsewhere.
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- All Retinobloastoma patients who were offered/received treatment of any type (i.e. focal therapy, surgery, chemotherapy, radiotherapy,
palliative approach (i.e. no intervention)).

    </Condition>
    <Intervention/>
    <Primary_outcome>To report on the presentation mode of children diagnosed with Rb throughout the world, during 2017, with special attention to intra- versus extraocular disease presentation.  &lt;br/ &gt;&lt;br&gt;Timepoint: 01/01/2017-31/12/2017 data to be collected
    </Primary_outcome>
    <Secondary_outcome>NATimepoint: NA
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Tata Memorial Hospital
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>18/06/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional ethics committee-II, Tata Memorial Hospital. Mumbai
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/11/2018
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12180196
    </Internal_Number>
    <TrialID>NCT03600844
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Evaluating the Effects of Community Delivery of Malaria Intermittent Preventive Treatment on Pregnant Women and Babies
    </Public_title>
    <Scientific_title>Evaluation of Community Delivery of Malaria Intermittent Preventive Treatment in Pregnancy (C-IPTp) (TIPTOP Project)
    </Scientific_title>
    <Acronym>TIPTOP
    </Acronym>
    <Primary_sponsor>Jhpiego
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180622
    </Date_registration3>
    <Date_registration>22/06/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03600844
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>49 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>April 2, 2018
    </Date_enrollement>
    <Target_size>10602
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Madagascar;Mozambique;Nigeria;Congo, The Democratic Republic of the;Madagascar;Mozambique;Nigeria
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Clara Menendez, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Barcelona Institute for Global Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who had a pregnancy that ended in the 12 months preceding the survey&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Being resident in the study area during for at least 4 months before the end of the&#x0D;&lt;br&gt;             pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to participate in the household survey (signing informed consent/assent, in&#x0D;&lt;br&gt;             line with country guidelines)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Anyone considered to be a minor in their country.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not willing to provide informed consent&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria in Pregnancy
    </Condition>
    <Intervention>Behavioral: Community distribution of SP for IPTp
    </Intervention>
    <Primary_outcome>IPTp3 Coverage
    </Primary_outcome>
    <Secondary_outcome>IPTp1 Coverage;ANC 4 coverage;ANC 1 Coverage;Early ANC Coverage;C-IPTp Knowledge
    </Secondary_outcome>
    <Secondary_ID>2017-13-TIPTOP;TIPTOP_HHS_2018
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Barcelona Institute for Global Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11941281
    </Internal_Number>
    <TrialID>NCT03568344
    </TrialID>
    <Last_Refreshed_on>21 February 2022
    </Last_Refreshed_on>
    <Public_title>Community Access to Rectal Artesunate for Malaria
    </Public_title>
    <Scientific_title>Community Access to Rectal Artesunate for Malaria (CARAMAL): Observational Research in Nigeria, Uganda and DR Congo
    </Scientific_title>
    <Acronym>CARAMAL
    </Acronym>
    <Primary_sponsor>Swiss Tropical &amp; Public Health Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180516
    </Date_registration3>
    <Date_registration>16/05/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03568344
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 15, 2018
    </Date_enrollement>
    <Target_size>13758
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the;Nigeria;Uganda;Congo, The Democratic Republic of the;Nigeria;Uganda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Christian Burri, Prof;Christian Lengeler, Prof
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Swiss Tropical &amp; Public Health Institute;Swiss Tropical &amp; Public Health Institute
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient surveillance system:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children &lt; 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of fever plus danger signs indicative of severe febrile illness / suspected&#x0D;&lt;br&gt;             severe malaria, according to local iCCM guidelines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Child referred to higher level facility by CHW/primary health facility, or, child&#x0D;&lt;br&gt;             directly attending a referral facility.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Signed full consent form from parent / guardian&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Health care provider interview:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  CHW or health worker at peripheral health facility enrolled in the iCCM referral&#x0D;&lt;br&gt;             system who treats children &lt; 5 years OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Health care provider at referral hospitals treating children &lt; 5 years OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other health care provider in project area treating children &lt; 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed consent form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Household survey:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Household head and parent / caregiver of children &lt; 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed consent form from parent / guardian&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient surveillance system:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children = 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children with no permanent residence in project area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Health care provider interview:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Health workers not treating children &lt; 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Health workers outside project area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Health workers who do not speak any of the local languages&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Health workers employed since &lt; 1 month&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Household survey:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents / guardians with no children &lt; 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents / guardians with no permanent residence in project area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents / guardians who do not speak any of the local languages&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Primary_outcome>Proportion of children &lt;5 years with severe febrile illness seen by CHW/primary HF that resulted in death within 28 days
    </Primary_outcome>
    <Secondary_outcome>Proportion of children &lt;5 years with severe febrile illness without parasites on day 28;Proportion of children &lt;5 years with a recent history of fever (mild or severe) who attend CHW/primary HF;Proportion of children &lt;5 years with severe febrile illness seen by CHW/primary HF who completed referral;Number of children &lt;5 years with severe febrile illness who report directly to referral health facility;Proportion of children &lt;5 years with severe febrile illness managed pre-referral according to guidelines;Proportion of children &lt;5 years with severe febrile illness managed post-referral according to guidelines;Frequency of passively reported adverse events after RAS administration;Frequency of delayed haemolytic anaemia within 28 days after RAS administration;Proportion of trained and functional CHW and primary HF who provide QA RAS;Proportion of CHW/primary HF with RAS in stock;Proportion of referral health facilities that have the capacity to manage severe malaria in children in line with global guidance;Proportion of CHW/primary HF that received at least one supervisory visit in the past 3 months;Acceptability of pre-referral RAS among health workers;Acceptability of pre-referral RAS among caretakers;Total financial cost of managing severe case at community level. Marginal financial cost of adding RAS to the management;Financial cost of RAS interventions per death averted
    </Secondary_outcome>
    <Secondary_ID>P 001-17-1.2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>UNITAID;UNICEF;Kinshasa School of Public Health;Akena Associates Ltd.;Clinton Health Access Initiative Inc.;Makerere University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10298135
    </Internal_Number>
    <TrialID>NCT03520621
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The Role of Sulfur Amino Acids in Risk of Kwashiorkor
    </Public_title>
    <Scientific_title>The Role of Sulfur Amino Acids in Risk of Kwashiorkor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tufts University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180417
    </Date_registration3>
    <Date_registration>17/04/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03520621
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>36 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2016
    </Date_enrollement>
    <Target_size>360
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Daniel Maxwell, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Tufts University, Friedman School
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  resident of the selected population&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  in the appropriate age range&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  caregiver reports the child has an illness that has required treatment for at least 6&#x0D;&lt;br&gt;             months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Kwashiorkor
    </Condition>
    <Intervention>Other: No intervention
    </Intervention>
    <Primary_outcome>Dietary sulfur amino acid;dietary sulfur amino acid above or below WHO estimated average requirement (EAR)
    </Primary_outcome>
    <Secondary_outcome>calories and protein in diet per kg of body weight;urinary sulfate
    </Secondary_outcome>
    <Secondary_ID>1605004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>World Concern;Action Contre la Faim;Rebuild Hope for Africa;Dignitas International
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11640018
    </Internal_Number>
    <TrialID>CTRI/2018/04/013100
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Study of different methods of disease management done for Diabetic Patients with various methods of evaluation of Diabetes and Treatment patterns adapted by doctors.
    </Public_title>
    <Scientific_title>International Diabetes Management Practices Study
 - IDMPS Wave 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Sanofi India Limited
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180409
    </Date_registration3>
    <Date_registration>09-04-2018
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14390
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>07-03-2016
    </Date_enrollement>
    <Target_size>8910
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>India;Algeria;Bangladesh;Cameroon;Congo;Egypt;Iran (Islamic Republic of);Iraq;Jordan;Kenya;Kuwait;Lebanon;Madagascar;Morocco;Nigeria;Pakistan;Russian Federation;Senegal;South Africa;Tunisia;Ukraine;United Arab Emirates
    </Countries>
    <Contact_Firstname>Ms Vaishali Kanade
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Sanofi House, CTS No.117-B,
L&amp;T Business Park,Saki Vihar Road, Powai, 
    </Contact_Address>
    <Contact_Email>deepa.chodankar@sanofi.com
    </Contact_Email>
    <Contact_Tel>9096867313
    </Contact_Tel>
    <Contact_Affiliation>Sanofi India Limited
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.All male and female adult people (who have attained his/her majority) diagnosed with type 1 or type 2 diabetes, visiting the physician during the recruitment period of the crossâ??sectional study, up to the number of patients allocated to the physician. &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt;2. Written informed consent. &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Concomitant participation to a clinical trial. &lt;br/ &gt;&lt;br&gt;2. Previous participation in this study. &lt;br/ &gt;&lt;br&gt;3. Current temporary insulin therapy (gestational &lt;br/ &gt;&lt;br&gt;diabetes, surgery, pancreas cancer). &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- Diabetes

Health Condition 2: E088- Diabetes mellitus due to underlying condition with unspecified complications

    </Condition>
    <Intervention/>
    <Primary_outcome>To assess the management of care of people with type 2 diabetes in current medical practice &lt;br/ &gt;&lt;br&gt;Timepoint: 1 year
    </Primary_outcome>
    <Secondary_outcome>1. To assess the management of care of people with type 1 diabetes in current medical practice.Timepoint: This is cross sectional study means the data would be collected in the one specific point of time from the patient during the course of the study.;2. To assess the predictive factors for reaching target HbA1c in people with type 1 and type 2 diabetes.Timepoint: Not applicable
    </Secondary_outcome>
    <Secondary_ID>OBS14510_Version 2, dated 15â??Decâ??2015
    </Secondary_ID>
    <Source_Support>Sanofi India Limited
Sanofi House, CTS No.117-B,
L&amp;T Business Park,Saki Vihar Road, Powai,Mumbai 400 072

    </Source_Support>
    <Ethics_review_status>Not Approved;Not Approved;Not Approved;Not Approved;Approved;Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Not Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900;01/01/1900;01/01/1900;02/03/2016;07/03/2016;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;01/01/1900;29/02/2016;11/03/2016;16/03/2016;11/03/2016;16/03/2016;04/03/2016;16/03/2016;16/03/2016;29/02/2016;04/03/2016;16/03/2016;04/03/2016;04/03/2016;11/03/2016;04/03/2016;04/03/2016;04/03/2016;04/03/2016;11/03/2016;11/03/2016;11/03/2016;04/03/2016;16/03/2016;11/03/2016;04/03/2016;29/02/2016;29/02/2016;14/03/2016;15/02/2016;08/02/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr . Parag Shah;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr .Ajay Kumar Sinha;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Chaitanya Buva;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Faraz Farishta;IECCS of Apollo Hospital _Dr. Rajeeva Moger;Institutional Ethics Committee of Kovai Diabetes Speciality Centre &amp; Hospital_Coimbatore_Dr.R. Balamurugan;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr .Shunmugavelu Meenakshisundaram;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr .Tom Babu;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr. Sandeep Jhulka;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Anirban Majumdar;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Bijay Patni;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Brij Mohan Makkar;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Ganesh hande;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Manoj Chawla;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Mrinalkanti Guha;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Navnit Agrawal;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.RP Mathur;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Sagarika Mukherjee;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Sandeep Reddy;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Sanjay Pandey;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Sudhir Ranjan Samal;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Vipin Porwal;Jehangir Clinical Development Centre Pvt. Ltd._Pune_Dr.Vishal Garg;Jehangir Clinical Development Centre_Pune _ Dr. Sailesh Lodha;Jehangir Clinical Development Centre_Pune _Dr.  Jugal Bihari Gupta;Jehangir Clinical Development Centre_Pune _Dr.  KathigeNageshappa Manohar;Jehangir Clinical Development Centre_Pune _Dr.  Sreenivasmurthy Lakshminarayanappa;Jehangir Clinical Development Centre_Pune _Dr.  Sunil Jain;Jehangir Clinical Development Centre_Pune _Dr. Ajay Ajmani;Jehangir Clinical Development Centre_Pune _Dr. Alpana Sowani;Jehangir Clinical Development Centre_Pune _Dr. Ambady Ramachandran;Jehangir Clinical Development Centre_Pune _Dr. Anantaraman Ramakrishnan;Jehangir Clinical Development Centre_Pune _Dr. Anuj Maheshwari;Jehangir Clinical Development Centre_Pune _Dr. Arun Vadavi;Jehangir Clinical Development Centre_Pune _Dr. Jay Chordia;Jehangir Clinical Development Centre_Pune _Dr. Manoj Chawla;Jehangir Clinical Development Centre_Pune _Dr. N Vijay Kumar;Jehangir Clinical Development Centre_Pune _Dr. Navin Sinha;Jehangir Clinical Development Centre_Pune _Dr. Neeta Deshpande;Jehangir Clinical Development Centre_Pune _Dr. Pankaj Patel;Jehangir Clinical Development Centre_Pune _Dr. Rohit Mahajan;Jehangir Clinical Development Centre_Pune _Dr. Sanjay Gupta;Jehangir Clinical Development Centre_Pune _Dr. Sanjeev Phatak;Jehangir Clinical Development Centre_Pune _Dr. Shaibal Guha;Jehangir Clinical Development Centre_Pune _Dr. Shailendra Kumar Singh;Jehangir Clinical Development Centre_Pune _Dr. Shailesh Pitale;Jehangir Clinical Development Centre_Pune _Dr. Subhash Kumar;Jehangir Clinical Development Centre_Pune _Dr. Sunil Menon;Jehangir Clinical Development Centre_Pune _Dr. Suresh Damodharan;Jehangir Clinical Development Centre_Pune _Dr. V. K Abichandani;Regional Ethics Committee_Coimbatore _Dr. Girithara Gopalkrishnan Jayaram Naidu;Supe Hospital Ethics Committee_Nasik_Pravin Supe;Yalamanchi Hospital Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_email>
    <results_date_completed>12/03/2016
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10286551
    </Internal_Number>
    <TrialID>NCT03363308
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effects of a Health Workforce Capacity Building and Quality Improvement Intervention in Kinshasa
    </Public_title>
    <Scientific_title>Effects of a Health Workforce Capacity Building and Quality Improvement Intervention on Intrapartum Stillbirth, Early Newborn Mortality and Post-pregnancy Family Planning in Kinshasa: a Cluster Randomized Evaluation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Jhpiego
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171130
    </Date_registration3>
    <Date_registration>30/11/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03363308
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 16, 2017
    </Date_enrollement>
    <Target_size>250
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Virgile Kikaya
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Jhpiego DRC
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Health providers:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Currently on the roster of maternity ward providers working at one of the 16&#x0D;&lt;br&gt;                  selected facilities at the time of the training module.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Willing to attend a Jhpiego clinical training workshop and offer consent as study&#x0D;&lt;br&gt;                  participant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Age 18 or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  there are no exclusion criteria&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Maternal Death;Infant Death;Stillbirth
    </Condition>
    <Intervention>Behavioral: training for health care workers supplmented by QI teams
    </Intervention>
    <Primary_outcome>Mean number or percent of items correctly answered;Intrapartum perinatal death ratio;Percent of women after childbirth who adopt a family planning method immediately post-pregnancy or intend to adopt a method by six weeks post-pregnancy.
    </Primary_outcome>
    <Secondary_outcome>maternal mortality
    </Secondary_outcome>
    <Secondary_ID>OPP1156220
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Bill and Melinda Gates Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12559962
    </Internal_Number>
    <TrialID>DRKS00012842
    </TrialID>
    <Last_Refreshed_on>4 October 2022
    </Last_Refreshed_on>
    <Public_title>Nutritional status of mother-infant pairs in Bukavu, DR Congo. 
Study part I: Impact of breastfeeding practices, dietary intake and food habits of lactating women on the nutritional status of infants aged 0-6 months.
Study part II: Impact of specific nutrition interventions on breast milk quality and nutritional status of under- and overweight lactating mothers.
    </Public_title>
    <Scientific_title>Nutritional status of mother-infant pairs in Bukavu, DR Congo. 
Study part I: Impact of breastfeeding practices, dietary intake and food habits of lactating women on the nutritional status of infants aged 0-6 months.
Study part II: Impact of specific nutrition interventions on breast milk quality and nutritional status of under- and overweight lactating mothers.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Brot für die Welt - Evangelischer Entwicklungsdienst. Evengelisches Wert für Diakonie und Entwicklung e.V.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171127
    </Date_registration3>
    <Date_registration>27/11/2017
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://www.drks.de/DRKS00012842
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>05/12/2017
    </Date_enrollement>
    <Target_size>420
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled trial;. Masking: Open (masking not used). Control: Active control (effective treament of control group)|Control group receives no treatment. Assignment: Parallel. Study design purpose: Treatment;
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, the Democratic Republic of the
    </Countries>
    <Contact_Firstname>Céline
    </Contact_Firstname>
    <Contact_Lastname>Kavira Malengera
    </Contact_Lastname>
    <Contact_Address>B.P. 2232
    </Contact_Address>
    <Contact_Email>kavira.celine@gmail.com
    </Contact_Email>
    <Contact_Tel>00243 970323626
    </Contact_Tel>
    <Contact_Affiliation>Faculté de Médecine et Santé Communautaire, Université Evangelique en Afrique
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The study will focus on lactating mothers and their infants below 1 year of age living in the study area. Women living in the study area who deliver at the maternity ward in one of the selected health centers and their newborns will be eligible to participate in the study. Inclusion criteria are the ages of 18-45 years and the intention to breastfeed the newborn. Under-, normal, overweight, and obese women will be included, matched as far as possible for age and parity. Healthy infants born at full-term (37-42 weeks) as single child who do not have any severe congenital abnormality are eligible for the study. Inclusion will occur on condition of written informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Women not living in the catchment health area even if they came for antenatal visit and delivery to the study area. &lt;br&gt;- Women who delivered a premature or stillborn baby. &lt;br&gt;- Women suffering from any immunodeficiency disease with immunodeficiency in the last stage. &lt;br&gt;- Women who experienced complications during pregnancy (e.g. preeclampsia, vaginal bleeding).
    </Exclusion_Criteria>
    <Condition>Malnutrition: Underweight, overweight #
    </Condition>
    <Intervention>Intervention 1: Nutritional counseling for one group of undernourished (mid-upper arm circumference (MUAC) = 21 cm and &lt; 25 cm) and one group of overnourished mothers (MUAC = 28 cm) regarding healthy nutrition in a biweekly rhythm:&lt;br&gt;Every second week the mothers will receive nutrition education in small groups (6 sessions in total). Contents of the couseling will be the locally common system of the "3 food types", malnutrition in general, anemia, and vitamin A deficiency. The lessons shall be conducted in an interactive way by encouraging the mothers to actively take part in the discussion and use of locally adapted pictures. Further, nutrient rich recipes and simple methods to improve nutrient intake (fermentation, roasting of flour) will be introduced to the women by use of cooking demonstrations. The infants grandmothers will be invited to participate in the education sessions as well. Intervention 2: Daily lipid-based nutrient supplement for a second group undernourished mothers (MUAC = 21 cm and &lt; 25 cm):&lt;br&gt;The mothers will receive an energy- and nutrient-rich supplement designed for the needs of pregnant and lactating women. The supplement shall be taken every day in the intervention period. Intervention 3: Control croup without intervention: third group of undernourished mothers (MUAC = 21 cm and &lt; 25 cm), second group of overnourished mothers (MUAC = 28 cm), and normally nourished mothers (MUAC = 25 and &lt; 28)
    </Intervention>
    <Primary_outcome>Hemoglobin level of mothers and infants:&lt;br&gt;- at 6 months postpartum (in comparison to the measurement at 3 months postpartum)&lt;br&gt;- measured with the HemoCue Hemoglobin 201+ Analyser (direct analysis of a blood drop gained per finger prick for mothers and heel prick for infants)
    </Primary_outcome>
    <Secondary_outcome>anthropometric parameters: mid-upper arm circumference (MUAC) of the mother, weight, length, head circumference, MUAC of the infant:&lt;br&gt;measured by measuring tape, scale, measuring rod by seca; &lt;br&gt;infant feeding practices: by questionnaires; &lt;br&gt;maternal dietary intake: by 24h dietary recall; &lt;br&gt;nutrient composition of breast milk: analysis of iron, zinc, calcium, vitamin A in breast milk; &lt;br&gt;maternal nutritional status: analysis of iron and vitamin A in maternal serum; &lt;br&gt;morbidity and mortality rates: by questionnaires and medical check-ups
    </Secondary_outcome>
    <Secondary_ID>017/1161
    </Secondary_ID>
    <Source_Support>Brot für die Welt - Evangelischer Entwicklungsdienst. Evengelisches Wert für Diakonie und Entwicklung e.V.;Food Security Center, Universität Hohenheim
    </Source_Support>
    <Ethics_review_status>approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/02/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>14/06/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10683127
    </Internal_Number>
    <TrialID>NCT03356665
    </TrialID>
    <Last_Refreshed_on>1 March 2021
    </Last_Refreshed_on>
    <Public_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection
    </Public_title>
    <Scientific_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection
    </Scientific_title>
    <Acronym>DiTECT-WP2
    </Acronym>
    <Primary_sponsor>Institut de Recherche pour le Developpement
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171124
    </Date_registration3>
    <Date_registration>24/11/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03356665
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>4 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2017
    </Date_enrollement>
    <Target_size>10700
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Côte D'Ivoire;Guinea;Congo, The Democratic Republic of the;Côte D'Ivoire;Guinea
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Veerle Lejon, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institut de Recherche pour le Developpement
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Visit of or residence in a HAT endemic area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical suspicion of HAT based on: Recurrent fever not responding to anti-malarial&#x0D;&lt;br&gt;             medication; or Headache for a long duration (&gt;14 days); or presence of swollen lymph&#x0D;&lt;br&gt;             nodes in the neck; or Important weight loss; or Weakness; or Important scratching; or&#x0D;&lt;br&gt;             Amenorrhea, abortion(s), or sterility; or Coma; or Psychiatric problems&#x0D;&lt;br&gt;             (aggressiveness, apathy, mental confusion, increasing unusual hilarity, ...); or Sleep&#x0D;&lt;br&gt;             disruption (nocturnal insomnia and excessive diurnal sleeping); or Motor abnormalities&#x0D;&lt;br&gt;             (convulsions, abnormal movements, shaking, walking difficulties); or Speech disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previously treated for HAT (irrespective of time elapsed since treatment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  &lt; 4 years old&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>African Trypanosomiases;West African; Trypanosomiasis;Sleeping Sickness; West African;Trypanosoma Brucei Gambiense; Infection
    </Condition>
    <Intervention>Diagnostic Test: Rapid diagnostic test (RDT);Diagnostic Test: Serological and molecular tests on DBS
    </Intervention>
    <Primary_outcome>Sensitivity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on HAT clinical suspects;Specificity for HAT diagnosis of RDT, RDT combinations, algorithms of RDT and serological and/or molecular tests on HAT clinical suspects
    </Primary_outcome>
    <Secondary_ID>DiTECT-HAT-WP2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Public Health, Democratic Republic of the Congo;Ministry of Health, Guinea;Institut National de Sante Publique;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;CIRDES;Institute of Tropical Medicine, Belgium;University of Liverpool
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12447719
    </Internal_Number>
    <TrialID>NCT03303963
    </TrialID>
    <Last_Refreshed_on>15 August 2022
    </Last_Refreshed_on>
    <Public_title>DIAgnostics for Multidrug Resistant Tuberculosis in Africa
    </Public_title>
    <Scientific_title>Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients
    </Scientific_title>
    <Acronym>DIAMA
    </Acronym>
    <Primary_sponsor>Dissou AFFOLABI
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170924
    </Date_registration3>
    <Date_registration>24/09/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03303963
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 4, 2017
    </Date_enrollement>
    <Target_size>2840
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Belgium;Benin;Cameroon;Congo, The Democratic Republic of the;Ethiopia;Guinea;Mali;Nigeria;Rwanda;Senegal;Belgium;Benin;Cameroon;Congo, The Democratic Republic of the;Ethiopia;Guinea;Mali;Nigeria;Rwanda;Senegal
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dissou AFFOLABI, MD, MSc, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Laboratoire de Référence des Mycobactéries
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11636812
    </Internal_Number>
    <TrialID>CTRI/2017/09/009894
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Heat therapy(agnikarma) in Tennis Elbow
    </Public_title>
    <Scientific_title>An Open Label Comparative Clinical Study to assess the Efficacy of Agnikarma in Snayugatavata Treatment Protocol with Agnikarma Alone in Tennis Elbow                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>AMRITA SCHOOL OF AYURVEDA
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170922
    </Date_registration3>
    <Date_registration>22-09-2017
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16586
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>11-11-2016
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Case Record Numbers  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;Andorra;Angola;Antigua and Barbuda;Argentina;Armenia;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bhutan;Bolivia;Bosnia and Herzegovina;Botswana;Brazil;Brunei Darussalam;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Central African Republic;Chad;Chile;China;Colombia;Comoros;Congo;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Cyprus;Czech Republic;Democratic People's Republic of Korea;Democratic Republic of the Congo;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Fiji;Finland;France;Gabon;Gambia;Georgia;Germany;Ghana;Greece;Grenada;Guatemala;Guinea;Guinea-Bissau;Guyana;Haiti;Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran (Islamic Republic of);Iraq;Ireland;Israel;Italy;Jamaica;Japan;Jordan;Kazakhstan;Kenya;Kiribati;Kuwait;Kyrgyzstan;Lao People's Democratic Republic;Latvia;Lebanon;Lesotho;Liberia;Libyan Arab Jamahiriya;Lithuania;Luxembourg;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Mauritania;Mauritius;Mexico;Micronesia (Federated States of);Monaco;Mongolia;Montenegro;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norway;Oman;Other;Pakistan;Palau;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Poland;Portugal;Qatar;Republic of Korea;Republic of Moldova;Romania;Russian Federation;Rwanda;Saint Kitts and Nevis;Saint Lucia;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia ;Seychelles;Sierra Leone;Singapore;Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;Spain;Sri Lanka;Sudan;Suriname;Swaziland;Sweden;Switzerland;Syrian Arab Republic;Taiwan;Tajikistan;Thailand;The former Yugoslav Republic of Macedonia;Timor-Leste;Togo;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United Republic of Tanzania;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela (Bolivarian Republic of);Viet Nam;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Dr Lakshmy C Senan
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Amrita School of Ayurveda,Amrita Viswavidyapeetham
Vallikavu, Clappana PO, Kollam, Kerala, India, PIN- 690525 
    </Contact_Address>
    <Contact_Email>drrabi73@gmail.com
    </Contact_Email>
    <Contact_Tel>9567554883
    </Contact_Tel>
    <Contact_Affiliation>AMRITA SCHOOL OF AYURVEDA
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.Patients  selected irrespective of sex, religion, Occupation, socioeconomic status etc &lt;br/ &gt;&lt;br&gt;2.Diagnosis on the basis of signs and symptoms found in Tennis elbow like  &lt;br/ &gt;&lt;br&gt;3.Pain on the outer side of the elbow jt.  &lt;br/ &gt;&lt;br&gt;4.Radiation of pain from elbow to forearm or hand.  &lt;br/ &gt;&lt;br&gt;5.Tenderness over the lateral epicondyle  &lt;br/ &gt;&lt;br&gt;6.Weak grip so that there is Inability to do daily routine work  &lt;br/ &gt;&lt;br&gt;7.Pricking sensation  &lt;br/ &gt;&lt;br&gt;8.Cozenâ??s test positive[13] &lt;br/ &gt;&lt;br&gt;9.Millâ??s maneuver positive[14] &lt;br/ &gt;&lt;br&gt;10.Patient who are willing to undergo trial, are only registered.  &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria:  &lt;br/ &gt;&lt;br&gt;1.Patients not willing to undergo trial.  &lt;br/ &gt;&lt;br&gt;2.Patients below 20 years and above 60 years of age. &lt;br/ &gt;&lt;br&gt;3.Pregnant women. &lt;br/ &gt;&lt;br&gt;4.Patients having joint disorders (viz. RA, OA, GA of elbow joint), Tuberculosis, Diabetes or having associated some other constitutional disorders etc &lt;br/ &gt;&lt;br&gt;5.Malignant tumors, senile osteoporosis etc in and around the elbow region. &lt;br/ &gt;&lt;br&gt;6.Patients associated with Golferâ??s elbow, Olecranon bursitis, Radial tunnel syndrome etc. &lt;br/ &gt;&lt;br&gt;7.Patients with history of compound fracture, Pathological fracture, non united fracture and mal-united fracture of complaining limb  &lt;br/ &gt;&lt;br&gt;8.Agnikarma anarhas &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- tennis elbow patients

    </Condition>
    <Intervention>Intervention1: thermal cauterization&lt;br&gt;: 1.AGNIKARMA(thermal cauterization/ application of heat energy over the specific site)&lt;br&gt;&lt;br&gt;&lt;br&gt;Control Intervention1: upanaha,pichu,agnikarma: 1. upanaha-12 hourly bandage with hot medicated paste of kottamchukkadichoorna, kottamchukkadi taila, saindhava and dhanyamla&lt;br&gt;&lt;br&gt;2.pichu- oil applied over cotton in a localized area&lt;br&gt;&lt;br&gt;3. agnikarma-(thermal cauterization/ application of heat energy over the specific site)&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>1.Pain on the outer side of the elbow joint assessed by Visual Analogue Scale.  &lt;br/ &gt;&lt;br&gt;2. Radiation of pain towards forearm or hand.  &lt;br/ &gt;&lt;br&gt;3. Restricted range of movements. &lt;br/ &gt;&lt;br&gt;4. Pricking sensation  &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt; OBJECTIVE CRITERIA: &lt;br/ &gt;&lt;br&gt;1. Tenderness over the lateral epicondyle &lt;br/ &gt;&lt;br&gt;2. Cozenâ??s test positive &lt;br/ &gt;&lt;br&gt;3. Millâ??s maneuver positive &lt;br/ &gt;&lt;br&gt;Timepoint: Periodic observation will be done on 0th day, 8th day, 15 th, 30 th, and 90 th day.
    </Primary_outcome>
    <Secondary_outcome>recurrenceTimepoint: within 90 days
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Amrita School OF Ayurveda,
Amrita Vishwa Vidyapeetam,
Vallikavu,
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/06/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Amrita Institute of Medical Science-Institutional Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10301722
    </Internal_Number>
    <TrialID>NCT03567382
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Arresting Vertical Transmission of Hepatitis B Virus
    </Public_title>
    <Scientific_title>Arresting Vertical Transmission of Hepatitis B Virus in the Democratic Republic of the Congo: The AVERT-HBV Study
    </Scientific_title>
    <Acronym>AVERT-HBV
    </Acronym>
    <Primary_sponsor>University of North Carolina, Chapel Hill
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170913
    </Date_registration3>
    <Date_registration>13/09/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03567382
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 24, 2018
    </Date_enrollement>
    <Target_size>179
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Steven Meshnick, MD;Peyton Thompson, MD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women receiving care at Binza and Kingasani maternity centers presenting&#x0D;&lt;br&gt;             prior to 24 weeks gestation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants born to HBV-positive women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants who are severely sick and who require prolonged hospitalization.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any women who do not intend to stay in Kinshasa for prenatal care through delivery&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hepatitis B;Vertical Transmission of Infectious Disease
    </Condition>
    <Intervention>Drug: Tenofovir Disoproxil Fumarate;Biological: Monovalent HBV vaccine
    </Intervention>
    <Primary_outcome>Number of Participants with Lab Testing Acceptability Survey Scores &gt;80%;Number of Participants with Intervention Acceptability Survey Scores &gt;80%
    </Primary_outcome>
    <Secondary_outcome>Incidence of mother-to-child transmission of HBV;Number of mothers with high-risk HBV demonstrating adherence to tenofovir therapy;Number of infants receiving timely birth dose vaccination
    </Secondary_outcome>
    <Secondary_ID>IGHID 11720;17-2090
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health;Ohio State University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11636512
    </Internal_Number>
    <TrialID>CTRI/2017/09/009594
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Use of triple combination for falciparum malaria
    </Public_title>
    <Scientific_title>A multi-centre, open-label randomised trial to assess the effi-cacy, safety and tolerability of Triple Artemisinin-based Combination Therapies (TACTs) compared to Artemisinin-based Combination Therapies (ACTs) in uncomplicated fal-ciparum malaria and to map the geographical spread of artemisinin and partner drug resistance.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>UK Department for International Development  DFID
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170901
    </Date_registration3>
    <Date_registration>01-09-2017
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=15207
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>12-06-2016
    </Date_enrollement>
    <Target_size>1560
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Open Label
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Bangladesh;India;Cambodia;Democratic Republic of the Congo;Myanmar;Thailand;Viet Nam
    </Countries>
    <Contact_Firstname>Dr Anup Anvikar
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>National Institute of Malaria Research rm no 432 Epidemiology and clinical research division 
Sector 8
Dwarka
New Delhi National Institute of Malaria Research rm no 432 Epidemiology and clinical research division Sector 8
Dwarka
New Delhi
    </Contact_Address>
    <Contact_Email>neenavalecha@gmail.com
    </Contact_Email>
    <Contact_Tel>01125307105
    </Contact_Tel>
    <Contact_Affiliation>National Institute of Malaria Research
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Acute uncomplicated P. falciparum malaria confirmed by positive blood smear with asexual forms of P. falciparum  &lt;br/ &gt;&lt;br&gt;Asexual P. falciparum parasitaemia: 5,000 to 200,000/uL, determined on a thin or thick blood film  &lt;br/ &gt;&lt;br&gt;Fever defined as  &gt; 37.5Â°C tympanic temperature or a history of fever within the last 24 hours &lt;br/ &gt;&lt;br&gt;Written informed consent (by parent/guardian in case of chil-dren) &lt;br/ &gt;&lt;br&gt;Willingness and ability of the patients or parents/guardians to comply with the study protocol for the duration of the study &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Signs of severe/complicated malaria  &lt;br/ &gt;&lt;br&gt;Haematocrit &lt; 25% or Hb &lt; 8 g/dL at enrollment  &lt;br/ &gt;&lt;br&gt;Acute illness other than malaria requiring treatment &lt;br/ &gt;&lt;br&gt;For females: pregnancy, breast feeding  &lt;br/ &gt;&lt;br&gt;Patients who have received artemisinin or a derivative or an artemisinin-containing combination therapy (ACT) within the previous 7 days &lt;br/ &gt;&lt;br&gt;Antimalarial therapy in past Two months &lt;br/ &gt;&lt;br&gt;Previous splenectomy &lt;br/ &gt;&lt;br&gt;Documented or claimed history of cardiac conduction prob-lems &lt;br/ &gt;&lt;br&gt;Earlier participation within the TRACII trial or another trial in the previous 3 months. &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- Male or female aged  6 months to 65 years old with 
Acute uncomplicated P falciparum malaria

    </Condition>
    <Intervention>Intervention1: Artemether-lumefantrine AL&lt;br&gt;plus&lt;br&gt;Amodiaquine AQ&lt;br&gt;Primaquine PQ&lt;br&gt;&lt;br&gt;: Day 1 AL Oral tab 3.4/24 mg/kg/day plus AQ 10mg /kg/day &lt;br&gt;&lt;br&gt;Day 2 AL Oral tab 3.4/24 mg/kg/day plus &lt;br&gt;AQ 10 mg/kg/day &lt;br&gt;Day 3 AL Oral tab 3.4/24 mg/kg/day plus AQ 10mg /kg/day &lt;br&gt;PQ 0.75 mg base/kg as per who guildlines  &lt;br&gt;&lt;br&gt;Control Intervention1: Artemether Lumifanthrine AL&lt;br&gt;Primaquine PQ: Day1 Oral tablets AL 3.4/24 mg/kg/day &lt;br&gt;&lt;br&gt;Day 2 Oral tablets AL 3.4/24 mg/kg/&lt;br&gt;Day 3Oral tablets AL 3.4/24 mg/kg/&lt;br&gt;Primaquine oral tablets 0.75mg  base/kg as per WHO guidelines&lt;br&gt;
    </Intervention>
    <Primary_outcome>Endpoint 42 day PCR corrected efficacy defined as adequate clinical and parasitolog-ical response (ACPR). WHO definition: absence of parasitaemia at day 42 irrespective of axillary temperature and without previously meeting any of the WHO criteria for early or late treatment failure, or late parasitological failure.Timepoint: 42 days
    </Primary_outcome>
    <Secondary_outcome>Parasite clearance half-life assessed by microscopy  &lt;br/ &gt;&lt;br&gt;Fever clearance time  &lt;br/ &gt;&lt;br&gt;Incidence of adverse events and serious adverse events by study arms within the first 42 days. &lt;br/ &gt;&lt;br&gt;Incidence of prolongation of the Qtc-interval above 500 ms or 30ms above baseline values. &lt;br/ &gt;&lt;br&gt;Prevalence of Kelch13 mutations  &lt;br/ &gt;&lt;br&gt;Timepoint: 42 days
    </Secondary_outcome>
    <Source_Support>NA
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>30/03/2015;16/01/2015;04/06/2015;20/04/2015
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Institutional Ethics Committee;Institutional Ethics Committee;Institutional Ethics Committee for clinical studies;Institutional Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10280932
    </Internal_Number>
    <TrialID>NCT03265756
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Multimometer - Vital Signs Device for Diagnosis of Pneumonia
    </Public_title>
    <Scientific_title>Multimometer - Vital Signs Device for Diagnosis of Pneumonia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Alberta
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170826
    </Date_registration3>
    <Date_registration>26/08/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03265756
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 20, 2017
    </Date_enrollement>
    <Target_size>350
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Canada;Congo, The Democratic Republic of the;Canada;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Israel Amirav
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Alberta
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For the first part of the study (3D facial images):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        • Healthy children under 5y of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        For the second phase of the study (Comparison of vital signs):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        • Children under 5y of age with suspected pneumonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        • Children older than 5y of age&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pneumonia
    </Condition>
    <Intervention>Device: Multimometer
    </Intervention>
    <Primary_outcome>Vital Signs Comparison
    </Primary_outcome>
    <Secondary_outcome>3D facial images
    </Secondary_outcome>
    <Secondary_ID>Pro00072555
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Grand Challenges Canada
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>8681476
    </Internal_Number>
    <TrialID>ISRCTN89017827
    </TrialID>
    <Last_Refreshed_on>6 January 2020
    </Last_Refreshed_on>
    <Public_title>Wasting and stunting in young children in developing countries
    </Public_title>
    <Scientific_title>Children who are both wasted and stunted are also underweight and have a high risk of death – policy implications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Emergency Nutrition Network
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170821
    </Date_registration3>
    <Date_registration>21/08/2017
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN89017827
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/1992
    </Date_enrollement>
    <Target_size>1796991
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational cross-sectional study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;American Samoa;Angola;Bahrain;Bangladesh;Benin;Burkina Faso;Burundi;Cambodia;Cameroon;Cape Verde;Central African Republic;Chad;Congo;Congo, Democratic Republic;Cote d'Ivoire;Djibouti;Ecuador;Equatorial Guinea;Eritrea;Ethiopia;Gabon;Gambia;Ghana;Guinea-Bissau;Haiti;India;Indonesia;Kenya;Laos;Lesotho;Liberia;Madagascar;Malawi;Mali;Mauritania;Mozambique;Myanmar;Namibia;Nepal;Niger;Nigeria;Pakistan;Rwanda;Senegal;Sierra Leone;Somalia;South Sudan;Sudan;Tajikistan;Tanzania;Timor-Leste;Uganda;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. 6-59 month old children&lt;br&gt;                2. Males and females&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children over 59 months of age
    </Exclusion_Criteria>
    <Condition>Nutrition &lt;br&gt;Nutritional, Metabolic, Endocrine
    </Condition>
    <Intervention>A database of cross-sectional survey datasets containing data for almost 1.8 million children was compiled. This was analysed to determine the intersection between sets of wasted, stunted, and underweight children; the association between being wasted and being stunted; the severity of wasting and stunting in WaSt children; and the prevalence of WaSt by age and sex. An additional analysis of the WHO Growth Standards sought the maximum possible weight-for-age z-score for WaSt children.
    </Intervention>
    <Primary_outcome>Overlap between wasted, stunted and underweight children as measured by &lt;-2SD WHZ, HAZ, WAZ
    </Primary_outcome>
    <Secondary_outcome>Degree of concurrence i.e. &lt;-2SDWHZ AND ,-2SDHAZ in children and by age (6-59 months) and by sex (male/female) 
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>United States Agency for International Development, 295 Grant Number: ENN AID-OFDA-G-15-00190 , Irish Aid
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>This is an observational study so does not need ethical approval. All data was anonymous and was secondary and readily available for further analysis. There were no human or animal subjects.
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/12/2015
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10282288
    </Internal_Number>
    <TrialID>NCT03289663
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effectiveness Study of New Generation Bednets in the Context of Conventional Insecticide Resistance in the Democratic Republic of the Congo
    </Public_title>
    <Scientific_title>Effectiveness Study of Bednets Treated With Synegistic Combination of Insectcides in an Area With Pyrethroid-resistant Vectors in the Democratic Republic of the Congo
    </Scientific_title>
    <Acronym>Net-PBO
    </Acronym>
    <Primary_sponsor>Université de Lubumbashi
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170810
    </Date_registration3>
    <Date_registration>10/08/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03289663
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>10 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2, 2017
    </Date_enrollement>
    <Target_size>1680
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria : -households where there are one or more children below the age of 10&#x0D;&lt;br&gt;        years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability and willingness of the head of the household to participate based on signed&#x0D;&lt;br&gt;             informed consent (or fingerprint) and with the assistance of an impartial witness (if&#x0D;&lt;br&gt;             the head of the household is illiterate)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria :&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refusal of the head of household to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  known allergy to insecticides&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Insecticide Resistance
    </Condition>
    <Intervention>Drug: synergistic combination of insecticides;Drug: Pyrethroids
    </Intervention>
    <Primary_outcome>Incidence rate of laboratory confirmed clinical cases of Malaria;Sporozoite rate
    </Primary_outcome>
    <Secondary_ID>NET-06-08-76
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Universiteit Antwerpen;Centers for Disease Control and Prevention
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10279002
    </Internal_Number>
    <TrialID>NCT03231449
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa
    </Public_title>
    <Scientific_title>A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa
    </Scientific_title>
    <Acronym>FEVRIER
    </Acronym>
    <Primary_sponsor>Cardiologie et Développement
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170721
    </Date_registration3>
    <Date_registration>21/07/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03231449
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2017
    </Date_enrollement>
    <Target_size>5000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Benin;Burkina Faso;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Côte D'Ivoire;Gabon;Guinea;Mozambique;Niger;Senegal;Sudan;Benin;Burkina Faso;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Côte D'Ivoire;Gabon;Guinea;Mozambique;Niger;Senegal;Sudan
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Xavier Jouven, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>cardiologie et Developpement
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  to be hospitalized in a cardiology department of a participating center during the&#x0D;&lt;br&gt;             month of February&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refusal&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Acute Coronary Syndrome;Heart Failure;Syncope;Stroke;Pericarditis;Endocarditis;Conduction Abnormalities;Rhythm; Abnormal;Pulmonary Embolism;Deep Vein Thrombosis;Other Cardiovascular Conditions
    </Condition>
    <Intervention>Other: observation of current care
    </Intervention>
    <Primary_outcome>Description of patients in cardiology unit in sub-Saharan Africa:socio-demographic characterization;Description of patients in cardiology unit in sub-Saharan Africa:causes of hospitalization;Description of patients in cardiology unit in sub-Saharan Africa: co-morbidities;Description of patients in cardiology unit in sub-Saharan Africa: hospital examinations;Description of patients in cardiology unit in sub-Saharan Africa: duration of hospitalization;Description of patients in cardiology unit in sub-Saharan Africa: discharge diagnosis
    </Primary_outcome>
    <Secondary_outcome>number of patients with heart failure;number of patients with myocardial infarction;number of patients with atrial fibrillation
    </Secondary_outcome>
    <Secondary_ID>001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de la Santé Et de la Recherche Médicale, France
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11485908
    </Internal_Number>
    <TrialID>NCT03199755
    </TrialID>
    <Last_Refreshed_on>18 October 2021
    </Last_Refreshed_on>
    <Public_title>Dried Leaf Artemisia (DLA) Compared to Artemisinin Combination Therapy (ACT) vs Malaria
    </Public_title>
    <Scientific_title>Efficacy of Dried Leaf Artemisia (DLA) Versus Coartem (ACT): A Randomized Controlled Clinical Trial for Comparing DLA vs. ACT to Treat Malaria
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Worcester Polytechnic Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170622
    </Date_registration3>
    <Date_registration>22/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03199755
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 20, 2018
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Pamela J Weathers, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>WPI
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Positive RDT for malaria and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Positive blood smear for malaria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All pregnant mothers less than 12 weeks gestational age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children weighing less than 5 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who have taken any antimalarial immediately prior to study admission.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All patients with any form of severe malaria.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: ACT;Drug: DLA1;Drug: DLA2
    </Intervention>
    <Primary_outcome>Change in gametocyte reduction/elimination;Change in parasitemia elimination
    </Primary_outcome>
    <Secondary_outcome>Reduced side effects by DLA vs. ACT among the 3 arms
    </Secondary_outcome>
    <Secondary_ID>16-297
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Plesion International, Coatesville, PA;HEAL Africa Hospital, Goma, Democratic Republic of Congo;Rwanguba Reference Hospital, Rwanguba, Democratic Republic of Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10277371
    </Internal_Number>
    <TrialID>NCT03201770
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Cohort Event Monitoring Study of Pyramax®
    </Public_title>
    <Scientific_title>Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax®
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Shin Poong Pharmaceutical Co. Ltd.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170621
    </Date_registration3>
    <Date_registration>21/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03201770
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 22, 2017
    </Date_enrollement>
    <Target_size>8572
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Cameroon;Congo, The Democratic Republic of the;Congo;Côte D'Ivoire;Gabon;Cameroon;Congo;Congo, The Democratic Republic of the;Côte D'Ivoire;Gabon
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Michael Ramharter, MD, DTM&amp;H
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>CERMEL, University of Tübingen, Germany
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncomplicated malaria (Plasmodia of any species) diagnosed as per national policies&#x0D;&lt;br&gt;             and in line with WHO recommendations:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Fever or history of fever in the previous 24 h and/or the presence of anaemia,&#x0D;&lt;br&gt;                  for which pallor of the palms appears to be the most reliable sign in young&#x0D;&lt;br&gt;                  children.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Confirmation of malaria by a parasitological diagnosis (RDT or Microscopy (thick&#x0D;&lt;br&gt;                  blood smear). analysis).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight =5 kg - &lt; 20 kg (granules); =20 kg (tablets).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to take an oral medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability and willingness to participate based on signed informed consent (a parent or a&#x0D;&lt;br&gt;             guardian has to sign for children below 18 years old) and on signed assent form for&#x0D;&lt;br&gt;             minors that could be required per national regulations in each participating country.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has to comply with all scheduled follow-up visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with clinical signs or symptoms of hepatic injury (such as nausea, abdominal&#x0D;&lt;br&gt;             pain associated with jaundice) or known severe liver disease (i.e. decompensated&#x0D;&lt;br&gt;             cirrhosis, Child-Pugh stage 3 or 4).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergy to artemisinin and/or to pyronaridine.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known pregnancy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lactating women should be excluded if other anti-malarial treatments are available.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Complicated malaria as per WHO definition (Annex 2)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients that the investigator considers would be at particular risk if receiving an&#x0D;&lt;br&gt;             anti-malarial or if participating in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients having been treated with Pyramax in the previous 28 days.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria,Falciparum
    </Condition>
    <Intervention>Drug: pyronaridine artesunate
    </Intervention>
    <Primary_outcome>Evaluation and identification of hepatic safety events, including raised liver function tests
    </Primary_outcome>
    <Secondary_outcome>Overall safety;Evaluation of Efficacy
    </Secondary_outcome>
    <Secondary_ID>SP-C-021-15
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medicines for Malaria Venture
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10275176
    </Internal_Number>
    <TrialID>NCT03161366
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine
    </Public_title>
    <Scientific_title>An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSV?G-ZEBOV-GP
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Epicentre
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170518
    </Date_registration3>
    <Date_registration>18/05/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03161366
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Year
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 28, 2018
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Uganda;Congo, The Democratic Republic of the;Uganda
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals aged 6 years or older will be enrolled in the study if they are a contact&#x0D;&lt;br&gt;             or contact of contact of a laboratory-confirmed Ebola virus disease case. Children&#x0D;&lt;br&gt;             aged between 1 and 6 years may also be enrolled in the study in case there is a&#x0D;&lt;br&gt;             confirmed contact with a laboratory-confirmed Ebola patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  willing to accept weekly visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  intending to remain in the study area for three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  providing informed consent, and where applicable, assent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of EVD (self-report or laboratory confirmed)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of having received other investigational research agents in the previous 28&#x0D;&lt;br&gt;             days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of anaphylaxis to a vaccine or vaccine component (self-report)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe illness that makes the person bed-bound or requiring hospitalization at the&#x0D;&lt;br&gt;             time of the vaccination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe immunocompromised status&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of having received immunosuppressant therapies that would substantially&#x0D;&lt;br&gt;             interfere with the mode of action of the Ebola vaccine in the previous 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unwilling to accept weekly visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  not intending to remain in the study area for three months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  informed consent or assent not provided&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  any other condition in which, in the judgment of the investigator, would interfere&#x0D;&lt;br&gt;             with or serve as a contraindication to protocol adherence, or impair the subject or&#x0D;&lt;br&gt;             caregiver's ability to give informed consent, and where applicable, assent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  fever above 38°C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  previous receipt of rVSV?G-ZEBOV-GP in the last 3 years or at being part of another&#x0D;&lt;br&gt;             Ebola vaccine clinical trial.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Ebola Virus Disease
    </Condition>
    <Intervention>Biological: rVSV?G-ZEBOV-GP
    </Intervention>
    <Primary_outcome>Cumulative incidence
    </Primary_outcome>
    <Secondary_outcome>Assessment of Adverse and Serious Adverse Events
    </Secondary_outcome>
    <Secondary_ID>V920-01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medecins Sans Frontieres, Netherlands
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12349566
    </Internal_Number>
    <TrialID>NCT03157336
    </TrialID>
    <Last_Refreshed_on>13 June 2022
    </Last_Refreshed_on>
    <Public_title>Cassava Intervention Project
    </Public_title>
    <Scientific_title>Toxicodietary and Genetic Determinants of Susceptibility to Neurodegeneration
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ministry of Public Health, Democratic Republic of the Congo
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170512
    </Date_registration3>
    <Date_registration>12/05/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03157336
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>12 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 30, 2017
    </Date_enrollement>
    <Target_size>1200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Mumba Ngoyi
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Ministry of Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Households with a konzo child and non-konzo sibling between 5 and 12 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of a biological mother primarily responsible for the household food&#x0D;&lt;br&gt;             preparation and caring for the children&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mother consenting to participate in this study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of cerebral malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of retroviral (HIV-HTLV) infections&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Neurotoxicity Syndrome, Cassava;Neurotoxicity Syndrome, Cyanate;Neurotoxicity Syndrome, Cyanide;Neurotoxicity Syndrome, Thiocyanate
    </Condition>
    <Intervention>Other: Non Inferiority WTM Interventional Trial
    </Intervention>
    <Primary_outcome>Change in food cyanogenic exposure;Change in internal cyanogenic exposure;Change in oxidation damage;Change in carbamoylation;Change in carbamoylation surrogate
    </Primary_outcome>
    <Secondary_outcome>Change in cognition performance;Change in motor proficiency
    </Secondary_outcome>
    <Secondary_ID>R01ES019841;FWA00017202
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institutes of Health (NIH);Oregon Health and Science University;Michigan State University;University of Kinshasa;National Institute of Environmental Health Sciences (NIEHS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12517974
    </Internal_Number>
    <TrialID>ISRCTN11594437
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>Primaquine in African Children: PAC study
    </Public_title>
    <Scientific_title>Assessing the tolerability and safety of single low dose primaquine in African children with acute uncomplicated falciparum malaria and glucose 6 phosphate dehydrogenase deficiency in Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>The University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170509
    </Date_registration3>
    <Date_registration>09/05/2017
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN11594437
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>17/07/2017
    </Date_enrollement>
    <Target_size>1600
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Multi-centre double blind open randomised parallel safety trial (Treatment)
    </Study_design>
    <Phase>Phase III/IV
    </Phase>
    <Countries>Congo, Democratic Republic;Uganda
    </Countries>
    <Contact_Firstname>Bob
    </Contact_Firstname>
    <Contact_Lastname>Taylor
    </Contact_Lastname>
    <Contact_Address>
                    Mahidol Oxford Tropical Medicine Clinical Research Unit (MORU)
                    Mahidol University
                    420/6 Rajvithi Road
                    Rajthevee
                
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Aged six months to 11 years old&lt;br&gt;                2. Clinically uncomplicated disease&lt;br&gt;                3. Fever (= 37.5°C aural) or history of fever within the previous 72 hours&lt;br&gt;                4. Positive malaria RDT (Uganda only)&lt;br&gt;                5. Positive malaria slide for P. falciparum (mono or mixed infection) of any parasitaemia (Kinshasa only)&lt;br&gt;                6. Informed consent provided by patient or relative/legal guardian&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Malaria danger signs, sign(s) of severe malaria, or decompensated anaemia, including: an inability to take or retain fluids or oral medications, confusion, prostration, convulsions, respiratory distress, passing of red or cola-coloured urine (putative “blackwater fever”)&lt;br&gt;                2. Severe anaemia (Hb &lt;6 g/dL)&lt;br&gt;                3. Comorbid illness that requires treatment in hospital (physician’s judgement)&lt;br&gt;                4. Patients on drugs known to cause haemolysis in G6PDd e.g. dapsone, nalidixic acid&lt;br&gt;                5. Known to be allergic to PQ, AL, or DHAPP&lt;br&gt;                6. Previous enrolment in the current trial or current enrolment in another trial&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Uncomplicated falciparum Malaria, G6PD deficiency, Single low dose primaquine (SLDPQ) &lt;br&gt;Infections and Infestations &lt;br&gt;Uncomplicated falciparum Malaria, G6PD deficiency, Single low dose primaquine (SLDPQ)
    </Condition>
    <Intervention>&lt;br&gt;                Participants are allocated to either the G6PDd group or the G6PD normal group based on their the results of a G6PD rapid diagnostic test (RDT).&lt;br&gt;&lt;br&gt;                Participants are then randomly allocated as to which dosing group they receive using a computer generated randomisation list generated for each site. Treatment allocation is placed in a sealed envelope which is opened once participants receive their study number. The treatment allocation described the Artemisinin based combination treatment (ACT) to be given and the number of PQ/placebo pack.&lt;br&gt;&lt;br&gt;                The four dosing groups are the following:&lt;br&gt;                1. Artemether Lumefantrine (AL) + single low-dose primaquine (SLDPQ)&lt;br&gt;                2. Artemether Lumefantrine (AL) + single low-dose primaquine (SLDPQ) placebo&lt;br&gt;                3. Dihydroartemisinin-piperaquine (DHAPP) + single low-dose primaquine (SLDPQ)&lt;br&gt;                4. Dihydroartemisinin-piperaquine (DHAPP) + single low-dose primaquine (SLDPQ) placebo&lt;br&gt;&lt;br&gt;                The dosages for primaquine depends vary with age and the dosing for AL vary with weight (in kg). DHAPP+SLDPQ dosages are given daily for three days and vary with body weight (in kg). Those who receive the primaquine/placebo receive it once only at baseline. Follow up continues until day 42.&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;br&gt;                1. Profound anaemia (Hb concentration &lt; 4g/dL) is measured using the HemoCue machine during the first days 21 days of follow up&lt;br&gt;                2. Severe anaemia (Hb &lt;5g/dL) with clinical features of severe malaria is measured using the HemoCue machine during the first 21 days of follow up&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Fractional change in haemoglobin on day seven vs. baseline, measured by HemoCue® at baseline and day seven&lt;br&gt;                2. Proportion of patients with a fractional change of = 25% measured by HemoCue® over the follow up period of 42 days&lt;br&gt;                3. Determinants of changes in HemoCue® measured haemoglobin over the follow up period of 42 days&lt;br&gt;                4. G6PD genotype (hemizygous male, homo-, heterozygous female, normal) and selected G6PD variants (e.g. G6PD A- 202 mutations) are assessed by polymerase chain reaction (PCR) at baseline&lt;br&gt;                5. G6PD enzyme activity is measured using a quantitative spectrophotometric method at baseline&lt;br&gt;                6. Genotypes of other inherited blood disorders are assessed by polymerase chain reaction (PCR) at baseline&lt;br&gt;                7. Incidence of adverse events are measured using clinical and laboratory records over the follow up period of 42 days&lt;br&gt;                8. Pharmacokinetic characteristics of PQ and carboxyPQ by measuring drug concentrations at baseline and at hours one, one and a half, two, three, four, six, eight, ten, 12, 24 hours&lt;br&gt;                9. Pharmacokinetic characteristics of lumefantrine and piperaquine are measured using their drug concentrations at baseline, day three, seven and 28&lt;br&gt;                10. CYP 2D6 genotypes are assessed by polymerase chain reaction (PCR) at baseline&lt;br&gt;                11. Asexual parasitaemia clearance time and half life are measured using malaria slide results at days one, two and three&lt;br&gt;                12. Therapeutic efficacy of AL and DHAPP is measured using the WHO criteria at day 42&lt;br&gt;                13. Gametocytaemia over time is measured using thick blood films at baseline and days one, two, three, seven, 14, 21, 28, 35 and 42&lt;br&gt;                14. Proportion of patients with gametocytes over time is measured using those with a positive thick blood film at baseline and on days one, two, three, seven, 14, 21, 28, 35 and 42&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>BAKMAL1606, 106698/Z/14/Z
    </Secondary_ID>
    <Source_Support>DFID/MRC/Wellcome Trust
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Oxford Tropical Research Ethics Committee, 01/03/2017, ref: 53-16
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>02/11/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12600381
    </Internal_Number>
    <TrialID>PACTR201704002215604
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
    </Public_title>
    <Scientific_title>An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>DNDi
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170419
    </Date_registration3>
    <Date_registration>19/04/2017
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=2215
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>100 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>10/11/2016
    </Date_enrollement>
    <Target_size>174
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single group: all participants receive same intervention throughout study,Non-randomised
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo;Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Antoine
    </Contact_Firstname>
    <Contact_Lastname>Tarral
    </Contact_Lastname>
    <Contact_Address> Chemin Louis Dunant 15
    </Contact_Address>
    <Contact_Email>atarral@dndi.org
    </Contact_Email>
    <Contact_Tel>+41229069260
    </Contact_Tel>
    <Contact_Affiliation>Head of HAT Clinical Program/DNDi
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: * Male or female patient, including breastfeeding or pregnant women in the second or third trimester.&#x0D;&lt;br&gt;* ¿ 6 years of age.&#x0D;&lt;br&gt;* ¿ 20 kg body weight.&#x0D;&lt;br&gt;* Signed Informed Consent Form&#x0D;&lt;br&gt;* Trypanosomes detected in any body fluid.&#x0D;&lt;br&gt;* Physically able to ingest at least one solid meal per day.&#x0D;&lt;br&gt;* Able to take oral medication.&#x0D;&lt;br&gt;* Karnofsky Performance Status &gt; 40%.&#x0D;&lt;br&gt;* Able to comply with the schedule of follow-up visits and with the study constraints.&#x0D;&lt;br&gt;* Easily reachable during the out-patient follow-up period.&#x0D;&lt;br&gt;* Willing to undergo lumbar punctures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Eligibility Criteria for Out-patient Treatment:&#x0D;&lt;br&gt; - Accepting to be treated on an out-patient basis.&#x0D;&lt;br&gt; - Karnofsky Performance Status &gt; 50%.&#x0D;&lt;br&gt; - Good understanding of the method of administration of fexinidazole by the patient and/or caregiver (checked using a questionnaire at the time of IMP dispensing).&#x0D;&lt;br&gt; - Residing close to the investigational centre, i.e. approximately one hour by road and/or boat, during the treatment period*.&#x0D;&lt;br&gt; - Easily reachable during the treatment period.&#x0D;&lt;br&gt; - No medical or psychiatric contraindications for treatment as out-patient.&#x0D;&lt;br&gt; - No pregnancy or breastfeeding.&#x0D;&lt;br&gt; - No neurological symptoms.&#x0D;&lt;br&gt;*The patient (and caregiver) is permitted to reside in a place different from his/her main place of residence during the treatment period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: * Active clinically relevant medical conditions other than HAT that, in the Investigator¿s opinion, could jeopardise patient safety or interfere with participation in the study, including but not limited to significant liver or cardiovascular diseases, HIV infection, CNS trauma or seizure disorders, coma or altered consciousness not related to HAT.&#x0D;&lt;br&gt;* Severe renal or hepatic impairment defined as:&#x0D;&lt;br&gt;  o elevated creatinine at &gt; 3 times the upper limit of normal (ULN)&#x0D;&lt;br&gt;  o elevated ALT, AST or bilirubin at &gt; 3 ULN&#x0D;&lt;br&gt;* Severely deteriorated general condition, such as cardiovascular shock, respiratory distress or terminal illness.&#x0D;&lt;br&gt;* Any condition (except symptoms of HAT) that compromises ability to communicate with the Investigator as required for completion of the study.&#x0D;&lt;br&gt;* Any contraindication to imidazole products (known hypersensitivity to imidazoles).&#x0D;&lt;br&gt;* Treatment for HAT within 2 years prior to inclusion.&#x0D;&lt;br&gt;* Prior enrolment in the study or prior intake of fexinidazole.&#x0D;&lt;br&gt;* Foreseeable difficulty in complying with the schedule of follow-up visits (migrants, refugees, itinerant traders, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Temporary Non-inclusion Criteria:&#x0D;&lt;br&gt;* Recovery period after antimalarial treatment and/or treatment of helminthiasis (at least 3 days).&#x0D;&lt;br&gt;* Uncontrolled diabetes or hypertension or any patients requiring clinical stabilisation; wait until appropriate treatment to control the disease has been initiated.&#x0D;&lt;br&gt;* First trimester of pregnancy.&#x0D;&lt;br&gt;* Traumatic lumbar puncture at Screening i.e. red blood cells visible in CSF; wait for 48 hours before repeating lumbar puncture.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Human African Trypanosomiasis due to T.b. gambiense &lt;br&gt;Human African Trypanosomiasis due to T.b. gambiense;Human African Trypanosomiasis due to T.b. gambiense;Human African Trypanosomiasis due to T.b. gambiense
    </Condition>
    <Intervention>;Fexinidazole
    </Intervention>
    <Primary_outcome>Success or failure for patients any stage HAT
    </Primary_outcome>
    <Secondary_outcome>Occurrence of grade ¿ 3 adverse events (AEs);Occurrence of any serious adverse event (SAE);PK measure: Presence of fexinidazole and/or its main metabolites in the blood for PK analyses;Outpatients compliance: Number of tablets left over and patient's responses to the questionnaire;Outpatients compliance: Patient's responses to the questionnaire;Feasibility of self-management of treatment intake in outpatients based on interview and left over tablets at D11;questionnaire on acceptability of packaging for outpatients only questionnaire to be completed by patients and caregivers;Whole blood concentration of fexinidazole and its metabolites from dry blood spot of inpatients
    </Secondary_outcome>
    <Source_Support>DNDi
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>13/09/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Comité d'Ethique de l'université protestante au Congo
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10682751
    </Internal_Number>
    <TrialID>NCT03112655
    </TrialID>
    <Last_Refreshed_on>1 March 2021
    </Last_Refreshed_on>
    <Public_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure
    </Public_title>
    <Scientific_title>Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure
    </Scientific_title>
    <Acronym>DiTECT-WP4
    </Acronym>
    <Primary_sponsor>Institut de Recherche pour le Developpement
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170331
    </Date_registration3>
    <Date_registration>31/03/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03112655
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 24, 2017
    </Date_enrollement>
    <Target_size>88
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Veerle Lejon, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institut de Recherche pour le Developpement
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Eligible for participation in DNDi-OXA-02-HAT clinical trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Excluded for DNDi-OXA-02-HAT clinical trial; No informed consent for participation in&#x0D;&lt;br&gt;             the DiTECT-HAT-WP4 study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>African Trypanosomiasis;African; Trypanosomiasis, West;Sleeping Sickness; West African;Trypanosoma Brucei Gambiense; Infection
    </Condition>
    <Intervention>Diagnostic Test: RNA and neopterin detection
    </Intervention>
    <Primary_outcome>Sensitivity of SL-RNA detection in blood, SL-RNA detection in cerebrospinal fluid and of neopterin &amp; 5-hydroxytryptophan quantification in cerebrospinal fluid for relapse after human African trypanosomiasis treatment;Specificity of SL-RNA detection in blood, SL-RNA detection in cerebrospinal fluid and of neopterin &amp; 5-hydroxytryptophan quantification in cerebrospinal fluid for cure after human African trypanosomiasis treatment
    </Primary_outcome>
    <Secondary_outcome>Sensitivity and specificity SL-RNA detection in blood for outcome assesment after treatment for human African trypanosomiasis;Sensitivity and specificity SL-RNA detection in cerebrospinal fluid for outcome assesment after treatment for human African trypanosomiasis;Sensitivity and specificity by ROC analysis of neopterin &amp; 5-hydroxytryptophan quantification in cerebrospinal fluid for outcome assesment after treatment for human African trypanosomiasis
    </Secondary_outcome>
    <Secondary_ID>DiTECT-HAT-WP4
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institute of Tropical Medicine, Belgium;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Ministry of Public Health, Democratic Republic of the Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10272641
    </Internal_Number>
    <TrialID>NCT03114137
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose
    </Public_title>
    <Scientific_title>Heart, Arteries and Sikle Cell Disease, a Multicentric Cohort of Cardiovascular Complications in Subsaharan Africa
    </Scientific_title>
    <Acronym>CADRE
    </Acronym>
    <Primary_sponsor>Cardiologie et Développement
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170330
    </Date_registration3>
    <Date_registration>30/03/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03114137
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 2012
    </Date_enrollement>
    <Target_size>4500
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Cameroon;Congo, The Democratic Republic of the;Côte D'Ivoire;Gabon;Mali;Senegal;Cameroon;Congo, The Democratic Republic of the;Côte D'Ivoire;Gabon;Mali;Senegal
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Xavier Jouven, MD PhD;Brigitte Ranque, MD PhD
    </Contact_Lastname>
    <Contact_Email>;brigitte.ranque@aphp.fr
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Cardiologie et Developpement;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age: five-year-old or more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signature of informed consent Patients : major sickle cell syndrome confirmed by&#x0D;&lt;br&gt;             hemoglobin phenotyping: SS, SC, SBeta+ or Sbeta0 Controls : healthy parents or&#x0D;&lt;br&gt;             siblings of the patients, hospital staff or their children, matched on age+/- 3 years&#x0D;&lt;br&gt;             and country (1 control for 4 patients)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        unstable clinical status such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  vaso-occlusive crisis in the previous 15 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  fever or infectious disease in the previous 15 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  transfusion in the previous 2 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Sickle Cell Anemia;Sickle Cell Disease
    </Condition>
    <Primary_outcome>Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: glomerulopathy;Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: cardiopathy;Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: pulmonary hypertension;Prevalence and incidence and the 10 year-incidence of the main SCD-related vascular complications in different phenotypes of SCD: retinopathy;Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD:stroke;Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD:osteonecrosis;Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: leg ulcers;Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: priapism
    </Primary_outcome>
    <Secondary_outcome>Potential biological risk marker measured at baseline and follow up visits: carotid-femoral pulse wave velocity;Potential biological risk marker measured at baseline and follow up visits: complete blood count;Potential biological risk marker measured at baseline and follow up visits: LDH level;Potential biological risk marker measured at baseline and follow up visits: bilirubin level;Potential biological risk marker measured at baseline and follow up visits: microparticules measure;Potential biological risk marker measured at baseline and follow up visits: free heme level;Potential biological risk marker measured at baseline and follow up visits: inflammatory cytokines;Potential biological risk marker measured at baseline and follow up visits: neutrophil extracellular traps
    </Secondary_outcome>
    <Secondary_ID>002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de la Santé Et de la Recherche Médicale, France;University of Paris 5 - Rene Descartes;laboratory of excellence GR-Ex
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11876669
    </Internal_Number>
    <TrialID>NCT03087955
    </TrialID>
    <Last_Refreshed_on>31 January 2022
    </Last_Refreshed_on>
    <Public_title>Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense
    </Public_title>
    <Scientific_title>Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study
    </Scientific_title>
    <Acronym>OXA002
    </Acronym>
    <Primary_sponsor>Drugs for Neglected Diseases
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170307
    </Date_registration3>
    <Date_registration>07/03/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03087955
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 11, 2016
    </Date_enrollement>
    <Target_size>260
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Guinea;Congo, The Democratic Republic of the;Guinea
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Victor Kande Betu Kumeso, Dr
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Ministère de la Santé
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female patient&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  15 years of age or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed informed consent form (as well as assent from illiterate and under-age&#x0D;&lt;br&gt;             patients, and those unable to give consent)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky Performance Status above 50&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to ingest oral tablets&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having a permanent address or being traceable by other persons&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to comply with the schedule of follow-up visits and requirements of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agreement to be hospitalised in order to receive treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For patients with late-stage HAT:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Confirmation of g-HAT by detection of the parasite in the blood and/or the lymph&#x0D;&lt;br&gt;                  and/or the CSF, at the investigational centre&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  If trypanosomes are found in the blood or lymph, but not in the CSF, the CSF WBC,&#x0D;&lt;br&gt;                  measured at the investigational centre, must be above 20/µL for the patient to be&#x0D;&lt;br&gt;                  included in the cohort of patients with late-stage HAT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For patients with early- or intermediate-stage HAT:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Confirmation of g-HAT by detection of the parasite in the blood and/or the lymph,&#x0D;&lt;br&gt;                  at the investigational centre&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Absence of parasites in the CSF&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  The CSF WBC, measured at the investigational centre, must be between 6 and 20/µL&#x0D;&lt;br&gt;                  for the patient to be included in the cohort of patients with intermediate-stage&#x0D;&lt;br&gt;                  HAT and equal to or below 5/µL for the patient to be included in the cohort of&#x0D;&lt;br&gt;                  patients with early-stage HAT.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malnourishment, defined as body-mass index (BMI) below 16&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or breastfeeding (for women of child-bearing potential, confirmed pregnancy&#x0D;&lt;br&gt;             on a urine pregnancy test performed within 24 hours prior to administration of&#x0D;&lt;br&gt;             SCYX-7158)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant medical condition that could, in the opinion of the&#x0D;&lt;br&gt;             Investigator, jeopardise the patient's safety or interfere with participation in the&#x0D;&lt;br&gt;             study, including, but not limited to significant liver or cardiovascular disease,&#x0D;&lt;br&gt;             suspected or proven active infection, central nervous system trauma or seizure&#x0D;&lt;br&gt;             disorder, coma or consciousness disturbances&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severely deteriorated health status, e.g. due to cardiovascular shock, respiratory&#x0D;&lt;br&gt;             distress syndrome or end-stage disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previously treated for HAT (except prior treatment with pentamidine)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior enrolment in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Foreseeable difficulty complying with follow-up, including migrant worker, refugee&#x0D;&lt;br&gt;             status, itinerant trader etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current alcohol abuse or drug addiction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not tested for malaria and/or not having received appropriate treatment for malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not having received appropriate treatment for soil-transmitted helminthiasis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant abnormal laboratory values including Aspartate&#x0D;&lt;br&gt;             AminoTransferase(AST) and/or AlanineAminoTransferase (ALT) more than 2 times the upper&#x0D;&lt;br&gt;             limit of normal (ULN), total bilirubin more than 1.5 ULN, severe leukopenia at less&#x0D;&lt;br&gt;             than 2000/mm3, Potassium below 3.5 mmol/L, any other clinically significant abnormal&#x0D;&lt;br&gt;             laboratory value&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Trypanosomiasis, African;Gambiense Trypanosomiasis;Sleeping Sickness
    </Condition>
    <Intervention>Drug: Acoziborole (SCYX-7158)
    </Intervention>
    <Primary_outcome>Success or failure for patients in late stage HAT
    </Primary_outcome>
    <Secondary_outcome>Success or failure for all stage HAT patients;Time to Failure in Patients with Late-stage HAT;Occurence of adverse events;Occurence of serious advers events;Pharmacokinetics measure;Pharmacokinetics measure;Electrocardiogram measure;Electrocardiogram measure;Electrocardiogram measure;Electrocardiogram measure;Electrocardiogram measure
    </Secondary_outcome>
    <Secondary_ID>DNDi-OXA-02-HAT
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10269339
    </Internal_Number>
    <TrialID>NCT03052998
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
    </Public_title>
    <Scientific_title>Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial
    </Scientific_title>
    <Acronym>OAETREAT
    </Acronym>
    <Primary_sponsor>Robert Colebunders
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170210
    </Date_registration3>
    <Date_registration>10/02/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03052998
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 1, 2017
    </Date_enrollement>
    <Target_size>91
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Michel Mandro, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Chef de Bureau Inspection&amp;Contrôle et Associé de Recherche Clinique
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 5 years and above&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed informed consent form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal neurological development until onset of epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Onset of epilepsy between ages of 5 and 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Seizure frequency of =2 seizures per month&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of microfilaria in skin snip and/or antibodies against Ov16&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ivermectin intake the last 9 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or breastfeeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known or suspected allergy to Ivermectin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Loa Loa microfilariae in blood&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy with known cause (e.g. severe head trauma, perinatal asphyxia, patients with&#x0D;&lt;br&gt;             a history of cerebral malaria, meningitis or encephalitis)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Ivermectin;Onchocerciasis;Epilepsy
    </Condition>
    <Intervention>Drug: Ivermectin
    </Intervention>
    <Primary_outcome>seizure freedom
    </Primary_outcome>
    <Secondary_outcome>&gt;50 % reduction in seizure frequency
    </Secondary_outcome>
    <Secondary_ID>ERC grant No.671055;B300201730821
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12423870
    </Internal_Number>
    <TrialID>NCT03048669
    </TrialID>
    <Last_Refreshed_on>29 July 2022
    </Last_Refreshed_on>
    <Public_title>Long Term Outcomes of Therapy in Women Initiated on Lifelong ART Because of Pregnancy in DR Congo
    </Public_title>
    <Scientific_title>Continuous Quality Improvement Interventions to Improve Long Term Outcomes of Antiretroviral Therapy in Women Initiated on Therapy During Pregnancy or Breastfeeding in the Democratic Republic of Congo
    </Scientific_title>
    <Acronym>CQI-PMTCT
    </Acronym>
    <Primary_sponsor>Albert Einstein College of Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170207
    </Date_registration3>
    <Date_registration>07/02/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03048669
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2016
    </Date_enrollement>
    <Target_size>5053
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Marcel Yotebieng, MD, PhD;Emile W Okitolonda, MD, PhD;Marcel Yotebieng, MD, PhD;Emile W Okitolonda, MD, PhD;Marcel Yotebieng, MD, PhD;Emile W Okitolonda, MD, PhD;Marcel Yotebieng, MD, PhD;Emile W Okitolonda, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;;;
    </Contact_Tel>
    <Contact_Affiliation>Albert Einstein College of Medicine;Kinshasa School of Public Health;Albert Einstein College of Medicine;Kinshasa School of Public Health;Albert Einstein College of Medicine;Kinshasa School of Public Health;Albert Einstein College of Medicine;Kinshasa School of Public Health
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6672945
    </Internal_Number>
    <TrialID>NCT03044899
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>African Surgical Outcomes Study (ASOS)
    </Public_title>
    <Scientific_title>African Surgical Outcomes Study (ASOS): An African, Multi-centre Seven Day Evaluation of Patient Care and Clinical Outcomes for Patients Undergoing Surgery
    </Scientific_title>
    <Acronym>ASOS
    </Acronym>
    <Primary_sponsor>University of KwaZulu
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170203
    </Date_registration3>
    <Date_registration>03/02/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03044899
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2016
    </Date_enrollement>
    <Target_size>11422
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo, The Democratic Republic of the;Congo;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Nigeria;Niger;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe;Algeria;Benin;Burundi;Cameroon;Congo;Congo, The Democratic Republic of the;Egypt;Ethiopia;Gambia;Ghana;Kenya;Libyan Arab Jamahiriya;Madagascar;Mali;Mauritius;Namibia;Niger;Nigeria;Senegal;South Africa;Tanzania;Togo;Uganda;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Bruce Biccard, MD, PhD;Bruce Biccard, MD, PhD;Bruce Biccard, MD, PhD;Bruce Biccard, MD, PhD;Bruce Biccard, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of KwaZulu;University of KwaZulu;University of KwaZulu;University of KwaZulu;University of KwaZulu
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All consecutive patients admitted to participating centres undergoing elective and&#x0D;&lt;br&gt;             non-elective surgery commencing during a seven day study cohort period with a planned&#x0D;&lt;br&gt;             overnight hospital stay following surgery. The recruitment week will run between&#x0D;&lt;br&gt;             February and May 2016.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing planned day-case surgery or radiological procedures not requiring&#x0D;&lt;br&gt;             anaesthesia.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All consecutive patients admitted to participating centres undergoing elective and&#x0D;&lt;br&gt;             non-elective surgery commencing during a seven day study cohort period with a planned&#x0D;&lt;br&gt;             overnight hospital stay following surgery. The recruitment week will run between&#x0D;&lt;br&gt;             February and May 2016.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing planned day-case surgery or radiological procedures not requiring&#x0D;&lt;br&gt;             anaesthesia.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All consecutive patients admitted to participating centres undergoing elective and&#x0D;&lt;br&gt;             non-elective surgery commencing during a seven day study cohort period with a planned&#x0D;&lt;br&gt;             overnight hospital stay following surgery. The recruitment week will run between&#x0D;&lt;br&gt;             February and May 2016.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing planned day-case surgery or radiological procedures not requiring&#x0D;&lt;br&gt;             anaesthesia.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All consecutive patients admitted to participating centres undergoing elective and&#x0D;&lt;br&gt;             non-elective surgery commencing during a seven day study cohort period with a planned&#x0D;&lt;br&gt;             overnight hospital stay following surgery. The recruitment week will run between&#x0D;&lt;br&gt;             February and May 2016.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients undergoing planned day-case surgery or radiological procedures not requiring&#x0D;&lt;br&gt;             anaesthesia.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Surgery;Surgery- Complications;Mortality;Surgery;Surgery- Complications;Mortality;Surgery;Surgery- Complications;Mortality;Surgery;Surgery- Complications;Mortality
    </Condition>
    <Intervention>Procedure: All surgeries in adult patients;Procedure: All surgeries in adult patients;Procedure: All surgeries in adult patients;Procedure: All surgeries in adult patients
    </Intervention>
    <Primary_outcome>Incidence of in-hospital postoperative complications in adult surgical patients in Africa;Incidence of in-hospital postoperative complications in adult surgical patients in Africa;Incidence of in-hospital postoperative complications in adult surgical patients in Africa
    </Primary_outcome>
    <Secondary_outcome>Rate of mortality on the day of surgery for patients undergoing surgery in Africa;The in-hospital mortality rate for patients undergoing surgery in Africa
    </Secondary_outcome>
    <Secondary_ID>ASOS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medical Research Council, South Africa
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5982626
    </Internal_Number>
    <TrialID>ISRCTN63527489
    </TrialID>
    <Last_Refreshed_on>6 February 2017
    </Last_Refreshed_on>
    <Public_title>Validation of the UDI- and IIQ-7 questionnaire in Lingala and Kikongo in an obstetric fistula population
    </Public_title>
    <Scientific_title>Validation of the UDI- and IIQ-7 questionnaire in Lingala and Kikongo in an obstetric fistula population - an observational study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>KU Leuven - dept. of urology
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20161215
    </Date_registration3>
    <Date_registration>15/12/2016
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN63527489
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>01/10/2014
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational study  (Quality of life)
    </Study_design>
    <Phase/>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Female patient with a vesicovaginal fistula due to obstetric complications. 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Male&lt;br&gt;2. Unable to fill in a questionnaire&lt;br&gt;3. Fistula not due to obstetric complications
    </Exclusion_Criteria>
    <Condition>Vesicovaginal fistula due to obstetric complications in a rural hospital in DR Congo &lt;br&gt;Urological and Genital Diseases &lt;br&gt;Vesicovaginal fistula
    </Condition>
    <Intervention>Questionnaires, according to following methodologies. &lt;br&gt;- UDI-6 and IIQ-7 translated and undergoing  content validity checks using focus groups. &lt;br&gt;- Final versions tested in a normal population and in an obstetric fistula  population for internal consistency and test-retest reliability. &lt;br&gt;- Responsiveness tested in an obstetric fistula population and effect sizes calculated. &lt;br&gt;
    </Intervention>
    <Primary_outcome>Validation parameters: Crohnbach alpha, reliability, responsiveness 
    </Primary_outcome>
    <Secondary_outcome>1. Fistula closure rate -  number of healed fistula vs the number of persistent fistula after fistula surgery. This is assessed by clinical examination after 3 weeks. &lt;br&gt;2. Incontinence rate - number of patients with urinary incontinence ( stress and/or urgency incontinence) while the fistula is healed. This is assessed by clinical examination at 3 weeks and 3 months after surgery. &lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>UDIIIQ-1
    </Secondary_ID>
    <Source_Support>Investigator initiated and self funded
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6675161
    </Internal_Number>
    <TrialID>NCT03073707
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Reservoir of Invasive Salmonellosis in Children, DRC
    </Public_title>
    <Scientific_title>The Potential Role of the Household Environment as the Reservoir for Invasive Salmonellosis in Children, Kisangani, DR Congo.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161116
    </Date_registration3>
    <Date_registration>16/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03073707
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2017
    </Date_enrollement>
    <Target_size>96
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Dadi Falay, Pediatrician;Dadi Falay, Pediatrician;Dadi Falay, Pediatrician;Dadi Falay, Pediatrician;Dadi Falay, Pediatrician
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Kisangani;University of Kisangani;University of Kisangani;University of Kisangani;University of Kisangani
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Households where at least one child is diagnosed with NTS bloodstream infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refusal of participation&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Households where at least one child is diagnosed with NTS bloodstream infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refusal of participation&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Households where at least one child is diagnosed with NTS bloodstream infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refusal of participation&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Households where at least one child is diagnosed with NTS bloodstream infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refusal of participation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Salmonella Infections;Infection of Bloodstream;Salmonella Infections;Infection of Bloodstream;Salmonella Infections;Infection of Bloodstream;Salmonella Infections;Infection of Bloodstream
    </Condition>
    <Intervention>Behavioral: Sample collection;Behavioral: Sample collection;Behavioral: Sample collection;Behavioral: Sample collection
    </Intervention>
    <Primary_outcome>Environmental presence of NTS in household of index patients;Genetic relatedness of environmental/household and index patient results;Environmental presence of NTS in household of index patients;Genetic relatedness of environmental/household and index patient results;Environmental presence of NTS in household of index patients;Genetic relatedness of environmental/household and index patient results
    </Primary_outcome>
    <Secondary_outcome>Potential demonstration of common source of Salmonella infections in the community by sampling of household environment for NTS, guided by the answers given to questionnaires;Public health knowledge for blood stream infections caused by NTS in DR Congo;Targeted control prevention measures for blood stream infections caused by NTS in DR Congo by training provided by health personnel
    </Secondary_outcome>
    <Secondary_ID>1113/16
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Katholieke Universiteit Leuven;Université de Kisangani
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11485707
    </Internal_Number>
    <TrialID>NCT03025789
    </TrialID>
    <Last_Refreshed_on>18 October 2021
    </Last_Refreshed_on>
    <Public_title>Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
    </Public_title>
    <Scientific_title>An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Drugs for Neglected Diseases
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161111
    </Date_registration3>
    <Date_registration>11/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03025789
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 17, 2016
    </Date_enrollement>
    <Target_size>174
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Guinea;Congo, The Democratic Republic of the;Guinea
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Victor Kande Betu Kumeso, Dr
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Ministère de la Santé
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female patient, including breastfeeding or pregnant women in the second or&#x0D;&lt;br&gt;             third trimester.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  = 6 years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  = 20 kg body weight.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed Informed Consent Form and Assent Form for patients less than 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Trypanosomes detected in any body fluid.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Physically able to ingest at least one solid meal per day.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to take oral medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky Performance Status &gt; 40%.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to comply with the schedule of follow-up visits and with the study constraints.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Easily reachable during the out-patient follow-up period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to undergo lumbar punctures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active clinically relevant medical conditions other than HAT that, in the&#x0D;&lt;br&gt;             Investigator's opinion, could jeopardise patient safety or interfere with&#x0D;&lt;br&gt;             participation in the study, including but not limited to significant liver or&#x0D;&lt;br&gt;             cardiovascular diseases, HIV infection, CNS trauma or seizure disorders, coma or&#x0D;&lt;br&gt;             altered consciousness not related to HAT.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe renal or hepatic impairment defined as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        elevated creatinine at &gt; 3 times the upper limit of normal (ULN) elevated ALT, AST or&#x0D;&lt;br&gt;        bilirubin at &gt; 3 ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severely deteriorated general condition, such as cardiovascular shock, respiratory&#x0D;&lt;br&gt;             distress or terminal illness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any condition (except symptoms of HAT) that compromises ability to communicate with&#x0D;&lt;br&gt;             the Investigator as required for completion of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication to imidazole products (known hypersensitivity to imidazoles).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment for HAT within 2 years prior to inclusion.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior enrolment in the study or prior intake of fexinidazole.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Foreseeable difficulty in complying with the schedule of follow-up visits (migrants,&#x0D;&lt;br&gt;             refugees, itinerant traders, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Temporary Non-inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Recovery period after antimalarial treatment and/or treatment of helminthiasis (at&#x0D;&lt;br&gt;             least 3 days).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncontrolled diabetes or hypertension or any patients requiring clinical&#x0D;&lt;br&gt;             stabilisation; wait until appropriate treatment to control the disease has been&#x0D;&lt;br&gt;             initiated.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  First trimester of pregnancy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Traumatic lumbar puncture at Screening i.e. red blood cells visible in CSF; wait for&#x0D;&lt;br&gt;             48 hours before repeating lumbar puncture.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Eligibility Criteria for Out-patient Treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accepting to be treated on an out-patient basis;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky Performance Status &gt; 50%;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Good understanding of the method of administration of fexinidazole by the patient&#x0D;&lt;br&gt;             and/or caregiver* (checked using a questionnaire at the time of dispensing&#x0D;&lt;br&gt;             fexinidazole);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Residing close to the investigational centre, i.e. approximately one hour by road&#x0D;&lt;br&gt;             and/or boat, during the treatment period**;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Easily reachable during the treatment period;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No medical or psychiatric contraindications for treatment as out-patient;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No pregnancy or breastfeeding;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No neurological symptoms.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Trypanosomiasis, African;Sleeping Sickness;Trypanosomiasis; Gambian
    </Condition>
    <Intervention>Drug: Fexinidazole
    </Intervention>
    <Primary_outcome>Outcome (success or failure);Outcome (success or failure)
    </Primary_outcome>
    <Secondary_outcome>Occurrence of grade = 3 adverse events (AEs) including laboratory and haematological abnormalities;Occurrence of any serious adverse event (SAE);Pharmacokinetic measure to assess patient compliance;Outpatients compliance;Outpatients compliance;Feasibility of self-management of treatment intake in outpatients;questionnaire on acceptability of packaging for outpatients only;Whole blood concentration of fexinidazole and its metabolites from dry blood spot of inpatients
    </Secondary_outcome>
    <Secondary_ID>DNDi-FEX-09-HAT
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Sanofi
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10263584
    </Internal_Number>
    <TrialID>NCT02940756
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo
    </Public_title>
    <Scientific_title>Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial
    </Scientific_title>
    <Acronym>TETRDC2016
    </Acronym>
    <Primary_sponsor>Ministry of Public Health, Democratic Republic of the Congo
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161019
    </Date_registration3>
    <Date_registration>19/10/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02940756
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 15, 2017
    </Date_enrollement>
    <Target_size>1615
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Gauthier Mesia Kahunu, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Kinshasa
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  children aged 6 to 59 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  axillary temperature = 37.5 °C or history of fever during the 24 h before recruitment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  monoinfection with Plasmodium falciparum with asexual parasite count of 2,000 to&#x0D;&lt;br&gt;             200,000/µL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to swallow oral medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability and willingness to comply with the protocol for the duration of the study and&#x0D;&lt;br&gt;             to comply with the study visit schedule&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  informed consent from a parent/guardian&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  absence of general danger signs or signs of severe falciparum malaria according to the&#x0D;&lt;br&gt;             definitions of WHO (2000)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  absence of severe malnutrition according to WHO child growth standards&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  absence of febrile condition due to diseases other than malaria (e.g. measles, acute&#x0D;&lt;br&gt;             lower respiratory tract infection, severe diarrhoea with dehydration) or other known&#x0D;&lt;br&gt;             underlying chronic or severe diseases (e.g. cardiac, renal or hepatic diseases,&#x0D;&lt;br&gt;             HIV/AIDS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  absence of regular medication, which might interfere with antimalarial&#x0D;&lt;br&gt;             pharmacokinetics&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  absence of history of hypersensitivity reactions or contraindication to any medicine&#x0D;&lt;br&gt;             being tested or used as alternative treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of general danger signs in children aged under 5 years or signs of severe&#x0D;&lt;br&gt;             falciparum malaria according to the definitions of WHO&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  body weight &lt; 5kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hemoglobin level &lt; 5g/ dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mixed or monoinfection with another Plasmodium species detected by microscopy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of severe malnutrition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of febrile conditions due to diseases other than malaria (e.g. measles, acute&#x0D;&lt;br&gt;             lower respiratory tract infection, severe diarrhoea with dehydration) or other known&#x0D;&lt;br&gt;             underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases,&#x0D;&lt;br&gt;             HIV/AIDS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  regular medication, which may interfere with antimalarial pharmacokinetics;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of hypersensitivity reactions or contraindications to any of the medicine(s)&#x0D;&lt;br&gt;             being tested or used as alternative treatment(s)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: artesunate-amodiaquine;Drug: artemether-lumefantrine;Drug: Dihydroartemisinine-piperaquine
    </Intervention>
    <Primary_outcome>PCR-adjusted efficacy
    </Primary_outcome>
    <Secondary_outcome>PCR-unadjusted efficacy;K-13 propeller polymorphisms;incidence of adverse events
    </Secondary_outcome>
    <Secondary_ID>ASAQ-LA-DHAPQP 2015 DRC
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>8764856
    </Internal_Number>
    <TrialID>ACTRN12616001423404
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Evaluation of therapeutic efficacy and safety of artesunate-amodiaquine, artemether-lumefantrine and dihydroartemisinine-piperaquine for the treatment of uncomplicated Plasmodium falciparum  in Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Evaluation of therapeutic efficacy and safety of artesunate-amodiaquine, artemether-lumefantrine and dihydroartemisinine-piperaquine for the treatment of uncomplicated Plasmodium falciparum  in Democratic Republic of Congo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Ministry of Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161012
    </Date_registration3>
    <Date_registration>12/10/2016
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12616001423404.aspx
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>11/04/2017
    </Date_enrollement>
    <Target_size>534
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Other;Type of endpoint: Safety/efficacy;
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic Of The
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: 1. age between six  to 59 months;&#x0D;&lt;br&gt;2. mono-infection with P. falciparum detected by microscopy;&#x0D;&lt;br&gt;3. parasitaemia of 2000–200,000/microliter asexual forms;&#x0D;&lt;br&gt;4. presence of axillary temperature greater or equal to 37.5 degrees C or history of fever during the past 24 h&#x0D;&lt;br&gt;5. ability to swallow oral medication;&#x0D;&lt;br&gt;6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;&#x0D;&lt;br&gt;7. informed consent from the parent or guardian.&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;&#x0D;&lt;br&gt;2. weight under 5 kg;&#x0D;&lt;br&gt;3. Haemoglobin &lt; 8g/dl;&#x0D;&lt;br&gt;4. mixed or mono-infection with another Plasmodium species detected by microscopy;&#x0D;&lt;br&gt;5. presence of severe malnutrition defined as a child aged 6-60 months has a mid-upper arm circumference belo 115 mm)&#x0D;&lt;br&gt;6. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);&#x0D;&lt;br&gt;7. regular medication, which may interfere with antimalarial pharmacokinetics;&#x0D;&lt;br&gt;8. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Malaria; &lt;br&gt;Malaria;Infection - Studies of infection and infectious agents
    </Condition>
    <Intervention>To assess the efficacy and safety of the three drugs, the following dosages will be give:&lt;br&gt;Artesunate-amodiaquine: 4 mg/kg artesunate + 10mg/kg amodiaquine once daily for 3 consecutive days will be given.&lt;br&gt;Artemether-lumefantrine containing 2o mg artemether+ 120 mg lumefantrine in each tablet (twice a day for 3 days) will be administered according to the recommended weight bands as follows: 1 tablet to those weighing 5 to 14 kg; 2 tablets for 15 to 24 kg; 3 tablets for 25 to 34 kg and 4 tablets for equal or greater than 35 kg. The total target dose ranges are 5-24 mg/kg bw of artemether and 29-144 mg/kg bw of lumefantrine.&lt;br&gt;Dihydroartemisinin-piperaquine:  4 mg/kg dihydroartemisinin and 18 mg/kg piperaquine once a day for 3 days. &lt;br&gt;&lt;br&gt;All treatments will be taken orally under direct supervision by the health worker. These three artemisinin-based combinations will be tested separately. The patient will be given either artesunate+amodiaquine, artemether+lumefantrine or dihydroartemisinin+piperaquine. enrolled patients will be followed up for 28 days (artesunate+amodiaquine, artemether+lumefantrine) for or 42 days (dihydroartemisinin+piperaquine).&lt;br&gt;
    </Intervention>
    <Primary_outcome>Percent of treatment failures (early treatment failure + late clinical failure +late parasitological failure). This is composite primary outcome.&lt;br&gt;&lt;br&gt;Enrolled patients will be assessed for parasitological and clinical responses during the 42 days follow-up and treatment outcomes will be classified according to the latest WHO protocol.&lt;br&gt;[At days 1, 2, 3, 7, 14, 21 and 28 following artesunate+amodiquine or artemether-lumefantrine treatments; and days 1, 2, 3, 7, 14, 21 and 28, 35 and 42 following dihydroartemisinin-piperaquine treatment.]
    </Primary_outcome>
    <Secondary_outcome>Percent of adverse event following treatment of each drugs will be documented. &#x0D;&lt;br&gt;The known adverse events of:&#x0D;&lt;br&gt;Artesunate+amodiaquine are abdominal pain, asthenia, cough, diarrhoea, dizziness, insomnia, loss of appetite, nausea, vomiting.&#x0D;&lt;br&gt;Atemether+lumefantrine are abdominal pain, asthenia, cough, diarrhoea, dizziness, fever, headache, joint and muscle pain, loss of appetite, rush, nausea, vomiting.&#x0D;&lt;br&gt;Dihydroartemisinine – piperaquine are Asthenia, cough, diarrhoea, fever, loss of appetite, nausea,    vomiting.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Parents or guardians of all enrolled children will be asked routinely about previous symptoms and about symptoms that have emerged since the previous follow-up visit. When clinically indicated, patients will be evaluated and treated appropriately. All adverse events will be recorded on the case report form.&#x0D;&lt;br&gt;[At days 1, 2, 3, 7, 14, 21 and 28 following artesunate+amodiquine or artemether-lumefantrine treatments; and days 1, 2, 3, 7, 14, 21 and 28, 35 and 42 following dihydroartemisinin-piperaquine treatment.];Prevalence of artemisinin resistance molecular markers (K13).&#x0D;&lt;br&gt;Parasite DNA extracted from the dried blood spots will be analyzed by PCR and sequencing for the presence of K13 (molecular marker for artemisinin resistance).&#x0D;&lt;br&gt;[Day 0 (before treatment)]
    </Secondary_outcome>
    <Secondary_ID>None
    </Secondary_ID>
    <Source_Support>Ministry of Health
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>WHO ERC
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>8764819
    </Internal_Number>
    <TrialID>ACTRN12616001422415
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum in Dolisie, Republic of Congo
    </Public_title>
    <Scientific_title>Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum in Dolisie, Republic of Congo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Ministry of Health and Population
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161012
    </Date_registration3>
    <Date_registration>12/10/2016
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12616001422415.aspx
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>11 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>17/01/2017
    </Date_enrollement>
    <Target_size>176
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety/efficacy;
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: 1.	age between 6 months and 11 years.&#x0D;&lt;br&gt;2.	mono-infection with P. falciparum detected by microscopy;&#x0D;&lt;br&gt;3.	parasitaemia of 1000–200000/microliter asexual forms;&#x0D;&lt;br&gt;4.	presence of axillary  temperature equal  to or greater than 37.5 degrees centigrade or history of fever during the past 24 h;&#x0D;&lt;br&gt;5.	ability to swallow oral medication;&#x0D;&lt;br&gt;6.	ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; &#x0D;&lt;br&gt;7.	informed consent from the parent of children &#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.	presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);&#x0D;&lt;br&gt;2.	weight under 5 kg;&#x0D;&lt;br&gt;3.	mixed or mono-infection with another Plasmodium species detected by microscopy;&#x0D;&lt;br&gt;4.	presence of severe malnutrition defined as a child aged 6-60 months who has a mid-upper arm circumference &lt; 115 mm;&#x0D;&lt;br&gt;5.	presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);&#x0D;&lt;br&gt;6.	regular medication, which may interfere with antimalarial pharmacokinetics;&#x0D;&lt;br&gt;7.	history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Malaria; &lt;br&gt;Malaria;Infection - Studies of infection and infectious agents
    </Condition>
    <Intervention>The efficacy and safety of artemether-lumefantrine (twice daily doses for 3 days) and artesunate-amodiaquine (one daily dose for 3 days)  for the treatment of uncomplicated P. falciparum malaria will be evaluated. For artemether-lumefantrine, each tablet contains 20 mg artemether and 120 mg lumefantrine, A total target dose ranges 5-24 mg/kg bw of artemether and 29-144 mg/kg bw of lumefantrine. Artemether+lumefantrine will be given by weight bands: 1 tablet for children 5 to less than 15kg, 2 tablets per dose for children 15 to less than 25kg, 3 tablets for children 25 to less than 35 kg. For artesunate+amodiaquine treatment, a daily dose of 4 mg of artesunate/kg body weight and 10 mg of amodiaquine base/kg body weight will be given. The treatment will be given orally in tablets. Eligible children will be treated for three days and followed up for 28 days. The daily doses of the study medicines will be administered under direct supervision by the study team. &lt;br&gt;&lt;br&gt;Patients will be enrolled sequentially. The first cohort of recruited patients will be treated with artesunate+amodiaquine. When 88 patients have been enrolled and treated with artesunate+amodiaquine, the recruitment of the second cohort will begin; patients in the second cohort will be treated with artemether+lumefantrine and recruitment will continue until the target number of patients was reached.&lt;br&gt;
    </Intervention>
    <Primary_outcome>Percent of treatment failures (early treatment failure + late clinical failure + late parasitological failure). This is a composite primary outcome.&lt;br&gt;&lt;br&gt;Enrolled children will be evaluated for parasitological (using microscopy) and clinical responses. Treatment outcomes will be classified according to the WHO protocol 2009[Primary outcome (treatment failures) will be assessed on days 1, 3, 7, 14, 21 and 28 following treatment of artesunate+amodiaquin or artemether+lumefantrine ]
    </Primary_outcome>
    <Secondary_outcome>Percent of adverse events&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Known adverse events of the study drugs are:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;1. Artemether-lumefantrine: Abdominal pain, asthenia, cough, diarrhoea, dizziness, fever, headache, joint and muscle pain, loss of appetite, rush, nausea, vomiting.&#x0D;&lt;br&gt;2.Artesunate-amodiaquine: abdominal pain, asthenia, cough, diarrhoea, dizziness, insomnia, loss of appetite, nausea, vomiting.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Parents/guardians of children enrolled in the study will be asked routinely about previous symptoms and about symptoms that have emerged since the previous follow-up visit. When clinically indicated, patients will be assessed and treated appropriately. All adverse events will be recorded on the case report form.&#x0D;&lt;br&gt;[Secondary outcome (adverse events) will be assessed on days days 1, 3, 7, 14, 21 and 28 following treatment of artesunate+amodiaquin or artemether+lumefantrine ];Prevalence of artemisinin resistance molecular markers (K13).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Parasite DNA extracted from the dried blood spots will be analyzed by PCR and sequencing for the presence of K13 (molecular marker for artemisinin resistance).[At day 0 (prior initiation of treatments)]
    </Secondary_outcome>
    <Secondary_ID>None
    </Secondary_ID>
    <Source_Support>Ministry of Health and Population of Congo
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>WHO ethics and research committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12511626
    </Internal_Number>
    <TrialID>NCT02928341
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal in Uvira, Democratic Republic of Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>London School of Hygiene and Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161007
    </Date_registration3>
    <Date_registration>07/10/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02928341
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2016
    </Date_enrollement>
    <Target_size>4556
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Congo
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Oliver Cumming, MSc;Karin Gallandat, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5777741
    </Internal_Number>
    <TrialID>NCT02911441
    </TrialID>
    <Last_Refreshed_on>3 October 2016
    </Last_Refreshed_on>
    <Public_title>Evaluating CBT Delivered by Community Health Workers on Maternal Mental Health and Infant Cognitive Development in Insecure Environments
    </Public_title>
    <Scientific_title/>
    <Acronym/>
    <Primary_sponsor>Heartland Alliance
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160919
    </Date_registration3>
    <Date_registration>19/09/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02911441
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>December 2015
    </Date_enrollement>
    <Target_size>262
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Constantin Kahorha
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Heartland Alliance International
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women in their third trimester of pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Who exhibited symptoms of anxiety and depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women who express suicidality&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Maternal Anxiety;Maternal Depression;Infant Cognitive Development
    </Condition>
    <Intervention>Behavioral: Cognitive Behavioral Therapy
    </Intervention>
    <Primary_outcome>Symptoms of anxiety and depression as measured by Hopkins Symptoms Checklist;Infant Cognitive Development as measured by Mullen Scales of Early Learning
    </Primary_outcome>
    <Secondary_ID>0721-03
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12600174
    </Internal_Number>
    <TrialID>PACTR201609001784334
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Effectiveness of a package of postpartum family planning interventions on the uptake of contraceptive methods until 9 months postpartum in Burkina Faso
    </Public_title>
    <Scientific_title>Effectiveness of a package of postpartum family planning interventions on the uptake of contraceptive methods until 9 months postpartum in Burkina Faso and the Democratic Republic of Congo.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Department of Reproductive Health Research, World Health Organization, Geneva, Switzerland
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160917
    </Date_registration3>
    <Date_registration>17/09/2016
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1784
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>18 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>21/03/2016
    </Date_enrollement>
    <Target_size>560
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Simple randomization of study sites using a randomization table criteria. Health centers selected for the formative phase does not participate in the intervention phase.,This is a cluster RCT
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Burkina Faso;Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Mary Lyn
    </Contact_Firstname>
    <Contact_Lastname>Gaffield,
    </Contact_Lastname>
    <Contact_Address> Avenue Appia 20
    </Contact_Address>
    <Contact_Email>gaffieldm@who.int
    </Contact_Email>
    <Contact_Tel>0041227911806
    </Contact_Tel>
    <Contact_Affiliation>Technical Officer, World Health Organization
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All pregnant women will be eligible to participate in the intervention phase of the study if (1) they are in their third pregnancy trimester; (2) the status of the pregnancy and of the woman allows for a birth at the health center; (3) the woman has the intention to attend ANC, delivery and PNC at the health center; (4) the woman does not participate in another study; and (5) an informed consent is obtained.  
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: All pregnant women that will not be eligible to participate in the intervention phase of the study if (1) they are not in their third pregnancy trimester; (2) the status of the pregnancy and of the woman do not allow for a birth at the health center; (3) the woman has not the intention to attend ANC, delivery and PNC at the health center; (4) the woman does participate in another study; and (5) an informed consent is not obtained. 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Postpartum family planning ;Postpartum family planning 
    </Condition>
    <Intervention>;Routine PPFP care;PPFP intervention package
    </Intervention>
    <Primary_outcome>The primary outcome is the uptake of a modern contraceptive method at nine months postpartum.
    </Primary_outcome>
    <Secondary_outcome>Intention to use a contraceptive method, and decision made to use a contraceptive method;Use of a modern contraceptive method
    </Secondary_outcome>
    <Secondary_ID>RPC757
    </Secondary_ID>
    <Source_Support>Government of France
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>21/03/2016;03/02/2016;11/02/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ct_ethics@who.int;bocar@fastnet.bf;contact@unikin.ac.cd
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Research Ethics Committe The World Health Organization;Comite dethique pour la recherche en sante Ministere de la recherche scientifique et de l innovation Ministere de la sante;Comite d ethique Ecole de sante publique Universite de Kinshasa
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>000000000000;22650324159;243812227298
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ct_ethics@who.int;bocar@fastnet.bf;contact@unikin.ac.cd
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5761795
    </Internal_Number>
    <TrialID>EUCTR2015-003063-12-Outside-EU/EEA
    </TrialID>
    <Last_Refreshed_on>19 September 2016
    </Last_Refreshed_on>
    <Public_title>2-Iminobiotin vas a treatment for neonates born with severe oxygen shortage at birth
    </Public_title>
    <Scientific_title>TIBC study:
A multiple-centre Phase 2 trial comparing the efficacy of 2-Iminobiotin (2-IB) treatment to standard care in neonates with gestational age of =36 weeks with moderate to severe perinatal asphyxia in DR Congo.

 - TIBC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Neurophyxia B.V.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160914
    </Date_registration3>
    <Date_registration>14/09/2016
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003063-12
    </web_address>
    <Recruitment_Status>Not Available
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement/>
    <Target_size>94
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: yes
Other trial design description: Randomised phase will be preceded by open lable pilot phase with 8 patients. 
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>VP Regulatory Affairs
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Onderwijsboulevard 225
    </Contact_Address>
    <Contact_Email>info@neurophyxia.com
    </Contact_Email>
    <Contact_Tel>+31629056631
    </Contact_Tel>
    <Contact_Affiliation>Neurophyxia B.V.
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Neonates with = 36 weeks gestation with moderate to severe perinatal asphyxia with a Thompson score = 7 within 6h after birth &lt;br&gt;Ability to start treatment within 6 hours after birth&lt;br&gt;2.Ability to start treatment within 6 hours after birth&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: 94&lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Inability to insert an umbilical venous catheter for administration of the study drug. &lt;br&gt;2. Major congenital or chromosomal abnormalities, such as hernia diaphragmatica, omphalocele, trisomy 13 or trisomy 18&lt;br&gt;3. Birth weight &lt; 1800 grams &lt;br&gt;4. Clear signs of infection&lt;br&gt;5. Moribund patients&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Perinatal asphyxia &lt;br&gt;MedDRA version: 19.0
Level: LLT
Classification code 10003500
Term: Asphyxia neonatal
System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
 &lt;br&gt;MedDRA version: 19.0
Level: PT
Classification code 10028923
Term: Neonatal asphyxia
System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
 &lt;br&gt;MedDRA version: 19.0
Level: LLT
Classification code 10004943
Term: Birth asphyxia
System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
 &lt;br&gt;MedDRA version: 19.0
Level: HLT
Classification code 10028946
Term: Neonatal hypoxia and asphyxia
System Organ Class: 100000004868
 &lt;br&gt;MedDRA version: 19.0
Level: LLT
Classification code 10021147
Term: Hypoxic encephalopathy
System Organ Class: 100000004852
 &lt;br&gt;MedDRA version: 19.0
Level: LLT
Classification code 10022820
Term: Intrauterine hypoxia and birth asphyxia
System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
 &lt;br&gt;MedDRA version: 19.0
Level: LLT
Classification code 10040441
Term: Severe birth asphyxia
System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
 &lt;br&gt;MedDRA version: 19.0
Level: LLT
Classification code 10070512
Term: Hypoxic-ischemic encephalopathy
System Organ Class: 100000004852
;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: 2-Iminobiotin&lt;br&gt;Product Code: Neu 01&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: 2-Iminobiotin&lt;br&gt;CAS Number: 13395-35-2&lt;br&gt;Current Sponsor code: NEU 01&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: This study will consist of two parts, an initial open label pilot part with as main objective to study the pharmacokinetic profile of 2-Iminobiotin (2-IB), followed by a randomised part with as main objective to study the efficacy of 2-IB in a population of new-borns with perinatal asphyxia. ;Secondary Objective: In both the pilot part and the randomised part the safety profile will be evaluated.;Primary end point(s): Pilot part: &lt;br&gt;In an open label pilot part the pharmacokinetic and safety profile will be studied. Results will be used to decide on adjustment of the dose in the randomised part of the study. &lt;br&gt;&lt;br&gt;Randomised part: &lt;br&gt;The short term efficacy will be evaluated as determined by the number of surviving patients with a normal aEEG (continuous normal voltage (CNV)) at 36h after birth.;Timepoint(s) of evaluation of this end point: Pilot Phase: Pharmacokinetic profile will be determined at 5 time points:directly after completion of the first infusion, just before the second and last infusion, and 1h and 4h after the last infusion.&lt;br&gt;Randomised phase: aEEG and mortalitry will be evaluated at 36h after birth.&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): In addition to the main efficacy end point described above: several other parameters will be evaluated, including Thompson score, aEEG at other time points, presence of seizures, neuronal markers and neonatal mortality.&lt;br&gt;For evaluation of  safety vital signs, need for intervention, basic biochemistry, renal function and (serious) adverse events will be monitored. ;Timepoint(s) of evaluation of this end point: Efficacy end-points: aEEG, Thompson score, neuronal biomarkers at selected time points during first 72 hours after birth; seizures and mortality during first 7 days after birth.&lt;br&gt;Safety end-points: vital signs, blood biochemistry, renal function and need for intervention will be monitored at selected time points within 48 hours after birth; (Serious) Adverse Events will monitored during stay at the NICU for up to a maximum of 7 days. 
    </Secondary_outcome>
    <Secondary_ID>NEU-01-02-1A
    </Secondary_ID>
    <Source_Support>Neurophyxia B.V.
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12277846
    </Internal_Number>
    <TrialID>NCT02977715
    </TrialID>
    <Last_Refreshed_on>23 May 2022
    </Last_Refreshed_on>
    <Public_title>IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo
    </Public_title>
    <Scientific_title>An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Centers for Disease Control and Prevention
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160907
    </Date_registration3>
    <Date_registration>07/09/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02977715
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 23, 2017
    </Date_enrollement>
    <Target_size>1600
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Brett Petersen, MD, MPH;Kinkodi Didine Kaba, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Centers for Disease Control and Prevention;DRC
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Males and nonpregnant females (as indicated by a negative urine pregnancy test prior&#x0D;&lt;br&gt;             to first dose of vaccine) age 18 years and older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Healthcare personnel at risk of monkeypox infection working in the Tshuapa Province of&#x0D;&lt;br&gt;             DRC or laboratory personnel performing diagnostic testing for monkeypox at the time of&#x0D;&lt;br&gt;             enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Willing to adhere to infection control recommendations to the extent possible based on&#x0D;&lt;br&gt;             availability of resources.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Able and willing to complete the informed consent process and study procedures&#x0D;&lt;br&gt;             (including blood sample collection, urine pregnancy test, and completion of adverse&#x0D;&lt;br&gt;             event diary and exposure forms).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Available for all study visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Any history of allergy or anaphylaxis to any prior vaccines, eggs, or aminoglycosides.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Current pregnancy (a negative urine pregnancy test is required for women participants&#x0D;&lt;br&gt;             who self-report as not pregnant). Enrollment for such participants may be deferred to&#x0D;&lt;br&gt;             a later time at which this criteria can be met.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Acute illness that is accompanied by an axillary temperature =37.2°C (99.0°F) at the&#x0D;&lt;br&gt;             time of vaccination. Enrollment for such participants may be deferred to a later time&#x0D;&lt;br&gt;             at which this criteria can be met.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Known experimental research agents or other vaccine within 28 days (4 weeks) prior to&#x0D;&lt;br&gt;             vaccination. Enrollment for such participants may be deferred to a later time at which&#x0D;&lt;br&gt;             this criteria can be met.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Any reason the PIs suspect that data collected from this person would be incomplete or&#x0D;&lt;br&gt;             of poor quality.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Any condition that the PIs suspect may place the participant at an unacceptable risk&#x0D;&lt;br&gt;             of injury or render the participant unable to meet the requirements of the protocol.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Monkeypox Virus Infection
    </Condition>
    <Intervention>Biological: IMVAMUNE
    </Intervention>
    <Primary_outcome>Proportion of participants who develop suspected or confirmed monkeypox virus infection following receipt of IMVAMUNE;Proportion of participants who experience exposure to monkeypox virus following receipt of IMVAMUNE
    </Primary_outcome>
    <Secondary_outcome>Adverse event and serious adverse event information;Proportion of participants who have orthopoxvirus antibody responses on days 0, 14, 28, 42, 180, 365, 545, and 730 days after the receipt of the first dose of vaccine;Distribution of geometric means (GMTs) on days 0, 14, 28, 42, 180, 365, 545, and 730 days after the receipt of the first dose of vaccine
    </Secondary_outcome>
    <Secondary_ID>CDC-IRB-6859
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Public Health, Democratic Republic of the Congo;Kinshasa School of Public Health;Bavarian Nordic
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11633888
    </Internal_Number>
    <TrialID>CTRI/2016/05/006970
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>ASPIRIN- Preterm Birth Prevention Study
    </Public_title>
    <Scientific_title>Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) - ASPIRIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160531
    </Date_registration3>
    <Date_registration>31-05-2016
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14886
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-06-2016
    </Date_enrollement>
    <Target_size>11920
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Placebo Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Permuted block randomization, variable  Method of allocation concealment:Centralized  Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Democratic Republic of the Congo;Guatemala;India;Kenya;Pakistan;Zambia
    </Countries>
    <Contact_Firstname>Dr Shivaprasad S Goudar
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Womens and Childrens Health Research Unit KLE Universitys J N Medical College Nehru Nagar 
    </Contact_Address>
    <Contact_Email>sgoudar@jnmc.edu
    </Contact_Email>
    <Contact_Tel>9448126371
    </Contact_Tel>
    <Contact_Affiliation>KLE Universitys J N Medical College
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: -Nulliparous women between 18 â?? 40 years of age. &lt;br/ &gt;&lt;br&gt;-No more than two previous first trimester pregnancy losses  &lt;br/ &gt;&lt;br&gt;-No medical contraindications to aspirin; &lt;br/ &gt;&lt;br&gt;-Single live intrauterine pregnancy (IUP) between 6 0/7 and 13 6/7 weeks GA corroborated by an early dating ultrasound and with heart rate greater than 110 bpm &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -Women prescribed daily aspirin for more than 7 days &lt;br/ &gt;&lt;br&gt;-Multiple gestations; &lt;br/ &gt;&lt;br&gt;-Fetal anomaly by ultrasound (Note most fetal anomalies are not detectable by ultrasounds done at this early gestation. Subsequent discovery of a fetal anomaly is not viewed as an exclusion &lt;br/ &gt;&lt;br&gt;-Hemoglobin   &lt; 7.0 gm/dl at screening &lt;br/ &gt;&lt;br&gt;-Any other medical conditions that may be considered a contraindication per the judgment of the site investigator (e.g., Lupus, Type 1 Diabetes, hypertension, or any other known significant disease) &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: P073- Preterm [premature] newborn [other]

    </Condition>
    <Intervention>Intervention1: Low dose Aspirin: 81 mg of aspirin administered daily beginning between 6 0/7 weeks and 13 6/7 weeks through 36 0/7 weeks or delivery&lt;br&gt;Control Intervention1: Placebo: Identical appearing placebo administered daily beginning between 6 0/7 weeks and 13 6/7 weeks through 36 0/7 weeks or delivery&lt;br&gt;Control Intervention2: Placebo: Identical appearing placebo administered daily beginning between 6 0/7 weeks and 13 6/7 weeks through 36 0/7 weeks or delivery&lt;br&gt;
    </Intervention>
    <Primary_outcome>Preterm birthTimepoint: delivery after 20 0/7 weeks and prior to 37 0/7 weeks
    </Primary_outcome>
    <Secondary_outcome>Birth weight less than 2500g and 1500gTimepoint: At Delivery;Antepartum hemorrhageTimepoint: Bleeding from the genital tract at any time after the 22nd week of pregnancy and before the birth of the baby;Change in maternal hemoglobinTimepoint: Hemoglobin level less than 7.0 gm/dL or a 3.5 gm/dL decrease between measurements;Fetal LossTimepoint: Spontaneous loss more than or equal to 16 weeks GA plus perinatal mortality;Late abortionTimepoint: Spontaneous fetal loss after or equal to 16 weeks;Maternal mortalityTimepoint: death of a woman during pregnancy (i.e. conception to delivery) and the puerperium (i.e. up to 42 days after delivery;Medical termination of pregnancyTimepoint: an operation or other procedure to terminate pregnancy before the fetus is viable;Perinatal mortalityTimepoint: until 7 days after delivery;Postpartum hemorrhageTimepoint: Blood loss of 1000 ml or more from the genital tract after delivery and up to six weeks post-delivery;Preeclampsia and eclampsiaTimepoint: upto 42 days postpartum period;Preterm birth less than 34 0/7 weeks of pregnancyTimepoint: live birth before 34 0/7 weeks of pregnancy are completed;Small for Gestational ageTimepoint: Day of delivery;Spontaneous abortionTimepoint: Premature expulsion of a non-viable fetus from the uterus at less than 20 weeks gestation;StillbirthTimepoint: Birth of a baby that shows no signs of life at birth;Vaginal bleedingTimepoint: Bleeding during pregnancy
    </Secondary_outcome>
    <Secondary_ID>GN-LDA.8.1, Version 1.1, March 21, 2015;NCT02409680
    </Secondary_ID>
    <Source_Support>Eunice Kennedy Shriver National Institute of Child Health and Human Development
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/05/2016;04/05/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethics Review Committee, Lata Medical Research Foundation Nagpur;JNMC â?? Institutional Ethics Committee on Human Subjects Research Belgaum
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_date_completed>11/04/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10255547
    </Internal_Number>
    <TrialID>NCT02765139
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Preventing Intimate-partner Violence: Impact Evaluation of Engaging Men Through Accountable Practice in Eastern DRC
    </Public_title>
    <Scientific_title>Preventing Intimate-partner Violence: Impact Evaluation of Engaging Men Through Accountable Practice in Eastern DRC
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>World Bank
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160504
    </Date_registration3>
    <Date_registration>04/05/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02765139
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>February 2016
    </Date_enrollement>
    <Target_size>1387
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Julia Vaillant, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>World Bank
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 20 or older but preferably at least 25;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident of their village, having lived in the community for a minimum of six months&#x0D;&lt;br&gt;             with plans to continue living there for at least the coming six months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to participate actively in group work and reflection activities;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Commitment to attend meetings, sessions and other activities regularly without&#x0D;&lt;br&gt;             incentives;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Commitment to non-violence toward women and girls for the duration of the EMAP&#x0D;&lt;br&gt;             intervention;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Involved in the IRC-led adolescent girl intervention (COMPASS).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Intimate Partner Violence;Domestic Violence;Family Relations
    </Condition>
    <Intervention>Behavioral: Engaging Men through Accountable Practice;Other: Alternative intervention
    </Intervention>
    <Primary_outcome>Change in baseline prevalence of intimate-partner violence
    </Primary_outcome>
    <Secondary_outcome>Change in acceptability of intimate partner violence;Change in intention to commit violence
    </Secondary_outcome>
    <Secondary_ID>P149394
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>International Rescue Committee
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10252115
    </Internal_Number>
    <TrialID>NCT02689193
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres
    </Public_title>
    <Scientific_title>IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres
    </Scientific_title>
    <Acronym>IDIS
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160129
    </Date_registration3>
    <Date_registration>29/01/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02689193
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>2 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2014
    </Date_enrollement>
    <Target_size>2500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Belgium;Cambodia;Congo, The Democratic Republic of the;Belgium;Cambodia;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Laura Kuijpers, MD, MSc;Panha Chung;Ange Landela, MD
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>Institute of Tropical Medicine, Antwerp, Belgium;Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        A. Travel clinic Institute of Tropical Medicine (ITM) Antwerp&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Adults (= 18 years) and children aged 3 years to 18 years with (suspicion of) fever and:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. presenting at ITM travel clinic with history of fever (axillary T° = 38°C) and/or&#x0D;&lt;br&gt;             chills/rigor and sweats within 3 days prior to consultation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. presenting at ITM travel clinic for routine check-up ("apparently healthy")&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. with recent (&lt; 2 weeks) stay in tropical country&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Refusal to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        B. Sihanouk Hospital Center of HOPE (SHCH)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Adults (= 18 years) with (suspicion of) fever and:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. Presenting at the in- and outpatient department of SHCH with a history of fever&#x0D;&lt;br&gt;        (axillary T= 38°C) and/or/chills/rigor and sweats within 3 days prior to consultation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Refusal to participate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Not able to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Adults (= 18 years) and children aged 2 months to 18 years with (suspicion of) fever and:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. Blood culture request by treating physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Not able or willing to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. A hemoglobin level that is considered too low for weight and age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Adults (= 18 years) and children aged 2 months to 18 years with (suspicion of) fever and:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. Blood culture request by treating physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Not able or willing to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. A hemoglobin level that is considered too low for weight and age&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Salmonella Septicemia;Salmonella Infections;Fever;Blood Stream Infections;Parasitic Infections
    </Condition>
    <Intervention>Other: Blood sampling
    </Intervention>
    <Primary_outcome>Detection of bacterial proteins through Selected Reaction Monitoring (SRM) measured in the unit m/z;Quantification of bacterial proteins measured through Selected Reaction Monitoring (SRM) as ion counts;Ranking of detected bacterial proteins based on detection per number of samples and on ion counts;Colorimetric detection of the selected proteins by ELISA measured in the unit optical density;Integration of the selected proteins into a rapid diagnostic test based on a lateral flow format;Evaluation of the test expressed as percentage positive in samples
    </Primary_outcome>
    <Secondary_ID>IDIS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Sihanouk Hospital Center of HOPE;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;Vlaams Instituut voor Biotechnologie
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6655112
    </Internal_Number>
    <TrialID>NCT02656862
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Causes of Acute Undifferentiated Fever in Outpatients in the Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Causes of Acute Undifferentiated Fever in Outpatients in the Democratic Republic of Congo
    </Scientific_title>
    <Acronym>RESFANDI
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160105
    </Date_registration3>
    <Date_registration>05/01/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02656862
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>2 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2015
    </Date_enrollement>
    <Target_size>301
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Pascal Lutumba, PhD;Pascal Lutumba, PhD;Pascal Lutumba, PhD;Pascal Lutumba, PhD;Pascal Lutumba, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Institut National de Recherche Biomédicale (INRB), Kinshasa;Institut National de Recherche Biomédicale (INRB), Kinshasa;Institut National de Recherche Biomédicale (INRB), Kinshasa;Institut National de Recherche Biomédicale (INRB), Kinshasa;Institut National de Recherche Biomédicale (INRB), Kinshasa
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  at least 2 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a history of acute fever (i.e. = 2 days and = 7 days)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  an axillary temperature of =37.5°C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  written informed consent obtained;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  main complaint for consultation is an injury, trauma or poisoning&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hospitalization or delivery in the preceding 2 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suspicion of meningitis/encephalitis&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  at least 2 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a history of acute fever (i.e. = 2 days and = 7 days)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  an axillary temperature of =37.5°C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  written informed consent obtained;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  main complaint for consultation is an injury, trauma or poisoning&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hospitalization or delivery in the preceding 2 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suspicion of meningitis/encephalitis&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  at least 2 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a history of acute fever (i.e. = 2 days and = 7 days)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  an axillary temperature of =37.5°C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  written informed consent obtained;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  main complaint for consultation is an injury, trauma or poisoning&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hospitalization or delivery in the preceding 2 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suspicion of meningitis/encephalitis&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  at least 2 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a history of acute fever (i.e. = 2 days and = 7 days)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  an axillary temperature of =37.5°C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  written informed consent obtained;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  main complaint for consultation is an injury, trauma or poisoning&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hospitalization or delivery in the preceding 2 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suspicion of meningitis/encephalitis&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Undifferentiated Acute Fever;Undifferentiated Acute Fever;Undifferentiated Acute Fever;Undifferentiated Acute Fever
    </Condition>
    <Intervention>Other: No intervention;Other: No intervention;Other: No intervention;Other: No intervention
    </Intervention>
    <Primary_outcome>Proportion of key pathogens among study participants with 'undifferentiated fever';Proportion of key pathogens among study participants with 'undifferentiated fever';Proportion of key pathogens among study participants with 'undifferentiated fever'
    </Primary_outcome>
    <Secondary_ID>RESFANDI
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de recherche Biomédicale (INRB), Kinshasa, DRC;Universiteit Antwerpen;Université de Kinshasa, DRC
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6652653
    </Internal_Number>
    <TrialID>NCT02595827
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Non-inferiority Trial of Conditional vs Universal Follow up for Children With Fever in Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Universal Versus Conditional Follow Up for Children With Unclassified Fever at the Community Level: A Cluster-Randomized, Community-based, Non-Inferiority Trial in Kalemie, Democratic Republic of Congo (DRC)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins Bloomberg School of Public Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151102
    </Date_registration3>
    <Date_registration>02/11/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02595827
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>2 Months
    </Inclusion_agemin>
    <Inclusion_agemax>60 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 9, 2015
    </Date_enrollement>
    <Target_size>4451
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Luke C Mullany, PhD;Luke C Mullany, PhD;Luke C Mullany, PhD;Luke C Mullany, PhD;Luke C Mullany, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Johns Hopkins Bloomberg School of Public Health;Johns Hopkins Bloomberg School of Public Health;Johns Hopkins Bloomberg School of Public Health;Johns Hopkins Bloomberg School of Public Health;Johns Hopkins Bloomberg School of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agree to recruitment script provided by CHWs at the time of identification of eligible&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agree to recruitment script provided by CHWs at the time of identification of eligible&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agree to recruitment script provided by CHWs at the time of identification of eligible&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agree to recruitment script provided by CHWs at the time of identification of eligible&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Fever;Fever;Fever;Fever
    </Condition>
    <Intervention>Other: Conditional Advice;Other: Conditional Advice;Other: Conditional Advice;Other: Conditional Advice
    </Intervention>
    <Primary_outcome>Clinical failure at 7 days;Clinical failure at 7 days;Clinical failure at 7 days
    </Primary_outcome>
    <Secondary_ID>68295
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>International Rescue Committee;University Research Co, LLC;Centers for Disease Control and Prevention
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>8763171
    </Internal_Number>
    <TrialID>ACTRN12615001110572
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Efficacy and safety of artesunate+amodiaquine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in two health centres of Pointe-Noire, Republique of Congo.
    </Public_title>
    <Scientific_title>Efficacy and safety of artesunate+amodiaquine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in two health centres of Pointe-Noire, Republique of Congo.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Ministry of Health and Populations
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20151021
    </Date_registration3>
    <Date_registration>21/10/2015
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12615001110572.aspx
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>11 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>12/09/2015
    </Date_enrollement>
    <Target_size>176
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Other;Type of endpoint: Safety/efficacy;
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: 1. age between six months and 11 years;&#x0D;&lt;br&gt;2. mono-infection with P. falciparum detected by microscopy;&#x0D;&lt;br&gt;3. parasitaemia of 1000–200,000/microliter asexual forms;&#x0D;&lt;br&gt;4. presence of axillary temperature greater or equal to 37.5 degrees C or history of fever during the past 24 h&#x0D;&lt;br&gt;5. ability to swallow oral medication;&#x0D;&lt;br&gt;6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;&#x0D;&lt;br&gt;7.informed consent from the parent or guardian.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;&#x0D;&lt;br&gt;2. weight under 5 kg;&#x0D;&lt;br&gt;3. mixed or mono-infection with another Plasmodium species detected by microscopy;&#x0D;&lt;br&gt;4. presence of severe malnutrition defined as a child aged 6-60 months has a mid-upper arm circumference belo 115 mm)&#x0D;&lt;br&gt;5. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);&#x0D;&lt;br&gt;6. regular medication, which may interfere with antimalarial&#x0D;&lt;br&gt;pharmacokinetics;&#x0D;&lt;br&gt;7. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
    </Exclusion_Criteria>
    <Condition>Malaria; &lt;br&gt;Malaria;Infection - Studies of infection and infectious agents
    </Condition>
    <Intervention>To assess the efficacy and safety of artesunate+amodiaquine  (artesunate 4 mg/kg body weight + amodiaquine 10mg/kg body weight once daily for 3 consecutive days) and artemether+lumefantrine (20 mg artemether and 120 mg lumefantrine in a tablet) for the treatment of uncomplicated P. falciparum infection.. The doses of artemether+lumefantrine is based on weight bands: one tablet to those weighing 5-14kg; two tablets for 15-24 kg; three tablets for 25-34 kg and four tablets for greater than or equal to 35 kg;  once daily for 3 consecutive days.. The treatment will be taken orally under direct supervision by the health worker. These two artemisinin-based combinations will be tested separately. The patient will be given either artesunate+amodiaquine or artemether+lumefantrine. Both of these drugs will be tested in each site. Eligibile subjects will be treated for three days and followed up for 28 days.
    </Intervention>
    <Primary_outcome>Percent of treatment failures (early treatment failure + late clinical failure +late parasitological failure). This is composite primary outcome.&lt;br&gt;&lt;br&gt;Enrolled patients will be assessed for parasitological (using microscopy), clinical responses during the 28 days follow-up and treatment outcomes will be classified according to the latest WHO protocol.[At day 28 following initiation of artemether+lumefantrine.]
    </Primary_outcome>
    <Secondary_outcome>Prevalence of artemisinin resistance molecular markers (K13).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Parasite DNA extracted from the dried blood spots will be analyzed by PCR and sequencing for the presence of K13 (molecular marker for artemisinin resistance).[At Day 0 (prior initiation of treatment)];Percent of adverse event will be documented. &#x0D;&lt;br&gt;The known adverse events of:&#x0D;&lt;br&gt;a. artesunate+amodiaquine are abdominal pain, asthenia, cough, diarrhoea, dizziness, insomnia, loss of appetite, nausea, vomiting.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;b. artemether+lumefantrine are abdominal pain, asthenia, cough, diarrhoea, dizziness, fever, headache, joint and muscle pain, loss of appetite, rush, nausea, vomiting.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Parents or guardians of all enrolled patients will be asked routinely about previous symptoms and about symptoms that have emerged since the previous follow-up visit. When clinically indicated, patients will be evaluated and treated appropriately. All adverse events will be recorded on the case report form.[At day 28 following initiation of treatment.]
    </Secondary_outcome>
    <Secondary_ID>Nil
    </Secondary_ID>
    <Source_Support>Ministry of Health and Populations
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethical Committe of reseach and Health Sciences ;WHO ERC
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12599898
    </Internal_Number>
    <TrialID>PACTR201512001261363
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Miniaturized point-of-care diagnosis of intectious diseases
    </Public_title>
    <Scientific_title>Miniaturized point-of-care diagnosis of intectious diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>University Hospital Basel (MIPS)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150910
    </Date_registration3>
    <Date_registration>10/09/2015
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1261
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>100 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/09/2015
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single group: all participants receive same intervention throughout study,Non-randomised
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo;Ethiopia;Senegal
    </Countries>
    <Contact_Firstname>Georgette
    </Contact_Firstname>
    <Contact_Lastname>Salieb-Beugelaar
    </Contact_Lastname>
    <Contact_Address>Petersgraben 4
    </Contact_Address>
    <Contact_Email>beugelaar@swissnano.org
    </Contact_Email>
    <Contact_Tel>+ 41 61 328 65 81 
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: The trial population exists of patients who contact a healthcare worker at a study site in sub-Saharan Africa and are being investigated for the presence of an infectious disease such as malaria and using the clinical standard of care methods. &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Inclusion criteria&#x0D;&lt;br&gt;1) Informed Consent&#x0D;&lt;br&gt;2) Age ¿ 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criteria &#x0D;&lt;br&gt;1) Age &lt; 18 years&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria &lt;br&gt;dengue, typhoid fever, pneumoccocal disease;Malaria;dengue, typhoid fever, pneumoccocal disease
    </Condition>
    <Intervention>;standard therapy;Standard therapy;Standard therapy;Standard therapy
    </Intervention>
    <Primary_outcome>Comparison of diagnostics accuracy of the new assays and point-of-care technologies with the conventional diagnosis.
    </Primary_outcome>
    <Source_Support>FP7 - European Union
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>30/07/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethikkommission Nordwest- und Zentralschweiz EKNZ
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5273038
    </Internal_Number>
    <TrialID>NCT02492178
    </TrialID>
    <Last_Refreshed_on>14 December 2015
    </Last_Refreshed_on>
    <Public_title>Bio-availability of Rectal Artesunate in Children With Severe Falciparum Malaria
    </Public_title>
    <Scientific_title/>
    <Acronym>REACH
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150622
    </Date_registration3>
    <Date_registration>22/06/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02492178
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2015
    </Date_enrollement>
    <Target_size>82
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight =6 kilograms and = 34 kilograms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malaria (WHO Guidelines 2013; Appendix 1)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  P. falciparum infection confirmed by Rapid Diagnostic Test (P. falciparum&#x0D;&lt;br&gt;             monoinfection or mixed infection with P. ovale or P. malariae)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents or guardian signed Informed Consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute diarrhoea defined as &gt; 3 liquid stools in the previous 24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Visible anorectal malformations or a disease of the rectum&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known hypersensitivity to quinine or artesunate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A documented history of an effective dose of parenteral antimalarial in the preceding&#x0D;&lt;br&gt;             24 hours or a single dose of rectal artesunate in the previous 12 hours or a dose of&#x0D;&lt;br&gt;             an artemisinin based combination therapy in the previous 6 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Co-morbidity which in the judgement of the investigator would interfere with the&#x0D;&lt;br&gt;             patient treatment or results of the study or place the subject at undue risk&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another clinical trial or earlier in the same clinical trial&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: Intrarectal artesunate;Drug: Intravenous artesunate;Drug: Intravenous quinine
    </Intervention>
    <Primary_outcome>Pharmacokinetics profile of rectal artesunate
    </Primary_outcome>
    <Secondary_ID>REACH
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5327045
    </Internal_Number>
    <TrialID>NCT02460848
    </TrialID>
    <Last_Refreshed_on>18 January 2016
    </Last_Refreshed_on>
    <Public_title>Effects of Cash Transfers on Severe Acute Malnutrition
    </Public_title>
    <Scientific_title>Effects of Unconditional Cash Transfers on the Management of Severe Acute Malnutrition (SAM) in the Democratic Republic of Congo: a Cluster Randomized Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>UNICEF
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150527
    </Date_registration3>
    <Date_registration>27/05/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02460848
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2015
    </Date_enrollement>
    <Target_size>1600
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Eric Alain Ategbo, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>United Nations Children's Fund (UNICEF)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Living in the catchment area of one of the 20 outpatient therapeutic program site&#x0D;&lt;br&gt;             participating in this cluster randomized trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  6-59 months of age;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight for Height Zscore &lt;-3 SD (WHO Growth Standards 2006) and/or Mid-Upper Arm&#x0D;&lt;br&gt;             Circumference &lt;115mm and/or with bilateral edema;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No major clinical complications;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Positive appetite test;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Accept to participate at the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not living in the catchment area of the outpatient therapeutic program site of the&#x0D;&lt;br&gt;             cluster randomized trial;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight-for-Height Z-score =-3 (WHO Growth Standards 2006) and Mid-Upper Arm&#x0D;&lt;br&gt;             Circumference =115mm without bilateral edema;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major clinical complications;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Failure to appetite test;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refuse to participate at the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Severe Malnutrition
    </Condition>
    <Intervention>Other: Outpatient therapeutic program, counseling and cash transfer;Other: Outpatient therapeutic program and counseling
    </Intervention>
    <Primary_outcome>Recovery rate in the outpatient therapeutic program
    </Primary_outcome>
    <Secondary_outcome>Recovery rate in the outpatient therapeutic program;Length of stay in the outpatient therapeutic program;Default rate in the outpatient therapeutic program;Relapse rate;Transfer rate from outpatient therapeutic program to inpatient therapeutic program;Failure rate in the outpatient therapeutic program;Morbidity rate;Death rate;Weight gain;Mid-Upper Arm Circumference gain;Change in Growth rates;Diet replacement &amp; Intra-household dispatching of the therapeutic food;Change in the Individual Dietary Diversity Score (IDDS);Change in the Household Dietary Diversity Score (HDDS);Satisfaction of parents and acceptability
    </Secondary_outcome>
    <Secondary_ID>ARCCII-Nutrition
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Save the Children
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10242428
    </Internal_Number>
    <TrialID>NCT02453308
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)
    </Public_title>
    <Scientific_title>A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies (TACTs) Com-pared to Artemisinin-based Combination Therapies (ACTs) in Uncomplicated Falciparum Malaria and to Map the Geographical Spread of Artemisinin and Partner Drug Resistance
    </Scientific_title>
    <Acronym>TRACII
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150420
    </Date_registration3>
    <Date_registration>20/04/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02453308
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2015
    </Date_enrollement>
    <Target_size>1110
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Bangladesh;Cambodia;Congo, The Democratic Republic of the;India;Lao People's Democratic Republic;Myanmar;Thailand;Vietnam;Bangladesh;Cambodia;Congo, The Democratic Republic of the;India;Lao People's Democratic Republic;Myanmar;Thailand;Vietnam
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Arjen Dondorp, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Mahidol Oxford Tropical Medicine Research Unit (MORU)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female, aged from 6 months to 65 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with&#x0D;&lt;br&gt;             asexual forms of P. falciparum (or mixed with non-falciparum species)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Asexual P. falciparum parasitaemia: 5,000 to 200,000/uL, de-termined on a thin or&#x0D;&lt;br&gt;             thick blood film (In Cambodia patients with a parasitaemia of 16 to 200,000/uL are&#x0D;&lt;br&gt;             eligible. In DRC patients with a parasitaemia of 10,000 to 250,000/ul are eligi-ble)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fever defined as &gt;/= 37.5°C tympanic temperature or a history of fever within the last&#x0D;&lt;br&gt;             24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent (by parent/guardian in case of children)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness and ability of the patients or parents/guardians to comply with the study&#x0D;&lt;br&gt;             protocol for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of severe/complicated malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Haematocrit &lt; 25% or Hb &lt; 5 g/dL at screening (DRC: Hct&lt;15% and Hb &lt;5 g/dL due to high&#x0D;&lt;br&gt;             prevalence of anemia).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute illness other than malaria requiring treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For females: pregnancy, breast feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who have received artemisinin or a derivative or an artemisinin containing&#x0D;&lt;br&gt;             combination therapy (ACT) within the previous 7 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment with mefloquine in the 2 months prior to presentation will be an exclusion&#x0D;&lt;br&gt;             criteria in the DHA-P+MQ sites&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of allergy or known contraindication to artemisinins, or to the ACT or TACT to&#x0D;&lt;br&gt;             be used at the site e.g. neuropsychiatric disorders will be a contraindication for the&#x0D;&lt;br&gt;             use of mefloquine.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous splenectomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  QTc-interval &gt; 450 milliseconds at moment of presentation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Documented or claimed history of cardiac conduction problems&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Earlier participation within the TRACII trial or another trial in the previous 3&#x0D;&lt;br&gt;             months.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria, Falciparum
    </Condition>
    <Intervention>Drug: ACT;Drug: TACT
    </Intervention>
    <Primary_outcome>PCR corrected efficacy defined as adequate clinical and parasitological response (ACPR)
    </Primary_outcome>
    <Secondary_outcome>Parasite clearance half-life;Parasite reduction rates and ratios at 24 and 48 hours assessed by microscopy;Time for parasite count to fall to 50% of initial parasite density;Time for parasite count to fall to 90% of initial parasite density;Time for parasite count to fall to 99% of initial parasite density;Fever clearance time;Incidence of adverse events and serious adverse events;Incidence of adverse events concerning markers of hepatic toxicity;Incidence of adverse events concerning markersof renal toxicity;Incidence of prolongation of the QTc-interval;Change in hemoglobin/hematocrit;Proportion of patients that reports completing a full course of observed TACT or ACT without withdrawal of consent or exclusion from study;Prevalence of Kelch13 mutations of known functional significance;Prevalence/incidence of other genetic markers of antimalarial drug resistance;Genome wide association with in vivo/in vitro sensitivity parasite phenotype;Correlation between SNPs measured in dry blood spots and whole genome sequencing in leukocyte depleted blood samples;Transcriptomic patterns at t=0 and t=6h comparing sensitive and resistant parasites;Correlation between qPCR based versus microscopy based assessments of parasite clearance dynamics;Proportion of patients with gametocytemia before,after treatment with Primaquine;Levels of RNA transcription coding for male or female specific gametocytes;In vitro sensitivity (expressed in IC50 values among others) of P. falciparum to artemisinins and partner drugs;• Pharmacokinetic profiles and interactions of artemisinin-derivatives and partner drugs (half-life, Cmax, AUC, Tmax) in 20 ACT treated and 20 TACT treated patients of both study arms;Day 7 drug levels of partner drugs in association with treatment efficacy and treatment arm
    </Secondary_outcome>
    <Secondary_ID>BAKMAL1502
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10240777
    </Internal_Number>
    <TrialID>NCT02409680
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
    </Public_title>
    <Scientific_title>Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
    </Scientific_title>
    <Acronym>ASPIRIN
    </Acronym>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150330
    </Date_registration3>
    <Date_registration>30/03/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02409680
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>40 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>March 23, 2016
    </Date_enrollement>
    <Target_size>11976
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States;Congo, The Democratic Republic of the;Guatemala;India;Kenya;Pakistan;Zambia;Congo, The Democratic Republic of the;Guatemala;India;Kenya;Pakistan;United States;Zambia;Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Marion Koso-Thomas, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>NIH-NICHD
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Nulliparous women between 18 - 40 years of age. Minors who are = 14 years of age may&#x0D;&lt;br&gt;             be enrolled if permitted by the country's ethical guidelines.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No more than two previous first trimester pregnancy losses&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No medical contraindications to aspirin;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Single live intrauterine pregnancy (IUP) between 6 0/7 and 13 6/7 weeks GA&#x0D;&lt;br&gt;             corroborated by an early dating ultrasound and with presence of a heartbeat.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women prescribed daily aspirin for more than 7 days;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Multiple gestations;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fetal anomaly by ultrasound (Note most fetal anomalies are not detectable by&#x0D;&lt;br&gt;             ultrasounds done at this early gestation. Subsequent discovery of a fetal anomaly is&#x0D;&lt;br&gt;             not viewed as an exclusion.);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hemoglobin &lt; 7.0 gm/dl at screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other medical conditions that may be considered a contraindication per the&#x0D;&lt;br&gt;             judgment of the site investigator (e.g., Lupus, Type 1 Diabetes, or any other known&#x0D;&lt;br&gt;             significant disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Blood pressure = 140/90 (Systolic blood pressure = 140 and diastolic = 90 at&#x0D;&lt;br&gt;             screening)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Premature Birth
    </Condition>
    <Intervention>Drug: Low dose aspirin;Drug: Placebo
    </Intervention>
    <Primary_outcome>Preterm Birth
    </Primary_outcome>
    <Secondary_outcome>Hypertensive disorders of pregnancy;Small for gestational age (SGA);Perinatal mortality
    </Secondary_outcome>
    <Secondary_ID>CP ASPIRIN
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Thomas Jefferson University;KLE University's Jawaharlal Nehru Medical College
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12599805
    </Internal_Number>
    <TrialID>PACTR201505001076143
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Moringa Oleifera and Nutriton oh HIV patients
    </Public_title>
    <Scientific_title>IMPACT OF MORINGA OLEIFERA SUPPLEMENTATION ON BODY MASS INDEX AND IMMUNE RESPONSE OF  HIV-PATIENTS UNDER  ANTIRETROVIRAL THERAPY   A SINGLE BLIND RANDOMIZED CLINICAL TRIAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Public Health School, Université Libre de Brussels
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150317
    </Date_registration3>
    <Date_registration>17/03/2015
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1076
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>60 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>15/03/2013
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Simple randomisation,Allocation was determined by the holder (social worker) of the sequence who is situated off-site
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Mboma
    </Contact_Firstname>
    <Contact_Lastname>Bibi
    </Contact_Lastname>
    <Contact_Address>15 Mbankana
    </Contact_Address>
    <Contact_Email>bimbo_tshi@yahoo.fr
    </Contact_Email>
    <Contact_Tel>0024385044288
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: the patients included in the study had 18 years old above, treated with ART, at clinical stages 2  and 3 or 4 according to WHO classification but stabilied (without opportunisctic affection upon inclusion in the study). Without renal dysfunction, without adverse symptoms of malabsorption (digestive i.d without diarrhea in the three weeks preceding the beginning of study), and with a stable weight curve tree going months preceding the intervention study.  &#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: were excluded from study pregnant women patients and patient who were in stages 1,2 ,3 and 4 but not stabilized, as welle as those who did attend not consent, or who did not attend the consultation. In addition to those with renal dysfunction.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;HIV/AIDS;HIV/AIDS
    </Condition>
    <Intervention>;Moringa oleifera powder ;counseling nutritonal
    </Intervention>
    <Primary_outcome>were changes in body mass index and biological parameters;Changes in biological parameters
    </Primary_outcome>
    <Secondary_outcome>Changes in BMI according to chacteristiques of patients
    </Secondary_outcome>
    <Secondary_ID>ESP/CE/005/2010
    </Secondary_ID>
    <Source_Support>Fonds David &amp; Alice Van Buuren
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethics committee of the School for Public Health at the University of Kinshasa
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6447865
    </Internal_Number>
    <TrialID>ISRCTN10419317
    </TrialID>
    <Last_Refreshed_on>9 October 2017
    </Last_Refreshed_on>
    <Public_title>The impact of improved sanitation on the diarrhoeal reduction of under-five children in Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Effect of improved sanitation on diarrhoea incidence of under-five children in Idiofa territory, Bandundu province, DR Congo using cluster randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Korea International Cooperation Agency
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150313
    </Date_registration3>
    <Date_registration>13/03/2015
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN10419317
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>15/12/2014
    </Date_enrollement>
    <Target_size>720
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Intervention study using phased-in and factorial design: cluster randomized control trial (Prevention)
    </Study_design>
    <Phase/>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Household with children under five years
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Households rejecting registration&lt;br&gt;2. Households rejecting filling in informed consent form
    </Exclusion_Criteria>
    <Condition>The coverage of improved sanitation is exceedingly low in many rural area of DR Congo although diarrhoea is the main killer of children under five. &lt;br&gt;Digestive System
    </Condition>
    <Intervention>For intervention arms, sanitation compaign will be conducted for increasing latrine coverage using CLTS principle and boreholdes will be drilled in the communities of both arms. Drilling boreholes will be undertaken in the second phase of the project.
    </Intervention>
    <Primary_outcome>Diarrhoeal incidence of under-five children (cases /child*weeks)
    </Primary_outcome>
    <Secondary_outcome>1. Uptake of improved latrine (%)&lt;br&gt;2. Utilization of improved latrine (%)
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>Korea International Cooperation Agency
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10240389
    </Internal_Number>
    <TrialID>NCT02398981
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Implementation of a Web Based Real Time Clinical Decision Support Tool.
    </Public_title>
    <Scientific_title>Design and Pilot Implementation of a Web Based Real Time Clinical Decision Support Tool. (Checklist for Early Recognition and Treatment of Acute Illness in Pediatrics. CERTAINp
    </Scientific_title>
    <Acronym>CERTAINp
    </Acronym>
    <Primary_sponsor>Mayo Clinic
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150213
    </Date_registration3>
    <Date_registration>13/02/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02398981
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>17 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 2015
    </Date_enrollement>
    <Target_size>962
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China;Congo;Croatia;Fiji;India;Peru;China;Congo;Croatia;Fiji;India;Peru
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All pediatric patients (&lt; 18 years) admitted for the first time to the participating&#x0D;&lt;br&gt;             PICUs will be included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not critically ill, admitted for low risk monitoring, planned PICU admission for&#x0D;&lt;br&gt;             routine post operative surveillance for less than 24 hours after uncomplicated&#x0D;&lt;br&gt;             surgery, readmission and transfer from outside PICU.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Critical Illness;Sepsis;Respiratory Failure;Shock;Bleeding
    </Condition>
    <Intervention>Other: Clinical decision support tool
    </Intervention>
    <Primary_outcome>ICU and hospital lengths of stay
    </Primary_outcome>
    <Secondary_outcome>Adherence to best critical care practices as measured by composite measures of best practice guidelines.
    </Secondary_outcome>
    <Secondary_ID>14-004429
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of British Columbia
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10238752
    </Internal_Number>
    <TrialID>NCT02353117
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Preventing Congenital Syphilis
    </Public_title>
    <Scientific_title>Preventing Congenital Syphilis
    </Scientific_title>
    <Acronym>PCS
    </Acronym>
    <Primary_sponsor>Tulane University School of Public Health and Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150121
    </Date_registration3>
    <Date_registration>21/01/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02353117
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>January 11, 2016
    </Date_enrollement>
    <Target_size>60386
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States;Argentina;Congo, The Democratic Republic of the;Zambia;Argentina;Congo, The Democratic Republic of the;United States;Zambia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Pierre Buekens, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Tulane SPHTM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria: Pregnant women who present for prenatal care at a participating&#x0D;&lt;br&gt;        prenatal care clinic for the first time who consent to participate in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria: Pregnant women who do not agree to participate in the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Congenital Syphilis
    </Condition>
    <Intervention>Behavioral: Congenital Syphilis Intervention Group
    </Intervention>
    <Primary_outcome>The frequency of pregnant women attending prenatal care screened for syphilis and treated if infected
    </Primary_outcome>
    <Secondary_outcome>The number of women who receive screening for other components of prenatal care (anemia, HIV, proteinuria).
    </Secondary_outcome>
    <Secondary_ID>OPP1116131
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Instituto de Efectividad Clinica y Sanitaria (IECS);Kinshasa School of Public Health;University of Zambia
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12626013
    </Internal_Number>
    <TrialID>PER-059-14
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>A 52-WEEK, DOUBLE-BLIND, RANDOMISED, MULTI-CENTRE, PHASE III, PARALLEL-GROUP STUDY IN PATIENTS 12 YEARS AND OLDER WITH ASTHMA, EVALUATING THE EFFICACY AND SAFETY OF SYMBICORT (BUDESONIDE/FORMOTEROL) TURBUHALER 160/4.5 &amp;#956;G ‘AS NEEDED’ COMPARED WITH PULMICORT (BUDESONIDE) TURBUHALER 200 &amp;#956;G TWICE DAILY PLUS TERBUTALINE TURBUHALER 0.4 MG ‘AS NEEDED’
    </Public_title>
    <Scientific_title>A 52-WEEK, DOUBLE-BLIND, RANDOMISED, MULTI-CENTRE, PHASE III, PARALLEL-GROUP STUDY IN PATIENTS 12 YEARS AND OLDER WITH ASTHMA, EVALUATING THE EFFICACY AND SAFETY OF SYMBICORT (BUDESONIDE/FORMOTEROL) TURBUHALER 160/4.5 &amp;#956;G ‘AS NEEDED’ COMPARED WITH PULMICORT (BUDESONIDE) TURBUHALER 200 &amp;#956;G TWICE DAILY PLUS TERBUTALINE TURBUHALER 0.4 MG ‘AS NEEDED’                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>ASTRAZENECA - PERU,
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20141224
    </Date_registration3>
    <Date_registration>24/12/2014
    </Date_registration>
    <Source_Register>REPEC
    </Source_Register>
    <web_address>https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=059-14
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12
    </Inclusion_agemin>
    <Inclusion_agemax>100
    </Inclusion_agemax>
    <Inclusion_gender>--
    </Inclusion_gender>
    <Date_enrollement>02/01/2015
    </Date_enrollement>
    <Target_size>250
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>This is a 52-week, double-blind, randomised, multi-centre, parallel-group, phase III study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 &amp;#956;g ‘as needed’ compared with Pulmicort (budesonide) Turbuhaler 200 &amp;#956;g twice daily plus terbutaline Turbuhaler 0.4 mg ‘as needed’.
    </Study_design>
    <Phase>III
    </Phase>
    <Countries>Korea South;Congo;Vietnam;Germany;Bulgaria;Slovakia;Spain;France;Hungary;Italy;Romania;Russian Federation;Sweden;Ukraine;Australia;New Zealand;Czech Republic;South Africa;Argentina;Brazil;Chile;Colombia
    </Countries>
    <Contact_Firstname>Ursula
    </Contact_Firstname>
    <Contact_Lastname>Rodriguez-Frias
    </Contact_Lastname>
    <Contact_Address>Av. El Derby Nº 055 Torre II oficina 503
    </Contact_Address>
    <Contact_Email>ursula.rodriguezfrias@astrazeneca.com
    </Contact_Email>
    <Contact_Tel>6101515
    </Contact_Tel>
    <Contact_Affiliation>ASTRAZENECA PERU S.A. 
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &#x0D;&lt;br&gt;				1.	Provision of informed consent prior to any study specific procedures.  For patients under-age, signed informed consent from both the patient and the patient’s parent/legal guardian is required&#x0D;&lt;br&gt;				2.	Outpatients of either gender aged &amp;#8805;12 years at Visit 1&#x0D;&lt;br&gt;				3.	Diagnosis of asthma according to GINA criteria with a documented history of at least 6 months prior to Visit 1&#x0D;&lt;br&gt;				4.	Patients who are in need of GINA (2012) step 2 treatment:&#x0D;&lt;br&gt;				-	uncontrolled on SABA ‘as needed’ as judged by the investigator for the last 30 days before Visit 2, or&#x0D;&lt;br&gt;				-	controlled on mono-maintenance therapy with low stable dose ICS (&amp;#8804; 400 &amp;#956;g budesonide per day or corresponding dose of other ICS) (see Appendix E for conversion) or LTRA as judged by the investigator for the last 30 days prior to Visit  2&#x0D;&lt;br&gt;				5.	Based on lung function tests (see Section 5.1.2) at Visit 2, patients pre-treated with&#x0D;&lt;br&gt;				-	a SABA only should have pre-bronchodilator FEV1 &amp;#8805; 60 % of predicted normal (PN) and post-bronchodilator FEV1 &amp;#8805; 80 % of PN according to the European Respiratory Society (ERS) guidelines (Quanjer et al 2012)&#x0D;&lt;br&gt;				-	low dose ICS or LTRA medication should have pre-bronchodilator FEV1 &amp;#8805;80 % PN according to the ERS guidelines&#x0D;&lt;br&gt;				6.	Reversible airway obstruction according to a reversibility test (see Section 5.1.2.2) performed at Visit 2 defined as an increase in FEV1 &amp;#8805;12% and &amp;#8805;200 ml relative to baseline, after inhalation of 1 mg Bricanyl Turbuhaler.  The test can be repeated at Visit 3 in case the patients fail at Visit 2.  If patients on low dose ICS or LTRA fail at both occasions, they can still be included if they have a documented historical reversibility test within the last 12 months prior to Visit 3, with an increase in FEV1 &amp;#8805;12% and &amp;#8805;200 ml relative to baseline after administration of a rapid acting &amp;#946;2-agonist.&#x0D;&lt;br&gt;			
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &#x0D;&lt;br&gt;				1.Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)&#x0D;&lt;br&gt;				2.Previous enrolment in the present study&#x0D;&lt;br&gt;				3.Participation in another clinical study with a non-biologic investigational product or new formulation of a marketed non-biologic drug during the last 30 days prior to Visit 1&#x0D;&lt;br&gt;				4.Participation in another clinical trial with any marketed or investigational biologic drug within 4 months or 5 half-lives whichever is longer, prior to Visit 1&#x0D;&lt;br&gt;				5.Any asthma worsening requiring change in asthma treatment other than SABA within 30 days prior to Visit 1&#x0D;&lt;br&gt;				6.Use of oral, rectal or parenteral GCS within 30 days and/or depot parenteral GCS within 12 weeks prior to Visit 1&#x0D;&lt;br&gt;				7.Use of any &amp;#946;-blocking agent including eye-drops&#x0D;&lt;br&gt;				8.Known or suspected hypersensitivity to study drugs or excipient&#x0D;&lt;br&gt;				9.Smoker (current or previous) with a smoking history of &amp;#8805; 10 pack years&#x0D;&lt;br&gt;				10.Medical history of life-threatening asthma including intubation and intensive care unit admission&#x0D;&lt;br&gt;				11.Any significant disease or disorder (e.g., cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient’s ability to participate in the study&#x0D;&lt;br&gt;				12.Any clinically relevant abnormal findings in physical examination and/or vital signs at Visit 2, which, in the opinion of the investigator, may put the patient at risk if participating in the study&#x0D;&lt;br&gt;				13.Pregnancy, breast-feeding or planned pregnancy during the study.  Fertile women not using acceptable contraceptive measures, as judged by the investigator&#x0D;&lt;br&gt;				14.Planned hospitalisation during the study&#x0D;&lt;br&gt;				15.Suspected poor capability, as judged by the investigator, of following instructions of the study.&#x0D;&lt;br&gt;				For randomisation at Visit 3, patients should not fulfil any of the following criteria:&#x0D;&lt;br&gt;				16.Use of &amp;#8805; 6 Bricanyl Turbuhaler ‘as needed’ inhalations per day, for a certain number of days depending on the actual length of run-in:  for &amp;#8805; 2 days out of 14 days; for &amp;#8805; 3 days out of 15-21 days; for &amp;#8805; 4 days out of 22 or more days of run-in&#x0D;&lt;br&gt;				17.Any asthma worsening requiring change in treatment other than SABA from Visit 1 until randomisation.&#x0D;&lt;br&gt;			
    </Exclusion_Criteria>
    <Condition>&#x0D;
				-J45&#x0D;
			;J45 
    </Condition>
    <Intervention>&lt;br&gt;				This study starts with an enrolment visit (Visit 1) where informed consent is obtained and inclusion and exclusion criteria are reviewed.  At Visit 2 patients will enter a 2-4 week run-in period during which all of them will be treated with a short acting &amp;#946;2 agonist (Bricanyl) ‘as needed’.  Eligible patients will be randomised at Visit 3 and enter a 52-week double-blind treatment period.  Two weeks after the completion of study treatment a follow-up telephone contact will be performed.  The total expected duration of the study for a patient will be 56-59 weeks.&lt;br&gt;				Investigational product, dosage and mode of administration&lt;br&gt;				Symbicort Turbuhaler 160/4.5 µg (budesonide 160 &amp;#956;g and formoterol fumarate dihydrate 4.5 &amp;#956;g per inhalation, powder for inhalation in a dry powder inhaler) used ‘as needed’ (to relieve asthma symptoms) in addition to Placebo for budesonide (powder for inhalation in a dry powder inhaler matching the Pulmicort Turbuhaler) administered two times daily.&lt;br&gt;				Comparators, dosage and mode of administration&lt;br&gt;				Terbutaline Turbuhaler 0.4 mg (terbutaline sulphate 0.4 mg per inhalation, powder for inhalation in a dry powder inhaler) used ‘as needed’ (to relieve asthma symptoms) in addition to Pulmicort Turbuhaler 200 µg (budesonide 200 µg per inhalation, powder for inhalation in a dry powder inhaler) administered two times daily.&lt;br&gt;				Non-investigational medicinal product, dosage and mode of administration&lt;br&gt;				Bricanyl Turbuhaler 0.5 mg (terbutaline sulphate 0.5 mg per inhalation, powder for inhalation in a dry powder inhaler) used ‘as needed’ during the run-in period and as a bronchodilator for the lung function measurements.&lt;br&gt;			
    </Intervention>
    <Source_Support>AstraZeneca Peru S.A.
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>28/01/2016;05/02/2015;12/08/2015;15/09/2014;15/12/2014;18/05/2015;22/06/2015;16/02/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>mmateo@prisma.org.pe  ;juan.lema@upch.pe;demetrio.molero@essalud.gob.pe  ;avargas@usmp.edu.pe - avargasguerra@hotmail.com;avargas@usmp.edu.pe - avargasguerra@hotmail.com;avargas@usmp.edu.pe - avargasguerra@hotmail.com;avargas@usmp.edu.pe - avargasguerra@hotmail.com;avargas@usmp.edu.pe - avargasguerra@hotmail.com
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite Institucional de Etica en Investigacion de la Asociacion Benefica Prisma;Hospital Nacional Arzobispo Loayza;Hospital Nacional Guillermo Almenara Irigoyen - EsSalud;Universidad San Martin de  Porres;Universidad San Martin de  Porres;Universidad San Martin de  Porres;Universidad San Martin de  Porres;Universidad San Martin de  Porres
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>616-5500 Anx. 246;88339014 - 3301677;999436950;999098514;999098514;999098514;999098514;999098514
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>mmateo@prisma.org.pe  ;juan.lema@upch.pe;demetrio.molero@essalud.gob.pe  ;avargas@usmp.edu.pe - avargasguerra@hotmail.com;avargas@usmp.edu.pe - avargasguerra@hotmail.com;avargas@usmp.edu.pe - avargasguerra@hotmail.com;avargas@usmp.edu.pe - avargasguerra@hotmail.com;avargas@usmp.edu.pe - avargasguerra@hotmail.com
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10238502
    </Internal_Number>
    <TrialID>NCT02346227
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix
    </Public_title>
    <Scientific_title>Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo
    </Scientific_title>
    <Acronym>KINVAV
    </Acronym>
    <Primary_sponsor>Jean-Pierre Van geertruyden
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20141108
    </Date_registration3>
    <Date_registration>08/11/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02346227
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>25 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>January 2015
    </Date_enrollement>
    <Target_size>327
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Congo
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Yves Jacquemyn, MD PhD;Alex Mutombo Baleka, MD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>University Hospital, Antwerp;University of Kinshasa
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sexually-active women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women with intact uterine cervix&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Voluntary written informed consent to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Virgin women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breast-feeding women, and women in the post-partum period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject is already diagnosed with cervical cancer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical history of any severe diseases like hepatitis, renal or liver dysfunction,&#x0D;&lt;br&gt;             cardiovascular, gastrointestinal, malignant tumor, or psychiatric disorders etc.,&#x0D;&lt;br&gt;             which might influence the assessments or conduct of the trial by the discretion of the&#x0D;&lt;br&gt;             investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intake or application of antivirals or other prohibited concomitant medication within&#x0D;&lt;br&gt;             30 days prior to application of AV2®, or patients who plan to take such drugs during&#x0D;&lt;br&gt;             the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known or suspected allergic or adverse response to the investigational product AV2 or&#x0D;&lt;br&gt;             its components (olive oil or d-limonene)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to follow the study protocol&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Uterine Cervical Dysplasia;Papillomavirus Infections
    </Condition>
    <Intervention>Drug: AV2;Drug: Placebo
    </Intervention>
    <Primary_outcome>Change of lesions
    </Primary_outcome>
    <Secondary_outcome>absence of HPV DNA;correlation between change of lesions and change in HPV DNA;Change in HPV viral particle load
    </Secondary_outcome>
    <Secondary_ID>UA-IHU- 2012-01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Kinshasa;University Hospital, Antwerp
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11631683
    </Internal_Number>
    <TrialID>CTRI/2014/07/004764
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Phase 3 trial with dispersible arterolane maleate and PQP tablets in pediatric malaria patients
    </Public_title>
    <Scientific_title>A Phase 3 open label randomized multicenter trial to assess the efficacy and safety of the dispersible arterolane maleate 37.5 mg and piperaquine phosphate (PQP) 187.5 mg tablets in comparison with Coartem dispersible in pediatric patients with acute uncomplicated Plasmodium falciparum malaria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Sun Pharmaceutical Industries Ltd
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140725
    </Date_registration3>
    <Date_registration>25-07-2014
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=7539
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>08-08-2015
    </Date_enrollement>
    <Target_size>840
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Mozambique;Cote d'Ivoire;Democratic Republic of the Congo;India;Malawi;Mali;Rwanda;Senegal
    </Countries>
    <Contact_Firstname>Dr Rajinder K Jalali
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Medical Affairs and Clinical Research
Sector 18, Sarhaul, Udyog Vihar Industrial Area, Gurgaon 
Haryana â?? 122 015, India 
    </Contact_Address>
    <Contact_Email>SanjayK.Sharma2@sunpharma.com
    </Contact_Email>
    <Contact_Tel>91-124-4016858
    </Contact_Tel>
    <Contact_Affiliation>Sun Pharmaceutical Industries Ltd
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients must fulfil the following inclusion criteria to be eligible for enrolment into the study: &lt;br/ &gt;&lt;br&gt;1.Children of either gender (male or female) aged between 6 months to 12 years, both inclusive. &lt;br/ &gt;&lt;br&gt;2.Minimum body weight of 5 kg. &lt;br/ &gt;&lt;br&gt;3.Able to take drugs under study by the oral route &lt;br/ &gt;&lt;br&gt;4.Absence of severe malnutrition (defined as a child who has symmetrical oedema involving at least the feet and whose weight-for-height is below -3 standard deviation or less than 70% of the median of the NCHS/ WHO normalized reference values or mid-upper arm circumference  &lt; 110 mm) &lt;br/ &gt;&lt;br&gt;5.Minimum Hemoglobin (Hb) level of  &gt; 8 gm/dL. &lt;br/ &gt;&lt;br&gt;6.Presence of acute symptomatic uncomplicated malaria with a diagnosis confirmed by a positive blood smear with asexual forms of P. falciparum parasites only. &lt;br/ &gt;&lt;br&gt;7.Initial parasite densities appropriate for inclusion will be between 1,000 and 100,000 asexual parasites/Î¼L blood (both inclusive). &lt;br/ &gt;&lt;br&gt;8.Presence of fever (axillary temperature â?¥ 37.5 Â°C) or a history of fever in the past 24 hours. &lt;br/ &gt;&lt;br&gt;9.Written informed consent, provided by parent/guardian. If parent/guardian is unable to provide informed consent in writing, a thumbprint to indicate consent in the presence of at least one witness is acceptable. &lt;br/ &gt;&lt;br&gt;10.Willingness and ability to comply with the study protocol for the duration of the study. &lt;br/ &gt;&lt;br&gt;11.Patient resides within a reasonable distance of the investigational site, so that attendance of all study visits and follow-up by medical staff are logistically feasible. &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: If any of the following conditions apply, the patient should not be enrolled in the study. &lt;br/ &gt;&lt;br&gt;1.Known allergy to artesunate, artemether, artemisinin derived products, piperaquine or any other related drug. &lt;br/ &gt;&lt;br&gt;2.Infants with a history of hyperbilirubinemia during the neonatal period. &lt;br/ &gt;&lt;br&gt;3.Use of concomitant medications that may induce haemolysis or haemolytic anaemia from the World Health Organization (WHO) list of essential drugs. &lt;br/ &gt;&lt;br&gt;4.Evidence of any concomitant infection at the time of presentation (including P. vivax, P. ovale and P. malariae). &lt;br/ &gt;&lt;br&gt;5.Any other underlying disease that may compromise the diagnosis and the evaluation of the response to the study medication (including clinical symptoms of immunosuppression, tuberculosis, bacterial infection; cardiac or pulmonary disease). &lt;br/ &gt;&lt;br&gt;6.Patients with severe malaria as per WHO criteria. &lt;br/ &gt;&lt;br&gt;7.Presence of general danger signs of severe malaria among children 5 years old (as per WHO). &lt;br/ &gt;&lt;br&gt;8.Female patients between the age group of 8 to 12 years (both inclusive) who are pregnant at screening. The selection of the candidate for pregnancy screening test would be as per the judgment of the Investigator. &lt;br/ &gt;&lt;br&gt;9.Female patients between the age group of 8 to 12 years who are lactating at the time of screening. &lt;br/ &gt;&lt;br&gt;10.Any antimalarial treatment during 1 month prior to screening, as assessed by medical history. &lt;br/ &gt;&lt;br&gt;11.Participation in any investigational drug study during the 30 days prior to screening. &lt;br/ &gt;&lt;br&gt;12.Electrocardiogram (ECG) abnormalities with clinical significance or relevance that require urgent management. These abnormalities include QTc interval  450 msec at screening and cardiac conduction disorders, with the exception of right bundle branch block. &lt;br/ &gt;&lt;br&gt;13.Gastrointestinal dysfunction that could alter absorption or motility (e.g., diarrhoea defined as  3 episodes of watery stools in the previous 24 hours or patients who have had 3 episodes of vomiting within 24 hours prior to screening). &lt;br/ &gt;&lt;br&gt;14.Patients with known significant renal or hepatic impairment indicated by the following laboratory evaluations at screening: &lt;br/ &gt;&lt;br&gt;Serum creatinine  1.5Ã?upper limit of normal (ULN). &lt;br/ &gt;&lt;br&gt;Aspartate transaminase  2.5 Ã? ULN. &lt;br/ &gt;&lt;br&gt;Alanine transaminase  2.5 Ã? ULN. &lt;br/ &gt;&lt;br&gt;Serum bilirubin  3 mg/dL. &lt;br/ &gt;&lt;br&gt;15.Patients who have had a splenectomy as confirmed by history or clinical examination. &lt;br/ &gt;&lt;br&gt;16.Patients with known history of human immunodeficiency virus (HIV) infection or other immunosuppressive disorders. &lt;br/ &gt;&lt;br&gt;17.Evidence of clinically significant cardiovascular, pulmonary, metabolic, gastrointestinal, neurological, or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied). &lt;br/ &gt;&lt;br&gt;18.Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprolol, imipramine, amitriptyline, clomipramine, etc) &lt;br/ &gt;&lt;br&gt;19.With known disturbances of electrolyte balance at screening:  &lt;br/ &gt;&lt;br&gt;Serum potassium LLN  &lt;br/ &gt;&lt;br&gt;Serum Sodium LLN  &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- acute uncomplicated P.falciparum malaria in pediatric patients

    </Condition>
    <Intervention>Intervention1: FDC of arterolane maleate and piperaquine phosphate dispersible formulation: Arterolane maleate 37.5 mg and piperaquine phosphate 187.5 mg&lt;br&gt;&lt;br&gt;Investigational drug product will be administered orally as a single daily dose for 3 consecutive days. Number (No.) of tablets in a single dose will be provided according to the following age category of the patients.&lt;br&gt;6 months to 2yrs :1 tablet; &lt;br&gt;2 yrs to 6yrs :2 tablets; &lt;br&gt;6 yrs to â?¤12yrs:3 tablets&lt;br&gt;&lt;br&gt;Control Intervention1: Coartem Dispersible tablets: CoartemÂ® dispersible (artemether 20mg and lumefantrine 120mg)&lt;br&gt;A 3-day treatment schedule with a total of 6 oral doses will be given to patients  randomized to CoartemÂ® dispersible (artemether 20mg and lumefantrine 120mg) regimen according to the following bodyweight category of the patients:&lt;br&gt;5 to 15kg  : 1 tablet; &lt;br&gt;15 to 25kg : 2 tablets; &lt;br&gt;25 to 35kg : 3 tablets &lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Day 28 PCR corrected ACPRTimepoint: Day 28 PCR corrected ACPR
    </Primary_outcome>
    <Secondary_outcome>â?¢Median parasite clearance time (time to reach 100% clearance) (PCT). &lt;br/ &gt;&lt;br&gt;â?¢Fever clearance time (FCT). &lt;br/ &gt;&lt;br&gt;â?¢Proportion of patients with PCR-uncorrected ACPR on Day 28 and Day 42. &lt;br/ &gt;&lt;br&gt;â?¢Safety endpoints: Incidence of adverse events or clinically significant changes in laboratory parameters, physical examination, ECG, or vital signs. &lt;br/ &gt;&lt;br&gt;Timepoint: parasitology and body temperature at 6 hour intervals, discharge/ Day 3, on follow-up Days 7 (Â±1), 14(Â±1), 28(Â±1) and 42(Â±1)   &lt;br/ &gt;&lt;br&gt;Laboratory assessment Day 2, Day 28(Â±1) and Day 42(Â±1) &lt;br/ &gt;&lt;br&gt;ECG screening, and Day 2 between 2 and 4 hrs   &lt;br/ &gt;&lt;br&gt;Vital signs Days 1, 2, 3, 7(Â±1), 14(Â±1), 28(Â±1) and 42(Â±1)
    </Secondary_outcome>
    <Secondary_ID>R2012005, version 2, dated April 02, 2013
    </Secondary_ID>
    <Source_Support>Sun Pharmaceutical Industries Ltd. Plot No 20 Sector 18 Udyog Vihar Industrial Area Gurgaon 122015 Haryana
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/06/2014;08/08/2014;14/07/2014;20/09/2013;28/10/2014;30/10/2014;08/05/2015;06/06/2014;16/08/2014;08/09/2015;02/02/2015;24/08/2015;29/08/2013;22/09/2015;15/11/2013;09/12/2013;12/03/2014;12/11/2013;02/04/2014;11/11/2014;23/08/2013;13/12/2013;21/01/2014;24/09/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite D Ethique de la FMPOS, Mali;Comite D Ethique KUTH for Gakurazo Health center Rwanda;Comite National Dethique Et De La Recherche Ivory Coast;Ecole de Sante Publique Comite D Ethique DRC;Ecole de Sante Publique Comite D Ethique DRC for kinshasa site;Ethics Cimmittee for Human Research LHMC and associated Hospitals new delhi;Ethics Committee AIIMS, Bhubaneswar;Ethics Committee Centre Hospitlier Universtaire University Teaching Hospital Kigali Rwanda;Ethics Committee St Theresas Hospital, Hyderabad;Institutional Ethics Comittee;Institutional Ethics Comittee, IGH, Rourkela;Institutional Ethics Committee;Institutional Ethics Committee for Human Research of Medical College, Kolkata;Institutional Ethics Committee ICH;Institutional Ethics Committee of Kalinga Institute of Medical Sciences (KIMS) Bhubaneswar;Institutional Ethics Committee Seth GS medical College &amp; KEM hospital Mumbai;Institutional Ethics Committee, AJMC, Mangalore;Institutional Ethics Committee, Calcutta School of Tropical Medicines, Kolkata;Institutional Ethics Committee, KGH, Visakhapatnam;Institutional Ethisc Committee BJMC Pune;Ministere de lenseignement Superieur Et De La Recherche Scientifique Mali;National Health Sciences Research Committee Malawi;Pentamed Ethics Committee, Medipoint Hospital Pune;Republique Du Senegal Ministere De La Sante Et De La Prevention Direction De la  Sante Dakar senegal
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;;;;;;;;;;;;;;;
    </Ethics_review_contact_email>
    <results_date_completed>27/01/2016
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10233240
    </Internal_Number>
    <TrialID>NCT02184689
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study
    </Public_title>
    <Scientific_title>Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Drugs for Neglected Diseases
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140619
    </Date_registration3>
    <Date_registration>19/06/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02184689
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>14 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 3, 2014
    </Date_enrollement>
    <Target_size>125
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent form signed by one of the parents or the child's legal representative&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Child assent to participate in the study collected in the presence of an impartial&#x0D;&lt;br&gt;             witness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 6 and 15 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  &gt; 20 Kg bodyweight&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Boy or girl&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to ingest at least one complete meal per day (or at least one Plumpy'Nut® sachet)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to swallow 600mg fexinidazole tablets&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky index &gt; 50&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of trypanosomes in blood and/or lymph and/or CSF&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Permanent address and ability to comply with follow-up visit schedule&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Child refusing to be included in the trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Bodyweight &lt; 20 Kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malnutrition, defined as having a BMI below 16 (- 2 Z-score of the norm&#x0D;&lt;br&gt;             according to WHO 2007 Growth reference data)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to take oral medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or breastfeeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically relevant medical condition other than HAT that, in the Investigator's&#x0D;&lt;br&gt;             opinion, may jeopardize subject safety or interfere with participation in the study,&#x0D;&lt;br&gt;             including but not limited to significant liver or cardiovascular disease, active&#x0D;&lt;br&gt;             documented or suspected infection, central nervous system (CNS) trauma or seizure&#x0D;&lt;br&gt;             disorders, coma or altered consciousness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severely deteriorated general condition, such as cardiovascular shock, respiratory&#x0D;&lt;br&gt;             distress, or terminal illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any medical condition (except HAT-specific symptoms) hindering communication with the&#x0D;&lt;br&gt;             Investigator as required for the completion of this study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication to imidazole products (known hypersensitivity to imidazoles)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of HAT treatment in the past 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients previously enrolled in the study or having already received fexinidazole.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Expected follow-up difficulties (migrants, refugees, itinerant vendors, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current alcohol or drug abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant abnormal laboratory findings, including ASAT and/or ALAT &gt; 2&#x0D;&lt;br&gt;             times ULN // Total bilirubin &gt; 1.5 times ULN // Severe leukopenia (&lt; 2000/mm3) //&#x0D;&lt;br&gt;             Potassium (K+) &lt; 3.5 mmol // Any other clinically significant abnormal laboratory&#x0D;&lt;br&gt;             value (see details in Investigator Manual)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy confirmed by a positive urine pregnancy test obtained within 24 hours (h)&#x0D;&lt;br&gt;             prior to start of study treatment (see Section 5.8.3 Contraception; p36) for girls&#x0D;&lt;br&gt;             over 12 years old and over&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ECG abnormalities assessed by a central cardiologist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  QTcF= 450 ms, as measured automatically (if first measurement is abnormal, a second&#x0D;&lt;br&gt;             assessment will be done at least 10-20 min later, with the patient in resting&#x0D;&lt;br&gt;             position).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not tested for malaria and/or not treated adequately for this infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not treated adequately for soil transmitted helminthic diseases&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Human African Trypanosomiasis (HAT)
    </Condition>
    <Intervention>Drug: fexinidazole
    </Intervention>
    <Primary_outcome>Outcome (success or failure) at the test of cure (ToC)
    </Primary_outcome>
    <Secondary_ID>DNDiHATFEX006
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10232846
    </Internal_Number>
    <TrialID>NCT02169557
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study
    </Public_title>
    <Scientific_title>Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Drugs for Neglected Diseases
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140515
    </Date_registration3>
    <Date_registration>15/05/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02169557
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 30, 2014
    </Date_enrollement>
    <Target_size>230
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  15 years old or more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to ingest at least one complete meal per day (or at least one Plumpy'Nut®&#x0D;&lt;br&gt;             sachet)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky index &gt; 50&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of trypanosomes in blood or lymph&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of trypanosomes in CSF&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Permanent address and ability to comply with the follow-up visit schedule&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient agreeing to be hospitalized to receive the treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severely malnutrition, defined as BMI &lt; 16.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to take oral medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or breastfeeding (a urine pregnancy test will be performed in all women of&#x0D;&lt;br&gt;             childbearing age within 24 h prior to treatment).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically relevant medical condition other than HAT that, in the Investigator's&#x0D;&lt;br&gt;             opinion, may jeopardize patient safety or interfere with participation in the study,&#x0D;&lt;br&gt;             including but not limited to significant liver or cardiovascular disease, documented&#x0D;&lt;br&gt;             or suspected active infection (including AIDS), CNS trauma or seizure disorders, coma&#x0D;&lt;br&gt;             or altered consciousness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severely deteriorated general condition, e.g. cardiovascular shock, respiratory&#x0D;&lt;br&gt;             distress syndrome, or terminal illness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any medical condition (except HAT specific symptoms) hindering communication with the&#x0D;&lt;br&gt;             Investigator as required for the completion of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication to imidazole products (known hypersensitivity to imidazoles).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of HAT treatment in the past 2 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients previously enrolled in the study or having already received fexinidazole.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Expected follow-up difficulties (migrants, refugees, itinerant vendors, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current alcohol or drug abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant abnormal laboratory value, such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) &gt; 2 times ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Total bilirubin (TBIL) &gt; 1.5 times ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe leukopenia (&lt; 2000/mm3)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Potassium (K+) &lt; 3.5 mmol/L&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any clinically significant abnormal value (see details in Investigator Manual)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy confirmed by a positive urine pregnancy test obtained within 24 h prior to&#x0D;&lt;br&gt;             start of study treatment (see Section 5.8.3 Contraception; p35) QTcF = 450 ms as&#x0D;&lt;br&gt;             measured automatically (if the first measurement is abnormal, a second assessment will&#x0D;&lt;br&gt;             be done at least 10-20 min later, with the patient in resting position)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not tested for malaria and/or not treated adequately for this infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not treated adequately for soil-transmitted helminthic diseases&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Human African Trypanosomiasis (HAT)
    </Condition>
    <Intervention>Drug: Fexinidazole
    </Intervention>
    <Primary_outcome>Outcome (success or failure) at the test of cure (ToC) visit 12 months after the end of treatment (EOT).
    </Primary_outcome>
    <Secondary_outcome>Success or failure at each visit between the End of treatment and 18 months visit.
    </Secondary_outcome>
    <Secondary_ID>DNDiHATFEX005
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4750047
    </Internal_Number>
    <TrialID>NCT02102321
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Does Treating Hookworm Improve Productivity of Small Subsistence Farmers
    </Public_title>
    <Scientific_title>A Randomized Effectiveness Trial of Hookworm Treatment of Women Smallholder Farmers to Evaluate Improved Productivity of Their Farming and/or Household Labor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Salmon, Margaret, M.D.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140329
    </Date_registration3>
    <Date_registration>29/03/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02102321
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>17 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>March 2014
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Margaret Salmon, MD MPH;Christian Salmon, DrSc;Margaret Salmon, MD MPH;Maurice Masoda, MD
    </Contact_Lastname>
    <Contact_Email>;;margiesalmon@gmail.com;mauricemas@yahoo.fr
    </Contact_Email>
    <Contact_Tel>;;647 704 5938;
    </Contact_Tel>
    <Contact_Affiliation>University Health Network, Toronto;Western New England University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All women of childbearing years (age 16 - 50)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Identify as a small subsistence farmer&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No clinical evidence of acute malaria, who are with hookworm + stool, and are not&#x0D;&lt;br&gt;             pregnant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        If women become pregnant during the period of study and tests + at the 6 or 12 month study&#x0D;&lt;br&gt;        visit then based on last menstrual period, we will wait until she has completed her first&#x0D;&lt;br&gt;        trimester to initiate the 6 or 12 month study visit based on protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women with acute symptoms of malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  1st trimester pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hookworm - stool&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Declines study participation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &lt;16 or &gt; 50&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Muscular or neurologic defect that preclude them from stepping on and off a stairs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment such that they cannot understand study purpose and consenting&#x0D;&lt;br&gt;             procedure&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hookworm Stool Burden;Anemia;Exercise Tolerance
    </Condition>
    <Intervention>Drug: albendazole;Drug: placebo
    </Intervention>
    <Primary_outcome>Exercise Tolerance Harvard STEP Test
    </Primary_outcome>
    <Secondary_outcome>albendazole efficacy;hemoglobin
    </Secondary_outcome>
    <Secondary_ID>HW0001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Akeso Associates;Bill and Melinda Gates Foundation;Eastern Congo Initiative;HEAL Hospital, DRC
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4951390
    </Internal_Number>
    <TrialID>NCT02092766
    </TrialID>
    <Last_Refreshed_on>8 June 2015
    </Last_Refreshed_on>
    <Public_title>Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria
    </Public_title>
    <Scientific_title>Parenteral Artesunate Compared to Quinine as a Cause of Late Post-treatment Anaemia in African Children With Hyperparasitaemic P. Falciparum Malaria
    </Scientific_title>
    <Acronym>DHART
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140313
    </Date_registration3>
    <Date_registration>13/03/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02092766
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>14 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>June 2014
    </Date_enrollement>
    <Target_size>217
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 6 months and = 14 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with&#x0D;&lt;br&gt;             asexual forms of P. falciparum or mixed with non-falciparum species&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Asexual P. falciparum parasitaemia = 100,000/uL and =500,000/uL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Haemoglobin =5.0 g/dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents/guardians agree to hospitalize the child for the length of treatment (3 days)&#x0D;&lt;br&gt;             and bring the patient for planned follow-up visits at day 7, 14, 21, 28, 35, 42&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed consent from the guardian/parents&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight = 5 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malaria or signs of severe malaria as defined by WHO Guidelines 2013&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of hypersensitivity or contraindication to quinine or artesunate&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A clear history of adequate antimalarial treatment in the preceding 24 hours with&#x0D;&lt;br&gt;             drugs expected to be effective&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of intercurrent illness or any condition which in the judgement of the&#x0D;&lt;br&gt;             investigator would place the subject at undue risk or interfere with the patient&#x0D;&lt;br&gt;             treatment or results of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in another clinical trial&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Anaemia
    </Condition>
    <Intervention>Drug: artesunate;Drug: quinine
    </Intervention>
    <Primary_outcome>Late onset anaemia
    </Primary_outcome>
    <Secondary_ID>KIMORU005
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4748657
    </Internal_Number>
    <TrialID>NCT02084225
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Ultrasound Guided Regional Anesthesia for Acute Injury in Low Resource Settings
    </Public_title>
    <Scientific_title>Feasibility, Perceived Utility and Sustainability of Using Ultrasound-guided Regional Anesthesia by Local Providers in a Limited Resource Conflict Setting
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Salmon, Margaret, M.D.
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140309
    </Date_registration3>
    <Date_registration>09/03/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02084225
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>January 2012
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Time Perspective: Prospective
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo;Ethiopia;Congo;Ethiopia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Margaret Salmon, MD MPH
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>HEAL Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  participants were chosen by hospital administration&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  only chosen participants were included&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pain Management;Acute Injuries
    </Condition>
    <Intervention>Procedure: ultrasound guided regional nerve block
    </Intervention>
    <Primary_outcome>Participant perceived utility of ultrasound guided nerve block
    </Primary_outcome>
    <Secondary_outcome>Participant course satisfaction
    </Secondary_outcome>
    <Secondary_ID>NB0001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Sonosite/Fuji Film - (in kind);The ultrasound for the study was given to the sites by Sonosite/Fuji but the company;had no other role in the study.;MedShare - (in kind);The needles and syringes and kit contents were given to the sites by MedShare but the;company had no role in the study.
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6635519
    </Internal_Number>
    <TrialID>NCT02083380
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Phase II Efficacy Study of Artefenomel &amp; Piperaquine in Adults &amp; Children With P. Falciparum Malaria.
    </Public_title>
    <Scientific_title>Randomised Phase IIb Study of Efficacy, Safety, Tolerability &amp; Pharmacokinetics of a Single Dose Regimen of Artefenomel (OZ439) in Loose Combination With Piperaquine in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medicines for Malaria Venture
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140307
    </Date_registration3>
    <Date_registration>07/03/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02083380
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 2014
    </Date_enrollement>
    <Target_size>448
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Colombia;Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Colombia;Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Colombia;Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Colombia;Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Benin;Burkina Faso;Congo, The Democratic Republic of the;Gabon;Mozambique;Uganda;Vietnam;Colombia
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Fiona Macintyre, PhD;Michael Ramharter, MD;Fiona Macintyre, PhD;Michael Ramharter, MD;Fiona Macintyre, PhD;Michael Ramharter, MD;Fiona Macintyre, PhD;Michael Ramharter, MD;Fiona Macintyre, PhD;Michael Ramharter, MD
    </Contact_Lastname>
    <Contact_Email>;;;;;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;;;;;
    </Contact_Tel>
    <Contact_Affiliation>Medicines for Malaria Venture (MMV);CERMEL (Centre de Recherches Médicale de Lambaréné);Medicines for Malaria Venture (MMV);CERMEL (Centre de Recherches Médicale de Lambaréné);Medicines for Malaria Venture (MMV);CERMEL (Centre de Recherches Médicale de Lambaréné);Medicines for Malaria Venture (MMV);CERMEL (Centre de Recherches Médicale de Lambaréné);Medicines for Malaria Venture (MMV);CERMEL (Centre de Recherches Médicale de Lambaréné)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patient age &gt;6 months &lt;70 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Body weight &gt;5 kg &lt;90 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Presence of mono-infection of P. falciparum with:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Fever, as defined by axillary temperature = 37.5°C or oral/rectal/tympanic&#x0D;&lt;br&gt;                  temperature = 38°C, or history of fever in the previous 24 hours (history of&#x0D;&lt;br&gt;                  fever must be documented) and,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual&#x0D;&lt;br&gt;                  parasites /µL of blood.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Written informed consent provided by the adult patient, or parent or legally&#x0D;&lt;br&gt;             acceptable representative (LAR) of the minor patient or by an impartial witness (if&#x0D;&lt;br&gt;             the patient or patient's LAR is illiterate), and by the medically qualified&#x0D;&lt;br&gt;             Investigator. Children will be asked to provide assent where appropriate. The age from&#x0D;&lt;br&gt;             which this will be sought will be defined by local legislation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Presence of severe malaria (according to World Health Organization (WHO) definition -&#x0D;&lt;br&gt;             WHO 2013)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Anti-malarial treatment:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. With piperaquine -based compound, mefloquine, naphthoquine or&#x0D;&lt;br&gt;                  sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their&#x0D;&lt;br&gt;                  inhibition of new infections has fallen below 50%).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. With amodiaquine or chloroquine within the previous 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. With quinine, halofantrine, lumefantrine-based compounds and any other&#x0D;&lt;br&gt;                  anti-malarial treatment or antibiotics with anti-malarial activity (including&#x0D;&lt;br&gt;                  cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin)&#x0D;&lt;br&gt;                  within the past 14 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. With any herbal products or traditional medicines, within the past 7 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Known history or evidence of clinically significant disorders such as, respiratory&#x0D;&lt;br&gt;             (including active tuberculosis), hepatic, renal, gastrointestinal, immunological,&#x0D;&lt;br&gt;             neurological (including auditory), endocrine, infectious, malignancy, psychiatric,&#x0D;&lt;br&gt;             history of convulsions or other abnormality (including head trauma).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Family history of sudden death or of congenital or clinical conditions known to&#x0D;&lt;br&gt;             prolong QTcB or QTcF interval or e.g. patients with a history of symptomatic cardiac&#x0D;&lt;br&gt;             arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left&#x0D;&lt;br&gt;             ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac&#x0D;&lt;br&gt;             failure accompanied by reduced left ventricle ejection fraction.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Any treatment which can induce a lengthening of QT interval, such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide,&#x0D;&lt;br&gt;                  procainamide, quinidine, hydroquinidine, sotalol),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine,&#x0D;&lt;br&gt;                  haloperidol, mesoridazine, pimozide, or thioridazine),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Anti-depressive agents, certain antimicrobial agents, including agents of the&#x0D;&lt;br&gt;                  following classes macrolides (e.g. erythromycin, clarithromycin),&#x0D;&lt;br&gt;                  fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and triazole&#x0D;&lt;br&gt;                  antifungal agents, and also pentamidine and saquinavir,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine),&#x0D;&lt;br&gt;                  cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,&#x0D;&lt;br&gt;                  methadone, vinca alkaloids, arsenic trioxide.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Anti-emetics with known QT prolongation potential such as domperidone&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Mixed Plasmodium infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Severe vomiting, defined as more than three times in the 24 hours prior to enrolment&#x0D;&lt;br&gt;             in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3&#x0D;&lt;br&gt;             or more watery stools per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Severe malnutrition (defined for subjects aged ten years or less as the&#x0D;&lt;br&gt;             weight-for-height being below -3 standard deviation or less than 70% of median of the&#x0D;&lt;br&gt;             National Centre for Health Statistics (NCHS)/WHO normalised reference values, and for&#x0D;&lt;br&gt;             subjects aged greater than ten years, a body mass index (BMI) of less than 16 (WFP&#x0D;&lt;br&gt;             Manual, Chapter 1)).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Known history of hypersensitivity, allergic or adverse reactions to piperaquine or&#x0D;&lt;br&gt;             other aminoquinolones or to OZ439 or OZ277&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or&#x0D;&lt;br&gt;             Hepatitis C antibody (HCV Ab).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. If Total Bilirubin is normal, exclude the patient if liver function tests Aspartate&#x0D;&lt;br&gt;             transaminase (AST)/ Alanine transaminase (ALT) = 2x Upper limit of normal (ULN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. If Total Bilirubin is &gt; 1 and = 1.5xULN, exclude the patient if AST/ALT &gt;1.5xULN.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Total Bilirubin &gt; 1.5XULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Haemoglobin level below 8 g/dL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Serum creatinine levels =2 x ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. Female patients of child bearing potential must be neither pregnant (as demonstrated&#x0D;&lt;br&gt;             by a negative pregnancy test) nor lactating, and must be willing to take measures not&#x0D;&lt;br&gt;             to become pregnant during the study period and safety follow-up period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Have received an investigational drug within the past 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. Previous participation in any malaria vaccine study or received malaria vaccine in any&#x0D;&lt;br&gt;             other circumstance.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patient age &gt;6 months &lt;70 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Body weight &gt;5 kg &lt;90 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Presence of mono-infection of P. falciparum with:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Fever, as defined by axillary temperature = 37.5°C or oral/rectal/tympanic&#x0D;&lt;br&gt;                  temperature = 38°C, or history of fever in the previous 24 hours (history of&#x0D;&lt;br&gt;                  fever must be documented) and,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual&#x0D;&lt;br&gt;                  parasites /µL of blood.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Written informed consent provided by the adult patient, or parent or legally&#x0D;&lt;br&gt;             acceptable representative (LAR) of the minor patient or by an impartial witness (if&#x0D;&lt;br&gt;             the patient or patient's LAR is illiterate), and by the medically qualified&#x0D;&lt;br&gt;             Investigator. Children will be asked to provide assent where appropriate. The age from&#x0D;&lt;br&gt;             which this will be sought will be defined by local legislation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Presence of severe malaria (according to World Health Organization (WHO) definition -&#x0D;&lt;br&gt;             WHO 2013)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Anti-malarial treatment:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. With piperaquine -based compound, mefloquine, naphthoquine or&#x0D;&lt;br&gt;                  sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their&#x0D;&lt;br&gt;                  inhibition of new infections has fallen below 50%).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. With amodiaquine or chloroquine within the previous 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. With quinine, halofantrine, lumefantrine-based compounds and any other&#x0D;&lt;br&gt;                  anti-malarial treatment or antibiotics with anti-malarial activity (including&#x0D;&lt;br&gt;                  cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin)&#x0D;&lt;br&gt;                  within the past 14 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. With any herbal products or traditional medicines, within the past 7 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Known history or evidence of clinically significant disorders such as, respiratory&#x0D;&lt;br&gt;             (including active tuberculosis), hepatic, renal, gastrointestinal, immunological,&#x0D;&lt;br&gt;             neurological (including auditory), endocrine, infectious, malignancy, psychiatric,&#x0D;&lt;br&gt;             history of convulsions or other abnormality (including head trauma).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Family history of sudden death or of congenital or clinical conditions known to&#x0D;&lt;br&gt;             prolong QTcB or QTcF interval or e.g. patients with a history of symptomatic cardiac&#x0D;&lt;br&gt;             arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left&#x0D;&lt;br&gt;             ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac&#x0D;&lt;br&gt;             failure accompanied by reduced left ventricle ejection fraction.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Any treatment which can induce a lengthening of QT interval, such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide,&#x0D;&lt;br&gt;                  procainamide, quinidine, hydroquinidine, sotalol),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine,&#x0D;&lt;br&gt;                  haloperidol, mesoridazine, pimozide, or thioridazine),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Anti-depressive agents, certain antimicrobial agents, including agents of the&#x0D;&lt;br&gt;                  following classes macrolides (e.g. erythromycin, clarithromycin),&#x0D;&lt;br&gt;                  fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and triazole&#x0D;&lt;br&gt;                  antifungal agents, and also pentamidine and saquinavir,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine),&#x0D;&lt;br&gt;                  cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,&#x0D;&lt;br&gt;                  methadone, vinca alkaloids, arsenic trioxide.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Anti-emetics with known QT prolongation potential such as domperidone&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Mixed Plasmodium infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Severe vomiting, defined as more than three times in the 24 hours prior to enrolment&#x0D;&lt;br&gt;             in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3&#x0D;&lt;br&gt;             or more watery stools per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Severe malnutrition (defined for subjects aged ten years or less as the&#x0D;&lt;br&gt;             weight-for-height being below -3 standard deviation or less than 70% of median of the&#x0D;&lt;br&gt;             National Centre for Health Statistics (NCHS)/WHO normalised reference values, and for&#x0D;&lt;br&gt;             subjects aged greater than ten years, a body mass index (BMI) of less than 16 (WFP&#x0D;&lt;br&gt;             Manual, Chapter 1)).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Known history of hypersensitivity, allergic or adverse reactions to piperaquine or&#x0D;&lt;br&gt;             other aminoquinolones or to OZ439 or OZ277&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or&#x0D;&lt;br&gt;             Hepatitis C antibody (HCV Ab).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. If Total Bilirubin is normal, exclude the patient if liver function tests Aspartate&#x0D;&lt;br&gt;             transaminase (AST)/ Alanine transaminase (ALT) = 2x Upper limit of normal (ULN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. If Total Bilirubin is &gt; 1 and = 1.5xULN, exclude the patient if AST/ALT &gt;1.5xULN.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Total Bilirubin &gt; 1.5XULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Haemoglobin level below 8 g/dL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Serum creatinine levels =2 x ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. Female patients of child bearing potential must be neither pregnant (as demonstrated&#x0D;&lt;br&gt;             by a negative pregnancy test) nor lactating, and must be willing to take measures not&#x0D;&lt;br&gt;             to become pregnant during the study period and safety follow-up period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Have received an investigational drug within the past 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. Previous participation in any malaria vaccine study or received malaria vaccine in any&#x0D;&lt;br&gt;             other circumstance.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patient age &gt;6 months &lt;70 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Body weight &gt;5 kg &lt;90 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Presence of mono-infection of P. falciparum with:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Fever, as defined by axillary temperature = 37.5°C or oral/rectal/tympanic&#x0D;&lt;br&gt;                  temperature = 38°C, or history of fever in the previous 24 hours (history of&#x0D;&lt;br&gt;                  fever must be documented) and,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual&#x0D;&lt;br&gt;                  parasites /µL of blood.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Written informed consent provided by the adult patient, or parent or legally&#x0D;&lt;br&gt;             acceptable representative (LAR) of the minor patient or by an impartial witness (if&#x0D;&lt;br&gt;             the patient or patient's LAR is illiterate), and by the medically qualified&#x0D;&lt;br&gt;             Investigator. Children will be asked to provide assent where appropriate. The age from&#x0D;&lt;br&gt;             which this will be sought will be defined by local legislation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Presence of severe malaria (according to World Health Organization (WHO) definition -&#x0D;&lt;br&gt;             WHO 2013)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Anti-malarial treatment:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. With piperaquine -based compound, mefloquine, naphthoquine or&#x0D;&lt;br&gt;                  sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their&#x0D;&lt;br&gt;                  inhibition of new infections has fallen below 50%).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. With amodiaquine or chloroquine within the previous 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. With quinine, halofantrine, lumefantrine-based compounds and any other&#x0D;&lt;br&gt;                  anti-malarial treatment or antibiotics with anti-malarial activity (including&#x0D;&lt;br&gt;                  cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin)&#x0D;&lt;br&gt;                  within the past 14 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. With any herbal products or traditional medicines, within the past 7 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Known history or evidence of clinically significant disorders such as, respiratory&#x0D;&lt;br&gt;             (including active tuberculosis), hepatic, renal, gastrointestinal, immunological,&#x0D;&lt;br&gt;             neurological (including auditory), endocrine, infectious, malignancy, psychiatric,&#x0D;&lt;br&gt;             history of convulsions or other abnormality (including head trauma).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Family history of sudden death or of congenital or clinical conditions known to&#x0D;&lt;br&gt;             prolong QTcB or QTcF interval or e.g. patients with a history of symptomatic cardiac&#x0D;&lt;br&gt;             arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left&#x0D;&lt;br&gt;             ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac&#x0D;&lt;br&gt;             failure accompanied by reduced left ventricle ejection fraction.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Any treatment which can induce a lengthening of QT interval, such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide,&#x0D;&lt;br&gt;                  procainamide, quinidine, hydroquinidine, sotalol),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine,&#x0D;&lt;br&gt;                  haloperidol, mesoridazine, pimozide, or thioridazine),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Anti-depressive agents, certain antimicrobial agents, including agents of the&#x0D;&lt;br&gt;                  following classes macrolides (e.g. erythromycin, clarithromycin),&#x0D;&lt;br&gt;                  fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and triazole&#x0D;&lt;br&gt;                  antifungal agents, and also pentamidine and saquinavir,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine),&#x0D;&lt;br&gt;                  cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,&#x0D;&lt;br&gt;                  methadone, vinca alkaloids, arsenic trioxide.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Anti-emetics with known QT prolongation potential such as domperidone&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Mixed Plasmodium infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Severe vomiting, defined as more than three times in the 24 hours prior to enrolment&#x0D;&lt;br&gt;             in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3&#x0D;&lt;br&gt;             or more watery stools per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Severe malnutrition (defined for subjects aged ten years or less as the&#x0D;&lt;br&gt;             weight-for-height being below -3 standard deviation or less than 70% of median of the&#x0D;&lt;br&gt;             National Centre for Health Statistics (NCHS)/WHO normalised reference values, and for&#x0D;&lt;br&gt;             subjects aged greater than ten years, a body mass index (BMI) of less than 16 (WFP&#x0D;&lt;br&gt;             Manual, Chapter 1)).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Known history of hypersensitivity, allergic or adverse reactions to piperaquine or&#x0D;&lt;br&gt;             other aminoquinolones or to OZ439 or OZ277&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or&#x0D;&lt;br&gt;             Hepatitis C antibody (HCV Ab).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. If Total Bilirubin is normal, exclude the patient if liver function tests Aspartate&#x0D;&lt;br&gt;             transaminase (AST)/ Alanine transaminase (ALT) = 2x Upper limit of normal (ULN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. If Total Bilirubin is &gt; 1 and = 1.5xULN, exclude the patient if AST/ALT &gt;1.5xULN.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Total Bilirubin &gt; 1.5XULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Haemoglobin level below 8 g/dL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Serum creatinine levels =2 x ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. Female patients of child bearing potential must be neither pregnant (as demonstrated&#x0D;&lt;br&gt;             by a negative pregnancy test) nor lactating, and must be willing to take measures not&#x0D;&lt;br&gt;             to become pregnant during the study period and safety follow-up period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Have received an investigational drug within the past 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. Previous participation in any malaria vaccine study or received malaria vaccine in any&#x0D;&lt;br&gt;             other circumstance.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patient age &gt;6 months &lt;70 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Body weight &gt;5 kg &lt;90 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Presence of mono-infection of P. falciparum with:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Fever, as defined by axillary temperature = 37.5°C or oral/rectal/tympanic&#x0D;&lt;br&gt;                  temperature = 38°C, or history of fever in the previous 24 hours (history of&#x0D;&lt;br&gt;                  fever must be documented) and,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual&#x0D;&lt;br&gt;                  parasites /µL of blood.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Written informed consent provided by the adult patient, or parent or legally&#x0D;&lt;br&gt;             acceptable representative (LAR) of the minor patient or by an impartial witness (if&#x0D;&lt;br&gt;             the patient or patient's LAR is illiterate), and by the medically qualified&#x0D;&lt;br&gt;             Investigator. Children will be asked to provide assent where appropriate. The age from&#x0D;&lt;br&gt;             which this will be sought will be defined by local legislation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Presence of severe malaria (according to World Health Organization (WHO) definition -&#x0D;&lt;br&gt;             WHO 2013)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Anti-malarial treatment:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. With piperaquine -based compound, mefloquine, naphthoquine or&#x0D;&lt;br&gt;                  sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their&#x0D;&lt;br&gt;                  inhibition of new infections has fallen below 50%).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. With amodiaquine or chloroquine within the previous 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. With quinine, halofantrine, lumefantrine-based compounds and any other&#x0D;&lt;br&gt;                  anti-malarial treatment or antibiotics with anti-malarial activity (including&#x0D;&lt;br&gt;                  cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin)&#x0D;&lt;br&gt;                  within the past 14 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. With any herbal products or traditional medicines, within the past 7 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Known history or evidence of clinically significant disorders such as, respiratory&#x0D;&lt;br&gt;             (including active tuberculosis), hepatic, renal, gastrointestinal, immunological,&#x0D;&lt;br&gt;             neurological (including auditory), endocrine, infectious, malignancy, psychiatric,&#x0D;&lt;br&gt;             history of convulsions or other abnormality (including head trauma).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Family history of sudden death or of congenital or clinical conditions known to&#x0D;&lt;br&gt;             prolong QTcB or QTcF interval or e.g. patients with a history of symptomatic cardiac&#x0D;&lt;br&gt;             arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left&#x0D;&lt;br&gt;             ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac&#x0D;&lt;br&gt;             failure accompanied by reduced left ventricle ejection fraction.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Any treatment which can induce a lengthening of QT interval, such as:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide,&#x0D;&lt;br&gt;                  procainamide, quinidine, hydroquinidine, sotalol),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine,&#x0D;&lt;br&gt;                  haloperidol, mesoridazine, pimozide, or thioridazine),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Anti-depressive agents, certain antimicrobial agents, including agents of the&#x0D;&lt;br&gt;                  following classes macrolides (e.g. erythromycin, clarithromycin),&#x0D;&lt;br&gt;                  fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and triazole&#x0D;&lt;br&gt;                  antifungal agents, and also pentamidine and saquinavir,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine),&#x0D;&lt;br&gt;                  cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,&#x0D;&lt;br&gt;                  methadone, vinca alkaloids, arsenic trioxide.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Anti-emetics with known QT prolongation potential such as domperidone&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Mixed Plasmodium infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Severe vomiting, defined as more than three times in the 24 hours prior to enrolment&#x0D;&lt;br&gt;             in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3&#x0D;&lt;br&gt;             or more watery stools per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Severe malnutrition (defined for subjects aged ten years or less as the&#x0D;&lt;br&gt;             weight-for-height being below -3 standard deviation or less than 70% of median of the&#x0D;&lt;br&gt;             National Centre for Health Statistics (NCHS)/WHO normalised reference values, and for&#x0D;&lt;br&gt;             subjects aged greater than ten years, a body mass index (BMI) of less than 16 (WFP&#x0D;&lt;br&gt;             Manual, Chapter 1)).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Known history of hypersensitivity, allergic or adverse reactions to piperaquine or&#x0D;&lt;br&gt;             other aminoquinolones or to OZ439 or OZ277&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or&#x0D;&lt;br&gt;             Hepatitis C antibody (HCV Ab).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. If Total Bilirubin is normal, exclude the patient if liver function tests Aspartate&#x0D;&lt;br&gt;             transaminase (AST)/ Alanine transaminase (ALT) = 2x Upper limit of normal (ULN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. If Total Bilirubin is &gt; 1 and = 1.5xULN, exclude the patient if AST/ALT &gt;1.5xULN.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Total Bilirubin &gt; 1.5XULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Haemoglobin level below 8 g/dL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Serum creatinine levels =2 x ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. Female patients of child bearing potential must be neither pregnant (as demonstrated&#x0D;&lt;br&gt;             by a negative pregnancy test) nor lactating, and must be willing to take measures not&#x0D;&lt;br&gt;             to become pregnant during the study period and safety follow-up period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Have received an investigational drug within the past 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. Previous participation in any malaria vaccine study or received malaria vaccine in any&#x0D;&lt;br&gt;             other circumstance.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Uncomplicated Plasmodium Falciparum Malaria;Uncomplicated Plasmodium Falciparum Malaria;Uncomplicated Plasmodium Falciparum Malaria;Uncomplicated Plasmodium Falciparum Malaria
    </Condition>
    <Intervention>Drug: Artefenomel 800mg: piperaquine 640mg;Drug: Artefenomel 800mg: piperaquine 960mg;Drug: Artefenomel 800mg: piperaquine 1440mg;Drug: Artefenomel 800mg: piperaquine 640mg;Drug: Artefenomel 800mg: piperaquine 960mg;Drug: Artefenomel 800mg: piperaquine 1440mg;Drug: Artefenomel 800mg: piperaquine 640mg;Drug: Artefenomel 800mg: piperaquine 960mg;Drug: Artefenomel 800mg: piperaquine 1440mg;Drug: Artefenomel 800mg: piperaquine 640mg;Drug: Artefenomel 800mg: piperaquine 960mg;Drug: Artefenomel 800mg: piperaquine 1440mg
    </Intervention>
    <Primary_outcome>PCR-adjusted ACPR at Day 28 in the PP Population (All Patients);PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt; Than 5 Years);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&lt; = 5 Years);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;2 to &lt;= 5 Years);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;= 0.5 to &lt;= 2 Years);PCR-adjusted ACPR at Day 28 in the PP Population (All Patients);PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt; Than 5 Years);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&lt; = 5 Years);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;2 to &lt;= 5 Years);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;= 0.5 to &lt;= 2 Years);PCR-adjusted ACPR at Day 28 in the PP Population (All Patients);PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt; Than 5 Years);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&lt; = 5 Years);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;2 to &lt;= 5 Years);PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;= 0.5 to &lt;= 2 Years)
    </Primary_outcome>
    <Secondary_outcome>PCR - Adjusted ACPR at Day 42 in the PP Population;PCR-adjusted ACPR at Day 63 in the PP Population;Crude ACPR at Day 28 in the PP Population;Crude ACPR at Day 42 in the PP Population;Crude ACPR at Day 63 in the PP Population;PCR-adjusted ACPR at Day 28 in the ITT Population;PCR-adjusted ACPR at Day 42 in the ITT Population;PCR-adjusted ACPR at Day 63 in the ITT Population;Crude ACPR at Day 28 in the ITT Population;Crude ACPR at Day 42 in the ITT Population;Crude ACPR at Day 63 in the ITT Population;Kaplan-Meier Estimate of Recurrence;Kaplan-Meier Estimate of Recrudescence;Kaplan-Meier Estimate of New Infection Rate;Parasite Clearance Time;Fever Clearance Time;PRR48
    </Secondary_outcome>
    <Secondary_ID>MMV_OZ439_13_003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>30/01/2017
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02083380
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5781845
    </Internal_Number>
    <TrialID>NCT01990625
    </TrialID>
    <Last_Refreshed_on>10 October 2016
    </Last_Refreshed_on>
    <Public_title>A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings
    </Public_title>
    <Scientific_title>Global Network First Look: A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20131115
    </Date_registration3>
    <Date_registration>15/11/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01990625
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>55 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>April 2014
    </Date_enrollement>
    <Target_size>45038
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo;Guatemala;Kenya;Pakistan;Zambia;Congo;Guatemala;Kenya;Pakistan;Zambia;Congo;Guatemala;Kenya;Pakistan;Zambia;Congo;Guatemala;Kenya;Pakistan;Zambia
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women who provide consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident of study cluster&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Enrolled/eligible for the Global Network Maternal and Neonatal Health Registry&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women &gt;16 weeks gestation at enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - Women who are in labor at time of consent&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women who provide consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident of study cluster&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Enrolled/eligible for the Global Network Maternal and Neonatal Health Registry&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women &gt;16 weeks gestation at enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - Women who are in labor at time of consent&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pregnancy;Eclampsia;Placenta Previa;Stillbirth;Fetal Growth Restriction;Pregnancy;Eclampsia;Placenta Previa;Stillbirth;Fetal Growth Restriction
    </Condition>
    <Intervention>Device: Antenatal Ultrasound Scan;Device: Antenatal Ultrasound Scan
    </Intervention>
    <Primary_outcome>Composite outcome;Composite outcome
    </Primary_outcome>
    <Secondary_outcome>Rate of Women with Complicated Deliveries at Health Facilities;Rate of Women with Complicated Deliveries at Health Facilities
    </Secondary_outcome>
    <Secondary_ID>GN First Look Ultrasound;GN First Look Ultrasound
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors;Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Bill and Melinda Gates Foundation;GE Healthcare;Bill and Melinda Gates Foundation;GE Healthcare
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5867127
    </Internal_Number>
    <TrialID>NCT01992900
    </TrialID>
    <Last_Refreshed_on>14 November 2016
    </Last_Refreshed_on>
    <Public_title>A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria
    </Public_title>
    <Scientific_title>A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>sigma-tau i.f.r. S.p.A.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20131111
    </Date_registration3>
    <Date_registration>11/11/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01992900
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>12 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>November 2013
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Gambia;Mozambique;Tanzania;Burkina Faso;Congo, The Democratic Republic of the;Gambia;Mozambique;Tanzania
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Enrique O Bassat, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Manica's health Research Centre, centre de investigacao Saude-Manica (CISM)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male and Female infants aged from 6 months to = 12 months included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to swallow oral suspension.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight &gt;5 kg.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncomplicated malaria, with microscopically confirmed mono-infection by P. falciparum&#x0D;&lt;br&gt;             (parasitaemia =1000/microL and &lt;200000/microL).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of fever anytime during the preceding 48 hours or presence of fever (axillary&#x0D;&lt;br&gt;             temperature =37.5 °C or =38.0 °C rectally).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability of parents or guardians to understand the nature of the trial and providing&#x0D;&lt;br&gt;             signed informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stable residence in the study area during the two months after recruitment and&#x0D;&lt;br&gt;             willingness to comply with the study protocol and the study visit schedule.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antimalarial treatment with amodiaquine, chloroquine, quinine or lumefantrine-based&#x0D;&lt;br&gt;             compounds within the previous 6 weeks, with piperaquine-based compound, or&#x0D;&lt;br&gt;             mefloquine, or sulphadoxine pyrimethamine within the previous 3 months and with&#x0D;&lt;br&gt;             halofantrine within the 30 days prior to screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other antimalarial treatment or antibiotics with antimalarial activity (including&#x0D;&lt;br&gt;             cotrimoxazol) and any herbal products, within the 7 days prior to screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malnutrition (defined as weight for height &lt;70% of the median National Center&#x0D;&lt;br&gt;             for Health Statistics(NCHS)/WHO reference).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe vomiting or dehydration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of jaundice.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known hypersensitivity to the artemisinin-based therapy or piperaquine.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of relevant clinical allergic reaction of any origin.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical and/or laboratory features of severe malaria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known moderate/ severe renal or liver insufficiency.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of clinically relevant haematological, pulmonary, metabolic-endocrine,&#x0D;&lt;br&gt;             neurological, urogenital diseases as judged by the investigator.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Already diagnosed HIV infection, hepatitis B virus (HBV) or hepatitis C virus (HCV)&#x0D;&lt;br&gt;             infection.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous admission for, or evidence of symptomatic cardiac arrhythmias or with&#x0D;&lt;br&gt;             clinically relevant bradycardia at screening (bpm &lt; 90).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of sudden death, or known congenital prolongation of the QT interval,&#x0D;&lt;br&gt;             or any clinical condition known to prolong the QT interval.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ECG abnormality that requires urgent management.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any treatment which can induce a lengthening of QT interval.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Gastrointestinal dysfunction that could alter absorption or motility (i.e.&#x0D;&lt;br&gt;             malabsorption syndromes, intestinal sub-occlusion or previous major gastrointestinal&#x0D;&lt;br&gt;             surgery).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication to blood sampling.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Moderate and severe anaemia (Hb &lt; 7 g/dL).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who have used any drugs or substances known to be strong inhibitors of&#x0D;&lt;br&gt;             Cytochrome P enzymes (formerly known as cytochrome P450 enzymes) within 10 days prior&#x0D;&lt;br&gt;             to screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who have used any drugs or substances known to be strong inducers of CYP&#x0D;&lt;br&gt;             enzymes (formerly known as cytochrome P450 enzymes)within 28 days prior to screening.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children lactated by HIV positive women who are undergoing treatment with&#x0D;&lt;br&gt;             antiretroviral drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participation in any investigational drug study during the 30 days prior to screening&#x0D;&lt;br&gt;             or previously randomised in the present trial.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria,Falciparum
    </Condition>
    <Intervention>Drug: Eurartesim dispersible oral tablet;Drug: eurartesim film coated tablet
    </Intervention>
    <Primary_outcome>Comparison of peak plasma concentration of Dihydroartemisinin in the two studied formulations;Comparison of area under the plasma concentration versus time curve of Dihydroartemisinin in the two studied formulations.;Comparison of peak plasma concentration of Piperaquine in the two studied formulations;Comparison of area under the plasma concentration versus time curve of Piperaquine in the two studied formulations.
    </Primary_outcome>
    <Secondary_outcome>Parasite clearance time;Fever clearance time;Change from baseline of electrocardiographic QT interval at 4-6 hours after the last study drug intake;Blood chemistry: proportion of patients with deterioration of parameters at day 7 respect to screening.;Hematology: proportion of patients with deterioration of parameters at day 7 respect to screening;Adverse Events occurrence to calculate percentage of patients experiencing Adverse Events and Serious Adverse Events
    </Secondary_outcome>
    <Secondary_ID>2013-002255-15;ST3073-ST3074-DM-12-002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10228113
    </Internal_Number>
    <TrialID>NCT02008695
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Youth and Adult Microfinance to Improve Resilience Outcomes in Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Youth and Adult Microfinance to Improve Resilience Outcomes in Democratic Republic of Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20131007
    </Date_registration3>
    <Date_registration>07/10/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02008695
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2012
    </Date_enrollement>
    <Target_size>988
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Nancy E Glass, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Johns Hopkins University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  girls/boys (ages 10-15 years) and women/men head of households (ages 16 years and&#x0D;&lt;br&gt;             older)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Resident in participating 10 village in Walungu Territory in Democratic Republic of&#x0D;&lt;br&gt;             Congo&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  girls/boys under 10 years of age&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Mental Health Disorders
    </Condition>
    <Intervention>Behavioral: adult microfinance;Behavioral: Youth microfinance only;Behavioral: youth and adult micro finance
    </Intervention>
    <Primary_outcome>Change in baseline Mental health distress at 18 months
    </Primary_outcome>
    <Secondary_ID>R01HD071958;NA_00067820
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6633451
    </Internal_Number>
    <TrialID>NCT02008708
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Microfinance Intervention to Improve Health of Trauma Survivors in DRC
    </Public_title>
    <Scientific_title>Microfinance Intervention to Improve Health of Trauma Survivors in DRC
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20131007
    </Date_registration3>
    <Date_registration>07/10/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02008708
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2011
    </Date_enrollement>
    <Target_size>878
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo;Congo;Congo;Congo;Congo
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Nancy Glass, PhD, MPH, RN;Nancy Glass, PhD, MPH, RN;Nancy Glass, PhD, MPH, RN;Nancy Glass, PhD, MPH, RN;Nancy Glass, PhD, MPH, RN
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Johns Hopkins University School of Nursing;Johns Hopkins University School of Nursing;Johns Hopkins University School of Nursing;Johns Hopkins University School of Nursing;Johns Hopkins University School of Nursing
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  household in participating 10 villages with at least one member:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  16 years or older,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  male or female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  interest in animal husbandry microfinance,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  vulnerable, including survivor of sexual violence, widow, single mother&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  children under age 18 in the home.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  do not live in villages included in study&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  household in participating 10 villages with at least one member:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  16 years or older,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  male or female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  interest in animal husbandry microfinance,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  vulnerable, including survivor of sexual violence, widow, single mother&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  children under age 18 in the home.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  do not live in villages included in study&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  household in participating 10 villages with at least one member:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  16 years or older,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  male or female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  interest in animal husbandry microfinance,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  vulnerable, including survivor of sexual violence, widow, single mother&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  children under age 18 in the home.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  do not live in villages included in study&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  household in participating 10 villages with at least one member:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  16 years or older,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  male or female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  interest in animal husbandry microfinance,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  vulnerable, including survivor of sexual violence, widow, single mother&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  children under age 18 in the home.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  do not live in villages included in study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Mental Disorders;Multiple Trauma;Mental Disorders;Multiple Trauma;Mental Disorders;Multiple Trauma;Mental Disorders;Multiple Trauma
    </Condition>
    <Intervention>Behavioral: Livestock Microfinance;Other: Delayed Control Group;Behavioral: Livestock Microfinance;Other: Delayed Control Group;Behavioral: Livestock Microfinance;Other: Delayed Control Group;Behavioral: Livestock Microfinance;Other: Delayed Control Group
    </Intervention>
    <Primary_outcome>Change from baseline Mental health distress at 18 months;Change from baseline Mental health distress at 18 months;Change from baseline Mental health distress at 18 months
    </Primary_outcome>
    <Secondary_ID>R01MD006075;R01MD006075
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute on Minority Health and Health Disparities (NIMHD)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11767229
    </Internal_Number>
    <TrialID>NCT01966731
    </TrialID>
    <Last_Refreshed_on>27 December 2021
    </Last_Refreshed_on>
    <Public_title>Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
    </Public_title>
    <Scientific_title>Realizing Effectiveness Across Continents With Hydroxyurea (REACH): A Phase I/II Pilot Study Of Hydroxyurea For Children With Sickle Cell Anemia
    </Scientific_title>
    <Acronym>REACH
    </Acronym>
    <Primary_sponsor>Children's Hospital Medical Center, Cincinnati
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20131004
    </Date_registration3>
    <Date_registration>04/10/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01966731
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Year
    </Inclusion_agemin>
    <Inclusion_agemax>10 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2014
    </Date_enrollement>
    <Target_size>635
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>Kenya;Uganda;Angola;Congo, The Democratic Republic of the;Kenya;Uganda;Congo;Angola;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Russell Ware, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Children's Hospital Medical Center, Cincinnati
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Pediatric patients with documented sickle cell anemia (typically HbSS supported by&#x0D;&lt;br&gt;             hemoglobin electrophoresis, complete blood count, and peripheral blood smear)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age range of 1.00-9.99 years, inclusive, at the time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Weight at least 10.0 kg at the time of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Parent or guardian willing and able to provide written informed consent, with child's&#x0D;&lt;br&gt;             verbal assent as per local IRB/Ethics Board requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Willingness to comply with all study-related treatments, evaluations, and follow-up&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Known medical condition making participation ill-advised, (e.g., acute or chronic&#x0D;&lt;br&gt;             infectious disease, HIV, or malignancy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Acute or chronic severe malnutrition determined by impaired growth parameters as&#x0D;&lt;br&gt;             defined by WHO (weight for length/height or weight-for-length/height &gt;3 z-scores below&#x0D;&lt;br&gt;             the median WHO growth standards, as defined in Appendix I)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Pre-existing severe hematological toxicity (temporary exclusions)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Anemia: Hb &lt;4.0 gm/dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Anemia: Hb &lt;6.0 gm/dL with ARC &lt;100 x 109/L&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Reticulocytopenia: ARC &lt;80 x 109/L with Hb &lt;7.0 gm/dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Thrombocytopenia: Platelets &lt;80 x 109/L&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Neutropenia: ANC &lt;1.0 x 109/L&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Blood transfusion within 60 days before enrollment (temporary exclusion)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Hydroxyurea use within 6 months before enrollment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Sickle Cell Disease
    </Condition>
    <Intervention>Drug: Hydroxyurea
    </Intervention>
    <Primary_outcome>Percentage of Participants With Dose Limiting Toxic Events
    </Primary_outcome>
    <Secondary_outcome>Efficacy of Hydroxyurea;Medication Adherence and the Ability for Families to Adhere to Monthly Clinic Visits Are Important Feasibility Outcomes
    </Secondary_outcome>
    <Secondary_ID>2013-4221
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Bristol-Myers Squibb
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>09/11/2020
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01966731
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4735827
    </Internal_Number>
    <TrialID>NCT01916954
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy
    </Public_title>
    <Scientific_title>Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Pregnant Women in the Democratic Republic of Congo
    </Scientific_title>
    <Acronym>ALN5P
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130801
    </Date_registration3>
    <Date_registration>01/08/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01916954
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>July 2013
    </Date_enrollement>
    <Target_size>96
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Nicholas P Day, MD PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Oxford
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria for non pregnant women:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age =18 and = 45 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  P. falciparum parasitemia = 100 parasites/µL and less than 200.000 parasites/µL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hematocrit =21%&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Negative HIV test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Negative pregnancy test*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent provided&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to stay for 3 or 5 days at the hospital and to comply with the follow-up&#x0D;&lt;br&gt;             schedule&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria for pregnant women (in addition to the above criteria except*):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Gestational Age = 14 weeks confirmed by ultrasound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Singleton viable fetus&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria for non-pregnant women:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malaria or signs of severe malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical conditions requiring concomitant drug treatment or transfer to a different&#x0D;&lt;br&gt;             hospital&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intake of artemether-lumefantrine within the two previous 2 weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergy to the study drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous participation in this study or current participation in other studies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria for pregnant women (in addition to the above criteria):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of labour&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fetal abnormalities identified by ultrasound&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: 3-day artemether-lumefantrine;Drug: 5-day artemether-lumefantrine
    </Intervention>
    <Primary_outcome>Pharmacokinetics measures
    </Primary_outcome>
    <Secondary_outcome>Tolerability and safety measures
    </Secondary_outcome>
    <Secondary_ID>ALN5P
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Kinshasa
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11166619
    </Internal_Number>
    <TrialID>NCT01883193
    </TrialID>
    <Last_Refreshed_on>21 July 2021
    </Last_Refreshed_on>
    <Public_title>Women First: Preconception Maternal Nutrition
    </Public_title>
    <Scientific_title>Women First: Preconception Maternal Nutrition
    </Scientific_title>
    <Acronym>WF
    </Acronym>
    <Primary_sponsor>University of Colorado, Denver
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130618
    </Date_registration3>
    <Date_registration>18/06/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01883193
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Years
    </Inclusion_agemin>
    <Inclusion_agemax>35 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>August 2013
    </Date_enrollement>
    <Target_size>7374
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Guatemala;India;Pakistan;Congo, The Democratic Republic of the;Guatemala;India;Pakistan
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Nancy Krebs, MD,MS;Michael Hambidge, MD, SciD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>University of Colorado, Denver;University of Colorado, Denver
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  16-35 years of age;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  expectation to have first or further pregnancy without intent to utilize contraception&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hb &gt;8 g/dL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Nulliparous women who do not agree to hospital delivery (equipped for caesarian&#x0D;&lt;br&gt;             section) or/and do not have ready access to such a facility.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Maternal Malnutrition;Growth Failure;Mortality;Morbidity;Stunting
    </Condition>
    <Intervention>Dietary Supplement: Comprehensive Maternal Nutrition Intervention
    </Intervention>
    <Primary_outcome>Neonatal linear growth
    </Primary_outcome>
    <Secondary_outcome>Length-for-age Z-scores;Estimate fetal growth;Mean birth weight;Incidence of low birth weight (LBW) infants;Perinatal Mortality;Incidence of severe neonatal and infant infectious disease;Epigenome (Maternal);Epigenome (Infant);Deep phenotyping of maternal metabolic and nutritional status;Microbiome (maternal);Microbiome (infant);Composition of breast milk;Neurodevelopment assessment;Gestational weight gain (GWG)
    </Secondary_outcome>
    <Secondary_ID>OPP1055867;U10HD076474-01;12-1672
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);Instituto de Nutricion de Centroamerica y Panama (INCAP);Kinshasa School of Public Health;Jawaharlal Nehru Medical College;Aga Khan University;RTI International
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6629235
    </Internal_Number>
    <TrialID>NCT01838005
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Conditional Cash Transfers to Increase Uptake of and Retention of PMTCT Services
    </Public_title>
    <Scientific_title>Conditional Cash Transfers to Increase Uptake of and Retention of PMTCT Services
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of North Carolina, Chapel Hill
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130322
    </Date_registration3>
    <Date_registration>22/03/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01838005
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>April 2013
    </Date_enrollement>
    <Target_size>433
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: Single (Care Provider). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo;Congo;Congo;Congo;Congo
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Marcel Yotebieng, MD;Emile W Okitolonda, MD;Marcel Yotebieng, MD;Emile W Okitolonda, MD;Marcel Yotebieng, MD;Emile W Okitolonda, MD;Marcel Yotebieng, MD;Emile W Okitolonda, MD;Marcel Yotebieng, MD;Emile W Okitolonda, MD
    </Contact_Lastname>
    <Contact_Email>;;;;;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;;;;;
    </Contact_Tel>
    <Contact_Affiliation>Ohio State University;Kinshasa School of Public Health;Ohio State University;Kinshasa School of Public Health;Ohio State University;Kinshasa School of Public Health;Ohio State University;Kinshasa School of Public Health;Ohio State University;Kinshasa School of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Newly diagnosed as HIV-positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant between 28 and 32 weeks of gestation (&gt;27 and &lt;32 completed weeks of&#x0D;&lt;br&gt;             pregnancy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intend to stay in Kinshasa through delivery and six weeks postpartum&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to participate (provide informed consent)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women will be excluded from the study if they are severely ill and require extended&#x0D;&lt;br&gt;             hospitalization or need to be cared for at a referral hospital out of the PMTCT&#x0D;&lt;br&gt;             network&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Newly diagnosed as HIV-positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant between 28 and 32 weeks of gestation (&gt;27 and &lt;32 completed weeks of&#x0D;&lt;br&gt;             pregnancy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intend to stay in Kinshasa through delivery and six weeks postpartum&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to participate (provide informed consent)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women will be excluded from the study if they are severely ill and require extended&#x0D;&lt;br&gt;             hospitalization or need to be cared for at a referral hospital out of the PMTCT&#x0D;&lt;br&gt;             network&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Newly diagnosed as HIV-positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant between 28 and 32 weeks of gestation (&gt;27 and &lt;32 completed weeks of&#x0D;&lt;br&gt;             pregnancy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intend to stay in Kinshasa through delivery and six weeks postpartum&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to participate (provide informed consent)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women will be excluded from the study if they are severely ill and require extended&#x0D;&lt;br&gt;             hospitalization or need to be cared for at a referral hospital out of the PMTCT&#x0D;&lt;br&gt;             network&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Newly diagnosed as HIV-positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant between 28 and 32 weeks of gestation (&gt;27 and &lt;32 completed weeks of&#x0D;&lt;br&gt;             pregnancy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intend to stay in Kinshasa through delivery and six weeks postpartum&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able and willing to participate (provide informed consent)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women will be excluded from the study if they are severely ill and require extended&#x0D;&lt;br&gt;             hospitalization or need to be cared for at a referral hospital out of the PMTCT&#x0D;&lt;br&gt;             network&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV;HIV;HIV;HIV
    </Condition>
    <Intervention>Behavioral: Conditional cash transfer;Behavioral: Conditional cash transfer;Behavioral: Conditional cash transfer;Behavioral: Conditional cash transfer
    </Intervention>
    <Primary_outcome>proportion of women who were adherent to all conditionalities and received the most effective ARV intervention they were eligible to receive and delivered at an affiliated maternity;proportion of women who were adherent to all conditionalities and received the most effective ARV intervention they were eligible to receive and delivered at an affiliated maternity;proportion of women who were adherent to all conditionalities and received the most effective ARV intervention they were eligible to receive and delivered at an affiliated maternity
    </Primary_outcome>
    <Secondary_outcome>Mother to child transmission rate at six weeks and HIV-free survival.;HIV-free survival at 18 month.;Proportion of HIV-exposed infants who at their six week visit received extended Nevirapine (NVP) had a DNA PCR test
    </Secondary_outcome>
    <Secondary_ID>1R01HD075171-01;12-1676
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);Kinshasa School of Public Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4729043
    </Internal_Number>
    <TrialID>NCT01828333
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Malaria Treatment With Injectable ArteSunate
    </Public_title>
    <Scientific_title>Treatment of Severe Malaria - An Operational Comparative Study Between Quinine and Artesunate for the Treatment of Severe Malaria in Hospitals and Health Centers of Kinshasa and Lower Congo
    </Scientific_title>
    <Acronym>MATIAS
    </Acronym>
    <Primary_sponsor>Swiss Tropical &amp; Public Health Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130314
    </Date_registration3>
    <Date_registration>14/03/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01828333
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>2 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>April 2013
    </Date_enrollement>
    <Target_size>350
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Time Perspective: Prospective
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Christian Burri, PhD;Antoinette Tshefu, MD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Swiss Tropical &amp; Public Health Institute;Kinshasa School of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients (= 2 months old) admitted to one of the study sites and treated for severe&#x0D;&lt;br&gt;        malaria with IV quinine in the first part of the study and patients treated with IV/IM&#x0D;&lt;br&gt;        artesunate in the second part of the study will be included. Patients need to fulfill the&#x0D;&lt;br&gt;        WHO criteria for severe malaria and must be unable to take oral treatment (WHO, 2010, WHO,&#x0D;&lt;br&gt;        2011). In addition all participants need to give their informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Conditions: Positive rapid diagnostic test (RDT) for Plasmodium falciparum HRP2 or lactate&#x0D;&lt;br&gt;        dehydrogenase and/or a positive blood slide (thick smear). Patient will be considered to&#x0D;&lt;br&gt;        be positive if one of the two tests is positive. In case of negative result of both tests,&#x0D;&lt;br&gt;        the patient will not be enrolled in the study and will receive care according to the usual&#x0D;&lt;br&gt;        routine practice in the hospital/health center in question.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Definition of severe malaria according to WHO (WHO, 2010): In a patient with P. falciparum&#x0D;&lt;br&gt;        asexual parasitaemia and no other obvious cause for the symptoms, the presence of one or&#x0D;&lt;br&gt;        more of the following clinical or laboratory features classifies the patient as suffering&#x0D;&lt;br&gt;        from severe malaria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Clinical features (hospitals and health centers):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  impaired consciousness or unrousable coma&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  prostration, i.e. generalized weakness so that the patient is unable walk or sit up&#x0D;&lt;br&gt;             without assistance&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  failure to feed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  multiple convulsions - more than two episodes in 24 h&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  deep breathing, respiratory distress (acidotic breathing)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  circulatory collapse or shock, systolic blood pressure &lt; 70 mm Hg in adults and &lt; 50&#x0D;&lt;br&gt;             mm Hg in children&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  clinical jaundice plus evidence of other vital organ dysfunction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Complementary Laboratory findings (hospitals only)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe anaemia (Hb &lt; 5g/dl, packed cell volume &lt; 15%)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hypoglycemia (blood glucose &lt; 2.2 mmol/l or &lt; 40 mg/dl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  metabolic acidosis (plasma bicarbonate &lt; 15 mmol/l)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  serum creatinine &gt; 265 ìmol/l suggesting renal impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients with known serious adverse reactions to quinine and artemisinin derivatives or&#x0D;&lt;br&gt;        patients who have received adequate antimalarial treatment 24 hours before admission will&#x0D;&lt;br&gt;        not be included in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Women with known or suspected pregnancy in all trimesters will not be included in the&#x0D;&lt;br&gt;        study and will be treated with quinine infusions according to the new national DRC&#x0D;&lt;br&gt;        guidelines (Programme Nationale de Lutte contre le Paludisme, 2012). According to current&#x0D;&lt;br&gt;        routine procedures determination of pregnancy will be done by medical anamnesis and/ or by&#x0D;&lt;br&gt;        a positive pregnancy test.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Severe Malaria
    </Condition>
    <Intervention>Other: No intervention
    </Intervention>
    <Primary_outcome>Duration of hospitalization (from registration to discharge)
    </Primary_outcome>
    <Secondary_ID>Swiss TPH P 001-01-12
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medicines for Malaria Venture
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4724795
    </Internal_Number>
    <TrialID>NCT01772940
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting
    </Public_title>
    <Scientific_title>Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Centre Hospitalier Universitaire Saint Pierre
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130114
    </Date_registration3>
    <Date_registration>14/01/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01772940
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>December 2008
    </Date_enrollement>
    <Target_size>425
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Nathan Clumeck, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Centre Hospitalier Universitaire Saint Pierre
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Antiretroviral-therapy naïve HIV-1 infected Adults&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  WHO clinical stage 3 and CD4 &lt;350/mm3 or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  WHO clinical stage 4 or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  CD4 cell count &lt; 200/mm3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Negative pregnancy test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hemoglobin &lt; 8.5 g/dL (female) or 9.0 g/dL (male)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Estimated Glomerular Filtration Rate &lt; 50 ml/ minute (Cockcroft-Gault equation)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hepatic transaminases (AST and ALT)&gt; 3 x upper limit of normal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active tuberculosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Females who are breastfeeding&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV-1 Infection
    </Condition>
    <Intervention>Drug: nevirapine;Drug: ritonavir-boosted Lopinavir;Drug: Tenofovir/emtricitabine;Drug: Zidovudine/lamivudine
    </Intervention>
    <Primary_outcome>Incidence of therapeutic failure
    </Primary_outcome>
    <Secondary_outcome>HIV-1 RNA viral load less than 50 copies/ml;Immunologic response;HIV-1 resistance mutations;Safety and tolerability;Changes in laboratory parameters
    </Secondary_outcome>
    <Secondary_ID>Lubumbashi trial
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University Hospital of Liege;Ministry of Public Health, Democratic Republic of the Congo;Pierre and Marie Curie University;University Paris 7 - Denis Diderot;Gilead Sciences;Abbott
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5837597
    </Internal_Number>
    <TrialID>NCT01766830
    </TrialID>
    <Last_Refreshed_on>7 November 2016
    </Last_Refreshed_on>
    <Public_title>Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
    </Public_title>
    <Scientific_title>Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (=1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University Hospital, Geneva
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130109
    </Date_registration3>
    <Date_registration>09/01/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01766830
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>January 2013
    </Date_enrollement>
    <Target_size>1927
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Cambodia;Congo, The Democratic Republic of the;Nepal;Sudan;Cambodia;Congo, The Democratic Republic of the;Nepal;Sudan
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>François Chappuis, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospitals, Geneva
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  fever for = 1 week&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  = 5 years old (18 years onward in Cambodia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unwilling or unable to give written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unable in the study physician's opinion to comply with the study requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  existing laboratory confirmed diagnosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  need of immediate intensive care due to shock or respiratory distress&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Visceral Leishmaniasis;Human African Trypanosomiasis;Enteric Fever;Melioidosis;Brucellosis;Leptospirosis;Relapsing Fever;Rickettsial Diseases;HIV;Tuberculosis;Malaria;Amoebic Liver Abscess
    </Condition>
    <Intervention>Device: rk28 ICT;Device: IT LEISH (rK39);Device: Immunochromatographic HAT test;Device: HAT Serostrip;Device: Card Agglutination Trypanosoma Test (CATT)-10;Device: Typhidot M;Device: S. typhi IgM/IgG;Device: Test-it Typhoid IgM;Device: Test-it Leptospirosis IgM;Device: Leptospira IgG/IgM
    </Intervention>
    <Primary_outcome>Prevalence of Visceral Leishmaniasis (VL), Human African Trypanosomiasis (HAT) and other Neglected Tropical Diseases (NTDs);Identification of clinical and laboratory diagnostic indicators;Identification of reliable Rapid Diagnostic Tests (RDTs);Predictive values of RDTs
    </Primary_outcome>
    <Secondary_outcome>Cost-effectiveness of the diagnostic tests
    </Secondary_outcome>
    <Secondary_ID>260260;WP2-01-FEV
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institute of Tropical Medicine, Belgium;B.P. Koirala Institute of Health Sciences;Institut National de Recherche Biomédicale, Kinshasa, DRC;University of Khartoum;Sihanouk Hospital Center of HOPE
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12599497
    </Internal_Number>
    <TrialID>PACTR201302000476155
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants &lt; 5 kg
    </Public_title>
    <Scientific_title>An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants &lt;5 kg Body Weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Novartis Pharma AG
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20121217
    </Date_registration3>
    <Date_registration>17/12/2012
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=476
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>0 Day(s)
    </Inclusion_agemin>
    <Inclusion_agemax>1 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>08/10/2012
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single group: all participants receive same intervention throughout study,Non-randomised
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Togo;Burkina Faso;Democratic Republic of the Congo;Benin;Burkina Faso;Nigeria
    </Countries>
    <Contact_Firstname>Study
    </Contact_Firstname>
    <Contact_Lastname>Director
    </Contact_Lastname>
    <Contact_Address>&#x0D;
        
    </Contact_Address>
    <Contact_Email>clinicaltrial.enquiries@novartis.com
    </Contact_Email>
    <Contact_Tel>+ 41 61 324 1111 
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. Neonates or infants&#x0D;&lt;br&gt;2. Body weight less than 5kg&#x0D;&lt;br&gt;3. In cohort 1 infants older than 28 days&#x0D;&lt;br&gt;   In cohort 2 neonates of term age 0 to 28daysincl&#x0D;&lt;br&gt;4. Microscopically confirmed diagnosis of acure uncomplicated Plasmodium falciparum malaria or mixed infections with an asexual Plasmofium falciparum parasitaemis off more than 1000 and les thatn 100 000 parasites per µL
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Presence of severe malaria (according to World Health Organization definition)&#x0D;&lt;br&gt;2. Presence of the following signs of a critical condition: apnea-bradycardia, sustained bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely deteriorated general condition (based on IMCI criteria in sick infants)&#x0D;&lt;br&gt;3. Presence of any clinically significant neurological condition&#x0D;&lt;br&gt;4. Presence of clinically significant abnormality of the hepatic and renal systems&#x0D;&lt;br&gt;5. Patients who sustained a significant blood volume loss (&gt; 3% of calculated blood volume) in the past 30 days&#x0D;&lt;br&gt;6. Patients unable to swallow or whose drinking is impaired&#x0D;&lt;br&gt;7. Family history of congenital prolongation of the QTc interval or sudden death or with any other clinical condition known to be associated with prolongation of the QTc interval such as history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease&#x0D;&lt;br&gt;8. Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)&#x0D;&lt;br&gt;9. Presence of any age-adjusted clinically or hematologically relevant laboratory and blood chemistry abnormalities&#x0D;&lt;br&gt;10. Other protocol-defined inclusion/exclusion criteria may apply.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;artemether-lumefantrine 20 mg/120 mg dispersible tablet;artemether-lumefantrine 20 mg/120 mg dispersible tablet
    </Intervention>
    <Primary_outcome>Polymerase Chain Reaction (PCR) corrected 28 day parasitological cure rate 
    </Primary_outcome>
    <Secondary_outcome>Polymerase Chain Reaction (PCR) corrected parasitological cure rate at day 14 ;Polymerase Chain Reaction (PCR) corrected parasitological cure rate at day 42 ;Parasitological uncorrected cure rate at day 3 ;Parasitological uncorrected cure rate at day 7 ;Parasitological uncorrected cure rate at day 14 ;Parasitological uncorrected cure rate at day 28;Parasitological uncorrected cure rate at day 42 ;Number of patients with parasitaemia at 72 hours after treatment initiation greater than or equal to 25 percent of count at baseline ;Number of patients with parasitaemia at 48 hours after treatment initiation greater than at baseline ;Time to parasite clearance (PCT);Time to fever clearance (FCT) ;Time to gametocyte clearance (GCT) ;Gametocyte carriage over time ;Incidence of adverse events (AEs) ;Biochemical and haematological changes ;Parasite reduction at 24 hours after treatment initiation ;Incidence of serious adverse events (SAEs)
    </Secondary_outcome>
    <Secondary_ID>2011-005858-33; NCT01619878 
    </Secondary_ID>
    <Source_Support>Novartis Pharma AG;Medicines for Malaria Venture (MMV)
    </Source_Support>
    <Secondary_Sponsor>Medicines for Malaria venture (MMV)
    </Secondary_Sponsor>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;06/06/2012;30/07/2012;02/11/2012;07/06/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethics Committee Basle (EKBB);Comité d'Ethique pour la recherche en Santé;Comité d'éthique- Ecole de Santé Publique - Université de Kinshasa;Comité de bioéthique pour la recherche en santé;Cross River state Research Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>&#x0D;
        ;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12599496
    </Internal_Number>
    <TrialID>PACTR201303000475166
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>SMS-RUTF efficacy
    </Public_title>
    <Scientific_title>Efficacy of Soya Maize Based RUTF in Treating Severe Acute Malnutrition in Children Under-Five in South Kivu, Eastern Democratic Republic of Congo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor/>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121214
    </Date_registration3>
    <Date_registration>14/12/2012
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=475
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Month(s)
    </Inclusion_agemin>
    <Inclusion_agemax>59 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>19/12/2012
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,simple randomisation using a randomisation table created by a computer software programme with separate tables for under 24 months and 24 months and over,sealed opaques envoloppe prepared by the supervisor who will not be involved in group allocation
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>Paluku
    </Contact_Firstname>
    <Contact_Lastname>Bahwere
    </Contact_Lastname>
    <Contact_Address> Fond Tasnier,6
    </Contact_Address>
    <Contact_Email>paluku@validinternational.org
    </Contact_Email>
    <Contact_Tel>+32473199253
    </Contact_Tel>
    <Contact_Affiliation>Research coordinator
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: For the intervention and active control arms&#x0D;&lt;br&gt;-Age between 6 months and 59 months&#x0D;&lt;br&gt;-Presence of SAM defined by MUAC&lt;115mm or presence of bilateral pitting oedema of any grade or presence of clinical signs of wasting confirmed by the supervisor. &#x0D;&lt;br&gt;-Residing within 1 hour walking distance from the day-care centre&#x0D;&lt;br&gt;-Caregivers consent to participate&#x0D;&lt;br&gt;For the community control arm&#x0D;&lt;br&gt;-well-nourished children with no history of treatment for acute malnutrition  who are stable resident of the study area &#x0D;&lt;br&gt;-caregivers consent to participate&#x0D;&lt;br&gt;-matching the case for age, gender, village, height and HIV status.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -Presence of disability including congenital or acquired disorders affecting growth&#x0D;&lt;br&gt;-Refusal to participate &#x0D;&lt;br&gt;-Children of visiting families who risk to return to their location before completing the study &#x0D;&lt;br&gt;-Children from villages distant from the therapeutic feeding centres by more than one hour walk&#x0D;&lt;br&gt;-Children with history of any food allergy&#x0D;&lt;br&gt;-Children with previous admission for severe acute malnutrition in the previous 3 months&#x0D;&lt;br&gt;-children with chronic diseases such us sickle cells anemia, mental disability and cardiac or reanal disease. 
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Nutritional, Metabolic, Endocrine &lt;br&gt;Paediatrics &lt;br&gt;severe acute malnutrition;Nutritional, Metabolic, Endocrine;Paediatrics;severe acute malnutrition
    </Condition>
    <Intervention>;SMS-RUTF arm;P-RUTF arm;Community comparison
    </Intervention>
    <Primary_outcome>recovery rate
    </Primary_outcome>
    <Secondary_outcome>weight gain (weight velocity);lenght of stay in therapeutic feeding phase;fat free mass proportion;Height gain;aneamia rate;12 months survival after discharge from nutrition therapeutic feeding programme
    </Secondary_outcome>
    <Source_Support>Irish Aid
    </Source_Support>
    <Secondary_Sponsor>Valid Nutrition
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/12/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethic committtee of the Catholic University of Bukavu
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11630012
    </Internal_Number>
    <TrialID>CTRI/2012/11/003093
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Using Ongoing Newborn Intervention Trials to Obtain Additional Data Critical to Maternal, Fetal and Newborn Health in a Harmonized Way
    </Public_title>
    <Scientific_title>Using Ongoing Newborn Intervention Trials to Obtain Additional Data Critical to Maternal, Fetal and Newborn Health in a Harmonized Way: The Alliance for Maternal and Newborn Health Improvement (AMANHI) - AMANHI Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>CHRD Society for Applied Studies
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121108
    </Date_registration3>
    <Date_registration>08-11-2012
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5349
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-08-2012
    </Date_enrollement>
    <Target_size>10500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Other&lt;br&gt;  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>India;Bangladesh;Democratic Republic of the Congo;Ghana;Kenya;Pakistan;South Africa;Zambia
    </Countries>
    <Contact_Firstname>Sarmila Mazumder
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>45, Kalu Sarai 
    </Contact_Address>
    <Contact_Email>CHRD@sas.org.in
    </Contact_Email>
    <Contact_Tel>01146043751
    </Contact_Tel>
    <Contact_Affiliation>Centre for Health Research and Development, Society for Applied Studies
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Verbal Autopsies will be conducted for all still births and deaths in women of reporductive age group.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Non consent for verbal autopsy
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- All deaths in women in reproductive age group and still births

    </Condition>
    <Intervention/>
    <Primary_outcome>The objective of this study is to determine the burden, timing, and causes of maternal deaths, stillbirths and neonatal deaths.Timepoint: Verbal Autopsies will be conducted within a window period of 1 year post mortality
    </Primary_outcome>
    <Secondary_outcome>-Timepoint: -
    </Secondary_outcome>
    <Secondary_ID>NCT01699945
    </Secondary_ID>
    <Source_Support>World Health Organization, Geneva, Switzerland
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/05/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Society for Applied Studies Ethics Review Committee, New Delhi (PI: Dr. Sarmila Mazumder)
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12599480
    </Internal_Number>
    <TrialID>PACTR201211000449232
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Intermittent Preventive Treatment: efficacy and safety of sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine plus piperaquine in schoolchildren.
    </Public_title>
    <Scientific_title>Intermittent Preventive Treatment: efficacy and safety of sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine plus piperaquine in schoolchildren of the Democratic Republic of Congo. A Randomised Control Trial.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>University of Antwerp
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20121101
    </Date_registration3>
    <Date_registration>01/11/2012
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=449
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>15 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>15/09/2012
    </Date_enrollement>
    <Target_size>1100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomisation (block of three with variable block size) using a randomisation table created by a computer software program,Allocation was determined by the holder of the sequence who is situated off site
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>JP
    </Contact_Firstname>
    <Contact_Lastname>Van geertruyden
    </Contact_Lastname>
    <Contact_Address> Universiteitplein
    </Contact_Address>
    <Contact_Email>jean-pierre.vangertruyden@uantwerpen.uantwerpen.be
    </Contact_Email>
    <Contact_Tel>003232652528
    </Contact_Tel>
    <Contact_Affiliation>International Health Unit, University of Antwerp
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: -	males and females primary school children, &#x0D;&lt;br&gt;anticipated local residence for the study duration, &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;signed or thumb-printed informed consent by the parents or guardians and witnessed by an impartial witness (whenever parents/guardians are illiterate)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;informed ascent for 12-year children or more
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children of the 6th primary school year &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Participation in any other investigational drug study (antimalarial or others) during the previous 30 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Known hypersensitivity or serious adverse events (AE) to study drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Clinical malaria at baseline irrespectively of the severity (World Health Organisation malaria treatment guideline 2010) (Annex III). &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Febrile conditions caused by diseases other than malaria at first visit. &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Clinical symptoms of severe anaemia &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Illness or conditions like hematologic, cardiac, renal, hepatic diseases which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study, including known G6PD deficiency and sickle cell.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Body weight &lt; 14 Kg  &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Children with major chronic infectious diseases.   
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;SP-PQ;Control group
    </Intervention>
    <Primary_outcome>Hemoglobin concentration
    </Primary_outcome>
    <Secondary_outcome>malaria incidence ;Malaria prevalence ;Prevalence of P. falciparum dihydrofolate reductase and dihydropteroate synthase markers;malaria parasitemia;Rate of malnutrition;Educational performance ;School attendance 
    </Secondary_outcome>
    <Secondary_ID>ESP/CE/045/2012;B300201214729;NCT01722539
    </Secondary_ID>
    <Source_Support>Fonds Wetenschappelijk Onderzoek
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>25/10/2012;12/07/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>University Antwerp Ethics Committee;Comité Ethique de l'Ecole de Santé Publique
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10220247
    </Internal_Number>
    <TrialID>NCT01685827
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
    </Public_title>
    <Scientific_title>Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Drugs for Neglected Diseases
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120912
    </Date_registration3>
    <Date_registration>12/09/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01685827
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2012
    </Date_enrollement>
    <Target_size>394
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Central African Republic;Congo, The Democratic Republic of the;Congo;Central African Republic;Congo;Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Victor KANDE, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>HAT National Control Program in DRC
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  15 years old or more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to ingest at least one complete meal per day (or at least one Plumpy'Nut® sachet)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky index&gt;50 (see Appendix 2 - Karnofsky Scale; p81)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parasitologically confirmed late-stage African trypanosomiasis infection with T. b.&#x0D;&lt;br&gt;             gambiense in the blood and/or lymph and/or CSF, attested by mobile team report (with&#x0D;&lt;br&gt;             detail of exams performed and values of WBC measured in CSF) or done at the study&#x0D;&lt;br&gt;             centre. If parasitologically negative in CSF, WBC &gt;20/µl detected in the CSF to&#x0D;&lt;br&gt;             document stage 2 infection.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having a permanent address and able to comply with follow-up visit schedule&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed Informed Consent Form&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severely malnourished patients, defined as having a BMI &lt; 16.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients unable to take oral medication.*&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or lactation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active clinically relevant medical conditions that, in the Investigator's opinion, may&#x0D;&lt;br&gt;             jeopardize subject safety or interfere with participation in the study, including but&#x0D;&lt;br&gt;             not limited to significant liver or cardiovascular disease, active documented or&#x0D;&lt;br&gt;             suspected infection, CNS trauma or seizure disorders, coma or altered consciousness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severely deteriorated general condition, such as cardiovascular shock, respiratory&#x0D;&lt;br&gt;             distress, or terminal illness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any condition which compromises ability to communicate with the Investigator as&#x0D;&lt;br&gt;             required for the completion of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication to imidazole products (known hypersensitivity to imidazoles) and&#x0D;&lt;br&gt;             NECT (known hypersensitivity to eflornithine).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients previously treated for HAT.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients previously enrolled in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Follow-up expectable difficulties (migrants, refugees, traders, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of alcohol abuse or any drug addiction.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant abnormal laboratory value&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unstable ECG abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  QTcF= 450 msec in resting position (confirmed by 2 measurement).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not tested for malaria and/or treated adequately for this infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients not treated adequately for soil transmitted helminthic diseases&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Human African Trypanosomiasis (HAT);Sleeping Sickness
    </Condition>
    <Intervention>Drug: Fexinidazole;Drug: Nifurtimox;Drug: Eflornithine
    </Intervention>
    <Primary_outcome>success or failure at 18 months FU visit
    </Primary_outcome>
    <Secondary_outcome>Safety endpoint;Safety endpoint;Pharmacokinetics endpoint;QT evaluation
    </Secondary_outcome>
    <Secondary_ID>DNDiFEX004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>8759097
    </Internal_Number>
    <TrialID>ACTRN12612000940875
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Efficacy and safety of  artesunate/amodiaquine and  Artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Brazzaville and Owando - Republic of the Congo
    </Public_title>
    <Scientific_title>Efficacy and safety of  artesunate/amodiaquine and  Artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Brazzaville and Owando - Republic of the Congo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Ministry of Health and Population of the Republic of Congo
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20120904
    </Date_registration3>
    <Date_registration>04/09/2012
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12612000940875.aspx
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>10 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>01/05/2012
    </Date_enrollement>
    <Target_size>352
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Safety/efficacy;
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Congo
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: 1. age between 6 months and 10 yeasr;&#x0D;&lt;br&gt;2. mono-infection with P. falciparum detected by microscopy;&#x0D;&lt;br&gt;3. parasitaemia of 1000-200,000/microlitre asexual forms;&#x0D;&lt;br&gt;4. presence of axillary (greater or equal to) 37.5 degrees C or history of fever during the past 24 h;&#x0D;&lt;br&gt;5. ability to swallow oral medication;&#x0D;&lt;br&gt;6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and&#x0D;&lt;br&gt;7. informed consent from a parent or guardian of children.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. presence of general danger signs or signs of severe falciparum malaria according to the definitions of WHO;&#x0D;&lt;br&gt;2. mixed or mono-infection with another Plasmodium species detected by microscopy;&#x0D;&lt;br&gt;3. presence of severe malnutrition (defined as a child whose growth standard is below –3 (z-score), having a symmetrical oedema involving at least the feet or having a mid-upper arm circumference &lt; 110 mm);&#x0D;&lt;br&gt;4. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);&#x0D;&lt;br&gt;5. regular medication, which may interfere with antimalarial pharmacokinetics;&#x0D;&lt;br&gt;6. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s).
    </Exclusion_Criteria>
    <Condition>Malaria; &lt;br&gt;Malaria;Infection - Studies of infection and infectious agents
    </Condition>
    <Intervention>To assess the efficacy and safety of artesunate/amodiaquine  (4 mg/kg of artesunate, 10 mg/kg of amodiaquine, 1/day for 3 days) (oral administration) for the treatment of uncomplicated P. falciparum infections in two sites in the Republic of Congo
    </Intervention>
    <Primary_outcome>Percent of treatment failures (early treatment failure + late clinical failure + late parasitological failure)&lt;br&gt;&lt;br&gt;Enrolled patients will be assessed for parasitological (using microscopy), clinical responses during the 28 days follow-up and treatment outcomes will be classified according to the latest WHO protocol.[At day 28 following initiation of treatment]
    </Primary_outcome>
    <Secondary_outcome>Percent of adverse event will be documented. Parents or guardians of all enrolled patients will be asked routinely about previous symptoms and about symptoms that have emerged since the previous follow-up visit. When clinically indicated, patients will be evaluated and treated appropriately. All adverse events will be recorded on the case report form. &#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Possible medicine related adverse effects include dizziness, itching, vomiting, abdominal pain, flatulence, headache, bodyache, diarrhoea, tinnitus and increased hair loss, macular rash, reduction in neutrophil counts and convulsions. However, it is likely that many of these effects are disease-related rather than medicine-induced.[At day 28 following initiation of treatment.]
    </Secondary_outcome>
    <Secondary_ID>Nil
    </Secondary_ID>
    <Source_Support>World Health Organization
    </Source_Support>
    <Secondary_Sponsor>Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna
    </Secondary_Sponsor>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ministere de la Recherche Scientifique;Ethical Review Committee, World Health Organization
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4713512
    </Internal_Number>
    <TrialID>NCT01624987
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Intervention to Support the Reintegration of Former Combatants and Soldiers
    </Public_title>
    <Scientific_title/>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120619
    </Date_registration3>
    <Date_registration>19/06/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01624987
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>June 2012
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Thomas Elbert, Prof. Dr.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Konstanz
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ex-combatants who live in a transit camp in Goma, Congo.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Appetitive Aggression;Post-traumatic Stress Disorder
    </Condition>
    <Intervention>Behavioral: NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy;Other: Control group
    </Intervention>
    <Primary_outcome>Appetitive Aggression (Appetitive Aggression Scale);Symptoms of post-traumatic stress disorder (Post-traumatic Diagnostic Scale, PDS)
    </Primary_outcome>
    <Secondary_outcome>Symptoms of depression (Patient Health Questionnaire (PHQ-9);Functionality (Work and Social Adjustment Scale);Substance abuse;Re-integration questionnaire
    </Secondary_outcome>
    <Secondary_ID>WB_2012
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>World Bank
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6503562
    </Internal_Number>
    <TrialID>NCT01619878
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants &lt; 5 kg
    </Public_title>
    <Scientific_title>An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants &lt;5 kg Body Weight
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Novartis Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120612
    </Date_registration3>
    <Date_registration>12/06/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01619878
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2012
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Benin;Burkina Faso;Congo;Nigeria;Togo;Benin;Burkina Faso;Congo;Nigeria;Togo;Benin;Burkina Faso;Congo;Nigeria;Togo;Benin;Burkina Faso;Congo;Nigeria;Togo;Benin;Burkina Faso;Congo;Nigeria;Togo;Benin;Burkina Faso;Congo;Nigeria;Togo;Benin;Burkina Faso;Congo;Nigeria;Togo;Benin;Burkina Faso;Congo;Nigeria;Togo
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Novartis Pharmaceuticals;Novartis Pharmaceuticals;Novartis Pharmaceuticals;Novartis Pharmaceuticals
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Novartis Pharmaceuticals;Novartis Pharmaceuticals;Novartis Pharmaceuticals;Novartis Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neonates / infants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight &lt; 5 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In cohort 1, infants aged &gt; 28 days; in cohort 2, neonates of a term age 0 to = 28&#x0D;&lt;br&gt;             days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Microscopically confirmed diagnosis of acute uncomplicated Plasmodium falciparum&#x0D;&lt;br&gt;             malaria or mixed infections with an asexual Plasmodium falciparum parasitaemia of &gt;&#x0D;&lt;br&gt;             1,000 and &lt; 100,000 parasites/µL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of severe malaria (according to World Health Organization definition)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of the following signs of a critical condition: apnea-bradycardia, sustained&#x0D;&lt;br&gt;             bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely&#x0D;&lt;br&gt;             deteriorated general condition (based on IMCI criteria in sick infants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any clinically significant neurological condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of clinically significant abnormality of the hepatic and renal systems&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who sustained a significant blood volume loss (&gt; 3% of calculated blood&#x0D;&lt;br&gt;             volume) in the past 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients unable to swallow or whose drinking is impaired&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of congenital prolongation of the QTc interval or sudden death or with&#x0D;&lt;br&gt;             any other clinical condition known to be associated with prolongation of the QTc&#x0D;&lt;br&gt;             interval such as history of symptomatic cardiac arrhythmias, with clinically relevant&#x0D;&lt;br&gt;             bradycardia or with severe cardiac disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any age-adjusted clinically or hematologically relevant laboratory and&#x0D;&lt;br&gt;             blood chemistry abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other protocol-defined inclusion/exclusion criteria may apply.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neonates / infants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight &lt; 5 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In cohort 1, infants aged &gt; 28 days; in cohort 2, neonates of a term age 0 to = 28&#x0D;&lt;br&gt;             days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Microscopically confirmed diagnosis of acute uncomplicated Plasmodium falciparum&#x0D;&lt;br&gt;             malaria or mixed infections with an asexual Plasmodium falciparum parasitaemia of &gt;&#x0D;&lt;br&gt;             1,000 and &lt; 100,000 parasites/µL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of severe malaria (according to World Health Organization definition)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of the following signs of a critical condition: apnea-bradycardia, sustained&#x0D;&lt;br&gt;             bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely&#x0D;&lt;br&gt;             deteriorated general condition (based on IMCI criteria in sick infants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any clinically significant neurological condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of clinically significant abnormality of the hepatic and renal systems&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who sustained a significant blood volume loss (&gt; 3% of calculated blood&#x0D;&lt;br&gt;             volume) in the past 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients unable to swallow or whose drinking is impaired&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of congenital prolongation of the QTc interval or sudden death or with&#x0D;&lt;br&gt;             any other clinical condition known to be associated with prolongation of the QTc&#x0D;&lt;br&gt;             interval such as history of symptomatic cardiac arrhythmias, with clinically relevant&#x0D;&lt;br&gt;             bradycardia or with severe cardiac disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any age-adjusted clinically or hematologically relevant laboratory and&#x0D;&lt;br&gt;             blood chemistry abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other protocol-defined inclusion/exclusion criteria may apply.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neonates / infants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight &lt; 5 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In cohort 1, infants aged &gt; 28 days; in cohort 2, neonates of a term age 0 to = 28&#x0D;&lt;br&gt;             days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Microscopically confirmed diagnosis of acute uncomplicated Plasmodium falciparum&#x0D;&lt;br&gt;             malaria or mixed infections with an asexual Plasmodium falciparum parasitaemia of &gt;&#x0D;&lt;br&gt;             1,000 and &lt; 100,000 parasites/µL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of severe malaria (according to World Health Organization definition)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of the following signs of a critical condition: apnea-bradycardia, sustained&#x0D;&lt;br&gt;             bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely&#x0D;&lt;br&gt;             deteriorated general condition (based on IMCI criteria in sick infants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any clinically significant neurological condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of clinically significant abnormality of the hepatic and renal systems&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who sustained a significant blood volume loss (&gt; 3% of calculated blood&#x0D;&lt;br&gt;             volume) in the past 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients unable to swallow or whose drinking is impaired&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of congenital prolongation of the QTc interval or sudden death or with&#x0D;&lt;br&gt;             any other clinical condition known to be associated with prolongation of the QTc&#x0D;&lt;br&gt;             interval such as history of symptomatic cardiac arrhythmias, with clinically relevant&#x0D;&lt;br&gt;             bradycardia or with severe cardiac disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any age-adjusted clinically or hematologically relevant laboratory and&#x0D;&lt;br&gt;             blood chemistry abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other protocol-defined inclusion/exclusion criteria may apply.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neonates / infants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight &lt; 5 kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In cohort 1, infants aged &gt; 28 days; in cohort 2, neonates of a term age 0 to = 28&#x0D;&lt;br&gt;             days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Microscopically confirmed diagnosis of acute uncomplicated Plasmodium falciparum&#x0D;&lt;br&gt;             malaria or mixed infections with an asexual Plasmodium falciparum parasitaemia of &gt;&#x0D;&lt;br&gt;             1,000 and &lt; 100,000 parasites/µL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of severe malaria (according to World Health Organization definition)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of the following signs of a critical condition: apnea-bradycardia, sustained&#x0D;&lt;br&gt;             bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely&#x0D;&lt;br&gt;             deteriorated general condition (based on IMCI criteria in sick infants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any clinically significant neurological condition&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of clinically significant abnormality of the hepatic and renal systems&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who sustained a significant blood volume loss (&gt; 3% of calculated blood&#x0D;&lt;br&gt;             volume) in the past 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients unable to swallow or whose drinking is impaired&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of congenital prolongation of the QTc interval or sudden death or with&#x0D;&lt;br&gt;             any other clinical condition known to be associated with prolongation of the QTc&#x0D;&lt;br&gt;             interval such as history of symptomatic cardiac arrhythmias, with clinically relevant&#x0D;&lt;br&gt;             bradycardia or with severe cardiac disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any age-adjusted clinically or hematologically relevant laboratory and&#x0D;&lt;br&gt;             blood chemistry abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other protocol-defined inclusion/exclusion criteria may apply.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Acute Uncomplicated Falciparum Malaria;Acute Uncomplicated Falciparum Malaria;Acute Uncomplicated Falciparum Malaria;Acute Uncomplicated Falciparum Malaria
    </Condition>
    <Intervention>Drug: Artemether-lumefantrine (COA566);Drug: Artemether-lumefantrine (COA566);Drug: Artemether-lumefantrine (COA566);Drug: Artemether-lumefantrine (COA566)
    </Intervention>
    <Primary_outcome>Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate;Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate
    </Primary_outcome>
    <Secondary_outcome>Polymerase Chain Reaction (PCR) Corrected Parasitological Cure Rate at Day 14 and 42;Number of Participants With Parasitological Uncorrected Cure Rate at Day 3, 7, 14, 28 and 42;Percent Change of Parasite Count From Baseline at 24 Hours;Number of Participants With Parasitaemia at 48 Hours After Treatment Initiation Greater Than at Baseline;Number of Participants With Parasitaemia at 72 Hours After Treatment Initiation Greater Than or Equal to 25 Percent of Count at Baseline;Time to Parasite Clearance (PCT);Time to Fever Clearance (FCT);Time to Gametocyte Clearance (GCT)
    </Secondary_outcome>
    <Secondary_ID>2011-005852-33;2011-005858-33;CCOA566B2306
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medicines for Malaria Venture
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>17/06/2015
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01619878
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12626145
    </Internal_Number>
    <TrialID>PER-032-12
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF GDC-0941 OR GDC-0980 WITH FULVESTRANT VERSUS FULVESTRANT IN ADVANCED OR METASTATIC BREAST CANCER IN PATIENTS RESISTANT TO AROMA TASE INHIBITOR THERAPY
    </Public_title>
    <Scientific_title>A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF GDC-0941 OR GDC-0980 WITH FULVESTRANT VERSUS FULVESTRANT IN ADVANCED OR METASTATIC BREAST CANCER IN PATIENTS RESISTANT TO AROMA TASE INHIBITOR THERAPY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>GENENTECH, INC.,
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120516
    </Date_registration3>
    <Date_registration>16/05/2012
    </Date_registration>
    <Source_Register>REPEC
    </Source_Register>
    <web_address>https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=032-12
    </web_address>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>100
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement/>
    <Target_size>52
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>&lt;br&gt;				THIS IS A MULTICENTER, INTERNATIONAL, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE II TRIAL WITH THREE STUDY ARMS. PATIENTS WITH ADVANCED OR MBC WHO HAVE EXPERIENCED RECURRENCE OR PROGRESSION OF THEIR DISEASE WHILE RECEIVING AI THERAPY OR WHO HAVE RELAPSED WITHIN 6 MONTHS (I.E., 26 WEEKS) AFTER COMPLETING ADJUVANT AI THERAPY WILL BE ENROLLED IN THIS STUDY.&lt;br&gt;			
    </Study_design>
    <Phase>II
    </Phase>
    <Countries>Angola;Camboia;Korea South;Israel;Malasya;Congo;Congo Democratic Republic;Germany;Ivory Coast;Croatia;Denmark;Djibouti;New Zealand;Czech Republic;Burkina Faso;Barbados;Costa Rica;Cuba;Dominica;United States;Arabia Saudi;Armenia;Azerbaijan;Bahrain;Bhutan;Brunei
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &#x0D;&lt;br&gt;				• 101 	SIGNED INFORMED CONSENT FORM&#x0D;&lt;br&gt;				102 	AGE &amp;#8805; 18 YEARS&#x0D;&lt;br&gt;				103 	EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS OF 0 OR 1&#x0D;&lt;br&gt;				104 	POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED BREAST CANCER OR MBC WHOSE DISEASE RELAPSED DURING TREATMENT WITH (OR WITHIN 6 MONTHS AFTER DISCONTINUATION OF) AN AL IN THE ADJUVANT SETTING OR PROGRESSED DURING TREATMENT WITH AN AL IN THE METASTATIC SETTING. THE AL MUST BE MOST RECENT TREATMENT PRIOR TO ENROLLMENT AND PATIENTS MUST HAVE RECEIVED AT LEAST 4 WEEKS OF TREATMENT WITH AN AL PRIOR TO RECURRENCE OR DISEASE PROGRESSION. POSTMENOPAUSAL IS DEFINED AS:&#x0D;&lt;br&gt;				. 	AGE &amp;#8805; 60 YEARS&#x0D;&lt;br&gt;				. 	AGE &lt; 60 YEARS AND FOLLICLE STIMULATING HORMONE (FSH) AND PLASMA ESTRADIOL LEVELS WITHIN POSTMENOPAUSAL RANGE. (NOTE: PATIENTS WITHOUT DOCUMENTATION OF FSH AND ESTRADIOL LEVELS IN THE POSTMENOPAUSAL RANGE WILL BE REQUIRED TO HAVE THESE LABORATORY TESTS PERFORMED AT SCREENING)&#x0D;&lt;br&gt;				. 	PRIOR BILATERAL OOPHORECTOMY (~28 DAYS PRIOR TO FIRST FULVESTRANT TREATMENT ON DAY 1 OF CYCLE 1)&#x0D;&lt;br&gt;				105 	ER-POSITIVE DISEASE (DEFINED AS EXPRESSION OF ER IN &amp;#8805; 1 % CELLS) AND HER2-NEGATIVE DISEASE (ACCEPTABLE METHODS OF HER2 ANALYSIS INCLUDE IHC, FLUORESCENCE IN SITU HYBRIDIZATION [FISH], AND/OR CHROMOGENIC IN SITU HYBRIDIZATION [CISH])&#x0D;&lt;br&gt;			
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &#x0D;&lt;br&gt;				• TREATMENT-RELATED&#x0D;&lt;br&gt;				201 	PRIOR TREATMENT WITH FULVESTRANT, PI3K INHIBITOR, OR MTOR INHIBITOR FOR ADVANCED BREAST CANCER OR MBC (INCLUDING BUT NOT LIMITED TO GOC-0941, GOC-0980, BEZ235, BKM120, LY294002, PIK-75, TGX-221, XL147, XL765, SF1126, PX-866, D-87503, D-106669, GSK615, CAL101, EVEROLIMUS, TEMSIROLIMUS, RIDAFOROLIMUS, ETC.)&#x0D;&lt;br&gt;				202 	PRIOR ANTI-CANCER THERAPY OR RADIOTHERAPY WITHIN 2 WEEKS PRIOR TO DAY 1 OF CYCLE 1. ALL ACUTE TREATMENT-RELATED TOXICITY MUST HAVE RESOLVED TO GRADE &amp;#8805; 1 OR BE DEEMED STABLE BY THE INVESTIGATOR.&#x0D;&lt;br&gt;				203 	PRIOR TREATMENT WITH &gt; 1 CYTOTOXIC CHEMOTHERAPY REGIMENS OR &gt; 2 ENDOCRINE THERAPIES FOR MBC&#x0D;&lt;br&gt;				CLINICAL&#x0D;&lt;br&gt;				204 	PATIENTS REQUIRING ANTI-HYPERGLYCEMIC THERAPY&#x0D;&lt;br&gt;				205 	HISTORY OF CLINICALLY SIGNIFICANT CARDIAC OR PULMONARY DYSFUNCTION, INCLUDING THE FOLLOWING:&#x0D;&lt;br&gt;				. 	CURRENT UNCONTROLLED GRADE &amp;#8805; 2 HYPERTENSION OR UNSTABLE ANGINA&#x0D;&lt;br&gt;				. 	HISTORY OF SYMPTOMATIC CONGESTIVE HEART FAILURE OF ANY NEW YORK HEART ASSOCIATION CLASS (SEE APPENDIX 1) OR SERIOUS CARDIAC ARRHYTHMIA REQUIRING TREATMENT, WITH THE EXCEPTIONS OF ATRIAL FIBRILLATION AND PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA&#x0D;&lt;br&gt;			
    </Exclusion_Criteria>
    <Condition/>
    <Intervention>&lt;br&gt;				THE STUDY IS DESIGNED TO ESTIMATE THE EFFECT OF THE ADDITION OF GDC-0941 TO FULVESTRANT (ARM A) AND OF GDC-0980 TO FULVESTRANT (ARM B) ON PFS COMPARED WITH FULVESTRANT+PLACEBO (ARM C). THESE TWO COMPARISONS (ARM A VS. ARM C AND ARM B VS. ARM C) WILL BE PERFORMED IN ALL TREATED PATIENTS (INDEPENDENT OF RESULTS FROM THE DIAGNOSTIC ASSESSMENTS OF THE TUMOR) AND IN SPECIFIC SUBSETS OF DIAGNOSTIC-POSITIVE PATIENTS (SEE SECTION 4.10).&lt;br&gt;				EACH CYCLE WILL BE 28 DAYS IN DURATION. PROSPECTIVE ANALYSIS OF PIK3CA MUTATION STATUS AND PTEN EXPRESSION IN ARCHIVAL TUMOR SAMPLES WILL BE REQUIRED PRIOR TO RANDOMIZATION. TO MINIMIZE THE POSSIBILITY OF DELAYING TREATMENT TO COMPLETE THE MOLECULAR ANALYSIS OF ARCHIVAL TUMOR SAMPLES REQUIRED FOR PATIENT STRATIFICATION, A SINGLE DOSE OF INTRAMUSCULAR (1M) FULVESTRANT (500 MG) WILL BE GIVEN TO PATIENTS WHO QUALIFY FOR ENROLLMENT ON CYCLE 1 DAY 1 (WHICH WILL INITIATE THE FULVESTRANT "RUN-IN" PERIOD), PRIOR TO RANDOMIZATION.&lt;br&gt;				PATIENTS WILL BE RANDOMIZED DURING THE FULVESTRANT RUN-IN PERIOD (CYCLE 1 DAY 1 TO CYCLE 1 DAY 14) TO THE EXPERIMENTAL TREATMENT ARMS (DESCRIBED BELOW AND IN FIGURE 1) IN A 1: 1: 1 RATIO&lt;br&gt;			
    </Intervention>
    <Ethics_review_status>Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>24/11/2011;13/12/2011;23/02/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>mmateo@prisma.org.pe  ;mmateo@prisma.org.pe  ;investigacion@inen.sld.pe 
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite Institucional de Etica en Investigacion de la Asociacion Benefica Prisma;Comite Institucional de Etica en Investigacion de la Asociacion Benefica Prisma;Instituto Nacional de Enfermedades Neoplasicas
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>616-5500 Anx. 246;616-5500 Anx. 246;7106099-3001
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>mmateo@prisma.org.pe  ;mmateo@prisma.org.pe  ;investigacion@inen.sld.pe 
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5331776
    </Internal_Number>
    <TrialID>NCT01589289
    </TrialID>
    <Last_Refreshed_on>25 January 2016
    </Last_Refreshed_on>
    <Public_title>Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
    </Public_title>
    <Scientific_title>Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo
    </Scientific_title>
    <Acronym>Nidiag-Neuro
    </Acronym>
    <Primary_sponsor>Institute of Tropical Medicine, Belgium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120426
    </Date_registration3>
    <Date_registration>26/04/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01589289
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>September 2012
    </Date_enrollement>
    <Target_size>352
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Emmanuel Bottieau, MD;Marleen Boelaert, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>ITM;ITM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients &gt; 5 years-old AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Altered state of consciousness (confusion to coma) OR/AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Changes of sleep pattern (daytime slumber, night insomnia)OR/AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive decline OR/AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Changes in personality/behaviour (e.g. bouts of mania)OR/AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epileptic seizure(s)OR/AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Daily severe/progressive headache OR/AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Meningismus (headache, neck stiffness, nausea/vomiting, photophobia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cranial nerve lesions OR/AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sensory-motor deficits or other focal neurological signs (e.g. dysphagia, dysarthria,&#x0D;&lt;br&gt;             ataxia, dystonia,...)OR/AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Gait disorders (e.g. spastic or ataxic gait)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Those unwilling or unable to give written informed consent (either directly or via&#x0D;&lt;br&gt;             proxy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Those unable in the physician's opinion to comply with the study requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological symptom unequivocally related with recent trauma&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological symptom as sequelae of previous well-established neurological events&#x0D;&lt;br&gt;             (e.g. stroke,…)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  First seizure below 6 years of age (early onset seizure)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Neurological Disorders;Cerebral Malaria;Bacterial Meningitis;Central Nervous System Tuberculosis;Neurosyphilis;Cryptococcal Meningitis
    </Condition>
    <Intervention>Device: Immunochromatographic HAT tests (DSD);Device: Card Agglutination Trypanosoma Test;Device: TB POC Nucleic Acid Amplification Test (Molbio Diagnostics);Device: TB 3-marker RDT (Tulip diagnostics);Device: Cryptococcal Antigen Lateral Flow Assay (Immy)
    </Intervention>
    <Primary_outcome>Prevalence of HAT and other NTDs/IDs;Identification of reliable diagnostic tests;Predictive values of RDTs;Identification of clinical and laboratory diagnostic indicators
    </Primary_outcome>
    <Secondary_outcome>Cure rate;Cost-effectiveness of the diagnostic tests
    </Secondary_outcome>
    <Secondary_ID>WP2-01-NEU
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;University Hospital, Geneva
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10217401
    </Internal_Number>
    <TrialID>NCT01542398
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Family-based, Resilience-focused Intervention for War-affected Communities in North-eastern Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Title: Is a Family-based, Life Skills Focused Intervention Effective in Reducing Psychological Distress and Stigma and Improving Inter-personal Relations and Functioning Among Former LRA Abductees and Other War-affected Children in Their Community in Dungu, the Democratic Republic of Congo?
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Queen's University, Belfast
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120221
    </Date_registration3>
    <Date_registration>21/02/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01542398
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>99 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 2012
    </Date_enrollement>
    <Target_size>159
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ciarán Shannon, BA, MA, DClin
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>British Psychological Society (Chartered Clinical Psychologist)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  War-affected&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  eastern Democratic Republic of Congo&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Formerly abducted child or vulnerable child&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe/violent behavioural problems&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe learning difficulties&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Psychological Distress
    </Condition>
    <Intervention>Behavioral: Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention
    </Intervention>
    <Primary_outcome>Reduction in Post-traumatic Stress Reaction Symptoms Among Participants
    </Primary_outcome>
    <Secondary_outcome>African Youth Psychosocial Assessment Inventory - Depression and Anxiety Subscales
    </Secondary_outcome>
    <Secondary_ID>PREC 06-2012
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Harvard School of Public Health;Discover the Journey
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>28/12/2018
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01542398
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12599429
    </Internal_Number>
    <TrialID>PACTR201203000351114
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>An RCT to measure the impact of retreatment  with artemisinin-based combination on malaria incidence and resistant strains selection
    </Public_title>
    <Scientific_title>A Randomized Clinical Trial to measure the impact of retreatment  with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Jean-Pierre Van geertruyden
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120130
    </Date_registration3>
    <Date_registration>30/01/2012
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=351
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Month(s)
    </Inclusion_agemin>
    <Inclusion_agemax>59 Month(s)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/03/2012
    </Date_enrollement>
    <Target_size>310
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,A randomisation list of blocks of varying size and stratified according to the number of recruitment points in each site will be used. ,Sealed envelopes labelled with the patients unique code and containing the treatment allocated to the patient will be used. The envelopes will be opened only after recruitment.
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Democratic Republic of the Congo;Uganda
    </Countries>
    <Contact_Firstname>Joachim Y
    </Contact_Firstname>
    <Contact_Lastname>Doua
    </Contact_Lastname>
    <Contact_Address> Universiteitplein
    </Contact_Address>
    <Contact_Email>joachimy.doua@ua.ac.be
    </Contact_Email>
    <Contact_Tel>+32 326 528 74
    </Contact_Tel>
    <Contact_Affiliation>Research assistant
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: In order to be eligible, patients should satisfy the following inclusion criteria:&#x0D;&lt;br&gt;1. Males and Females aged between 12 months and 59 months inclusive. &#x0D;&lt;br&gt;2. Body weight of 9 Kg and above.&#x0D;&lt;br&gt;3. Microscopically confirmed, mono-infection of Plasmodium falciparum (parasitaemia 2,000/microliter to 200,000/microliter).&#x0D;&lt;br&gt;4. Fever (tympanic temperature at ¿ 38.0°C) or history of fever in the previous 24 hours.&#x0D;&lt;br&gt;5. Haemoglobin value ¿  6.0 g/dl;&#x0D;&lt;br&gt;6. Signed informed consents by the parents or guardians. &#x0D;&lt;br&gt;7. Parents¿ or guardians¿ willingness and ability to comply with the study protocol for the duration of the study.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with at least one of the following criteria will be excluded:&#x0D;&lt;br&gt;1. Participation in any other investigational drug study (antimalarial or others) during the previous 30 days.&#x0D;&lt;br&gt;2. Known hypersensitivity and previous Serious Adverse Events related to the study drugs.&#x0D;&lt;br&gt;3. Severe malaria( WHO 2000) or danger signs: not able to drink or breast-feed, vomiting (&gt; twice in 24hours), recent history of convulsions (&gt;1 in 24h), unconscious state, unable to sit or stand.&#x0D;&lt;br&gt;4. Presence of intercurrent illness or any condition (cardiac, renal, hematologic, hepatic diseases) which  would place the subject at undue risk or interfere with the results of the study, including known G6PD deficiency.&#x0D;&lt;br&gt;5. Patients who are taking drug which may prolong the QT (imidazole and triazole, antifungal agent). &#x0D;&lt;br&gt;6. Severe malnutrition (defined as weight for height &lt;70% of the median NCHS/WHO reference).&#x0D;&lt;br&gt;7. Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole for the prevention of Pneumocisti carini pneumonia in children born to HIV+ women
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Malaria;Malaria
    </Condition>
    <Intervention>;Artemether-Lumefantrine Tablets 20 mg of Artemether and 120 mg of Lumefantrine;Artesunate-amodiaquine tablets 25mg/67,5 mg of Artesunate/Amodiaquine;Quinine + Clindamycin
    </Intervention>
    <Primary_outcome>PCR adjusted efficacy: the proportion of children with PCR adequate clinical and parasitological response at day 28 (ACPR28A): all early failures before day 7 plus the recurrent parasitaemias detected later and classified by genotyping as recrudescence.
    </Primary_outcome>
    <Secondary_outcome>PCR unadjusted efficacy:  the proportion of children without (PCR not adjusted) treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping;Clinical efficacy:  all clinical treatment failures detected during the 42 days follow up for the first line treatment, with and without PCR adjustment. As no active monitoring of parasitaemia after day 3 is planned this includes Early Treatment Failure and Late Clinical Failure following WHO criteria;Fever clearance time (FCT): Fever clearance time is defined as the time (in days) from the time of randomization to the first two consecutive measurements on 2 different days of tympanic temperature below 38.0°C.;Asexual parasite clearance time (PCT): Asexual parasite clearance time is defined as the time (in days) from time of randomization to 2 consecutive negative blood slides (collected at different days). The time to the event will be taken as the time to the first negative slide.;Gametocytaemia (prevalence and density) ;Hb changes 
    </Secondary_outcome>
    <Source_Support>Research Foundation Flanders / Fond voor Wetenschappelijk Onderzoek (FWO);EDCTP  ;Belgium Development Agency
    </Source_Support>
    <Ethics_review_status>Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/09/2011;16/02/2012;21/03/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Universitary Hospital Antwerp (UZA) Ethics Committee;Comité Ethique, Ecole de Santé Publique, Université de Kinshasa;Uganda National Council for Science and Technology 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6567668
    </Internal_Number>
    <TrialID>ISRCTN86247213
    </TrialID>
    <Last_Refreshed_on>20 November 2017
    </Last_Refreshed_on>
    <Public_title>Mobile Phone Diabetes Support Study
    </Public_title>
    <Scientific_title>Mobile Phone Diabetes Self-Management Support: a multi-country analysis of its implementation in existing Diabetes Self-Management Education Programmes in the Democratic Republic of Congo, Cambodia and the Philippines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Institute of Tropical Medicine, Antwerp (Belgium)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120125
    </Date_registration3>
    <Date_registration>25/01/2012
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN86247213
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/06/2012
    </Date_enrollement>
    <Target_size>1200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional randomised non-blinded multicenter study (Quality of life)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Cambodia;Congo, Democratic Republic;Philippines
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosed as having (pre-)diabetes based on the WHO/IDF guidelines&lt;br&gt;2. Above 18 years old&lt;br&gt;3. Presently included in an existing Diabetes Self-Management Education strategy in a participating centre&lt;br&gt;4. Having received at least one session with an educator in the DSME strategy&lt;br&gt;5. Willing and able to provide written informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>Diabetes mellitus &lt;br&gt;Nutritional, Metabolic, Endocrine &lt;br&gt;Diabetes mellitus
    </Condition>
    <Intervention>The project introduces a Diabetes Self-Management Support intervention in addition to an existing Diabetes Self-Management Education strategy in each country, by providing mobile phones to randomly chosen patients with diabetes to use this for support when needed and to communicate about behaviour change, results and reminders.&lt;br&gt;&lt;br&gt;Control Group: Routine care only
    </Intervention>
    <Primary_outcome>Current primary outcome measures as of 19/10/2012:&lt;br&gt;The percentage of people with a controlled HBA1c level; controlled being defined as &lt;7.0%. &lt;br&gt;&lt;br&gt;Previous primary outcome measures until 19/10/2012:&lt;br&gt;Mean change in glycosated haemoglobin (HbA1C) at the last available time-point after start of the intervention
    </Primary_outcome>
    <Secondary_outcome>1. Health outcomes:&lt;br&gt;1.1. Mean blood pressure &lt;br&gt;1.2. Mean body mass index (BMI)/waist circumference&lt;br&gt;1.3. Diabetic foot lesions &lt;br&gt;2. Access and quality of care:&lt;br&gt;2.1. Failure to attend rate: number of planned versus actual contacts between patient and educator in the last year&lt;br&gt;2.2. Perceived quality of care (adapted Patient Assessment of Chronic Illness Care - PACIC)&lt;br&gt;2.3. Direct and indirect health care expenditure in the last month &lt;br&gt;3. Enablement:&lt;br&gt;3.1. Level of knowledge on diabetes and diabetes care (adapted from Michigan Diabetes Research &amp; Training Center?s Brief Diabetes Knowledge Test &amp; the Diabetes Knowledge Questionnaire)&lt;br&gt;3.2. Self-management and feeling of coping (Howie score)&lt;br&gt;3.3. Adherence to glucose monitoring and control regimes - adherence to healthy lifestyle &lt;br&gt;4. Process indicators: &lt;br&gt;4.1. Number and type (conversation or SMS) of Project Initiated Communications towards the person with diabetes &lt;br&gt;4.2. number and type (conversation or SMS) of Patient  Initiated Communications towards educators and other patients&lt;br&gt;4.3. Intervention cost at the level of the DSMS programme
    </Secondary_outcome>
    <Secondary_ID>11245776
    </Secondary_ID>
    <Source_Support>International Diabetes Federation (Belgium) - Long term Bridges Project (ref: LT10-341)
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4863758
    </Internal_Number>
    <TrialID>NCT01518218
    </TrialID>
    <Last_Refreshed_on>20 April 2015
    </Last_Refreshed_on>
    <Public_title>Effectiveness of Laying-on-of-hands for Sickle Cell Disease
    </Public_title>
    <Scientific_title>Effectiveness of Laying-on-of-hands for Patients With Sickle Cell Disease in Africa
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>MOA Health Science Foundation
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20120121
    </Date_registration3>
    <Date_registration>21/01/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01518218
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3 Years
    </Inclusion_agemin>
    <Inclusion_agemax>40 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2006
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Kodondi K Koto, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>The Institute of Scientific Research for Health, Kinshasa
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with symptoms associated with sickle cell disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  those able to receive laying-on-of-hands every weekday for 1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  those able to receive conventional medical treatment whenever necessary&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  those able to receive blood test at the beginning, after 6 month and after  1 year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  those who wish to use other complementary and alternative therapies along with&#x0D;&lt;br&gt;             laying-on-of-hands&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Sickle Cell Disease;Pain Crisis Recurrent;Anemia;Infection;Death
    </Condition>
    <Intervention>Behavioral: laying-on-of-hands
    </Intervention>
    <Primary_outcome>disease-related episodes and mortality
    </Primary_outcome>
    <Secondary_outcome>blood data
    </Secondary_outcome>
    <Secondary_ID>MOA-002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4713522
    </Internal_Number>
    <TrialID>NCT01625117
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Mental Health and Aggression in Congolese Ex-combatants
    </Public_title>
    <Scientific_title/>
    <Acronym/>
    <Primary_sponsor>University of Konstanz
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20120116
    </Date_registration3>
    <Date_registration>16/01/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01625117
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Years
    </Inclusion_agemin>
    <Inclusion_agemax>35 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>May 2011
    </Date_enrollement>
    <Target_size>38
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Thomas Elbert, Prof. Dr.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Konstanz
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ex-combatants in Congo who live in a re-integration camp&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Appetitive Aggression;Posttraumatic Stress Disorder
    </Condition>
    <Intervention>Behavioral: A variant of Narrative Exposure Therapy
    </Intervention>
    <Primary_outcome>Appetitive aggression (Appetitive Aggression Scale);Symptoms of posttraumatic stress disorder (Posttraumatic Diagnostic Scale, PDS)
    </Primary_outcome>
    <Secondary_outcome>Symptoms of depression (Mini-International Neuropsychiatric Interview);Functionality (Work and Social Adjustment Scale)
    </Secondary_outcome>
    <Secondary_ID>DFG_2011
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>German Research Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10216784
    </Internal_Number>
    <TrialID>NCT01509872
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Psychological and Psychosocial Intervention With War-Affected Children
    </Public_title>
    <Scientific_title>An RCT Comparing Trauma-Focused Cognitive Behavioral Therapy (a Specific Psychological Intervention) and A Child Friendly Space (a Non-trauma Focused Psychosocial Intervention) in Reducing Psychological Distress Among War-affected Children
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Queen's University, Belfast
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20120106
    </Date_registration3>
    <Date_registration>06/01/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01509872
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2011
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dr Ciarán Shannon, BA, MA, DClin
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>British Psychological Society (Chartered Clinical Psychologist)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  under 18 years of age,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  witness to a violent event involving a real or perceived direct threat to life,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to attend a 3-week intervention&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  psychosis,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mental retardation,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  inability to understand Swahili,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe emotional &amp; behavioral problems that made group participation impossible&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Stress Disorders, Post-Traumatic;Depression;Anxiety;Conduct;Pro-social Behavior
    </Condition>
    <Intervention>Behavioral: Trauma Focused Cognitive Behavioral Therapy;Behavioral: Child Friendly Space
    </Intervention>
    <Primary_outcome>Change in Post-traumatic Stress Symptoms as Measured by the University of California Los Angelus Post Traumatic Stress Disorder -Reaction Index
    </Primary_outcome>
    <Secondary_outcome>Change in Internalizing Symptoms as Measured by the African Youth Psychosocial Assessment Instrument;Change in Externalizing Symptoms as Measured by the African Youth Psychosocial Assessment Instrument;Change in Pro-Social Behaviors as Measured by the African Youth Psychosocial Assessment Instrument
    </Secondary_outcome>
    <Secondary_ID>PREC73-2011
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Transcultural Psychosocial Organisation;UNICEF
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>09/04/2019
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01509872
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4702673
    </Internal_Number>
    <TrialID>NCT01483261
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>An RCT of Trauma Focused-Cognitive Behavioral Therapy With Sexually Exploited, War-affected Girls in the DRC
    </Public_title>
    <Scientific_title>Is Trauma-Focused Cognitive Behavioral Therapy Effective in Reducing Post-traumatic Stress and Psychosocial Distress Among Sexually Exploited, War-affected Girls in the Democratic Republic of Congo.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Queen's University, Belfast
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20111129
    </Date_registration3>
    <Date_registration>29/11/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01483261
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>May 2011
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dr Ciaran Shannon, BA, MA, DClin
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Chartered Clinical Psychologist (British Psychological Society)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -Suicidal ideation (irrespective of score on any other measure)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  psychosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mental retardation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  inability to understand Swahili&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  one standard deviation below the mean on every measure&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Post-traumatic Stress Symptoms;Psychosocial Distress
    </Condition>
    <Intervention>Behavioral: Trauma-Focused Cognitive Behavioral Therapy
    </Intervention>
    <Primary_outcome>Change in Post-traumatic Stress Symptoms as measured by the University of California Los Angelus Post Traumatic Stress Disorder -Reaction Index
    </Primary_outcome>
    <Secondary_outcome>Change in Psychosocial Distress as measured by the African Youth Psychosocial Assessment Instrument
    </Secondary_outcome>
    <Secondary_ID>PREC23-2011
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>World Vision
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5808402
    </Internal_Number>
    <TrialID>ISRCTN20984426
    </TrialID>
    <Last_Refreshed_on>17 October 2016
    </Last_Refreshed_on>
    <Public_title>To assess the efficacy and tolerability of three antimalarial treatments in The Democratic Republic of Congo (DRC)
    </Public_title>
    <Scientific_title>A randomised study to assess the efficacy and tolerability of three Artemisinin-based combination therapy (ACT) in The Democratic Republic of Congo (DRC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>The Centre for Tropical Medicine (UK)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20111006
    </Date_registration3>
    <Date_registration>06/10/2011
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN20984426
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>08/09/2011
    </Date_enrollement>
    <Target_size>684
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomised three-arm open study (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. Children aged 3 to 59 months &lt;br&gt;2. Weight = 5 kg [the minimum weight for treatment with artemether-lumefantrine (ALN)]&lt;br&gt;3. Mono-infection with P. falciparum &lt;br&gt;4. Parasitaemia of =2,000 and =200,000 asexual parasites per µL &lt;br&gt;5. Axillary temperature 37.5 °C or history of fever in the preceding 24 hrs&lt;br&gt;6. Ability to swallow oral medication&lt;br&gt;7. Haemoglobin =5.0 g/dL&lt;br&gt;8. Parents/guardians agree to hospitalize the child for the length of treatment (34 days) and bring the patient for planned follow-up visits at day 7, 14, 21, 28, 35, 42 &lt;br&gt;9. Signed consent from guardian / parents
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Danger signs of severe malaria or signs of severe malaria (WHO 2000) &lt;br&gt;2. Children with severe malnutrition, marasmus or oedematous malnutrition (WHO 2006)&lt;br&gt;3. Febrile condition due to diseases other than malaria [e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal or hepatic diseases, human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS)]&lt;br&gt;4. History of hypersensitivity reactions or contraindication to any medicine being tested&lt;br&gt;5. A clear history of adequate antimalarial treatment in the preceding 72 hours with drugs expected to be effective&lt;br&gt;6. Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole for the prevention of Pneumocisti carini pneumonia in children born to HIV positive women
    </Exclusion_Criteria>
    <Condition>Malaria &lt;br&gt;Infections and Infestations &lt;br&gt;Plasmodium falciparum malaria
    </Condition>
    <Intervention>This is a randomised, open study, comparing three ACTs, dihydroartemisinin-piperaquine (DHA-PQ), artemether?lumefantrine (ALN) and amodiaquine-artesunate coformulated (AQ-AS), for the treatment of symptomatic uncomplicated falciparum malaria. The study is post-marketing, all three study drugs are in fact commercialized and used worldwide. Our aim is to monitor their efficacy and tolerability in this particular geographical area. Dosage and length of treatment are according to manufacturer. Children aged 6 to 59 months with uncomplicated P. falciparum malaria are randomly assigned to one of the three arms. All children are hospitalized for 3 days and given supervised treatment. Treatment efficacy is measured according to WHO (Methods for surveillance of antimalarial drug, WHO 2009). Patients are followed-up actively weekly for 42 days after treatment. Treatment allocation is concealed until recruitment is confirmed and the laboratory technicians reading all malaria smears have no knowledge of the treatment received by individual patients. Randomisation is in blocks of 15.
    </Intervention>
    <Primary_outcome>1. Clinical and parasitological cure by day 42 post-treatment &lt;br&gt;2. Treatment tolerability
    </Primary_outcome>
    <Secondary_outcome>1. The median parasite clearance time (PCT) &lt;br&gt;3. Fever clearance time (FCT)
    </Secondary_outcome>
    <Secondary_ID>Version # 1.01  30 March 2011
    </Secondary_ID>
    <Source_Support>Oxford University (UK)
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4698517
    </Internal_Number>
    <TrialID>NCT01428830
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Non-inferiority of Short-term Catheterization Following Fistula Repair Surgery
    </Public_title>
    <Scientific_title>Non-inferiority of Short-term Catheterization Following Fistula Repair Surgery
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>EngenderHealth
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110902
    </Date_registration3>
    <Date_registration>02/09/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01428830
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>January 2012
    </Date_enrollement>
    <Target_size>524
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Ethiopia;Guinea;Kenya;Nigeria;Niger;Sierra Leone;Uganda;Congo, The Democratic Republic of the;Ethiopia;Guinea;Kenya;Niger;Nigeria;Sierra Leone;Uganda
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Mark A Barone, DVM, MS;Mariana Widmer
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>EngenderHealth;World Health Organization
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a "simple" fistula, as determined at the end of fistula repair surgery&#x0D;&lt;br&gt;             (irrespective of the number of prior repair attempts and the cause of the fistula,&#x0D;&lt;br&gt;             with the exceptions noted under the exclusion criteria below)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a closed fistula at completion of surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a closed fistula 7 days after surgery (i.e. at the time of randomization)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Understand study procedures and requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agree to return to the facility for one follow-up visit three month after the date of&#x0D;&lt;br&gt;             surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Provide informed consent to participate in the study or in the case of&#x0D;&lt;br&gt;             non-emancipated minors, both consent to the study and receive proxy consent to&#x0D;&lt;br&gt;             participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have no contraindications precluding their participation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a fistula that is determined to be "not simple" (i.e. intermediate or complex)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a fistula that is radiation-induced, associated with cancer or due to&#x0D;&lt;br&gt;             lymphogranuloma venereum (These cases will be excluded because the healing process is&#x0D;&lt;br&gt;             very different from fistula resulting from other causes. We expect there to be few&#x0D;&lt;br&gt;             cases of these fistulas at the study sites)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a fistula that is not closed immediately after surgery or 7 days after surgery&#x0D;&lt;br&gt;             (i.e. at the time of randomization)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Vaginal Fistula
    </Condition>
    <Intervention>Procedure: 7-day catheterization following fistula repair surgery;Procedure: 14 day catheterization
    </Intervention>
    <Primary_outcome>Fistula repair breakdown three months following fistula repair surgery as assessed by a urinary dye test.
    </Primary_outcome>
    <Secondary_outcome>Repair breakdown one week following catheter removal;Intermittent catheterization due to urinary retention;Prolonged hospitalization;Catheter blockage;Self-reported residual incontinence;The occurrence of septic or febrile episodes
    </Secondary_outcome>
    <Secondary_ID>A65783
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>World Health Organization;United States Agency for International Development (USAID)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>6621162
    </Internal_Number>
    <TrialID>NCT01428232
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Effectiveness of Well-child Clinics as the "Community" Basis of Step 10 of the Baby Friendly Hospital Initiative
    </Public_title>
    <Scientific_title>Comparison of Two Clinic-based Interventions to Promote Early Initiation and Exclusive Breastfeeding Through 6 Months After Birth in Kinshasa, Democratic Republic of Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of North Carolina, Chapel Hill
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110829
    </Date_registration3>
    <Date_registration>29/08/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01428232
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>3 Days
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 2012
    </Date_enrollement>
    <Target_size>992
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo;Congo;Congo;Congo;Congo
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Marcel Yotebieng, M.D, MPH, Ph.D;Miriam Labbok, MD, MPH, FACPM, IBCLC;Frieda Behets, Ph.D, MPH;Marcel Yotebieng, M.D, MPH, Ph.D;Miriam Labbok, MD, MPH, FACPM, IBCLC;Frieda Behets, Ph.D, MPH;Marcel Yotebieng, M.D, MPH, Ph.D;Miriam Labbok, MD, MPH, FACPM, IBCLC;Frieda Behets, Ph.D, MPH;Marcel Yotebieng, M.D, MPH, Ph.D;Miriam Labbok, MD, MPH, FACPM, IBCLC;Frieda Behets, Ph.D, MPH;Marcel Yotebieng, M.D, MPH, Ph.D;Miriam Labbok, MD, MPH, FACPM, IBCLC;Frieda Behets, Ph.D, MPH
    </Contact_Lastname>
    <Contact_Email>;;;;;;;;;;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;;;;;;;;;;
    </Contact_Tel>
    <Contact_Affiliation>University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill;University of North Carolina, Chapel Hill
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mothers of healthy infants being discharged from participating maternities who intend&#x0D;&lt;br&gt;             to attend well-baby clinic visits in the same health care facilities until the child&#x0D;&lt;br&gt;             will be at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refusal to participate, not speaking Lingala nor French, unable to breastfeed&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mothers of healthy infants being discharged from participating maternities who intend&#x0D;&lt;br&gt;             to attend well-baby clinic visits in the same health care facilities until the child&#x0D;&lt;br&gt;             will be at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refusal to participate, not speaking Lingala nor French, unable to breastfeed&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mothers of healthy infants being discharged from participating maternities who intend&#x0D;&lt;br&gt;             to attend well-baby clinic visits in the same health care facilities until the child&#x0D;&lt;br&gt;             will be at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refusal to participate, not speaking Lingala nor French, unable to breastfeed&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mothers of healthy infants being discharged from participating maternities who intend&#x0D;&lt;br&gt;             to attend well-baby clinic visits in the same health care facilities until the child&#x0D;&lt;br&gt;             will be at least 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refusal to participate, not speaking Lingala nor French, unable to breastfeed&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Breastfeeding;Breastfeeding;Breastfeeding;Breastfeeding
    </Condition>
    <Intervention>Other: implementation of the Baby-Friendly Hospital Initiative;Other: BFHI steps 1-9 +well-child clinic;Other: implementation of the Baby-Friendly Hospital Initiative;Other: BFHI steps 1-9 +well-child clinic;Other: implementation of the Baby-Friendly Hospital Initiative;Other: BFHI steps 1-9 +well-child clinic;Other: implementation of the Baby-Friendly Hospital Initiative;Other: BFHI steps 1-9 +well-child clinic
    </Intervention>
    <Primary_outcome>Early initiation of breastfeeding;Exclusive breastfeeding rate;Early initiation of breastfeeding;Exclusive breastfeeding rate;Early initiation of breastfeeding;Exclusive breastfeeding rate
    </Primary_outcome>
    <Secondary_outcome>Episodes of diarrhea;Episodes of Lower Respiratory Track Infection;Partial Breastfeeding rate;Number of hospitalization;Number of mothers seeking breastfeeding help;Amount and type of breastfeeding support given by Health care provider to mothers
    </Secondary_outcome>
    <Secondary_ID>09-000076-AT11-123-UNC-DRC
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health (DR, Congo);Centre for the Coordination of Social Science Research and Documentation in Africa South of the Sahara (CERDAS) (DR,Congo);Bureau Diocésain des Œuvres Médicales de Kinshasa (BDOM), (DR, Congo);Salvation Army (DR, Congo);Ministry of Public Health, Democratic Republic of the Congo
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4695174
    </Internal_Number>
    <TrialID>NCT01385163
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Intervention Effectiveness in Improving Psychosocial and Economic Well-being of Sexual Violence Survivors in DRC
    </Public_title>
    <Scientific_title>Study of Intervention Effectiveness in Improving Psychosocial and Economic Well-being of Sexual Violence Survivors in DRC
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins Bloomberg School of Public Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20110622
    </Date_registration3>
    <Date_registration>22/06/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01385163
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>October 2010
    </Date_enrollement>
    <Target_size>1000
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Judith Bass, PhD;Judith Bass, PhD
    </Contact_Lastname>
    <Contact_Email>;jbass@jhsph.edu
    </Contact_Email>
    <Contact_Tel>;410-502-9840
    </Contact_Tel>
    <Contact_Affiliation>Johns Hopkins Bloomberg School of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  survivor of sexual violence&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  mental health symptom severity cut-off&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  functional impairment cut-off&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  active suicidality&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  not living in the study site&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Depression;Anxiety;PTSD
    </Condition>
    <Intervention>Behavioral: Treatment as usual;Behavioral: Voluntary Savings/Loans Assoc;Behavioral: Cognitive Processing Therapy
    </Intervention>
    <Primary_outcome>Severity of mental health symptoms
    </Primary_outcome>
    <Secondary_outcome>Economic development
    </Secondary_outcome>
    <Secondary_ID>JHU-AMHR-IRC-2010
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4694366
    </Internal_Number>
    <TrialID>NCT01374581
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria
    </Public_title>
    <Scientific_title>A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains
    </Scientific_title>
    <Acronym>QuinAct
    </Acronym>
    <Primary_sponsor>Universiteit Antwerpen
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110609
    </Date_registration3>
    <Date_registration>09/06/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01374581
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>May 2012
    </Date_enrollement>
    <Target_size>2117
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo;Uganda;Congo;Uganda
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Hypolite M. Mavoko, MD MPH;Carolyn Nabasumba, M.B.Ch.B;Jean-Pierre Van geertruyden, MD MPH PhD
    </Contact_Lastname>
    <Contact_Email>;;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>Kinshasa University, RDCongo;Kazo health centre IV Uganda;International Health Unit Antwerp university
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Have been enrolled in the first phase&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Recurrent Plasmodium falciparum infection with clinical symptoms.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Parents' or guardians' willingness and ability to comply with the study protocol for&#x0D;&lt;br&gt;             the duration of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Signed (or thumb-printed whenever parents/guardians are illiterate) (second) informed&#x0D;&lt;br&gt;             consent by the parents or guardians. Note: the informed consent will cover the whole&#x0D;&lt;br&gt;             period of the study, including additional active follow ups&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients with at least one of the following criteria will be excluded:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Participation in any other investigational drug study (antimalarial or others) during&#x0D;&lt;br&gt;             the previous 30 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Known hypersensitivity and previous Serious Adverse Events related to the study&#x0D;&lt;br&gt;             drugsto the study drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Severe malaria( WHO 2000) or danger signs: not able to drink or breast-feed, vomiting&#x0D;&lt;br&gt;             (&gt; twice in 24hours), recent history of convulsions (&gt;1 in 24h), unconscious state,&#x0D;&lt;br&gt;             unable to sit or stand.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Presence of intercurrent illness or any condition (cardiac, renal, hematologic,&#x0D;&lt;br&gt;             hepatic diseases) which in the judgement of the investigator would place the subject&#x0D;&lt;br&gt;             at undue risk or interfere with the results of the study, including known G6PD&#x0D;&lt;br&gt;             deficiency.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients who are taking drug which may prolong the QT (imidazole and triazole,&#x0D;&lt;br&gt;             antifungal agent).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Severe malnutrition (defined as weight for height &lt;70% of the median NCHS/WHO&#x0D;&lt;br&gt;             reference).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole for&#x0D;&lt;br&gt;             the prevention of Pneumocisti carini pneumonia in children born to HIV+ women.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: Artemether/Lumefantrine;Drug: Artesunate/Amodiaquine;Drug: Quinine + Clindamycin
    </Intervention>
    <Primary_outcome>Late Parasitological Failure
    </Primary_outcome>
    <Secondary_outcome>PCR unadjusted efficacy;Day 42 clinical efficacy;Change in Fever clearance time (FCT);Change in Asexual parasite clearance time;Hb changes;Early Treatment Failure;Late Clincial Failure
    </Secondary_outcome>
    <Secondary_ID>UA-IHU-2010-01 version 1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>European and Developing Countries Clinical Trials Partnership (EDCTP);Fund for Scientific Research, Flanders, Belgium;Institute of Tropical Medicine, Belgium;University of Kinshasa;Centre Muraz;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Makerere University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4948714
    </Internal_Number>
    <TrialID>NCT01350856
    </TrialID>
    <Last_Refreshed_on>8 June 2015
    </Last_Refreshed_on>
    <Public_title>Tracking Resistance to Artemisinin (TRAC)
    </Public_title>
    <Scientific_title>A Multicentre, Randomised Trial to Detect in Vivo Resistance of Plasmodium Falciparum to Artesunate in Patients With Uncomplicated Malaria.
    </Scientific_title>
    <Acronym>TRAC
    </Acronym>
    <Primary_sponsor>University of Oxford
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110419
    </Date_registration3>
    <Date_registration>19/04/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01350856
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>May 2011
    </Date_enrollement>
    <Target_size>1700
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Bangladesh;Cambodia;Congo, The Democratic Republic of the;India;Kenya;Lao People's Democratic Republic;Myanmar;Nigeria;Thailand;Vietnam;Bangladesh;Cambodia;Congo, The Democratic Republic of the;India;Kenya;Lao People's Democratic Republic;Myanmar;Nigeria;Thailand;Vietnam
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Nicholas J White, DSc MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Mahidol Oxford Research Unit
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female, aged from 6 months to 65 years old, inclusive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with&#x0D;&lt;br&gt;             asexual forms of P. falciparum (or mixed with non-falciparum species)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Asexual P. falciparum parasitaemia: 10,000 to 200,000/uL, determined on a thin or&#x0D;&lt;br&gt;             thick blood film&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fever defined as &gt; 37.5°C tympanic temperature or a history of fever within the last&#x0D;&lt;br&gt;             24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent (by legally acceptable representative in case of children)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness and ability of the patients/guardians to comply with the study protocol&#x0D;&lt;br&gt;             for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of severe/complicated malaria (WHO, 2000)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Haematocrit &lt; 25% or haemoglobin (Hb) &lt; 8 g/dL at enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute illness other than malaria requiring treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For females: pregnancy, breast feeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who have received artemisinin or a derivative or an artemisinin-containing&#x0D;&lt;br&gt;             combination therapy (ACT) within the previous 7 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of allergy or known contraindication to artemisinins, or to the ACT to be&#x0D;&lt;br&gt;             used at the site&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous splenectomy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Falciparum Malaria
    </Condition>
    <Intervention>Drug: Artesunate 2;Drug: Artesunate 4
    </Intervention>
    <Primary_outcome>Parasite clearance rate
    </Primary_outcome>
    <Secondary_outcome>Parasite clearance time;Parasite reduction rates and ratios;Time for parasite count to fall;Fever clearance time;Gametocytemia in patients;Gametocyte carriage rates;In vitro susceptibility of P.falciparum to artemisinins;Pharmacokinetics relationships for artesunate and Dihydroartemisinin (DHA);Parasite molecular markers of drug resistance;Identification of host factors that correlate with slow parasite clearance;Efficacy at D42;Pharmacodynamics relationships for artesunate and Dihydroartemisinin (DHA)
    </Secondary_outcome>
    <Secondary_ID>BAKMAL1101
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Mahidol University;Worldwide Antimalarial Resistance Network
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4687372
    </Internal_Number>
    <TrialID>NCT01282788
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Efficacy of Caterpillar Cereal for Complementary Feeding in the Democratic Republic of Congo
    </Public_title>
    <Scientific_title>A Novel Sustainable Complementary Feeding Product for Infants and Young Children in the Democratic Republic of Congo: Caterpillar Cereal
    </Scientific_title>
    <Acronym>CAT02
    </Acronym>
    <Primary_sponsor>University of North Carolina, Chapel Hill
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110121
    </Date_registration3>
    <Date_registration>21/01/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01282788
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>18 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>January 2011
    </Date_enrollement>
    <Target_size>222
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Carl L Bose, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of North Carolina, Chapel Hill
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants born in study communities who will reach 6 months of age during the six month&#x0D;&lt;br&gt;             period after initiation of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants likely to receive free or subsidized complementary foods (or infant formula)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Families likely to relocate during the study period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants with known congenital anomaly&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants of multiple birth&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants with neurological deficit apparent at the time of enrollment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malnutrition;Stunting of Growth;Iron Deficiency Anemia;Neurodevelopmental Impairment;Infectious Diseases Morbidity
    </Condition>
    <Intervention>Dietary Supplement: Caterpillar Cereal
    </Intervention>
    <Primary_outcome>Incidence of Stunting of Linear Growth
    </Primary_outcome>
    <Secondary_outcome>Rate of Head Growth;Incidence of wasting;Developmental Outcome;Infectious Disease Morbidity;All Cause Mortality;Compliance;Iron Deficiency Anemia
    </Secondary_outcome>
    <Secondary_ID>10-2071
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health;University of California, Davis;Bill and Melinda Gates Foundation;Thrasher Research Fund
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4685518
    </Internal_Number>
    <TrialID>NCT01258647
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Acceptability of a Cereal for Complementary Feeding of Infants and Young Children Made From Caterpillars
    </Public_title>
    <Scientific_title>Caterpillar Cereal: Maternal and Infant Acceptability
    </Scientific_title>
    <Acronym>CAT01
    </Acronym>
    <Primary_sponsor>University of North Carolina, Chapel Hill
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20101209
    </Date_registration3>
    <Date_registration>09/12/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01258647
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>8 Months
    </Inclusion_agemin>
    <Inclusion_agemax>10 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>October 2010
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Carl L Bose, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of North Carolina
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any mother-infant dyad living within each a study community in the Equateur Province.&#x0D;&lt;br&gt;              Infants must be 8-10 months of age at the time of recruitment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants with minor inter-current illness that may interfere with oral intake&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants of multiple gestation births&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants with congenital anomalies&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants likely to receive free or subsidized complementary foods (or infant formula)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malnutrition;Stunting of Growth
    </Condition>
    <Intervention>Dietary Supplement: caterpillar cereal
    </Intervention>
    <Primary_outcome>Maternal acceptability;Infant acceptability
    </Primary_outcome>
    <Secondary_outcome>Infant tolerance
    </Secondary_outcome>
    <Secondary_ID>10-0509
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health;University of California, Davis;Bill and Melinda Gates Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4537579
    </Internal_Number>
    <TrialID>ISRCTN20267635
    </TrialID>
    <Last_Refreshed_on>13 January 2015
    </Last_Refreshed_on>
    <Public_title>The Ready to Use Complementary Food (RUCF) Study
    </Public_title>
    <Scientific_title>The impact of high nutrient dense Ready to Use Complementary Food (RUCF) on growth of children below 2 years in South Kivu, Eastern Democratic Republic of Congo: a randomised controlled interventional trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Irish Aid (Ireland)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100428
    </Date_registration3>
    <Date_registration>28/04/2010
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN20267635
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>15/11/2009
    </Date_enrollement>
    <Target_size>1354
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomised controlled interventional trial (Quality of life)
    </Study_design>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. Full term born infants (gestational age greater than 37 weeks and birth weight greater than 2500 g) &lt;br&gt;2. Consent given
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Bottle-fed children&lt;br&gt;2. Children with any malformations or neurological impairment
    </Exclusion_Criteria>
    <Condition>Underweight/stunting &lt;br&gt;Pregnancy and Childbirth &lt;br&gt;Slow fetal growth and fetal malnutrition
    </Condition>
    <Intervention>Intervention group: infants enrolled in the intervention group will receive 50 g of RUCF providing 250 kcal/day during 12 months (from the age of 6 to 18 months). The RUCF will be administered daily by the mother. Extension health workers serving the villages of participating children will visits the couples mother-infant biweekly.  &lt;br&gt;&lt;br&gt;Control group: Infants enrolled in the control group will receive 1 kg of UNIMIX flour per week. The porridge offered to infant should provide 250 kcal/day.
    </Intervention>
    <Primary_outcome>Prevalence of stunting at 12, 18 and 24 months of age.
    </Primary_outcome>
    <Secondary_outcome>1. Average daily breast milk intake at 6 and 9 months of age&lt;br&gt;2. Prevalence of exclusive breast feeding at 6 months of age&lt;br&gt;3. Mean change in anthropometric indices at 12, 18 and 24 months of age&lt;br&gt;4. Risks factors of stunting at 12 months of age &lt;br&gt;5. Incidence of diarrhoea at 12 months of age  &lt;br&gt;6. Incidence of malaria at 12 months of age &lt;br&gt;7. Incidence of severe acute malnutrition at 12, 18 and 24 months of age&lt;br&gt;8. Proportion of children standing independently at 9 and 12 months of age&lt;br&gt;9. Proportion of children walking unassisted at 12 months of age&lt;br&gt;10. Mean cholesterol at 12 and 18 months of age&lt;br&gt;11. Mean triglycerides at 12 and 18 months of age&lt;br&gt;12. Mean haemoglobin at 12, 18 and 24 months of age
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>Irish Aid (Ireland)
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>8756159
    </Internal_Number>
    <TrialID>ACTRN12610000286044
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Simplified Regimens for Management of Possible Serious Bacterial Infections in Neonates and Young Infants for Use in Outpatient and Community Settings: A multi-centre Randomized Controlled Trial in Africa
    </Public_title>
    <Scientific_title>A comparison of treatment failure rate between three simplified regimens and a reference regimen for management of possible serious bacterial infections in neonates and young infants.: A multi-centre randomized controlled trial in Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>World Health Organization
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100409
    </Date_registration3>
    <Date_registration>09/04/2010
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12610000286044.aspx
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>1 Days
    </Inclusion_agemin>
    <Inclusion_agemax>59 Days
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>01/10/2010
    </Date_enrollement>
    <Target_size>6900
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Bio-equivalence;
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic Of The;Nigeria;Kenya
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: Stratum 1 (severe infection): One or more of the  following five signs of 'severe infection' - not feeding well, movement only when stimulated, severe chest indrawing, axillary temperature &gt;38.0 degree Centigrade or &lt;35.5 degree Centigrade and informed consent is provided by a parent (or legal guardian).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Stratum II (fast breathing only): Fast breathing i.e., respiratory rate 60 or more per minute and Informed consent is provided by a parent (or legal guardian)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Stratum I: Exclusion Criteria&#x0D;&lt;br&gt;- Critically ill infant characterized by presence of any of the following signs - unconscious, convulsions, unable to feed at all, apnea, unable to cry, cyanosis, bulging fontanelle, major congenital malformations inhibiting oral antibiotic intake, active bleeding requiring transfusion, surgical conditions needing hospital referral, persistent vomiting defined as vomiting following three attempts to feed the baby within ½ hour&#x0D;&lt;br&gt;- Very low weight (&lt;1500g at the time of presentation)&#x0D;&lt;br&gt;- Hospitalization for illness in the last two weeks &#x0D;&lt;br&gt;- Previous inclusion in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Stratum II: Exclusion Criteria&#x0D;&lt;br&gt;- Any signs of severe infection: not feeding well, movement only when stimulated, severe chest in-drawing, axillary temperature &gt;38.0 degree Centigrade or &lt;35.5 degree Centigrade , &#x0D;&lt;br&gt;- Any sign of being critically ill&#x0D;&lt;br&gt;- Very low weight (&lt;1500g at the time of presentation)&#x0D;&lt;br&gt;- Hospitalization for illness in the last two weeks &#x0D;&lt;br&gt;- Previous inclusion in the study
    </Exclusion_Criteria>
    <Condition>Possible serious bacterial infection; &lt;br&gt;Possible serious bacterial infection;Infection - Other infectious diseases
    </Condition>
    <Intervention>Stratum I (severe infection) &lt;br&gt;To test the efficacy of the following three simpler regimens, compared to the reference regimen, in children who have 'severe infection'&lt;br&gt;- Treatment regimen B: injection gentamicin once daily (4-6.5 mg/kg/day) and oral amoxicillin (75-100 mg/kg/day) twice daily for 7 days (7 injections in total)&lt;br&gt;- Treatment regimen C: injection gentamicin (4-6.5 mg/kg/day) once daily and injection procaine penicillin (40,000-60,000 units/kg/day) once daily for 2 days, thereafter oral amoxicillin (75-100 mg/kg/day) for 5 days (4 injections in total)&lt;br&gt;- Treatment regimen D: injection gentamicin (4-6.5 mg/kg/day) once daily and oral amoxicillin (75-100 mg/kg/day) for 5 days twice daily for 2 days, thereafter oral amoxicillin (75-100 mg/kg/day) twice daily for 5 days (2 injections in total)&lt;br&gt;&lt;br&gt;Stratum II (fast breathing only)&lt;br&gt;To test the efficacy of the following simpler regimen, compared to the reference regimen, in children who have fast breathing:&lt;br&gt;- Treatment regimen E: Oral amoxicillin (75-100 mg/kg/day) twice daily for 7 days
    </Intervention>
    <Primary_outcome>Treatment failure based on clinical criteria, which will be assessed clinically.&lt;br&gt;Definition of treatment failure in Stratum I&lt;br&gt;&lt;br&gt;1.	Death anytime within 7 days after randomization (day 1-8 of enrolment).&lt;br&gt;2.	Persistence of the presenting sign/symptom suggestive of severe infection (if single presenting sign) or persistence of &gt;1 presenting sign/symptom suggestive of severe infection (if multiple presenting signs) after 72 hours of randomization (day 4 of enrolment).&lt;br&gt;3.	After initial disappearance within 72 hours after randomization, re-emergence of any presenting sign (temperature should be at least 38.0 degree Centigrade or higher on 2 or more days) &lt;br&gt;4.	Clinical deterioration: emergence of any sign of being critically ill at any time after randomization [as defined in exclusion criteria]&lt;br&gt;5.	Emergence of any new sign of severe infection (any of the 5 signs) after 24 hours of randomization (day 3 of enrolment)&lt;br&gt;6.	Persistence of any sign of severe infection at 7 days (day 8 of enrolment).&lt;br&gt;7.	Development of serious adverse effect of the study antibiotics (death, organ failure, anaphylactic reaction, severe diarrhoea, disseminated and severe rash).&lt;br&gt;8.	Hospitalization decided by the family, anytime after admission in the study.&lt;br&gt;&lt;br&gt;Definition of treatment failure in Stratum II&lt;br&gt;&lt;br&gt;1.	Death anytime within 7 days after randomization (day 1-8 of enrolment).&lt;br&gt;2.	No improvement in respiratory rate at 72 hours (reduction in respiratory rate of &lt;10 breaths per minute compared to baseline) (day 4 of enrolment)&lt;br&gt;3.	Clinical deterioration: emergence of any sign of being critically ill or severe infection at any time after randomization [as defined in exclusion criteria] &lt;br&gt;4.	Persistence of fast breathing at 7 days (day 8 of enrolment).&lt;br&gt;5.	Development of serious adverse effect of the study antibiotics (death, organ failure, anaphylactic reaction, severe diarrhoea, disseminated and severe rash).&lt;br&gt;6.	Hospitalization decided by the family, anytime after admission in the study.[Within 7 days (day 1-8 of enrolment) of enrolment and treatment initation. Once daily clinical assessment.]
    </Primary_outcome>
    <Secondary_outcome>Adherence to study therapy by daily direct administration/obsvervation of therapy by study health worker and recording on a treatment form.[Within 7 days of enrolment and treatment initation];Relapse through clinical observation. Definition signs of 'severe infection' (stratum I) or' fast breathing' (stratum II) disappear on day 8 of enrolment, but develop any sign of severe infection or being critically ill between day 9 and day 14. In stratum II, an additional sign would be re-emergence of fast breathing.[Between 8-14 days of initiation of treatment. Observed on day 11 and day 15 of enrollment by the health worker. But if needed a patient could be seen on other days between this time.];Serious adverse effects (such as death, organ failure, anaphylactic reaction, severe diarrhoea, disseminated and severe rash) due to study drugs observed and recorded on serious adverse event or death form.[1-8 days after initiation of treatment (once daily observation)]
    </Secondary_outcome>
    <Secondary_ID>nil
    </Secondary_ID>
    <Source_Support>World Health Organization
    </Source_Support>
    <Secondary_Sponsor>Bill and Melinda Gates Foundation
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>WHO Ethical Review Committee (ERC)
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4672186
    </Internal_Number>
    <TrialID>NCT01084109
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>First Bites: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial
    </Public_title>
    <Scientific_title>Complementary Feeding - A Global Network Cluster Randomized Controlled Trial
    </Scientific_title>
    <Acronym>First Bites
    </Acronym>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100309
    </Date_registration3>
    <Date_registration>09/03/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01084109
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3 Months
    </Inclusion_agemin>
    <Inclusion_agemax>4 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2008
    </Date_enrollement>
    <Target_size>1236
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo;Guatemala;Pakistan;Zambia;Congo;Guatemala;Pakistan;Zambia
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion criteria for clusters: Each cluster will be a rural community characterized&#x0D;&lt;br&gt;             by inhabitants with low income and served by one community health center. A primary&#x0D;&lt;br&gt;             criterion is that national or other available statistics indicate a prevalence of&#x0D;&lt;br&gt;             stunting (mean length for age Z-scores in second year &lt; -2) of at least 20% in young&#x0D;&lt;br&gt;             children.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inclusion criteria for individual families:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Infant aged 3-4 months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Primarily or exclusively breast feeding with intent to continue breast feeding&#x0D;&lt;br&gt;                  through at least 1 year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exclusion criteria for individual families: Exclusion criteria include any&#x0D;&lt;br&gt;             population/family that is receiving or likely to receive free or subsidized&#x0D;&lt;br&gt;             complementary foods (or infant formula) through the health system or NGOs; any&#x0D;&lt;br&gt;             individual families who are feeding or intend to feed fortified infant formula or&#x0D;&lt;br&gt;             micronutrient-fortified commercial complementary foods.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exclusion criteria for infants: Infants meeting the following criteria will be&#x0D;&lt;br&gt;             excluded from participation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. known congenital anomaly;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. infant of multiple births;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. known neurological deficit apparent at the time of enrollment (including&#x0D;&lt;br&gt;                  seizures).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Complementary Feeding;Infant Growth
    </Condition>
    <Intervention>Other: Lyophilized meat;Other: Cereal
    </Intervention>
    <Primary_outcome>Linear growth velocity
    </Primary_outcome>
    <Secondary_outcome>Infant Zinc and Ferritin levels;Bayleys II;Incidence of diarrhea, lower respiratory infection, and malaria
    </Secondary_outcome>
    <Secondary_ID>GN CF
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Kinshasa School of Public Health;University of Zambia;INCAP, Chiimaltenango, Guatemala;Aga Khan University;University of Colorado, Denver;University of North Carolina, Chapel Hill;University of Alabama at Birmingham;Drexel University;RTI International
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11610232
    </Internal_Number>
    <TrialID>NCT01073475
    </TrialID>
    <Last_Refreshed_on>22 November 2021
    </Last_Refreshed_on>
    <Public_title>Maternal Newborn Health Registry
    </Public_title>
    <Scientific_title>Global Network for Women's and Children's Health Research Maternal Newborn Health Registry
    </Scientific_title>
    <Acronym>MNH
    </Acronym>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100221
    </Date_registration3>
    <Date_registration>21/02/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01073475
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 2008
    </Date_enrollement>
    <Target_size>950000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Zambia;Bangladesh;Congo, The Democratic Republic of the;Guatemala;India;Kenya;Pakistan;Zambia;Bangladesh;Congo, The Democratic Republic of the;Guatemala;India;Kenya;Pakistan;United States;United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Marion Koso-Thomas, MD;Marion Koso-Thomas, MD
    </Contact_Lastname>
    <Contact_Email>;marion.koso-thomas@nih.gov
    </Contact_Email>
    <Contact_Tel>;301-435-6873
    </Contact_Tel>
    <Contact_Affiliation>Center for Research for Mothers and Children (NICHD);
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Community-level&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Appropriate for long-term registry data collection and the conduct of ongoing&#x0D;&lt;br&gt;                  Global Network research&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  At least 300 deliveries per year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant-level&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Pregnant women intending to deliver within study cluster&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Women who deliver within the study cluster&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Women who reside in the community but are transferred for care at delivery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant-level&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Opt out of consent to include data in the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pregnancy Outcome Trends in Low-resource Geographic Areas
    </Condition>
    <Intervention>Other: There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.
    </Intervention>
    <Primary_outcome>Maternal mortality rate;Stillbirth rate;Early neonatal mortality rate
    </Primary_outcome>
    <Secondary_outcome>Cause of maternal death at less than or equal to 42 days;Cause of neonatal death at less than or equal to 28 days;Prevalence of COVID-19 antibody positive results during pregnancy;Fetal/neonatal outcomes (spontaneous abortion, stillbirth, birth weight (g), and fetal growth restriction, early (7-day) and late (28-day) neonatal death, cause of death, congenital infections, and malformations) associated with COVID-19 positivity;Maternal outcomes (rate of infection, timing of infection, types of symptoms, death, cause of death) associated with COVID-19 positivity;Knowledge, attitudes, and practices of pregnant women related to COVID-19 infection during pregnancy
    </Secondary_outcome>
    <Secondary_ID>CP MNH
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12599362
    </Internal_Number>
    <TrialID>PACTR201007000192283
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>WORLD MATERNAL ANTIFIBRINOLYTIC TRIAL
    </Public_title>
    <Scientific_title>Tranexamic acid for the treatment of postpartum haemorrhage: An international, randomised, double blind, placebo controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>London School of Hygiene and Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100209
    </Date_registration3>
    <Date_registration>09/02/2010
    </Date_registration>
    <Source_Register>PACTR
    </Source_Register>
    <web_address>https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=192
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Year(s)
    </Inclusion_agemin>
    <Inclusion_agemax>150 Year(s)
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>01/05/2009
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel: different groups receive different interventions at same time during study,Randomised,Permuted block randomisation. Treatment packs containing TXA and placebo will be packed in balanced blocks of 8 (4 TXA: 4 Placebo) into a box in random order,Randomisation codes will be generated and secured by an independent statistical consultant from Sealed Envelope Ltd (UK).
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Ethiopia;Uganda;Kenya;Cameroon;Nigeria;Sudan;Zambia;Ghana;Democratic Republic of the Congo;Burkina Faso
    </Countries>
    <Contact_Firstname>Haleema
    </Contact_Firstname>
    <Contact_Lastname>Shakur
    </Contact_Lastname>
    <Contact_Address>Keppel Street
    </Contact_Address>
    <Contact_Email>thewomantrial@lshtm.ac.uk
    </Contact_Email>
    <Contact_Tel>+44 (0)20 7299 4684
    </Contact_Tel>
    <Contact_Affiliation>Trial Manager
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Immediately after delivery, all usual care should be given for the prevention of PPH. If bleeding continues and a clinician diagnosis of PPH is made, all usual treatments should be given and at the same time assessment for inclusion in the WOMAN Trial should be done. As most women die within 2 - 4 hours of delivery, it is important to consider inclusion as early as possible. Clinician diagnosis of PPH may be based on any of the following:&#x0D;&lt;br&gt;1. Blood loss after vaginal delivery greater than 500 ml, or&#x0D;&lt;br&gt;2. Greater than 1000 ml after caesarian section, or&#x0D;&lt;br&gt;3. Blood loss enough to compromise the haemodynamic status of the woman&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Other inclusion criteria:&#x0D;&lt;br&gt;4. All women who are clinician-diagnosed with postpartum haemorrhage following vaginal delivery or caesarean section&#x0D;&lt;br&gt;5. Consent has been obtained in line with local procedures 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Women for whom the responsible clinician considers there is a clear indication for TXA should not be randomised.&#x0D;&lt;br&gt;2. Women for whom the responsible clinician considers there is a clear contraindication for TXA should not be randomised.&#x0D;&lt;br&gt;There are no other pre-specified exclusion criteria. Where the responsible clinician is substantially uncertain as to whether or not to use an antifibrinolytic agent in a particular woman with postpartum haemorrhage, the woman should be randomised.&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Circulatory System &lt;br&gt;Pregnancy and Childbirth &lt;br&gt;Postpartum haemorrhage;Circulatory System;Pregnancy and Childbirth;Postpartum haemorrhage
    </Condition>
    <Intervention>;Sodium chloride 0.9%;Tranexamic acid 
    </Intervention>
    <Primary_outcome>1. Composite of Death, and Peripartum hysterectomy 
    </Primary_outcome>
    <Secondary_outcome>	 1. Surgical interventions used to treat obstetric haemorrhage: 1.1. Hysterectomy 1.2. Any brace suture 1.3. Arterial ligation 1.4. Artery selective embolisation ;2. Transfusion requirements (blood/components) ;3. Thromboembolic events: 3.1. Deep venous thrombosis 3.2. Pulmonary thromboembolism 3.3. Stroke 3.4. Myocardial infarction ;4. Length of stay in hospital ;5. If an Intensive Care Unit is available, time spent in the ICU ;6. Suspected Unexpected Serious Adverse Reactions (SUSAR) ;7. Death;8. Health Related Quality of life (HRQoL) ;9. Receipt of mechanical ventilation;10. Status of baby/ies up to 6 weeks of delivery;11. Cost-effectiveness analysis
    </Secondary_outcome>
    <Secondary_ID>2008-008441-38;NCT00872469 ;ISRCTN76912190;ISRCTN76912190;2008-008441-38;NCT00872469 
    </Secondary_ID>
    <Source_Support>London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine;Department of Health and Wellcome Trust (UK);Bill and Melinda Gates Foundation 
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>28/07/2009
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>London School of Hygiene and Tropical Medicine Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>11627169
    </Internal_Number>
    <TrialID>CTRI/2009/091/000101
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>A Phase III, double-blind, randomised, multicenter trial comparing the safety and efficacy of fixed dose combination tablets of arterolane maleate and piperaquine phosphate (PQP) with CoartemÂ® (artemether-lumefantrine tablets) in patients with acute uncomplicated Plasmodium falciparum malaria
    </Public_title>
    <Scientific_title>A Phase III, double-blind, randomised, multicenter trial comparing the safety and efficacy of fixed dose combination tablets of arterolane maleate and piperaquine phosphate (PQP) with CoartemÂ® (artemether-lumefantrine tablets) in patients with acute uncomplicated Plasmodium falciparum malaria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Ranbaxy Laboratories Ltd
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20091216
    </Date_registration3>
    <Date_registration>16-12-2009
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=367
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>20-11-2009
    </Date_enrollement>
    <Target_size>1200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Parallel Group, Active Controlled Trial&lt;br&gt;  Method of generating randomization sequence:Permuted block randomization, fixed  Method of allocation concealment:Centralized  Blinding and masking:Double Blind Double Dummy
    </Study_design>
    <Phase>Phase 3/ Phase 4
    </Phase>
    <Countries>India;Thailand;Cote d'Ivoire;Democratic Republic of the Congo;Mali;Mozambique;Senegal
    </Countries>
    <Contact_Firstname>Dr Nilanjan Saha
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Department of Medical Affairs and Clinical Research, Ranbaxy Laboratories Ltd R&amp;D IV 77B Sector 18 
    </Contact_Address>
    <Contact_Email>nilanjan.saha@ranbaxy.com
    </Contact_Email>
    <Contact_Tel>91-124-4194340
    </Contact_Tel>
    <Contact_Affiliation>Ranbaxy Laboratories Limited
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients must fulfill the following inclusion criteria to be eligible for enrollment into the study:&lt;br&gt;1. M/F patients b/w age of 12 to 65 (Both incusive)&lt;br&gt;2. B/w  more than or equal to  35 kg at screening&lt;br&gt;3. presence of acute symptomatic uncomplicated malaria with confirmed diagnosis by blood smear with asexual forms of P. falciparum parasites only.&lt;br&gt;4. asexual parasites/&amp;micro;L in blood  in patients b/w 1,000 and 100,000 (both inclusive)&lt;br&gt;5. presence of fever (axillary temperature &amp;amp;#8805; 37.5 &amp;deg;C or oral &amp;amp;#8805; 38 &amp;deg;C) or a documented history of fever in the past 24 hours&lt;br&gt;6. Female patients, if of child-bearing potential must be non-lactating and willing to use contraceptive methods during the study period &lt;br&gt;7. Written informed consent, provided by patient in accordance with local practice. If a patient is unable to provide informed consent in writing, a thumbprint to indicate consent in the presence of at least one witness is acceptable. For adolescents written informed consent, in accordance with local practice, provided by parent/guardian.  If the parent/guardian is unable to write, thumb print witnessed consent is permitted. For patients &amp;lt; 18 yrs, wherever feasible, assent will also be obtained &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: If any of the following conditions apply, the patient should not be enrolled in the study. &lt;br/ &gt;&lt;br&gt; &lt;br/ &gt;&lt;br&gt;1.	Patients with severe malaria as per WHO criteria1 (Appendix B). &lt;br/ &gt;&lt;br&gt;2.	Mixed infection with another Plasmodium species at the time of presentation (including P. vivax, P. ovale and P. malariae). &lt;br/ &gt;&lt;br&gt;3.	Hemoglobin (Hb) level of  8 gm/dL. &lt;br/ &gt;&lt;br&gt;4.	A female patient who is lactating or pregnant at screening. &lt;br/ &gt;&lt;br&gt;5.	Known allergy to artesunate, artemether, artemisinin derived products, lumefanterine, piperaquine or any other related drug. &lt;br/ &gt;&lt;br&gt;6.	Gastrointestinal dysfunction that could alter absorption or motility (e.g., diarrhea defined as  3 episodes of watery stools in the previous 24 hours or patients who have had 3 episodes of vomiting within 24 hours prior to screening). &lt;br/ &gt;&lt;br&gt;7.	Use of concomitant medications that may induce haemolysis or haemolytic anaemia from the World Health Organization (WHO) list of essential drugs.  &lt;br/ &gt;&lt;br&gt;8.	Any antimalarial treatment during 1 month prior to screening, as assessed by medical history. &lt;br/ &gt;&lt;br&gt;9.	Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole for the prevention of Pneumocystis carini pneumonia in children born to HIV+ women.  &lt;br/ &gt;&lt;br&gt;10.	Participation in any investigational drug study during the 30 days prior to screening. &lt;br/ &gt;&lt;br&gt;11.	Any other underlying disease that may compromise the diagnosis and the evaluation of the response to the study medication (including clinical symptoms of immunosuppression, tuberculosis, bacterial infection; cardiac or pulmonary disease). &lt;br/ &gt;&lt;br&gt;12.	Electrocardiogram (ECG) abnormalities with clinical significance or relevance that require urgent management. These abnormalities include QTc interval  450 msec at screening and cardiac conduction disorders, with the exception of right bundle branch block. &lt;br/ &gt;&lt;br&gt;13.	Patients with known significant renal or hepatic impairment indicated by the following laboratory evaluations at screening: &lt;br/ &gt;&lt;br&gt;Serum creatinine  1.5 Ã? upper limit of normal (ULN) &lt;br/ &gt;&lt;br&gt;Aspartate transaminase  2.5 Ã? ULN &lt;br/ &gt;&lt;br&gt;Alanine transaminase  2.5 Ã? ULN &lt;br/ &gt;&lt;br&gt;Serum bilirubin  3 mg/dL  &lt;br/ &gt;&lt;br&gt;14.	Patients who have had a splenectomy as confirmed by history or clinical examination. &lt;br/ &gt;&lt;br&gt;15.	Patients with known history of human immunodeficiency virus (HIV) infection or other immunosuppressive disorders. &lt;br/ &gt;&lt;br&gt;16.	Evidence of clinically significant cardiovascular, pulmonary, metabolic, gastrointestinal, neurological, or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied) that may compromise the diagnosis and the evaluation of the response to the study medication. &lt;br/ &gt;&lt;br&gt;17.	Patients who have epilepsy or a history of convulsions.     &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- Acute Uncomplicated Plasmodium falciparum malaria

    </Condition>
    <Intervention>Intervention1: Fixed dose combination (FDC) tablets of arterolane maleate 150 mg and PQP 750 mg of Ranbaxy Laboratories Limited, India for oral administration: once daily for three days&lt;br&gt;Control Intervention1: CoartemÂ® tablets (each tablet containing artemether 20 mg and lumefantrine 120 mg in FDC) of Novartis for oral administration: Six dose treatment as a single dose of four tablets at the time of initial diagnosis followed by four tablets after eight hours then four tablets twice daily (morning and evening) on each of the following days&lt;br&gt;
    </Intervention>
    <Primary_outcome>Proportion of patients with PCR corrected ACPRTimepoint: On Day 28
    </Primary_outcome>
    <Secondary_outcome>Fever Clearance Time (FCT)Timepoint: time from first dosing to first normal reading of temperature (37.5 C) for 2 consecutive normal temperature readings and a confirmed normal temperature 24 hours after the first normal body temperature reading;Number of gametocytesTimepoint: Days 0,1,2,3,7,14,21,28,35 and 42;Parasite Clearance Time (PCT)Timepoint: Time in hours from initiation of therapy until first of the two consecutive negative smears are obtained;Pk parameters: Cmax, Tmax, AUC, CL/F, Vd/F, t1/2  and additional PK model dependant parameterTimepoint: Days 0,1,2,7,14,21,28,35 and 42;Proportion of aparasitemic patientsTimepoint: Days 1, 2 and 3;Proportion of patients with PCR corrected ACPRTimepoint: Day 42;Proportion of patients with PCR-uncorrected ACPRTimepoint: Day 28;Proportion of patients with PCR-uncorrected ACPRTimepoint: Day 42;safety endpoints: Incidence of adverse events, lab parameters, physical examination, ECG or vitalsTimepoint: Days 0,1,2,3,7,14,21,28,35 and 42
    </Secondary_outcome>
    <Secondary_ID>R11160083002
    </Secondary_ID>
    <Source_Support>Ranbaxy Laboratories Ltd. INDIA
    </Source_Support>
    <Secondary_Sponsor>Department of Science and Tecnology Govt Of India
    </Secondary_Sponsor>
    <Ethics_review_status>Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>06/07/2011;28/02/2011;03/03/2011;06/04/2011;19/12/2011;21/08/2010;03/08/2009;05/11/2009;22/08/2009;25/08/2009;03/09/2009;03/07/2009;03/08/2012
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;;;;;;;;;;;;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comite National Dâ??Ethique pour la Recherche en Sante, Senegal;Comite National dEthique et de Recherche (CNER) de CÃ´te dIvoire;Convite nacional De Bioetica Para A Saude, Mozambique;DEthique De La FMPOS, Mali;Ecole De sante publique Convite D Ethique DR Congo;Ethical Review Committee, Chittagong Medical College, Bangladesh;Ethics Committee of Faculty of Tropical medicine Mahidol University, Thailand;Institutional Ethics Committee for Tata Main Hospital, Jamshedpur;Institutional Ethics Committee, CWS Hospital, Jagda, Rourkela-769042;Institutional Ethics Committee, Ispat General Hospital, Orrisa;Institutional Ethics Committee, Kasturba Medical College, Mangalore-575001;Institutional Ethics Committee, National Institute Of Malaria Research (ICMR) For Mahadevi Birla Hospital &amp; Research Center, Ranchi	;Pharmacy, Medicines and Poisons Board, Malawi
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;;;;;;;;;;;;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;;;;;;;;;;;;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12626525
    </Internal_Number>
    <TrialID>PER-074-09
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>&#x0D;
					Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis STRIDE&#x0D;
				
    </Public_title>
    <Scientific_title>&#x0D;
					A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3&#x0D;
				                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS,
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20091012
    </Date_registration3>
    <Date_registration>12/10/2009
    </Date_registration>
    <Source_Register>REPEC
    </Source_Register>
    <web_address>https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=074-09
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>55
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/1900
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>The A5221 / STRIDE is a randomized, open-label study to determine whether the strategy of immediate versus delayed initiation of antiretroviral therapy (ART) reduces mortality and AIDS-defining diseases in participants who are treated for tuberculosis (TB).
    </Study_design>
    <Phase>IV
    </Phase>
    <Countries>India;Congo;Thailand;Kenya;Malawi;Botswana;South Africa;Uganda;Brazil;Haiti;Peru;United States
    </Countries>
    <Contact_Firstname>Pablo E.
    </Contact_Firstname>
    <Contact_Lastname>Campos
    </Contact_Lastname>
    <Contact_Address>Av. Almirante Miguel Grau Nº 1010
    </Contact_Address>
    <Contact_Email>pecampos@inmensa.org
    </Contact_Email>
    <Contact_Tel>511 4413993
    </Contact_Tel>
    <Contact_Affiliation>ASOCIACION CIVIL IMPACTA, SALUD Y EDUCACION     
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &#x0D;&lt;br&gt;					• HIV-infected.&#x0D;&lt;br&gt;					• Confirmed or probable TB (more information on the criterion can be found in the protocol).&#x0D;&lt;br&gt;					• Chest x-ray within 30 days prior to study entry.&#x0D;&lt;br&gt;					• Receipt of 1-14 cumulative days of rifampin- or other rifamycin-based TB treatment that was initiated within 28 days prior to study entry.&#x0D;&lt;br&gt;					• CD4 count less than 250 cells/mm^3 within 30 days prior to study entry.&#x0D;&lt;br&gt;					• Willing to use acceptable methods of contraception while on study drugs and for 6 weeks after stopping these drugs.&#x0D;&lt;br&gt;					• Able to swallow oral medications.&#x0D;&lt;br&gt;					• Parent of guardian willing to provide informed consent, if applicable.&#x0D;&lt;br&gt;					• Karnofsky performance score =&gt;20 at time of study entry.&#x0D;&lt;br&gt;				
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &#x0D;&lt;br&gt;					• ART for longer than 7 cumulative days prior to study entry or treatment for any period of time with one or more antiretrovirals. Participants who have taken ART during pregnancy or for occupational exposure are not excluded.&#x0D;&lt;br&gt;					• Allergy or sensitivity to any of the study drugs or their formulations.&#x0D;&lt;br&gt;					• History of multidrug-resistant TB.&#x0D;&lt;br&gt;					• Receipt of any investigational therapy or chemotherapy within 30 days prior to study entry.&#x0D;&lt;br&gt;					• Certain medications.&#x0D;&lt;br&gt;					• Breastfeeding.&#x0D;&lt;br&gt;				
    </Exclusion_Criteria>
    <Condition>&#x0D;
					-B24  Unspecified human immunodeficiency virus [HIV] disease&#x0D;
				 &lt;br&gt;Unspecified human immunodeficiency virus [HIV] disease;B24 ;Unspecified human immunodeficiency virus [HIV] disease
    </Condition>
    <Intervention>&lt;br&gt;					Group name:Group 1 Type of group;1 N° of participants:400 Intervention(s) description:The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.&lt;br&gt;&lt;br&gt;					Group name:Group 2 Type of group;1 N° of participants:400 Intervention(s) description:The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.&lt;br&gt;&lt;br&gt;				
    </Intervention>
    <Primary_outcome>&lt;br&gt;					Outcome name:As this was a study of the strategy of providing antiretroviral therapy (ART) during the initial treatment of TB versus deferring ART until TB was treated for 8-12 weeks, all eligible participants randomized were followed for 48 weeks, whether they started ART as scheduled, whether they started ART at all, or even if the participant did not have TB and discontinued TB treatment. The percent surviving without a new AIDS-defining illness was calculated using a Kaplan-Meier estimator with an associated standard error.&lt;br&gt;&lt;br&gt;					Measure:Percent of Participants Who Survived Without AIDS Progression.&lt;br&gt;					Timepoints:Through week 48&lt;br&gt;				
    </Primary_outcome>
    <Secondary_outcome>&#x0D;&lt;br&gt;					Outcome name:All eligible participants were included in this analysis. The percent of participants whose highest reported grade of adverse events and laboratory abnormalities was Grade 3 or 4 was calculated with an associated standard error, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening/disabling, and Grade 5=death.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;					Measure:Percent of Participants Reporting a Grade 3 or 4 Adverse Event or Laboratory Abnormality&#x0D;&lt;br&gt;					Timepoints:Through week 48&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:All eligible participants were included in this analysis. Weeks from randomization to first new AIDS-defining illness or death was analyzed using a stratified Cox proportional hazards regression model. The stratification was by screening CD4 cell count: &lt;50 cells/mm3 versus =&gt;50 cells/mm3.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;					Measure:Time to First New AIDS-defining Illness or Death.&#x0D;&lt;br&gt;					Timepoints:Through week 48&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:This analysis was based on 374 participants with culture-confirmed TB at entry. The percent with culture-confirmed TB surviving without a new AIDS-defining illness was calculated using a Kaplan-Meier estimator with an associated standard error.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;					Measure:Percent of Participants With Culture-confirmed Tuberculosis (TB) Who Survived Without AIDS Progression&#x0D;&lt;br&gt;					Timepoints:Through week 48&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:All eligible participants were included in this analysis. The percent of participants who interrupted at least one TB medication for more than one day due to toxicity or discontinued at least one TB medication due to toxicity was calculated with an associated standard error.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;					Measure:Percent of Participants Who Interrupted or Discontinued at Least One Tuberculosis (TB) Medication Due to Toxicity&#x0D;&lt;br&gt;					Timepoints:Through week 48&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:TB treatment outcome was assessed in the 800 eligible participants who had confirmed or probable TB at study entry. The sites determined if the TB was resolved. If TB was not resolved, TB treatment outcome status was determined based on whether TB treatment was ongoing at the last study visit; if the participant died while TB treatment was ongoing; or if the participant was lost to follow-up, withdrew consent, or other reason for lacking TB resolution status. Percents were calculated with associated standard errors.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;					Measure:Percent of Participants With Confirmed or Probable Tuberculosis (TB) Whose TB Resolved, or Who Required TB Treatment Through the End of Follow-up, or Died, or Were Lost to Follow-up.&#x0D;&lt;br&gt;					Timepoints:Through week 48&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:All eligible participants were included in the analysis. Participants who were lost-to-follow-up (LFU) prior to week 48 or who were alive with a CD4 cell count increase of less than 100 cells/mm^3 were grouped separately those who died or whose CD4 cell count increased by at least 100 cells/mm^3. Participants missing CD4 cell counts at week 48 were coded as LFU in this analysis. The percents were calculated with associated standard errors.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;					Measure:Percent of Participants Whose CD4 Increased by at Least 100 Cells/mm^3 Between Baseline and Week 48.&#x0D;&lt;br&gt;					Timepoints:Through week 48&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:All eligible participants were included in this analysis. The percent of participants with Mycobacteria tuberculosis (MTB)-associated immune reconstitution inflammatory syndrome (IRIS) was calculated with an associated standard error.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;					Measure:Percent of Participants With MTB IRIS.&#x0D;&lt;br&gt;					Timepoints:Through week 48&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:All eligible participants were included in this analysis. The percent of participants with HIV-associated immune reconstitution inflammatory syndrome (IRIS) was calculated with an associated standard error.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;					Measure:Percent of Participants With HIV IRIS.&#x0D;&lt;br&gt;					Timepoints:Through week 48&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:All eligible participants were included in the analysis. Participants who were lost-to-follow-up (LFU) prior to week 48 or who were alive with a HIV viral load at least 400 copies/mL were grouped separately those those who died or who had HIV viral loads below 400 copies/mL. Participants missing HIV viral loads at week 48 were coded as LFU in this analysis. Percents were calculated with associated standard errors.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;					Measure:Percent of Participants Whose HIV Viral Load Was Less Than 400 Copies/mL at Week 48&#x0D;&lt;br&gt;					Timepoints:Through week 48&#x0D;&lt;br&gt;				
    </Secondary_outcome>
    <Secondary_ID>NCT00108862
    </Secondary_ID>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>09/10/2008
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>andresparedesleon@yahoo.com  
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Asociacion Civil Impacta Salud y Educacion
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>2423072 anexo 130
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>andresparedesleon@yahoo.com  
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4658754
    </Internal_Number>
    <TrialID>NCT00906880
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase
    </Public_title>
    <Scientific_title>Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage
    </Scientific_title>
    <Acronym>NECT-FIELD
    </Acronym>
    <Primary_sponsor>Drugs for Neglected Diseases
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20090519
    </Date_registration3>
    <Date_registration>19/05/2009
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00906880
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>April 2009
    </Date_enrollement>
    <Target_size>630
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Johannes Blum, MD;Victor Kande, MD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Swiss Tropical &amp; Public Health Institute;PNLTHA-DRC;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        All patients diagnosed as stage 2 HAT according to the diagnostic protocols in use at the&#x0D;&lt;br&gt;        treatment center (generally, if presence of parasites in blood, lymph node fluid or CSF&#x0D;&lt;br&gt;        and an elevated white blood cell count in the CSF, but this can vary from center to&#x0D;&lt;br&gt;        center) will be included if a written Informed Consent is given by the patient or a&#x0D;&lt;br&gt;        legally acceptable representative if the patient is a minor or unable to communicate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy and breastfeeding women: On a case by case basis according to the&#x0D;&lt;br&gt;             guidelines of the National HAT Control Programme or the NGO, the Investigator will&#x0D;&lt;br&gt;             decide to treat the patient or to defer the treatment. In case of inclusion, the&#x0D;&lt;br&gt;             mother-child pairs or the children of lactating mothers will be closely monitored&#x0D;&lt;br&gt;             during treatment and follow up.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children under 2 years of age: On a case by case basis, the Investigator will decide&#x0D;&lt;br&gt;             to treat an infant with NECT or an alternative treatment (preferably eflornithine).&#x0D;&lt;br&gt;             In case of inclusion, these infants will be closely monitored during treatment and&#x0D;&lt;br&gt;             follow up like all children less than 12 years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to take oral medication, and impossibility to use a nasogastric tube.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment failure after nifurtimox-eflornithine treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other condition or reason for which the Investigator (or the responsible treating&#x0D;&lt;br&gt;             staff member) judges that another or no HAT treatment is warranted.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Human African Trypanosomiasis
    </Condition>
    <Intervention>Drug: Nifurtimox-Eflronithine Combination Treatment (NECT)
    </Intervention>
    <Primary_outcome>Proportion of patients discharged alive from the hospital or the treatment center
    </Primary_outcome>
    <Secondary_outcome>Incidence of serious AE (SAE) and severe AE (CTC score 3 and 4) related to treatment, and overall frequency and nature of AE and need for additional medications to manage these.;Effectiveness: The clinical cure rate (Survival without clinical and/or parasitological signs of HAT);Number of temporary treatment interruptions, number of premature treatment cessations, length of hospitalization stay (including observation period), treatment compliance (deviation in dosing), and other feasibility indicators.
    </Secondary_outcome>
    <Secondary_ID>HAT0208
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ministry of Public Health, Democratic Republic of the Congo;Swiss Tropical &amp; Public Health Institute
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>8754970
    </Internal_Number>
    <TrialID>ACTRN12609000198224
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>A cluster randomized controlled trial to evaluate the effectiveness of  the clinically integrated Reproductive Health Library (RHL) evidence -based medicine course
    </Public_title>
    <Scientific_title>Clinically integrated teaching versus  dissemination of worksop-based materials to improve knowledge, skills and competencies for evidence-based medicine in junior obstetrics and gynaecology trainees.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>World Health Organization; Department of Reproductive Health and Research
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20090421
    </Date_registration3>
    <Date_registration>21/04/2009
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12609000198224.aspx
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>01/03/2009
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Educational / counselling / training; Allocation: Randomised controlled trial;
    </Study_design>
    <Phase/>
    <Countries>Argentina;Brazil;Congo, The Democratic Republic Of The;India;Philippines;South Africa;Thailand
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: Participants are training institutions in obstetrics and gynaecology in the participating countries. Hospitals belonging to the same training institution will form the cluster.  Trainees are junior doctors in obstetrics and gynaecology training with no previous formal evidence-based medicine training.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: units with:&#x0D;&lt;br&gt;&lt;4 junior residents in training&#x0D;&lt;br&gt;no suitable facilitator/trainees agreeing to participate&#x0D;&lt;br&gt;computer/internet facilities inadequate &#x0D;&lt;br&gt;declining to participate
    </Exclusion_Criteria>
    <Condition>Educating junior obstetrics and gynaecology trainees to improve knowledge, skills and competencies for evidence-based medicine; &lt;br&gt;Educating junior obstetrics and gynaecology trainees to improve knowledge, skills and competencies for evidence-based medicine;Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)
    </Condition>
    <Intervention>The intervention consists of a curriculum with 5 modules, tought and learned over a period of 8 weeks.  Assessments are pre and one month post intervention. The modules are: 1) asking clinical questions, 2) searching the evidence, 3) critical appraisal of systematic reviews, 4)applicability of the evidence to the patient, 5) implementation of the evidence into practice.  Each module consists of an e-learning component (these are one to three 15-25 minutes online sessions for the trainee to complete in her/his own time), applying the theoretical knowledge during clinical wardrounds and formative and summative assessments. &lt;br&gt;A clinical facilitator guides trainees  to  &lt;br&gt;identifying learning opportunities in a clinical setting, directs appropriate use of learning resources (e-learning) and providies feedback on learning exercises/assignments. &lt;br&gt;Trainees will pursue independent study using the study guide and e-learning modules.
    </Intervention>
    <Primary_outcome>Gain in evidence-based medicine knowledge: measured by using multiple choice questions[pre -and post ( one month after completion of either intervention or control course)];change in attitude towards evidence-based medicine: measured by using multiple choice questions[pre -and post ( one month after completion of either intervention or control course)];skills competence in applying evidence-based medicine principles: measured by using adapted objective structured clinical questions (OSCE)[one month after completion of either intervention or control course]
    </Primary_outcome>
    <Secondary_outcome>educational environment towards evidence-based medicine (EBMEEM): measured by using multiple choice questions[pre -and post ( one month after completion of either intervention or control course)]
    </Secondary_outcome>
    <Source_Support>World Health Organization - Department of Reproductive Health and Research
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Research Ethics Review Committee (WHO ERC)
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4709105
    </Internal_Number>
    <TrialID>NCT01567423
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
    </Public_title>
    <Scientific_title>Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Pweto, Democratic Republic of Congo, 2008
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Epicentre
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20090127
    </Date_registration3>
    <Date_registration>27/01/2009
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01567423
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>April 2008
    </Date_enrollement>
    <Target_size>301
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Emmanuelle Espié, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Epicentre
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 6 and 59 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Weight = 5 Kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  P. falciparum infections (density threshold at inclusion between 2,000 and&#x0D;&lt;br&gt;             200,000/µl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Fever (= 37.5°C) or history of fever in the previous 24 hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe or complicated malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  reported hypersensitivities of the studied drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  serious concomitant febrile illness&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria, Falciparum
    </Condition>
    <Intervention>Drug: ASAQ Winthrop® Sanofi Aventis;Drug: Coartem®, Novartis
    </Intervention>
    <Primary_outcome>PCR-adjusted clinical and parasitological cure rate up to day 42 of the follow-up period determined in the per-protocol population
    </Primary_outcome>
    <Secondary_outcome>PCR-unadjusted clinical and parasitological cure rate up to day 42 of the follow-up period determined in the per-protocol population;PCR-adjusted clinical and parasitological cure rate up to day 42 of the follow-up period determined by a survival analysis;PCR-unadjusted clinical and parasitological cure rate up to day 42 of the follow-up period determined by a survival analysis;PCR-adjusted clinical and parasitological cure rate up to day 28 of the follow-up period determined in the per protocol population;PCR-unadjusted clinical and parasitological cure rate up to day 28 of the follow-up period determined in the per protocol population
    </Secondary_outcome>
    <Secondary_ID>ESP/CE/012/2008;CPP 08013;Epicentre-MSF-OCBA
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medecins Sans Frontieres, Spain
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4652188
    </Internal_Number>
    <TrialID>NCT00819858
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Effect of Ready to Use Therapeutic Food (RUTF) Supplement After an Episode of Malaria Falciparum on Weight
    </Public_title>
    <Scientific_title>The Effectiveness of Ready to Use Therapeutic Food (RUTF) in Catch up Growth in Children After an Episode of P. Falciparum Malaria
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medecins Sans Frontieres
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20090108
    </Date_registration3>
    <Date_registration>08/01/2009
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00819858
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>January 2009
    </Date_enrollement>
    <Target_size>180
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Saskia van der Kam, Ir
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>nutrition expert MSF
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 6 to 59 months, and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Positive rapid diagnostic test (Paracheck®) and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Thick smear showing infection with P. falciparum and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent from parents or guardian aged at least 18 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children who are exclusively breast fed or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children who are severely malnourished (MUAC &lt;110 mm and/or bilateral oedema, or WHO&#x0D;&lt;br&gt;             weight-for-Height criteria &lt;3 Z-scores) or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of general danger signs or signs of severe malaria as defined by the WHO&#x0D;&lt;br&gt;             criteria, or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known history of allergy to malaria drugs, or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having a sibling enrolled in the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Weight Loss;Weight Gain;Convalescence;Malaria
    </Condition>
    <Intervention>Dietary Supplement: RUTF (Plumpynut®)
    </Intervention>
    <Primary_outcome>weight gain
    </Primary_outcome>
    <Secondary_outcome>weight gain
    </Secondary_outcome>
    <Secondary_ID>MSF-nutcon01
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4650980
    </Internal_Number>
    <TrialID>NCT00803933
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
    </Public_title>
    <Scientific_title>Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Immtech Pharmaceuticals, Inc
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20081204
    </Date_registration3>
    <Date_registration>04/12/2008
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00803933
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>February 2003
    </Date_enrollement>
    <Target_size>111
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Victor Kande, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Programme Nationale de Lutte contre la Trypanosomiase Humaine Africaine
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient has early stage T. b. gambiense infection i.e. parasitologically&#x0D;&lt;br&gt;             confirmed infection in the blood or lymph node aspirate and greater than or equal to&#x0D;&lt;br&gt;             5 WBC mm-3 detected in the CSF by microscopic examination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient is 15 to 50 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has a minimal weight of 35 kilograms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. If the patient is female of child bearing potential (a women will be considered of&#x0D;&lt;br&gt;             non-child bearing potential only if she has been post menopausal for over 2 years or&#x0D;&lt;br&gt;             has had a hysterectomy):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. she is not lactating,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. she had a negative urine pregnancy test result within 24 hours prior to DB289&#x0D;&lt;br&gt;                  treatment and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. she agrees to use a medically proven method of contraception (abstinence from&#x0D;&lt;br&gt;                  sexual intercourse is an acceptable method) from the day of consent on until the&#x0D;&lt;br&gt;                  end of the observation period (day 7).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient has understood and signed the Informed Consent. If the patient is minor, a&#x0D;&lt;br&gt;             legal guardian has signed the Informed Consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient has late stage T.b. gambiense infection i.e. presence of parasite in the&#x0D;&lt;br&gt;             CSF upon microscopic examination or a WBC count of      &gt; 5mm-1&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Active clinically relevant medical conditions that in the Investigator opinion may&#x0D;&lt;br&gt;             jeopardize subject safety or interfere with participation in the study, including but&#x0D;&lt;br&gt;             not limited to: significant liver diseases, chronic pulmonary diseases, significant&#x0D;&lt;br&gt;             cardiovascular diseases, diabetes, thyroid diseases, gout, infection including known&#x0D;&lt;br&gt;             HIV infection, CNS trauma or seizure disorders (A list of typical signs and symptoms&#x0D;&lt;br&gt;             is provided for guidance of the investigator in attachment 1)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Coma Score of less than 9 on the Glasgow Coma Scale (Appendix 8)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Withdrawal of consent at any time during the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Any condition which compromises ability to communicate with the investigator as&#x0D;&lt;br&gt;             required for the completion of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. The subject has been previously treated for African Trypanosomiasis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. The subject has been previously enrolled in the study. -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>African Trypanosomiasis
    </Condition>
    <Intervention>Drug: DB289;Drug: Pentamidine
    </Intervention>
    <Primary_outcome>The primary efficacy endpoint was the parasitological cure at 3 months after completion of treatment.;The primary outcome measure for safety analysis was the rate of occurrence of Grade 3 or higher adverse events during the observation period.
    </Primary_outcome>
    <Secondary_outcome>The secondary outcome measure was the incidence rate of adverse events (all Grades combined) during the 7- to 9-day observation period in Treatment Sequence 1 and during the 12-day observation period in Treatment Sequence 2.;The number and percentage of subjects with parasitological cure, subjects with confirmed (parasitological) treatment failure, and subjects with suspected treatment failure at 6, 12, and 24 months after completion of treatment.
    </Secondary_outcome>
    <Secondary_ID>289-C-006
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Bill and Melinda Gates Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4650877
    </Internal_Number>
    <TrialID>NCT00802594
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
    </Public_title>
    <Scientific_title>Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Immtech Pharmaceuticals, Inc
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20081203
    </Date_registration3>
    <Date_registration>03/12/2008
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00802594
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>August 2001
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Angola;Congo;Angola;Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Christian Burri, MSc, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Swiss Tropical &amp; Public Health Institute
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient has early stage T. b. gambiense infection i.e. parasitologically&#x0D;&lt;br&gt;             confirmed infection in the blood or lymph and less than or equal to 5 WBC mm-3&#x0D;&lt;br&gt;             detected in the CSF by microscopic examination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patient is 16 years old or more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patient has a minimal weight of 45 kilograms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. If patient is female of child bearing potential (a women will be considered of&#x0D;&lt;br&gt;             non-child bearing potential only if she has been post menopausal for over 2 years or&#x0D;&lt;br&gt;             has had a hysterectomy), she is not lactating, she had a negative urine pregnancy&#x0D;&lt;br&gt;             test result within 24 hours prior to DB289 treatment and she agrees to use a&#x0D;&lt;br&gt;             medically proven method of contraception (abstinence from sexual intercourse&#x0D;&lt;br&gt;             acceptable) from the day of consent on until 7 Days after DB289 treatment completion&#x0D;&lt;br&gt;             (Study Day 12).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patient has signed the Informed Consent.  If the patient is minor, a legal guardian&#x0D;&lt;br&gt;             has signed the Informed Consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. The patient has late stage T.b. gambiense infection i.e. presence of parasite in the&#x0D;&lt;br&gt;             CSF upon microscopic examination, or a positive (titer greater than 1/4) latex / IgM&#x0D;&lt;br&gt;             test, or a positive latex / T.b.g.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Active clinically relevant medical conditions that in the Investigator opinion may&#x0D;&lt;br&gt;             jeopardize subject safety or interfere with participation in the study, including but&#x0D;&lt;br&gt;             not limited to: significant liver diseases, chronic pulmonary diseases, significant&#x0D;&lt;br&gt;             cardiovascular diseases or significant ECG anomaly such as elongated QTc (corrected)&#x0D;&lt;br&gt;             interval above 430 msec for men or above 450 msec for women, diabetes, thyroid&#x0D;&lt;br&gt;             diseases, gout, infection including known HIV infection, CNS trauma or seizure&#x0D;&lt;br&gt;             disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Clinically significant abnormal laboratory value at screening including:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Prothrombin Time &gt; 1.25 times upper limit of normal (ULN)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Liver enzyme AST and ALT &gt; 2 times ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Total bilirubin &gt; 1.5 times ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Serum Creatinine &gt; 1.5 times ULN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Traumatic lumbar puncture (i.e. red blood cells visible in CSF)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Coma Score of less than 9 on the Glasgow Coma Scale (Appendix 8)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Withdrawal of consent at any time during the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Any condition which compromises ability to communicate with the investigator as&#x0D;&lt;br&gt;             required for the completion of this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. The subject has been previously treated for African Trypanosomiasis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. The subject has been previously enrolled in the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Trypanosomiasis, African
    </Condition>
    <Intervention>Drug: DB289
    </Intervention>
    <Primary_outcome>The primary efficacy endpoint is the parasitological cure 24 hours after completion of treatment.;The primary outcome measure for safety analysis will be the rate of occurrence of Grade 3 or higher adverse events during the observation period.
    </Primary_outcome>
    <Secondary_outcome>A secondary endpoint is the parasitological cure 3, 6, 12, 24 months after completion of treatment.;The secondary outcome measure will be the incidence rate of adverse events (all Grades combined) during the observation period (as compared to literature values for pentamidine).
    </Secondary_outcome>
    <Secondary_ID>289-C-003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Bill and Melinda Gates Foundation
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10206417
    </Internal_Number>
    <TrialID>NCT00790998
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
    </Public_title>
    <Scientific_title>A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medicines Development for Global Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20081113
    </Date_registration3>
    <Date_registration>13/11/2008
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00790998
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 2009
    </Date_enrollement>
    <Target_size>1497
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Ghana;Liberia;Congo, The Democratic Republic of the;Ghana;Liberia;Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Special Programme for Research and Training in Tropical Diseases (TDR)
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>World Health Organization
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male and female subjects with Onchocerca volvulus infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breast feeding women; coincidental loiasis&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Onchocerciasis
    </Condition>
    <Intervention>Drug: Moxidectin;Drug: Ivermectin
    </Intervention>
    <Primary_outcome>skin microfilaria density (mf/mg)
    </Primary_outcome>
    <Secondary_outcome>skin microfilaria density (mf/mg);skin microfilaria density (mf/mg);skin microfilaria density (mf/mg);skin microfilaria reduction from baseline;skin microfilaria reduction from baseline;skin microfilaria reduction from baseline;skin microfilaria reduction from baseline;proportion of subjects with undetectable levels of skin microfilaria;proportion of subjects with undetectable levels of skin microfilaria;proportion of subjects with undetectable levels of skin microfilaria;proportion of subjects with undetectable levels of skin microfilaria;percent reduction in microfilaria levels in the anterior chamber of the eye
    </Secondary_outcome>
    <Secondary_ID>B1751006 - ONCBL60801;3110A1-3000
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>World Health Organization
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4531179
    </Internal_Number>
    <TrialID>ISRCTN03844341
    </TrialID>
    <Last_Refreshed_on>13 January 2015
    </Last_Refreshed_on>
    <Public_title>A randomised controlled trial to assess the LifeStraw® Family household gravity filter
    </Public_title>
    <Scientific_title>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               &#x20;
    </Scientific_title>
    <Primary_sponsor>Vestergaard Frandsen (Switzerland)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20080612
    </Date_registration3>
    <Date_registration>12/06/2008
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN03844341
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/06/2008
    </Date_enrollement>
    <Target_size>1200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Two-armed randomised placebo-controlled trial  (Prevention)
    </Study_design>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Households including members of all ages living in the study communities.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Households and individuals who treat their water in a way that is deemed effective to prevent diarrhoea (e.g. boiling, filtration with a state of the art filter, regular use of bleach). 
    </Exclusion_Criteria>
    <Condition>Diarrhoea &lt;br&gt;Infections and Infestations &lt;br&gt;Diarrhoea and gastroenteritis of presumed infectious origin 
    </Condition>
    <Intervention>A two-arm randomised placebo-controlled trial will be conducted over a 12-month period. The trial will include two groups of households: half of the participating households will receive the LifeStraw® filter and the other half will receive a filter which looks like the LifeStraw® filter but which does not remove pathogens from the water. &lt;br&gt;&lt;br&gt;The placebo has the same outside components as the real filter but the filtering membranes inside the cartridge have been replaced by some extra piping to imitate the weight of the real cartridge and the flow coming out of it. &lt;br&gt;&lt;br&gt;Within one month of distributing the filters, field investigators will visit each household once a month (i.e. 12 visits per household during the overall follow-up period) to conduct a health survey. They will record for each household member, whether she/he had experienced any illness in the past 7 days, prompting a list of symptoms - in which diarrhoea is included - if no answer was spontaneously given.
    </Intervention>
    <Primary_outcome>Diarrhoea longitudinal prevalence, measured as weekly period prevalence.
    </Primary_outcome>
    <Secondary_outcome>1. Use of device, measured every month&lt;br&gt;2. Bacterial load reduction in drinking water, measured every month&lt;br&gt;3. Acceptability, measured once at the end of the study
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>Vestergaard Frandsen (Switzerland)
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4638536
    </Internal_Number>
    <TrialID>NCT00640055
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Verbal Autopsy to Assess Early Neonatal Death and Stillbirth
    </Public_title>
    <Scientific_title>Using Verbal Autopsy to Determine Cause of Stillbirths and Early Neonatal Deaths Within the NICHD Global Network
    </Scientific_title>
    <Acronym>VA
    </Acronym>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20080318
    </Date_registration3>
    <Date_registration>18/03/2008
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00640055
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>7 Days
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2007
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>Congo;Guatemala;Pakistan;Zambia;Congo;Guatemala;Pakistan;Zambia
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Marion Koso-Thomas, MD;Cyril Engmann
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);UNC at CHapel Hill
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neonatal death with 7-days or stillbirth&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lives in study cluster&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mother died&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Delivery in hospital setting&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Perinatal Mortality;Cause of Neonatal Death;Cause of Stilbirth
    </Condition>
    <Intervention>Other: Coordinator;Other: Physician-assigned cause of death
    </Intervention>
    <Primary_outcome>Cause of death as assigned by a Community Coordinator compared to the cause of death assigned by the physician panel
    </Primary_outcome>
    <Secondary_outcome>The COD for stillbirth as assigned by the Community Coordinator compared to the COD for stillbirth as assigned by the Physician Panel;The agreement between mothers' and birth attendants' responses on selected items on the VA questionnaire (considering the mothers' response as the reference standard).
    </Secondary_outcome>
    <Secondary_ID>U01 HD 40636;CP03
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>12626790
    </Internal_Number>
    <TrialID>PER-039-07
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis (STRIDE)
    </Public_title>
    <Scientific_title>A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>ASOCIACION CIVIL IMPACTA, SALUD Y EDUCACION,
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20071130
    </Date_registration3>
    <Date_registration>30/11/2007
    </Date_registration>
    <Source_Register>REPEC
    </Source_Register>
    <web_address>https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=039-07
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>0
    </Inclusion_agemin>
    <Inclusion_agemax>0
    </Inclusion_agemax>
    <Inclusion_gender>--
    </Inclusion_gender>
    <Date_enrollement>09/05/2008
    </Date_enrollement>
    <Target_size>48
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>&lt;br&gt;					This is a phase IV, randomized, open label study for participants infected with HIV-1 treated for tuberculosis. It is designed to determine whether the strategy of initiating ART immediately (within approximately 2 weeks after starting treatment for TB) reduces mortality and the incidence of other AIDS defining events compared to late initiation in this population. The chosen participants include men and women at least 13 years of age, with an amount of CD4 cells &lt;200 cells / mm3 being treated for TB and virgins at ART. All participants will receive a rifampicin (RIF) or other regimen for TB based on rifamycin according to the World Health Organization (CMS) and national treatment guidelines.&lt;br&gt;					There will be two steps and two arms in this study. All participants will enter step 1 within 2 weeks after initiating TB therapy and will be randomized to either receive ART within 3 days after enrollment (immediate "group"; Arm A) or have ART delayed (group "postponed"
    </Study_design>
    <Phase>IV
    </Phase>
    <Countries>India;Congo;Thailand;Kenya;Malawi;Botswana;South Africa;Uganda;Zambia;Zimbabwe;Brazil;Haiti;Peru;United States
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &#x0D;&lt;br&gt;					1. HIV-1 infection.&#x0D;&lt;br&gt;					2. TB confirmed or probable.&#x0D;&lt;br&gt;					3. X-ray of the chest within 30 days prior to study entry.&#x0D;&lt;br&gt;					4. Current TB treatment based on rifampicin and other rifamycin derivatives initiated within 14 days prior to admission to the study.&#x0D;&lt;br&gt;					5. Amount of CD4 cells &lt;200 cells / mm3 obtained within 30 days before admission to the study in any of the laboratories approved by DAIDS.&#x0D;&lt;br&gt;					6. The following laboratory values &amp;#8203;&amp;#8203;obtained within 14 days prior to admission to the study: a) Absolute number of neutrophils &amp;#8805; 500 cells / mm3. b) Hemoglobin &amp;#8805; 7.0 g / dL. c) Amount of platelets &amp;#8805; 50,000 / mm3. d) Estimated creatinine clearance &amp;#8805; 60 mL / min. e) AST (SGOT), ALT (SGPT), bilirubin, and alkaline phosphatase &amp;#8804; 5 x ULN.&#x0D;&lt;br&gt;					7. Female participants with reproductive potential with a serum or negative urine pregnancy test within 7 days before admission to the study.&#x0D;&lt;br&gt;					8. All participants must agree to avoid any conception process.&#x0D;&lt;br&gt;					9. Female participants who are participating in a sexual activity that could lead to pregnancy must agree to use two reliable methods of contraception.&#x0D;&lt;br&gt;					10. Ability to swallow medications orally.&#x0D;&lt;br&gt;					11. Male and female participants, aged &amp;#8805; 13 years.&#x0D;&lt;br&gt;					12 The ability and availability of the participant or the tutor / representative to give informed consent.&#x0D;&lt;br&gt;				
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &#x0D;&lt;br&gt;					1. Having received at any time prior to admission to the study for&gt; 7 days of cumulative treatment with any ARV or treatment during any period of time with 2 or more ARVs in combination.&#x0D;&lt;br&gt;					2. Breastfeeding.&#x0D;&lt;br&gt;					3. Allergy / sensitivity to any study drug or its formulations.&#x0D;&lt;br&gt;					4. Having a prior history of documented multidrug resistant TB.&#x0D;&lt;br&gt;					5. Having received any research or chemotherapy therapy within 30 days prior to admission to the study.&#x0D;&lt;br&gt;					6. Anticipated reception of any of the prohibited medications.&#x0D;&lt;br&gt;				
    </Exclusion_Criteria>
    <Condition>&#x0D;
					-B200 HIV disease resulting in mycobacterial infection&#x0D;
				 &lt;br&gt;HIV disease resulting in mycobacterial infection;B200;HIV disease resulting in mycobacterial infection
    </Condition>
    <Intervention>&lt;br&gt;					Group name:ARM A Type of group;1 N° of participants:400 Intervention(s) description:Patients in this group will initiate antiretroviral therapy within 72 hours after randomization and within approximately 2 weeks after the start of TB treatment. Being treated with Efavirenz, in tablets, at a dose of 600 mg, PO, QD + Emtricitabine, in tablets, at a dose of 200 mg, PO, QD + Tenofovir, in tablets, at a dose of 300 mg, PO, QD. This scheme will be administered for 48 weeks.&lt;br&gt;					Group name:ARM B Type of group;2 N° of participants:400 Intervention(s) description:Patients in this group will start antiretroviral treatment between 8 and 12 weeks after the start of TB treatment. Being treated with Efavirenz, in tablets, at a dose of 600 mg, PO, QD + Emtricitabine, in tablets, at a dose of 200 mg, PO, QD + Tenofovir, in tablets, at a dose of 300 mg, PO, QD . This scheme will be administered for 48 weeks.&lt;br&gt;				
    </Intervention>
    <Primary_outcome>&lt;br&gt;					Outcome name:Clinical determination of the progression of AIDS, defined as a new disease defining AIDS.&lt;br&gt;					Measure:Proportion of participants who have survived without progression of AIDS.&lt;br&gt;					Timepoints:Week 48.&lt;br&gt;				
    </Primary_outcome>
    <Secondary_outcome>&#x0D;&lt;br&gt;					Outcome name:Criterion 1: Evaluation of the severity of adverse events, both physical and laboratory. Criterion 2: Determination of the number of patients who change / continue antiretroviral treatment due to toxicity or treatment failure (defined as 2 successive measurements of HIV-1 RNA plasma &amp;#8805; 1000 copies / mL.&#x0D;&lt;br&gt;					Measure:Safety and tolerability: 1) Proportion of participants with grade 3 or more of toxicity. 2) Proportion of participants who change / continue ART due to toxicities or failure to treat.&#x0D;&lt;br&gt;					Timepoints:Week 48.&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:Criterion 1: The final result is defined by the particular national program (NTP) of each research center. Criterion 2: Identify those patients who need to continue with TB treatment for longer time.&#x0D;&lt;br&gt;					Measure:Final result of TB treatment: 1) Overall final result. 2) Need for extended TB treatment.&#x0D;&lt;br&gt;					Timepoints:Week 48.&#x0D;&lt;br&gt;				;&#x0D;&lt;br&gt;					Outcome name:Criterion 1: Determination of those predictors of: a) Immune Reconstitution Syndrome (IRIS). b) Failure to cure TB. c) Recurrence of TB. d) Intolerance to treatment for TB in the presence of ART. Criterion 2: Determination of the response to treatment, using the CD4 count, viral load HIV-1 RNA, viral load time &lt;200 copies / mL and virological failure. Criterion 3: Tests for sensitivity to ARV treatment. Criterion 4: Serum concentration of EFV and NVP + Viral load RNA of HIV-1 + Evaluation of toxicity related to drugs in research. Criterion 5: Determine the proportion of participants with residual levels of EFV less than 1.0 mg / L.&#x0D;&lt;br&gt;					Measure:1) Determination of predictors. 2) Response to treatment with ART. 3) Resistance to the drug for HIV. 4) Relationship between the concentrations of EFV and NVP, virological response and toxicities. 5) Determine if the 600 mg dose of EFV provides exposure adequate 6) Impact of confirmed TB.&#x0D;&lt;br&gt;					Timepoints:Criteria 1, 2, 3, 5 and 6: Week 48. Criterion 4: Weeks 4 and 8.&#x0D;&lt;br&gt;				
    </Secondary_outcome>
    <Secondary_ID> NA;NCT00108862
    </Secondary_ID>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>andresparedesleon@yahoo.com  
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Asociacion Civil Impacta Salud y Educacion
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>2423072 anexo 130
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>andresparedesleon@yahoo.com  
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10203477
    </Internal_Number>
    <TrialID>NCT00541385
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients
    </Public_title>
    <Scientific_title>Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medicines for Malaria Venture
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20071009
    </Date_registration3>
    <Date_registration>09/10/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00541385
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>12 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2007
    </Date_enrollement>
    <Target_size>535
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Gabon;Kenya;Mali;Mozambique;Philippines;Burkina Faso;Congo, The Democratic Republic of the;Côte D'Ivoire;Gabon;Kenya;Mali;Mozambique;Philippines;Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Claude Oeuvray, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Medicines for Malaria Venture
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female patients =12 years of age.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Body weight = 5 kg and &lt; 25 kg with no clinical evidence of severe malnutrition&#x0D;&lt;br&gt;             (defined as a child whose weight-for-height is below -3 standard deviations or less&#x0D;&lt;br&gt;             than 70% of the median of the NCHS/WHO normalised reference values).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Presence of acute uncomplicated P. falciparum mono-infection confirmed by:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Fever, as defined by axillary temperature = 37.5°C or oral/tympanic/rectal&#x0D;&lt;br&gt;                  temperature = 38°C, or documented history of fever in the previous 24 hours and,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Positive microscopy of P. falciparum with parasite density between 1,000 and&#x0D;&lt;br&gt;                  200,000 asexual parasite count/µl of blood.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Written informed consent, in accordance with local practice, provided by&#x0D;&lt;br&gt;             parent/guardian. If the parent/guardian is unable to write, witnessed consent is&#x0D;&lt;br&gt;             permitted according to local ethical considerations. Where possible, patient assent&#x0D;&lt;br&gt;             will be sought.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Ability to swallow whole volume of liquid in which medication is suspended.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Female patients of child-bearing potential must be neither pregnant (as demonstrated&#x0D;&lt;br&gt;             by a negative pregnancy test) nor lactating, and must be willing to take measures to&#x0D;&lt;br&gt;             not become pregnant during the study period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Ability and willingness to participate based on information given to parent or&#x0D;&lt;br&gt;             guardian and access to health facility. The patient is to comply with all scheduled&#x0D;&lt;br&gt;             follow up visits until D42.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with signs and symptoms of severe/complicated malaria requiring parenteral&#x0D;&lt;br&gt;             treatment according to the World Health Organization Criteria 2000 [Attachment 3].&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Mixed Plasmodium infection.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Severe vomiting, defined as more than three times in the 24 hours prior to inclusion&#x0D;&lt;br&gt;             in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3&#x0D;&lt;br&gt;             or more watery stools per day.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Known history or evidence of clinically significant disorders such as cardiovascular&#x0D;&lt;br&gt;             (including arrhythmia, QTc interval greater or equal to 450 milliseconds), respiratory&#x0D;&lt;br&gt;             (including active tuberculosis), history of jaundice, hepatic, renal,&#x0D;&lt;br&gt;             gastrointestinal, immunological (including active HIV-AIDS), neurological (including&#x0D;&lt;br&gt;             auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or&#x0D;&lt;br&gt;             other abnormality (including recent head trauma).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Presence of significant anaemia, as defined by Hb &lt; 8 g/dL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Presence of febrile conditions caused by diseases other than malaria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Known history of hypersensitivity, allergic or adverse reactions to pyronaridine,&#x0D;&lt;br&gt;             lumefantrine or artesunate or other artemisinins.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patients with known disturbances of electrolytes balance, e.g., hypokalaemia or&#x0D;&lt;br&gt;             hypomagnesaemia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Use of any other antimalarial agent within 2 weeks prior to start of the study as&#x0D;&lt;br&gt;             evidenced by reported patient history.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6&#x0D;&lt;br&gt;             (flecainide, metoprol, imipramine, amitriptyline, clomipramine).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Received an investigational drug within the past 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or&#x0D;&lt;br&gt;             Hepatitis C antibody (HCV Ab).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Known positive for HIV antibody.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Liver function tests [ASAT/ALAT levels] more than 2.5 times upper limit of normal&#x0D;&lt;br&gt;             range.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Known significant renal impairment as indicated by serum creatinine of more than 1.4&#x0D;&lt;br&gt;             mg/dL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Previous participation in any clinical study with pyronaridine artesunate.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: pyronaridine artesunate;Drug: arthemeter lumefantrine
    </Intervention>
    <Primary_outcome>PCR corrected ACPR on Day 28
    </Primary_outcome>
    <Secondary_outcome>PCR-corrected ACPR on Day 14;Incidence and severity of adverse events and of cllinically significant laboratory results, ECG, vital signs or physical examination abnormalities
    </Secondary_outcome>
    <Secondary_ID>SP-C-007-07
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Shin Poong Pharmaceuticals
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4630906
    </Internal_Number>
    <TrialID>NCT00538382
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo
    </Public_title>
    <Scientific_title>Phase I Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20070928
    </Date_registration3>
    <Date_registration>28/09/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00538382
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>40 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>May 2007
    </Date_enrollement>
    <Target_size>51
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Congo, The Democratic Republic of the;The Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Carl Bose, M.D.;Antoinette Tshefu, M.D., M.P.H.
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>University of North Carolina;Kinshasa School of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria for Cases:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  2nd trimester (22-26 weeks) or 3rd trimester (32-36 weeks) of pregnancy, based on an&#x0D;&lt;br&gt;             ultrasound conducted at &lt;22 weeks gestation (composite of BPD, HC, AC, FL)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Singleton pregnancy documented by ultrasound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parasitemic (&gt; 500 parasites/µl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Afebrile and asymptomatic&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hematocrit = 30%&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Negative HIV test result&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 18 years of age and less than 40 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to spend three days in the clinic  following their laboratory screening visit&#x0D;&lt;br&gt;             and again at three months postpartum&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria for Non-pregnant Controls:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Negative urine pregnancy test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parasitemic (&gt; 500 parasites/µl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Afebrile and asymptomatic&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hematocrit  =  30%&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Negative Determine® HIV test result&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 18 years of age and less than 40 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to spend three days in the clinic following screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria for Internal controls:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Negative urine pregnancy test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for Cases:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parasitemia &gt; 300,000 parasites/µl or symptomatic malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical contraindications to participation or medical disorders (known high blood&#x0D;&lt;br&gt;             pressure, diabetes, sickle cell disease or tuberculosis)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have taken artesunate or any medicine containing artesunate during the current&#x0D;&lt;br&gt;             pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have taken any antimalarial in the past two weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have taken any medication in the past two weeks other than antipyretics (e.g.,&#x0D;&lt;br&gt;             acetyl- salicylic acid, acetaminophen), folic acid or iron&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a fetus with any ultrasonographically visible structural fetal abnormalities&#x0D;&lt;br&gt;             identified on entry by ultrasound&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Past or present pregnancy complications that would preclude participation in the&#x0D;&lt;br&gt;             study (gestational diabetes/diabetes, incompetent cervix, pre-eclampsia/ eclampsia,&#x0D;&lt;br&gt;             and high blood pressure)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Between 32-36 weeks gestation and have already participated in the study at 22-26&#x0D;&lt;br&gt;             weeks gestation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for Non-pregnant Controls:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parasitemia &gt; 300,000 parasites/µl or have symptomatic malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical contraindications to participation or medical disorders (known high blood&#x0D;&lt;br&gt;             pressure, diabetes, sickle cell disease or tuberculosis)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have taken any antimalarial in the past two weeks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have taken any medication in the past two weeks other than antipyretics (e.g.,&#x0D;&lt;br&gt;             acetyl- salicylic acid, acetaminophen), folic acid or iron&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria for Internal Controls:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parasitemia &gt; 300,000 parasites/µl or have symptomatic malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have taken antimalarial medication in the past two weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have taken any medication in the past two weeks other than antipyretics (e.g.,&#x0D;&lt;br&gt;             acetyl- salicylic acid, acetaminophen), folic acid or iron&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: Artesunate
    </Intervention>
    <Primary_outcome>Levels of the unbound active major metabolite, dihydroartemisinin (DHA), will be similar for parasitemic pregnant women during their 2nd and 3rd trimesters vs. the same women 3 months postpartum
    </Primary_outcome>
    <Secondary_outcome>The levels of unbound DHA will be similar for parasitemic pregnant women (during the second and third trimesters) vs. parasitemic non-pregnant women.;The pharmacokinetics of ARTS and total DHA will be similar for parasitemic pregnant women (during the second and third trimesters) vs. the same women three months postpartum and parasitemic non-pregnant women.;The pharmacodynamics of therapy will be similar for parasitemic pregnant women (during the 2nd and 3rd trimesters) vs. parasitemic non-pregnant women. Pharmacodynamics will be determined by measuring the parasite clearance time (PCT), PC50, and PC90.;The pharmacodynamics and pharmacokinetic outcomes (as elaborated above) will be similar between the 2nd and 3rd trimester in parasitemic pregnant women.;Description of safety and tolerability of Artesunate in the target population (pregnant women in the 2nd and 3rd trimester).
    </Secondary_outcome>
    <Secondary_ID>GN02- PK/PD of artesunate
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Global Network for Women's and Children's Health Research;Bill and Melinda Gates Foundation;John E. Fogarty International Center (FIC);National Center for Complementary and Integrative Health (NCCIH);National Institute of Dental and Craniofacial Research (NIDCR);National Cancer Institute (NCI);RTI International;University of North Carolina;Kinshasa School of Public Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4627221
    </Internal_Number>
    <TrialID>NCT00489619
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Safe Pregnancy by Infectious Disease Control
    </Public_title>
    <Scientific_title>Safe Pregnancy by Infectious Disease Control in the Democratic Republic of Congo - Pilot Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20070619
    </Date_registration3>
    <Date_registration>19/06/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00489619
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>April 2004
    </Date_enrollement>
    <Target_size>2008
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Time Perspective: Prospective
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Congo, The Democratic Republic of the;The Democratic Republic of the Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Robin Ryder, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of North Carolina
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  older than or equal to 15 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presenting for antenatal care at one of the two target maternities for the first time&#x0D;&lt;br&gt;             during the current pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  willing to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  refusal to participate in the HIV voluntary and counseling program at the maternity&#x0D;&lt;br&gt;             center or refusal to share HIV results with the study staff.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pregnancy;Malaria
    </Condition>
    <Secondary_ID>U01HD043475;GN 02 - Pilot
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Global Network for Women's and Children's Health Research;Bill and Melinda Gates Foundation;John E. Fogarty International Center (FIC);National Center for Complementary and Integrative Health (NCCIH);National Institute of Dental and Craniofacial Research (NIDCR);National Cancer Institute (NCI);RTI International;University of North Carolina;Kinshasa School of Public Health
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10202174
    </Internal_Number>
    <TrialID>NCT00422084
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients
    </Public_title>
    <Scientific_title>A Phase III Comparative, (Double-blind, Double-dummy), Randomised, Multi-centre, Clinical Study to Assess the Safety and Efficacy of Fixed Dose Formulation of Oral Pyronaridine Artesunate Tablet (180:60 mg) Versus Coartem® (Artemether Lumefantrine) in Children and Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medicines for Malaria Venture
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20070112
    </Date_registration3>
    <Date_registration>12/01/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00422084
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2007
    </Date_enrollement>
    <Target_size>1272
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Gambia;Ghana;Indonesia;Kenya;Mali;Mozambique;Philippines;Senegal;Congo, The Democratic Republic of the;Gambia;Ghana;Indonesia;Kenya;Mali;Mozambique;Philippines;Senegal;Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Claude Oeuvray, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Medicines for Malaria Venture
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female patients between the age of 3 and 60 years, inclusive.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of acute uncomplicated P. falciparum mono-infection confirmed by:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Fever, as defined by axillary/tympanic temperature = 37.5°C or oral/rectal&#x0D;&lt;br&gt;                  temperature = 38°C, or documented history of fever in the previous 24 hours and,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Positive microscopy of P. falciparum with parasite density between 1,000 and&#x0D;&lt;br&gt;                  100,000 asexual parasite count/µl of blood.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent, in accordance with local practice, provided by patient&#x0D;&lt;br&gt;             and/or parent/guardian/spouse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to swallow oral medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with signs and symptoms of severe/complicated malaria requiring parenteral&#x0D;&lt;br&gt;             treatment according to the World Health Organization Criteria 2000.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mixed Plasmodium infection.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe vomiting or severe diarrhoea.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known history or evidence of clinically significant disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of significant anaemia, as defined by Hb &lt; 8 g/dL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of febrile conditions caused by diseases other than malaria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known history of hypersensitivity, allergic or adverse reactions to pyronaridine,&#x0D;&lt;br&gt;             lumefantrine or artesunate or other artemisinins.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with known disturbances of electrolytes balance, e.g., hypokalaemia or&#x0D;&lt;br&gt;             hypomagnesaemia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of any other antimalarial agent within 2 weeks prior to start of the study as&#x0D;&lt;br&gt;             evidenced by positive urine test.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female patients of child-bearing potential must be neither pregnant (as demonstrated&#x0D;&lt;br&gt;             by a negative pregnancy test) nor lactating, and must be willing to take measures to&#x0D;&lt;br&gt;             not become pregnant during the study period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6&#x0D;&lt;br&gt;             (flecainide, metoprol, imipramine, amitriptyline, clomipramine).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Received an investigational drug within the past 4 weeks.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen. (HBsAg) or&#x0D;&lt;br&gt;             Hepatitis C antibody (HCV Ab).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known seropositive HIV antibody.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Liver function tests [ASAT/ALAT levels] more than 2.5 times upper limit of normal&#x0D;&lt;br&gt;             range.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known significant renal impairment as indicated by serum creatinine of more than 1.4&#x0D;&lt;br&gt;             mg/dL.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: Pyronaridine artesunate;Drug: Coartem® (artemether lumefantrine)
    </Intervention>
    <Primary_outcome>PCR-corrected adequate clinical and parasitological response (ACPR) rate on Day 28;Treatment success or failures will be classified according to WHO Guidelines 2005;Incidence and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities
    </Primary_outcome>
    <Secondary_outcome>Proportion of patients with PCR - corrected adequate clinical and parasitological response (ACPR) on Day 14;Crude ACPR (non-PCR corrected ACPR) on Day 14 and Day 28;Parasite Clearance Time;Fever Clearance Time;Proportion of patients who have cleared parasites at Day 1, 2 and 3;Proportion of patients who have fever cleared at Day 1, 2 and 3
    </Secondary_outcome>
    <Secondary_ID>SP-C-005-06
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Shin Poong Pharmaceuticals
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4537397
    </Internal_Number>
    <TrialID>ISRCTN36877262
    </TrialID>
    <Last_Refreshed_on>13 January 2015
    </Last_Refreshed_on>
    <Public_title>Clinical study on alternative treatment of patients with second stage Trypanosoma brucei gambiense sleeping sickness
    </Public_title>
    <Scientific_title>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               &#x20;
    </Scientific_title>
    <Primary_sponsor>Institute of Tropical Medicine (Belgium)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20051216
    </Date_registration3>
    <Date_registration>16/12/2005
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN36877262
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/02/1998
    </Date_enrollement>
    <Target_size>600
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>An open randomised trial was designed to test equivalence between standard melarsoprol and 3 other regimens. (Treatment)
    </Study_design>
    <Countries>Congo, Democratic Republic
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1, Older than 15 years&lt;br&gt;2. Second-stage parasitologically confirmed T. b. gambiense infection&lt;br&gt;3. Never previously treated for sleeping sickness&lt;br&gt;&lt;br&gt;Second stage disease was defined as: 1° cerebrospinal fluid (CSF) white blood cell (WBC) count &gt;20 /µl and detectable IgM in the CSF; or 2° trypanosomes detected in CSF.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Glasgow coma scale &lt;8&lt;br&gt;2. Pregnancy&lt;br&gt;3. Active tuberculosis&lt;br&gt;4. Positive syphilis serology&lt;br&gt;5. Bacterial or cryptococcal meningitis&lt;br&gt;6. Severe anaemia&lt;br&gt;7. Severe renal or hepatic dysfunction&lt;br&gt;8. Hemorrhagic CSF&lt;br&gt;9. Residence beyond 100 km from Bwamanda Hospital
    </Exclusion_Criteria>
    <Condition>Trypanosoma brucei gambiense Human African Trypanosomiasis in second stage &lt;br&gt;Infections and Infestations &lt;br&gt;African trypanosomiasis
    </Condition>
    <Intervention>A. Standard melarsoprol as administered in the DRC: 3 series of 3.6 mg/kg/day intravenously (IV) (maximum 180 mg/day) for 3 days with 7-day breaks in between series. Total dose: 32.4 mg/kg.&lt;br&gt;&lt;br&gt;B. Concise, consecutive lower-dose melarsoprol: IV during 10 days (0.6 mg/kg on day 1; 1.2 mg/kg on day 2; 1.8 mg/kg from days 3 to 10; maximum 90 mg/day). Total dose: 16.2 mg/kg.&lt;br&gt;&lt;br&gt;C. Nifurtimox monotherapy: orally, under nurse supervision, 5 mg/kg every 8 hours for 14 days. Total dose: 210 mg/kg.&lt;br&gt;&lt;br&gt;D. Low-dose concise, consecutive melarsoprol-nifurtimox combination: 2 days melarsoprol alone (0.6 mg/kg on day 1; 1.2 mg/kg on day 2) followed by 8 days 7.5 mg/kg nifurtimox every 12 hours combined with melarsoprol 1.2 mg/kg/day. Total melarsoprol dose: 11.4 mg/kg. Total nifurtimox dose: 120 mg/kg.
    </Intervention>
    <Primary_outcome>Primary outcomes were relapse, severe adverse events and death attributed to treatment.
    </Primary_outcome>
    <Secondary_outcome>Secondary outcomes were frequency of other adverse events
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>Institute of Tropical Medicine (Belgium), Belgian Directorate-General for Development Co-operation (Belgium)
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5779797
    </Internal_Number>
    <TrialID>NCT00146627
    </TrialID>
    <Last_Refreshed_on>10 October 2016
    </Last_Refreshed_on>
    <Public_title>Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
    </Public_title>
    <Scientific_title>Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Drugs for Neglected Diseases
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050906
    </Date_registration3>
    <Date_registration>06/09/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00146627
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>September 2004
    </Date_enrollement>
    <Target_size>280
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Congo, The Democratic Republic of the;Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda;Congo, The Democratic Republic of the;Congo;Congo, The Democratic Republic of the;The Democratic Republic of the Congo;Uganda
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Els Torreele, PhD;Gerardo Priotto, MD, MPH;Els Torreele, PhD;Gerardo Priotto, MD, MPH
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Drugs for Neglected Diseases;Epicentre;Drugs for Neglected Diseases;Epicentre
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  confirmed second-stage T.b. gambiense infection : presence of the parasite in blood,&#x0D;&lt;br&gt;             lymph node fluid or CSF and &gt;20 white blood cells/µL in CSF. In presence of blood in&#x0D;&lt;br&gt;             the CSF, lumbar puncture must be done again or the patient cannot be included in the&#x0D;&lt;br&gt;             study (see 10.9.1).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  and of age 15 years or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  and resident in __________ (each site will define boundaries or maximum distance)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  and written informed consent of the patient or of a legally acceptable representative&#x0D;&lt;br&gt;             if the patient is a minor (&lt;18 years for both genders in Uganda and Angola, &lt;18 years&#x0D;&lt;br&gt;             for males and &lt;16 years for females in the Democratic Republic of Congo) or unable to&#x0D;&lt;br&gt;             communicate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnant woman (systematic testing of women of childbearing potential)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  treated for late-stage HAT during the last 36 months. Patients previously treated for&#x0D;&lt;br&gt;             first-stage (pentamidine) can be included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unlikely to have access to the treatment centre or be accessible at their place of&#x0D;&lt;br&gt;             residence for 18 months after treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unable to take oral medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suffering from conditions other than second stage HAT that seriously limit the&#x0D;&lt;br&gt;             chances of survival over 18 months time&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe anemia (Hb&lt; 5g/dl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe underlying diseases upon admission (e.g. Active tuberculosis and/or being&#x0D;&lt;br&gt;             treated for TB; Bacterial or cryptococcal meningitis; Stages 3 or 4 HIV/AIDS&#x0D;&lt;br&gt;             according to the WHO clinical definition) (WHO, 1986).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe renal failure based on clinical examination combined with biochemistry if&#x0D;&lt;br&gt;             available: creatinine clearance &lt;20mL/min&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe hepatic failure based on clinical examination combined with biochemistry if&#x0D;&lt;br&gt;             available: total bilirubin &gt;50 µmol/L, ALAT/GPT &gt;70 UI/L, unless these laboratory&#x0D;&lt;br&gt;             values are determined by the investigator as likely due to conditions other than&#x0D;&lt;br&gt;             hepatic failure.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  confirmed second-stage T.b. gambiense infection : presence of the parasite in blood,&#x0D;&lt;br&gt;             lymph node fluid or CSF and &gt;20 white blood cells/µL in CSF. In presence of blood in&#x0D;&lt;br&gt;             the CSF, lumbar puncture must be done again or the patient cannot be included in the&#x0D;&lt;br&gt;             study (see 10.9.1).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  and of age 15 years or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  and resident in __________ (each site will define boundaries or maximum distance)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  and written informed consent of the patient or of a legally acceptable representative&#x0D;&lt;br&gt;             if the patient is a minor (&lt;18 years for both genders in Uganda and Angola, &lt;18 years&#x0D;&lt;br&gt;             for males and &lt;16 years for females in the Democratic Republic of Congo) or unable to&#x0D;&lt;br&gt;             communicate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnant woman (systematic testing of women of childbearing potential)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  treated for late-stage HAT during the last 36 months. Patients previously treated for&#x0D;&lt;br&gt;             first-stage (pentamidine) can be included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unlikely to have access to the treatment centre or be accessible at their place of&#x0D;&lt;br&gt;             residence for 18 months after treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unable to take oral medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  suffering from conditions other than second stage HAT that seriously limit the&#x0D;&lt;br&gt;             chances of survival over 18 months time&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe anemia (Hb&lt; 5g/dl)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe underlying diseases upon admission (e.g. Active tuberculosis and/or being&#x0D;&lt;br&gt;             treated for TB; Bacterial or cryptococcal meningitis; Stages 3 or 4 HIV/AIDS&#x0D;&lt;br&gt;             according to the WHO clinical definition) (WHO, 1986).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe renal failure based on clinical examination combined with biochemistry if&#x0D;&lt;br&gt;             available: creatinine clearance &lt;20mL/min&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe hepatic failure based on clinical examination combined with biochemistry if&#x0D;&lt;br&gt;             available: total bilirubin &gt;50 µmol/L, ALAT/GPT &gt;70 UI/L, unless these laboratory&#x0D;&lt;br&gt;             values are determined by the investigator as likely due to conditions other than&#x0D;&lt;br&gt;             hepatic failure.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Trypanosomiasis, African;Trypanosomiasis, African
    </Condition>
    <Intervention>Drug: Eflornithine;Drug: Nifurtimox;Drug: Eflornithine;Drug: Nifurtimox
    </Intervention>
    <Secondary_ID>DNDi-HAT0105; Epicentre-NECT;DNDi-HAT0105; Epicentre-NECT
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors;Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Medecins Sans Frontieres, Netherlands;PNLTHA-DRC;;PNLTHA-RoC;Epicentre;Swiss Tropical &amp; Public Health Institute;World Health Organization;Medecins Sans Frontieres, Netherlands;PNLTHA-DRC;;PNLTHA-RoC;Epicentre;Swiss Tropical &amp; Public Health Institute;World Health Organization
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4600729
    </Internal_Number>
    <TrialID>NCT00136708
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>First Breath: Neonatal Resuscitation in Developing Countries
    </Public_title>
    <Scientific_title>FIRST BREATH: Neonatal Resuscitation in Developing Countries
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20050825
    </Date_registration3>
    <Date_registration>25/08/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00136708
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>March 2005
    </Date_enrollement>
    <Target_size>120009
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Argentina;Congo;Guatemala;India;Pakistan;Zambia;Argentina;Congo;Guatemala;India;Pakistan;Zambia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Waldemar Carlo, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Alabama at Birmingham
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Live births with a weight = 1500 grams (community minimum)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants born in participating communities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stillbirths&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Infants with suspected/confirmed lethal malformations (e.g. anencephaly, Trisomy 13&#x0D;&lt;br&gt;             or 18, or cyanotic or left-sided congenital heart disease that will not be repaired)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any infant who is transported/brought to the center after delivery&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Asphyxia Neonatorum
    </Condition>
    <Intervention>Procedure: Neonatal Resuscitation
    </Intervention>
    <Primary_outcome>Neonatal mortality
    </Primary_outcome>
    <Secondary_outcome>Neonatal mortality due to perinatal asphyxia;Hypoxic ischemic encephalopathy;Need for advanced resuscitation;Apgar score at 5 minutes;Perinatal mortality at 7 days;Stillbirth or neonatal mortality;Stillbirth and/or neonatal mortality at 28 days
    </Secondary_outcome>
    <Secondary_ID>CP02 FIRST BREATH
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>5809699
    </Internal_Number>
    <TrialID>ISRCTN85534673
    </TrialID>
    <Last_Refreshed_on>17 October 2016
    </Last_Refreshed_on>
    <Public_title>International randomized controlled phase III trial of DB289 versus pentamidine for the treatment of first stage Human African Trypanosomiasis (HAT)
    </Public_title>
    <Scientific_title>International randomized controlled phase III trial of DB289 versus pentamidine for the treatment of first stage Human African Trypanosomiasis (HAT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Immtech Pharmaceuticals, Inc. (USA)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20050823
    </Date_registration3>
    <Date_registration>23/08/2005
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN85534673
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>15/07/2005
    </Date_enrollement>
    <Target_size>250
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomised controlled trial (Treatment)
    </Study_design>
    <Phase>Phase III
    </Phase>
    <Countries>Angola;Congo;Sudan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. The patient has first stage T. b. gambiense infection, i.e. parasitologically confirmed infection in the blood or lymph node aspirate and White Blood Cell count (WBC) less than or equal to 5 mm^3 detected in the CerebroSpinal Fluid (CSF) by microscopic examination. &lt;br&gt;2. Patient is male or female 12 years of age or older and more than or equal to 30 kg.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The patient has possible or confirmed second stage T. b. gambiense infection, i.e. presence of parasite in the CSF upon microscopic examination or a WBC count in the CSF of more than 5 mm^-3&lt;br&gt;2. Active clinically relevant medical conditions that in the Investigator's opinion may jeopardise subject safety or interfere with participation in the study, including but not limited to: significant liver diseases, chronic pulmonary diseases, significant cardiovascular diseases, diabetes, thyroid diseases, gout, infection including known Human Immunodeficiency Virus (HIV) infection, Central Nervous System (CNS) trauma or seizure disorders&lt;br&gt;3. Coma Score of less than nine on the Glasgow Coma Scale
    </Exclusion_Criteria>
    <Condition>Human African Trypanosomiasis (HAT) or sleeping sickness &lt;br&gt;Infections and Infestations &lt;br&gt;Human African Trypanosomiasis (HAT)
    </Condition>
    <Intervention>The subjects will receive either DB289 or pentamidine treatment according to their randomisation.
    </Intervention>
    <Primary_outcome>The primary efficacy variable will be the combined rate of clinical and parasitological cure at the Test of Cure evaluation (12 month evaluation) in the Per Protocol dataset.
    </Primary_outcome>
    <Secondary_outcome>Parasitological cure, clinical cure, probable relapse, relapse and death rates at the End of Treatment and at the 3, 6, 18 and 24 month evaluations will also be determined.
    </Secondary_outcome>
    <Secondary_ID>289-C-010 (C05-010)
    </Secondary_ID>
    <Source_Support>Bill and Melinda Gates Foundation (USA) - grant ref: 38381
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4534502
    </Internal_Number>
    <TrialID>ISRCTN50258054
    </TrialID>
    <Last_Refreshed_on>13 January 2015
    </Last_Refreshed_on>
    <Public_title>The Africa Quinine versus Artesunate in Severe Malaria Trial
    </Public_title>
    <Scientific_title>The AQUAMAT trial:  An open label randomised comparison of injectable artesunate and quinine in children with severe falciparum malaria in Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>University of Oxford (UK)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20050722
    </Date_registration3>
    <Date_registration>22/07/2005
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN50258054
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>08/10/2005
    </Date_enrollement>
    <Target_size>5300
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomised controlled trial (Treatment)
    </Study_design>
    <Countries>Congo, Democratic Republic;Gambia;Ghana;Kenya;Mozambique;Nigeria;Rwanda;Tanzania;Uganda
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: 1. OptiMal malaria rapid test positive, and &lt;br&gt;2. Treating physician considers patient to have severe malaria
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patient has received more than or equal to 24 hours of effective treatment with quinine or an artemisinin derivative, or&lt;br&gt;2. Patient has a known allergy to quinine or an artemisinin derivative
    </Exclusion_Criteria>
    <Condition>Malaria &lt;br&gt;Infections and Infestations &lt;br&gt;Malaria
    </Condition>
    <Intervention>Please note that as of 01/09/10 this trial has reached its target sample size and recruitment has been closed. The trial is now in follow-up. &lt;br&gt;&lt;br&gt;Current information as of 26/01/2009:&lt;br&gt;Patients are randomised to treatment with either intravenous (i.v.) or intramuscular (i.m.) artesunate or i.v. or i.m. quinine.  &lt;br&gt;&lt;br&gt;Initial information at time of registration:&lt;br&gt;In two of the study sites intramuscular artesunate will be compared with intramuscular quinine. In two other study sites the comparison will be between intravenous artesunate and intravenous quinine.
    </Intervention>
    <Primary_outcome>In-hospital mortality
    </Primary_outcome>
    <Secondary_outcome>Current information as of 20/04/2010:&lt;br&gt;1. Neurological sequelae at day 28 after discharge from the hospital&lt;br&gt;2. Combined in-hospital mortality and neurological sequelae at day 28 after discharge from the hospital&lt;br&gt;&lt;br&gt;Initial information at time of registration:&lt;br&gt;1. Neurological sequelae&lt;br&gt;2. Recovery times:&lt;br&gt;2.1. To localise pain&lt;br&gt;2.2. To speak&lt;br&gt;2.3. To sit unsupported&lt;br&gt;2.4. To eat or breast feed, and &lt;br&gt;2.5. To discharge from hospital&lt;br&gt;&lt;br&gt;Assessed at discharge.
    </Secondary_outcome>
    <Secondary_ID>076908
    </Secondary_ID>
    <Source_Support>The Wellcome Trust (UK) (grant ref: 076908)
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>4599570
    </Internal_Number>
    <TrialID>NCT00121368
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>GN Tobacco Use Survey
    </Public_title>
    <Scientific_title>Survey on Tobacco Use in the GN Sites
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>NICHD Global Network for Women's and Children's Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20050715
    </Date_registration3>
    <Date_registration>15/07/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT00121368
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>45 Years
    </Inclusion_agemax>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>February 2004
    </Date_enrollement>
    <Target_size>6000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Time Perspective: Prospective
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Argentina;Brazil;Congo;Ecuador;Guatemala;India;Pakistan;Zambia;Argentina;Brazil;Congo;Ecuador;Guatemala;India;Pakistan;Zambia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Michele Bloch, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>National Cancer Institute (NCI)
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women of legal consent and child-bearing age (18-45)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Attendance at a participating clinic&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant women with disabilities such as deafness, serious mental illness, or mental&#x0D;&lt;br&gt;             retardation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Smoking
    </Condition>
    <Primary_outcome>Tobacco use
    </Primary_outcome>
    <Secondary_ID>CP01 Tobacco Use
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Cancer Institute (NCI);Global Network for Women's and Children's Health Research;Bill and Melinda Gates Foundation;John E. Fogarty International Center (FIC);National Center for Complementary and Integrative Health (NCCIH);National Institute of Dental and Craniofacial Research (NIDCR);RTI International
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:22:53</Export_date>
    <Internal_Number>10199500
    </Internal_Number>
    <TrialID>NCT00108862
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis
    </Public_title>
    <Scientific_title>A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3
    </Scientific_title>
    <Acronym>STRIDE
    </Acronym>
    <Primary_sponsor>AIDS Clinical Trials Group
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20050419
    </Date_registration3>
    <Date_registration>19/04/2005
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00108862
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>13 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2006
    </Date_enrollement>
    <Target_size>809
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>United States;Botswana;Brazil;Haiti;India;Kenya;Malawi;Peru;South Africa;Thailand;Uganda;Zambia;Zimbabwe;Botswana;Brazil;Haiti;India;Kenya;Malawi;Peru;South Africa;Thailand;Uganda;United States;Zambia;Zimbabwe;Congo
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Diane Havlir, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>San Francisco General Hospital and University of California, San Francisco
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HIV-infected.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Confirmed or probable TB (more information on the criterion can be found in the&#x0D;&lt;br&gt;             protocol).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chest x-ray within 30 days prior to study entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Receipt of 1-14 cumulative days of rifampin- or other rifamycin-based TB treatment&#x0D;&lt;br&gt;             that was initiated within 28 days prior to study entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  CD4 count less than 250 cells/mm^3 within 30 days prior to study entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willing to use acceptable methods of contraception while on study drugs and for 6&#x0D;&lt;br&gt;             weeks after stopping these drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to swallow oral medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent of guardian willing to provide informed consent, if applicable.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky performance score =&gt;20 at time of study entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ART for longer than 7 cumulative days prior to study entry or treatment for any period&#x0D;&lt;br&gt;             of time with one or more antiretrovirals. Participants who have taken ART during&#x0D;&lt;br&gt;             pregnancy or for occupational exposure are not excluded.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Allergy or sensitivity to any of the study drugs or their formulations.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of multidrug-resistant TB.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Receipt of any investigational therapy or chemotherapy within 30 days prior to study&#x0D;&lt;br&gt;             entry.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Certain medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Breastfeeding.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>HIV Infection;Tuberculosis
    </Condition>
    <Intervention>Other: Strategy: Immediate ART;Other: Strategy: Deferred ART
    </Intervention>
    <Primary_outcome>Percent of Participants Who Survived Without AIDS Progression.
    </Primary_outcome>
    <Secondary_outcome>Percent of Participants Reporting a Grade 3 or 4 Adverse Event or Laboratory Abnormality;Time to First New AIDS-defining Illness or Death.;Percent of Participants With Culture-confirmed Tuberculosis (TB) Who Survived Without AIDS Progression.;Percent of Participants Who Interrupted or Discontinued at Least One Tuberculosis (TB) Medication Due to Toxicity.;Percent of Participants With Confirmed or Probable Tuberculosis (TB) Whose TB Resolved, or Who Required TB Treatment Through the End of Follow-up, or Died, or Were Lost to Follow-up.;Percent of Participants Whose CD4 Increased by at Least 100 Cells/mm^3 Between Baseline and Week 48.;Percent of Participants With MTB IRIS.;Percent of Participants With HIV IRIS.;Percent of Participants Whose HIV Viral Load Was Less Than 400 Copies/mL at Week 48.
    </Secondary_outcome>
    <Secondary_ID>1U01AI068636;ACTG A5221;ACTG A5221
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Allergy and Infectious Diseases (NIAID)
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>02/11/2011
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00108862
    </results_url_link>
    
  </Trial>
</Trials_downloaded_from_ICTRP>